adverse effects, Primary Sclerosing Cholangitis Literature

Primary Sclerosing Cholangitis Literature

Home Page

FAQ

PSC Partners

www Resources

Scientific Literature

Scientific Literature, adverse effects

Abalovich M, Amino N, Barbour LA, Cobin RH, De Groot LJ, Glinoer D, Mandel SJ, Stagnaro-Green A. Management of thyroid dysfunction during pregnancy and postpartum: an Endocrine Society Clinical Practice Guideline. J. Clin. Endocrinol. Metab. 92: S1-S47 (2007).
Abdel-Naser MB, Zouboulis C. Clindamycin phosphate/tretinoin gel formulation in the treatment of acne vulgaris. Expert Opin. Pharmacother. 9: 2931-2937 (2008).
Abdelli MN, Ben Abdallah H, Houissa F, Bouali MR, Khediri MF. Azathioprine for prevention of postoperative recurrence in Crohn's disease. Tunis. Med. 85: 569-572 (2007).
Abdelmalek MF, Angulo P, Jorgensen RA, Sylvestre PB, Lindor KD. Betaine, a promising new agent for patients with nonalcoholic steatohepatitis: results of a pilot study. Am. J. Gastroenterol. 96: 2711-2717 (2001). *
Abdin AA, Saeid EM. An experimental study on ulcerative colitis as a potential target for probiotic therapy by Lactobacillus acidophilus with or without “olsalazine”. Journal of Crohn's and Colitis 2: 296-303 (2008).
Abdulhamid I, Wise TL, Andrews S, Biglin K, Lehr VT. Elevated serum tobramycin concentrations after treatment with tobramycin inhalation in a preterm infant. Pharmacotherapy 28: 939-944 (2008).
Abe T, Takeuchi T, Miyasaka N, Hashimoto H, Kondo H, Ichikawa Y, Nagaya I. A multicenter, double-blind, randomized, placebo controlled trial of infliximab combined with low dose methotrexate in Japanese patients with rheumatoid arthritis. J. Rheumatol. 33: 37-44 (2006).
Abebe W. Herbal medication: potential for adverse interactions with analgesic drugs. J. Clin. Pharm. Ther. 27: 391-401 (2002). *
Abernethy AP. Palliative care pharmacotherapy literature summaries and analyses. J. Pain Palliat. Care Pharmacother. 23: 174-181 (2009).
Abitbol V, Briot K, Roux C, Roy C, Seksik P, Charachon A, Bouhnik Y, Coffin B, Allez M, Lamarque D, Chaussade S. A double-blind placebo-controlled study of intravenous clodronate for prevention of steroid-induced bone loss in inflammatory bowel disease. Clin. Gastroenterol. Hepatol. 5: 1184-1189 (2007).
Abraldes J, Albillos A, Banares R, Turnes J, Gonzalez R, Garcia-Pagan J, Bosch J. Simvastatin lowers portal pressure in patients with cirrhosis and portal hypertension: a randomized controlled trial. Gastroenterology 136: 1651-1658 (2009). *
Abramovits W. Calcitriol 3 microg/g ointment: an effective and safe addition to the armamentarium in topical psoriasis therapy. J. Drugs Dermatol. 8: s17-s22 (2009).
Abuzakouk M, Feighery C, Jackson J. Tumour necrosis factor blocking agents: a new therapeutic modality for inflammatory disorders. Br. J. Biomed. Sci. 59: 173-179 (2002).
Acamovic T, Brooker JD. Biochemistry of plant secondary metabolites and their effects in animals. Proc. Nutr. Soc. 64: 403-412 (2005). *
Acevedo Ribo M, Moreno Planas JM, Sanz Moreno C, Rubio Gonzalez EE, Rubio Gonzalez E, Boullosa Grana E, Sanchez-Turrion V, Sanz Guajardo D, Cuervas-Mons V. Therapy of intractable pruritus with MARS. Transplant. Proc. 37: 1480-1481 (2005). *
Aceves SS, Bastian JF, Newbury RO, Dohil R. Oral viscous budesonide: a potential new therapy for eosinophilic esophagitis in children. Am. J. Gastroenterol. 102: 2271-2279 (2007). *
Acharya SK, Bhatia V, Sreenivas V, Khanal S, Panda SK. Efficacy of L-ornithine L-aspartate in acute liver failure: a double-blind, randomized, placebo-controlled study. Gastroenterology 136: 2159-2168 (2009). *
Ackermann C, Kavanaugh A. Tumor necrosis factor as a therapeutic target of rheumatologic disease. Expert Opin. Ther. Targets 11: 1369-1384 (2007).
Acosta RD, Cash BD. Clinical effects of colonic cleansing for general health promotion: a systematic review. Am. J. Gastroenterol. 104: 2830-2836 (2009). *
Adachi R, Shulman AI, Yamamoto K, Shimomura I, Yamada S, Mangelsdorf DJ, Makishima M. Structural determinants for vitamin D receptor response to endocrine and xenobiotic signals. Mol. Endocrinol. 18: 43-52 (2004). *
Adamopoulos AB. Inflammatory bowel disease (IBD) and the liver. Annals of Gastroenterology 19: 146-151 (2006). *
Adams LA, Zein CO, Angulo P, Lindor KD. A pilot trial of pentoxifylline in nonalcoholic steatohepatitis. Am. J. Gastroenterol. 99: 2365-2368 (2004). *
Adams PC, Arthur MJ, Boyer TD, DeLeve LD, Di Bisceglie AM, Hall M, Levin TR, Provenzale D, Seeff L. Screening in liver disease: report of an AASLD clinical workshop. Hepatology 39: 1204-1212 (2004). *
Aghamohammadi A, Farhoudi A, Moin M, Pourpak Z, Rezaei N, Nikzad M, Movahedi M, Gharagozlou M, Atarod L, Ahmadi Afshar A, Bazargan N, Abolmaali K, Mahmoudi M. Adverse effects of intravenous immunoglobulin therapy in patients with antibody deficiency. Iran. J. Allergy Asthma Immunol. 2: 121-126 (2003).
Aghamohammadi A, Farhoudi A, Nikzad M, Moin M, Pourpak Z, Rezaei N, Gharagozlou M, Movahedi M, Atarod L, Afshar AA, Bazargan N, Hosseinpoor AR. Adverse reactions of prophylactic intravenous immunoglobulin infusions in Iranian patients with primary immunodeficiency. Ann. Allergy Asthma Immunol. 92: 60-64 (2004).
Agmon-Levin N, Paz Z, Israeli E, Shoenfeld Y. Vaccines and autoimmunity. Nat. Rev. Rheumatol. 5: 648-652 (2009).
Agostino M, Jene C, Boyle T, Ramsland PA, Yuriev E. Molecular docking of carbohydrate ligands to antibodies: structural validation against crystal structures. J. Chem. Inf. Model. Dec 8 [Epub ahead of print] (2009).
Aguillon JC, Contreras J, Dotte A, Cruzat A, Catalan D, Salazar L, Molina MC, Guerrero J, Lopez M, Soto L, Salazar-Onfray F, Cuchacovich M. New immunological weapons for medicine in the 21st Century: biological therapy based on the use of the latest generation monoclonal antibodies. Rev. Med. Chil. 131: 1445-1453 (2003).
Ahmad K, Rogers S. Two years of experience with etanercept in recalcitrant psoriasis. Br. J. Dermatol. 156: 1010-1014 (2007). *
Ahmed FE. Role of genes, the environment and their interactions in the etiology of inflammatory bowel diseases. Expert Rev. Mol. Diagn. 6: 345-363 (2006).
Aiko S, Yoshizumi Y, Ishizuka T, Horio T, Sakano T, Kumano I, Kanai N, Maehara T. Enteral immuno-enhanced diets with arginine are safe and beneficial for patients early after esophageal cancer surgery. Dis. Esophagus 21: 619-627 (2008).
Aithal GP. Dangerous liaisons: drug, host and the environment. J. Hepatol. 46: 995-998 (2007). *
Aithal GP, Ramsay L, Daly AK, Sonchit N, Leathart JBS, Alexander G, Kenna JG, Caldwell J, Day CP. Hepatic adducts, circulating antibodies, and cytokine polymorphisms in patients with diclofenac hepatotoxicity. Hepatology 39: 1430-1440 (2004). *
Aitken AE, Richardson TA, Morgan ET. Regulation of drug-metabolizing enzymes and transporters in inflammation. Annu. Rev. Pharmacol. Toxicol. 46: 123-149 (2006). *
Aiuti A, Cattaneo F, Galimberti S, Benninghoff U, Cassani B, Callegaro L, Scaramuzza S, Andolfi G, Mirolo M, Brigida I, Tabucchi A, Carlucci F, Eibl M, Aker M, Slavin S, Al-Mousa H, Al Ghonaium A, Ferster A, Duppenthaler A, et al. Gene therapy for immunodeficiency due to adenosine deaminase deficiency. N. Engl. J. Med. 360: 447-458 (2009). *
Ajit C, Suvannasankha A, Zaeri N, Munoz SJ. Terbinafine-associated hepatotoxicity. Am. J. Med. Sci. 325: 292-295 (2003).
Akobeng A, Thomas A. Enteral nutrition for maintenance of remission in Crohn's disease. Cochrane Database Syst. Rev. 3: CD005984 (2007). *
Akobeng A, Zachos M. Tumor necrosis factor-alpha antibody for induction of remission in Crohn's disease. Cochrane Database Syst. Rev. 1: CD003574 (2004). *
Akobeng AK. Crohn's disease: current treatment options. Arch. Dis. Child. 93: 787-792 (2008).
Akobeng AK, Gardener E. Oral 5-aminosalicylic acid for maintenance of medically-induced remission in Crohn's disease Cochrane Database Syst. Rev. 1: CD003715 (2004). *
Al-Attas OS, Al-Daghri NM, Al-Rubeaan KA, da Silva NF, Sabico SL, Kumar S, McTernan PG, Harte AL. Changes in endotoxin levels in T2DM subjects on anti-diabetic therapies. Cardiovasc. Diabetol. 8: 20 (2009).
Al-toma A, Visser OJ, van Roessel HM, von Blomberg BM, Verbeek WH, Scholten PE, Ossenkoppele GJ, Huijgens PC, Mulder CJ. Autologous hematopoietic stem cell transplantation in refractory celiac disease with aberrant T-cells. Blood 109: 2243-2249 (2007). *
Aladesanmi OA. Sarcoidosis: an update for the primary care physician. MedGenMed. 6: 7 (2004). *
Aldamiz-Echevarria L, Sanjurjo P, Elorz J, Prieto JA, Perez C, Andrade F, Rodriguez-Soriano J. Effect of docosahexaenoic acid administration on plasma lipid profile and metabolic parameters of children with methylmalonic acidaemia. J. Inherit. Metab. Dis. 29: 58-63 (2006). *
Alessandri C, Scrivo R, Spinelli FR, Ceccarelli F, Magrini L, Priori R, Valesini G. Autoantibody production in anti-TNF-alpha-treated patients. Ann. N. Y. Acad. Sci. 1110: 319-329 (2007). *
Alexander P, Roskams T, Van Steenbergen W, Peetermans W, Desmet V, Yap SH. Intrahepatic cholestasis induced by amoxicillin/clavulanic acid (Augmentin): a report on two cases. Acta Clin. Belg. 46: 327-332 (1991).
Alexander TH, Weisman MH, Derebery JM, Espeland MA, Gantz BJ, Gulya AJ, Hammerschlag PE, Hannley M, Hughes GB, Moscicki R, Nelson RA, Niparko JK, Rauch SD, Telian SA, Brookhouser PE, Harris JP. Safety of high-dose corticosteroids for the treatment of autoimmune inner ear disease. Otol. Neurotol. 30: 443-448 (2009).
Alexopoulou A, Koskinas J, Soultati A, Katsaounis P, Kilidireas K, Papageorgiou C, Antoniou C, Katsambas A, Archimandritis A. Acute bilateral phrenic neuropathy following treatment with adalimumab. Clin. Rheumatol. 28: 1337-1340 (2009). *
Alfadhli A, McDonald J, Feagan B. Methotrexate for induction of remission in refractory Crohn's disease. Cochrane Database Syst. Rev. 1: CD003459 (2005). *
Alfadhli AA, McDonald JW, Feagan BG. Methotrexate for induction of remission in refractory Crohn's disease. Cochrane Database Syst. Rev. 1: CD003459 (2003). *
Alfirevic A, Jorgensen AL, Williamson PR, Chadwick DW, Park BK, Pirmohamed M. HLA-B locus in Caucasian patients with carbamazepine hypersensitivity. Pharmacogenomics 7: 813-818 (2006).
Ali FR, Larche M. Peptide-based immunotherapy: a novel strategy for allergic disease. Expert Rev. Vaccines 4: 881-889 (2005).
Ali MF, Salah M, Rafea M, Saleh N. Liposomal methotrexate hydrogel for treatment of localized psoriasis: preparation, characterization and laser targeting. Med. Sci. Monit. 14: PI66-PI74 (2008). *
Ali YM, Kuriya B, Orozco C, Cush JJ, Keystone EC. Can tumor necrosis factor inhibitors be safely used in pregnancy? J. Rheumatol. Dec 14 [Epub ahead of print] (2009).
Alijotas-Reig J, Garcia-Gimenez V. Delayed immune-mediated adverse effects related to hyaluronic acid and acrylic hydrogel dermal fillers: clinical findings, long-term follow-up and review of the literature. J. Eur. Acad. Dermatol. Venereol. 22: 150-161 (2008). *
Alizadeh BZ, Njajou OT, Houwing-Duistermaat JJ, Jong Gd G, Vergeer JM, Hofman A, Pols HA, Duijn CM. Does bilirubin protect against hemochromatosis gene (HFE) related mortality? Am. J. Med. Genet. 129A: 39-43 (2004). *
Allen CE, Flores R, Rauch R, Dauser R, Murray JC, Puccetti D, Hsu DA, Sondel P, Hetherington M, Goldman S, McClain KL. Neurodegenerative central nervous system Langerhans cell histiocytosis and coincident hydrocephalus treated with vincristine/cytosine arabinoside. Pediatr. Blood Cancer Nov 11 [Epub ahead of print] (2009).
Almasio P, Bortolini M, Pagliaro L, Coltorti M. Role of S-adenosyl-L-methionine in the treatment of intrahepatic cholestasis. Drugs 40 Suppl. 3: 111-123 (1990).
Almasio PL. HALT-C in the final analysis: a molehill out of a mountain. J. Hepatol. 50: 1280-1282 (2009).
Almeida M, Ambrogini E, Han L, Manolagas SC, Jilka RL. Increased lipid oxidation causes oxidative stress, increased PPARgamma expression and diminished pro-osteogenic Wnt signaling in the skeleton. J. Biol. Chem. 284: 27438-27448 (2009). *
Almer SH, Hjortswang H, Hindorf U. 6-Thioguanine therapy in Crohn's disease - observational data in Swedish patients. Dig. Liver Dis. 41: 194-200 (2009).
Alonso-Navarro H, Jimenez-Jimenez FJ, Garcia-Agundez JA. The role of CYP2C19 polymorphism in the development of adverse effects to drugs and the risk for diseases. Med. Clin. (Barc.) 126: 697-706 (2006).
Als-Nielsen B, Koretz RL, Kjaergard LL, Gluud C. Branched-chain amino acids for hepatic encephalopathy. Cochrane Database Syst. Rev. 2: CD001939 (2003). *
Alstergren P, Larsson PT, Kopp S. Successful treatment with multiple intra-articular injections of infliximab in a patient with psoriatic arthritis. Scand. J. Rheumatol. 37: 155-157 (2008).
Altomare G, Ayala F, Berardesca E, Chimenti S, Giannetti A, Girolomoni G, Lotti T, Martini P, Peserico A, Guerra AP, Vena GA. Etanercept provides a more physiological approach in the treatment of psoriasis. Dermatol. Ther. 21 Suppl. 2: S1-S14 (2008).
Alvarez Beltran M, Infante Pina D, Tormo Carnice R, Segarra Canton O, Redecillas Ferreiro S. Optimising azathioprine treatment: determination of thiopurine methyltransferase activity and thiopurine metabolites. An. Pediatr. (Barc.) 70: 120-125 (2009).
Alves da Silva M, Martins A, Teixeira A, Reis RL, Neves NM. Impact of biological agents and tissue engineering approaches in the treatment of rheumatic diseases. Tissue Eng. Part B. Rev. Dec 21 [Epub ahead of print] (2009).
Alwawi EA, Krulig E, Gordon KB. Long-term efficacy of biologics in the treatment of psoriasis: what do we really know? Dermatol. Ther. 22: 431-440 (2009).
Amador-Noguez D, Dean A, Huang W, Setchell K, Moore D, Darlington G. Alterations in xenobiotic metabolism in the long-lived Little mice. Aging Cell 6: 453-470 (2007). *
Amantana A, Moulton HM, Cate ML, Reddy MT, Whitehead T, Hassinger JN, Youngblood DS, Iversen PL. Pharmacokinetics, biodistribution, stability and toxicity of a cell-penetrating peptide-morpholino oligomer conjugate. Bioconjug. Chem. 18: 1325-1331 (2007). *
Amin R, Noone PG, Ratjen F. Chemical pleurodesis versus surgical intervention for persistent and recurrent pneumothoraces in cystic fibrosis. Cochrane Database Syst. Rev. 2: CD007481 (2009). *
Amini R, Nosrati N, Yazdanparast R, Molaei M. Teucrium polium in prevention of steatohepatitis in rats. Liver Int. 29: 1216-1221 (2009). *
Amminger GP, Berger GE, Schafer MR, Klier C, Friedrich MH, Feucht M. Omega-3 fatty acids supplementation in children with autism: a double-blind randomized, placebo-controlled pilot study. Biol. Psychiatry 61: 551-553 (2007). *
Amminger GP, Schafer MR, Papageorgiou K, Klier CM, Cotton SM, Harrigan SM, Mackinnon A, McGorry PD, Berger GE. Long-chain omega-3 fatty acids for indicated prevention of psychotic disorders: a randomized, placebo-controlled trial. Arch. Gen. Psychiatry 67: 146-154 (2010).
Anagnostopoulos G, Sakorafas GH, Grigoriadis K, Margantinis G, Kostopoulos P, Tsiakos S, Arvanitidis D. Hepatitis caused by occupational chronic exposure to trichloroethylene. Acta Gastroenterol. Belg. 67: 355-357 (2004).
Anandarajah AP, Ritchlin CT. The diagnosis and treatment of early psoriatic arthritis. Nat. Rev. Rheumatol. 5: 634-641 (2009).
Ananthakrishnan AN, Attila T, Otterson MF, Lipchik RJ, Massey BT, Komorowski RA, Binion DG. Severe pulmonary toxicity after azathioprine/6-mercaptopurine initiation for the treatment of inflammatory bowel disease. J. Clin. Gastroenterol. 41: 682-688 (2007).
Anderson N, Borlak J. Drug-induced phospholipidosis. FEBS Lett. 580: 5533-5540 (2006). *
Andrade MC, Albernaz MJ, Araujo MS, Santos BP, Teixeira-Carvalho A, Faria AM, Martins-Filho OA. Short-term administration of ethanol in mice deviates antigen presentation activity towards B cells. Scand. J. Immunol. 70: 226-237 (2009). *
Andrade RJ, Lucena MI, Kaplowitz N, Garcia-Munoz B, Borraz Y, Pachkoria K, Garcia-Cortes M, Fernandez MC, Pelaez G, Rodrigo L, Duran JA, Costa J, Planas R, Barriocanal A, Guarner C, Romero-Gomez M, Munoz-Yague T, Salmeron J, Hidalgo R. Outcome of acute idiosyncratic drug-induced liver injury: long-term follow-up in a hepatotoxicity registry. Hepatology 44: 1581-1588 (2006). *
Andrade RJ, Robles M, Fernandez-Castaner A, Lopez-Ortega S, Lopez-Vega MC, Lucena MI. Assessment of drug-induced hepatotoxicity in clinical practice: a challenge for gastroenterologists. World J. Gastroenterol. 13: 329-340 (2007). *
Andre T, Boni C, Mounedji-Boudiaf L, Navarro M, Tabernero J, Hickish T, Topham C, Zaninelli M, Clingan P, Bridgewater J, Tabah-Fisch I, de Gramont A. Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N. Engl. J. Med. 350: 2343-2351 (2004). *
Andus T, Gross V, Caesar I, Schulz HJ, Lochs H, Strohm WD, Gierend M, Weber A, Ewe K, Scholmerich J; German/Austrian Budesonide Study Group. Replacement of conventional glucocorticoids by oral pH-modified release budesonide in active and inactive Crohn's disease: results of an open, prospective, multicenter trial. Dig. Dis. Sci. 48: 373-378 (2003). *
Andus T, Stange EF, Hoffler D, Keller-Stanislawski B. Suspected cases of severe side effects after infliximab (Remicade) in Germany. Med. Klin. (Munich) 98: 429-436 (2003).
Ang TL, Fock KM, Ng TM, Teo EK, Tan YL. Clinical utility, safety and tolerability of capsule endoscopy in urban Southeast Asian population. World J. Gastroenterol. 9: 2313-2316 (2003). *
Angeli P, Fasolato S, Mazza E, Okolicsanyi L, Maresio G, Velo E, Galioto A, Salinas F, D'Aquino M, Sticca A, Gatta A. Combined versus sequential diuretic treatment of ascites in nonazotemic patients with cirrhosis: results of an open randomized clinical trial. Gut 59: 98-104 (2010).
Angulo P, Jorgensen RA, Keach JC, Dickson ER, Smith C, Lindor KD. Oral budesonide in the treatment of patients with primary biliary cirrhosis with a suboptimal response to ursodeoxycholic acid. Hepatology 31: 318-323 (2000). *
Angulo P, Jorgensen RA, Lindor KD. Incomplete response to ursodeoxycholic acid in primary biliary cirrhosis: is a double dosage worthwhile? Am. J. Gastroenterol. 96: 3152-3157 (2001). *
Angulo P, MacCarty RL, Sylvestre PB, Jorgensen RA, Wiesner RH, LaRusso NA, Lindor KD. Pirfenidone in the treatment of primary sclerosing cholangitis. Dig. Dis. Sci. 47: 157-161 (2002). *
Angulo P, Patel T, Jorgensen RA, Therneau TM, Lindor KD. Silymarin in the treatment of patients with primary biliary cirrhosis with a suboptimal response to ursodeoxycholic acid. Hepatology 32: 897-900 (2000). *
Annese V, Latiano A, Rossi L, Lombardi G, Dallapiccola B, Serafini S, Damonte G, Andriulli A, Magnani M. Erythrocytes-mediated delivery of dexamethasone in steroid-dependent IBD patients - a pilot uncontrolled study. Am. J. Gastroenterol. 100: 1370-1375 (2005). *
Ansari A, Arenas M, Greenfield S, Morris D, Lindsay J, Smith M, Lewis C, Marinaki A, Duley J, Sanderson J. Prospective evaluation of the pharmacogenetics of azathioprine in the treatment of inflammatory bowel disease. Aliment. Pharmacol. Ther. 28: 973-983 (2008). *
Ansari A, Elliott T, Fong F, Arenas-Hernandez M, Rottenberg G, Portmann B, Lucas S, Marinaki A, Sanderson J. Further experience with the use of 6-thioguanine in patients with Crohn's disease. Inflamm. Bowel Dis. 14: 1399-1405 (2008). *
Antolic B, Gersak K, Verdenik I, Novak-Antolic Z. Adverse effects of thyroid dysfunction on pregnancy and pregnancy outcome: epidemiologic study in Slovenia. J. Matern. Fetal Neonatal Med. 19: 651-654 (2006).
Antoni CE, Kavanaugh A, Kirkham B, Tutuncu Z, Burmester GR, Schneider U, Furst DE, Molitor J, Keystone E, Gladman D, Manger B, Wassenberg S, Weier R, Wallace DJ, Weisman MH, Kalden JR, Smolen J. Sustained benefits of infliximab therapy for dermatologic and articular manifestations of psoriatic arthritis: results from the infliximab multinational psoriatic arthritis controlled trial (IMPACT). Arthritis Rheum. 52: 1227-1236 (2005). *
Antoniou C, Stefanaki I, Stratigos A, Moustou E, Vergou T, Stavropoulos P, Avgerinou G, Rigopoulos D, Katsambas AD. Infliximab for the treatment of psoriasis in Greece. Four years of clinical experience at a single center. Br. J. Dermatol. Nov 10 [Epub ahead of print] (2009). *
Antonucci A, Bardazzi F, Balestri R, Patrizi A. Efalizumab-associated papular psoriasis: an adverse reaction to efalizumab in three cases. J. Dermatolog. Treat. 20: 61-62 (2009). *
Antonucci A, Negosanti M, Tabanelli M, Varotti C. Treatment of refractory pemphigus vulgaris with anti-CD20 monoclonal antibody (rituximab): five cases. J. Dermatolog. Treat. 18: 178-183 (2007).
Araki Y, Mitsuyama K, Nagae T, Tou Y, Nakagawa M, Iwatani Y, Harada M, Ozasa H, Sata M, Noake T. Leukocytapheresis for the treatment of active pouchitis: a pilot study. J. Gastroenterol. 43: 571-575 (2008). *
Arat M, Idilman R, Soydan EA, Soykan I, Erden E, Karayalcin S, Akan H. Ursodeoxycholic acid treatment in isolated chronic graft-vs.-host disease of the liver. Clin. Transplant. 19: 798-803 (2005). *
Ardizzone S, Bollani S, Manzionna G, Imbesi V, Colombo E, Bianchi Porro G. Comparison between methotrexate and azathioprine in the treatment of chronic active Crohn's disease: a randomised, investigator-blind study. Dig. Liver Dis. 35: 619-627 (2003).
Ardizzone S, Maconi G, Sampietro GM, Russo A, Radice E, Colombo E, Imbesi V, Molteni M, Danelli PG, Taschieri AM, Bianchi Porro G. Azathioprine and mesalamine for prevention of relapse after conservative surgery for Crohn's disease. Gastroenterology 127: 730-740 (2004). *
Arellano F, Sacristan JA. Allopurinol hypersensitivity syndrome: a review. Ann. Pharmacother. 27: 337-343 (1993).
Arend LJ, Springate JE. Interstitial nephritis from mesalazine: case report and literature review. Pediatr. Nephrol. 19: 550-553 (2004). *
Aringer M, Graninger WB, Steiner G, Smolen JS. Safety and efficacy of tumor necrosis factor blockade in systemic lupus erythematosus: an open-label study. Arthritis Rheum. 50: 3161-3169 (2004). *
Aringer M, Houssiau F, Gordon C, Graninger WB, Voll RE, Rath E, Steiner G, Smolen JS. Adverse events and efficacy of TNF-alpha blockade with infliximab in patients with systemic lupus erythematosus: long-term follow-up of 13 patients. Rheumatology (Oxford) 48: 1451-1454 (2009).
Arnold DM, Nazi I, Santos A, Chan H, Heddle NM, Warkentin TE, Kelton JG. Combination immunosuppressant therapy for patients with chronic refractory immune thrombocytopenic purpura. Blood Nov 6 [Epub ahead of print] (2009). *
Arnott ID, McNeill G, Satsangi J. An analysis of factors influencing short-term and sustained response to infliximab treatment for Crohn's disease. Aliment. Pharmacol. Ther. 17: 1451-1457 (2003). *
Arnson Y, Shoenfeld Y, Amital H. Intravenous immunoglobulin therapy for autoimmune diseases. Autoimmunity 42: 553-560 (2009).
Arslan S, Kav T, Besisik F, Kaymakoglu S, Pinarbasi B, Tozun N, Hamzaoglu HO, Duman D, Ulker A, Parlak E, Palabiyikoglu M, Dokmeci A. Clinical outcome of Crohn's disease treated with infliximab. Hepatogastroenterology 50: 952-956 (2003).
Arterburn LM, Oken HA, Hoffman JP, Bailey-Hall E, Chung G, Rom D, Hamersley J, McCarthy D. Bioequivalence of docosahexaenoic acid from different algal oils in capsules and in a DHA-fortified food. Lipids 42: 1011-1024 (2007).
Artioukh DY, Smith RA, Gokul K. Risk factors for impaired healing of the perineal wound after abdominoperineal resection of rectum for carcinoma. Colorectal Dis. 9: 362-367 (2007). *
Arundel C, Lewis JH. Drug-induced liver disease in 2006. Curr. Opin. Gastroenterol. 23: 244-254 (2007).
Asarch A, Gurcan HM, Ahmed AR. A current review of juvenile pemphigus vulgaris: analysis of data on clinical outcomes. Am. J. Clin. Dermatol. 11: 21-33 (2010).
Ashcroft DM, Dimmock P, Garside R, Stein K, Williams HC. Efficacy and tolerability of topical pimecrolimus and tacrolimus in the treatment of atopic dermatitis: meta-analysis of randomised controlled trials. BMJ 330: 516 (2005). *
Ashcroft DM, Seston E, Griffiths CE. Trade-offs between the benefits and risks of drug treatment for psoriasis: a discrete choice experiment with U.K. dermatologists. Br. J. Dermatol. 155: 1236-1241 (2006). *
Ashizuka S, Nishiura R, Ishikawa N, Yamaga J, Inatsu H, Fujimoto S, Eto T. Leukocytapheresis for ulcerative colitis: a comparative study of anticoagulant (nafamostat mesilate vs. dalteparin sodium) for reducing clinical complications. Ther. Apher. Dial. 10: 54-58 (2006).
Ashraf-Benson S, Wall GC, Veach LA. Serum sickness-like reaction associated with efalizumab. Ann. Pharmacother. 43: 383-386 (2009).
Aslanidis S, Pyrpasopoulou A, Leontsini M, Zamboulis C. Anti-TNF-alpha-induced psoriasis: case report of an unusual adverse event. Int. J. Dermatol. 45: 982-983 (2006). *
Asquith DL, McInnes IB. Emerging cytokine targets in rheumatoid arthritis. Curr. Opin. Rheumatol. 19: 246-251 (2007). *
Asserhoj M, Nehammer S, Matthiessen J, Michaelsen KF, Lauritzen L. Maternal fish oil supplementation during lactation may adversely affect long-term blood pressure, energy intake, and physical activity of 7-year-old boys. J. Nutr. 139: 298-304 (2009). *
Astegiano M, Pagano N, Sapone N, Simondi D, Bertolusso L, Bresso F, Demarchi B, Pellicano R, Bonardi R, Marconi S, Rizzetto M. Efficacy and safety of oral beclomethasone dipropionate for ileal or ileal-right colon Crohn's disease of mild-to-moderate activity or in remission: retrospective study. Biomed. Pharmacother. 61: 370-376 (2007).
Asteria CR, Ficari F, Bagnoli S, Milla M, Tonelli F. Treatment of perianal fistulas in Crohn's disease by local injection of antibody to TNF-alpha accounts for a favourable clinical response in selected cases: a pilot study. Scand. J. Gastroenterol. 41: 1064-1072 (2006). *
Ates Y, Aslan M, Tuzun A, Bagci S, Dagalp K. Ulcerative colitis case beginning during pregnancy in a patient with antiphospholipid antibody syndrome. Turk. J. Gastroenterol. 15: 263-265 (2004). *
Athanasiadou S, Kyriazakis I. Plant secondary metabolites: antiparasitic effects and their role in ruminant production systems. Proc. Nutr. Soc. 63: 631-639 (2004). *
Athyros VG, Papageorgiou AA, Hatzikonstandinou HA, Didangelos TP, Carina MV, Kranitsas DF, Kontopoulos AG. Safety and efficacy of long-term statin-fibrate combinations in patients with refractory familial combined hyperlipidemia. Am. J. Cardiol. 80: 608-613 (1997). *
Atkins GJ, Cosby SL. Is an improved measles-mumps-rubella vaccine necessary or feasible? Crit. Rev. Immunol. 23: 323-338 2003.
Atteno M, Peluso R, Costa L, Padula S, Iervolino S, Caso F, Sanduzzi A, Lubrano E, Del Puente A, Scarpa R. Comparison of effectiveness and safety of infliximab, etanercept, and adalimumab in psoriatic arthritis patients who experienced an inadequate response to previous disease-modifying antirheumatic drugs. Clin. Rheumatol. Jan 12 [Epub ahead of print] (2010). *
Atzeni F, Ardizzone S, Sarzi-Puttini P, Colombo E, Maconi G, DE Portu S, Carrabba M, Bianchi Porro G. Autoantibody profile during short-term infliximab treatment for Crohn's disease: a prospective cohort study. Aliment. Pharmacol. Ther. 22: 453-461 (2005). *
Atzeni F, Doria A, Maurizio T, Sarzi-Puttini P. What is the role of rituximab in the treatment of rheumatoid arthritis? Autoimmun. Rev. 6: 553-558 (2007).
Atzeni F, Sarzi-Puttini P. Anti-cytokine antibodies for rheumatic diseases. Curr. Opin. Investig. Drugs 10: 1204-1211 (2009).
Aulakh R, Singh S. Strategies for minimizing corticosteroid toxicity: a review. Indian J. Pediatr. 75: 1067-1073 (2008).
Austria JA, Richard MN, Chahine MN, Edel AL, Malcolmson LJ, Dupasquier CM, Pierce GN. Bioavailability of alpha-linolenic acid in subjects after ingestion of three different forms of flaxseed. J. Am. Coll. Nutr. 27: 214-221 (2008).
Autret-Leca E, Bensouda-Grimaldi L, Jonville-Bera AP, Beau-Salinas F. Pharmacovigilance of vaccines. Arch. Pediatr. 13: 175-180 (2006).
Avila Alvarez A, García-Alonso L, Solar Boga A, Garcia-Silva J. Flexural psoriasis induced by infliximab and adalimumab in a patient with Crohn's disease. An. Pediatr. (Barc.) 70: 278-281 (2009).
Awad T, Thorlund K, Hauser G, Stimac D, Mabrouk M, Gluud C. Peginterferon alpha-2a is associated with higher sustained virological response than peginterferon alfa-2b in chronic hepatitis C: Systematic review of randomized trials. Hepatology Dec 23 [Epub ahead of print] (2009).
Aziz M, Patel AL, Losavio J, Iyengar A, Berven M, Schloemer N, Jakubowicz A, Mathai T, McAuley JB. Efficacy of fluconazole prophylaxis for prevention of invasive fungal infection in extremely low birth weight infants. Pediatr. Infect. Dis. J. Nov 19 [Epub ahead of print] (2009).
Babatin MA, Sanai FM, Swain MG. Methotrexate therapy for the symptomatic treatment of primary biliary cirrhosis patients, who are biochemical incomplete responders to ursodeoxycholic acid therapy. Aliment. Pharmacol. Ther. 24: 813-820 (2006). *
Bachelez H, Senet P, Cadranel J, Kaoukhov A, Dubertret L. The use of tetracyclines for the treatment of sarcoidosis. Arch. Dermatol. 137: 69-73 (2001). *
Backes JM, Gibson CA, Howard PA. Optimal lipid modification: the rationale for combination therapy. Vasc. Health Risk Manag. 1: 317-331 (2005).
Bagel J. LCD plus NB-UVB reduces time to improvement of psoriasis vs. NB-UVB alone. J. Drugs Dermatol. 8: 351-357 (2009).
Bahador M, Cross AS. From therapy to experimental model: a hundred years of endotoxin administration to human subjects. J. Endotoxin Res. 13: 251-279 (2007). *
Bai JP, Lesko LJ, Burckart GJ. Understanding the genetic basis for adverse drug effects: the calcineurin inhibitors. Pharmacotherapy 30: 195-209 (2010).
Bainy AC. Nuclear receptors and susceptibility to chemical exposure in aquatic organisms. Environ. Int. 33: 571-575 (2007).
Bajaj JS, Saeian K, Christensen KM, Hafeezullah M, Varma RR, Franco J, Pleuss JA, Krakower G, Hoffmann RG, Binion DG. Probiotic yogurt for the treatment of minimal hepatic encephalopathy. Am. J. Gastroenterol. 103: 1707-1715 (2008). *
Bajaj JS, Saeian K, Varma RR, Franco J, Knox J F, Podoll J, Emmons J, Levy M, Binion DG. Increased rates of early adverse reaction to azathioprine in patients with Crohn's disease compared to autoimmune hepatitis: a tertiary referral center experience. Am. J. Gastroenterol. 100: 1121-1125 (2005). *
Baker DE. Adalimumab: human recombinant immunoglobulin g1 anti-tumor necrosis factor monoclonal antibody. Rev. Gastroenterol. Disord. 4: 196-210 (2004). *
Baker DE. Pharmacogenomics of azathioprine and 6-mercaptopurine in gastroenterologic therapy. Rev. Gastroenterol. Disord. 3: 150-157 (2003). *
Baker DE. Natalizumab: overview of its pharmacology and safety. Rev. Gastroenterol. Disord. 7: 38-46 (2007).
Baker DE. Rifaximin: a nonabsorbed oral antibiotic. Rev. Gastroenterol. Disord. 5: 19-30 (2005).
Baker DE, Kane S. The short- and long-term safety of 5-aminosalicylate products in the treatment of ulcerative colitis. Rev. Gastroenterol. Disord. 4: 86-91 (2004). *
Baker K, Jewell DP. Cyclosporin for the treatment of severe inflammatory bowel disease. Aliment. Pharmacol. Ther. 3: 143-149 (1989).
Balaguer A, Gonzalez de Dios J. Home intravenous antibiotics for cystic fibrosis. Cochrane Database Syst. Rev. 3: CD001917 (2008). *
Balato A, La Bella S, Gaudiello F, Balato N. Efalizumab-induced guttate psoriasis. Successful management and re-treatment. J. Dermatolog. Treat. 19: 182-184 (2008).
Baldassano R, Braegger CP, Escher JC, DeWoody K, Hendricks DF, Keenan GF, Winter HS. Infliximab (REMICADE) therapy in the treatment of pediatric Crohn's disease. Am. J. Gastroenterol. 98: 833-838 (2003). *
Balfour-Lynn IM, Welch K. Inhaled corticosteroids for cystic fibrosis. Cochrane Database Syst. Rev. 1: CD001915 (2009).
Balistreri WF. Bile acid therapy in pediatric hepatobiliary disease: the role of ursodeoxycholic acid. J. Pediatr. Gastroenterol. Nutr. 24: 573-589 (1997). *
Balk EM, Lichtenstein AH, Chung M, Kupelnick B, Chew P, Lau J. Effects of omega-3 fatty acids on serum markers of cardiovascular disease risk: a systematic review. Atherosclerosis 189: 19-30 (2006).
Ballinger A. Adverse effects of nonsteroidal anti-inflammatory drugs on the colon. Curr. Gastroenterol. Rep. 10: 485-489 (2008).
Ballow M. Safety of IGIV therapy and infusion-related adverse events. Immunol. Res. 38: 122-132 (2007).
Ballow M. Biologic immune modifiers: trials and tribulations - are we there yet? J. Allergy Clin. Immunol. 118: 1209-1215 (2006). *
Ban L, Zhang J, Wang L, Kuhtreiber W, Burger D, Faustman DL. Selective death of autoreactive T cells in human diabetes by TNF or TNF receptor 2 agonism. Proc. Natl. Acad. Sci. U.S.A. 105: 13644-13649 (2008). *
Bandelier C, Guerne PA, Genevay S, Finckh A, Gabay C. Clinical experience with mycophenolate mofetil in systemic autoimmune conditions refractory to common immunosuppressive therapies. Swiss Med. Wkly. 139: 41-46 (2009). *
Bankar RN, Dafe CO, Kohnke A, Babu PS. Ulcerative colitis probably associated with isotretinoin. Indian J. Gastroenterol. 25: 171-172 (2006). *
Banwell B, Reder AT, Krupp L, Tenembaum S, Eraksoy M, Alexey B, Pohl D, Freedman M, Schelensky L, Antonijevic I. Safety and tolerability of interferon beta-1b in pediatric multiple sclerosis. Neurology 66: 472-476 (2006).
Bar-Meir S. Mild to moderate Crohn's disease: still room for step-up therapies? Dig. Dis. 27: 347-350 (2009).
Bar-Oz B, Bulkowstein M, Benyamini L, Greenberg R, Soriano I, Zimmerman D, Bortnik O, Berkovitch M. Use of antibiotic and analgesic drugs during lactation. Drug Saf. 26: 925-935 (2003).
Baraf HS. Efficacy of the newest COX-2 selective inhibitors in rheumatic disease. Curr. Pharm. Des. 13: 2228-2236 (2007).
Barde C, Thielen AM, Saurat JH. Infliximab then efalizumab, the 'hit and run' approach does not work. Dermatology 216: 171-172 (2008).
Barden L, Lipson A, Pert P, Walker-Smith JA. Mesalazine in childhood inflammatory bowel disease. Aliment. Pharmacol. Ther. 3: 597-603 (1989).
Bardou M, Barkun AN. Preventing the gastrointestinal adverse effects of nonsteroidal anti-inflammatory drugs: from risk factor identification to risk factor intervention. Joint Bone Spine Dec 17 [Epub ahead of print] (2009).
Bargallo A, Carrion S, Domenech E, Arevalo JA, Manosa M, Cabre E, Cabriada JL, Gassull MA. Infectious mononucleosis in patients with inflammatory bowel disease under treatment with azathioprine. Gastroenterol. Hepatol. 31: 289-292 (2008).
Barkham N, Keen HI, Coates LC, O'Connor P, Hensor E, Fraser AD, Cawkwell LS, Bennett A, McGonagle D, Emery P. Clinical and imaging efficacy of infliximab in HLA-B27-positive patients with magnetic resonance imaging-determined early sacroiliitis. Arthritis Rheum. 60: 946-954 (2009). *
Barnes DS. Intrahepatic cholestatic liver disease. http://www.clevelandclinicmeded.com/diseasemanagement/gastro/intrahepatic/intrahepatic1.htm (2002). *
Barnes PJ. Mechanisms and resistance in glucocorticoid control of inflammation. J. Steroid Biochem. Mol. Biol. Feb 24 [Epub ahead of print] (2010).
Barnes T, Moots RJ, Goodacre J. Cytokine medicines in clinical practice: current issues. Cytokine 32: 62-66 (2005).
Baron TH, Fleischer DE. Past, present, and future of endoscopic retrograde cholangiopancreatography: perspectives on the National Institutes of Health consensus conference. Mayo Clin. Proc. 77: 407-412 (2002). *
Baron TH, Truss CD, Elson CO. Low-dose oral methotrexate in refractory inflammatory bowel disease. Dig. Dis. Sci. 38: 1851-1856 (1993).
Barreiro-de Acosta M, Lorenzo A, Dominguez-Munoz JE. Adalimumab in ulcerative colitis: two cases of mucosal healing and clinical response at two years. World J. Gastroenterol. 15: 3814-3816 (2009). *
Barrera MV, Habicheyn S, Mendiola MV, Herrera Ceballos E. Etanercept in the treatment and retreatment of psoriasis in daily clinical practice. Eur. J. Dermatol. 18: 683-687 (2008).
Barrett AD, Teuwen DE. Yellow fever vaccine - how does it work and why do rare cases of serious adverse events take place? Curr. Opin. Immunol. 21: 308-313 (2009).
Barrie III AM, Plevy SE. The interleukin-12 family of cytokines: therapeutic targets for inflammatory disease mediation. Clin. Appl. Immunol. Rev. 5: 225-240 (2005). *
Bartel G, Regele H, Wahrmann M, Huttary N, Exner M, Horl WH, Bohmig GA. Posttransplant HLA alloreactivity in stable kidney transplant recipients: incidences and impact on long-term allograft outcomes. Am. J. Transplant. 8: 2652-2660 (2008).
Barth A, Braun J, Muller D. Influence of verapamil and cyclosporin A on bile acid metabolism and transport in rat liver slices. Exp. Toxicol. Pathol. 58: 31-37 (2006). *
Barthet M, Lesavre N, Desplats S, Panuel M, Gasmi M, Bernard JP, Dagorn JC, Grimaud JC. Frequency and characteristics of pancreatitis in patients with inflammatory bowel disease. Pancreatology 6: 464-471 (2006).
Barton JR, Sibai BM. Prediction and prevention of recurrent preeclampsia. Obstet. Gynecol. 112: 359-372 (2008).
Basch E, Bent S, Collins J, Dacey C, Hammerness P, Harrison M, Smith M, Szapary P, Ulbricht C, Vora M, Weissner W. Flax and flaxseed oil (Linum usitatissimum): a review by the Natural Standard Research Collaboration. J. Soc. Integr. Oncol. 5: 92-105 (2007).
Basile LA, Taylor SN, Wagner CL, Horst RL, Hollis BW. The effect of high-dose vitamin D supplementation on serum vitamin D levels and milk calcium concentration in lactating women and their infants. Breastfeed. Med. 1: 27-35 (2006).
Bassendine MF, Dewar PJ, James OF. HLA-DR antigens in primary biliary cirrhosis: lack of association. Gut 26: 625-628 (1985). *
Bastida Pa G, Nos Mate P, Aguas Peri M, Beltran Niclas B, Rodriguez Sole M, Ponce Garcia J. Optimization of immunomodulatory treatment with azathioprine or 6-mercaptopurine in inflammatory bowel disease. Gastroenterol. Hepatol. 30: 511-516 (2007).
Bathon JM, Fleischmann RM, Van der Heijde D, Tesser JR, Peloso PM, Chon Y, White B. Safety and efficacy of etanercept treatment in elderly subjects with rheumatoid arthritis. J. Rheumatol. 33: 234-243 (2006).
Baumgart DC, Macdonald JK, Feagan B. Tacrolimus (FK506) for induction of remission in refractory ulcerative colitis. Cochrane Database Syst. Rev. 3: CD007216 (2008). *
Baumgart DC, Targan SR, Dignass AU, Mayer L, Assche GV, Hommes DW, Hanauer SB, Mahadevan U, Reinisch W, Plevy SE, Salzberg BA, Buchman AL, Mechkov GM, Krastev ZA, Lowder JN, Frankel MB, Sandborn WJ. Prospective randomized open-label multicenter phase I/II dose escalation trial of visilizumab (HuM291) in severe steroid-refractory ulcerative colitis. Inflamm. Bowel Dis. Aug 27 [Epub ahead of print] (2009). *
Beani JC, Jeanmougin M. Narrow-band UVB therapy in psoriasis vulgaris: good practice guideline and recommendations of the French Society of Photodermatology. Ann. Dermatol. Venereol. 137: 21-31 (2010).
Becker KA, Riethmuller J, Luth A, Doring G, Kleuser B, Gulbins E. Acid sphingomyelinase inhibitors normalize pulmonary ceramide and inflammation in cystic fibrosis. Am. J. Respir. Cell. Mol. Biol. Jul 27 [Epub ahead of print] (2009). *
Becker MD, Smith JR, Max R, Fiehn C. Management of sight-threatening uveitis: new therapeutic options. Drugs 65: 497-519 (2005).
Becker ML, Visser LE, van Schaik RH, Hofman A, Uitterlinden AG, Ch Stricker BH. Influence of genetic variation in CYP3A4 and ABCB1 on dose decrease or switching during simvastatin and atorvastatin therapy. Pharmacoepidemiol. Drug Saf. 19: 75-81 (2009).
Beckles Willson N, Elliott TM, Everard ML. Omega-3 fatty acids (from fish oils) for cystic fibrosis. Cochrane Database Syst. Rev. 3: CD002201 (2002). *
Becquemont L. Pharmacogenomics of adverse drug reactions: practical applications and perspectives. Pharmacogenomics 10: 961-969 (2009).
Bedi MK. Successful treatment of long-standing, recalcitrant subcorneal pustular dermatosis with etanercept. Skinmed. 6: 245-247 (2007).
Behm B, Bickston S. Tumor necrosis factor-alpha antibody for maintenace of remission in Crohn's disease. Cochrane Database Syst. Rev. 1: CD006893 (2008). *
Behm BW, Bickston SJ. Humanized antibody to the alpha4beta7 integrin for induction of remission in ulcerative colitis. Cochrane Database Syst. Rev. 1: CD007571 (2009). *
Behshad R, Cooper KD, Korman NJ. A retrospective case series review of the peroxisome proliferator-activated receptor ligand rosiglitazone in the treatment of atopic dermatitis. Arch. Dermatol. 144: 84-88 (2008). *
Belanger SA, Vanasse M, Spahis S, Sylvestre MP, Lippe S, L'Heureux F, Ghadirian P, Vanasse CM, Levy E. Omega-3 fatty acid treatment of children with attention-deficit hyperactivity disorder: a randomized, double-blind, placebo-controlled study. Paediatr. Child Health 14: 89-98 (2009).
Belfort R, Harrison SA, Brown K, Darland C, Finch J, Hardies J, Balas B, Gastaldelli A, Tio F, Pulcini J, Berria R, Ma JZ, Dwivedi S, Havranek R, Fincke C, DeFronzo R, Bannayan GA, Schenker S, Cusi K. A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis. N. Engl. J. Med. 355: 2297-2307 (2006). *
Bellemere G, Stamatas GN, Bruere V, Bertin C, Issachar N, Oddos T. Antiaging action of retinol: from molecular to clinical. Skin Pharmacol. Physiol. 22: 200-209 (2009).
Belluzzi A, Serrani M, Roda G, Bianchi ML, Castellani L, Grazia M, Rosati G, Ugolini G, Roda E. Pilot study: the use of sulfasalazine for the treatment of acute pouchitis. Aliment. Pharmacol. Ther. 31: 228-232 (2010). *
Beltowski J, Wojcicka G, Jamroz-Wisniewska A. Adverse effects of statins - mechanisms and consequences. Curr. Drug Saf. 4: 209-228 (2009).
Ben Amar M. Cannabinoids in medicine: a review of their therapeutic potential. J. Ethnopharmacol. 105: 1-25 (2006). *
Benchimol E, Seow Ch, Steinhart A, Griffiths A. Traditional corticosteroids for induction of remission in Crohn's disease. Cochrane Database Syst. Rev. 2: CD006792 (2008). *
Bender NK, Heilig CE, Droll B, Wohlgemuth J, Armbruster FP, Heilig B. Immunogenicity, efficacy and adverse events of adalimumab in RA patients. Rheumatol. Int. 27: 269-274 (2007). *
Beniwal RS, Arena VC, Thomas L, Narla S, Imperiale TF, Chaudhry RA, Ahmad UA. A randomized trial of yogurt for prevention of antibiotic-associated diarrhea. Dig. Dis. Sci. 48: 2077-2082 (2003). *
Benson A, Barrett T, Sparberg M, Buchman AL. Efficacy and safety of tacrolimus in refractory ulcerative colitis and Crohn's disease: a single-center experience. Inflamm. Bowel Dis. 14: 7-12 (2008). *
Benten D, Staufer K, Sterneck M. Orthotopic liver transplantation and what to do during follow-up: recommendations for the practitioner. Nat. Clin. Pract. Gastroenterol. Hepatol. 6: 23-36 (2009). *
Benton D; ILSI Europe a i.s.b.l. Micronutrient status, cognition and behavioral problems in childhood. Eur. J. Nutr. 47 Suppl. 3: 38-50 (2008). *
Benucci M, Manfredi M, Saviola G, Baiardi P, Campi P. Correlation between atopy and hypersensitivity reactions during therapy with three different TNF-alpha blocking agents in rheumatoid arthritis. Clin. Exp. Rheumatol. 27: 333-336 (2009).
Berends MA, Driessen RJ, Langewouters AM, Boezeman JB, van de Kerkhof PC, de Jong EM. Etanercept and efalizumab treatment for high-need psoriasis. Effects and side effects in a prospective cohort study in outpatient clinical practice. J. Dermatolog. Treat. 18: 76-83 (2007).
Bergasa NV. Treatment of the pruritus of cholestasis: from unbearable lightness to substance. Hepatology 39: 1450-1453 (2004). *
Bergasa NV, Mason A, Floreani A, Heathcote J, Swain MG, Jones DE, Lindor KM, Bassendine MF, Worman HJ. Primary biliary cirrhosis: report of a focus study group. Hepatology 40: 1013-1020 (2004). *
Berger R, Barba A, Fleischer A, Leyden JJ, Lucky A, Pariser D, Rafal E, Thiboutot D, Wilson D, Grossman R, Nighland M. A double-blinded, randomized, vehicle-controlled, multicenter, parallel-group study to assess the safety and efficacy of tretinoin gel microsphere 0.04% in the treatment of acne vulgaris in adults. Cutis 80: 152-157 (2007).
Bergman J, Schjott J. Hepatitis caused by Lotus-f3? Basic Clin. Pharmacol. Toxicol. 104: 414-416 (2009). *
Berin MC, Mayer L. Immunophysiology of experimental food allergy. Mucosal Immunol. 2: 24-32 (2009).
Berkers CR, Ovaa H. Drug discovery and assay development in the ubiquitin-proteasome system. Biochem. Soc. Trans. 38: 14-20 (2010). *
Berkson BM, Rubin DM, Berkson AJ. The long-term survival of a patient with pancreatic cancer with metastases to the liver after treatment with the intravenous alpha-lipoic acid/low-dose naltrexone protocol. Integr. Cancer Ther. 5: 83-89 (2006).
Berkun Y, Atta IA, Rubinow A, Orbach H, Levartovsky D, Aamar S, Arbel O, Dresner-Pollak R, Friedman G, Ben-Yehuda A. 2756GG genotype of methionine synthase reductase gene is more prevalent in rheumatoid arthritis patients treated with methotrexate and is associated with methotrexate-induced nodulosis. J. Rheumatol. 34: 1664-1669 (2007).
Bermejo F, Lopez-Sanroman A, Hinojosa J, Castro L, Jurado C, Gomez-Beldal AB. Infliximab induces clinical, endoscopic and histological responses in refractory ulcerative colitis. Rev. Esp. Enferm. Dig. 96: 94-101 (2004).
Berni Canani R, Terrin G, Cirillo P, Castaldo G, Salvatore F, Cardillo G, Coruzzo A, Troncone R. Butyrate as an effective treatment of congenital chloride diarrhea. Gastroenterology 127: 630-634 (2004). *
Bernstein CN. Treatment of the extraintestinal manifestations of inflammatory bowel disease. Curr. Gastroenterol. Rep. 4: 513-516 (2002).
Bertolini A, Ottani A, Sandrini M. Selective COX-2 inhibitors and dual acting anti-inflammatory drugs: critical remarks. Curr. Med. Chem. 9: 1033-1043 (2002).
Berzigotti A, Bellot P, De Gottardi A, Garcia-Pagan JC, Gagnon C, Spenard J, Bosch J. NCX-1000, a nitric oxide-releasing derivative of UDCA, does not decrease portal pressure in patients with cirrhosis: results of a randomized, double-blind, dose-escalating study. Am. J. Gastroenterol. Nov 17 [Epub ahead of print] (2009). *
Bessard G, Hardy G, Chartier A, Stanke-Labesque F. Genetic polymorphism and treatment of chronic bowel inflammatory diseases: the example of azathioprine. Therapie 59: 71-75 (2004).
Besselink MG, Timmerman HM, Buskens E, Nieuwenhuijs VB, Akkermans LM, Gooszen HG; Dutch Acute Pancreatitis Study Group. Probiotic prophylaxis in patients with predicted severe acute pancreatitis (PROPATRIA): design and rationale of a double-blind, placebo-controlled randomised multicenter trial [ISRCTN38327949]. BMC Surg. 4: 12 (2004). *
Bessis N, Boissier MC. Gene therapy for patients with rheumatoid arthritis. Joint Bone Spine 73: 169-176 (2006). *
Bethune CA, Spickett GP. Common variable immunodeficiency: an update on therapeutic approaches. BioDrugs 13: 243-253 (2000).
Beyens MN, Guy C, Ollagnier M. Adverse effects of quinine in the treatment of leg cramps. Therapie 54: 59-62 (1999).
Bezabeh S, Flowers CM, Kortepeter C, Avigan M. Review article: clinically significant liver injury in patients treated with natalizumab (TYSABRI). Aliment. Pharmacol. Ther. Feb 16 [Epub ahead of print] (2010). *
Bhatia S, Huber BR, Upton MP, Thompson JA. Inflammatory enteric neuropathy with severe constipation after ipilimumab treatment for melanoma: a case report. J. Immunother. 32: 203-205 (2009).
Bhatnagar U, Arora S, Vishwase G, Tamboli S. Reproductive and developmental toxicity evaluation of desoris (LLL 3348) in Wistar rats. J. Environ. Pathol. Toxicol. Oncol. 28: 361-370 (2009).
Bhatt DL, Chew DP, Grines C, Mukherjee D, Leesar M, Gilchrist IC, Corbelli JC, Blankenship JC, Eres A, Steinhubl S, Tan WA, Resar JR, Almahameed A, Abdel-Latif A, Tang HW, Brennan D, McErlean E, Hazen SL, Topol EJ. Peroxisome proliferator-activated receptor gamma agonists for the prevention of adverse events following percutaneous coronary revascularization - results of the PPAR study. Am. Heart J. 154: 137-143 (2007). *
Bhutta ZA, Rizvi A, Raza F, Hotwani S, Zaidi S, Moazzam Hossain S, Soofi S, Bhutta S. A comparative evaluation of multiple micronutrient and iron-folic acid supplementation during pregnancy in Pakistan: impact on pregnancy outcomes. Food Nutr. Bull. 30: S496-S505 (2009).
Bibiloni R, Fedorak RN, Tannock GW, Madsen KL, Gionchetti P, Campieri M, De Simone C, Sartor RB. VSL#3 probiotic-mixture induces remission in patients with active ulcerative colitis. Am. J. Gastroenterol. 100: 1539-1546 (2005). *
Bielory L. Complementary and alternative interventions in asthma, allergy, and immunology. Ann. Allergy Asthma Immunol. 93 (2 Suppl. 1): S45-S54 (2004).
Binder EB, Holsboer F. Pharmacogenomics. Handb. Exp. Pharmacol. 169: 527-546 (2005).
Binder T, Salaj P, Zima T, Vitek L. Randomized prospective comparative study of ursodeoxycholic acid and S-adenosyl-L-methionine in the treatment of intrahepatic cholestasis of pregnancy. J. Perinat. Med. 34: 383-391 (2006).
Binder T, Salaj P, Zima T, Vitek L. Ursodeoxycholic acid, S-adenosyl-L-methionine and their combinations in the treatment of gestational intrahepatic cholestasis (ICP). Ceska. Gynekol. 71: 92-98 (2006).
Bingham CO, Ince A, Haraoui B, Keystone EC, Chon Y, Baumgartner S. Effectiveness and safety of etanercept in subjects with RA who have failed infliximab therapy: 16-week, open-label, observational study. Curr. Med. Res. Opin. 25: 1131-1142 (2009). *
Bischoff S, Crowe SE. Gastrointestinal food allergy: new insights into pathophysiology and clinical perspectives. Gastroenterology 128: 1089-1113 (2005). *
Bischoff S, Crowe SE. Food allergy and the gastrointestinal tract. Curr. Opin. Gastroenterol. 20: 156-161 (2004).
Bissonnette R, Ho V, Langley RG. Safety of conventional systemic agents and biologic agents in the treatment of psoriasis. J. Cutan. Med. Surg. 13 Suppl. 2: S67-S76 (2009).
Bjarnason I. Intestinal permeability. Gut 35: S18-S22 (1994). *
Bjarnason I. Ibuprofen and gastrointestinal safety: a dose-duration-dependent phenomenon. J. R. Soc. Med. 100 Suppl. 48: 11-14 (2007).
Bjarnason I, Hayllar J, MacPherson AJ, Russell AS. Side effects of nonsteroidal anti-inflammatory drugs on the small and large intestine in humans. Gastroenterology 104: 1832-1847 (1993).
Bjarnason I, Macpherson AJ. Intestinal toxicity of non-steroidal anti-inflammatory drugs. Pharmacol. Ther. 62: 145-157 (1994).
Bjarnsholt T, Tolker-Nielsen T, Givskov M, Janssen M, Christensen LH. Detection of bacteria by fluorescence in situ hybridization in culture-negative soft tissue filler lesions. Dermatol. Surg. 35 Suppl. 2: 1620-1624 (2009).
Bjelakovic G, Beninati S, Pavlovic D, Kocic G, Jevtovic T, Kamenov B, Saranac LJ, Bjelakovic B, Stojanovic I, Banic J. Glucocorticoids and oxidative stress. J. Basic Clin. Physiol. Pharmacol. 18: 115-127 (2007).
Bjelakovic G, Nikolova D, Simonetti RG, Gluud C. Systematic review: primary and secondary prevention of gastrointestinal cancers with antioxidant supplements. Aliment. Pharmacol. Ther. 28: 689-703 (2008). *
Bjelakovic G, Nikolova D, Simonetti RG, Gluud C. Antioxidant supplements for preventing gastrointestinal cancers. Cochrane Database Syst. Rev. 3: CD004183 (2008). *
Bjelakovic G, Nikolova D, Simonetti RG, Gluud C. Systematic review: primary and secondary prevention of gastrointestinal cancers with antioxidant supplements. Aliment. Pharmacol. Ther. 28: 689-703 (2008). *
Bjornsson E, Davidsdottir L. The long-term follow-up after idiosyncratic drug-induced liver injury with jaundice. J. Hepatol. 50: 511-517 (2009).
Bjornsson E, Jerlstad P, Bergqvist A, Olsson R. Fulminant drug-induced hepatic failure leading to death or liver transplantation in Sweden. Scand. J. Gastroenterol. 40: 1095-1101 (2005). *
Bjornsson E, Nordlinder H, Olsson R. Clinical characteristics and prognostic markers in disulfiram-induced liver injury. J. Hepatol. 44: 791-797 (2006). *
Bjornsson E, Olsson R. Serious adverse liver reactions associated with herbal weight-loss supplements. J. Hepatol. 47: 295-297 (2007). *
Bjornsson E, Olsson R. Outcome and prognostic markers in severe drug-induced liver disease. Hepatology 42: 481-489 (2005). *
Black DM, Delmas PD, Eastell R, Reid IR, Boonen S, Cauley JA, Cosman F, Lakatos P, Leung PC, Man Z, Mautalen C, Mesenbrink P, Hu H, Caminis J, Tong K, Rosario-Jansen T, Krasnow J, Hue TF, Sellmeyer D, Eriksen EF, Cummings SR. Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N. Engl. J. Med. 356: 1809-1822 (2007). *
Black M, Mignogna M, Scully C. Pemphigus vulgaris. Oral Dis. 11: 119-130 (2005). *
Blaise S, Salameire D, Carpentier PH. Interstitial granulomatous dermatitis: a misdiagnosed cutaneous form of systemic lupus erythematosus? Clin. Exp. Dermatol. 33: 712-714 (2008).
Blanc JF, Bioulac-Sage P, Balabaud C, Desmouliere A. Investigation of liver fibrosis in clinical practice. Hepatol. Res. 32: 1-8 (2005).
Blanc P, Daures JP, Rouillon JM, Peray P, Pierrugues R, Larrey D, Gremy F, Michel H. Lactitol or lactulose in the treatment of chronic hepatic encephalopathy: results of a meta-analysis. Hepatology 15: 222-228 (1992).
Blick SK, Curran MP. Certolizumab pegol in Crohn's disease. BioDrugs 21: 195-201 (2007).
Bliddal H, Terslev L, Qvistgaard E, Konig M, Holm CC, Rogind H, Boesen M, Danneskiold-Samsoe B, Torp-Pedersen S. A randomized, controlled study of a single intra-articular injection of etanercept or glucocorticosteroids in patients with rheumatoid arthritis. Scand. J. Rheumatol. 35: 341-345 (2006). *
Bloch AS. Low carbohydrate diets, pro: time to rethink our current strategies. Nutr. Clin. Pract. 20: 3-12 (2005).
Block SL, Brown DR, Chatterjee A, Gold MA, Sings HL, Meibohm A, Dana A, Haupt RM, Barr E, Tamms GM, Zhou H, Reisinger KS. Clinical trial and post-licensure safety profile of a prophylactic human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine. Pediatr. Infect. Dis. J. Nov 30 [Epub ahead of print] (2009).
Blom M, Kievit W, Fransen J, Kuper IH, den Broeder AA, De Gendt CM, Jansen TL, Brus HL, van de Laar MA, van Riel PL. The reason for discontinuation of the first tumor necrosis factor (TNF) blocking agent does not influence the effect of a second TNF blocking agent in patients with rheumatoid arthritis. J. Rheumatol. 36: 2171-2177 (2009).
Blonski W, Lichtenstein GR. Safety of biologic therapy. Inflamm. Bowel Dis. 13: 769-796 (2007). *
Blossom DB, Kallen AJ, Patel PR, Elward A, Robinson L, Gao G, Langer R, Perkins KM, Jaeger JL, Kurkjian KM, Jones M, Schillie SF, Shehab N, Ketterer D, Venkataraman G, Kishimoto TK, Shriver Z, McMahon AW, Austen KF, Kozlowski S, Srinivasan A, et al. Outbreak of adverse reactions associated with contaminated heparin. N. Engl. J. Med. 359: 2674-2684 (2008). *
Blumenauer B, Judd M, Wells G, Burls A, Cranney A, Hochberg M, Tugwell P. Infliximab for the treatment of rheumatoid arthritis. Cochrane Database Syst. Rev. 3: CD003785 (2002). *
Boberg J, Metzdorff S, Wortziger R, Axelstad M, Brokken L, Vinggaard AM, Dalgaard M, Nellemann C. Impact of diisobutyl phthalate and other PPAR agonists on steroidogenesis and plasma insulin and leptin levels in fetal rats. Toxicology 250: 75-81 (2008). *
Bock HH, Lammert F. Nuclear xeno-sensors as receptors for cholestatic bile acids: the second line of defense. Hepatology 35: 232-234 (2002). *
Boczkowski D, Lee J, Pruitt S, Nair S. Dendritic cells engineered to secrete anti-GITR antibodies are effective adjuvants to dendritic cell-based immunotherapy. Cancer Gene Ther. 16: 900-911 (2009).
Boden G, Zhang M. Recent findings concerning thiazolidinediones in the treatment of diabetes. Expert Opin. Investig. Drugs 15: 243-250 (2006).
Bodenheimer HC Jr, Schaffner F, Sternlieb I, Klion FM, Vernace S, Pezzullo J. A prospective clinical trial of D-penicillamine in the treatment of primary biliary cirrhosis. Hepatology 5: 1139-1142 (1985).
Bodmer M, Meier C, Kraenzlin ME, Meier CR. Risk of fractures with glitazones: a critical review of the evidence to date. Drug Saf. 32: 539-547 (2009).
Boehncke WH, Boehncke S. Managing comorbidities in psoriasis. Actas. Dermosifiliogr. 100: S22-S27 (2009).
Boehncke WH, Boehncke S. Cardiovascular morbidity in psoriasis: epidemiology, pathomechanisms, and clinical consequences. G. Ital. Dermatol. Venereol. 143: 307-313 (2008).
Boetticher NC, Peine CJ, Kwo P, Abrams GA, Patel T, Aqel B, Boardman L, Gores GJ, Harmsen WS, McClain CJ, Kamath PS, Shah VH. A randomized, double-blinded, placebo-controlled multicenter trial of etanercept in the treatment of alcoholic hepatitis. Gastroenterology 135: 1953-1960 (2008). *
Bogen KT, Gold LS. Trichloroethylene cancer risk: simplified calculation of PBPK-based MCLs for cytotoxic end points. Regul. Toxicol. Pharmacol. 25: 26-42 (1997).
Bohanec Grabar P, Grabnar I, Rozman B, Logar D, Tomsic M, Suput D, Trdan T, Peterlin Masic L, Mrhar A, Dolzan V. Investigation of the influence of CYP1A2 and CYP2C19 genetic polymorphism on A771726 pharmacokinetics in leflunomide treated patients with rheumatoid arthritis. Drug Metab. Dispos. 37: 2061-2068 (2009). *
Bohmer AE, Souza DG, Hansel G, Brum LM, Portela LV, Souza DO. Long-term cyclosporine treatment in non transplanted rats and metabolic risk factors of vascular diseases. Chem. Biol. Interact. Feb 23 [Epub ahead of print] (2010).
Boillot O, Mayer DA, Boudjema K, Salizzoni M, Gridelli B, Filipponi F, Trunecka P, Krawczyk M, Clavien PA, Ducerf C, Margarit C, Margreiter R, Pallardo JM, Hoeckerstedt K, Pageaux GP. Corticosteroid-free immunosuppression with tacrolimus following induction with daclizumab: a large randomized clinical study. Liver Transpl. 11: 61-67 (2005). *
Boitier E, Beaune P. Xenobiotic-metabolizing enzymes as autoantigens in human autoimmune disorders. An update. Clin. Rev. Allergy Immunol. 18: 215-239 (2000).
Bombardieri S, Ruiz AA, Fardellone P, Geusens P, McKenna F, Unnebrink K, Oezer U, Kary S, Kupper H, Burmester AG. Effectiveness of adalimumab for rheumatoid arthritis in patients with a history of TNF-antagonist therapy in clinical practice. Rheumatology (Oxford) 46: 1191-1199 (2007). *
Bongartz T, Warren FC, Mines D, Matteson EL, Abrams KR, Sutton AJ. Etanercept therapy in rheumatoid arthritis and the risk of malignancies. A systematic review and individual patient data meta-analysis of randomized controlled trials. Ann. Rheum. Dis. 68: 1177-1183 (2009).
Bongiorno MR, Pistone G, Doukaki S, Arico M. Adalimumab for treatment of moderate to severe psoriasis and psoriatic arthritis. Dermatol. Ther. 21 Suppl. 2: S15-S20 (2008).
Bonilla FA, Geha RS. 2. Update on primary immunodeficiency diseases. J. Allergy Clin. Immunol. 117: S435-S441 (2006). *
Bonnet J, McPherson R, Tedgui A, Simoneau D, Nozza A, Martineau P, Davignon J; for the CAP Investigators. Comparative effects of 10-mg versus 80-mg atorvastatin on high-sensitivity C-reactive protein in patients with stable coronary artery disease: results of the CAP (Comparative Atorvastatin Pleiotropic effects) study. Clin. Ther. 30: 2298-2313 (2008).
Bonnet N, Guis S, Koeppel MC, Roudier J, Grimaud JC, Jean-Pastor MJ, Berbis P. Cutaneous events during anti-TNF alpha therapy: a prospective observational study of 41 cases. Ann. Dermatol. Venereol. 137: 12-20 (2010).
Bonventre JV. Pathophysiology of acute kidney injury: roles of potential inhibitors of inflammation. Contrib. Nephrol. 156: 39-46 (2007).
Bookman AA, Williams KS, Shainhouse JZ. Effect of a topical diclofenac solution for relieving symptoms of primary osteoarthritis of the knee: a randomized controlled trial. CMAJ 171: 333-338 (2004). *
Boonsrirat U, Angsuthum S, Vannaprasaht S, Kongpunvijit J, Hirankarn N, Tassaneeyakul W, Avihingsanon Y. Azathioprine-induced fatal myelosuppression in systemic lupus erythematosus patient carrying TPMT*3C polymorphism. Lupus 17: 132-134 (2008). *
Boraschi P, Braccini G, Gigoni R, Cartei F, Perri G. MR enteroclysis using iron oxide particles (ferristene) as an endoluminal contrast agent: an open phase III trial. Magn. Reson. Imaging 22: 1085-1095 (2004). *
Borchers AT, Keen CL, Gershwin ME. Drug-induced lupus. Ann. N. Y. Acad. Sci. 1108: 166-182 (2007). *
Borchers AT, Naguwa SM, Keen CL, Gershwin ME. The implications of autoimmunity and pregnancy. J. Autoimmun. Dec 21 [Epub ahead of print] (2009).
Bordel-Gomez M, Sanchez-Estella J, Martinez-Gonzalez O, Cardenoso-Alvarez ME. Palmoplantar psoriasis: a paradoxical adverse reaction induced by adalimumab. J. Eur. Acad. Dermatol. Venereol. 23: 444-445 (2009). *
Boren E, Teuber SS, Naguwa SM, Gershwin ME. A critical review of local anesthetic sensitivity. Clin. Rev Allergy Immunol. 32: 119-128 (2007).
Borer JS. Cyclooxygenase inhibition: what should we do to resolve the confusion? An American perspective. J. Cardiovasc. Pharmacol. 47 Suppl. 1: S87-S91 (2006).
Boris M, Kaiser C, Golblatt A, Elice MW, Edelson SM, Adams JB, Feinstein DL. Effect of pioglitazone treatment on behavioral symptoms in autistic children. J. Neuroinflammation 4: 3 (2007). *
Borras-Blasco J, Gracia-Perez A, Rosique-Robles JD, Nunez-Cornejo C, Castera MD, Abad FJ. Urticaria due to etanercept in a patient with psoriatic arthritis. South. Med. J. 102: 304-305 (2009).
Borras-Blasco J, Navarro-Ruiz A, Borras C, Castera E. Adverse cutaneous reactions induced by TNF-alpha antagonist therapy. South. Med. J. 102: 1133-1140 (2009).
Borras-Blasco J, Nunez-Cornejo C, Gracia-Perez A, Rosique-Robles JD, Castera ME, Viosca E, Abad FJ. Parapharyngeal abscess in a patient receiving etanercept. Ann. Pharmacother. 41: 341-344 (2007).
Borrelli I. Endocrine disruptors: literature review on toxicology and application field in occupational medicine. G. Ital. Med. Lav. Ergon. 29: 526-528 (2007).
Borthne AS, Abdelnoor M, Rugtveit J, Perminow G, Reiseter T, Klow NE. Bowel magnetic resonance imaging of pediatric patients with oral mannitol MRI compared to endoscopy and intestinal ultrasound. Eur. Radiol. 16: 207-214 (2006).
Borthwick L; on behalf of the UK Study Group. The effects of an omega-3 ethyl ester concentrate on blood lipid concentrations in patients with hyperlipidaemia. Clin. Drug Investig. 15: 397-404 (1998).
Bosch J, Thabut D, Bendtsen F, D'amico G, Albillos A, Gonzalez Abraldes J, Fabricius S, Erhardtsen E, De Franchis R. Recombinant factor VIIa for upper gastrointestinal bleeding in patients with cirrhosis: a randomized, double-blind trial. Gastroenterology 127: 1123-1130 (2004). *
Bosch T. Therapeutic apheresis - state of the art in the year 2005. Ther. Apher. Dial. 9: 459-468 (2005). *
Bosch X, Guilabert A, Espinosa G, Mirapeix E. Immunotherapy for antineutrophil cytoplasmic antibody-associated vasculitis: challenging the therapeutic status quo? Trends Immunol. 29: 280-289 (2008). *
Bossa F, Colombo E, Andriulli A, Annese V. Treatment of steroid-naive ulcerative colitis. Expert Opin. Pharmacother. 10: 1449-1460 (2009).
Bossa F, Fiorella S, Caruso N, Accadia L, Napolitano G, Valvano MR, Andriulli A, Annese V. Continuous infusion versus bolus administration of steroids in severe attacks of ulcerative colitis: a randomized, double-blind trial. Am. J. Gastroenterol. 102: 601-608 (2007). *
Bossa F, Latiano A, Rossi L, Magnani M, Palmieri O, Dallapiccola B, Serafini S, Damonte G, De Santo E, Andriulli A, Annese V. Erythrocyte-mediated delivery of dexamethasone in patients with mild-to-moderate ulcerative colitis, refractory to mesalamine: a randomized, controlled study. Am. J. Gastroenterol. 103: 2509-2516 (2008). *
Botsios C. Safety of tumour necrosis factor and interleukin-1 blocking agents in rheumatic diseases. Autoimmun. Rev. 4: 162-170 (2005).
Botsios C, Sfriso P, Furlan A, Ostuni P, Biscaro M, Fiocco U, Todesco S, Punzi L. Anakinra, a recombinant human IL-1 receptor antagonist, in clinical practice. Outcome in 60 patients with severe rheumatoid arthritis. Reumatismo 59: 32-37 (2007).
Bougnoux P, Hajjaji N, Ferrasson MN, Giraudeau B, Couet C, Le Floch O. Improving outcome of chemotherapy of metastatic breast cancer by docosahexaenoic acid: a phase II trial. Br. J. Cancer 101: 1978-1985 (2009). *
Bournerias I. Methotrexate therapy in psoriasis. Rev. Prat. 54: 52-55 (2004).
Bourre JM. Effects of nutrients (in food) on the structure and function of the nervous system: update on dietary requirements for brain. Part 2: macronutrients. J. Nutr. Health Aging 10: 386-399 (2006).
Boursier J, Quentin V, Le Tallec V, Maurin A, Person B, O'Toole D, Boyer J. Endoscopic treatment of painful chronic pancreatitis: evaluation of a new flexible multiperforated plastic stent. Gastroenterol. Clin. Biol. 32: 801-805 (2008).
Bowie VL, Snella KA, Gopalachar AS, Bharadwaj P. Listeria meningitis associated with infliximab. Ann. Pharmacother. 38: 58-61 (2004).
Bowles CJ, Leicester R, Romaya C, Swarbrick E, Williams CB, Epstein O. A prospective study of colonoscopy practice in the UK today: are we adequately prepared for national colorectal cancer screening tomorrow? Gut 53: 277-283 (2004). *
Boyd AS. An overview of the retinoids. Am. J. Med. 86: 568-574 (1989).
Boyer TD, Kokenes DD, Hertzler G, Kutner MH, Henderson JM. Effect of distal splenorenal shunt on survival of patients with primary biliary cirrhosis. Hepatology 20: 1482-1486 (1994).
Boyle MP. Minocycline-induced pancreatitis in cystic fibrosis. Chest 119: 1283-1285 (2001). *
Bozina N, Bradamante V, Lovric M. Genetic polymorphism of metabolic enzymes P450 (CYP) as a susceptibility factor for drug response, toxicity, and cancer risk. Arh. Hig. Rada. Toksikol. 60: 217-242 (2009).
Braat H, Rottiers P, Hommes DW, Huyghebaert N, Remaut E, Remon JP, van Deventer SJ, Neirynck S, Peppelenbosch MP, Steidler L. A phase I trial with transgenic bacteria expressing interleukin-10 in Crohn's disease. Clin. Gastroenterol. Hepatol. 4: 754-759 (2006).
Bradley JD, Dmitrienko AA, Kivitz AJ, Gluck OS, Weaver AL, Wiesenhutter C, Myers SL, Sides GD. A randomized, double-blinded, placebo-controlled clinical trial of LY333013, a selective inhibitor of group II secretory phospholipase A2, in the treatment of rheumatoid arthritis. J. Rheumatol. 32: 417-423 (2005).
Braga MF, Grace MG, Lenis J, Kennedy FP, Teplinsky AL, Roederer G, Palumbo PJ, Colin P, Leiter LA. Efficacy and safety of ursodeoxycholic acid in primary, type IIa or IIb hypercholesterolemia: a multicenter, randomized, double-blind clinical trial. Atherosclerosis 203: 479-482 (2009).
Braithwaite M, Philip J, Finlayson F, Tranberg H, Gold M, Kotsimbos T, Wilson J. Adverse events arising from a palliative care survey. Palliat. Med. 23: 665-669 (2009).
Brancaccio D, Bommer J, Coyne D. Vitamin D receptor activator selectivity in the treatment of secondary hyperparathyroidism: understanding the differences among therapies. Drugs 67: 1981-1998 (2007).
Brand P, Schulte M, Wencker M, Herpich CH, Klein G, Hanna K, Meyer T. Lung deposition of inhaled alpha1-proteinase inhibitor in CF and alpha1-antitrypsin deficiency. Eur. Respir. J. 34: 354-360 (2009).
Brandt J, Khariouzov A, Listing J, Haibel H, Sorensen H, Rudwaleit M, Sieper J, Braun J. Successful short term treatment of patients with severe undifferentiated spondyloarthritis with the anti-tumor necrosis factor-alpha fusion receptor protein etanercept. J. Rheumatol. 31: 531-538 (2004).
Brandt J, Listing J, Haibel H, Sorensen H, Schwebig A, Rudwaleit M, Sieper J, Braun J. Long-term efficacy and safety of etanercept after readministration in patients with active ankylosing spondylitis. Rheumatology (Oxford) 44: 342-348 (2005). *
Brandtzaeg P. Impact of immunodeficiency on immunological hoemostasis in the gut. Falk Symposium 135. Immmunological diseases of liver and gut. Prague (Czech Republic). p. 61-62. September 12 - 13 (2003). *
Brandtzaeg P. Inflammatory bowel disease: clinics and pathology. Do inflammatory bowel disease and periodontal disease have similar immunopathogeneses? Acta Odontol. Scand. 59: 235-243 (2001). *
Brannon PM, Yetley EA, Bailey RL, Picciano MF. Summary of roundtable discussion on vitamin D research needs. Am. J. Clin. Nutr. 88: 587S-592S (2008). *
Braun F, Behrend M. Basic immunosuppressive drugs outside solid organ transplantation. Expert Opin. Investig. Drugs 15: 267-291 (2006).
Braun J, Sieper J. Biological therapies in the spondyloarthritides - the current state. Rheumatology (Oxford) 43: 1072-1084 (2004). *
Braun J, van der Heijde D. Novel approaches in the treatment of ankylosing spondylitis and other spondyloarthritides. Expert Opin. Investig. Drugs 12: 1097-1109 (2003).
Breen DP, Marinaki AM, Arenas M, Hayes PC. Pharmacogenetic association with adverse drug reactions to azathioprine immunosuppressive therapy following liver transplantation. Liver Transpl. 11: 826-833 (2005). *
Breneman D, Sheth P, Berger V, Naini V, Stevens V. Phase II clinical trial of bexarotene gel 1% in psoriasis. J. Drugs Dermatol. 6: 501-506 (2007).
Brenner DM, Moeller MJ, Chey WD, Schoenfeld PS. The utility of probiotics in the treatment of irritable bowel syndrome: a systematic review. Am. J. Gastroenterol. 104: 1033-1049 (2009). *
Briand JP, Muller S. Emerging peptide therapeutics for inflammatory autoimmune diseases. Curr. Pharm. Des. Dec 23 [Epub ahead of print] (2009).
Brimblecombe R. Mesalazine: a global safety evaluation. Scand. J. Gastroenterol. Suppl. 172: 66 (1990).
Brimhall AK, King LN, Licciardone JC, Jacobe H, Menter A. Safety and efficacy of alefacept, efalizumab, etanercept and infliximab in treating moderate to severe plaque psoriasis: a meta-analysis of randomized controlled trials. Br. J. Dermatol. 159: 274-285 (2008). *
Brinker AD, Wassel RT, Lyndly J, Serrano J, Avigan M, Lee WM, Seeff LB. Telithromycin-associated hepatotoxicity: clinical spectrum and causality assessment of 42 cases. Hepatology 49: 250-257 (2009). *
Brites D, Rodrigues CM, Oliveira N, Cardoso M, Graca LM. Correction of maternal serum bile acid profile during ursodeoxycholic acid therapy in cholestasis of pregnancy. J. Hepatol. 28: 91-98 (1998). *
British Society of Gastroenterology. Antibiotic prophylaxis in gastrointestinal endoscopy. BSG Guidelines in Gastroenterology, p. 1-10, January (2001). *
Brito-Zeron P, Ramos-Casals M, Bove A, Sentis J, Font J. Predicting adverse outcomes in primary Sjogren's syndrome: identification of prognostic factors. Rheumatology (Oxford) 46: 1359-1362 (2007). *
Broeyer FJ, van Aken BE, Suzuki J, Kemme MJ, Schoemaker HC, Cohen AF, Mizushima Y, Burggraaf J. The pharmacokinetics and effects of a long-acting preparation of superoxide dismutase (PC-SOD) in man. Br. J. Clin. Pharmacol. 65: 22-29 (2008). *
Brogden RN, Sorkin EM. Mesalazine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in chronic inflammatory bowel disease. Drugs 38: 500-523 (1989).
Brooks AJ, Begg EJ, Zhang M, Frampton CM, Barclay ML. Red blood cell methotrexate polyglutamate concentrations in inflammatory bowel disease. Ther. Drug Monit. 29: 619-625 (2007).
Brophy JM. Cardiovascular effects of cyclooxygenase-2 inhibitors. Curr. Opin. Gastroenterol. 23: 617-624 (2007).
Brophy S, Davies H, Bain S, Stephens JW, Cheung WY, Richards K, Wareham K, Beaverstock C, Lloyd J, Page D, Williams M, Russell I, Williams R. Randomized, controlled, parallel-group prospective study to investigate the clinical effectiveness of early insulin treatment in patients with latent autoimmune diabetes in adults. BMC Endocr. Disord. 8: 8 (2008). *
Brousil JA, Roberts RJ, Schlein AL. Cladribine: an investigational immunomodulatory agent for multiple sclerosis (CE). Ann. Pharmacother. 40: 1814-1821 (2006).
Brown AC, Shovic A, Ibrahim SA, Holck P, Huang A. A non-dairy probiotic's (poi) influence on changing the gastrointestinal tract's microflora environment. Altern. Ther. Health Med. 11: 58-64 (2005). *
Brown AP, Dunstan RW, Courtney CL, Criswell KA, Graziano MJ. Cutaneous lesions in the rat following administration of an irreversible inhibitor of erbB receptors, including the epidermal growth factor receptor. Toxicol. Pathol. 36: 410-419 (2008). *
Brown BA, Kantesaria PP, McDevitt LM. Fingolimod: a novel immunosuppressant for multiple sclerosis. Ann. Pharmacother. 41: 1660-1668 (2007).
Brown BC, Warren RB, Grindlay DJ, Griffiths CE. What's new in psoriasis? Analysis of the clinical significance of systematic reviews on psoriasis published in 2007 and 2008. Clin. Exp. Dermatol. 34: 664-667 (2009).
Brown RJ, Rother KI, Artman H, Mercurio MG, Wang R, Looney RJ, Cowen EW. Minocycline-induced drug hypersensitivity syndrome followed by multiple autoimmune sequelae. Arch. Dermatol. 145: 63-66 (2009). *
Brown SL, Greene MH, Gershon SK, Edwards ET, Braun MM. Tumor necrosis factor antagonist therapy and lymphoma development: twenty-six cases reported to the Food and Drug Administration. Arthritis Rheum. 46: 3151-3158 (2002). *
Brown WV. Expert commentary: the safety of fibrates in lipid-lowering therapy. Am. J. Cardiol. 99: S19-S21 (2007). *
Bruce SP, Boyce EG. Update on abatacept: a selective costimulation modulator for rheumatoid arthritis. Ann. Pharmacother. 41: 1153-1162 (2007).
Bruckner JV, Kyle GM, Luthra R, Acosta D, Mehta SM, Sethuraman S, Muralidhara S. Acute, short-term, and subchronic oral toxicity of 1,1,1-trichloroethane in rats. Toxicol. Sci. 60: 363-372 (2001). *
Brunner W. Pruritus - also a challenge in internal medicine. Schweiz. Med. Wochenschr. 125: 2244-2250 (1995).
Bruno NP, Beacham BE, Burnett JW. Adverse effects of isotretinoin therapy. Cutis 33: 484-486, 489 (1984).
Bruns T, Stallmach A. Drug monitoring in inflammatory bowel disease: helpful or dispensable? Dig. Dis. 27: 394-403 (2009).
Bruzzese V, Pepe J. Efficacy of cyclosporine in the treatment of a case of infliximab-induced erythrodermic psoriasis. Int. J. Immunopathol. Pharmacol. 22: 235-238 (2009).
Bryce AH, Dispenzieri A, Kyle RA, Lacy MQ, Rajkumar SV, Inwards DJ, Yasenchak CA, Kumar SK, Gertz MA. Response to rituximab in patients with type II cryoglobulinemia. Clin. Lymphoma Myeloma 7: 140-144 (2006).
Bryce J, Coitinho D, Darnton-Hill I, Pelletier D, Pinstrup-Andersen P; for the Maternal and Child Undernutrition Study Group. Maternal and child undernutrition: effective action at national level. Lancet 371: 510-526 (2008). *
Brynskov J, Feagan BG, Jewell D, McDonald JWD, Stange EF. Cyclosporine for maintenance of remission in Crohn’s disease. Cochrane Database Syst. Rev. 2: CD004377 (2004). *
Buchbinder R, March L, Lassere M, Briggs AM, Portek I, Reid C, Meehan A, Henderson L, Wengier L, van den Haak R. Effect of treatment with biological agents for arthritis in Australia: the Australian Rheumatology Association Database. Intern. Med. J. 37: 591-600 (2007).
Buchman AL, Katz S, Fang JC, Bernstein CN, Abou-Assi SG; for the Teduglutide Study Group. Teduglutide, a novel mucosally active analog of glucagon-like peptide-2 (GLP-2) for the treatment of moderate to severe Crohn's disease. Inflamm. Bowel Dis. Oct 9 [Epub ahead of print] (2009).
Buckland A, Bodger K. The cost-utility of high dose oral mesalazine for moderately active ulcerative colitis. Aliment. Pharmacol. Ther. 28: 1287-1296 (2008). *
Burakoff R, Barish CF, Riff D, Pruitt R, Chey WY, Farraye FA, Shafran I, Katz S, Krone CL, Vander Vliet M, Stevens C, Sherman ML, Jacobson E, Bleday R. A phase 1/2A trial of STA 5326, an oral interleukin-12/23 inhibitor, in patients with active moderate to severe Crohn's disease. Inflamm. Bowel Dis. 12: 558-565 (2006). *
Burg JR, Gist GL. The National Exposure Registry: procedures for establishing a registry of persons environmentally exposed to hazardous substances. Toxicol. Ind. Health 11: 231-248 (1995).
Burgermeister E, Schnoebelen A, Flament A, Benz J, Stihle M, Gsell B, Rufer A, Ruf A, Kuhn B, Marki HP, Mizrahi J, Sebokova E, Niesor E, Meyer M. A novel partial agonist of peroxisome proliferator-activated receptor-gamma (PPARgamma) recruits PPARgamma-coactivator-1 alpha (PGC1alpha), prevents triglyceride accumulation and potentiates insulin signaling in vitro. Mol. Endocrinol. 20: 809-830 (2006). *
Burks W, Jones SM, Berseth CL, Harris C, Sampson HA, Scalabrin DM. Hypoallergenicity and effects on growth and tolerance of a new amino acid-based formula with docosahexaenoic acid and arachidonic acid. J. Pediatr. 153: 266-271 (2008). *
Burmester GR, Mease PJ, Dijkmans BA, Gordon K, Lovell D, Panaccione R, Perez J, Pangan AL. Adalimumab safety and mortality rates from global clinical trials of six immune-mediated inflammatory diseases. Ann. Rheum. Dis. 68: 1863-1869 (2009). *
Burr ML, Dunstan FD, George CH. Is fish oil good or bad for heart disease? Two trials with apparently conflicting results. J. Membr. Biol. 206: 155-163 (2005). *
Burrows RF, Clavisi O, Burrows E. Interventions for treating cholestasis in pregnancy. Cochrane Database Syst. Rev. 4: CD000493 (2001). *
Burt RK, Loh Y, Pearce W, Beohar N, Barr WG, Craig R, Wen Y, Rapp JA, Kessler J. Clinical applications of blood-derived and marrow-derived stem cells for nonmalignant diseases. JAMA 299: 925-936 (2008). *
Buscher HP, Zietzschmann Y, Gerok W. Positive responses to methotrexate and ursodeoxycholic acid in patients with primary biliary cirrhosis responding insufficiently to ursodeoxycholic acid alone. J. Hepatol. 18: 9-14 (1993).
Buse JB, Rubin CJ, Frederich R, Viraswami-Appanna K, Lin KC, Montoro R, Shockey G, Davidson JA. Muraglitazar, a dual (alpha/gamma) PPAR activator: a randomized, double-blind, placebo-controlled, 24-week monotherapy trial in adult patients with type 2 diabetes. Clin. Ther. 27: 1181-1195 (2005). *
Bussel JB, Kuter DJ, George JN, McMillan R, Aledort LM, Conklin GT, Lichtin AE, Lyons RM, Nieva J, Wasser JS, Wiznitzer I, Kelly R, Chen CF, Nichol JL. AMG 531, a thrombopoiesis-stimulating protein, for chronic ITP. N. Engl. J. Med. 355: 1672-1681 (2006). *
Bussone G, Hachulla E, Sibilia J, Michel M, Godeau B, Guillevin L, Mouthon L. Treatment of systemic autoimmune and inflammatory diseases with rituximab. Presse. Med. 38: 808-823 (2009).
Buster EH, van Vuuren HJ, Zondervan PE, Metselaar HJ, Tilanus HW, de Man RA. Thiopurine-methyltransferase and inosine triphosphate pyrophosphatase polymorphism in a liver transplant recipient developing nodular regenerative hyperplasia on low-dose azathioprine. Eur. J. Gastroenterol. Hepatol. 20: 68-72 (2008).
Butler G, Michaels JC, Al-Waili N, Finkelstein M, Allen M, Petrillo R, Carrey Z, Kolanuvada B, Lee BY, Riera AG, Michaels CC, Urteaga G. Therapeutic effect of hyperbaric oxygen in psoriasis vulgaris: two case reports and a review of the literature. J. Med. Case Reports 3: 7023 (2009). *
Buttari B, Profumo E, Mancinelli R, Cesta Incani U, Tosti ME, Attilia ML, Ceccanti M, Rigano R. Chronic and acute alcohol exposure prevents monocyte-derived dendritic cells from differentiating and maturing. Int. J. Immunopathol. Pharmacol. 21: 929-939 (2008).
Buttgereit F, Burmester GR, Lipworth BJ. Optimised glucocorticoid therapy: the sharpening of an old spear. Lancet 365: 801-803 (2005). *
Buttgereit F, Song IH, Straub RH, Burmester GR. Current insights into the development of new glucocorticoid receptor ligands. Z. Rheumatol. 64: 170-176 (2005).
Buzkova H, Pechandova K, Slanar O, Perlik F. Genetic polymorphism of cytochrome P450 and methods for its determination. Prague Med. Rep. 107: 383-393 (2006).
Cabezas Gelabert R. Effect of ursodeoxycholic acid combined with statins in hypercholesterolemia treatment: a prospective clinical trial. Rev. Clin. Esp. 204: 632-635 (2004).
Cabriada Nuno JL, Hernandez Martin A, Bernal Martinez A, Zabalza Estevez I. Oral budesonide in the treatment of chronic refractory pouchitis. Gastroenterol. Hepatol. 31: 485-489 (2008).
Cabrijan L, Lipozencic J, Batinac T, Lenkovic M, Stanic Zgombic Z. Influence of PUVA and UVB radiation on expression of ICAM-1 and VCAM-1 molecules in psoriasis vulgaris. Coll. Antropol. 32 Suppl. 2: 53-56 (2008).
Cadle RM, Mansouri MD, Darouiche RO. Vancomycin-induced elevation of liver enzyme levels. Ann. Pharmacother. 40: 1186-1189 (2006).
Cafardi JA, Cantrell W, Wang W, Elmets CA, Elewski BE. The safety and efficacy of high-dose alefacept compared with a loading dose of alefacept in patients with chronic plaque psoriasis. Skinmed. 7: 67-72 (2008). *
Caire-Juvera G, Ritenbaugh C, Wactawski-Wende J, Snetselaar LG, Chen Z. Vitamin A and retinol intakes and the risk of fractures among participants of the Women's Health Initiative Observational Study. Am. J. Clin. Nutr. 89: 323-330 (2009). *
Calabrese L. The yin and yang of tumor necrosis factor inhibitors. Cleve. Clin. J. Med. 73: 251-256 (2006). *
Calabrese L, Resztak K. Thalidomide revisited: pharmacology and clinical applications. Expert Opin. Investig. Drugs 7: 2043-2060 (1998).
Calabresi PA, Giovannoni G, Confavreux C, Galetta SL, Havrdova E, Hutchinson M, Kappos L, Miller DH, O'Connor PW, Phillips JT, Polman CH, Radue EW, Rudick RA, Stuart WH, Lublin FD, Wajgt A, Weinstock-Guttman B, Wynn DR, Lynn F, Panzara MA. The incidence and significance of anti-natalizumab antibodies: results from AFFIRM and SENTINEL. Neurology 69: 1391-1403 (2007).
Calabuig E, Salavert M. Infectious risk. Actas Dermosifiliogr. 99 Suppl. 4: 14-22 (2008).
Calder PC. Hot topics in parenteral nutrition. Rationale for using new lipid emulsions in parenteral nutrition and a review of the trials performed in adults. Proc. Nutr. Soc. 68: 252-260 (2009). *
Calkin AC, Allen TJ, Lassila M, Tikellis C, Jandeleit-Dahm KA, Thomas MC. Increased atherosclerosis following treatment with a dual PPAR agonist in the ApoE knockout mouse. Atherosclerosis 195: 17-22 (2007).
Callen JP. Complications and adverse reactions in the use of newer biologic agents. Semin. Cutan. Med. Surg. 26: 6-14 (2007).
Calmelet P, Coumaros D, Viville B, Raiga J, Favreau JJ, Treisser A. Ursodeoxycholic acid: prospect for treatment of gravidic cholestasis? Report of 3 cases. J. Gynecol. Obstet. Biol. Reprod. (Paris) 27: 617-621 (1998).
Calmus Y. Immunosuppression after liver transplantation. Presse. Med. 38: 1307-1313 (2009).
Cameron NE, Cotter MA. The neurocytokine, interleukin-6, corrects nerve dysfunction in experimental diabetes. Exp. Neurol. 207: 23-29 (2007).
Camilleri M. Is there an experimental basis for the development of ischaemic colitis as a result of 5-HT(3) antagonist treatment? Neurogastroenterol. Motil. 19: 77-84 (2007). *
Caminha MD, Diniz AD, Falbo AR, Arruda IK, Serva VB, Albuquerque LL, Lola MM, Ebrahim GJ. Serum retinol concentrations in hospitalized severe protein-energy malnourished children. J. Trop. Pediatr. 54: 248-252 (2008).
Campi P, Benucci M, Manfredi M, Demoly P. Hypersensitivity reactions to biological agents with special emphasis on tumor necrosis factor-alpha antagonists. Curr. Opin. Allergy Clin. Immunol. 7: 393-403 (2007).
Cantarini L, Tinazzi I, Biasi D, Fioravanti A, Galeazzi M. Sulfasalazine-induced immune thrombocytopenia. Postgrad. Med. J. 83: e1 (2007). *
Cantin AM, Berthiaume Y, Cloutier D, Martel M. Prolastin aerosol therapy and sputum taurine in cystic fibrosis. Clin. Invest. Med. 29: 201-207 (2006).
Caporali R, Sarzi-Puttini P, Atzeni F, Gorla R, Filippini M, Marchesoni A, Favalli EG, Bobbio-Pallavicini F, Montecucco C. Switching TNF-alpha antagonists in rheumatoid arthritis: the experience of the LORHEN registry. Autoimmun. Rev. Dec 28 [Epub ahead of print] (2009).
Caprilli R, Angelucci E, Clemente V. Recent advances in the management of Crohn's disease. Dig. Liver Dis. 40: 709-716 (2008).
Carbone J. Adverse reactions and pathogen safety of intravenous immunoglobulin. Curr. Drug Saf. 2: 9-18 (2007).
Carella AM, Conte M. Therapeutic options for metabolic syndrome in obese patients. Clin. Ter. 158: 457-464 (2007).
Cariou B, Staels B. The expanding role of the bile acid receptor FXR in the small intestine. J. Hepatol. 44: 1213-1215 (2006). *
Carleton BC, Smith MA, Gelin MN, Heathcote SC. Paediatric adverse drug reaction reporting: understanding and future directions. Can. J. Clin. Pharmacol. 14: e45-e57 (2007). *
Carola V, Frazzetto G, Pascucci T, Audero E, Puglisi-Allegra S, Cabib S, Lesch KP, Gross C. Identifying molecular substrates in a mouse model of the serotonin transporter x environment risk factor for anxiety and depression. Biol. Psychiatry 63: 840-846 (2008). *
Carr D, Tusa MG, Carroll CL, Pearce DJ, Camacho F, Kaur M, Cook C, Willard J, McCarty A, Fleischer AB Jr, Liu CM, Goffe BS, Feldman SR. Open label trial of alefacept in palmoplantar pustular psoriasis. J. Dermatolog. Treat. 19: 97-100 (2008).
Carrascosa MF, Lucena MI, Andrade RJ, Caviedes JR, Lavín AC, Mones JC, Rivero AP, Serrano VB. Fatal acute hepatitis after sequential treatment with levofloxacin, doxycycline, and naproxen in a patient presenting with acute Mycoplasma pneumoniae infection. Clin. Ther. 31: 1014-1019 (2009).
Carrat Ugrave P, Dragonieri S, Nocerino MC, Trabucco SM, Lacedonia D, Parisi G, Resta O. A case of cryptogenic organizing pneumonia occurring in Crohn's disease. Can. Respir. J. 12: 437-439 (2005). *
Carrillo-Esper R, Gonzalez-Avila D, Uribe-Rios M, Mendez-Sanchez N. Interstitial pneumonitis associated with pegylated interferon alpha-2b therapy for chronic hepatitis C: case report. Ann. Hepatol. 7: 87-90 (2008).
Carson KR, Evens AM, Richey EA, Habermann TM, Focosi D, Seymour JF, Laubach J, Bawn SD, Gordon LI, Winter JN, Furman RR, Vose JM, Zelenetz AD, Mamtani R, Raisch DW, Dorshimer GW, Rosen ST, Muro K, Gottardi-Littell NR, Talley RL, Sartor O, Green D, et al. Progressive multifocal leukoencephalopathy following rituximab therapy in HIV negative patients: a report of 57 cases from the Research on Adverse Drug Event and Reports (RADAR) project. Blood 113: 4834-4840 (2009). *
Carson KR, Focosi D, Major EO, Petrini M, Richey EA, West DP, Bennett CL. Monoclonal antibody-associated progressive multifocal leucoencephalopathy in patients treated with rituximab, natalizumab, and efalizumab: a review from the Research on Adverse Drug Events and Reports (RADAR) Project. Lancet Oncol. 10: 816-824 (2009).
Carter JD, Ladhani A, Ricca LR, Valeriano J, Vasey FB. A safety assessment of tumor necrosis factor antagonists during pregnancy: a review of the Food and Drug Administration Database. J. Rheumatol. 36: 635-641 (2009).
Casa C, Arnaud JP, Serra-Maudet V, Georgeac G, Kanane S, Ronceray J. Mesocaval anastomosis in the treatment of recurring hemorrhage caused by portal hypertension. J. Chir. (Paris) 130: 517-521 (1993).
Casale TB, Kessler J, Romero FA. Safety of the intranasal Toll-like receptor 4 agonist CRX-675 in allergic rhinitis. Ann. Allergy Asthma Immunol. 97: 454-456 (2006).
Casellas Jorda F. TNF-alpha inhibitors in inflamatory bowel disease. Med. Clin. (Barc.) 123: 627-634 (2004).
Cashman KD, Hill TR, Cotter AA, Boreham CA, Dubitzky W, Murray L, Strain J, Flynn A, Robson PJ, Wallace JM, Kiely M. Low vitamin D status adversely affects bone health parameters in adolescents. Am. J. Clin. Nutr. 87: 1039-1044 (2008). *
Caspersen S, Elkjaer M, Riis L, Pedersen N, Mortensen C, Jess T, Sarto P, Hansen TS, Wewer V, Bendtsen F, Moesgaard F, Munkholm P; on behalf of the Danish Crohn Colitis Database. Infliximab for inflammatory bowel disease in Denmark 1999-2005: clinical outcome and follow-up evaluation of malignancy and mortality. Clin. Gastroenterol. Hepatol. 6: 1212-1217 (2008).
Cassano N, Loconsole F, Galluccio A, Miracapillo A, Pezza M, Vena GA. Once-weekly administration of high-dosage Etanercept in patients with plaque psoriasis: results of a pilot experience (power study). Int. J. Immunopathol. Pharmacol. 19: 225-229 (2006).
Cassano N, Mastrandrea V, Buquicchio R, Miracapillo A, Loconsole F, Filotico R, Vena GA. Efalizumab in moderate-to-severe plaque psoriasis: a retrospective case series analysis from clinical practice. J. Biol. Regul. Homeost. Agents 22: 185-194 (2008).
Cassina M, Fabris L, Okolicsanyi L, Gervasi MT, Memmo A, Tiboni GM, Di Gianantonio E, Clementi M. Therapy of inflammatory bowel diseases in pregnancy and lactation. Expert Opin. Drug Saf. 8: 695-707 (2009).
Cassinotti A, Annaloro C, Ardizzone S, Onida F, Volpe AD, Clerici M, Usardi P, Greco S, Maconi G, Porro GB, Deliliers GL. Autologous haematopoietic stem cell transplantation without CD34+ cell selection in refractory Crohn's disease. Gut 57: 211-217 (2008).
Cassinotti A, Massari A, Ferrara E, Greco S, Bosani M, Ardizzone S, Bianchi Porro G. New onset of atrial fibrillation after introduction of azathioprine in ulcerative colitis: case report and review of the literature. Eur. J. Clin. Pharmacol. 63: 875-878 (2007).
Castagna A, Biswas P, Beretta A, Lazzarin A. The appealing story of HIV entry inhibitors: from discovery of biological mechanisms to drug development. Drugs 65: 879-904 (2005).
Castano G, Fernandez L, Mas R, Illnait J, Mesa M, Fernandez JC. Comparison of the effects of policosanol and atorvastatin on lipid profile and platelet aggregation in patients with dyslipidaemia and type 2 diabetes mellitus. Clin. Drug Investig. 23: 639-650 (2003).
Castro B, Crespo J, Garcia-Suarez C, Fabrega E, Casafont F, Pons-Romero F. Triple immunosuppressive therapy in the treatment of severe ulcerative colitis. Gastroenterol. Hepatol. 27: 1-5 (2004).
Cato AC, Schacke H, Sterry W, Asadullah K. The glucocorticoid receptor as target for classic and novel anti-inflammatory therapy. Curr. Drug Targets Inflamm. Allergy 3: 347-353 (2004).
Cavailhes A, Balme B, Gilbert D, Skowron F. Successful use of combined corticosteroids and rituximab in the treatment of recalcitrant epidermolysis bullosa acquisita. Ann. Dermatol. Venereol. 136: 795-799 (2009).
Caviglia R, Boskoski I, Cicala M. Maintenance treatment with infliximab for the management of Crohn's disease in adults. Biologics 3: 39-49 (2009). *
Caviglia R, Boskoski I, Cicala M. Long-term treatment with infliximab in inflammatory bowel disease: safety and tolerability issues. Expert Opin. Drug Saf. 7: 617-632 (2008).
Caviglia R, Ribolsi M, Rizzi M, Emerenziani S, Annunziata ML, Cicala M. Maintenance of remission with infliximab in inflammatory bowel disease: efficacy and safety long-term follow-up. World J. Gastroenterol. 13: 5238-5244 (2007). *
Cavill I, Auerbach M, Bailie GR, Barrett-Lee P, Beguin Y, Kaltwasser P, Littlewood T, Macdougall IC, Wilson K. Iron and the anaemia of chronic disease: a review and strategic recommendations. Curr. Med. Res. Opin. 22: 731-737 (2006).
Cay HF, Gungor HA, Sezer I, Kacar C, Balci N. Adverse effect of TNF-alpha blocker? Demyelination in an ankylosing spondylitis patient: a case report. J. Clin. Pharm. Ther. 31: 645-648 (2006). *
Cazzola M, Matera MG, Rogliani P, Page C. Treating systemic effects of COPD. Trends Pharmacol. 28: 544-550 (2007). *
Celik S, Doesch A, Erbel C, Blessing E, Ammon K, Koch A, Katus HA, Dengler TJ. Beneficial effect of omega-3 fatty acids on sirolimus- or everolimus-induced hypertriglyceridemia in heart transplant recipients. Transplantation 86: 245-250 (2008).
Centers for Disease Control and Prevention (CDC). Update: Guillain-Barre syndrome among recipients of Menactra meningococcal conjugate vaccine - United States, June 2005-September 2006. MMWR Morb. Mortal. Wkly. Rep. 55: 1120-1124 (2006).
Centers for Disease Control and Prevention (CDC). Update: Guillain-Barre syndrome among recipients of Menactra meningococcal conjugate vaccine - United States, October 2005-February 2006. MMWR Morb. Mortal. Wkly. Rep. 55: 364-366 (2006).
Centers for Disease Control and Prevention (CDC). Tuberculosis associated with blocking agents against tumor necrosis factor-alpha - California, 2002-2003. MMWR Morb. Mortal. Wkly. Rep. 53: 683-686 (2004).
Cerveny P, Bortlík M, Kubena A, Vlcek J, Lakatos PL, Lukas M. Nonadherence in inflammatory bowel disease: results of factor analysis. Inflamm. Bowel Dis. 13: 1244-1249 (2007). *
Cezard JP, Munck A, Mouterde O, Morali A, Lenaerts C, Lachaux A, Turck D, Schmitz J, Maurage C, Girardet JP, Belli D, Lamireau T, Sarles J, Chouraqui JP, Descos B, Dabadi A, Meyer M, Olives JP, Mary JY. Prevention of relapse by mesalazine (pentasa) in pediatric Crohn's disease: a multicenter, double-blind, randomized, placebo-controlled trial. Gastroenterol. Clin. Biol. 33: 31-40 (2009).
Cha JM, Kim HJ. The frequency and the course of the adverse effects of azathioprine/6-mercaptopurine treatment in patients with inflammatory bowel disease. Korean J. Gastroenterol. 51: 319-322 (2008).
Chaarani J, Lebwohl M. Alefacept: where it stands today. Expert Opin. Drug Metab. Toxicol. 6: 355-361 (2010).
Chaby G, Viseux V, Poulain JF, De Cagny B, Denoeux JP, Lok C. Topical silver sulfadiazine-induced acute renal failure. Ann. Dermatol. Venereol. 132: 891-893 (2005).
Chalumeau S, Moussata D, Nancey S, Claudel-Bonvoisin S, Saurin JC, Flourie B. Pancytopenia induced by two low-dose injections of methotrexate in a patient treated for ulcerative colitis. Gastroenterol. Clin. Biol. 31: 1104-1106 (2007).
Chan EP, Lichtenstein GR. Chemoprevention: risk reduction with medical therapy of inflammatory bowel disease. Gastroenterol. Clin. North Am. 35: 675-712 (2006).
Chan TM. Lupus nephritis: induction therapy. Lupus 14 Suppl. 1: s27-s32 (2005).
Chande N. Microscopic colitis: an approach to treatment. Can. J. Gastroenterol. 22: 686-688 (2008). *
Chande N, McDonald J, Macdonald J. Unfractionated or low-molecular weight heparin for induction of remission in ulcerative colitis. Cochrane Database Syst. Rev. 2: CD006774 (2008). *
Chande N, Ponich T, Gregor J. A survey of Canadian gastroenterologists about the use of methotrexate in patients with Crohn's disease. Can. J. Gastroenterol. 19: 553-558 (2005). *
Chang AL, Badger J, Rehmus W, Kimball AB. Alefacept for erosive lichen planus: a case series. J. Drugs Dermatol. 7: 379-383 (2008).
Chang DM, Lan JL, Lin HY, Luo SF. Dehydroepiandrosterone treatment of women with mild-to-moderate systemic lupus erythematosus: a multicenter randomized, double-blind, placebo-controlled trial. Arthritis Rheum. 46: 2924-2927 (2002). *
Chang F, Jaber LA, Berlie HD, O'Connell MB. Evolution of peroxisome proliferator-activated receptor agonists. Ann. Pharmacother. 41: 973-983 (2007).
Chang L, Ameen VZ, Dukes GE, McSorley DJ, Carter EG, Mayer EA. A dose-ranging, phase II study of the efficacy and safety of alosetron in men with diarrhea-predominant IBS. Am. J. Gastroenterol. 100: 115-123 (2005). *
Chang L, Chey WD, Harris L, Olden K, Surawicz C, Schoenfeld P. Incidence of ischemic colitis and serious complications of constipation among patients using alosetron: systematic review of clinical trials and post-marketing surveillance data. Am. J. Gastroenterol. 101: 1069-1079 (2006). *
Chang L, Tong K, Ameen V. Ischemic colitis and complications of constipation associated with the use of alosetron under a risk management plan: clinical characteristics, outcomes, and incidences. Am. J. Gastroenterol. Mar 2 [Epub ahead of print] (2010).
Chang Y, Golkar L. The use of naltrexone in the management of severe generalized pruritus in biliary atresia: report of a case. Pediatr. Dermatol. 25: 403-404 (2008).
Chantarangsu S, Mushiroda T, Mahasirimongkol S, Kiertiburanakul S, Sungkanuparph S, Manosuthi W, Tantisiriwat W, Charoenyingwattana A, Sura T, Chantratita W, Nakamura Y. HLA-B*3505 allele is a strong predictor for nevirapine-induced skin adverse drug reactions in HIV-infected Thai patients. Pharmacogenet. Genomics 19: 139-146 (2009).
Chao M, Jiawei X, Guoming W, Jianbin L, Wanxia L, Driedger A, Shuyao Z, Qin Z. Radioiodine treatment for pediatric hyperthyroid Grave's disease. Eur. J. Pediatr. 168: 1165-1169 (2009).
Chao M, Jiawei X, Xia H, Guoming W, Yangang W, Xufu W, Shuyao Z. Thyroxine alone or thyroxine plus triiodothyronine replacement therapy for hypothyroidism. Nucl. Med. Commun. 30: 586-593 (2009).
Chapman RW. The management of primary sclerosing cholangitis. Curr. Gastroenterol. Rep. 5: 9-17 (2003).
Chapman RW. Primary sclerosing cholangitis: what is the role of ursodeoxycholic acid in therapy for PSC? Nat. Rev. Gastroenterol. Hepatol. 7: 74-75 (2010). *
Chapman RW. High-dose ursodeoxycholic acid in the treatment of primary sclerosing cholangitis: throwing the urso out with the bathwater? Hepatology 50: 671- 673 (2009). *
Charach G, Grosskopf I, Rotmensch HH, Kitzis I, Weintraub M. Bezafibrates cause moderate, reversible impairment in renal function in patients without prior renal disease. Nephron. Clin. Pract. 100: c120-c125 (2005).
Charach G, Grosskopf I, Weintraub M. Development of Crohn's disease in a patient with multiple sclerosis treated with copaxone. Digestion 77: 198-200 (2008). *
Charakida A, Mouser PE, Chu AC. Safety and side effects of the acne drug, oral isotretinoin. Expert Opin. Drug Saf. 3: 119-129 (2004). *
Charatcharoenwitthaya P, Levy C, Angulo P, Keach J, Jorgensen R, Lindor KD. Open-label pilot study of folic acid in patients with nonalcoholic steatohepatitis. Liver Int. 27: 220-226 (2007). *
Charli-Joseph Y, Cruz-Fuentes C, Orozco-Topete R. Incidence of adverse cutaneous drug reactions in a Mexican sample: an exploratory study on their association to tumour necrosis factor alpha TNF2 allele. J. Eur. Acad. Dermatol. Venereol. 23: 788-792 (2009). *
Charpignon C, Beau P. Methotrexate as single therapy in Crohn's disease: is its long-term efficacy limited? Gastroenterol. Clin. Biol. 32: 153-157 (2008). *
Chatfield SM, Brand C, Ebeling PR, Russell DM. Vitamin D deficiency in general medical inpatients in summer and winter. Intern. Med. J. 37: 377-382 (2007). *
Chauveau E, Terrier F, Casassus-Buihle D, Moncoucy X, Oddes B. Macrophage activation syndrome after treatment with infliximab for fistulated Crohn's disease. Presse. Med. 34: 583-584 (2005).
Chebli JM, Gaburri PD, De Souza AF, Pinto AL, Chebli LA, Felga GE, Forn CG, Pimentel CF. Long-term results with azathioprine therapy in patients with corticosteroid-dependent Crohn's disease: open-label prospective study. J. Gastroenterol. Hepatol. 22: 268-274 (2007). *
Chebli LA, Felga GG, Miranda Chaves LD, Pimentel FF, Guerra DM, Gaburri PD, Zanini A, Chebli JM. Early onset steroid-dependent ulcerative colitis is a predictor of azathioprine response: a longitudinal 12-month follow-up study. Med. Sci. Monit. 16: PI1-PI6 (2010).
Chen CC, Su MY, Tung SY, Chang FY, Wong JM, Geraint M. Evaluation of polyethylene glycol plus electrolytes in the treatment of severe constipation and faecal impaction in adults. Curr. Med. Res. Opin. 21: 1595-1602 (2005).
Chen DY, Chou SJ, Hsieh TY, Chen YH, Chen HH, Hsieh CW, Lan JL. Randomized, double-blind, placebo-controlled, comparative study of human anti-TNF antibody adalimumab in combination with methotrexate and methotrexate alone in Taiwanese patients with active rheumatoid arthritis. J. Formos. Med. Assoc. 108: 310-319 (2009). *
Chen HL, Su HJ, Wang YJ, Guo YL, Liao PC, Lee CC. Interactive effects between CYP1A1 genotypes and environmental polychlorinated dibenzo-p-dioxins and dibenzofurans exposures on liver function profile. J. Toxicol. Environ. Health A. 69: 269-281 (2006).
Chen J, Giovannucci EL, Hunter DJ. MTHFR polymorphism, methyl-replete diets and the risk of colorectal carcinoma and adenoma among U.S. men and women: an example of gene-environment interactions in colorectal tumorigenesis. J. Nutr. 129: 560S-564S (1999). *
Chen LJ, Nightingale G, Baer MR. Mercaptopurine-induced fever: hypersensitivity reaction in a patient with acute lymphoblastic leukemia. Pharmacotherapy 30: 113 (2010).
Chen M, Xia B, Chen B, Guo Q, Li J, Ye M, Hu Z. N-acetyltransferase 2 slow acetylator genotype associated with adverse effects of sulphasalazine in the treatment of inflammatory bowel disease. Can. J. Gastroenterol. 21: 155-158 (2007). *
Chen QK, Yuan SZ, Wen ZF, Zhong YQ, Li CJ, Wu HS, Mai CR, Xie PY, Lu YM, Yu ZL. Characteristics and therapeutic efficacy of sulfasalazine in patients with mildly and moderately active ulcerative colitis. World J. Gastroenterol. 11: 2462-2466 (2005). *
Chen W, Liu J, Gluud C. Bile acids for viral hepatitis. Cochrane Database Syst. Rev. 4: CD003181 (2007). *
Chen WD, Gluud C. Glucocorticosteroids for primary sclerosing cholangitis. Cochrane Database Syst. Rev. 3: CD004036 (2004). *
Chen WY, Chang WL, Tsai YC, Cheng HC, Lu CC, Sheu BS. Double-dosed pantoprazole accelerates the sustained symptomatic response in overweight and obese patients with reflux esophagitis in Los Angeles grades A and B. Am. J. Gastroenterol. Nov 10 [Epub ahead of print] (2009). *
Cheng L, You Q, Yin H, Holt M, Franklin C, Ju C. Effect of polyI:C cotreatment on halothane-induced liver injury in mice. Hepatology 49: 215-226 (2009). *
Cheng SH, Kwan P, Ng HK, Ng MH. New testing approach in HLA genotyping helps overcome barriers in effective clinical practice. Clin. Chem. 55: 1568-1572 (2009). *
Cheng Y, Desreumaux P. 5-Aminosalicylic acid is an attractive candidate agent for chemoprevention of colon cancer in patients with inflammatory bowel disease. World J. Gastroenterol. 11: 309-314 (2005). *
Cheon JH, Kim JH, Kim BY, Kim SW, Hong SY, Eun CS, Hong SS, Byeon JS, Kim TI, Han DS, Yang SK, Lee KR, Kim WH. Allele frequency of thiopurine methyltransferase and inosine triphosphate pyrophosphatase gene polymorphisms in Korean patients with inflammatory bowel diseases. Hepatogastroenterology 56: 421-423 (2009).
Chermesh I, Tamir A, Lachter J, Eliakim R. Intravenous cyclosporine for inflammatory bowel disease - safe and effective. Hepatogastroenterology 54: 2003-2006 (2007).
Chernoff AE, Granowitz EV, Shapiro L, Vannier E, Lonnemann G, Angel JB, Kennedy JS, Rabson AR, Wolff SM, Dinarello CA. A randomized, controlled trial of IL-10 in humans. Inhibition of inflammatory cytokine production and immune responses. J. Immunol. 154: 5492-5499 (1995).
Cheung J, Zeman M, van Zanten SV, Tandon P. Systematic review: secondary prevention with band ligation, pharmacotherapy or combination therapy after bleeding from esophageal varices. Aliment. Pharmacol. Ther. 30: 577-588 (2009). *
Chey WD, Chey WY, Heath AT, Dukes GE, Carter EG, Northcutt A, Ameen VZ. Long-term safety and efficacy of alosetron in women with severe diarrhea-predominant irritable bowel syndrome. Am. J. Gastroenterol. 99: 2195-2203 (2004). *
Chia FL, Leong KP. Severe cutaneous adverse reactions to drugs. Curr. Opin. Allergy Clin. Immunol. 7: 304-309 (2007).
Ching DW, McClintock A, Beswick F. Successful treatment with low-dose thalidomide in a patient with both Behcet's disease and complex regional pain syndrome type I: case report. J. Clin. Rheumatol. 9: 96-98 (2003).
Chinuck RS, Fortnum H, Baldwin DR. Appetite stimulants in cystic fibrosis: a systematic review. J. Hum. Nutr. Diet. 20: 526-537 (2007). *
Chiron D, Pellat-Deceunynck C, Maillasson M, Bataille R, Jego G. Phosphorothioate-modified TLR9 ligands protect cancer cells against TRAIL-induced apoptosis. J. Immunol. 183: 4371-4377 (2009).
Chitale S, Moots R. Abatacept: the first T lymphocyte co-stimulation modulator, for the treatment of rheumatoid arthritis. Expert Opin. Biol. Ther. 8: 115-122 (2008).
Chittasobhaktra T, Wannanukul W, Wattanakrai P, Pramoolsinsap C, Sohonslitdsuk A, Nitiyanant P. Fever, skin rash, jaundice and lymphadenopathy after trichloroethylene exposure: a case report. J. Med. Assoc. Thai. 80 Suppl. 1: S144-S148 (1997).
Chitturi S, Farrell GC. Drug-induced liver disease. Curr. Treat. Options Gastroenterol. 3: 457-462 (2000).
Chitturi S, George J. Hepatotoxicity of commonly used drugs: nonsteroidal anti-inflammatory drugs, antihypertensives, antidiabetic agents, anticonvulsants, lipid-lowering agents, psychotropic drugs. Semin. Liver Dis. 22: 169-183 (2002).
Chiu CC, Su KP, Cheng TC, Liu HC, Chang CJ, Dewey ME, Stewart R, Huang SY. The effects of omega-3 fatty acids monotherapy in Alzheimer's disease and mild cognitive impairment: a preliminary randomized double-blind placebo-controlled study. Prog. Neuropsychopharmacol. Biol. Psychiatry 32: 1538-1544 (2008).
Chmurova N, Svecova D. Pemphigus vulgaris: a 11-year review. Bratisl. Lek. Listy. 110: 500-503 (2009).
Cho SK, Oh IH, Park CK, Bae SC, Sung YK. Etanercept induced organizing pneumonia in a patient with rheumatoid arthritis. Rheumatol. Int. Jan 9 [Epub ahead of print] (2010). *
Choi GY, Yang HW, Cho SH, Kang DW, Go H, Lee WC, Lee YJ, Jung SH, Kim AN, Cha SW. Acute drug-induced hepatitis caused by albendazole. J. Korean Med. Sci. 23: 903-905 (2008).
Choi KD, Song HJ, Kim JS, Jung HC, Song IS. Efficacy and safety of treatment with infliximab in Crohn's disease - the experience of single center in Korea. Korean J. Gastroenterol. 46: 48-55 (2005).
Chopra S, Suri V, Bagga R, Thami MR, Sharma A, Bambery P. Autoimmune inflammatory myopathy in pregnancy. Medscape J. Med. 10: 17 (2008). *
Chow PK, Tai BC, Tan CK, Machin D, Win KM, Johnson PJ, Soo KC; Asian-Pacific Hepatocellular Carcinoma Trials Group. High-dose tamoxifen in the treatment of inoperable hepatocellular carcinoma: a multicenter randomized controlled trial. Hepatology 36: 1221-1226 (2002). *
Choy EH, Smith CM, Farewell V, Walker DJ, Hassell A, Chau L, Scott DL; CARDERA (Combination Anti-Rheumatic Drugs in Early Rheumatoid Arhritis) Trial Group. Factorial randomised controlled trial of glucocorticoids and combination disease modifying drugs in early rheumatoid arthritis. Ann. Rheum. Dis. 67: 656-663 (2008).
Christen U, Holdener M, Hintermann E. Animal models for autoimmune hepatitis. Autoimmun. Rev. 6: 306-311 (2007).
Christiansen SR, Broniscer A, Panetta JC, Stewart CF. Pharmacokinetics of erlotinib for the treatment of high-grade glioma in a pediatric patient with cystic fibrosis: case report and review of the literature. Pharmacotherapy 29: 858-66 (2009).
Christman AK, Fermo JD, Markowitz JS. Atomoxetine, a novel treatment for attention-deficit-hyperactivity disorder. Pharmacotherapy 24: 1020-1036 (2004).
Chroni E, Monastirli A, Tsambaos D. Neuromuscular adverse effects associated with systemic retinoid dermatotherapy: monitoring and treatment algorithm for clinicians. Drug Saf. 33: 25-34 (2010).
Chrubasik S, Chrubasik C, Kunzel O, Black A. Patient-perceived benefit during one year of treatment with Doloteffin. Phytomedicine 14: 371-376 (2007).
Chuchalin A, Csiszer E, Gyurkovics K, Bartnicka MT, Sands D, Kapranov N, Varoli G, Monici Preti PA, Mazurek H. A formulation of aerosolized tobramycin (Bramitob((R))) in the treatment of patients with cystic fibrosis and Pseudomonas aeruginosa infection: a double-blind, placebo-controlled, multicenter study. Paediatr. Drugs 9 Suppl. 1: 21-31 (2007).
Chung WH, Hung SI, Chen YT. Genetic predisposition of life-threatening antiepileptic-induced skin reactions. Expert Opin. Drug Saf. 9: 15-21 (2010).
Chung WH, Hung SI, Chen YT. Human leukocyte antigens and drug hypersensitivity. Curr. Opin. Allergy Clin. Immunol. 7: 317-323 (2007).
Chung WH, Hung SI, Hong HS, Hsih MS, Yang LC, Ho HC, Wu JY, Chen YT. Medical genetics: a marker for Stevens-Johnson syndrome. Nature 428: 486 (2004). *
Church MW, Catherine Jen KL, Stafferton T, Hotra JW, Adams BR. Reduced auditory acuity in rat pups from excess and deficient omega-3 fatty acid consumption by the mother. Neurotoxicol. Teratol. 29: 203-210 (2007).
Church MW, Jen KL, Dowhan LM, Adams BR, Hotra JW. Excess and deficient omega-3 fatty acid during pregnancy and lactation cause impaired neural transmission in rat pups. Neurotoxicol. Teratol. 30: 107-117 (2008). *
Church MW, Jen KL, Jackson DA, Adams BR, Hotra JW. Abnormal neurological responses in young adult offspring caused by excess omega-3 fatty acid (fish oil) consumption by the mother during pregnancy and lactation. Neurotoxicol. Teratol. 31: 26-33 (2009).
Cianchini G, Corona R, Frezzolini A, Ruffelli M, Didona B, Puddu P. Treatment of severe pemphigus with rituximab: report of 12 cases and a review of the literature. Arch. Dermatol. 143: 1033-1038 (2007). *
Cieslik P, Hrycek A, Klucinski P. Vasculopathy and vasculitis in systemic lupus erythematosus. Pol. Arch. Med. Wewn. 118: 57-63 (2008).
Cimaz R, Cazalis MA, Raynaud C, Gerloni V, Zulian F, Biggioggero M, Martini G, Pontikaki I, Fantini F, Mougin B, Miossec P. IL-1 and TNF gene polymorphisms in patients with juvenile idiopathic arthritis treated with TNF inhibitors. Ann. Rheum. Dis. 66: 900-904 (2007). *
Citores MJ, Castejon R, Villarreal M, Rosado S, Garcia-Marco JA, Vargas JA. CD154 expression triggered by purine analogues in vitro. Correlation with treatment response and autoimmune events in chronic lymphocytic leukemia. Exp. Hematol. Dec 18 [Epub ahead of print] (2009). *
Clare DF, Alexander FC, Mike S, Dan G, Allan F, Lisa W, Peter HJ. Accelerated infliximab infusions are safe and well tolerated in patients with inflammatory bowel disease. Eur. J. Gastroenterol. Hepatol. 21: 71-75 (2009).
Clark DW. Genetically determined variability in acetylation and oxidation. Therapeutic implications. Drugs 29: 342-375 (1985).
Clark DW, Harrison-Woolrych M. The role of the New Zealand Intensive Medicines Monitoring Programme in identification of previously unrecognised signals of adverse drug reactions. Curr. Drug Saf. 1: 169-178 (2006).
Clark SF. Iron deficiency anemia: diagnosis and management. Curr. Opin. Gastroenterol. 25: 122-128 (2009).
Clarke MW, Burnett JR, Croft KD. Vitamin E in human health and disease. Crit. Rev. Clin. Lab. Sci. 45: 417-450 (2008).
Clayton TA, Lindon JC, Cloarec O, Antti H, Charuel C, Hanton G, Provost JP, Le Net JL, Baker D, Walley RJ, Everett JR, Nicholson JK. Pharmaco-metabonomic phenotyping and personalized drug treatment. Nature 440: 1073-1077 (2006). *
Cleland LG, James MJ, Keen H, Danda D, Caughey G, Proudman SM. Fish oil - an example of an anti-inflammatory food. Asia Pac. J. Clin. Nutr. 14: S66-S71 (2005).
Cleland LG, James MJ, Proudman SM. Food inflammation and the anti-inflammatory aspects of food. Asia Pac. J. Clin. Nutr. 13: S26 (2004).
Coban S, Ceydilek B, Ekiz F, Erden R, Soykan I. Levofloxacin-induced acute fulminant hepatic failure in a patient with chronic hepatitis B infection. Ann. Pharmacother. 39: 1737-1740 (2005).
Coelho-Prabhu N, Baron TH. Assessment of need for repeat ERCP during biliary stent removal after clinical resolution of postcholecystectomy bile leak. Am. J. Gastroenterol. 105: 100-105 (2010). *
Cohen G, Courvoisier N, Cohen JD, Zaltni S, Sany J, Combe B. The efficiency of switching from infliximab to etanercept and vice-versa in patients with rheumatoid arthritis. Clin. Exp. Rheumatol. 23: 795-800 (2005).
Cohen RD. Evolving medical therapies for ulcerative colitis. Curr. Gastroenterol. Rep. 4: 497-505 (2002).
Cohen RD. Efficacy and safety of repeated infliximab infusions for Crohn's disease: 1-year clinical experience. Inflamm. Bowel Dis. 7 Suppl. 1: S17-S22 (2001). *
Cohen RD, Tsang JF, Hanauer SB. Infliximab in Crohn's disease: first anniversary clinical experience. Am. J. Gastroenterol. 95: 3469-3477 (2000). *
Cohen SB, Emery P, Greenwald MW, Dougados M, Furie RA, Genovese MC, Keystone EC, Loveless JE, Burmester GR, Cravets MW, Hessey EW, Shaw T, Totoritis MC. Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks. Arthritis Rheum. 54: 2793-2806 (2006). *
Cohen Z, Senagore AJ, Dayton MT, Koruda MJ, Beck DE, Wolff BG, Fleshner PR, Thirlby RC, Ludwig KA, Larach SW, Weiss EG, Bauer JJ, Holmdahl L. Prevention of postoperative abdominal adhesions by a novel, glycerol/sodium hyaluronate/carboxymethylcellulose-based bioresorbable membrane: a prospective, randomized, evaluator-blinded multicenter study. Dis. Colon Rectum 48: 1130-1139 (2005). *
Cohen-Cymberknoh M, Blau H, Shoseyov D, Mei-Zahav M, Efrati O, Armoni S, Kerem E. Intravenous monthly pulse methylprednisolone treatment for ABPA in patients with cystic fibrosis. J. Cyst. Fibros. 8: 253-257 (2009).
Cohran VC, Heubi JE. Treatment of pediatric cholestatic liver disease. Curr. Treat. Options Gastroenterol. 6: 403-415 (2003).
Collaco JM, Vanscoy L, Bremer L, McDougal K, Blackman SM, Bowers A, Naughton K, Jennings J, Ellen J, Cutting GR. Interactions between secondhand smoke and genes that affect cystic fibrosis lung disease. JAMA 299: 417-424 (2008). *
Collamer AN, Guerrero KT, Henning JS, Battafarano DF. Psoriatic skin lesions induced by tumor necrosis factor antagonist therapy: a literature review and potential mechanisms of action. Arthritis Rheum. 59: 996-1001 (2008). *
Collazo MH, González JR, Torres EA. Etanercept therapy for psoriasis in a patient with concomitant hepatitis C and liver transplant. P. R. Health Sci. J. 27: 346-347 (2008).
Colle I, Van Steenkiste C, Geerts A, Van Vlierberghe H. Hepatopulmonary syndrome and portopulmonary hypertension: what's new? Acta Gastroenterol. Belg. 70: 203-209 (2007).
Colli MV, Amaro TA, Pinto AL, Gaburri PD, Chebli JM. Azathioprine toxicity in Crohn's disease: incidence, approach and course. Rev. Assoc. Med. Bras. 54: 415-421 (2008).
Collin B, Vani A, Ogboli M, Moss C. Methotrexate treatment in 13 children with severe plaque psoriasis. Clin. Exp. Dermatol. 34: 295-298 (2009).
Colombel JF, Loftus EV Jr, Tremaine WJ, Egan LJ, Harmsen WS, Schleck CD, Zinsmeister AR, Sandborn WJ. The safety profile of infliximab in patients with Crohn's disease: the Mayo clinic experience in 500 patients. Gastroenterology 126: 19-31 (2004). *
Colombel JF, Rutgeerts P, Malchow H, Jacyna M, Nielsen OH, Rask-Madsen J, Van Deventer S, Ferguson A, Desreumaux P, Forbes A, Geboes K, Melani L, Cohard M. Interleukin 10 (Tenovil) in the prevention of postoperative recurrence of Crohn's disease. Gut 49: 42-46 (2001). *
Colombel JF, Sandborn WJ, Panaccione R, Robinson AM, Lau W, Li J, Cardoso AT. Adalimumab safety in global clinical trials of patients with Crohn's disease. Inflamm. Bowel Dis. 15: 1308-1319 (2009). *
Colombel JF, Sandborn WJ, Rutgeerts P, Enns R, Hanauer SB, Panaccione R, Schreiber S, Byczkowski D, Li J, Kent JD, Pollack PF. Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial. Gastroenterology 132: 52-65 (2007). *
Colombo C. Liver disease in cystic fibrosis. Falk Symposium 156. XIII Falk Liver Week (Part II). GENETICS IN LIVER DISEASES, Freiburg (Germany), October 8-9, 2006, p. 31-33 (2006). *
Colombo C, Fredella C, Russo MC, Faelli N, Motta V, Valmarana L, Longo L, D'Orazio C. Efficacy and tolerability of Creon for Children in infants and toddlers with pancreatic exocrine insufficiency caused by cystic fibrosis: an open-label, single-arm, multicenter study. Pancreas 38: 693-699 (2009).
Colquitt JL, Kirby J, Green C, Cooper K, Trompeter RS. The clinical effectiveness and cost-effectiveness of treatments for children with idiopathic steroid-resistant nephrotic syndrome: a systematic review. Health Technol. Assess. 11: 1-112 (2007). *
Colville-Nash PR, Gilroy DW. Potential adverse effects of cyclooxygenase-2 inhibition: evidence from animal models of inflammation. BioDrugs 15: 1-9 (2001).
Combe B, Codreanu C, Fiocco U, Gaubitz M, Geusens PP, Kvien TK, Pavelka K, Sambrook PN, Smolen JS, Khandker R, Singh A, Wajdula J, Fatenejad S. Efficacy, safety, and patient-reported outcomes of combination etanercept and sulfasalazine versus etanercept alone in patients with rheumatoid arthritis: a double-blind randomized two-year study. Ann. Rheum. Dis. 68: 1146-1152 (2009). *
Combe BG, Codreanu C, Fiocco U, Gaubitz M, Geusens PP, Kvien TK, Pavelka K, Sambrook PN, Smolen J, Wajdula J, Fatenejad S. Etanercept and sulfasalazine, alone and combined, in patients with active rheumatoid arthritis despite receiving sulfasalazine: a double-blind comparison. Ann. Rheum. Dis. 65: 1357-1362 (2006). *
Condino AA, Fidanza S, Hoffenberg EJ. A home infliximab infusion program. J. Pediatr. Gastroenterol. Nutr. 40: 67-69 (2005). *
Connell W, Miller A. Treating inflammatory bowel disease during pregnancy: risks and safety of drug therapy. Drug Saf. 21: 311-323 (1999).
Conseil G, Deeley RG, Cole SP. Polymorphisms of MRP1 (ABCC1) and related ATP-dependent drug transporters. Pharmacogenet. Genomics 15: 523-533 (2005).
Conti F, Ceccarelli F, Marocchi E, Magrini L, Romana Spinelli F, Spadaro A, Scrivo R, Valesini G. Switching tumour necrosis factor alpha antagonists in patients with ankylosing spondylitis and psoriatic arthritis: an observational study over a 5-year period. Ann. Rheum. Dis. 66: 1393-1397 (2007). *
Conway S, Morton A, Wolfe S. Enteral tube feeding for cystic fibrosis. Cochrane Database Syst. Rev. 2: CD001198 (2008). *
Conwell LS, Chang AB. Bisphosphonates for osteoporosis in people with cystic fibrosis. Cochrane Database Syst. Rev. 4: CD002010 (2009).
Cook PF, Emiliozzi S, El-Hajj D, McCabe MM. Telephone nurse counseling for medication adherence in ulcerative colitis: a preliminary study. Patient Educ. Couns. Jan 13 [Epub ahead of print] (2010).
Cooper BW, Cho TM, Thompson PM, Wallace AD. Phthalate induction of CYP3A4 is dependent on glucocorticoid regulation of PXR expression. Toxicol. Sci. 103: 268-277 (2008). *
Corinaldesi R, Stanghellini V, Cremon C, Gargano L, Cogliandro RF, DE Giorgio R, Bartesaghi G, Canovi B, Barbara G. Effect of mesalazine on mucosal immune biomarkers in irritable bowel syndrome: a randomized controlled proof of concept study. Aliment. Pharmacol. Ther. 30: 245-252 (2009). *
Cornish JA, Tan EK, Teare J, Teoh TG, Rai R, Clark SK, Tekkis PP. A meta-analysis on the influence of inflammatory bowel disease on pregnancy. Gut 56: 830-837 (2007). *
Coronel R, Wilms-Schopman FJ, Den Ruijter HM, Belterman CN, Schumacher CA, Opthof T, Hovenier R, Lemmens AG, Terpstra AH, Katan MB, Zock P. Dietary n-3 fatty acids promote arrhythmias during acute regional myocardial ischemia in isolated pig hearts. Cardiovasc. Res. 73: 386-394 (2007). *
Correa GH, Paredes SN. Serum liver tests in patients treated with methotrexate: a retrospective analysis. Rev. Med. Chil. 135: 1002-1008 (2007).
Corrigan G, Stevens PE. Review article: interstitial nephritis associated with the use of mesalazine in inflammatory bowel disease. Aliment. Pharmacol. Ther. 14: 1-6 (2000). *
Corzo D, Yunis JJ, Salazar M, Lieberman JA, Howard A, Awdeh Z, Alper CA, Yunis EJ. The major histocompatibility complex region marked by HSP70-1 and HSP70-2 variants is associated with clozapine-induced agranulocytosis in two different ethnic groups. Blood 86: 3835-3840 (1995). *
Cosmetic Ingredient Review Expert Panel. Final safety assessment of coal tar as used in cosmetics. Int. J. Toxicol. 27 Suppl. 2: 1-24 (2008).
Costa V, Foti D, Paonessa F, Chiefari E, Palaia L, Brunetti G, Gulletta E, Fusco A, Brunetti A. The insulin receptor: a new anticancer target for peroxisome proliferator-activated receptor-gamma (PPARgamma) and thiazolidinedione-PPARgamma agonists. Endocr. Relat. Cancer 15: 325-335 (2008).
Costanzo A, Talamonti M, Botti E, Spallone G, Papoutsaki M, Chimenti S. Efficacy of efalizumab in psoriasis patients previously treated with tumour necrosis factor blockers. Dermatology 219: 48-53 (2009).
Costanzo A, Talamonti M, Spallone G, Botti E, Chimenti MS, Papoutsaki M, Chimenti S. Efficacy of short-term cyclosporine treatment to control psoriasis-related events during efalizumab therapy. Dermatology 218: 146-150 (2009).
Costenbader KH, Liang MH, Chibnik LB, Aizer J, Kwon H, Gall V, Karlson EW. A pravastatin dose-escalation study in systemic lupus erythematosus. Rheumatol. Int. 27: 1071-1077 (2007). *
Courtney MG, Nunes DP, Bergin CF, O'Driscoll M, Trimble V, Keeling PW, Weir DG. Randomised comparison of olsalazine and mesalazine in prevention of relapses in ulcerative colitis. Lancet 339: 1279-1281 (1992).
Couvert P, Giral P, Dejager S, Gu J, Huby T, Chapman MJ, Bruckert E, Carrie A. Association between a frequent allele of the gene encoding OATP1B1 and enhanced LDL-lowering response to fluvastatin therapy. Pharmacogenomics 9: 1217-1227 (2008).
Cover TL, Blaser MJ. Helicobacter pylori in health and disease. Gastroenterology 136: 1863-1973 (2009). *
Cox LS. How safe are the biologicals in treating asthma and rhinitis? Allergy Asthma Clin. Immunol. 5: 4 (2009). *
Cozzolino M, Fallabrino G, Pasho S, Olivi L, Ciceri P, Volpi E, Gallieni M, Brancaccio D. Importance of vitamin D receptor activation in clinical practice. Contrib. Nephrol. 163: 213-218 (2009).
Cozzolino M, Gallieni M, Brancaccio D, Arcidiacono T, Bianchi G, Vezzoli G. Vitamin D retains an important role in the pathogenesis and management of secondary hyperparathyroidism in chronic v. J. Nephrol. 19: 566-577 (2006).
Cozzolino M, Olivi L, Voli E, Ciceri P, Brancaccio D. Prevention and treatment of secondary hyperparathyroidism in non-dialyzed patients with stage 3-5 chronic kidney diease. G. Ital. Nefrol. 26: S30-S35 (2009).
Crabtree BL. Review of naltrexone, a long-acting opiate antagonist. Clin. Pharm. 3: 273-280 (1984).
Craig D, Robins G, Howdle PD. Advances in celiac disease. Curr. Opin. Gastroenterol. 23: 142-148 (2007).
Crandall W, Hyams J, Kugathasan S, Griffiths A, Zrubek J, Olson A, Liu G, Heuschkel R, Markowitz J, Cohen S, Winter H, Veereman-Wauters G, Ferry G, Baldassano RN. Infliximab therapy in children with concurrent perianal Crohn disease: observations from REACH. J. Pediatr. Gastroenterol. Nutr. 49: 183-190 (2009).
Craxi A. PEG IFN alfa-2a vs. alfa-2b: and the winner is ...? J. Hepatol. 52: 133-135 (2010). *
Criado PR, de Oliveira Ramos R, Vasconcellos C, Jardim Criado RF, Valente NY. Two case reports of cutaneous adverse reactions following hepatitis B vaccine: lichen planus and granuloma annulare. J. Eur. Acad. Dermatol. Venereol. 18: 603-606 (2004).
Crinnion WJ. Environmental medicine, part 3: long-term effects of chronic low-dose mercury exposure. Altern. Med. Rev. 5: 209-223 (2000). *
Crinnion WJ. Environmental medicine, part 2: health effects of and protection from ubiquitous airborne solvent exposure. Altern. Med. Rev. 5: 133-143 (2000). *
Crinnion WJ. Environmental medicine, part 4: pesticides - biologically persistent and ubiquitous toxins. Altern. Med. Rev. 5: 432-447 (2000). *
Crisafulli C, Bruscoli S, Esposito E, Mazzon E, Di Paola R, Genovese T, Bramanti P, Migliorati G, Cuzzocrea S. PPAR-alpha contributes to the anti-inflammatory activity of 17beta-estradiol. J. Pharmacol. Exp. Ther. 331: 796-807 (2009). *
Crombie DE, Turer M, Zuasti BB, Wood B, McNaughton D, Nandakumar KS, Holmdahl R, Van Damme MP, Rowley MJ. Destructive effects of murine arthritogenic antibodies to type II collagen on cartilage explants in vitro. Arthritis Res. Ther. 7: R927-R937 (2005). *
Crosbie D, Black C, McIntyre L, Royle P, Thomas S. Dehydroepiandrosterone for systemic lupus erythematosus. Cochrane Database Syst. Rev. 4: CD005114 (2007). *
Csillag C, Borup R, Olsen J, Nielsen FC, Nielsen OH. Treatment response and colonic gene expression in patients with Crohn's disease. Scand. J. Gastroenterol. 42: 834-840 (2007). *
Cuarterolo M, Ciocca M, Velasco CC, Ramonet M, Gonzalez T, Lopez S, Garsd A, Alvarez F. Follow-up of children with autoimmune hepatitis treated with cyclosporine. J. Pediatr. Gastroenterol. Nutr. 43: 635-639 (2006). *
Cui Y, Xiao Z, Shuxia W, Zhenjun Z, Hengguo Z, Liangyi F, Weicheng G, Li L, Guangfeng Z, Yunzhen S, Guangfu D. Computed tomography guided intra-articular injection of etanercept in the sacroiliac joint is an effective mode of treatment of ankylosing spondylitis. Scand. J. Rheumatol. Jan 28 [Epub ahead of print] (2010). *
Cuoco L, Salvagnini M. Small intestine bacterial overgrowth in irritable bowel syndrome: a retrospective study with rifaximin. Minerva Gastroenterol. Dietol. 52: 89-95 (2006).
Curtis JR, Kramer JM, Martin C, Saag KG, Patkar N, Shatin D, Burgess M, Xie A, Braun MM. Heart failure among younger rheumatoid arthritis and Crohn's patients exposed to TNF-alpha antagonists. Rheumatology (Oxford) 46: 1688-1693 (2007). *
Cusack C, Buckley C. Etanercept: effective in the management of hidradenitis suppurativa. Br. J. Dermatol. 154: 726-729 (2006). *
Cusatis G, Gregorc V, Li J, Spreafico A, Ingersoll RG, Verweij J, Ludovini V, Villa E, Hidalgo M, Sparreboom A, Baker SD. Pharmacogenetics of ABCG2 and adverse reactions to gefitinib. J. Natl. Cancer Inst. 98: 1739-1742 (2006). *
Cush JJ. Biological drug use: US perspectives on indications and monitoring. Ann. Rheum. Dis. 64 Suppl. 4: iv18-iv23 (2005). *
Cush JJ, Yazici Y. Laboratory monitoring of biologic therapies. Clin. Exp. Rheumatol. 23: S90-S92 (2005).
Cutolo M, Straub RH. Circadian rhythms in arthritis: hormonal effects on the immune/inflammatory reaction. Autoimmun. Rev. 7: 223-238 (2008).
Cvetkovic RS, Scott LJ. Adalimumab: a review of its use in adult patients with rheumatoid arthritis. BioDrugs 20: 293-311 (2006).
Cvetkovic RS, Wellington K. Valganciclovir: a review of its use in the management of CMV infection and disease in immunocompromised patients. Drugs 65: 859-878 (2005).
Cysneiros RM, Terra VC, Machado HR, Arida RM, Schwartzman JS, Cavalheiro EA, Scorza FA. May the best friend be an enemy if not recognized early: possible role of omega-3 against cardiovascular abnormalities due antipsychotics in the treatment of autism. Arq. Neuropsiquiatr. 67: 922-926 (2009).
Czaja AJ. Autoimmune hepatitis - approach to diagnosis. MedGenMed. 8: 55 (2006). *
Czaja AJ. Autoimmune liver disease. Curr. Opin. Gastroenterol. 23: 255-262 (2007).
Czaja AJ. Clinical features, differential diagnosis and treatment of autoimmune hepatitis in the elderly. Drugs Aging 25: 219-239 (2008).
Czaja AJ, Carpenter HA. Empiric therapy of autoimmune hepatitis with mycophenolate mofetil: comparison with conventional treatment for refractory disease. J. Clin. Gastroenterol. 39: 819-825 (2005).
D’Haens G. Pratical use of steroids in IBD. Falk Symposium 146: GUT-LIVER INTERACTIONS: BASIC AND CLINICAL CONCEPTS, Innsbruck (Austria), March 11-12, 2005, p. 30 (2005). *
D'Haens G, Baert F, van Assche G, Caenepeel P, Vergauwe P, Tuynman H, De Vos M, van Deventer S, Stitt L, Donner A, Vermeire S, Van de Mierop FJ, Coche JC, van der Woude J, Ochsenkuhn T, van Bodegraven AA, Van Hootegem PP, Lambrecht GL, Mana F, Rutgeerts P. Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn's disease: an open randomised trial. Lancet 371: 660-667 (2008). *
D'Haens GR. Infliximab (Remicade), a new biological treatment for Crohn's disease. Ital. J. Gastroenterol. Hepatol. 31: 519-520 (1999).
da Silva AP, Ellen RP, Sorensen ES, Goldberg HA, Zohar R, Sodek J. Osteopontin attenuation of dextran sulfate sodium-induced colitis in mice. Lab. Invest. 89: 1169-1181 (2009). *
Dadamessi I, Leduc I, Duche A, Tiev K, Barbieux D, Sevestre H, Andrejak M, Ducroix JP. Autoimmune hepatitis and lupus syndrome associated with minocycline. Rev. Med. Interne. 20: 930-933 (1999).
Dai W, Pan H, Kwok O, Dubey JP. Human indoleamine 2,3-dioxygenase inhibits Toxoplasma gondii growth in fibroblast cells. J. Interferon Res. 14: 313-317 (1994).
Dalaker M, Bonesronning JH. Long-term maintenance treatment of moderate-to-severe plaque psoriasis with infliximab in combination with methotrexate or azathioprine in a retrospective cohort. J. Eur. Acad. Dermatol. Venereol. 23: 277-282 (2009). *
Dalbeth N, Yeoman S, Dockerty JL, Highton J, Robinson E, Tan PL, Herman D, McQueen FM. A randomised placebo controlled trial of delipidated, deglycolipidated Mycobacterium vaccae as immunotherapy for psoriatic arthritis. Ann. Rheum. Dis. 63: 718-722 (2004). *
Dale DC, Bolyard AA, Schwinzer BG, Pracht G, Bonilla MA, Boxer L, Freedman MH, Donadieu J, Kannourakis G, Alter BP, Cham BP, Winkelstein J, Kinsey SE, Zeidler C, Welte K. The Severe Chronic Neutropenia International Registry: 10-year follow-up report. Support Cancer Ther. 3: 220-231 (2006).
Dalvi V, Gonzalez EB, Lovett L. Lymphocytic interstitial pneumonitis (LIP) in Sjogren's syndrome: a case report and a review of the literature. Clin. Rheumatol. 26: 1339-1343 (2007).
Damore M, Minenna G, D'Amore S. Adverse events in rheumatoid arthritis patient with etanercept therapy: the appearance of osteomalacia. Recenti Prog. Med. 96: 552-555 (2005).
Danica J, Irena H, Davor R, Mate S, Marijana C, Boris V, Igor F. Vanishing bile duct syndrome associated with azithromycin in a 62-year-old man. Basic Clin. Pharmacol. Toxicol. Nov 9 [Epub ahead of print] (2009). *
Daniel C, Poiret S, Goudercourt D, Dennin V, Leyer G, Pot B. Selecting lactic acid bacteria for their safety and functionality by use of a mouse colitis model. Appl. Environ. Microbiol. 72: 5799-5805 (2006). *
Daperno M, Sostegni R, Scaglione N, Ercole E, Rigazio C, Rocca R, Pera A. Outcome of a conservative approach in severe ulcerative colitis. Dig. Liver Dis. 36: 21-28 (2004). *
Darabi K, Jaiswal R, Hostetler S, Bechtel M, Zirwas M. Infectious complications in patients with psoriasis and rheumatoid arthritis treated with antitumor necrosis factor agents and methotrexate. J. Drugs Dermatol. 8: 175-178 (2009).
Darlow SJ, Mandal A, Pick B, Thomas T, Mayberry JF, Robinson RJ. The short-term effects of Eudragit-L-coated prednisolone metasulphobenzoate (Predocol) on bone formation and bone mineral density in acute ulcerative colitis. Eur. J. Gastroenterol. Hepatol. 16: 1173-1176 (2004).
Darmawan J, Nasution AR, Chen SL, Haq SA, Zhao D, Zeng Q, Davatchi F. Excellent endpoints from step-down bridge combination therapy of 5 immunosuppressants in NSAID-refractory ankylosing spondylitis: 6 year international study in Asia - WHO-ILAR COPCORD Stage II Treatment of the Autoimmune Diseases. J. Rheumatol. 33: 2484-2492 (2006).
Dary O. Nutritional interpretation of folic acid interventions. Nutr. Rev. 67: 235-244 (2009). *
Das UN. Do polyunsaturated fatty acids behave like an endogenous "polypill"? Med. Hypotheses 70: 430-434 (2008).
Das UN. Essential fatty acids and their metabolites could function as endogenous HMG-CoA reductase and ACE enzyme inhibitors, anti-arrhythmic, anti-hypertensive, anti-atherosclerotic, anti-inflammatory, cytoprotective, and cardioprotective molecules. Lipids Health Dis. 7: 37 (2008). *
Dastmalchi M, Grundtman C, Alexanderson H, Mavragani CP, Einarsdottir H, Barbasso Helmers S, Elvin K, Crow MK, Nennesmo I, Lundberg IE. A high incidence of disease flares in an open pilot study of infliximab in patients with refractory inflammatory myopathies. Ann. Rheum. Dis. 67: 1670-1677 (2008).
Dauden E, Pedraz J, Alvarez-Ruiz S, Garcia-Rio I, Sanchez-Peinado C, Onate MJ, Garcia-Diez A. Therapeutic drug monitoring of mycophenolic acid in patients with psoriasis. Eur. J. Dermatol. Feb 10 [Epub ahead of print] (2010).
Davaine A, Saraux A, Prigent S, Kupfer-Bessaguet I, Roswag D, Plantin P, Schoenlaub P, Talarmin F, Zagnoli A, Misery L. Cutaneous events during treatment of chronic inflammatory joint disorders with anti-tumour necrosis factor alpha: a cross-sectional study. J. Eur. Acad. Dermatol. Venereol. 22: 1471-1477 (2008). *
Davidovici BB, Tuzun Y, Wolf R. Retinoid receptors. Dermatol. Clin. 25: 525-530 (2007).
Davidson ME, Kerepesi LA, Soto A, Chan VT. D-Serine exposure resulted in gene expression changes implicated in neurodegenerative disorders and neuronal dysfunction in male Fischer 344 rats. Arch. Toxicol. 83: 747-762 (2009). *
Davies CJ. Why is the fetal allograft not rejected? J. Anim. Sci. 85: E32-E35 (2007). *
Davies RJ, O'Connor BI, Victor C, Macrae HM, Cohen Z, McLeod RS. A prospective evaluation of sexual function and quality of life after ileal pouch-anal anastomosis. Dis. Colon Rectum 51: 1032-1035 (2008). *
Davis AJ, Kolios G, Alveyn CG, Robertson DA. Antibiotic prophylaxis for ERCP: a comparison of oral ciprofloxacin with intravenous cephazolin in the prophylaxis of high-risk patients. Aliment. Pharmacol. Ther. 12: 207-211 (1998). *
Davis JC Jr, Mease PJ. Insights into the pathology and treatment of spondyloarthritis: from the bench to the clinic. Semin. Arthritis Rheum. 38: 83-100 (2008). *
Davis JC Jr, Van Der Heijde D, Braun J, Dougados M, Cush J, Clegg DO, Kivitz A, Fleischmann R, Inman R, Tsuji W; Enbrel Ankylosing Spondylitis Study Group. Recombinant human tumor necrosis factor receptor (etanercept) for treating ankylosing spondylitis: a randomized, controlled trial. Arthritis Rheum. 48: 3230-3236 (2003). *
de Bievre MA, Vrij AA, Schoon EJ, Dijkstra G, de Jong AE, Oberndorff-Klein Woolthuis AH, Hemker HC, Stockbrugger RW. Randomized, placebo-controlled trial of low molecular weight heparin in active ulcerative colitis. Inflamm. Bowel Dis. 13: 753-758 (2007). *
de Boer NK, van Bodegraven AA, Jharap B, de Graaf P, Mulder CJ. Drug insight: pharmacology and toxicity of thiopurine therapy in patients with IBD. Nat. Clin. Pract. Gastroenterol. Hepatol. 4: 686-694 (2007). *
de Boer NK, van Nieuwkerk CM, Aparicio Pages MN, de Boer SY, Derijks LJ, Mulder CJ. Promising treatment of autoimmune hepatitis with 6-thioguanine after adverse events on azathioprine. Eur. J. Gastroenterol. Hepatol. 17: 457-461 (2005).
de Deckere EA. Possible beneficial effect of fish and fish n-3 polyunsaturated fatty acids in breast and colorectal cancer. Eur. J. Cancer Prev. 8: 213-221 (1999).
de Groot M, Appelman M, Spuls PI, de Rie MA, Bos JD. Initial experience with routine administration of etanercept in psoriasis. Br. J. Dermatol. 155: 808-814 (2006). *
de Jong DJ, Bac DJ, Tan G, de Boer SY, Grabowsky IL, Jansen JB, Greinwald R, Naber TH. Maintenance treatment with budesonide 6 mg versus 9 mg once daily in patients with Crohn's disease in remission. Neth. J. Med. 65: 339-345 (2007). *
de Jong DJ, Derijks LJ, Naber AH, Hooymans PM, Mulder CJ. Safety of thiopurines in the treatment of inflammatory bowel disease. Scand. J. Gastroenterol. Suppl. 239: 69-72 (2003). *
De Jong DJ, Goullet M, Naber TH. Side effects of azathioprine in patients with Crohn's disease. Eur. J. Gastroenterol. Hepatol. 16: 207-212 (2004).
De La Rue SA, Bickston SJ. Evidence-based medications for the treatment of the inflammatory bowel diseases. Curr. Opin. Gastroenterol. 22: 365-369 (2006).
de Lalla F, Nicolin R, Rinaldi E, Scarpellini P, Rigoli R, Manfrin V, Tramarin A. Prospective study of oral teicoplanin versus oral vancomycin for therapy of pseudomembranous colitis and Clostridium difficile-associated diarrhea. Antimicrob. Agents Chemother. 36: 2192-2196 (1992). *
de Man RA. Severe hepatitis attributed to paroxetine (Seroxat). Ned. Tijdschr. Geneeskd. 141: 540-542 (1997).
de Oca J, Vilar L, Castellote J, Sanchez Santos R, Pares D, Biondo S, Osorio A, del Rio C, Jaurrieta E, Marti Rague J. Immunodulation with tacrolimus (FK506): results of a prospective, open-label, non-controlled trial in patients with inflammatory bowel disease. Rev. Esp. Enferm. Dig. 95: 465-470, 459-464 (2003).
de Oliveira JP, Levy A, Morel P, Guibal F. Efficacy of infliximab for severe recalcitrant psoriasis after 6 weeks of treatment. J. Dermatol. 35: 575-580 (2008).
de Oliveira Silva-Junior G, da Silva Torres T, de Souza Mendonca L, Alberto Mandarim-de-Lacerda C. Rosiglitazone (peroxisome proliferator-activated receptor-gamma) counters hypertension and adverse cardiac and vascular remodeling in 2K1C hypertensive rats. Exp. Toxicol. Pathol. Sep 21 [Epub ahead of print] (2009). *
de Oliveira SK, de Almeida RG, Fonseca AR, Rodrigues MC, Sztajnbok F, Diniz C. Indications and adverse events with the use of anti-TNFalpha agents in pediatric rheumatology: experience of a single center. Acta Reumatol. Port. 32: 139-150 (2007).
de Ridder L, Benninga MA, Taminiau JA, Hommes DW, van Deventer SJ. Infliximab use in children and adolescents with inflammatory bowel disease. J. Pediatr. Gastroenterol. Nutr. 45: 3-14 (2007). *
de Ridder L, Rings EH, Damen GM, Kneepkens CM, Schweizer JJ, Kokke FT, Benninga MA, Norbruis OF, Hoekstra JH, Gijsbers CF, Escher JC. Infliximab dependency in pediatric Crohn's disease: long-term follow-up of an unselected cohort. Inflamm. Bowel Dis. 14: 353-358 (2008). *
de Ridder L, Van Dieren JM, Van Deventer HJ, Stokkers PC, Van der Woude JC, Van Vuuren AJ, Benninga MA, Escher JC, Hommes DW. Pharmacogenetics of thiopurine therapy in paediatric IBD patients. Aliment. Pharmacol. Ther. 23: 1137-1141 (2006). *
de Rooij SR, Painter RC, Phillips DI, Osmond C, Tanck MW, Defesche JC, Bossuyt PM, Michels RP, Bleker OP, Roseboom TJ. The effects of the Pro12Ala polymorphism of the peroxisome proliferator-activated receptor-gamma2 gene on glucose/insulin metabolism interact with prenatal exposure to famine. Diabetes Care 29: 1052-1057 (2006). *
de Serres FJ. Alpha-1 antitrypsin deficiency is not a rare disease but a disease that is rarely diagnosed. Environ. Health Perspect. 111: 1851-1854 (2003). *
de Silva HA, Saparamadu PA, Thabrew MI, Pathmeswaran A, Fonseka MM, de Silva HJ. Liv.52 in alcoholic liver disease: a prospective, controlled trial. J. Ethnopharmacol. 84: 47-50 (2003).
de Silva S, Devlin S, Panaccione R. Optimizing the safety of biologic therapy for IBD. Nat. Rev. Gastroenterol. Hepatol. 7: 93-101 (2010). *
De Souza AT, Cornwell PD, Dai X, Caguyong MJ, Ulrich RG. Agonists of the peroxisome proliferator activated receptor alpha induce a fiber-type selective transcriptional response in rat skeletal muscle. Toxicol. Sci. 92: 578-586 (2006). *
De Truchis P, Kirstetter M, Perier A, Meunier C, Zucman D, Force G, Doll J, Katlama C, Rozenbaum W, Masson H, Gardette J, Melchior JC; and the Maxepa-HIV Group. Reduction in triglyceride level with n-3 polyunsaturated fatty acids in HIV-infected patients taking potent antiretroviral therapy: a randomized prospective study. J. Acquir. Immune Defic. Syndr. 44: 278-285 (2007).
de Vlam K, Lories RJ. Efficacy, effectiveness and safety of etanercept in monotherapy for refractory psoriatic arthritis: a 26-week observational study. Rheumatology (Oxford) 45: 321-324 (2006). *
de Vries HS, van Oijen MG, de Jong DJ. Serious events with infliximab in patients with inflammatory bowel disease: a 9-year cohort study in the Netherlands. Drug Saf. 31: 1135-1144 (2008).
Dean JC, Robertson Z, Reid V, Wang Q, Hailey H, Moore S, Rasalam AD, Turnpenny P, Lloyd D, Shaw D, Little J. A high frequency of the MTHFR 677C>T polymorphism in Scottish women with epilepsy: possible role in pathogenesis. Seizure 17: 269-275 (2008).
Debes A, Bauer M, Kremer S. Tolerability and safety of the intravenous immunoglobulin Octagam(R): a 10-year prospective observational study. Pharmacoepidemiol. Drug Saf. 16: 1038-1047 (2007).
Dederichs F, Pinciu F, Gerhard H, Eveld K, Stallmach A. Listeria meningitis in a patient with Crohn's disease - a seldom, but clinically relevant adverse event of therapy with infliximab. Z. Gastroenterol. 44: 657-660 (2006).
Degner D, Grohmann R, Kropp S, Ruther E, Bender S, Engel RR, Schmidt LG. Severe adverse drug reactions of antidepressants: results of the German multicenter drug surveillance program AMSP. Pharmacopsychiatry 37 Suppl. 1: S39-S45 (2004).
Dejaco C, Duftner C, Wipfler E, Schirmer M. A novel treatment option in rheumatoid arthritis: abatacept, a selective modulator of T-cell co-stimulation. Wien. Med. Wochenschr. 159: 70-75 (2009).
Dekker L, Armbrust W, Rademaker CM, Prakken B, Kuis W, Wulffraat NM. Safety of anti-TNFalpha therapy in children with juvenile idiopathic arthritis. Clin. Exp. Rheumatol. 22: 252-258 (2004).
del Rincon I, Battafarano DF, Arroyo RA, Murphy FT, Escalante A. Heterogeneity between men and women in the influence of the HLA-DRB1 shared epitope on the clinical expression of rheumatoid arthritis. Arthritis Rheum. 46: 1480-1488 (2002). *
Del Rosso Do JQ. Combination topical therapy for the treatment of psoriasis. J. Drugs Dermatol. 5: 232-234 (2006).
Delacruz V, Weppler D, Island E, Gonzalez M, Tryphonopoulos P, Moon J, Smith L, Tzakis A, Ruiz P. Mycophenolate mofetil-related gastrointestinal mucosal injury in multivisceral transplantation. Transplant. Proc. 42: 82-84 (2010).
Delaini GG, Scaglia M, Colucci G, Hulten L. The ileoanal pouch procedure in the long-term perspective: a critical review. Tech. Coloproctol. 9: 187-192 (2005). *
Delco F, Tchambaz L, Schlienger R, Drewe J, Krahenbuhl S. Dose adjustment in patients with liver disease. Drug Saf. 28: 529-545 (2005).
Deltenre P, Berson A, Marcellin P, Degott C, Biour M, Pessayre D. Mesalazine (5-aminosalicylic acid) induced chronic hepatitis. Gut 44: 886-888 (1999). *
Demerjian M, Choi EH, Man MQ, Chang S, Elias PM, Feingold KR. Activators of PPARs and LXR decrease the adverse effects of exogenous glucocorticoids on the epidermis. Exp. Dermatol. 18: 643-649 (2009).
Demicheli V, Jefferson T, Rivetti A, Price D, Demicheli V. Vaccines for measles, mumps and rubella in children. Cochrane Database Syst. Rev. 4: CD004407 (2005). *
Denardo GL, Mirick GR, Hok S, Denardo SJ, Beckett LA, Adamson GN, Balhorn RL. Molecular specific and cell selective cytotoxicity induced by a novel synthetic HLA-DR antibody mimic for lymphoma and leukemia. Int. J. Oncol. 34: 511-516 (2009).
Deng A, Harvey V, Sina B, Strobel D, Badros A, Junkins-Hopkins JM, Samuels A, Oghilikhan M, Gaspari A. Interstitial granulomatous dermatitis associated with the use of tumor necrosis factor alpha inhibitors. Arch. Dermatol. 142: 198-202 (2006). *
Deng X, Stachlewitz RF, Liguori MJ, Blomme EA, Waring JF, Luyendyk JP, Maddox JF, Ganey PE, Roth RA. Modest inflammation enhances diclofenac hepatotoxicity in rats: role of neutrophils and bacterial translocation. J. Pharmacol. Exp. Ther. 319: 1191-1199 (2006). *
Denissen NH, Peters JG, Masereeuw R, Barrera P. Can sulfasalazine therapy induce or exacerbate Wegener's granulomatosis? Scand. J. Rheumatol. 37: 72-74 (2008). *
Dentale N, Manfredi R. Therapeutic use of interferons and their toxicity. Focus on peripheral neuropathy. Recenti Prog. Med. 98: 329-334 (2007).
Denton CP, Merkel PA, Furst DE, Khanna D, Emery P, Hsu VM, Silliman N, Streisand J, Powell J, Akesson A, Coppock J, Hoogen F, Herrick A, Mayes MD, Veale D, Haas J, Ledbetter S, Korn JH, Black CM, Seibold JR; Cat-192 Study Group. Recombinant human anti-transforming growth factor beta1 antibody therapy in systemic sclerosis: a multicenter, randomized, placebo-controlled phase I/II trial of CAT-192. Arthritis Rheum. 56: 323-333 (2007). *
Deodhar NS. Epidemiological perspective of domestic and personal hygiene in India. Int. J. Environ. Health Res. 13 Suppl. 1: S47-S56 (2003).
Derijk R, de Kloet ER. Corticosteroid receptor genetic polymorphisms and stress responsivity. Endocrine 28: 263-270 (2005).
Derijks LJ, de Jong DJ, Gilissen LP, Engels LG, Hooymans PM, Jansen JB, Mulder CJ. 6-Thioguanine seems promising in azathioprine- or 6-mercaptopurine-intolerant inflammatory bowel disease patients: a short-term safety assessment. Eur. J. Gastroenterol. Hepatol. 15: 63-67 (2003).
Derijks LJ, Gilissen LP, Engels LG, Bos LP, Bus PJ, Lohman JJ, van Deventer SJ, Hommes DW, Hooymans PM. Pharmacokinetics of 6-thioguanine in patients with inflammatory bowel disease. Ther. Drug Monit. 28: 45-50 (2006).
Derijks LJ, Wong DR. Pharmacogenetics of thiopurines in inflammatory bowel disease. Curr. Pharm. Des. Oct 15 [Epub ahead of print] (2009).
Derosa G, Cicero AE, Bertone G, Piccinni MN, Ciccarelli L, Roggeri DE. Comparison of fluvastatin + fenofibrate combination therapy and fluvastatin monotherapy in the treatment of combined hyperlipidemia, type 2 diabetes mellitus, and coronary heart disease: a 12-month, randomized, double-blind, controlled trial. Clin. Ther. 26: 1599-1607 (2004). *
Desai HG, Gupte PA. Increasing incidence of Crohn's disease in India: is it related to improved sanitation? Indian J. Gastroenterol. 24: 23-24 (2005). *
Desai SB, Furst DE. Problems encountered during anti-tumour necrosis factor therapy. Best Pract. Res. Clin. Rheumatol. 20: 757-790 (2006).
Descamps D, Hardt K, Spiessens B, Izurieta P, Verstraeten T, Breuer T, Dubin G. Safety of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine for cervical cancer prevention: a pooled analysis of 11 clinical trials. Hum. Vaccin. 5: 332-340 (2009).
Descotes J. Immunotoxicology: role in the safety assessment of drugs. Drug Saf. 28: 127-136 (2005).
Descotes J, Gouraud A. Clinical immunotoxicity of therapeutic proteins. Expert Opin. Drug Metab. Toxicol. 4: 1537-1549 (2008).
Deshpande GC, Simmer K, Mori T, Croft K. Parenteral lipid emulsions based on olive oil compared with soybean oil in preterm (<28 weeks' gestation) neonates: a randomised controlled trial. J. Pediatr. Gastroenterol. Nutr. 49: 619-625 (2009).
Deterding K, Grungreiff K, Lankisch TO, Potthoff A, Bahr MJ, Manns MP, Wedemeyer H, Strassburg CP. Gilbert's syndrome and antiviral therapy of hepatitis C. Ann. Hepatol. 8: 246-250 (2009).
Deterding RR, Lavange LM, Engels JM, Mathews DW, Coquillette SJ, Brody AS, Millard SP, Ramsey BW. Phase 2 randomized safety and efficacy trial of nebulized denufosol tetrasodium in cystic fibrosis. Am. J. Respir. Crit. Care Med. 176: 362-369 (2007). *
Dewey A, Baughan C, Dean T, Higgins B, Johnson I. Eicosapentaenoic acid (EPA, an omega-3 fatty acid from fish oils) for the treatment of cancer cachexia. Cochrane Database Syst. Rev. 1: CD004597 (2007). *
Dharamsi JW, Bhosle M, Balkrishnan R, Yentzer BA, Feldman SR. Using 'number needed to treat' to help conceptualize the magnitude of benefit and risk of tumour necrosis factor-alpha inhibitors for patients with severe psoriasis. Br. J. Dermatol. 161: 605-616 (2009). *
Dharmani P, Chadee K. Biologic therapies against inflammatory bowel disease: a dysregulated immune system and the cross talk with gastrointestinal mucosa hold the key. Curr. Mol. Pharmacol. 1: 195-212 (2008).
Dharmaraj P, Smyth RL. Vaccines for preventing influenza in people with cystic fibrosis. Cochrane Database Syst. Rev. 4: CD001753 (2009).
Dhiman RK, Chawla YK. Herbal medicines for liver diseases. Dig. Dis. Sci. 50: 1807-1812 (2005). *
Dhimolea E. Canakinumab. MAbs. Jan 15 [Epub ahead of print] (2010).
Di Giacomo AM, Danielli R, Guidoboni M, Calabro L, Carlucci D, Miracco C, Volterrani L, Mazzei MA, Biagioli M, Altomonte M, Maio M. Therapeutic efficacy of ipilimumab, an anti-CTLA-4 monoclonal antibody, in patients with metastatic melanoma unresponsive to prior systemic treatments: clinical and immunological evidence from three patient cases. Cancer Immunol. Immunother. 58: 1297-1306 (2009).
Di Palma JA, Rodriguez R, McGowan J, Cleveland MV. A randomized clinical study evaluating the safety and efficacy of a new, reduced-volume, oral sulfate colon-cleansing preparation for colonoscopy. Am. J. Gastroenterol. 104: 2275-2284 (2009). *
Diaferia A, Nicastri PL, Tartagni M, Loizzi P, Iacovizzi C, Di Leo A. Ursodeoxycholic acid therapy in pregnant women with cholestasis. Int. J. Gynaecol. Obstet. 52: 133-140 (1996).
Díaz Gomez JM. Cardiovascular mortality in kidney transplatation. Nefrologia 28: 27-30 (2008).
Diaz-Cervantes E, De-la-Torre-Bravo A, Spechler SJ, Torres-Durazo E, Sobrino-Cossio S, Martínez-Carrillo O, Gamboa-Robles J. Banding without resection (endoscopic mucosal ligation) as a novel approach for the ablation of short-segment Barrett's epithelium: results of a pilot study. Am. J. Gastroenterol. 102: 1640-1645 (2007). *
Diaz-Jouanen E, Abud-Mendoza C, Garza-Elizondo MA, Medrano-Ramirez G, Burgos-Vargas R, Orozco-Alcala JJ, Pacheco-Tena CF, Pineda C, Pozos-Espíndola JC, Ramos-Niembro F, Robles-San-Roman M, Santana-Sahagun JE. Guidelines in RA treatment: concepts on safety and recommendations using anti-TNF-alpha inhibitors. Rev. Invest. Clin. 61: 252-266 (2009).
Dickson ER. The syndrome of primary biliary cirrhosis. J. Rheumatol. Suppl. 7: 121-123 (1981).
Dieckgraefe BK, Korzenik JR. Treatment of active Crohn's disease with recombinant human granulocyte-macrophage colony-stimulating factor. Lancet 360: 1478-1480 (2002). *
Diez M, Sanchez E, Garcia Lopez S, Arroyo MT, Gomollon F. Infliximab therapy in ulcerative colitis: initial experience in two referral centers. Gastroenterol. Hepatol. 30: 449-453 (2007).
Dignass AU, Bokemeyer B, Ad Amek H, Mross M, Vinter-Jensen L, Borner N, Silvennoinen J, Tan G, Pool MO, Stijnen T, Dietel P, Klugmann T, Vermeire S, Bhatt A, Veerman H. Mesalamine once daily is more effective than twice daily in patients with quiescent ulcerative colitis. Clin. Gastroenterol. Hepatol. 7: 762-769 (2009).
Dijkstra G, Rings EH, van Dullemen HM, Bijleveld CM, Meessen NE, Karrenbeld A, Hofker HS, Porte RJ, Naber AH, Ploeg RJ. Small bowel transplantation as a treatment option for intestinal failure in children and adults. Ned. Tijdschr. Geneeskd. 149: 391-398 (2005).
Dillard T, Yedinak CG, Alumkal J, Fleseriu M. Anti-CTLA-4 antibody therapy associated autoimmune hypophysitis: serious immune related adverse events across a spectrum of cancer subtypes. Pituitary Jul 29 [Epub ahead of print] (2009).
Ding C, Cicuttini F, Li J, Jones G. Targeting IL-6 in the treatment of inflammatory and autoimmune diseases. Expert Opin. Investig. Drugs 18: 1457-1466 (2009).
Ding C, Jones G. Anti-interleukin-6 receptor antibody treatment in inflammatory autoimmune diseases. Rev. Recent Clin. Trials 1: 193-200 (2006).
Ding SY, Tigno XT, Braileanu GT, Ito K, Hansen BC. A novel peroxisome proliferator-activated receptor alpha/gamma dual agonist ameliorates dyslipidemia and insulin resistance in prediabetic rhesus monkeys. Metabolism 56: 1334-1339 (2007). *
Dinler G, Kocak N, Yuce A, Gurakan F, Ozen H. Ursodeoxycholic acid therapy in children with cholestatic liver disease. Turk. J. Pediatr. 41: 91-98 (1999).
Dinter H. Phosphodiesterase type 4 inhibitors: potential in the treatment of multiple sclerosis? BioDrugs 13: 87-94 (2000).
Dipaola RS, Chen YH, Stein M, Vaughn D, Patrick-Miller L, Carducci M, Roth B, White E, Wilding G. A randomized phase II trial of mitoxantrone, estramustine and vinorelbine or bcl-2 modulation with 13-cis retinoic acid, interferon and paclitaxel in patients with metastatic castrate-resistant prostate cancer: ECOG 3899. J. Transl. Med. 8: 20 (2010). *
Dixit SP. Liver and the contraceptive pill. Can. J. Surg. 23: 222-227, 255 (1980).
Do VT, Baird BG, Kockler DR. Probiotics for maintaining remission of ulcerative colitis in adults. Ann. Pharmacother. Feb 2 [Epub ahead of print] (2010).
Dobson J. Toxicological aspects and applications of nanoparticles in paediatric respiratory disease. Paediatr. Respir. Rev. 8: 62-66 (2007).
Doctor P, Sultan A, Syed S, Christen W, Bhat P, Quinones K, Foster S. Infliximab for the treatment of refractory scleritis. Br. J. Ophthalmol. Dec 2 [Epub ahead of print] (2009).
Doggrell SA. Lyprinol - is it a useful anti-inflammatory agent? Evid. Based Complement. Alternat. Med. Apr 21 [Epub ahead of print] (2009). *
Doherty G, Bennett G, Patil S, Cheifetz A, Moss AC. Interventions for prevention of post-operative recurrence of Crohn's disease. Cochrane Database Syst. Rev. 4: CD006873 (2009).
Doherty GA, Bennett GC, Cheifetz AS, Moss AC. Meta-analysis: targeting the intestinal microbiota in prophylaxis for post-operative Crohn's disease. Aliment. Pharmacol. Ther. Jan 4 [Epub ahead of print] (2010). *
Dohmen K, Miyamoto Y, Irie K, Takeshita T, Ishibashi H. Manifestation of cutaneous polyarteritis nodosa during interferon therapy for chronic hepatitis C associated with primary biliary cirrhosis. J. Gastroenterol. 35: 789-793 (2000). *
Dohmen K, Mizuta T, Nakamuta M, Shimohashi N, Ishibashi H, Yamamoto K. Fenofibrate for patients with asymptomatic primary biliary cirrhosis. World J. Gastroenterol. 10: 894-898 (2004). *
Domenech E, Nos P, Papo M, Lopez-San Roman A, Garcia-Planella E, Gassull MA. 6-Mercaptopurine in patients with inflammatory bowel disease and previous digestive intolerance of azathioprine. Scand. J. Gastroenterol. 40: 52-55 (2005). *
Domenech E, Zabana Y, Manosa M, Garcia-Planella E, Cabre E, Gassull MA. Infliximab reintroduction is not associated to a higher rate of immune-related adverse effects in patients with inflammatory bowel disease initially treated with a three-infusion induction regimen. J. Clin. Gastroenterol. 44: 34-37 (2010).
Domingo JL. Omega-3 fatty acids and the benefits of fish consumption: is all that glitters gold? Environ. Int. 33: 993-998 (2007).
Domingo JL, Bocio A, Falco G, Llobet JM. Benefits and risks of fish consumption Part I. A quantitative analysis of the intake of omega-3 fatty acids and chemical contaminants. Toxicology 230: 219-226 (2007). *
Domingo JL, Bocio A, Marti-Cid R, Llobet JM. Benefits and risks of fish consumption II. RIBEPEIX, a computer program to optimize the balance between the intake of omega-3 fatty acids and chemical contaminants. Toxicology 230: 227-233 (2007). *
Dominguez Ortega J, Trindade C, Alonso Llamazares A, Castellano Bravo A, Cimarra Alvarez-Lovel M, Martinez-Cocera C. Hypersensitivity to allopurinol. Efficacy of a desensitizing protocol in 3 cases. An. Med. Interna. 18: 27-28 (2001).
Donaldson PT. Basic concepts in PSC. Falk Symposium 146: GUT-LIVER INTERACTIONS: BASIC AND CLINICAL CONCEPTS, Innsbruck (Austria), March 11-12, 2005, pp. 73-75 (2005). *
Donofrio PD, Berger A, Brannagan TH 3rd, Bromberg MB, Howard JF, Latov N, Quick A, Tandan R. Consensus statement: the use of intravenous immunoglobulin in the treatment of neuromuscular conditions report of the Aanem AD HOC committee. Muscle Nerve 40: 890-900 (2009).
Donovan M, Lunney K, Carter-Pokras O, Cross RK. Prescribing patterns and awareness of adverse effects of infliximab: a health survey of gastroenterologists. Dig. Dis. Sci. 52: 1798-1805 (2007). *
Dooley MA, Falk RJ. Human clinical trials in lupus nephritis. Semin. Nephrol. 27: 115-127 (2007).
Dopheide JA, Pliszka SR. Attention-deficit-hyperactivity disorder: an update. Pharmacotherapy 29: 656-679 (2009).
Dore RK, Mathews S, Schechtman J, Surbeck W, Mandel D, Patel A, Zhou L, Peloso P. The immunogenicity, safety, and efficacy of etanercept liquid administered once weekly in patients with rheumatoid arthritis. Clin. Exp. Rheumatol. 25: 40-46 (2007).
Dorne JL. Metabolism, variability and risk assessment. Toxicology Nov 19 [Epub ahead of print] (2009). *
Dorner T, Lipsky PE. B-cell targeting: a novel approach to immune intervention today and tomorrow. Expert Opin. Biol. Ther. 7: 1287-1299 (2007).
Doshi DR, Weinberger MM. Experience with cyclosporine in children with chronic idiopathic urticaria. Pediatr. Dermatol. 26: 409-413 (2009).
Dosiou C, Sanders GD, Araki SS, Crapo LM. Screening pregnant women for autoimmune thyroid disease: a cost-effectiveness analysis. Eur. J. Endocrinol. 158: 841-851 (2008).
Dotan I, Hallak A, Arber N, Santo M, Alexandrowitz A, Knaani Y, Hershkoviz R, Brazowski E, Halpern Z. Low-dose low-molecular weight heparin (enoxaparin) is effective as adjuvant treatment in active ulcerative colitis: an open trial. Dig. Dis. Sci. 46: 2239-2244 (2001). *
Doubremelle M, Bourreille A, Zerbib F, Heresbach D, Metman EH, Beau P, Gournay J, Galmiche JP. Treatment of Crohn's disease with anti-TNF alpha antibodies (infliximab): results of a multicentric and retrospective study. Gastroenterol. Clin. Biol. 26: 973-979 (2002).
Dove LM, Rosen RC, Ramcharran D, Wahed AS, Belle SH, Brown RS, Hoofnagle JH; Virahep-C Study Group. Decline in male sexual desire, function, and satisfaction during and after antiviral therapy for chronic hepatitis C. Gastroenterology 137: 873-884.e1 (2009). *
Dove-Edwin I, Thomas HJ. Review article: the prevention of colorectal cancer. Aliment. Pharmacol. Ther. 15: 323-336 (2001). *
Draper HM. Depressive disorder associated with mycophenolate mofetil. Pharmacotherapy 28: 136-139 (2008).
Dreno B, Blouin E, Moyse D. Lithium gluconate 8% in the treatment of seborrheic dermatitis. Ann. Dermatol. Venereol. 134: 347-351 (2007).
Dreyer L, Mellemkjaer L, Hetland ML. Cancer in arthritis patients after anti-tumour necrosis factor therapy. Ugeskr. Laeger. 171: 506-511 (2009).
Driessen RJ, Berends MA, Boezeman JB, van de Kerkhof PC, de Jong EM. Psoriasis treatment with etanercept and efalizumab: clinical strategies influencing treatment outcome. Br. J. Dermatol. 158: 1098-1106 (2008). *
Driessen RJ, van de Kerkhof PC, de Jong EM. Etanercept combined with methotrexate for high-need psoriasis. Br. J. Dermatol. 159: 460-463 (2008). *
Drosou A, Kirsner RS, Welsh E, Sullivan TP, Kerdel FA. Use of infliximab, an anti-tumor necrosis alpha antibody, for inflammatory dermatoses. J. Cutan. Med. Surg. 7: 382-386 (2003). *
Drossman DA, Leserman J, Li Z, Keefe F, Hu YJ, Toomey TC. Effects of coping on health outcome among women with gastrointestinal disorders. Psychosom. Med. 62: 309-317 (2000). *
Drutskaya MS, Efimov GA, Kruglov AA, Kuprash DV, Nedospasov SA. Tumor necrosis factor, lymphotoxin and cancer. IUBMB Life Feb 12 [Epub ahead of print] (2010).
Dua KS, Surapaneni SN, Santharam R, Knuff D, Hofmann C, Shaker R. Effect of systemic alcohol and nicotine on airway protective reflexes. Am. J. Gastroenterol. 104: 2431-2438 (2009).
Dube SR, Fairweather D, Pearson WS, Felitti VJ, Anda RF, Croft JB. Cumulative childhood stress and autoimmune diseases in adults. Psychosom. Med. 71: 243-250 (2009).
Dubey AP, Banerjee S. Measles, mumps, rubella (MMR) vaccine. Indian J. Pediatr. 70: 579-584 (2003).
Dubinsky MC. Diffuse jejunoileitis in adolescence. Falk Symposium 140. Inflammatory Bowel Disease: Translation from Basic Research to Clinical Practice. Dubrovnik (Croatia). p. 70. May 7-8 (2004). *
Dubinsky MC. Optimizing immunomodulator therapy for inflammatory bowel disease. Curr. Gastroenterol. Rep. 5: 506-511 (2003).
Dubinsky MC, Fleshner PP. Treatment of Crohn's disease of inflammatory, stenotic, and fistulizing phenotypes. Curr. Treat. Options Gastroenterol. 6: 183-200 (2003).
Dubinsky MC, Yang H, Hassard PV, Seidman EG, Kam LY, Abreu MT, Targan SR, Vasiliauskas EA. 6-MP metabolite profiles provide a biochemical explanation for 6-MP resistance in patients with inflammatory bowel disease. Gastroenterology 122: 904-915 (2002). *
Ducharme E, Weinberg JM. Etanercept. Expert Opin. Biol. Ther. 8: 491-502 (2008).
Duclos P. Safety of immunisation and adverse events following vaccination against hepatitis B. Expert Opin. Drug Saf. 2: 225-231 (2003).
Duclos-Vallee JC, Di Martino V, Cazier A, Ballot E, Johanet C, Yamamoto AM, Emile JF, Guettier C, Coutarel P, Cadranel JF. Remission with ursodeoxycholic acid of type 1 autoimmune hepatitis resistant to azathioprine and steroids. Gastroenterol. Clin. Biol. 29: 1173-1176 (2005).
Ducoulombier V, Solau E, Coquerelle P, Houvenagel E, Siame JL, Desprez X, Fauquert P, Guyot MH, Delcambre B, Flipo RM. Long-term results of infliximab therapy in rheumatoid arthritis: experience acquired by the North-Pas-de-Calais hospital network. Joint Bone Spine 74: 56-59 (2007). *
Dunand M, Botez SA, Borruat FX, Roux-Lombard P, Spertini F, Kuntzer T. Unsatisfactory outcomes in myasthenia gravis: influence by care providers. J. Neurol. Sep 17 [Epub ahead of print] (2009).
Duparc A, Staumont-Salle D, Broly F, Piette F, Delaporte E. Treatment of chronic lupus erythematosus with sulfasalazine in 18 patients: reappraisal. Presse. Med. 35: 1138-1142 (2006).
Duret C, Daujat-Chavanieu M, Pascussi JM, Pichard-Garcia L, Balaguer P, Fabre JM, Vilarem MJ, Maurel P, Gerbal-Chaloin S. Ketoconazole and miconazole are antagonists of the human glucocorticoid receptor: consequences on the expression and function of the constitutive androstane receptor and the pregnane X receptor. Mol. Pharmacol. 70: 329-339 (2006). *
Duro D, Duggan C, Valim C, Bechard L, Fitzgibbons S, Jaksic T, Yu YM. Novel intravenous (13)C-methionine breath test as a measure of liver function in children with short bowel syndrome. J. Pediatr. Surg. 44: 236-240 (2009).
Duvic M. EGFR inhibitor-associated acneiform folliculitis: assessment and management. Am. J. Clin. Dermatol. 9: 285-294 (2008).
Duvic M, Talpur R. Optimizing denileukin diftitox (Ontak) therapy. Future Oncol. 4: 457-469 (2008).
Duvnjak M, Lerotic I, Tomasic V, Pavic T, Virovic L. Inflammatory bowel disease and pregnancy. Lijec. Vjesn. 128: 48-55 (2006).
Duzova A, Bakkaloglu A. Central nervous system involvement in pediatric rheumatic diseases: current concepts in treatment. Curr. Pharm. Des. 14: 1295-1301 (2008).
Dy GK, Bekele L, Hanson LJ, Furth A, Mandrekar S, Sloan JA, Adjei AA. Complementary and alternative medicine use by patients enrolled onto phase I clinical trials. J. Clin. Oncol. 22: 4810-4815 (2004). *
Earnshaw SR, Klok RM, Iyer S, McDade C. Review article: methylnaltrexone bromide for the treatment of opioid-induced constipation in patients with advanced illness - a cost-effectiveness analysis. Aliment. Pharmacol. Ther. Jan 22 [Epub ahead of print] (2010). *
Eaton PA, Callen JP. Mycophenolate mofetil as therapy for pyoderma gangrenosum. Arch. Dermatol. 145: 781-785 (2009). *
Ebbesson SO, Tejero ME, Nobmann ED, Lopez-Alvarenga JC, Ebbesson L, Romenesko T, Carter EA, Resnick HE, Devereux RB, Maccluer JW, Dyke B, Laston SL, Wenger CR, Fabsitz RR, Comuzzie AG, Howard BV. Fatty acid consumption and metabolic syndrome components: the GOCADAN study. J. Cardiometab. Syndr. 2: 244-249 (2007).
Edwards G. Ivermectin: does P-glycoprotein play a role in neurotoxicity? Filaria J. 2 Suppl. 1: S8 (2003). *
Efimov GA, Kruglov AA, Tillib SV, Kuprash DV, Nedospasov SA. Tumor necrosis factor and the consequences of its ablation in vivo. Mol. Immunol. 47: 19-27 (2009). *
Efrati E, Adler L, Krivoy N, Sprecher E. Distribution of TPMT risk alleles for thioupurine toxicity in the Israeli population. Eur. J. Clin. Pharmacol. 65: 257-262 (2009).
Egan LJ, Sandborn WJ. Advances in the treatment of Crohn's disease. Gastroenterology 126: 1574-1581 (2004). *
Egger SS, Studer IG, Bravo AE, Krahenbuhl S. Minocycline-induced lupus erythematodes. Schweiz. Rundsch. Med. Prax. 95: 1297-1303 (2006).
Eghdamian B, Ghose K. Mode of action and adverse effects of lipid lowering drugs. Drugs Today (Barc.) 34: 943-956 (1998).
Eguchi Y, Wakitani S, Imai Y, Naka Y, Hashimoto Y, Nakamura H, Takaoka K. Antitumor necrotic factor agent promotes BMP-2-induced ectopic bone formation. J. Bone Miner. Metab. Oct 29 [Epub ahead of print] (2009). *
Eibl MM. History of immunoglobulin replacement. Immunol. Allergy Clin. North Am. 28: 737-764 (2008).
Eickhoff A, Van Dam J, Jakobs R, Kudis V, Hartmann D, Damian U, Weickert U, Schilling D, Riemann JF. Computer-assisted colonoscopy (The NeoGuide Endoscopy System): results of the first human clinical trial ("PACE Study"). Am. J. Gastroenterol. 102: 261-266 (2007). *
Eidelwein AP, Cuffari C, Abadom V, Oliva-Hemker M. Infliximab efficacy in pediatric ulcerative colitis. Inflamm. Bowel Dis. 11: 213-218 (2005). *
Einarson A, Ho E, Koren G. Can we use metronidazole during pregnancy and breastfeeding? Putting an end to the controversy. Can. Fam. Physician 46: 1053-1054 (2000).
Einstein M, Akiyama T, Castriota G, Wang C, McKeever B, Mosley R, Becker J, Moller D, Meinke P, Wood H, Berger J. The differential interactions of peroxisome proliferator-activated receptor gamma ligands with Tyr473 is a physical basis for their unique biological activities. Mol. Pharmacol. 73: 62-74 (2008). *
Ejskjaer N, Vestergaard ET, Hellstrom PM, Gormsen LC, Madsbad S, Madsen JL, Jensen TA, Pezzullo JC, Christiansen JS, Shaughnessy L, Kosutic G. Ghrelin receptor agonist (TZP-101) accelerates gastric emptying in adults with diabetes and symptomatic gastroparesis. Aliment. Pharmacol. Ther. 29: 1179-1187 (2009). *
Ekinci S, Karnak I, Gurakan F, Yuce A, Senocak ME, Cahit Tanyel F, Buyukpamukcu N. Partial external biliary diversion for the treatment of intractable pruritus in children with progressive familial intrahepatic cholestasis: report of two cases. Surg. Today 38: 726-730 (2008).
Ekins S, Kortagere S, Iyer M, Reschly EJ, Lill MA, Redinbo MR, Krasowski MD. Challenges predicting ligand-receptor interactions of promiscuous proteins: the nuclear receptor PXR. PLoS Comput. Biol. 5: e1000594 (2009). *
El Miedany Y, Youssef S, Ahmed I, El Gaafary M. The gastrointestinal safety and effect on disease activity of etoricoxib, a selective cox-2 inhibitor in inflammatory bowel diseases. Am. J. Gastroenterol. 101: 311-317 (2006). *
El-Azhary RA, Brunner KL, Gibson LE. Sweet syndrome as a manifestation of azathioprine hypersensitivity. Mayo Clin. Proc. 83: 1026-1030 (2008). *
El-Hag K, Dercken HG, Prenzel R, Holzle E. Drug-induced alveolitis associated with infliximab/azathioprine therapy. Pneumologie 62: 204-208 (2008).
El-Hallak M, Binstadt BA, Leichtner AM, Bennett CM, Neufeld EJ, Fuhlbrigge RC, Zurakowski D, Sundel RP. Clinical effects and safety of rituximab for treatment of refractory pediatric autoimmune diseases. J. Pediatr. 150: 376-382 (2007). *
El-Karaksy HM, El-Hawary MI, El-Koofy NM, El-Sayed R, El-Raziky MA, Mansour SA, Taha GM, El-Mougy F. Safety and efficacy of hepatitis A vaccine in children with chronic liver disease. World J. Gastroenterol. 12: 7337-7340 (2006). *
Eleftheriou D, Melo M, Marks SD, Tullus K, Sills J, Cleary G, Dolezalova P, Ozen S, Pilkington C, Woo P, Klein N, Dillon MJ, Brogan PA. Biologic therapy in primary systemic vasculitis of the young. Rheumatology (Oxford) 48: 978-986 (2009).
Elias E. Hepatology highlights. Hepatology 39: 1467-1468 (2004). *
Elinav E, Pinsker G, Safadi R, Pappo O, Bromberg M, Anis E, Keinan-Boker L, Broide E, Ackerman Z, Kaluski DN, Lev B, Shouval D. Association between consumption of Herbalife((R)) nutritional supplements and acute hepatotoxicity. J. Hepatol. 47: 514-520 (2007). *
Elizur A, Cannon CL, Ferkol TW. Airway inflammation in cystic fibrosis. Chest 133: 489-495 (2008). *
Elmunzer BJ, Waljee AK, Elta GH, Taylor JR, Fehmi SM, Higgins PD. A meta-analysis of rectal NSAIDs in the prevention of post-ERCP pancreatitis. Gut 57: 1262-1267 (2008).
Elson CO. The effects of immunosuppressive agents on cytokines. Aliment. Pharmacol. Ther. 10 Suppl. 2: 100-105 (1996).
Ely LK, Burrows SR, Purcell AW, Rossjohn J, McCluskey J. T-cells behaving badly: structural insights into alloreactivity and autoimmunity. Curr. Opin. Immunol. 20: 575-580 (2008). *
Emanuele E, Brondino N, Re S, Bertona M, Geroldi D. Serum omega-3 fatty acids are associated with ultimatum bargaining behavior. Physiol. Behav. 96: 180-183 (2009).
Emara AM, Abo El-Noor MM, Hassan NA, Wagih AA. Immunotoxicity and hematotoxicity induced by tetrachloroethylene in Egyptian dry cleaning workers. Inhal. Toxicol. Jan 4 [Epub ahead of print] (2010). *
Emery P, Keystone E, Tony HP, Cantagrel A, van Vollenhoven R, Sanchez A, Alecock E, Lee J, Kremer J. IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-TNF biologics: results from a 24-week multicentre Randomised Placebo Controlled Trial. Ann. Rheum. Dis. 67: 1516-1523 (2008).
Emi Aikawa N, de Carvalho JF, Artur Almeida Silva C, Bonfa E. Immunogenicity of anti-TNF-alpha agents in autoimmune diseases. Clin. Rev. Allergy Immunol. Jun 30 [Epub ahead of print] (2009). *
Emmert MY, Salzberg SP, Emmert LS, Behjati S, Plass A, Felix C, Falk V, Gruenenfelder J. Severe cardiomyopathy following treatment with the tumour necrosis factor-alpha inhibitor adalimumab for Crohn's disease. Eur. J. Heart Fail. 11: 1106-1109 (2009).
Emsley R, Niehaus DJ, Oosthuizen PP, Koen L, Ascott-Evans B, Chiliza B, van Rensburg SJ, Smit RM. Safety of the omega-3 fatty acid, eicosapentaenoic acid (EPA) in psychiatric patients: results from a randomized, placebo-controlled trial. Psychiatry Res. 161: 284-291 (2008).
Endo H, Rees TD, Matsue M, Kuyama K, Nakadai M, Yamamoto H. Early detection and successful management of oral pemphigus vulgaris: a case report. J. Periodontol. 76: 154-160 (2005).
Enomoto A, Endou H. Roles of organic anion transporters (OATs) and a urate transporter (URAT1) in the pathophysiology of human disease. Clin. Exp. Nephrol. 9: 195-205 (2005). *
Enrico V, Ivano B, Gregoriana Z, Silvia F, Claudia F, Riccardo R, Livio DC. Homocysteine and heart failure: an overview. Recent Patents Cardiovasc. Drug Discov. 4: 15-21 (2009).
Eraly SA, Bush KT, Sampogna RV, Bhatnagar V, Nigam SK. The molecular pharmacology of organic anion transporters: from DNA to FDA? Mol. Pharmacol. 65: 479-487 (2004). *
Erdeljic V, Francetic I, Likic R, Bakran I, Makar-Ausperger K, Simic P. Is referring patients with a positive history of allergic drug reactions or atopy for allergy testing to local anesthetics justified? Methods Find. Exp. Clin. Pharmacol. 31: 177-182 (2009).
Erdmann M, Schuler-Thurner B. Dendritic cell vaccines in metastasized malignant melanoma. G. Ital. Dermatol. Venereol. 143: 235-250 (2008).
Ericsson CD. Safety and tolerability of the antibacterial rifaximin in the treatment of travellers' diarrhoea. Drug Saf. 29: 201-207 (2006).
Eriksson P. Nine patients with anti-neutrophil cytoplasmic antibody-positive vasculitis successfully treated with rituximab. J. Intern. Med. 257: 540-548 (2005). *
Erkkila A, de Mello VD, Riserus U, Laaksonen DE. Dietary fatty acids and cardiovascular disease: an epidemiological approach. Prog. Lipid Res. 47: 172-187 (2008). *
Ernst E, Pittler MH. Risks associated with herbal medicinal products. Wien. Med. Wochenschr. 152: 183-189 (2002).
Ernstgard L, Iregren A, Sjogren B, Johanson G. Acute effects of exposure to vapours of dioxane in humans. Hum. Exp. Toxicol. 25: 723-729 (2006).
Ersoy H, Rybicki FJ. Biochemical safety profiles of gadolinium-based extracellular contrast agents and nephrogenic systemic fibrosis. J. Magn. Reson. Imaging 26: 1190-1197 (2007).
Ersoy-Evans S, Altaykan A, Sahin S, Kolemen F. Phototherapy in childhood. Pediatr. Dermatol. 25: 599-605 (2008). *
Esmaillzadeh A, Azadbakht L. Home use of vegetable oils, markers of systemic inflammation, and endothelial dysfunction among women. Am. J. Clin. Nutr. 88: 913-921 (2008). *
Esmailzadeh A, Yousefi P, Farhi D, Bachmeyer C, Cosnes J, Berenbaum F, Duriez P, Aractingi S, Khosrotehrani K. Predictive factors of eczema-like eruptions among patients without cutaneous psoriasis receiving infliximab: a cohort study of 92 patients. Dermatology 219: 263-267 (2009).
Espinoza-Gonzalez NA, Herz-Ruelas M, Ocampo-Candiani J, Gonzalez-Soto R. Biologic therapy: a new and promising option to treat psoriasis. Rev. Med. Inst. Mex. Seguro. Soc. 46: 405-414 (2008).
Esser C, Jux B. Small chemicals, bioactivation, and the immune system - a fragile balance of i-Tox and benefits? Chem. Biodivers. 6: 2138-2143 (2009).
Etchevers MJ, Ordas I, Ricart E. Optimizing the use of tumour necrosis factor inhibitors in Crohn's disease: a practical approach. Drugs 70: 109-120 (2010).
Eum SY, Andras IE, Couraud PO, Hennig B, Toborek M. PCBS and tight junction expression. Environ. Toxicol. Pharmacol. 25: 234-240 (2008). *
Evans CH, Robbins PD, Ghivizzani SC, Wasko MC, Tomaino MM, Kang R, Muzzonigro TA, Vogt M, Elder EM, Whiteside TL, Watkins SC, Herndon JH. Gene transfer to human joints: progress toward a gene therapy of arthritis. Proc. Natl. Acad. Sci. U.S.A. 102: 8698-8703 (2005). *
Evans S, Daly A, Davies P, Macdonald A. Fibre content of enteral feeds for the older child. J. Hum. Nutr. Diet. 22: 414-421 (2009). *
Evereklioglu C. Current concepts in the etiology and treatment of Behcet disease. Surv. Ophthalmol. 50: 297-350 (2005).
Evon DM, Ramcharran D, Belle SH, Terrault NA, Fontana RJ, Fried MW; the Virahep-C Study Group. Prospective analysis of depression during peginterferon and ribavirin therapy of chronic hepatitis C: results of the Virahep-C study. Am. J. Gastroenterol. 104: 2949-2958 (2009). *
Ewe K, Eckardt V, Kanzler G. Treatment of ulcerative colitis with olsalazine and sulphasalazine: efficacy and side-effects. Scand. J. Gastroenterol. Suppl. 148: 70-75 (1988).
Exley C, Swarbrick L, Gherardi RK, Authier FJ. A role for the body burden of aluminium in vaccine-associated macrophagic myofasciitis and chronic fatigue syndrome. Med. Hypotheses 72: 135-139 (2009).
Ezerzer C, Harris N. Physiological immunity or pathological autoimmunity - a question of balance. Autoimmun. Rev. 6: 488-496 (2007).
Faber KN, Muller M, Jansen PL. Drug transport proteins in the liver. Adv. Drug Deliv. Rev. 55: 107-124 (2003). *
Fagan EA. Intrahepatic cholestasis of pregnancy. Clin. Liver Dis. 3: 603-632 (1999).
Fakhfouri G, Rahimian R, Daneshmand A, Bahremand A, Rasouli MR, Dehpour AR, Mehr SE, Mousavizadeh K. Granisetron ameliorates acetic acid-induced colitis in rats. Hum. Exp. Toxicol. Feb 12 [Epub ahead of print] (2010).
Farahani P, Levine M, Gaebel K, Wang EC, Khalidi N. Community-based evaluation of etanercept in patients with rheumatoid arthritis. J. Rheumatol. 33: 665-670 (2006).
Fardel O, Jigorel E, Le Vee M, Payen L. Physiological, pharmacological and clinical features of the multidrug resistance protein 2. Biomed. Pharmacother. 59: 104-114 (2005).
Fardy JM, Lloyd DA, Reynolds RP. Adverse effects with oral 5-aminosalicyclic acid. J. Clin. Gastroenterol. 10: 635-637 (1988).
Farinotti M, Simi S, Di Pietrantonj C, McDowell N, Brait L, Lupo D, Filippini G. Dietary interventions for multiple sclerosis. Cochrane Database Syst. Rev. 1: CD004192 (2007). *
Farmer JA, Gotto AM Jr. Currently available hypolipidaemic drugs and future therapeutic developments. Baillieres Clin. Endocrinol. Metab. 9: 825-847 (1995).
Farrell GC. Drug-induced hepatic injury. J. Gastroenterol. Hepatol. 12: S242-S250 (1997).
Farrell RJ, Peppercorn MA, Fine SN, Michetti P. Mesalamine-associated thrombocytopenia. Am. J. Gastroenterol. 94: 2304-2306 (1999). *
Farrell RJ, Shah SA, Lodhavia PJ, Alsahli M, Falchuk KR, Michetti P, Peppercorn MA. Clinical experience with infliximab therapy in 100 patients with Crohn's disease. Am. J. Gastroenterol. 95: 3490-3497 (2000). *
Farver DK, Lavin MN. Quinine-induced hepatotoxicity. Ann. Pharmacother. 33: 32-34 (1999).
Farzaneh-Far R, Harris WS, Garg S, Na B, Whooley MA. Inverse association of erythrocyte n-3 fatty acid levels with inflammatory biomarkers in patients with stable coronary artery disease: The Heart and Soul Study. Atherosclerosis 205: 538-543 (2009).
Fass R, Chey WD, Zakko SF, Andhivarothai N, Palmer RN, Perez MC, Atkinson SN. Clinical trial: the effects of the proton pump inhibitor dexlansoprazole MR on daytime and nighttime heartburn in patients with nonerosive reflux disease. Aliment. Pharmacol. Ther. 29: 1261-1272 (2009). *
Fass R, Pieniaszek HJ, Thompson JR. Pharmacokinetic comparison of orally disintegrating metoclopramide with conventional metoclopramide tablet formulation in healthy volunteers. Aliment. Pharmacol. Ther. 30: 301-306 (2009). *
Fattinger K, Funk C, Pantze M, Weber C, Reichen J, Stieger B, Meier PJ. The endothelin antagonist bosentan inhibits the canalicular bile salt export pump: a potential mechanism for hepatic adverse reactions. Clin. Pharmacol. Ther. 69: 223-231 (2001). *
Faulds D, Goa KL, Benfield P. Cyclosporin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in immunoregulatory disorders. Drugs 45: 953-1040 (1993).
Faure E. Multiple sclerosis and hepatitis B vaccination: could minute contamination of the vaccine by partial Hepatitis B virus polymerase play a role through molecular mimicry? Med. Hypotheses 65: 509-520 (2005).
Fauser S, Kalbacher H, Alteheld N, Koizumi K, Krohne TU, Joussen AM. Pharmacokinetics and safety of intravitreally delivered etanercept. Graefes Arch. Clin. Exp. Ophthalmol. 242: 582-586 (2004). *
Faux JA, Moffatt MF, Lalvani A, Dekker J, Warrell DA, Cookson WO. Sensitivity to bee and wasp venoms: association with specific IgE responses to the bee and wasp venom and HLA DRB1 and DPB1. Clin. Exp. Allergy 27: 578-583 (1997).
Favalli EG, Varenna M, Sinigaglia L. Drug-induced agranulocytosis during treatment with infliximab in enteropathic spondyloarthropathy. Clin. Exp. Rheumatol. 23: 247-250 (2005).
Feagan B. Infliximab, adalimumab and certolizumab: beneficial and adverse effects (past). Inflamm. Bowel Dis. 12 Suppl. 3: S6 (2006).
Feagan BG. Maintenance therapy for inflammatory bowel disease. Am. J. Gastroenterol. 98: S6-S17 (2003). *
Feagan BG, Enns R, Fedorak RN, Panaccione R, Pare P, Steinhart AH, Wild G. Infliximab for the treatment of Crohn's disease: efficacy, safety and pharmacoeconomics. Can. J. Clin. Pharmacol. 8: 188-198 (2001).
Feagan BG, Fedorak RN, Irvine EJ, Wild G, Sutherland L, Steinhart AH, Greenberg GR, Koval J, Wong CJ, Hopkins M, Hanauer SB, McDonald JW. A comparison of methotrexate with placebo for the maintenance of remission in Crohn's disease. North American Crohn's Study Group Investigators. N. Engl. J. Med. 342: 1627-1632 (2000). *
Feagan BG, Greenberg GR, Wild G, Fedorak RN, Pare P, McDonald JW, Cohen A, Bitton A, Baker J, Dube R, Landau SB, Vandervoort MK, Parikh A. Treatment of active Crohn's disease with MLN0002, a humanized antibody to the alpha4beta7 integrin. Clin. Gastroenterol. Hepatol. 6: 1370-1377 (2008).
Feagan BG, Sandborn WJ. Initial therapy for mild to moderate Crohn's disease: mesalamine or budesonide? Rev. Gastroenterol. Disord. 2 Suppl. 2: S9-S15 (2002). *
Feagan BG, Sandborn WJ, Baker JP, Cominelli F, Sutherland LR, Elson CO, Salzberg BA, Archambault A, Bernstein CN, Lichtenstein GR, Heath PK, Cameron S, Hanauer SB. A randomized, double-blind, placebo-controlled trial of CDP571, a humanized monoclonal antibody to tumour necrosis factor-alpha, in patients with corticosteroid-dependent Crohn's disease. Aliment. Pharmacol. Ther. 21: 373-384 (2005). *
Feagan BG, Sandborn WJ, Lichtenstein G, Radford-Smith G, Patel J, Innes A. CDP571, a humanized monoclonal antibody to tumour necrosis factor-alpha, for steroid-dependent Crohn's disease: a randomized, double-blind, placebo-controlled trial. Aliment. Pharmacol. Ther. 23: 617-628 (2006). *
Feagan BG, Sandborn WJ, Mittmann U, Bar-Meir S, D'Haens G, Bradette M, Cohen A, Dallaire C, Ponich TP, McDonald JW, Hebuterne X, Pare P, Klvana P, Niv Y, Ardizzone S, Alexeeva O, Rostom A, Kiudelis G, Spleiss J, Gilgen D, Vandervoort MK, Wong CJ, et al. Omega-3 free fatty acids for the maintenance of remission in Crohn disease: the EPIC Randomized Controlled Trials. JAMA 299: 1690-1697 (2008). *
Fecht S, Distl O. Review of prevalence, genetic aspects and adverse effects of the mdr1-1Delta mutation in dogs. Dtsch. Tierarztl. Wochenschr. 115: 212-219 (2008).
Fedorak RN, Bistritz L. Targeted delivery, safety, and efficacy of oral enteric-coated formulations of budesonide. Adv. Drug Deliv. Rev. 57: 303-316 (2005). *
Fedorak RN, Gangl A, Elson CO, Rutgeerts P, Schreiber S, Wild G, Hanauer SB, Kilian A, Cohard M, LeBeaut A, Feagan B. Recombinant human interleukin 10 in the treatment of patients with mild to moderately active Crohn's disease. The Interleukin 10 Inflammatory Bowel Disease Cooperative Study Group. Gastroenterology 119: 1473-1482 (2000). *
Feldman S, Nighland M. Photographic assessment of tretinoin microsphere gel in moderate acne. J. Drugs Dermatol. 7: s19-s24 (2008).
Feldman SR, Koo JY, Johnson LA, Preston NJ. Clobetasol propionate spray 0.05% add-on therapy to a stable regimen of biologic treatment in patients with moderate to very severe plaque psoriasis. Cutis 84: S25-S32 (2009).
Feldman SR, Koo JY, Menter A, Bagel J. Decision points for the initiation of systemic treatment for psoriasis. J. Am. Acad. Dermatol. 53: 101-107 (2005).
Feletar M, Brockbank JE, Schentag CT, Lapp V, Gladman DD. Treatment of refractory psoriatic arthritis with infliximab: a 12 month observational study of 16 patients. Ann. Rheum. Dis. 63: 156-161 (2004). *
Fellermann K, Tanko Z, Herrlinger KR, Witthoeft T, Homann N, Bruening A, Ludwig D, Stange EF. Response of refractory colitis to intravenous or oral tacrolimus (FK506). Inflamm. Bowel Dis. 8: 317-324 (2002). *
Felley C, Michetti P. Engineered lymphocytes to treat dinitrobenzene sulphonic acid colitis in mice. Eur. J. Gastroenterol. Hepatol. 15: 1253-1255 (2003).
Feng B, Xu JJ, Bi YA, Mireles R, Davidson R, Duignan DB, Campbell S, Kostrubsky VE, Dunn MC, Smith AR, Wang HF. Role of hepatic transporters in the disposition and hepatotoxicity of a Her2 tyrosine kinase inhibitor CP-724,714. Toxicol. Sci. 108: 492-500 (2009). *
Fenton C, Plosker GL. Calcipotriol/Betamethasone dipropionate: a review of its use in the treatment of psoriasis vulgaris. Am. J. Clin. Dermatol. 5: 463-478 (2004).
Ferahbas A, Turan MT, Esel E, Utas S, Kutlugun C, Kilic CG. A pilot study evaluating anxiety and depressive scores in acne patients treated with isotretinoin. J. Dermatolog. Treat. 15: 153-157 (2004).
Ferguson A. Mechanisms in adverse reactions to food. The gastrointestinal tract. Allergy 50: S32-S38 (1995).
Ferguson A, Sedgwick DM, Drummond J. Morbidity of juvenile onset inflammatory bowel disease: effects on education and employment in early adult life. Gut 35: 665-668 (1994). *
Ferguson JH, Chang AB. Vitamin D supplementation for cystic fibrosis. Cochrane Database Syst. Rev. 4: CD007298 (2009).
Fernandes A, Brites D. Contribution of inflammatory processes to nerve cell toxicity by bilirubin and efficacy of potential therapeutic agents. Curr. Pharm. Des. 15: 2915-2926 (2009).
Fernandez E, Galan AI, Moran D, Gonzalez-Buitrago JM, Munoz ME, Jimenez R. Reversal of cyclosporine A-induced alterations in biliary secretion by S-adenosyl-L-methionine in rats. J. Pharmacol. Exp. Ther. 275: 442-449 (1995).
Fernandez-Nebro A, Irigoyen MV, Urena I, Belmonte-Lopez MA, Coret V, Jimenez-Nunez FG, Diaz-Cordoves G, Lopez-Lasanta MA, Ponce A, Rodriguez-Perez M, Calero E, Gonzalez-Santos P. Effectiveness, predictive response factors, and safety of anti-tumor necrosis factor (TNF) therapies in anti-TNF-naive rheumatoid arthritis. J. Rheumatol. 34: 2334-2342 (2007).
Fernando SL, Broadfoot AJ. Treatment options for pemphigus foliaceus. G. Ital. Dermatol. Venereol. 144: 363-377 (2009).
Ferno J, Vik-Mo AO, Jassim G, Havik B, Berge K, Skrede S, Gudbrandsen OA, Waage J, Lunder N, Mork S, Berge RK, Jorgensen HA, Steen VM. Acute clozapine exposure in vivo induces lipid accumulation and marked sequential changes in the expression of SREBP, PPAR, and LXR target genes in rat liver. Psychopharmacology (Berl.) 203: 73-84 (2009).
Ferran M, Pujol RM. Safety of adalimumab. Actas. Dermosifiliogr. 99 Suppl. 3: 15-24 (2008).
Ferrante M, D'Haens G, Rutgeerts P, Vermeire S, Van Assche G. Optimizing biologic therapies for inflammatory bowel disease (ulcerative colitis and Crohn's disease). Curr. Gastroenterol. Rep. 11: 504-508 (2009).
Ferrante M, Vermeire S, Fidder H, Schnitzler F, Noman M, Van Assche G, De Hertogh G, Hoffman I, D'Hoore A, Van Steen K, Geboes K, Penninckx F, Rutgeerts P. Long-term outcome after infliximab for refractory ulcerative colitis. Journal of Crohn's and Colitis 2: 219-225 (2008).
Ferraro PM, Ferraccioli GF, Gambaro G, Fulignati P, Costanzi S. Combined treatment with renin-angiotensin system blockers and polyunsaturated fatty acids in proteinuric IgA nephropathy: a randomized controlled trial. Nephrol. Dial. Transplant. 24: 156-160 (2009).
Ferreira AR, Roquete ML, Penna FJ, Toppa NH. Autoimmune hepatitis in children and adolescents: clinical study, diagnosis and therapeutic response. J. Pediatr. (Rio. J.) 78: 309-314 (2002). *
Ferrero S, Ragni N. Inflammatory bowel disease: management issues during pregnancy. Arch. Gynecol. Obstet. 270: 79-85 (2004).
Ferry GD, Kirschner BS, Grand RJ, Issenman RM, Griffiths AM, Vanderhoof JA, Fiedorek SC, Winter HS, Hassall EG, Watkins JB, et al. Olsalazine versus sulfasalazine in mild to moderate childhood ulcerative colitis: results of the Pediatric Gastroenterology Collaborative Research Group Clinical Trial. J. Pediatr. Gastroenterol. Nutr. 17: 32-38 (1993).
Fervenza FC, Sethi S, Specks U. Idiopathic membranous nephropathy: diagnosis and treatment. Clin. J. Am. Soc. Nephrol. 3: 905-919 (2008). *
Fetterman JW Jr, Zdanowicz MM. Therapeutic potential of n-3 polyunsaturated fatty acids in disease. Am. J. Health Syst. Pharm. 66: 1169-1179 (2009). *
Fiallo P. Yellow nails as an adverse reaction to the topical use of 5-fluorouracil for the treatment of nail psoriasis. J. Dermatolog. Treat. Jan 1 [Epub ahead of print] (2009).
Fidder HH, Schnitzler F, Ferrante M, Noman M, Katsanos K, Segaert S, Van Assche G, Vermeire S, Rutgeerts P. Long-term safety of infliximab for the treatment of inflammatory bowel disease: a single center cohort study. Gut 58: 501-508 (2009).
Fiegenbaum M, da Silveira FR, Van der Sand CR, Van der Sand LC, Ferreira ME, Pires RC, Hutz MH. The role of common variants of ABCB1, CYP3A4, and CYP3A5 genes in lipid-lowering efficacy and safety of simvastatin treatment. Clin. Pharmacol. Ther. 78: 551-558 (2005). *
Fields CL, Robinson JW, Roy TM, Ossorio MA, Byrd RP Jr. Hypersensitivity reaction to azathioprine. South. Med. J. 91: 471-474 (1998).
Fijal B, Ricci D, Vercammen E, Palmer PA, Fotiou F, Fife D, Lindholm A, Broderick E, Francke S, Wu X, Colaianne J, Cohen N. Case-control study of the association between select HLA genes and anti-erythropoietin antibody-positive pure red-cell aplasia. Pharmacogenomics 9: 157-167 (2008).
Filippatos TD, Mikhailidis DP. Lipid-lowering drugs acting at the level of the gastrointestinal tract. Curr. Pharm. Des. 15: 490-516 (2009).
Filippini M, Bazzani C, Favalli EG, Marchesoni A, Atzeni F, Sarzi-Puttini P, Pallavicini FB, Caporali R, Gorla R. Efficacy and safety of anti-tumour necrosis factor in elderly patients with rheumatoid arthritis: an observational study. Clin. Rev. Allergy Immunol. Jun 23 [Epub ahead of print] (2009). *
Filler G, Lepage N. To what extent does the understanding of pharmacokinetics of mycophenolate mofetil influence its prescription. Pediatr. Nephrol. 19: 962-965 (2004).
Finckh A, Dehler S, Gabay C. The effectiveness of leflunomide as co-therapy of tumour necrosis factor inhibitors in rheumatoid arthritis: a population based study. Ann. Rheum. Dis. 68: 33-39 (2009).
Finco C, Magnanini P, Sarzo G, Vecchiato M, Luongo B, Savastano S, Bortoliero M, Barison P, Merigliano S. Prospective randomized study on perioperative enteral immunonutrition in laparoscopic colorectal surgery. Surg. Endosc. 21: 1175-1179 (2007). *
Fiorentini MT, Fracchia M, Galatola G, Barlotta A, de la Pierre M. Acute pancreatitis during oral 5-aminosalicylic acid therapy. Dig. Dis. Sci. 35: 1180-1182 (1990).
Fiorucci S, Antonelli E, Tocchetti P, Morelli A. Treatment of portal hypertension with NCX-1000, a liver-specific NO donor. A review of its current status. Cardiovasc. Drug Rev. 22: 135-146 (2004). *
Firmin D, Roguedas AM, Lemasson G, Abgrall JF, Misery L. Eczematous dermatosis and thrombocytosis induced by efalizumab: two new side effects. Dermatology 217: 203-206 (2008).
Firooz A, Ghandi N, Hallaji Z, Chams-Davatchi C, Valikhani M, Karbakhsh Davari M. Role of thiopurine methyltransferase activity in the safety and efficacy of azathioprine in the treatment of pemphigus vulgaris. Arch. Dermatol. 144: 1143-1147 (2008). *
Firpi RJ, Tran TT, Flores P, Nissen N, Colquhoun S, Shackleton C, Martin P, Vierling JM, Poordad FF. Sirolimus-induced hyperlipidaemia in liver transplant recipients is not dose-dependent. Aliment. Pharmacol. Ther. 19: 1033-1039 (2004). *
Fischer B, Elias D, Bretzel RG, Linn T. Immunomodulation with heat shock protein DiaPep277 to preserve beta cell function in type 1 diabetes - an update. Expert Opin. Biol. Ther. Dec 25 [Epub ahead of print] (2009).
Fischman D, Nookala VK. Cystic fibrosis-related diabetes mellitus: etiology, evaluation, and management. Endocr. Pract. 14: 1169-1179 (2008).
Fisher MA, Eklund SA, James SA, Lin X. Adverse events associated with hepatitis B vaccine in U.S. children less than six years of age, 1993 and 1994. Ann. Epidemiol. 11: 13-21 (2001).
Fiszenson-Albala F, Auzerie V, Mahe E, Farinotti R, Durand-Stocco C, Crickx B, Descamps V. A 6-month prospective survey of cutaneous drug reactions in a hospital setting. Br. J. Dermatol. 149: 1018-1022 (2003). *
Fitzgerald DA, Heagerty AH, Stephens M, Smith AG. Follicular toxic pustuloderma associated with allopurinol. Clin. Exp. Dermatol. 19: 243-245 (1994).
Fitzpatrick LA. Secondary causes of osteoporosis. Mayo Clin. Proc. 77: 453-468 (2002). *
Fleischer AB, Abramovits W, Breneman D, Jaracz E. Tacrolimus ointment is more effective than pimecrolimus cream in adult patients with moderate to very severe atopic dermatitis. J. Dermatolog. Treat. 18: 151-157 (2007).
Fleischmann R, Baumgartner SW, Weisman M, Liu T, White B, Peloso PM. Long-term safety of etanercept in elderly subjects with rheumatic diseases. Ann. Rheum. Dis. 65: 379-384 (2006). *
Fleischmann R, Iqbal I, Nandeshwar P, Quiceno A. Safety and efficacy of disease-modifying anti-rheumatic agents: focus on the benefits and risks of etanercept. Drug Saf. 25: 173-197 (2002).
Fleischmann R, Vencovsky J, van Vollenhoven R, Borenstein D, Box J, Coteur G, Goel N, Brezinschek HP, Innes A, Strand V. Efficacy and safety of certolizumab pegol monotherapy every 4 weeks in patients with rheumatoid arthritis failing previous disease-modifying antirheumatic therapy: the FAST4WARD study. Ann. Rheum. Dis. 68: 805-811 (2009). *
Fleischmann RM. Safety of biologic therapy in rheumatoid arthritis and other autoimmune diseases: focus on rituximab. Semin. Arthritis Rheum. 38: 265-280 (2009). *
Fleischmann RM, Tesser J, Schiff M, Schechtman J, Burmester GR, Bennett R, Modafferi D, Zhou L, Bell D, Appleton B. Safety of extended treatment with anakinra in patients with rheumatoid arthritis. Ann. Rheum. Dis. 65: 1006-1012 (2006). *
Fleishmann RM. Safety of anakinra, a recombinant interleukin-1 receptor antagonist (r-metHuIL-1ra), in patients with rheumatoid arthritis and comparison to anti-TNF-alpha agents. Clin. Exp. Rheumatol. 20 (5 Suppl. 27): S35-S41 (2002).
Fletcher S, Steffy K, Averett D. Masked oral prodrugs of Toll-like receptor 7 agonists: a new approach for the treatment of infectious disease. Curr. Opin. Investig. Drugs 7: 702-708 (2006).
Flierl MA, Rittirsch D, Gao H, Hoesel LM, Nadeau BA, Day DE, Zetoune FS, Sarma JV, Huber-Lang MS, Ferrara JL, Ward PA. Adverse functions of IL-17A in experimental sepsis. FASEB J. 22: 2198-2205 (2008). *
Flisiak R, Feinman SV, Jablkowski M, Horban A, Kryczka W, Pawlowska M, Heathcote JE, Mazzella G, Vandelli C, Nicolas-Metral V, Grosgurin P, Liz JS, Scalfaro P, Porchet H, Crabbe R. The cyclophilin inhibitor Debio 025 combined with PEG IFNalpha2a significantly reduces viral load in treatment-naive hepatitis C patients. Hepatology 49: 1460-1468 (2009).
Floreani A, Paternoster D, Melis A, Grella PV. S-Adenosylmethionine versus ursodeoxycholic acid in the treatment of intrahepatic cholestasis of pregnancy: preliminary results of a controlled trial. Eur. J. Obstet. Gynecol. Reprod. Biol. 67: 109-113 (1996).
Flotte TR. Gene therapy: the first two decades and the current state-of-the-art. J. Cell. Physiol. 213: 301-305 (2007). *
Flotte TR, Laube BL. Gene therapy in cystic fibrosis. Chest 120: 124S-131S (2001). *
Folzenlogen D. A case of atorvastatin combined toxic myopathy and inflammatory myositis. J. Clin. Rheumatol. 7: 340-345 (2001).
Fontana RJ. Side effects of long-term oral antiviral therapy for hepatitis B. Hepatology 49: S185-S195 (2009).
Forbes A, Al-Damluji A, Ashworth S, Bramble M, Herbert K, Ho J, Kang JY, Przemioslo R, Shetty A. Multicentre randomized-controlled clinical trial of Ipocol, a new enteric-coated form of mesalazine, in comparison with Asacol in the treatment of ulcerative colitis. Aliment. Pharmacol. Ther. 21: 1099-1104 (2005). *
Ford AC, Brandt LJ, Young C, Chey WD, Foxx-Orenstein AE, Moayyedi P. Efficacy of 5-HT3 antagonists and 5-HT4 agonists in irritable bowel syndrome: systematic review and meta-analysis. Am. J. Gastroenterol. 104: 1831-1843 (2009). *
Forman MR, Hursting SD, Umar A, Barrett JC. Nutrition and cancer prevention: a multidisciplinary perspective on human trials. Annu. Rev. Nutr. 24: 223-254 (2004). *
Fouache D, Goeb V, Massy-Guillemant N, Avenel G, Bacquet-Deschryver H, Kozyreff-Meurice M, Menard JF, Muraine M, Savoye G, Loet XL, Tharasse C, Vittecoq O. Paradoxical adverse events of anti-tumour necrosis factor therapy for spondyloarthropathies: a retrospective study. Rheumatology (Oxford) 48: 761-764 (2009).
Fouad TR, Abdel-Razek WM, Burak KW, Bain VG, Lee SS. Prediction of cardiac complications after liver transplantation. Transplantation 87: 763-770 (2009).
Fouassier L, Kinnman N, Lefevre G, Lasnier E, Rey C, Poupon R, Oude Elferink RP, Housset C. Contribution of mrp2 in alterations of canalicular bile formation by the endothelin antagonist bosentan. J. Hepatol. 37: 184-191 (2002). *
Fousteri G, Dave A, Juntti T, von Herrath M. CD103 is dispensable for anti-viral immunity and autoimmunity in a mouse model of virally-induced autoimmune diabetes. J. Autoimmun. 32: 70-77 (2009).
Fox CC, Moore WC, Lichtenstein LM. Modulation of mediator release from human intestinal mast cells by sulfasalazine and 5-aminosalicylic acid. Dig. Dis. Sci. 36: 179-184 (1991).
Fox RI, Herrmann ML, Frangou CG, Wahl GM, Morris RE, Kirschbaum BJ. How does leflunomide modulate the immune response in rheumatoid arthritis? BioDrugs 12: 301-315 (1999).
Fracchiolla G, Laghezza A, Piemontese L, Tortorella P, Mazza F, Montanari R, Pochetti G, Lavecchia A, Novellino E, Pierno S, Conte Camerino D, Loiodice F. New 2-aryloxy-3-phenyl-propanoic acids as peroxisome proliferator-activated receptors alpha/gamma dual agonists with improved potency and reduced adverse effects on skeletal muscle function. J. Med. Chem. 52: 6382-6393 (2009). *
Fraenkel L, Bogardus ST, Concato J, Felson DT, Wittink DR. Patient preferences for treatment of rheumatoid arthritis. Ann. Rheum. Dis. 63: 1372-1378 (2004). *
Frais AT. Depression and the causal role of specific memory system degenerations: link may be supported by reported therapeutic benefits of omega 3 fatty acids. Med. Hypotheses 69: 67-69 (2007).
Franchimont D. Mechanisms of steroid refractory disease. Falk Symposium 140. Inflammatory Bowel Disease: Translation from Basic Research to Clinical Practice. Dubrovnik (Croatia). p. 72-73. May 7-8 (2004). *
Franchin G, Diamond B. Pulse steroids: how much is enough? Autoimmun. Rev. 5: 111-113 (2006).
Franchini M, Gandini G, Veneri D, De Matteis G, Federici F, Solero P, Aprili G. Efficacy and safety of phlebotomy to reduce transfusional iron overload in adult, long-term survivors of acute leukemia. Transfusion 44: 833-837 (2004). *
Franciotta D, Kwan P, Perucca E. Genetic basis for idiosyncratic reactions to antiepileptic drugs. Curr. Opin. Neurol. 22: 144-149 (2009).
Frank FM, Cazorla SI, Sartori MJ, Corral RS. Elicitation of specific, Th1-biased immune response precludes skeletal muscle damage in cruzipain-vaccinated mice. Exp. Mol. Pathol. 84: 64-70 (2008). *
Freeman HJ. Osteomyelitis and osteonecrosis in inflammatory bowel disease. Can. J. Gastroenterol. 11: 601-606 (1997). *
French LE. Toxic epidermal necrolysis and Stevens Johnson syndrome: our current understanding. Allergol. Int. 55: 9-16 (2006). *
Freston JW, Hisada M, Peura DA, Haber MM, Kovacs TO, Atkinson S, Hunt B. The clinical safety of long-term lansoprazole for the maintenance of healed erosive esophagitis. Aliment. Pharmacol. Ther. 29: 1249-1260 (2009). *
Fried RH, Murakami CS, Fisher LD, Willson RA, Sullivan KM, McDonald GB. Ursodeoxycholic acid treatment of refractory chronic graft-versus-host disease of the liver. Ann. Intern. Med. 116: 624-629 (1992).
Friedel HA, Goa KL, Benfield P. S-Adenosyl-L-methionine. A review of its pharmacological properties and therapeutic potential in liver dysfunction and affective disorders in relation to its physiological role in cell metabolism. Drugs 38: 389-416 (1989).
Friedman A, Moe S. Review of the effects of omega-3 supplementation in dialysis patients. Clin. J. Am. Soc. Nephrol. 1: 182-192 (2006). *
Friedman JD, Dello Buono FA. Opioid antagonists in the treatment of opioid-induced constipation and pruritus. Ann. Pharmacother. 35: 85-91 (2001).
Friedman S. Medical therapy and birth outcomes in women with Crohn's disease: what should we tell our patients? Am. J. Gastroenterol. 102: 1414-1416 (2007). *
Friese MA, Montalban X, Willcox N, Bell JI, Martin R, Fugger L. The value of animal models for drug development in multiple sclerosis. Brain 129: 1940-1952 (2006). *
Friesen RW, Innis SM. Dietary arachidonic acid to EPA and DHA balance is increased among Canadian pregnant women with low fish intake. J. Nutr. 139: 2344-2350 (2009).
Fromm MF. Importance of P-glycoprotein at blood-tissue barriers. Trends Pharmacol. Sci. 25: 423-429 (2004). *
Frudinger A, Kolle D, Schwaiger W, Pfeifer J, Paede J, Halligan S. Muscle derived cell injection to treat anal incontinence due to obstetric trauma: pilot study with one-year follow-up. Gut 59: 55-61 (2010).
Fuhr U. Induction of drug metabolising enzymes: pharmacokinetic and toxicological consequences in humans. Clin. Pharmacokinet. 38: 493-504 (2000).
Fujimori S, Gudis K, Mitsui K, Seo T, Yonezawa M, Tanaka S, Tatsuguchi A, Sakamoto C. A randomized controlled trial on the efficacy of synbiotic versus probiotic or prebiotic treatment to improve the quality of life in patients with ulcerative colitis. Nutrition 25: 520-525 (2009). *
Fujimori S, Tatsuguchi A, Gudis K, Kishida T, Mitsui K, Ehara A, Kobayashi T, Sekita Y, Seo T, Sakamoto C. High dose probiotic and prebiotic cotherapy for remission induction of active Crohn's disease. J. Gastroenterol. Hepatol. 22: 1199-1204 (2007). *
Fujio K, Okamura T, Okamoto A, Yamamoto K. T cell receptor gene therapy for autoimmune diseases. Ann. N. Y. Acad. Sci. 1110: 222-232 (2007). *
Fukuda H, Ebara M, Okabe S, Yoshikawa M, Sugiura N, Saisho H, Kondo F, Yukawa M. Metal contents of liver parenchyma after percutaneous ethanol injection or radiofrequency ablation in patients with hepatocellular carcinoma before and after trientine hydrochloride therapy. J. Lab. Clin. Med. 143: 333-339 (2004). *
Fukuda Y, Takazoe M, Sugita A, Kosaka T, Kinjo F, Otani Y, Fujii H, Koganei K, Makiyama K, Nakamura T, Suda T, Yamamoto S, Ashida T, Majima A, Morita N, Murakami K, Oshitani N, Takahama K, Tochihara M, Tsujikawa T, Watanabe M. Oral spherical adsorptive carbon for the treatment of intractable anal fistulas in Crohn's disease: a multicenter, randomized, double-blind, placebo-controlled trial. Am. J. Gastroenterol. 103: 1721-1729 (2008). *
Fung KL, Gottesman MM. A synonymous polymorphism in a common MDR1 (ABCB1) haplotype shapes protein function. Biochim. Biophys. Acta 1794: 860-871 (2009). *
Furie R, Stohl W, Ginzler EM, Becker M, Mishra N, Chatham WW, Merrill JT, Weinstein A, McCune WJ, Zhong J, Cai W, Freimuth W, Study Group B. Biologic activity and safety of belimumab, a neutralizing anti-B-lymphocyte stimulator (BLyS) monoclonal antibody: a phase I trial in patients with systemic lupus erythematosus. Arthritis Res. Ther. 10: R109 (2008). *
Furst DE, Gaylis N, Bray V, Olech E, Yocum D, Ritter J, Weisman M, Wallace D, Crues J, Khanna D, Eckel G, Yeilding N, Callegari P, Visvanathan S, Rojas J, Hegedus R, George L, Mamun K, Gilmer K, Troum O. Open-label, pilot protocol of patients with rheumatoid arthritis who switch to infliximab after an incomplete response to etanercept: the OPPOSITE study. Ann. Rheum. Dis. 66: 893-899 (2007). *
Furst DE, Schiff MH, Fleischmann RM, Strand V, Birbara CA, Compagnone D, Fischkoff SA, Chartash EK. Adalimumab, a fully human anti tumor necrosis factor-alpha monoclonal antibody, and concomitant standard antirheumatic therapy for the treatment of rheumatoid arthritis: results of STAR (Safety Trial of Adalimumab in Rheumatoid Arthritis). J. Rheumatol. 30: 2563-2571 (2003).
Gade JN. Clinical update on alefacept: consideration for use in patients with psoriasis. J. Manag. Care Pharm. 10 (3 Suppl. B): S33-S37 (2004).
Gaedigk A, Ndjountche L, Divakaran K, Dianne Bradford L, Zineh I, Oberlander TF, Brousseau DC, McCarver DG, Johnson JA, Alander SW, Wayne Riggs K, Steven Leeder J. Cytochrome P4502D6 (CYP2D6) gene locus heterogeneity: characterization of gene duplication events. Clin. Pharmacol. Ther. 81: 242-251 (2007). *
Galeazzi M, Giannitti C, Manganelli S, Benucci M, Scarpato S, Bazzani C, Caporali R, Sebastiani GD. Treatment of rheumatic diseases in patients with HCV and HIV infection. Autoimmun. Rev. 8: 100-103 (2008).
Galindo MP, Bartlett BL, Gewirtzman A, Mendoza N, Tremaine AM, Tyring SK. Etanercept: an overview of its role in the treatment of psoriasis. Expert Opin. Drug Metab. Toxicol. 4: 305-310 (2008).
Gallagher MJ, Quinones K, Cervantes-Castaneda RA, Yilmaz T, Foster CS. Biologic response modifier therapy for refractory childhood uveitis. Br. J. Ophthalmol. 91: 1341-1344 (2007). *
Gallo AP, Silva LB, Franco M, Burdmann EA, Bueno V. Tacrolimus in combination with FTY720 - an analysis of renal and blood parameters. Int. Immunopharmacol. 6: 1723-1728 (2006).
Gallo AP, Silva LB, Franco M, Burdmann EA, Bueno V. Tacrolimus in combination with FTY720 - an analysis of renal and blood parameters. Int. Immunopharmacol. 6: 1919-1924 (2006).
Galus R, Zandecki L, Jozwiak J, Wlodarski K. Statins and their pleiotropic effects. Pol. Merkur. Lekarski. 24: 545-548 (2008).
Gammill HS, Nelson JL. Naturally acquired microchimerism. Int. J. Dev. Biol. Nov 2 [Epub ahead of print] (2009).
Gan JH, Zhou XQ, Qin AL, Luo EP, Zhao WF, Yu H, Xu J. Hybrid artificial liver support system for treatment of severe liver failure. World J. Gastroenterol. 11: 890-894 (2005). *
Ganguli SC, Cawdron R, Irvine EJ. Alternative medicine use by Canadian ambulatory gastroenterology patients: secular trend or epidemic? Am. J. Gastroenterol. 99: 319-326 (2004). *
Gao D, Wagner AH, Fankhaenel S, Stojanovic T, Schweyer S, Panzner S, Hecker M. CD40 antisense oligonucleotide inhibition of trinitrobenzene sulphonic acid induced rat colitis. Gut 54: 70-77 (2005). *
Garcia CE, Garcia RF, Mayer AD, Neuberger J. Liver transplantation in patients over sixty years of age. Transplantation 72: 679-684 (2001).
Garcia Hernandez FJ, Ocana Medina C, Gonzalez Leon R, Garrido Rasco R, Colorado Bonilla R, Castillo Palma MJ, Sanchez Roman J. Rituximab for treatment of patients with systemic autoimmune diseases. Med. Clin. (Barc.) 128: 458-462 (2007).
Garcia JM, Espanol T, Gurbindo MD, Casas CC. Update on the treatment of primary immunodeficiencies. Allergol. Immunopathol. (Madr.) 35: 184-192 (2007).
Garcia-Erce JA, Gomollon F, Munoz M. Blood transfusion for the treatment of acute anaemia in inflammatory bowel disease and other digestive diseases. World J. Gastroenterol. 15: 4686-4694 (2009). *
Garcia-Herrera J, Marca MC, Brot-Laroche E, Guillen N, Acin S, Navarro MA, Osada J, Rodriguez-Yoldi MJ. Protein kinases, TNF-alpha and proteasome contribute in the inhibition of fructose intestinal transport by sepsis in vivo. Am. J. Physiol. Gastrointest. Liver Physiol. 294: G155-G164 (2008). *
Garcia-Olmo D, Garcia-Arranz M, Herreros D, Pascual I, Peiro C, Rodriguez-Montes JA. A phase I clinical trial of the treatment of Crohn's fistula by adipose mesenchymal stem cell transplantation. Dis. Colon Rectum 48: 1416-1423 (2005). *
Garcia-Pagan JC, Villanueva C, Albillos A, Banares R, Morillas R, Abraldes JG, Bosch J. Nadolol plus isosorbide mononitrate alone or associated with band ligation in the prevention of recurrent bleeding: a multicenter randomized controlled trial. Gut 58: 1144-1150 (2009).
Garnett WR, Yunker N. Treatment of Crohn's disease with infliximab. Am. J. Health Syst. Pharm. 58: 307-316 (2001).
Garnock-Jones KP, Perry CM. Alitretinoin: in severe chronic hand eczema. Drugs 69: 1625-1634 (2009).
Garratt LW, Mistry V, Singh R, Sandhu J, Sheil B, Cooke MS, Sly PD; on behalf of ARESTCF. Interpretation of urinary 8-oxo-7,8-dihydro-2'-deoxyguanosine is adversely affected by methodological inaccuracies when using a commercial ELISA. Free Radic. Biol. Med. Feb 17 [Epub ahead of print] (2010).
Garred P, Pressler T, Lanng S, Madsen HO, Moser C, Laursen I, Balstrup F, Koch C, Koch C. Mannose-binding lectin (MBL) therapy in an MBL-deficient patient with severe cystic fibrosis lung disease. Pediatr. Pulmonol. 33: 201-207 (2002).
Gartlehner G, Hansen RA, Jonas BL, Thieda P, Lohr KN. Biologics for the treatment of juvenile idiopathic arthritis: a systematic review and critical analysis of the evidence. Clin. Rheumatol. 27: 67-76 (2008). *
Gartlehner G, Hansen RA, Jonas BL, Thieda P, Lohr KN. The comparative efficacy and safety of biologics for the treatment of rheumatoid arthritis: a systematic review and metaanalysis. J. Rheumatol. 33: 2398-2408 (2006).
Garvey B. Rituximab in the treatment of autoimmune haematological disorders. Br. J. Haematol. 141: 149-169 (2008). *
Gaspar HB, Parsley KL, Howe S, King D, Gilmour KC, Sinclair J, Brouns G, Schmidt M, Von Kalle C, Barington T, Jakobsen MA, Christensen HO, Al Ghonaium A, White HN, Smith JL, Levinsky RJ, Ali RR, Kinnon C, Thrasher AJ. Gene therapy of X-linked severe combined immunodeficiency by use of a pseudotyped gammaretroviral vector. Lancet 364: 2181-2187 (2004). *
Gaspari R, Cavaliere F, Sollazzi L, Perilli V, Melchionda I, Agnes S, Gasbarrini A, Avolio AW. Molecular adsorbent recirculating system (MARS) in patients with primary nonfunction and other causes of graft dysfunction after liver transplantation in the era of extended criteria donor organs. Transplant. Proc. 41: 253-258 (2009). *
Gatanaga H, Honda H, Oka S. Pharmacogenetic information derived from analysis of HLA alleles. Pharmacogenomics 9: 207-214 (2008).
Gazouli M, Pachoula I, Panayotou I, Mantzaris G, Syriopoulou VP, Goutas N, Vlachodimitropoulos D, Anagnou NP, Roma-Giannikou E. Thiopurine S-methyltransferase genotype and the use of thiopurines in paediatric inflammatory bowel disease Greek patients. J. Clin. Pharm. Ther. 35: 93-97 (2010). *
Gearry R, Barclay M, Gardiner S, Zhang M. 6-Thioguanine nucleotides and thiopurine methyltransferase activity: important factors determining response to treatment and incidence of adverse effects from azathioprine and 6-MP. N. Z. Med. J. 116: U531 (2003). *
Gearry RB, Barclay ML, Burt MJ, Collett JA, Chapman BA. Thiopurine drug adverse effects in a population of New Zealand patients with inflammatory bowel disease. Pharmacoepidemiol. Drug Saf. 13: 563-567 (2004). *
Gearry RB, Barclay ML, Burt MJ, Collett JA, Chapman BA, Roberts RL, Kennedy MA. Thiopurine S-methyltransferase (TPMT) genotype does not predict adverse drug reactions to thiopurine drugs in patients with inflammatory bowel disease. Aliment. Pharmacol. Ther. 18: 395-400 (2003). *
Gearry RB, Roberts RL, Barclay ML, Kennedy MA. Lack of association between the ITPA 94C>A polymorphism and adverse effects from azathioprine. Pharmacogenetics 14: 779-781 (2004).
Geddes MR, Sinnreich M, Chalk C. Minocycline-induced dermatomyositis. Muscle Nerve Jan 29 [Epub ahead of print] (2010).
Geddes R. Minocycline-induced lupus in adolescents: clinical implications for physical therapists. J. Orthop. Sports Phys. Ther. 37: 65-71 (2007).
Geenes V, Williamson C. Intrahepatic cholestasis of pregnancy. World J. Gastroenterol. 15: 2049-2066 (2009). *
Geese WJ, Achanzar W, Rubin C, Hariharan N, Cheng P, Tomlinson L, Ordway N, Dracopoli NC, Delmonte T, Hui L, Krishnan B, Cosma G, Ranade K. Genetic and gene expression studies implicate renin and endothelin-1 in edema caused by peroxisome proliferator-activated receptor gamma agonists. Pharmacogenet. Genomics 18: 903-910 (2008).
Geier DA, Geier MR. Hepatitis B vaccination and adult associated gastrointestinal reactions: a follow-up analysis. Hepatogastroenterology 49: 1571-1575 (2002).
Geier DA, Geier MR. A one year followup of chronic arthritis following rubella and hepatitis B vaccination based upon analysis of the Vaccine Adverse Events Reporting System (VAERS) database. Clin. Exp. Rheumatol. 20: 767-771 (2002).
Geier DA, Geier MR. Anthrax vaccination and joint related adverse reactions in light of biological warfare scenarios. Clin. Exp. Rheumatol. 20: 217-220 (2002).
Geier DA, Geier MR. A case-control study of serious autoimmune adverse events following hepatitis B immunization. Autoimmunity 38: 295-301 (2005).
Geier MR, Geier DA. Gastrointestinal adverse reactions following anthrax vaccination: an analysis of the Vaccine Adverse Events Reporting System (VAERS) database. Hepatogastroenterology 51: 762-767 (2004).
Geier MR, Geier DA. Hepatitis B vaccination safety. Ann. Pharmacother. 36: 370-374 (2002).
Geier MR, Geier DA. A case-series of adverse events, positive re-challenge of symptoms, and events in identical twins following hepatitis B vaccination: analysis of the Vaccine Adverse Event Reporting System (VAERS) database and literature review. Clin. Exp. Rheumatol. 22: 749-755 (2004).
Geier MR, Geier DA, Zahalsky AC. A review of hepatitis B vaccination. Expert Opin. Drug Saf. 2: 113-122 (2003).
Gencoglan G, Tosun M, Aktepe F. The molecular mechanism of etanercept, an anti-tumour necrosis factor-alpha receptor-fusion protein, in the treatment of acute generalized exanthematous pustulosis. J. Dermatolog. Treat. 20: 241-245 (2009).
Gendzekhadze K, Rivas-Vetencourt P, Montano RF. Risk of adverse post-transplant events after kidney allograft transplantation as predicted by CTLA-4 +49 and TNF-alpha -308 single nucleotide polymorphisms: a preliminary study. Transpl. Immunol. 16: 194-199 (2006).
Gene E, Calvet X, Azagra R, Gisbert JP. Triple vs. quadruple therapy for treating Helicobacter pylori infection: a meta-analysis. Aliment. Pharmacol. Ther. 17: 1137-1143 (2003). *
Geng A, Weinstock MA, Hall R, Eilers D, Naylor M, Kalivas J; for the VATTC Trial Group. Tolerability of high-dose topical tretinoin: the Veterans Affairs Topical Tretinoin Chemoprevention Trial. Br. J. Dermatol. 161: 918-924 (2009). *
Genovese M, Van den Bosch F, Roberson S, Bojin S, Biagini I, Ryan P, Sloan-Lancaster J. LY2439821, a humanized anti-IL-17 monoclonal antibody, in the treatment of patients with rheumatoid arthritis. Arthritis Rheum. Jan 21 [Epub ahead of print] (2010). *
Genovese MC, Becker JC, Schiff M, Luggen M, Sherrer Y, Kremer J, Birbara C, Box J, Natarajan K, Nuamah I, Li T, Aranda R, Hagerty DT, Dougados M. Abatacept for rheumatoid arthritis refractory to tumor necrosis factor alpha inhibition. N. Engl. J. Med. 353: 1114-1123 (2005). *
Genovese MC, McKay JD, Nasonov EL, Mysler EF, da Silva NA, Alecock E, Woodworth T, Gomez-Reino JJ. Interleukin-6 receptor inhibition with tocilizumab reduces disease activity in rheumatoid arthritis with inadequate response to disease-modifying antirheumatic drugs: the tocilizumab in combination with traditional disease-modifying antirheumatic drug … Arthritis Rheum. 58: 2968-2980 (2008). *
Genovese MC, Mease PJ, Thomson GT, Kivitz AJ, Perdok RJ, Weinberg MA, Medich J, Sasso EH. Safety and efficacy of adalimumab in treatment of patients with psoriatic arthritis who had failed disease modifying antirheumatic drug therapy. J. Rheumatol. 34: 1040-1050 (2007).
George R, Stevens A, Berkenbosch JW, Turpin J, Tobias J. Ursodeoxycholic acid in the treatment of cholestasis and hyperbilirubinemia in pediatric intensive care unit patients. South. Med. J. 95: 1276-1279 (2002).
Gerard L, Garey KW, Dupont HL. Rifaximin: a nonabsorbable rifamycin antibiotic for use in nonsystemic gastrointestinal infections. Expert Rev. Anti. Infect. Ther. 3: 201-211 (2005).
Gercek A, Yildirim O, Konya D, Bozkurt S, Ozgen S, Kilic T, Sav A, Pamir N. Effects of parenteral fish-oil emulsion (omegaven) on cutaneous wound healing in rats treated with dexamethasone. JPEN J. Parenter. Enteral Nutr. 31: 161-166 (2007). *
Gerloni V, Pontikaki I, Gattinara M, Fantini F. Biological therapy with TNF-inhibitors in pediatric rheumatology. Review of the literature and personal experience. Reumatismo 59: 244-261 (2007).
Gerloni V, Pontikaki I, Gattinara M, Fantini F. Focus on adverse events of tumour necrosis factor alpha blockade in juvenile idiopathic arthritis in an open monocentric long-term prospective study of 163 patients. Ann. Rheum. Dis. 67: 1145-1152 (2008).
German JB, Roberts MA, Watkins SM. Genomics and metabolomics as markers for the interaction of diet and health: lessons from lipids. J. Nutr. 133: 2078S-2083S (2003). *
Gernsheimer TB. The pathophysiology of ITP revisited: ineffective thrombopoiesis and the emerging role of thrombopoietin receptor agonists in the management of chronic immune thrombocytopenic purpura. Hematology Am. Soc. Hematol. Educ. Program 2008: 219-226 (2008).
Gervasini G. Polymorphisms in methotrexate pathways: what is clinically relevant, what is not, and what is promising. Curr. Drug Metab. 10: 547-566 (2009).
Geschwind JF, Salem R, Carr BI, Soulen MC, Thurston KG, Goin KA, Van Buskirk M, Roberts CA, Goin JE. Yttrium-90 microspheres for the treatment of hepatocellular carcinoma. Gastroenterology 127 (5 Suppl. 2): S194-S205 (2004). *
Ghent CN, Carruthers SG. Treatment of pruritus in primary biliary cirrhosis with rifampin. Results of a double-blind, crossover, randomized trial. Gastroenterology 94: 488-493 (1988).
Gheorghe L, Gheorghe C, Badea M, Vadan R, Parvulescu I, Toader C, Tugui L, Papuc O, Ionescu R, Preda C, Calin I, Diculescu M. Infliximab for Crohn's disease in clinical practice: the experience of a single center in Romania. Rom. J. Gastroenterol. 12: 7-13 (2003).
Ghislain PD, Roujeau JC. Treatment of severe drug reactions: Stevens-Johnson syndrome, toxic epidermal necrolysis and hypersensitivity syndrome. Dermatol. Online J. 8: 5 (2002).
Ghosh M, Wang H, Ai Y, Romeo E, Luyendyk JP, Peters JM, Mackman N, Dey SK, Hla T. COX-2 suppresses tissue factor expression via endocannabinoid-directed PPARdelta activation. J. Exp. Med. 204: 2053-2061 (2007). *
Ghosh S, Goldin E, Gordon FH, Malchow HA, Rask-Madsen J, Rutgeerts P, Vyhnalek P, Zadorova Z, Palmer T, Donoghue S; Natalizumab Pan-European Study Group. Natalizumab for active Crohn's disease. N. Engl. J. Med. 348: 24-32 (2003). *
Giaffer MH, O'Brien CJ, Holdsworth CD. Clinical tolerance to three 5-aminosalicylic acid releasing preparations in patients with inflammatory bowel disease intolerant or allergic to sulphasalazine. Aliment. Pharmacol. Ther. 6: 51-59 (1992).
Giagounidis AA, Anhuf J, Schneider P, Germing U, Sohngen D, Quabeck K, Aul C. Treatment of relapsed idiopathic thrombocytopenic purpura with the anti-CD20 monoclonal antibody rituximab: a pilot study. Eur. J. Haematol. 69: 95-100 (2002). *
Gibbons LJ, Hyrich KL. Biologic therapy for rheumatoid arthritis: clinical efficacy and predictors of response. BioDrugs 23: 111-124 (2009).
Gibson PR, Fixa B, Pekarkova B, Batovsky M, Radford-Smith G, Tibitanzl J, Gabalec L, Florin TH, Greinwald R. Comparison of the efficacy and safety of Eudragit-L-coated mesalazine tablets with ethylcellulose-coated mesalazine tablets in patients with mild to moderately active ulcerative colitis. Aliment. Pharmacol. Ther. 23: 1017-1026 (2006). *
Gibson PR, Muir JG. Reinforcing the mucus: a new therapeutic approach for ulcerative colitis? Gut 54: 900-903 (2005). *
Gibson RL, Emerson J, Mayer-Hamblett N, Burns JL, McNamara S, Accurso FJ, Konstan MW, Chatfield BA, Retsch-Bogart G, Waltz DA, Acton J, Zeitlin P, Hiatt P, Moss R, Williams J, Ramsey BW. Duration of treatment effect after tobramycin solution for inhalation in young children with cystic fibrosis. Pediatr. Pulmonol. 42: 610-623 (2007).
Giembycz MA, Smith SJ. Phosphodiesterase 7A: a new therapeutic target for alleviating chronic inflammation? Curr. Pharm. Des. 12: 3207-3220 (2006).
Gilbert J, Kelleher J, Littlewood JM, Evans DF. Ileal pH in cystic fibrosis. Scand. J. Gastroenterol. Suppl. 143: 132-134 (1988). *
Giles JT, Post W, Blumenthal RS, Bathon JM. Therapy insight: managing cardiovascular risk in patients with rheumatoid arthritis. Nat. Clin. Pract. Rheumatol. 2: 320-329 (2006). *
Gilissen LP, Derijks LJ, Bos LP, Verhoeven HM, Bus PJ, Hooymans PM, Engels LG. Some cases demonstrating the clinical usefulness of therapeutic drug monitoring in thiopurine-treated inflammatory bowel disease patients. Eur. J. Gastroenterol. Hepatol. 16: 705-710 (2004).
Giljaca V, Poropat G, Stimac D, Gluud C. Glucocorticosteroids for primary sclerosing cholangitis. Cochrane Database Syst. Rev. 1: CD004036 (2010). *
Gines P, Wong F, Watson H, Milutinovic S, del Arbol LR, Olteanu D; HypoCAT Study Investigators. Effects of satavaptan, a selective vasopressin V(2) receptor antagonist, on ascites and serum sodium in cirrhosis with hyponatremia: a randomized trial. Hepatology 48: 204-213 (2008). *
Gines P, Wong F, Watson H, Terg R, Bruha R, Zarski JP. Clinical trial: short-term effects of combination of satavaptan, a selective vasopressin V receptor antagonist, and diuretics on ascites in patients with cirrhosis without hyponatremia - a randomized, double-blind, placebo-controlled study. Aliment. Pharmacol. Ther. Jan 22 [Epub ahead of print] (2010). *
Gionchetti P, D'arienzo A, Rizzello F, Manguso F, Maieron R, Lecis PE, Valpiani D, Iaquinto G, Annese V, Balzano A, Varoli G, Campieri M; and the Italian BDP Study Group. Topical treatment of distal active ulcerative colitis with beclomethasone dipropionate or mesalamine: a single-blind randomized controlled trial. J. Clin. Gastroenterol. 39: 291-297 (2005).
Girona E, Borras-Blasco J, Conesa-Garcia V, Navarro-Ruiz A, Solis J, Garcia-Sepulcre MF, Oliver-Garcia I. Successful treatment of severe gastrointestinal bleeding secondary to Crohn disease with recombinant factor VIIa. South. Med. J. 100: 601-604 (2007).
Gironi M, Martinelli-Boneschi F, Sacerdote P, Solaro C, Zaffaroni M, Cavarretta R, Moiola L, Bucello S, Radaelli M, Pilato V, Rodegher M, Cursi M, Franchi S, Martinelli V, Nemni R, Comi G, Martino G. A pilot trial of low-dose naltrexone in primary progressive multiple sclerosis. Mult. Scler. 14: 1076-1083 (2008). *
Gisbert JP, Bermejo F, Pajares R, Perez-Calle JL, Rodriguez M, Algaba A, Mancenido N, de la Morena F, Carneros JA, McNicholl AG, Gonzalez-Lama Y, Mate J. Oral and intravenous iron treatment in inflammatory bowel disease: hematological response and quality of life improvement. Inflamm. Bowel Dis. 15: 1485-1491 (2009).
Gisbert JP, Gomollon F. Thiopurine-induced myelotoxicity in patients with inflammatory bowel disease: a review. Am. J. Gastroenterol. 103: 1783-1800 (2008). *
Gisbert JP, Gonzalez-Lama Y, Mate J. Monitoring of thiopurine methyltransferase and thiopurine metabolites to optimize azathioprine therapy in inflammatory bowel disease. Gastroenterol. Hepatol. 29: 568-583 (2006).
Gisbert JP, Gonzalez-Lama Y, Mate J. Thiopurine-induced liver injury in patients with inflammatory bowel disease: a systematic review. Am. J. Gastroenterol. 102: 1518-1527 (2007). *
Gisbert JP, Gonzalez-Lama Y, Mate J. Systematic review: infliximab therapy in ulcerative colitis. Aliment. Pharmacol. Ther. 25: 19-37 (2007). *
Gisbert JP, Luna M, Mate J, Gonzalez-Guijarro L, Cara C, Pajares JM. Choice of azathioprine or 6-mercaptopurine dose based on thiopurine methyltransferase (TPMT) activity to avoid myelosuppression. A prospective study. Hepatogastroenterology 53: 399-404 (2006).
Gisbert JP, Luna M, Mate J, Gonzalez-Guijarro L, Cara C, Pajares JM. Thiopurine methyltransferase activity and myelosuppression in inflammatory bowel disease patients treated with azathioprine and 6-mercaptopurine. Med. Clin. (Barc.) 121: 1-5 (2003).
Gisbert JP, Nino P, Rodrigo L, Cara C, Guijarro LG. Thiopurine methyltransferase (TPMT) activity and adverse effects of azathioprine in inflammatory bowel disease: long-term follow-up study of 394 patients. Am. J. Gastroenterol. 101: 2769-2776 (2006). *
Gissi-Hf Investigators. Effect of n-3 polyunsaturated fatty acids in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind, placebo-controlled trial. Lancet 372: 1223-1230 (2008). *
Gjurow D, Grzelewski T, Sobocinska A, Stelmach I. Tumor necrosis factor inhibitors in pediatric asthma. Recent Pat. Inflamm. Allergy Drug Discov. 3: 143-148 (2009).
Glass-Marmor L, Paperna T, Ben-Yosef Y, Miller A. Chronotherapy using corticosteroids for multiple sclerosis relapses. J. Neurol. Neurosurg. Psychiatry 78: 886-888 (2007). *
Gloro R, Hourmand-Ollivier I, Mosquet B, Mosquet L, Rousselot P, Salame E, Piquet MA, Dao T. Fulminant hepatitis during self-medication with hydroalcoholic extract of green tea. Eur. J. Gastroenterol. Hepatol. 17: 1135-1137 (2005).
Gluud C, Christensen E. Ursodeoxycholic acid for primary biliary cirrhosis. Cochrane Database Syst. Rev. 1: CD000551 (2002). *
Gluud LL, Marchesini E, Iorio A. Peginterferon plus ribavirin for chronic hepatitis C in patients with human immunodeficiency virus. Am. J. Gastroenterol. 104: 2335-2341 (2009). *
Goerres MS, Meijer JWR, Wahab PJ, Kerckhaert JAM, Groenen PJTA, Van Krieken JHJM, Mulder CJJ. Azathioprine and prednisone combination therapy in refractory Coeliac disease. Aliment. Pharmacol. Ther. 18: 487-494 (2003). *
Goetz M, Atreya R, Ghalibafian M, Galle PR, Neurath MF. Exacerbation of ulcerative colitis after rituximab salvage therapy. Inflamm. Bowel Dis. 13: 1365-1368 (2007). *
Goffe B, Papp K, Gratton D, Krueger GG, Darif M, Lee S, Bozic C, Sweetser MT, Ticho B. An integrated analysis of thirteen trials summarizing thelong-term safety of alefacept in psoriasis patients who have received up to nine courses of therapy. Clin. Ther. 27: 1912-1921 (2005). *
Gogia S, Sachdev HS. Neonatal vitamin A supplementation for prevention of mortality and morbidity in infancy: systematic review of randomised controlled trials. BMJ 338: b919 (2009).
Goh J, O'Morain CA. Review article: nutrition and adult inflammatory bowel disease. Aliment. Pharmacol. Ther. 17: 307-320 (2003). *
Goke B, Gause-Nilsson I, Persson A; On Behalf Of The Gallant 8 Study Group. The effects of tesaglitazar as add-on treatment to metformin in patients with poorly controlled type 2 diabetes. Diab. Vasc. Dis. Res. 4: 204-213 (2007).
Gold LF. Calcitriol ointment: optimizing psoriasis therapy. J. Drugs Dermatol. 8: s23-s27 (2009).
Goldbach-Mansky R, Dailey NJ, Canna SW, Gelabert A, Jones J, Rubin BI, Kim HJ, Brewer C, Zalewski C, Wiggs E, Hill S, Turner ML, Karp BI, Aksentijevich I, Pucino F, Penzak SR, Haverkamp MH, Stein L, Adams BS, Moore TL, Fuhlbrigge RC, et al. Neonatal-onset multisystem inflammatory disease responsive to interleukin-1beta inhibition. N. Engl. J. Med. 355: 581-592 (2006). *
Golding J, Steer C, Emmett P, Davis JM, Hibbeln JR. High levels of depressive symptoms in pregnancy with low omega-3 fatty acid intake from fish. Epidemiology 20: 598-603 (2009).
Goldstein BJ, Rosenstock J, Anzalone D, Tou C, Ohman KP. Effect of tesaglitazar, a dual PPARalpha/gamma agonist, on glucose and lipid abnormalities in patients with type 2 diabetes: a 12-week dose-ranging trial. Curr. Med. Res. Opin. 22: 2575-2590 (2006).
Goldstein DB, Need AC, Singh R, Sisodiya SM. Potential genetic causes of heterogeneity of treatment effects. Am. J. Med. 120: S21-S25 (2007). *
Goldstein ES, Rubin PH. Endoscopic therapy for inflammatory bowel disease. Curr. Treat. Options Gastroenterol. 6: 237-243 (2003).
Goldstein F. Look out for toxic effects of mesalamines! J. Clin. Gastroenterol. 32: 98 (2001).
Gomes ER, Demoly P. Epidemiology of hypersensitivity drug reactions. Curr. Opin. Allergy Clin. Immunol. 5: 309-316 (2005).
Gomes Mde B. Glitazones and the metabolic syndrome: mechanism of action, pathophysiology and therapeutic indications. Arq. Bras. Endocrinol. Metabol. 50: 271-280 (2006).
Gomez-Reino JJ, Carmona L, Valverde VR, Mola EM, Montero MD; BIOBADASER Group. Treatment of rheumatoid arthritis with tumor necrosis factor inhibitors may predispose to significant increase in tuberculosis risk: a multicenter active-surveillance report. Arthritis Rheum. 48: 2122-2127 (2003). *
Gomez-Reino JJ, Carmona L; the BIOBADASER Group. Switching TNF antagonists in patients with chronic arthritis: an observational study of 488 patients over a four-year period. Arthritis Res. Ther. 8: R29 (2006). *
Gomollon F, Gisbert JP. Must immunomodulators be added to biological treatment in inflammatory bowel disease? Gastroenterol. Hepatol. Jul 17 [Epub ahead of print] (2009).
Gong JF, Niu LY, Wei XW, Zhu WM, Li N, Li JS. Therapeutic effects of combined enteral nutrition with Tripterygium Wilfordii Polyglycosidium in remission induction of active adult Crohn's disease. Zhonghua Wai Ke Za Zhi 47: 1213-1217 (2009).
Gong Y, Christensen E, Gluud C. Cyclosporin A for primary biliary cirrhosis. Cochrane Database Syst. Rev. 3: CD005526 (2007). *
Gong Y, Christensen E, Gluud C. Azathioprine for primary biliary cirrhosis. Cochrane Database Syst. Rev. 3: CD006000 (2007). *
Gong Y, Frederiksen S, Gluud C. D-penicillamine for primary biliary cirrhosis. Cochrane Database Syst. Rev. 4: CD004789 (2004). *
Gong Y, Gluud C. Methotrexate for primary biliary cirrhosis. Cochrane Database Syst. Rev. 3: CD004385 (2005). *
Gong Y, Gluud C. Colchicine for primary biliary cirrhosis: a Cochrane hepato-biliary group systematic review of randomized clinical trials. Am. J. Gastroenterol. 100: 1-10 (2005). *
Gong Y, Gluud C. Colchicine for primary biliary cirrhosis. Cochrane Database Syst. Rev. 2: CD004481 (2004). *
Gong Y, Huang Z, Christensen E, Gluud C. Ursodeoxycholic acid for patients with primary biliary cirrhosis: an updated systematic review and meta-analysis of randomized clinical trials using Bayesian approach as sensitivity analyses. Am. J. Gastroenterol. 102: 1799-1807 (2007). *
Gong Y, Huang ZB, Christensen E, Gluud C. Ursodeoxycholic acid for primary biliary cirrhosis. Cochrane Database Syst. Rev. 3: CD000551 (2008). *
Gong Y, Klingenberg SL, Gluud C. Systematic review and meta-analysis: D-penicillamine vs. placebo/no intervention in patients with primary biliary cirrhosis - Cochrane Hepato-Biliary Group. Aliment. Pharmacol. Ther. 24: 1535-1544 (2006). *
Gonzaga JE, Ananthakrishnan AN, Issa M, Beaulieu DB, Skaros S, Zadvornova Y, Johnson K, Otterson MF, Binion DG. Durability of infliximab in Crohn's disease: a single-center experience. Inflamm. Bowel Dis. 15: 1837-1843 (2009).
Gonzalez E. Vitamin D receptor ligand therapy in chronic kidney disease. Clin. Nephrol. 70: 271-283 (2008).
Gonzalez FJ, Fernandez-Salguero P, Lee SS, Pineau T, Ward JM. Xenobiotic receptor knockout mice. Toxicol. Lett. 82-83: 117-121 (1995).
Gonzalez U, Reyes E, Kershenovich J, Orozco-Topete RL. Hypersensitivity syndrome caused by allopurinol. A case of massive hepatic necrosis. Rev. Invest. Clin. 47: 409-413 (1995).
Gonzalez-Huix F, Fernandez-Banares F, Esteve-Comas M, Abad-Lacruz A, Cabre E, Acero D, Figa M, Guilera M, Humbert P, de Leon R, et al. Enteral versus parenteral nutrition as adjunct therapy in acute ulcerative colitis. Am. J. Gastroenterol. 88: 227-232 (1993).
Gonzalez-Koch A, Brahm J, Antezana C, Smok G, Cumsille MA. The combination of ursodeoxycholic acid and methotrexate for primary biliary cirrhosis is not better than ursodeoxycholic acid alone. J. Hepatol. 27: 143-149 (1997). *
Gonzalez-Lama Y, Abreu L, Vera MI, Pastrana M, Tabernero S, Revilla J, Duran JG, Escartin P. Long-term oral tacrolimus therapy in refractory to infliximab fistulizing Crohn's disease: a pilot study. Inflamm. Bowel Dis. 11: 8-15 (2005). *
Gonzalez-Lama Y, Fernandez-Blanco I, Lopez-SanRoman A, Taxonera C, Casis B, Tabernero S, Bermejo F, Martinez-Silva F, Mendoza JL, Martinez-Montiel P, Carneros JA, Sanchez F, Mate J, Gisbert JP. Open-label infliximab therapy in ulcerative colitis: a multicenter survey of results and predictors of response. Hepatogastroenterology 55: 1609-1614 (2008).
Gonzalez-Lama Y, Lopez-San Roman A, Marin-Jimenez I, Casis B, Vera I, Bermejo F, Perez-Calle JL, Taxonera C, Martinez-Silva F, Menchen L, Martinez-Montiel P, Calvo M, Carneros JA, Lopez P, Mendoza JL, Milicua JM, Huerta A, Sanchez F, Abreu L, et al. Open-label infliximab therapy in Crohn's disease: a long-term multicenter study of efficacy, safety and predictors of response. Gastroenterol. Hepatol. 31: 421-426 (2008).
Gonzalez-Lama Y, Vera MI, Calvo M, Abreu L. Markers of the course of inflammatory bowel disease treated with immunomodulators or biological agents. Gastroenterol. Hepatol. Jan 30 [Epub ahead of print] (2010).
Gonzalez-Perez O, Luquin S, Garcia-Estrada J, Ramos-Remus C. Deflazacort: a glucocorticoid with few metabolic adverse effects but important immunosuppressive activity. Adv. Ther. 24: 1052-1060 (2007).
Goodhand JR, Wahed M, Rampton DS. Management of stress in inflammatory bowel disease: a therapeutic option? Expert Rev. Gastroenterol. Hepatol. 3: 661-679 (2009).
Gordon FH, Lai CW, Hamilton MI, Allison MC, Srivastava ED, Fouweather MG, Donoghue S, Greenlees C, Subhani J, Amlot PL, Pounder RE. A randomized placebo-controlled trial of a humanized monoclonal antibody to alpha4 integrin in active Crohn's disease. Gastroenterology 121: 268-274 (2001). *
Gordon KB, Langley RG, Leonardi C, Toth D, Menter MA, Kang S, Heffernan M, Miller B, Hamlin R, Lim L, Zhong J, Hoffman R, Okun MM. Clinical response to adalimumab treatment in patients with moderate to severe psoriasis: double-blind, randomized controlled trial and open-label extension study. J. Am. Acad. Dermatol. 55: 598-606 (2006).
Gorman JD, Sack KE, Davis JC Jr. Treatment of ankylosing spondylitis by inhibition of tumor necrosis factor alpha. N. Engl. J. Med. 346: 1349-1356 (2002). *
Gosai P, Liu J, Doyle RT, Johnson J, Carter R, Sica D, McKenney JM. Effect of omega-3-acid ethyl esters on the steady-state plasma pharmacokinetics of rosuvastatin in healthy adults. Expert Opin. Pharmacother. 9: 2947-2953 (2008).
Gottenberg JE, Guillevin L, Lambotte O, Combe B, Allanore Y, Cantagrel A, Larroche C, Soubrier M, Anaya JM, Sibilia J, Mariette X. Tolerance and short-term efficacy of rituximab in 43 patients with systemic autoimmune diseases. Ann. Rheum. Dis. 64: 913-920 (2005). *
Gottlieb A, Menter A, Mendelsohn A, Shen YK, Li S, Guzzo C, Fretzin S, Kunynetz R, Kavanaugh A. Ustekinumab, a human interleukin 12/23 monoclonal antibody, for psoriatic arthritis: randomised, double-blind, placebo-controlled, crossover trial. Lancet 373: 633-640 (2009). *
Gottlieb AB. Alefacept is well tolerated in patients with chronic plaque psoriasis. J. Cutan. Med. Surg. 8 Suppl. 2: 14-19 (2004).
Gottlieb AB, Cooper KD, McCormick TS, Toichi E, Everitt DE, Frederick B, Zhu Y, Pendley CE, Graham MA, Mascelli MA. A phase 1, double-blind, placebo-controlled study evaluating single subcutaneous administrations of a human interleukin-12/23 monoclonal antibody in subjects with plaque psoriasis. Curr. Med. Res. Opin. 23: 1081-1092 (2007).
Gottlieb AB, Gordon KB, Lebwohl MG, Caro I, Walicke PA, Li N, Leonardi CL; EFALIZUMAB STUDY GROUP. Extended efalizumab therapy sustains efficacy without increasing toxicity in patients with moderate to severe chronic plaque psoriasis. J. Drugs Dermatol. 3: 614-624 (2004).
Gottlieb AB, Griffiths CE, Ho VC, Lahfa M, Mrowietz U, Murrell DF, Ortonne JP, Todd G, Cherill R, Marks I, Emady-Azar S, Paul CF; the Multi-Centre Investigator Group. Oral pimecrolimus in the treatment of moderate to severe chronic plaque-type psoriasis: a double-blind, multicentre, randomized, dose-finding trial. Br. J. Dermatol. 152: 1219-1227 (2005). *
Gottlieb AB, Leonardi CL, Goffe BS, Ortonne JP, van der Kerkhof PC, Zitnik R, Nakanishi A, Jahreis A. Etanercept monotherapy in patients with psoriasis: a summary of safety, based on an integrated multistudy database. J. Am. Acad. Dermatol. 54: S92-S100 (2006).
Gottlieb AB, Matheson RT, Lowe N, Krueger GG, Kang S, Goffe BS, Gaspari AA, Ling M, Weinstein GD, Nayak A, Gordon KB, Zitnik R. A randomized trial of etanercept as monotherapy for psoriasis. Arch. Dermatol. 139: 1627-1632 (2003). *
Gottlieb AB, Strober B, Krueger JG, Rohane P, Zeldis JB, Hu CC, Kipnis C. An open-label, single-arm pilot study in patients with severe plaque-type psoriasis treated with an oral anti-inflammatory agent, apremilast. Curr. Med. Res. Opin. 24: 1529-1538 (2008).
Gottlieb PA, Quinlan S, Krause-Steinrauf H, Greenbaum CJ, Wilson DM, Rodriguez H, Schatz DA, Moran AM, Lachin JM, Skyler JS; for the Type 1 Diabetes TrialNet MMF/DZB Study Group. Failure to preserve beta-cell function with mycophenolate mofetil and daclizumab combined therapy in patients with new onset type 1 diabetes. Diabetes Care Jan 12 [Epub ahead of print] (2010).
Gotto AM Jr. Risks and benefits of continued aggressive statin therapy. Clin. Cardiol. 26: III3-III12 (2003).
Gould Rothberg BE, Sundseth SS, DiPippo VA, Brown PJ, Winegar DA, Gottshalk WK, Shenoy SG, Rothberg JM. The characterization of PPAR alpha ligand drug action in an in vivo model by comprehensive differential gene expression profiling. Funct. Integr. Genomics 1: 294-304 (2001). *
Goverdhana S, Puntel M, Xiong W, Zirger JM, Barcia C, Curtin JF, Soffer EB, Mondkar S, King GD, Hu J, Sciascia SA, Candolfi M, Greengold DS, Lowenstein PR, Castro MG. Regulatable gene expression systems for gene therapy applications: progress and future challenges. Mol. Ther. 12: 189-211 (2005).
Gradman AH, Pinto R. Vaccination: a novel strategy for inhibiting the renin-angiotensin-aldosterone system. Curr. Hypertens. Rep. 10: 473-479 (2008).
Graff GR, Maguiness K, McNamara J, Morton R, Boyd D, Beckmann K, Bennett D. Efficacy and tolerability of a new formulation of pancrelipase delayed-release capsules in children aged 7 to 11 years with exocrine pancreatic insufficiency and cystic fibrosis: a multicenter, randomized, double-blind, placebo-controlled, two-period … Clin. Ther. 32: 89-103 (2010).
Granath A, Hellgren M, Gunnarsson R. Lactose intolerance and long-standing pelvic pain after pregnancy: a case control study. Acta Obstet. Gynecol. Scand. Feb 19 [Epub ahead of print] (2007).
Grandjean EM, Aubry JM. Lithium: updated human knowledge using an evidence-based approach: part III: clinical safety. CNS Drugs 23: 397-418 (2009).
Granio O, Excoffon KA, Henning P, Melin P, Norez C, Gonzalez G, Karp P, Magnusson M, Habib N, Lindholm L, Becq F, Boulanger P, Zabner J, Hong SS. Adenovirus 5-fiber 35 chimeric vector mediates efficient apical correction of the CFTR defect in cystic fibrosis primary airway epithelia. Hum. Gene Ther. Sep 29 [Epub ahead of print] (2009).
Grant WB, Strange RC, Garland CF. Sunshine is good medicine. The health benefits of ultraviolet-B induced vitamin D production. J. Cosmet. Dermatol. 2: 86-98 (2003).
Grassberger M, Hoch W. Ichthyotherapy as alternative treatment for patients with psoriasis: a pilot study. Evid. Based Complement. Alternat. Med. 3: 483-488 (2006). *
Grasset L, Guy C, Ollagnier M. Cyclines and acne: pay attention to adverse drug reactions! A recent literature review. Rev. Med. Interne. 24: 305-316 (2003).
Graziadei IW, Obermoser GE, Sepp NT, Erhart KH, Vogel W. Drug-induced lupus-like syndrome associated with severe autoimmune hepatitis. Lupus 12: 409-412 (2003). *
Graziadei IW, Wiesner RH, Marotta PJ, Porayko MK, Hay JE, Charlton MR, Poterucha JJ, Rosen CB, Gores GJ, LaRusso NF, Krom RA. Long-term results of patients undergoing liver transplantation for primary sclerosing cholangitis. Hepatology 30: 1121-1127 (1999). *
Grbovic L, Radenkovic M. Therapeutic use of glucocorticoids and immunosuppressive agents. Srp. Arh. Celok. Lek. 133 Suppl. 1: 67-73 (2005).
Green AS, Schwartz A. Is universal screening for thyroid disease in pregnancy a cost-effective strategy? Nat. Clin. Pract. Endocrinol. Metab. 4: 598-599 (2008).
Green JR, Gibson JA, Kerr GD, Swarbrick ET, Lobo AJ, Holdsworth CD, Crowe JP, Schofield KJ, Taylor MD. Maintenance of remission of ulcerative colitis: a comparison between balsalazide 3 g daily and mesalazine 1.2 g daily over 12 months. ABACUS Investigator group. Aliment. Pharmacol. Ther. 12: 1207-1216 (1998). *
Green JR, Lobo AJ, Holdsworth CD, Leicester RJ, Gibson JA, Kerr GD, Hodgson HJ, Parkins KJ, Taylor MD. Balsalazide is more effective and better tolerated than mesalamine in the treatment of acute ulcerative colitis. The Abacus Investigator Group. Gastroenterology 114: 15-22 (1998). *
Green JR, Mansfield JC, Gibson JA, Kerr GD, Thornton PC. A double-blind comparison of balsalazide, 6.75 g daily, and sulfasalazine, 3 g daily, in patients with newly diagnosed or relapsed active ulcerative colitis. Aliment. Pharmacol. Ther. 16: 61-68 (2002). *
Greenberg LE, Nguyen T, Miller SM. Suspected allopurinol-induced aseptic meningitis. Pharmacotherapy 21: 1007-1009 (2001).
Greenbloom SL, Steinhart AH, Greenberg GR. Combination ciprofloxacin and metronidazole for active Crohn's disease. Can. J. Gastroenterol. 12: 53-56 (1998). *
Greene CM, McElvaney NG. Proteases and antiproteases in chronic neutrophilic lung disease - relevance to drug discovery. Br. J. Pharmacol. 158: 1048-1058 (2009). *
Greene JP. An adolescent with abdominal pain taking isotretinoin for severe acne. South. Med. J. 99: 992-994 (2006).
Greenough A. Emerging drugs for the prevention of bronchopulmonary dysplasia. Expert Opin. Emerg. Drugs 13: 537-546 (2008).
Gregorio GV, Ball CS, Mowat AP, Mieli-Vergani G. Effect of rifampicin in the treatment of pruritus in hepatic cholestasis. Arch. Dis. Child. 69: 141-143 (1993).
Gresser U. Amoxicillin-clavulanic acid therapy may be associated with severe side effects - review of the literature. Eur. J. Med. Res. 6: 139-149 (2001). *
Gressier L, Pruvost-Balland C, Dubertret L, Viguier M. Atorvastatin-induced drug reaction with eosinophilia and systemic symptoms (DRESS). Ann. Dermatol. Venereol. 136: 50-53 (2009).
Grey A. Thiazolidinedione-induced skeletal fragility - mechanisms and implications. Diabetes Obes. Metab. 11: 275-284 (2009). *
Gribetz CH, Blum R, Brady C, Cohen S, Lebwohl M. An extended 16-week course of alefacept in the treatment of chronic plaque psoriasis. J. Am. Acad. Dermatol. 53: 73-75 (2005).
Grieco A, Miele L, Pompili M, Biolato M, Vecchio FM, Grattagliano I, Gasbarrini G. Acute hepatitis caused by a natural lipid-lowering product: when “alternative” medicine is no “alternative” at all? J. Hepatol. 50: 1273-1277 (2009).
Griffiths CE, Katsambas A, Dijkmans BA, Finlay AY, Ho VC, Johnston A, Luger TA, Mrowietz U, Thestrup-Pedersen K. Update on the use of ciclosporin in immune-mediated dermatoses. Br. J. Dermatol. 155 Suppl. 2: 1-16 (2006). *
Griffiths CE, Strober BE, van de Kerkhof P, Ho V, Fidelus-Gort R, Yeilding N, Guzzo C, Xia Y, Zhou B, Li S, Dooley LT, Goldstein NH, Menter A; ACCEPT Study Group. Comparison of ustekinumab and etanercept for moderate-to-severe psoriasis. N. Engl. J. Med. 362: 118-128 (2010). *
Grimaud JC, Munoz-Bongrand N, Siproudhis L, Abramowitz L, Senejoux A, Vitton V, Gambiez L, Flourie B, Hebuterne X, Louis E, Coffin B, De Parades V, Savoye G, Soule JC, Bouhnik Y, Colombel JF, Contou JF, Francois Y, Mary JY, Lemann M. Fibrin glue is effective healing perianal fistulas in patients with Crohn's disease. Gastroenterology Feb 20 [Epub ahead of print] (2010). *
Grimble RF. Immunonutrition. Curr. Opin. Gastroenterol. 21: 216-222 (2005).
Grimble RF. Nutritional modulation of immune function. Proc. Nutr. Soc. 60: 389-397 (2001). *
Grimble RF, Howell WM, O'Reilly G, Turner SJ, Markovic O, Hirrell S, East JM, Calder PC. The ability of fish oil to suppress tumor necrosis factor alpha production by peripheral blood mononuclear cells in healthy men is associated with polymorphisms in genes that influence tumor necrosis factor alpha production. Am. J. Clin. Nutr. 76: 454-459 (2002). *
Grimley Evans J, Malouf R, Huppert F, van Niekerk JK. Dehydroepiandrosterone (DHEA) supplementation for cognitive function in healthy elderly people. Cochrane Database Syst. Rev. 4: CD006221 (2006). *
Grimstein C, Choi YK, Satoh M, Lu Y, Wang X, Campbell-Thompson M, Song S. Combination of alpha-1 antitrypsin and doxycycline suppresses collagen-induced arthritis. J. Gene Med. 12: 35-44 (2010).
Grogan PM, Katz JS. Inflammatory myopathies. Curr. Treat. Options Neurol. 6: 155-161 (2004).
Grossman AB, Noble AJ, Mamula P, Baldassano RN. Increased dosing requirements for 6-mercaptopurine and azathioprine in inflammatory bowel disease patients six years and younger. Inflamm. Bowel Dis. 14: 750-755 (2008). *
Groszmann RJ, Garcia-Tsao G, Bosch J, Grace ND, Burroughs AK, Planas R, Escorsell A, Garcia-Pagan JC, Patch D, Matloff DS, Gao H, Makuch R; Portal Hypertension Collaborative Group. Beta-blockers to prevent gastroesophageal varices in patients with cirrhosis. N. Engl. J. Med. 353: 2254-2261 (2005). *
Grover JK, Uppal G, Raina V. The adverse effects of thalidomide in relapsed and refractory patients of multiple myeloma. Ann. Oncol. 13: 1636-1640 (2002). *
Grover JK, Yadav S, Vats V, Joshi YK. Cyclo-oxygenase 2 inhibitors: emerging roles in the gut. Int. J. Colorectal Dis. 18: 279-291 (2003). *
Gruenwald J, Graubaum HJ, Hansen K, Grube B. Efficacy and tolerability of a combination of Lyprinol and high concentrations of EPA and DHA in inflammatory rheumatoid disorders. Adv. Ther. 21: 197-201 (2004).
Grundmann SA, Beissert S. Regulation of cellular immunity by photo(chemo)therapy. Front. Biosci. 14: 4326-4336 (2009).
Grunhage F, Fischer HP, Sauerbruch T, Reichel C. Drug- and toxin-induced hepatotoxicity. Z. Gastroenterol. 41: 565-578 (2003).
Gruttadauria S, Vasta F, Mandala L, Cintorino D, Piazza T, Spada M, Verzaro R, Gridelli B. Basiliximab in a triple-drug regimen with tacrolimus and steroids in liver transplantation. Transplant. Proc. 37: 2611-2613 (2005). *
Guagnozzi D, Caprilli R. Natalizumab in the treatment of Crohn's disease. Biologics 2: 275-284 (2008). *
Gualandi F, Bruno B, Van Lint MT, Luchetti S, Uccelli A, Capello E, Mancardi GL, Bacigalupo A, Marmont A. Autologous stem cell transplantation for severe autoimmune diseases: a 10-year experience. Ann. N. Y. Acad. Sci. 1110: 455-464 (2007). *
Guan Q, Ma Y, Hillman CL, Ma A, Zhou G, Qing G, Peng Z. Development of recombinant vaccines against IL-12/IL-23 p40 and in vivo evaluation of their effects in the downregulation of intestinal inflammation in murine colitis. Vaccine 27: 7096-7104 (2009). *
Guanabens N, Pares A, Ros I, Alvarez L, Pons F, Caballeria L, Monegal A, Martinez de Osaba MJ, Roca M, Peris P, Rodes J. Alendronate is more effective than etidronate for increasing bone mass in osteopenic patients with primary biliary cirrhosis. Am. J. Gastroenterol. 98: 2268-2274 (2003). *
Guarner F. Studies with inulin-type fructans on intestinal infections, permeability, and inflammation. J. Nutr. 137: 2568S-2571S (2007). *
Guazzone VA, Jacobo P, Theas MS, Lustig L. Cytokines and chemokines in testicular inflammation: a brief review. Microsc. Res. Tech. 72: 620-628 (2009).
Gueant JL, Gueant-Rodriguez RM, Gastin IA, Cornejo-Garcia JA, Viola M, Barbaud A, Mertes PM, Blanca M, Romano A. Pharmacogenetic determinants of immediate and delayed reactions of drug hypersensitivity. Curr. Pharm. Des. 14: 2770-2777 (2008).
Guenther LC. Treatments for scalp psoriasis with emphasis on calcipotriol plus betamethasone dipropionate gel (xamiol(R)). Skin Therapy Lett. 14: 1-4 (2009). *
Guevara M, Fernandez-Esparrach G, Alessandria C, Torre A, Terra C, Montana X, Piera C, Alvarez ML, Jimenez W, Gines P, Arroyo V. Effects of contrast media on renal function in patients with cirrhosis: a prospective study. Hepatology 40: 646-651 (2004). *
Guijarro LG, Mate J, Gisbert JP, Perez-Calle JL, Marin-Jimenez I, Arriaza E, Olleros T, Delgado M, Castillejo MS, Prieto-Merino D, Gonzalez Lara V, Pena AS. N-Acetyl-L-cysteine combined with mesalamine in the treatment of ulcerative colitis: randomized, placebo-controlled pilot study. World J. Gastroenterol. 14: 2851-2857 (2008). *
Guilpain P, Viallard JF, Lagarde P, Cohen P, Kambouchner M, Pellegrin JL, Guillevin L. Churg-Strauss syndrome in two patients receiving montelukast. Rheumatology (Oxford) 41: 535-539 (2002). *
Gujja D, Friedenberg FK. Predictors of serious complications due to Clostridium difficile infection. Aliment. Pharmacol. Ther. 29: 635-642 (2009). *
Gul U, Gonul M, Kilic A, Erdem R, Cakmak SK, Gunduz H. Treatment of psoriatic arthritis with etanercept, methotrexate, and cyclosporin A. Clin. Ther. 28: 251-254 (2006). *
Guldutuna S, Leuschner U, Imhof M, Zimmer G. Treatment of chronic active hepatitis and primary biliary cirrhosis with ursodeoxycholic acid. Z. Gastroenterol. 30 Suppl. 1: 49-54 (1992).
Gunawan B, Kaplowitz N. Clinical perspectives on xenobiotic-induced hepatotoxicity. Drug Metab. Rev. 36: 301-312 (2004). *
Gunther S, Hempel D, Dunkel M, Rother K, Preissner R. SuperHapten: a comprehensive database for small immunogenic compounds. Nucleic Acids Res. 35: D906-D910 (2007). *
Gunton JE, Stiel J, Clifton-Bligh P, Wilmshurst E, McElduff A. Prevalence of positive anti-neutrophil cytoplasmic antibody (ANCA) in patients receiving anti-thyroid medication. Eur. J. Endocrinol. 142: 587 (2000).
Guo L, Fang H, Collins J, Fan XH, Dial S, Wong A, Mehta K, Blann E, Shi L, Tong W, Dragan YP. Differential gene expression in mouse primary hepatocytes exposed to the peroxisome proliferator-activated receptor alpha agonists. BMC Bioinformatics 7: S18 (2006). *
Gurcan HM, Ahmed AR. Efficacy of dapsone in the treatment of pemphigus and pemphigoid: analysis of current data. Am. J. Clin. Dermatol. 10: 383-396 (2009).
Gurwitz JH. Serious adverse drug effects - seeing the trees through the forest. N. Engl. J. Med. 354: 1413-1415 (2006). *
Guthrie B, Rouster-Stevens KA, Reynolds SL. Review of medications used in juvenile rheumatoid arthritis. Pediatr. Emerg. Care 23: 38-46 (2007).
Gutierrez Macia MM, Mateo García MG, Vidal Marsal F, Domingo Pedrol P. Toxicogenetics of antiretroviral treatment (1): lipodystrophy, metabolic perturbations and atherosclerosis. Enferm. Infecc. Microbiol. Clin. 26 Suppl. 6: 18-23 (2008).
Gutkowski K, Hartleb M. Inflammatory bowel diseases in pregnancy. Ginekol. Pol. 80: 379-382 (2009).
Gvozdjakova A, Kucharska J, Bartkovjakova M, Gazdikova K, Gazdik FE. Coenzyme Q10 supplementation reduces corticosteroids dosage in patients with bronchial asthma. Biofactors 25: 235-240 (2005).
Haarmann-Stemmann T, Bothe H, Abel J. Growth factors, cytokines and their receptors as downstream targets of arylhydrocarbon receptor (AhR) signaling pathways. Biochem. Pharmacol. 77: 508-520 (2009). *
Habal FM, Greenberg GR. Treatment of ulcerative colitis with oral 5-aminosalicylic acid including patients with adverse reactions to sulfasalazine. Am. J. Gastroenterol. 83: 15-19 (1988).
Haber P, DeStefano F, Angulo FJ, Iskander J, Shadomy SV, Weintraub E, Chen RT. Guillain-Barre syndrome following influenza vaccination. JAMA 292: 2478-2481 (2004). *
Haberhauer G. Induction of anticentromere antibody in patients receiving treatment with D-penicillamine. Klin. Wochenschr. 67: 535-537 (1989).
Habib SS. Exhaled nitric oxide. An emerging marker of inflammation in respiratory diseases. Saudi Med. J. 29: 1697-1702 (2008).
Hadithi M, Heine GD, Jacobs MA, v Bodegraven AA, Mulder CJ. A prospective study comparing video capsule endoscopy with double-balloon enteroscopy in patients with obscure gastrointestinal bleeding. Am. J. Gastroenterol. 101: 52-57 (2006). *
Hagen AD, Sulit DJ, Sulit AK. Cutaneous psoriasis in a military flight surgeon. Aviat. Space Environ. Med. 77: 140-144 (2006).
Hagen KB, Byfuglien MG, Falzon L, Olsen SU, Smedslund G. Dietary interventions for rheumatoid arthritis. Cochrane Database Syst. Rev. 1: CD006400 (2009).
Hagiwara K, Sato T, Kobayashi ST, Hasegawa S, Shigihara N, Akiyama O. Acute exacerbation of preexisting interstitial lung disease after administration of etanercept for rheumatoid arthritis. J. Rheumatol. 34: 1151-1154 (2007).
Haglund S, Taipalensuu J, Peterson C, Almer S. IMPDH activity in thiopurine-treated patients with inflammatory bowel disease - relation to TPMT activity and metabolite concentrations. Br. J. Clin. Pharmacol. 65: 69-77 (2008). *
Haitz KA, Kalb RE. Infliximab for the treatment of psoriasis in patients previously treated with etanercept. J. Am. Acad. Dermatol. 57: 120-125 (2007).
Hale LP, Greer PK, Trinh CT, Gottfried MR. Treatment with oral bromelain decreases colonic inflammation in the IL-10-deficient murine model of inflammatory bowel disease. Clin. Immunol. 116: 135-142 (2005). *
Halevy S, Ghislain PD, Mockenhaupt M, Fagot JP, Bouwes Bavinck JN, Sidoroff A, Naldi L, Dunant A, Viboud C, Roujeau JC; EuroSCAR Study Group. Allopurinol is the most common cause of Stevens-Johnson syndrome and toxic epidermal necrolysis in Europe and Israel. J. Am. Acad. Dermatol. 58: 25-32 (2008).
Hall WL. Dietary saturated and unsaturated fats as determinants of blood pressure and vascular function. Nutr. Res. Rev. 22: 18-38 (2009).
Haller MJ, Wasserfall CH, McGrail KM, Cintron M, Brusko TM, Wingard JR, Kelly SS, Shuster JJ, Atkinson MA, Schatz DA. Autologous umbilical cord blood transfusion in very young children with type 1 diabetes. Diabetes Care 32: 2041-2046 (2009).
Halverstam CP, Lebwohl M. Nonstandard and off-label therapies for psoriasis. Clin. Dermatol. 26: 546-553 (2008).
Hamer RJ. Coeliac disease: background and biochemical aspects. Biotechnol. Adv. 23: 401-408 (2005). *
Hamilton T, Menter A, Caro I, Compton P, Sobell J, Papp KA. Safety of efalizumab therapy in patients with moderate to severe psoriasis: an open-label extension of a phase IIIb trial. Drug Saf. 31: 715-726 (2008).
Hamilton TK. Treatment of psoriatic arthritis and recalcitrant skin disease with combination therapy. J. Drugs Dermatol. 7: 1089-1093 (2008).
Hammond BG, Lemen JK, Ahmed G, Miller KD, Kirkpatrick J, Fleeman T. Safety assessment of SDA soybean oil: results of a 28-day gavage study and a 90-day/one generation reproduction feeding study in rats. Regul. Toxicol. Pharmacol. 52: 311-323 (2008).
Hamon MA, Nicolas G, Deviere F, Letournel F, Dubas F. Demyelinating neuropathy during anti-TNF alpha treatment with a review of the literature. Rev. Neurol. (Paris) 163: 1232-1235 (2007).
Han BC, Xia HF, Sun J, Yang Y, Peng JP. Retinoic acid-metabolizing enzyme cytochrome P450 26a1 (cyp26a1) is essential for implantation: functional study of its role in early pregnancy. J. Cell. Physiol. Jan 28 [Epub ahead of print] (2010).
Han L, Somani AK, Huang Q, Fang X, Jin Y, Xiang LH, Zheng ZZ. Evaluation of 308-nm monochromatic excimer light in the treatment of psoriasis vulgaris and palmoplantar psoriasis. Photodermatol. Photoimmunol. Photomed. 24: 231-236 (2008).
Han PD, Cohen RD. Managing immunogenic responses to infliximab: treatment implications for patients with Crohn's disease. Drugs 64: 1767-1777 (2004).
Hanai H, Iida T, Takeuchi K, Arai O, Watanabe F, Abe J, Maruyama Y, Oohata A, Ikeya K, Kageoka M, Miwa I, Yoshirou S, Hosoda Y, Kubota T. Thiopurine maintenance therapy for ulcerative colitis: the clinical significance of monitoring 6-thioguanine nucleotide. Inflamm. Bowel Dis. Jan 4 [Epub ahead of print] (2010). *
Hanauer S, Sandborn WJ, Persson A, Persson T. Budesonide as maintenance treatment in Crohn's disease: a placebo-controlled trial. Aliment. Pharmacol. Ther. 21: 363-371 (2005). *
Hanauer SB. New lessons: classic treatments, expanding options in ulcerative colitis. Colorectal Dis. 8 Suppl. 1: 20-24 (2006).
Hanauer SB. Review article: safety of infliximab in clinical trials. Aliment. Pharmacol. Ther. 13 Suppl. 4: 16-22 (1999). *
Hanauer SB, Krawitt EL, Robinson M, Rick GG, Safdi MA. Long-term management of Crohn's disease with mesalamine capsules (Pentasa). Pentasa Crohn's Disease Compassionate Use Study Group. Am. J. Gastroenterol. 88: 1343-1351 (1993).
Hanauer SB, Present DH. The state of the art in the management of inflammatory bowel disease. Rev. Gastroenterol. Disord. 3: 81-92 (2003). *
Hanauer SB, Sandborn WJ, Dallaire C, Archambault A, Yacyshyn B, Yeh C, Smith-Hall N. Delayed-release oral mesalamine 4.8 g/day (800 mg tablets) compared to 2.4 g/day (400 mg tablets) for the treatment of mildly to moderately active ulcerative colitis: the ASCEND I trial. Can. J. Gastroenterol. 21: 827-834 (2007). *
Hanauer SB, Sandborn WJ, Kornbluth A, Katz S, Safdi M, Woogen S, Regalli G, Yeh C, Smith-Hall N, Ajayi F. Delayed-release oral mesalamine at 4.8 g/day (800 mg tablet) for the treatment of moderately active ulcerative colitis: the ASCEND II trial. Am. J. Gastroenterol. 100: 2478-2485 (2005). *
Hanauer SB, Sandborn WJ, Rutgeerts P, Fedorak RN, Lukas M, MacIntosh D, Panaccione R, Wolf D, Pollack P. Human anti-tumor necrosis factor monoclonal antibody (Adalimumab) in Crohn’s disease: the CLASSIC-I trial. Gastroenterology 130: 323-333 (2006). *
Handel ML. Transcription factors AP-1 and NF-kappaB: where steroids meet the gold standard of anti-rheumatic drugs. Inflamm. Res. 46: 282-286 (1997). *
Hanefeld M, Marx N, Pfutzner A, Baurecht W, Lubben G, Karagiannis E, Stier U, Forst T. Anti-inflammatory effects of pioglitazone and/or simvastatin in high cardiovascular risk patients with elevated high sensitivity C-reactive protein: the PIOSTAT study. J. Am. Coll. Cardiol. 49: 290-297 (2007).
Hanje AJ, Shamp JL, Thomas FB, Meis GM. Thalidomide-induced severe hepatotoxicity. Pharmacotherapy 26: 1018-1022 (2006). *
Hansen KE, Cush J, Singhal A, A Cooley D, Cohen S, Patel SR, Genovese M, Sundaramurthy S, Schiff M. The safety and efficacy of leflunomide in combination with infliximab in rheumatoid arthritis. Arthritis Rheum. 51: 228-232 (2004). *
Hanses F, Zierhut S, Scholmerich J, Salzberger B, Wrede CE. Severe and long lasting cholestasis after high-dose co-trimoxazole treatment for Pneumocystis pneumonia in HIV-infected patients - a report of two cases. Int. J. Infect. Dis. 13: e467-e469 (2009).
Hanslik T, Vaillant JN, Audrain L, Jubault V, Prinseau J, Baglin A, Flahault A. Systemic lupus erythematosus and risk of hepatitis B vaccination: from level of evidence to prescription. Rev. Med. Interne. 21: 785-790 (2000).
Hanslik T, Valleron AJ, Flahault A. Risk-benefit assessment of hepatitis B vaccination in France, 2005. Rev. Med. Interne. 27: 40-45 (2006).
Hansson M, Abedi-Valugerdi M. Mercuric chloride induces a strong immune activation, but does not accelerate the development of dermal fibrosis in tight skin 1 mice. Scand. J. Immunol. 59: 469-477 (2004). *
Hao L, Noguchi S, Kamada Y, Sasaki A, Matsuda M, Shimizu K, Hiramatsu Y, Nakatsuka M. Adverse effects of advanced glycation end products on embryonal development. Acta Med. Okayama 62: 93-99 (2008).
Hara M, Abe T, Sugawara S, Mizushima Y, Hoshi K, Irimajiri S, Hashimoto H, Yoshino S, Matsui N, Nobunaga M, Nakano S. Efficacy and safety of iguratimod compared with placebo and salazosulfapyridine in active rheumatoid arthritis: a controlled, multicenter, double-blind, parallel-group study. Mod. Rheumatol. 17: 1-9 (2007). *
Haram K, Gjelland K. Foetal growth restriction. Tidsskr. Nor. Laegeforen. 127: 2665-2669 (2007).
Haroon M, Bond U, Phelan M. Sinusitis: a possible link with adalimumab. Clin. Rheumatol. 27: 1189-1190 (2008).
Haroutiunian S, Lecht S, Zur AA, Hoffman A, Davidson E. The challenge of pain management in patients with myasthenia gravis. J. Pain Palliat. Care Pharmacother. 23: 242-260 (2009).
Harris CL, Raisch DW, Abhyankar U, Marfatia S, Campbell HM, Sather MR. GI risk factors and use of GI protective agents among patients receiving nonsteroidal antiinflammatory drugs. Ann. Pharmacother. 40: 1924-1931 (2006).
Harrison MJ, Dixon WG, Watson KD, King Y, Groves R, Hyrich KL, Symmons DP. Rates of new-onset psoriasis in patients with rheumatoid arthritis receiving anti-tumour necrosis factor alpha therapy: results from the British Society for Rheumatology Biologics Register. Ann. Rheum. Dis. 68: 209-215 (2009). *
Hart AL, Plamondon S, Kamm MA. Topical tacrolimus in the treatment of perianal Crohn's disease: exploratory randomized controlled trial. Inflamm. Bowel Dis. 13: 245-253 (2007). *
Hartleb M, Biernat L, Kochel A. Drug-induced liver damage - a three-year study of patients from one gastroenterological department. Med. Sci. Monit. 8: CR292-CR296 (2002). *
Hartley DP, Dai X, He YD, Carlini EJ, Wang B, Huskey SE, Ulrich RG, Rushmore TH, Evers R, Evans DC. Activators of the rat pregnane X receptor differentially modulate hepatic and intestinal gene expression. Mol. Pharmacol. 65: 1159-1171 (2004). *
Hartman C, Eliakim R, Shamir R. Nutritional status and nutritional therapy in inflammatory bowel diseases. World J. Gastroenterol. 15: 2570-2578 (2009). *
Hartweg J, Farmer AJ, Perera R, Holman RR, Neil HA. Meta-analysis of the effects of n-3 polyunsaturated fatty acids on lipoproteins and other emerging lipid cardiovascular risk markers in patients with type 2 diabetes. Diabetologia 50: 1593-1602 (2007). *
Hartweg J, Perera R, Montori V, Dinneen S, Neil H, Farmer A. Omega-3 polyunsaturated fatty acids (PUFA) for type 2 diabetes mellitus. Cochrane Database Syst. Rev. 1: CD003205 (2008). *
Hasan U. Tumour necrosis factor inhibitors - what we need to know. N. Z. Med. J. 119: U2336 (2006).
Hasegawa M, Abe M, Ohnishi K, Shoji C, Ishikawa O. Clinical usefulness of a long-term treatment with an antithyroid drug for psoriasis vulgaris. J. Dermatol. 31: 794-797 (2004).
Hassard PV, Vasiliauskas EA, Kam LY, Targan SR, Abreu MT. Efficacy of mycophenolate mofetil in patients failing 6-mercaptopurine or azathioprine therapy for Crohn's disease. Inflamm. Bowel Dis. 6: 16-20 (2000). *
Hauber HP, Schulz M, Pforte A, Mack D, Zabel P, Schumacher U. Inhalation with fucose and galactose for treatment of Pseudomonas aeruginosa in cystic fibrosis patients. Int. J. Med. Sci. 5: 371-376 (2008). *
Haubitz M. Exploring new territory: the move towards individualised treatment. Lupus 16: 227-231 (2007).
Hauser R, Duty S, Godfrey-Bailey L, Calafat AM. Medications as a source of human exposure to phthalates. Environ. Health Perspect. 112: 751-753 (2004). *
Hauser SL, Waubant E, Arnold DL, Vollmer T, Antel J, Fox RJ, Bar-Or A, Panzara M, Sarkar N, Agarwal S, Langer-Gould A, Smith CH; HERMES Trial Group. B-cell depletion with rituximab in relapsing-remitting multiple sclerosis. N. Engl. J. Med. 358: 676-688 (2008). *
Havrdova E, Horakova D, Kovarova I, Krasulova E. Future possibilities of the multiple sclerosis treatment. Cas. Lek. Cesk. 144: 663-665 (2005).
Hawkey CJ, Gitton X, Hoexter G, Richard D, Weinstein WM. Gastrointestinal tolerability of lumiracoxib in patients with osteoarthritis and rheumatoid arthritis. Clin. Gastroenterol. Hepatol. 4: 57-66 (2006).
Hawwa AF, Millership JS, Collier PS, Vandenbroeck K, McCarthy A, Dempsey S, Cairns C, Collins J, Rodgers C, McElnay JC. Pharmacogenomic studies of the anticancer and immunosuppressive thiopurines mercaptopurine and azathioprine. Br. J. Clin. Pharmacol. 66: 517-528 (2008). *
Hayashi T, Takahashi T, Minami T, Akaike J, Kasahara K, Adachi M, Hinoda Y, Takahashi S, Hirayama T, Imai K. Fatal acute hepatic failure induced by danazol in a patient with endometriosis and aplastic anemia. J. Gastroenterol. 36: 783-786 (2001). *
Hayes BB, Cook-Norris RH, Miller JL, Rodriguez A, Zic JA. Amantadine-induced livedo reticularis: a report of two cases. J. Drugs Dermatol. 5: 288-289 (2006).
Hazra S, Peebles KA, Sharma S, Mao JT, Dubinett SM. The role of PPARgamma in the cyclooxygenase pathway in lung cancer. PPAR Res. 2008: 790568 (2008). *
He K. Fish, long-chain omega-3 polyunsaturated fatty acids and prevention of cardiovascular disease - eat fish or take fish oil supplement? Prog. Cardiovasc. Dis. 52: 95-114 (2009).
He SH. Key role of mast cells and their major secretory products in inflammatory bowel disease. World J. Gastroenterol. 10: 309-318 (2004). *
Heemstra K, Toes R, Sepers J, Pereira A, Corssmit E, Huizinga T, Romijn J, Smit J. Rituximab in relapsing Graves' disease. Eur. J. Endocrinol. 159: 609-615 (2008).
Heffernan MP, Smith DI, Bentley D, Tabacchi M, Graves JE. A single-center, open-label, prospective pilot study of subcutaneous efalizumab for oral erosive lichen planus. J. Drugs Dermatol. 6: 310-314 (2007).
Heidt MC, Vician M, Stracke SK, Stadlbauer T, Grebe MT, Boening A, Vogt PR, Erdogan A. Beneficial effects of intravenously administered N-3 fatty acids for the prevention of atrial fibrillation after coronary artery bypass surgery: a prospective randomized study. Thorac. Cardiovasc. Surg. 57: 276-280 (2009).
Heininger K. A unifying hypothesis of Alzheimer's disease. III. Risk factors. Hum. Psychopharmacol. 15: 1-70 (2000).
Helliwell PS, Taylor WJ. Treatment of psoriatic arthritis and rheumatoid arthritis with disease modifying drugs - comparison of drugs and adverse reactions. J. Rheumatol. 35: 472-476 (2008).
Hempfling W, Dilger K, Beuers U. Ursodeoxycholic acid - adverse effects and drug interactions. Aliment. Pharmacol. Ther. 18: 963-972 (2003). *
Hempfling W, Grunhage F, Dilger K, Reichel C, Beuers U, Sauerbruch T. Pharmacokinetics and pharmacodynamic action of budesonide in early- and late-stage primary biliary cirrhosis. Hepatology 38: 196-202 (2003). *
Henderson S, Hoffman N, Prince R. A double-blind placebo-controlled study of the effects of the bisphosphonate risedronate on bone mass in patients with inflammatory bowel disease. Am. J. Gastroenterol. 101: 119-123 (2006). *
Hendrickx BW, Punt CJ, Boerman OC, Postema EJ, Oosterwijk E, Mavridu A, Corstens FH, Oyen WJ. Targeting of biliary cancer with radiolabeled chimeric monoclonal antibody CG250. Cancer Biother. Radiopharm. 21: 263-268 (2006).
Hengge UR, Krause W, Hofmann H, Stadler R, Gross G, Meurer M, Brinkmeier T, Frosch P, Moll I, Fritsch P, Muller K, Meykadeh N, Marini A, Ruzicka T, Gollnick H. Multicentre, phase II trial on the safety and efficacy of topical tacrolimus ointment for the treatment of lichen sclerosus. Br. J. Dermatol. 155: 1021-1028 (2006). *
Henker J, Muller S, Laass MW, Schreiner A, Schulze J. Probiotic Escherichia coli Nissle 1917 (EcN) for successful remission maintenance of ulcerative colitis in children and adolescents: an open-label pilot study. Z. Gastroenterol. 46: 874-875 (2008).
Hennig C, Baumann U, Ilginus C, Horneff G, Foell J, Hansen G. Successful treatment of autoimmune and lymphoproliferative complications of patients with intrinsic B-cell immunodeficiencies with rituximab. Br. J. Haematol. Nov 17 [Epub ahead of print] (2009). *
Henriette Tanja L, Guchelaar HJ, Gelderblom H. Pharmacogenetics in chemotherapy of colorectal cancer. Best Pract. Res. Clin. Gastroenterol. 23: 257-273 (2009).
Henriksen C, Haugholt K, Lindgren M, Aurvag AK, Ronnestad A, Grønn M, Solberg R, Moen A, Nakstad B, Berge RK, Smith L, Iversen PO, Drevon CA. Improved cognitive development among preterm infants attributable to early supplementation of human milk with docosahexaenoic acid and arachidonic acid. Pediatrics 121: 1137-1145 (2008). *
Henry RR, Lincoff AM, Mudaliar S, Rabbia M, Chognot C, Herz M. Effect of the dual peroxisome proliferator-activated receptor-alpha/gamma agonist aleglitazar on risk of cardiovascular disease in patients with type 2 diabetes (SYNCHRONY): a phase II, randomised, dose-ranging study. Lancet 374: 126-135 (2009). *
Herath CB, Warner FJ, Lubel JS, Dean RG, Jia Z, Lew RA, Smith AI, Burrell LM, Angus PW. Upregulation of hepatic angiotensin-converting enzyme 2 (ACE2) and angiotensin-(1-7) levels in experimental biliary fibrosis. J. Hepatol. 47: 387-395 (2007). *
Herfarth H. Are we ready for top-down therapy for inflammatory bowel diseases: con. Expert Rev. Gastroenterol. Hepatol. 1: 249-255 (2007).
Herfarth H, Tjaden C, Lukas M, Obermeier F, Dilger K, Muller R, Scholmerich J. Adverse events in clinical trials with azathioprine and mesalamine for prevention of postoperative recurrence of Crohn's disease. Gut 55: 1525-1526 (2006). *
Herfarth HH, Osterman MT, Isaacs KL, Lewis JD, Sands BE. Efficacy of methotrexate in ulcerative colitis: failure or promise. Inflamm. Bowel Dis. Feb 23 [Epub ahead of print] (2010). *
Hering BJ, Kandaswamy R, Ansite JD, Eckman PM, Nakano M, Sawada T, Matsumoto I, Ihm SH, Zhang HJ, Parkey J, Hunter DW, Sutherland DE. Single-donor, marginal-dose islet transplantation in patients with type 1 diabetes. JAMA 293: 830-835 (2005). *
Hernandez Garcia I. Severe erythroderma in a patient under intermittent therapy with efalizumab. J. Drugs Dermatol. 7: 987-989 (2008).
Hernandez-Diaz S, Mitchell AA, Kelley KE, Calafat AM, Hauser R. Medications as a potential source of exposure to phthalates in the U.S. population. Environ. Health Perspect. 117: 185-189 (2009). *
Hernandez-Salazar A, de Leon-Rosales SP, Rangel-Frausto S, Criollo E, Archer-Dubon C, Orozco-Topete R. Epidemiology of adverse cutaneous drug reactions. A prospective study in hospitalized patients. Arch. Med. Res. 37: 899-902 (2006).
Herrlinger KR, Deibert P, Schwab M, Kreisel W, Fischer C, Fellermann K, Stange EF. Remission maintenance by tioguanine in chronic active Crohn's disease. Aliment. Pharmacol. Ther. 17: 1459-1464 (2003). *
Herrlinger KR, Jewell DP. Review article: interactions between genotype and response to therapy in inflammatory bowel diseases. Aliment. Pharmacol. Ther. 24: 1403-1412 (2006). *
Herrmann M, Tami A, Wildemann B, Wolny M, Wagner A, Schorr H, Taban-Shomal O, Umanskaya N, Ross S, Garcia P, Hubner U, Herrmann W. Hyperhomocysteinemia induces a tissue specific accumulation of homocysteine in bone by collagen binding and adversely affects bone. Bone 44: 467-475 (2009). *
Herszenyi L, Farinati F, Miheller P, Tulassay Z. Chemoprevention of colorectal cancer: feasibility in everyday practice? Eur. J. Cancer Prev. 17: 502-514 (2008).
Hervey PS, Keam SJ. Abatacept. BioDrugs 20: 53-61 (2006).
Herzer M, Umfress K, Aljadeff G, Ghai K, Zakowski SG. Interactions with parents and friends among chronically ill children: examining social networks. J. Dev. Behav. Pediatr. 30: 499-508 (2009).
Hess LM, Krutzsch MF, Guillen J, Chow HH, Einspahr J, Batta AK, Salen G, Reid ME, Earnest DL, Alberts DS. Results of a phase I multiple-dose clinical study of ursodeoxycholic acid. Cancer Epidemiol. Biomarkers Prev. 13: 861-867 (2004). *
Hetland ML. DANBIO: a nationwide registry of biological therapies in Denmark. Clin. Exp. Rheumatol. 23: S205-S207 (2005).
Hibbeln JR, Davis JM. Considerations regarding neuropsychiatric nutritional requirements for intakes of omega-3 highly unsaturated fatty acids. Prostaglandins Leukot. Essent. Fatty Acids 81: 179-186 (2009). *
Hibbeln JR, Davis JM, Steer C, Emmett P, Rogers I, Williams C, Golding J. Maternal seafood consumption in pregnancy and neurodevelopmental outcomes in childhood (ALSPAC study): an observational cohort study. Lancet 369: 578-585 (2007). *
Hibi T, Naganuma M, Kitahora T, Kinjyo F, Shimoyama T. Low-dose azathioprine is effective and safe for maintenance of remission in patients with ulcerative colitis. J. Gastroenterol. 38: 740-746 (2003). *
Hibi T, Sameshima Y, Sekiguchi Y, Hisatome Y, Maruyama F, Moriwaki K, Shima C, Saniabadi AR, Matsumoto T. Treating ulcerative colitis by adacolumn therapeutic leucocytapheresis: clinical efficacy and safety based on surveillance of 656 patients in 53 centres in Japan. Dig. Liver Dis. 41: 570-577 (2009).
Hider SL, Bruce IN, Thomson W. The pharmacogenetics of methotrexate. Rheumatology (Oxford) 46: 1520-1524 (2007). *
Higuchi N, Tahara N, Yanagihara K, Fukushima K, Suyama N, Inoue Y, Miyazaki Y, Kobayashi T, Yoshiura K, Niikawa N, Wen CY, Isomoto H, Shikuwa S, Omagari K, Mizuta Y, Kohno S, Tsukamoto K. NAT2*6A, a haplotype of the N-acetyltransferase 2 gene, is an important biomarker for risk of anti-tuberculosis drug-induced hepatotoxicity in Japanese patients with tuberculosis. World J. Gastroenterol. 13: 6003-6008 (2007). *
Hilditch JR. Adverse reaction to salazopyrin. Can. Med. Assoc. J. 106: 1064 (1972). *
Hillingso J, Kjeldsen J, Laursen LS, Lauritsen K, von Spreckelsen S, Depre M, Friedman BS, Malmstrom K, Shingo S, Bukhave K, et al. Blockade of leukotriene production by a single oral dose of MK-0591 in active ulcerative colitis. Clin. Pharmacol. Ther. 57: 335-341 (1995).
Hilsden RJ, Hodgins DC, Timmer A, Sutherland LR. Helping patients with Crohn's disease quit smoking. Am. J. Gastroenterol. 95: 352-358 (2000). *
Himmelfarb J, Phinney S, Ikizler TA, Kane J, McMonagle E, Miller G. Gamma-tocopherol and docosahexaenoic acid decrease inflammation in dialysis patients. J. Ren. Nutr. 17: 296-304 (2007).
Hindorf U, Lindqvist M, Peterson C, Soderkvist P, Strom M, Hjortswang H, Pousette A, Almer S. Pharmacogenetics during standardised initiation of thiopurine therapy in inflammatory bowel disease. Gut 55: 1423-1431 (2006). *
Hindorf U, Johansson M, Eriksson A, Kvifors E, Almer SH. Mercaptopurine treatment should be considered in azathioprine intolerant patients with inflammatory bowel disease. Aliment. Pharmacol. Ther. 29: 654-661 (2009). *
Hindorf U, Lindqvist M, Hildebrand H, Fagerberg U, Almer S. Adverse events leading to modification of therapy in a large cohort of patients with inflammatory bowel disease. Aliment. Pharmacol. Ther. 24: 331-342 (2006). *
Hinojosa J, Borras-Blasco J, Maroto N, Rosique-Robles JD, Alos R, Castera ME. Severe myalgia associated with adalimumab treatment in a patient with Crohn's disease. Ann. Pharmacother. 42: 1130-1133 (2008).
Hinojosa J, Gomollon F, Garcia S, Bastida G, Cabriada JL, Saro C, Ceballos D, Penate M, Gassull MA; ON BEHALF OF SPANISH SCIENTIFIC GROUP ON CROHN'S DISEASE AND ULCERATIVE COLITIS. Efficacy and safety of short-term adalimumab treatment in patients with active Crohn's disease who lost response or showed intolerance to infliximab: a prospective, open-label, multicentre trial. Aliment. Pharmacol. Ther. 25: 409-418 (2007). *
Hirano Y, Kojima T, Kanayama Y, Shioura T, Hayashi M, Kida D, Kaneko A, Eto Y, Ishiguro N. Influences of anti-tumour necrosis factor agents on postoperative recovery in patients with rheumatoid arthritis. Clin. Rheumatol. Jan 13 [Epub ahead of print] (2010). *
Hivelin M, Siemionow M, Grimbert P, Lantieri L. Extra corporeal photopheresis: from solid organs to face transplantation. Transpl. Immunol. 21: 117-128 (2009).
Hjardem E, Ostergaard M, Podenphant J, Tarp U, Andersen LS, Bing J, Peen E, Lindegaard HM, Ringsdal VS, Rodgaard A, Skot J, Hansen A, Mogensen HH, Unkerskov J, Hetland ML. Do rheumatoid arthritis patients in clinical practice benefit from switching from infliximab to a second tumor necrosis factor alpha inhibitor? Ann. Rheum. Dis. 66: 1184-1189 (2007). *
Ho GT, Mowat A, Potts L, Cahill A, Mowat C, Lees CW, Hare NC, Wilson JA, Boulton-Jones R, Priest M, Watts DA, Shand AG, Arnott ID, Russell RK, Wilson DC, Morris AJ, Satsangi J. Efficacy and complications of adalimumab treatment for medically-refractory Crohn's disease: analysis of nationwide experience in Scotland (2004-2008). Aliment. Pharmacol. Ther. 29: 527-534 (2009). *
Ho RH, Kim RB. Transporters and drug therapy: implications for drug disposition and disease. Clin. Pharmacol. Ther. 78: 260-277 (2005). *
Hodge JA, Hodge KD. Ischemic colitis related to sumatriptan overuse. J. Am. Board Fam. Med. 23: 124-127 (2010). *
Hodge L, Swain A, Faulkner-Hogg K. Food allergy and intolerance. Aust. Fam. Physician 38: 705-707 (2009).
Hodulik S, Hadi S. Efalizumab: a biological agent for the treatment of psoriasis. Rev. Recent Clin. Trials 1: 165-168 (2006).
Hoefnagel JJ, van Leeuwen RL, Mattie H, Bastiaens MT. Side effects of minocycline in the treatment of acne vulgaris. Ned. Tijdschr. Geneeskd. 141: 1424-1427 (1997).
Hoes JN, Jacobs JW, Verstappen SM, Bijlsma JW, van der Heijden GJ. Adverse events of low-to-medium-dose oral glucocorticoids in inflammatory diseases: a meta-analysis. Ann. Rheum. Dis. 68: 1833-1838 (2009).
Hofer KN. Oral budesonide in the management of Crohn's disease. Ann. Pharmacother. 37: 1457-1464 (2003).
Hohlfeld R, Wekerle H. Drug insight: using monoclonal antibodies to treat multiple sclerosis. Nat. Clin. Pract. Neurol. 1: 34-44 (2005). *
Holland ML, Panetta JA, Hoskins JM, Bebawy M, Roufogalis BD, Allen JD, Arnold JC. The effects of cannabinoids on P-glycoprotein transport and expression in multidrug resistant cells. Biochem. Pharmacol. 71: 1146-1154 (2006). *
Holliday SM, Benfield P. Interferon-beta-1a: a review of its pharmacological properties and therapeutic potential in multiple sclerosis. BioDrugs 8: 317-330 (1997).
Hollmuller I, Stadlmann S, Graziadei I, Vogel W. Clinico-histopathological characteristics of clopidogrel-induced hepatic injury: case report and review of literature. Eur. J. Gastroenterol. Hepatol. 18: 931-934 (2006).
Holloway KP, Rouphael NG, Wells JB, King MD, Blumberg HM. Polymyxin B and doxycycline use in patients with multidrug-resistant Acinetobacter baumannii infections in the intensive care unit. Ann. Pharmacother. 40: 1939-1945 (2006).
Holman DM, Kalaaji AN. Cytokines in dermatology. J. Drugs Dermatol. 5: 520-524 (2006).
Holme O, Thiis-Evensen E, Vatn MH. Treatment of fulminant ulcerative colitis with cyclosporine A. Scand. J. Gastroenterol. 44: 1310-1314 (2009).
Holtmann MH, Gerts AL, Weinman A, Galle PR, Neurath MF. Treatment of Crohn's disease with leflunomide as second-line immunosuppression: a phase 1 open-label trial on efficacy, tolerability and safety. Dig. Dis. Sci. 53: 1025-1032 (2008). *
Homan M, Baldassano RN, Mamula P. Managing complicated Crohn's disease in children and adolescents. Nat. Clin. Pract. Gastroenterol. Hepatol. 2: 572-579 (2005). *
Hommes D, van den Blink B, Plasse T, Bartelsman J, Xu C, Macpherson B, Tytgat G, Peppelenbosch M, Van Deventer S. Inhibition of stress-activated MAP kinases induces clinical improvement in moderate to severe Crohn's disease. Gastroenterology 122: 7-14 (2002). *
Hommes DW, Erkelens W, Ponsioen C, Stokkers P, Rauws E, van der Spek M, Kate FT, van Deventer SJ. A double-blind, placebo-controlled, randomized study of infliximab in primary sclerosing cholangitis. J. Clin. Gastroenterol. 42: 522-526 (2008).
Hommes DW, Mikhajlova TL, Stoinov S, Timac D, Vucelic B, Lonovics J, Zakuciova M, D'Haens G, Van Assche G, Ba S, Lee S, Pearce T. Fontolizumab, a humanised anti-interferon-gamma antibody, demonstrates safety and potential clinical activity in patients with moderate-to-severe Crohn's disease. Gut 55: 1131-1137 (2006). *
Hommes DW, van de Heisteeg BH, van der Spek M, Bartelsman JF, van Deventer SJ. Infliximab treatment for Crohn's disease: one-year experience in a Dutch academic hospital. Inflamm. Bowel Dis. 8: 81-86 (2002). *
Hommes DW, van Deventer SJ. Infliximab therapy in Crohn's disease: safety issues. Neth. J. Med. 61: 100-104 (2003). *
Homnick DN, Marks JH, Rubin BK. The effect of a first-generation antihistamine on sputum viscoelasticity in cystic fibrosis. J. Aerosol. Med. 20: 45-49 (2007).
Hong YG, Riegler JL. Is melatonin associated with the development of autoimmune hepatitis? J. Clin. Gastroenterol. 25: 376-378 (1997).
Horne R, Parham R, Driscoll R, Robinson A. Patients' attitudes to medicines and adherence to maintenance treatment in inflammatory bowel disease. Inflamm. Bowel Dis. 15: 837-844 (2009). *
Horneff G, Ebert A, Fitter S, Minden K, Foeldvari I, Kummerle-Deschner J, Thon A, Girschick HJ, Weller F, Huppertz HI. Safety and efficacy of once weekly etanercept 0.8 mg/kg in a multicentre 12 week trial in active polyarticular course juvenile idiopathic arthritis. Rheumatology (Oxford) 48: 916-919 (2009).
Hou Y, Wang L, Ding B, Liu Y, Zhu H, Liu J, Li Y, Wu X, Yin Y, Wu G. Dietary alpha-ketoglutarate supplementation ameliorates intestinal injury in lipopolysaccharide-challenged piglets. Amino Acids Feb 2 [Epub ahead of print] (2010). *
Houtchens MK. Pregnancy and multiple sclerosis. Semin. Neurol. 27: 434-441 (2007).
Hovdenak N, Schlichting E. Inflammatory bowel disease and pregnancy. Tidsskr. Nor. Laegeforen. 118: 1201-1203 (1998).
Howes LG, Howes JB, Huang JL, Walker C. Phase IB single- and multiple-dose pharmacokinetic study of oral NV-52 in healthy volunteers. Drugs R. D. 9: 159-166 (2008).
Howes LG, James MJ, Florin T, Walker C. NV-52. Expert Opin. Investig. Drugs 16: 1255-1266 (2007).
Hoy SM, Keating GM. Omega-3 ethylester concentrate: a review of its use in secondary prevention post-myocardial infarction and the treatment of hypertriglyceridaemia. Drugs 69: 1077-1105 (2009).
Hsieh MM, Kang EM, Fitzhugh CD, Link MB, Bolan CD, Kurlander R, Childs RW, Rodgers GP, Powell JD, Tisdale JF. Allogeneic hematopoietic stem-cell transplantation for sickle cell disease. N. Engl. J. Med. 361: 2309-2317 (2009). *
Hu S, Cohen D, Murphy G, Mody E, Qureshi AA. Interstitial granulomatous dermatitis in a patient with rheumatoid arthritis on etanercept. Cutis 81: 336-338 (2008).
Hu W, Metselaar J, Ben LH, Cravens PD, Singh MP, Frohman EM, Eagar TN, Racke MK, Kieseier BC, Stuve O. PEG minocycline-liposomes ameliorate CNS autoimmune disease. PLoS ONE 4: e4151 (2009). *
Huang Y. Pharmacogenetics/genomics of membrane transporters in cancer chemotherapy. Cancer Metastasis Rev. 26: 183-201 (2007). *
Huang Z, Mancini JA. Phosphodiesterase 4 Inhibitors for the treatment of asthma and COPD. Curr. Med. Chem. 13: 3253-3262 (2006).
Hubert D, Leroy S, Nove-Josserand R, Murris-Espin M, Mely L, Dominique S, Delaisi B, Kho P, Kovarik JM. Pharmacokinetics and safety of tobramycin administered by the PARI eFlow rapid nebulizer in cystic fibrosis. J. Cyst. Fibros. 8: 332-337 (2009).
Huet E, Morand K, Blanchet B, Astier A, Hulin A. Evaluation of the new heterogeneous ACMIA immunoassay for the determination of whole-blood cyclosporine concentrations in bone marrow, kidney, heart, and liver transplant recipients. Transplant. Proc. 36: 1317-1320 (2004). *
Hughes AR, Brothers CH, Mosteller M, Spreen WR, Burns DK. Genetic association studies to detect adverse drug reactions: abacavir hypersensitivity as an example. Pharmacogenomics 10: 225-233 (2009).
Hughes LB, Beasley TM, Patel H, Tiwari HK, Morgan SL, Baggott JE, Saag KG, McNicholl J, Moreland LW, Alarcon GS, Bridges Jr SL. Racial/ethnic differences in allele frequencies of single nucleotide polymorphisms in the methylenetetrahydrofolate reductase gene and their Influence on response to methotrexate in rheumatoid arthritis. Ann. Rheum. Dis. 65: 1213-1218 (2006). *
Hughes RA. Intravenous immunoglobulin for chronic inflammatory demyelinating polyradiculoneuropathy: the ICE trial. Expert Rev. Neurother. 9: 789-795 (2009).
Hughes S, Hughes A, Brothers C, Spreen W, Thorborn D; on behalf of the CNA106030 Study Team. PREDICT-1 (CNA106030): the first powered, prospective trial of pharmacogenetic screening to reduce drug adverse events. Pharm. Stat. 7: 121-129 (2007).
Huguet Malaves JM, Ruiz Sanchez L, Dura Ayet AB, Rodriguez Garcia I, Latorre Sanchez M, Ferrer Arranz L, Tuset Ruiz JA, Tome Toyosato A, Medina Chulia E. Effectiveness of maintenance azathioprine therapy without oral cyclosporine after severe attacks of ulcerative colitis refractory to endovenous steroids. Gastroenterol. Hepatol. 31: 280-284 (2008).
Huhn RD, Fogarty PF, Nakamura R, Read EJ, Leitman SF, Rick ME, Kimball J, Greene A, Hansmann K, Gratwohl A, Young N, Barrett AJ, Dunbar CE. High-dose cyclophosphamide with autologous lymphocyte-depleted peripheral blood stem cell (PBSC) support for treatment of refractory chronic autoimmune thrombocytopenia. Blood 101: 71-77 (2003). *
Huiras E, Preda V, Maurer T, Whitfeld M. Cutaneous manifestations of immune reconstitution inflammatory syndrome. Curr. Opin. HIV AIDS 3: 453-460 (2008).
Hull PR, Demkiw-Bartel C. Isotretinoin use in acne: prospective evaluation of adverse events. J. Cutan. Med. Surg. 4: 66-70 (2000).
Hull KM, Drewe E, Aksentijevich I, Singh HK, Wong K, McDermott EM, Dean J, Powell RJ, Kastner DL. The TNF receptor-associated periodic syndrome (TRAPS): emerging concepts of an autoinflammatory disorder. Medicine (Baltimore) 81: 349-368 (2002).
Hull M, Berger M, Heneka M. Disease-modifying therapies in Alzheimer's disease: how far have we come? Drugs 66: 2075-2093 (2006).
Humar A. Living donor liver transplants: potential disadvantages. J. Gastroenterol. Hepatol. 19: S304-S306 (2004). *
Humayun F, Shehab TM, Tworek JA, Fontana RJ. A fatal case of bupropion (Zyban) hepatotoxicity with autoimmune features: a case report. J. Med. Case Reports 1: 88 (2007). *
Hung SI, Chung WH, Jee SH, Chen WC, Chang YT, Lee WR, Hu SL, Wu MT, Chen GS, Wong TW, Hsiao PF, Chen WH, Shih HY, Fang WH, Wei CY, Lou YH, Huang YL, Lin JJ, Chen YT. Genetic susceptibility to carbamazepine-induced cutaneous adverse drug reactions. Pharmacogenet. Genomics 16: 297-306 (2006).
Hung SI, Chung WH, Liou LB, Chu CC, Lin M, Huang HP, Lin YL, Lan JL, Yang LC, Hong HS, Chen MJ, Lai PC, Wu MS, Chu CY, Wang KH, Chen CH, Fann CS, Wu JY, Chen YT. HLA-B*5801 allele as a genetic marker for severe cutaneous adverse reactions caused by allopurinol. Proc. Natl. Acad. Sci. U.S.A. 102: 4134-4139 (2005). *
Hunt PJ, Gurnell EM, Huppert FA, Richards C, Prevost AT, Wass JA, Herbert J, Chatterjee VK. Improvement in mood and fatigue after dehydroepiandrosterone replacement in Addison's disease in a randomized, double blind trial. J. Clin. Endocrinol. Metab. 85: 4650-4656 (2000). *
Huo TI, Lee SD. Management of inoperable hepatocellular carcinoma. J. Gastroenterol. Hepatol. 19: S272-S278 (2004). *
Hurst CH, Waxman DJ. Environmental phthalate monoesters activate pregnane X receptor-mediated transcription. Toxicol. Appl. Pharmacol. 199: 266-274 (2004). *
Hussain I, Kline JN. DNA, the immune system, and atopic disease. J. Investig. Dermatol. Symp. Proc. 9: 23-28 (2004). *
Hussaini SH, Farrington EA. Idiosyncratic drug-induced liver injury: an overview. Expert Opin. Drug Saf. 6: 673-684 (2007).
Hutchins H. Omega-3 fatty acids: recommendations for therapeutics and prevention. MedGenMed. 7: 18 (2005). *
Huynh HQ, deBruyn J, Guan L, Diaz H, Li M, Girgis S, Turner J, Fedorak R, Madsen K. Probiotic preparation VSL#3 induces remission in children with mild to moderate acute ulcerative colitis: a pilot study. Inflamm. Bowel Dis. 15: 760-768 (2009). *
Hvatum M, Kanerud L, Hallgren R, Brandtzaeg P. The gut-joint axis: cross-reactive food antibodies in rheumatoid arthritis. Gut 55: 1240-1247 (2006). *
Hyams JS, Markowitz J, Wyllie R. Use of infliximab in the treatment of Crohn's disease in children and adolescents. J. Pediatr. 137: 192-196 (2000). *
Hyams JS, Markowitz JF. Can we alter the natural history of Crohn disease in children? J. Pediatr. Gastroenterol. Nutr. 40: 262-272 (2005). *
Hyams JS, Wilson DC, Thomas A, Heuschkel R, Mitton S, Mitchell B, Daniels R, Libonati MA, Zanker S, Kugathasan S; International Natalizumab CD305 Trial Group. Natalizumab therapy for moderate to severe Crohn disease in adolescents. J. Pediatr. Gastroenterol. Nutr. 44: 185-191 (2007). *
Hyrich KL. Assessing the safety of biologic therapies in rheumatoid arthritis: the challenges of study design. J. Rheumatol. Suppl. 72: 48-50 (2005). *
Hyrich KL, Silman AJ, Watson KD, Symmons DP. Anti-tumour necrosis factor alpha therapy in rheumatoid arthritis: an update on safety. Ann. Rheum. Dis. 63: 1538-1543 (2004). *
Iannone F, Trotta F, Montecucco C, Giacomelli R, Galeazzi M, Matucci-Cerinic M, Ferri C, Cutolo M, Bambara LM, Triolo G, Ferraccioli G, Valentini G, Lapadula G. Etanercept maintains the clinical benefit achieved by infliximab in patients with rheumatoid arthritis who discontinued infliximab due to side effects. Ann. Rheum. Dis. 66: 249-252 (2007). *
Ichikawa Y, Saito T, Yamanaka H, Akizuki M, Kondo H, Kobayashi S, Oshima H, Kawai S, Hama N, Yamada H, Mimori T, Amano K, Tanaka Y, Matsuoka Y, Yamamoto S, Matsubara T, Murata N, Asai T, Suzuki Y; MTX-BUC Combination Study Group. Therapeutic effects of the combination of methotrexate and bucillamine in early rheumatoid arthritis: a multicenter, double-blind, randomized controlled study. Mod. Rheumatol. 15: 323-328 (2005).
Igarashi M, Hirata A, Yamaguchi H, Jimbu Y, Tominaga M. Pioglitazone reduces atherogenic outcomes in type 2 diabetic patients. J. Atheroscler. Thromb. 15: 34-40 (2008).
Iglesias Alzueta J, Matamoros Florí N. Common variable immunodeficiency. Review. Allergol. Immunopathol. (Madr.) 29: 113-118 (2001).
Iida A, Saito S, Sekine A, Mishima C, Kitamura Y, Kondo K, Harigae S, Osawa S, Nakamura Y. Catalog of 605 single-nucleotide polymorphisms (SNPs) among 13 genes encoding human ATP-binding cassette transporters: ABCA4, ABCA7, ABCA8, ABCD1, ABCD3, ABCD4, ABCE1, ABCF1, ABCG1, ABCG2, ABCG4, ABCG5, and ABCG8. J. Hum. Genet. 47: 285-310 (2002). *
Iikuni N, H Hahn B, La Cava A. Potential for anti-DNA immunoglobulin peptide therapy in systemic lupus erythematosus. Expert Opin. Biol. Ther. 9: 201-206 (2009).
Iikuni N, La Cava A. Antibody-based therapies in systemic lupus erythematosus. Mini Rev. Med. Chem. 9: 829-846 (2009).
Ijichi H, Soejima Y, Taketomi A, Yoshizumi T, Uchiyama H, Harada N, Yonemura Y, Maehara Y. Successful management of chylous ascites after living donor liver transplantation with somatostatin. Liver Int. 28: 143-145 (2008). *
Illingworth DR. An overview of lipid-lowering drugs. Drugs 36 Suppl. 3: 63-71 (1988).
Imanishi H, Okamura N, Yagi M, Noro Y, Moriya Y, Nakamura T, Hayakawa A, Takeshima Y, Sakaeda T, Matsuo M, Okumura K. Genetic polymorphisms associated with adverse events and elimination of methotrexate in childhood acute lymphoblastic leukemia and malignant lymphoma. J. Hum. Genet. 52: 166-171 (2007). *
Imperato AK, Smiles S, Abramson SB. Long-term risks associated with biologic response modifiers used in rheumatic diseases. Curr. Opin. Rheumatol. 16: 199-205 (2004).
Inagaki T, Moschetta A, Lee YK, Peng L, Zhao G, Downes M, Yu RT, Shelton JM, Richardson JA, Repa JJ, Mangelsdorf DJ, Kliewer SA. Regulation of antibacterial defense in the small intestine by the nuclear bile acid receptor. Proc. Natl. Acad. Sci. U.S.A. 103: 3920-3925 (2006). *
Ingelman-Sundberg M. The human genome project and novel aspects of cytochrome P450 research. Toxicol. Appl. Pharmacol. 207: S52-S56 (2005). *
Ingelman-Sundberg M. Pharmacogenomic biomarkers for prediction of severe adverse drug reactions. N. Engl. J. Med. 358: 637-639 (2008). *
Ingelman-Sundberg M, Rodriguez-Antona C. Pharmacogenetics of drug-metabolizing enzymes: implications for a safer and more effective drug therapy. Philos. Trans. R. Soc. Lond. B. Biol. Sci. 360: 1563-1570 (2005). *
Ingelman-Sundberg M, Sim SC, Gomez A, Rodriguez-Antona C. Influence of cytochrome P450 polymorphisms on drug therapies: pharmacogenetic, pharmacoepigenetic and clinical aspects. Pharmacol. Ther. 116: 496-526 (2007).
Ingram JR, Rhodes J, Evans BK, Thomas GA. Preliminary observations of oral nicotine therapy for inflammatory bowel disease: an open-label phase I-II study of tolerance. Inflamm. Bowel Dis. 11: 1092-1096 (2005). *
Ingram JR, Rhodes J, Evans BK, Thomas GA. Nicotine enemas for active Crohn's colitis: an open pilot study. Gastroenterol. Res. Pract. 2008: 237185 (2008). *
Ingram JR, Routledge P, Rhodes J, Marshall RW, Buss DC, Evans BK, Feyerabend C, Thomas GA. Nicotine enemas for treatment of ulcerative colitis: a study of the pharmacokinetics and adverse events associated with three doses of nicotine. Aliment. Pharmacol. Ther. 20: 859-865 (2004). *
Ingram JR, Thomas GA, Rhodes J, Green JT, Hawkes ND, Swift JL, Srivastava ED, Evans BK, Williams GT, Newcombe RG, Courtney E, Pillai S. A randomized trial of nicotine enemas for active ulcerative colitis. Clin. Gastroenterol. Hepatol. 3: 1107-1114 (2005).
Insogna KL. The effect of proton pump-inhibiting drugs on mineral metabolism. Am. J. Gastroenterol. 104: S2-S4 (2009).
Invernizzi P, Bianchi I, Locati M, Bonecchi R, Selmi C. Chapter 7. Cytokines in liver health and disease. In "Liver Immunology: Principles and Practice" (eds. Gershwin ME, Vierling JM, Manns MP), Humana Press Inc., Totowa, NJ, p. 83-93 (2007). *
Ireland A, Mason CH, Jewell DP. Controlled trial comparing olsalazine and sulphasalazine for the maintenance treatment of ulcerative colitis. Gut 29: 835-837 (1988). *
Irish A, Dogra G, Mori T, Beller E, Heritier S, Hawley C, Kerr P, Robertson A, Rosman J, Paul-Brent PA, Starfield M, Polkinghorne K, Cass A. Preventing AVF thrombosis: the rationale and design of the omega-3 fatty acids (fish oils) and aspirin in vascular access outcomes in renal disease (FAVOURED) study. BMC Nephrol. 10: 1 (2009). *
Isaacs D. Fungal prophylaxis in very low birth weight neonates: nystatin, fluconazole or nothing? Curr. Opin. Infect. Dis. 21: 246-250 (2008).
Isaacs KL. Severe bone pain as an adverse effect of cyclosporin therapy for Crohn's disease. Inflamm. Bowel Dis. 4: 95-97 (1998). *
Ishibashi H, Komori A, Shimoda S, Gershwin ME. Guidelines for therapy of autoimmune liver disease. Semin. Liver Dis. 27: 214-226 (2007). *
Ishii M, Miyazaki Y, Yamamoto T, Miura M, Ueno Y, Takahashi T, Toyota T. A case of drug-induced ductopenia resulting in fatal biliary cirrhosis. Liver 13: 227-231 (1993).
Ishii N, Hashimoto T, Zillikens D, Ludwig RJ. High-dose intravenous immunoglobulin (IVIG) therapy in autoimmune skin blistering diseases. Clin. Rev. Allergy Immunol. Jun 27 [Epub ahead of print] (2009). *
Ishizawa M, Matsunawa M, Adachi R, Uno S, Ikeda K, Masuno H, Shimizu M, Iwasaki KI, Yamada S, Makishima M. Lithocholic acid derivatives act as selective vitamin D receptor modulators without inducing hypercalcemia. J. Lipid Res. 49: 763-772 (2008). *
Iskedjian M, Bereza B, Gordon A, Piwko C, Einarson TR. Meta-analysis of cannabis based treatments for neuropathic and multiple sclerosis-related pain. Curr. Med. Res. Opin. 23: 17-24 (2007).
Israeli E, Agmon-Levin N, Blank M, Shoenfeld Y. Adjuvants and autoimmunity. Lupus 18: 1217-1225 (2009).
Israeli E, Goldin E, Shibolet O, Klein A, Hemed N, Engelhardt D, Rabbani E, Ilan Y. Oral immune regulation using colitis extracted proteins for treatment of Crohn's disease: results of a phase I clinical trial. World J. Gastroenterol. 11: 3105-3111 (2005). *
Itabashi M, Ikeuchi H, Araki T, Kono T, Nakamura T, Takesue Y, Kameoka S, Kusunoki M. Effectiveness of leukocytapheresis in suppressing the occurrence of surgical site infections following surgery for ulcerative colitis. Surg. Today 38: 609-617 (2008).
Ito H. Novel therapy for Crohn's disease targeting IL-6 signalling. Expert Opin. Ther. Targets 8: 287-294 (2004).
Ito H, Furuta S, Sasaki H, Yoshida T, Takano Y, Hibi T. Pharmacokinetics and safety of single and multiple doses of asacol tablets in Japanese healthy volunteers. Adv. Ther. 26: 749-761 (2009).
Ito H, Takazoe M, Fukuda Y, Hibi T, Kusugami K, Andoh A, Matsumoto T, Yamamura T, Azuma J, Nishimoto N, Yoshizaki K, Shimoyama T, Kishimoto T. A pilot randomized trial of a human anti-interleukin-6 receptor monoclonal antibody in active Crohn's disease. Gastroenterology 126: 989-996 (2004). *
Ivanenkov YA, Balakin KV, Tkachenko SE. New approaches to the treatment of inflammatory disease : focus on small-molecule inhibitors of signal transduction pathways. Drugs R. D. 9: 397-434 (2008).
Iverson SL, Uetrecht JP. Identification of a reactive metabolite of terbinafine: insights into terbinafine-induced hepatotoxicity. Chem. Res. Toxicol. 14: 175-181 (2001). *
Jacob A, Matiello M, Weinshenker BG, Wingerchuk DM, Lucchinetti C, Shuster E, Carter J, Keegan BM, Kantarci OH, Pittock SJ. Treatment of neuromyelitis optica with mycophenolate mofetil: retrospective analysis of 24 patients. Arch. Neurol. 66: 1128-1133 (2009).
Jacobs MN, Nolan GT, Hood SR. Lignans, bacteriocides and organochlorine compounds activate the human pregnane X receptor (PXR). Toxicol. Appl. Pharmacol. 209: 123-133 (2005). *
Jacobson IG, Smith TC, Smith B, Wells TS, Reed RJ, Ryan MA. US military service members vaccinated against smallpox in 2003 and 2004 experience a slightly higher risk of hospitalization postvaccination. Vaccine 26: 4048-4056 (2008).
Jacobson TA. Statin safety: lessons from new drug applications for marketed statins. Am. J. Cardiol. 97: S44-S51 (2006).
Jacobstein DA, Markowitz JE, Kirschner BS, Ferry G, Cohen SA, Gold BD, Winter HS, Heyman MB, Baldassano RN. Premedication and infusion reactions with infliximab: results from a pediatric inflammatory bowel disease consortium. Inflamm. Bowel Dis. 11: 442-446 (2005). *
James SL, Irving PM, Gearry RB, Gibson PR. Management of distal ulcerative colitis: frequently asked questions analysis. Intern. Med. J. 38: 114-119 (2008). *
Janatuinen EK, Kemppainen TA, Pikkarainen PH, Holm KH, Kosma VM, Uusitupa MI, Maki M, Julkunen RJ. Lack of cellular and humoral immunological responses to oats in adults with coeliac disease. Gut 46: 327-331 (2000). *
Janczewska I, Mejhert M, Hast R, Runarsson G, Sandstedt B. Primary AL-amyloidosis, ulcerative colitis and collagenous colitis in a 57-year-old woman: a case study. Scand. J. Gastroenterol. 39: 1306-1309 (2004). *
Janovska L, Vetchy D, Rabiskova M. New systems for colonic drug targeting. Ceska. Slov. Farm. 55: 203-209 (2006).
Janssen SP, Phernambucq M, Martinez-Martinez P, De Baets MH, Losen M. Immunosuppression of experimental autoimmune myasthenia gravis by mycophenolate mofetil. J. Neuroimmunol. 201-202: 111-120 (2008).
Jarand J, Zochodne DW, Martin LO, Voll C. Neurological complications of infliximab. J. Rheumatol. 33: 1018-1020 (2006).
Jaturasitha S, Khiaosa-Ard R, Pongpiachan P, Kreuzer M. Early deposition of n-3 fatty acids from tuna oil in lean and adipose tissue of fattening pigs is mainly permanent. J. Anim. Sci. 87: 693-703 (2009). *
Javouhey E, Ranchin B, Lachaux A, Boillot O, Martin X, Floret D, Cochat P. Long-lasting extracorporeal albumin dialysis in a child with end-stage renal disease and severe cholestasis. Pediatr. Transplant. 13: 235-239 (2009). *
Jawan B, de Villa V, Luk HN, Wang CS, Huang CJ, Chen YS, Wang CC, Cheng YF, Huang TL, Eng HL, Liu PP, Chiu KW, Chen CL. Perioperative normovolemic anemia is safe in pediatric living-donor liver transplantation. Transplantation 77: 1394-1398 (2004).
Jeannesson E, Albertini L, Siest G, Gomes AM, Ribeiro V, Aslanidis C, Schmitz G, Visvikis-Siest S. Determination of ABCB1 polymorphisms and haplotypes frequencies in a French population. Fundam. Clin. Pharmacol. 21: 411-418 (2007).
Jebabli N, Klouz A, Bahlous A, Gaïes E, Trabelsi S, Lakhal M, Belkahia C. Comparison of three methods for cyclosporine therapeutic monitoring. Transplant. Proc. 39: 2557-2559 (2007). *
Jeppesen PB, Lund P, Gottschalck IB, Nielsen HB, Holst JJ, Mortensen J, Poulsen SS, Quistorff B, Mortensen PB. Short bowel patients treated for two years with glucagon-like peptide 2 (GLP-2): compliance, safety, and effects on quality of life. Gastroenterol. Res. Pract. 2009: 425759 (2009).
Jessop S, Khumalo NP. Pemphigus: a treatment update. Am. J. Clin. Dermatol. 9: 147-154 (2008).
Jew S, AbuMweis SS, Jones PJ. Evolution of the human diet: linking our ancestral diet to modern functional foods as a means of chronic disease prevention. J. Med. Food 12: 925-934 (2009).
Jewell DP, Ireland A. Controlled trial comparing olsalazine and sulphasalazine for maintenance treatment of ulcerative colitis. Scand. J. Gastroenterol. Suppl. 148: 45-47 (1988).
Jharap B, Seinen ML, de Boer NK, van Ginkel JR, Linskens RK, Kneppelhout JC, Mulder CJ, van Bodegraven AA. Thiopurine therapy in inflammatory bowel disease patients: analyses of two 8-year intercept cohorts. Inflamm. Bowel Dis. Feb 12 [Epub ahead of print] (2010). *
Ji JD, Kim HJ, Rho YH, Choi SJ, Lee YH, Cheon HJ, Sohn J, Song GG. Inhibition of IL-10-induced STAT3 activation by 15-deoxy-Delta12,14-prostaglandin J2. Rheumatology (Oxford) 44: 983-988 (2005). *
Jigorel E, Le Vee M, Boursier-Neyret C, Parmentier Y, Fardel O. Differential regulation of sinusoidal and canalicular hepatic drug transporter expression by xenobiotics activating drug-sensing receptors in primary human hepatocytes. Drug Metab. Dispos. 34: 1756-1763 (2006). *
Jimenez-Puya R, Gomez-García F, Amorrich-Campos V, Moreno-Gimenez JC. Etanercept: efficacy and safety. J. Eur. Acad. Dermatol. Venereol. 23: 402-405 (2009). *
Jimenez-Rivera C, Avitzur Y, Fecteau AH, Jones N, Grant D, Ng VL. Sirolimus for pediatric liver transplant recipients with post-transplant lymphoproliferative disease and hepatoblastoma. Pediatr. Transplant. 8: 243-248 (2004).
Jin CY, Wang DL, Fang ZD. Effect of integrative Chinese and Western medicine in treating chronic urticaria and its impact on interleukin-10 and interleukin-8 in peripheral blood. Zhongguo Zhong Xi Yi Jie He Za Zhi 28: 358-360 (2008).
Jo Y, Matsumoto T, Iida M. Drug therapy for ulcerative colitis: salazosulfapyridine and 5-ASA. Nippon Rinsho 63: 820-824 (2005).
Johannesen J. Aspects of the molecular and functional genetics in T1DM - a study of selected candidate genes. Dan. Med. Bull. 53: 122-171 (2006).
Johansen HK, Gotzsche PC. Vaccines for preventing infection with Pseudomonas aeruginosa in cystic fibrosis. Cochrane Database Syst. Rev. 4: CD001399 (2008).
Johanson JF, Popp JW, Cohen LB, Lottes SR, Forbes WP, Walker K, Carter E, Zhang B, Rose M. A randomized, multicenter study comparing the safety and efficacy of sodium phosphate tablets with 2L polyethylene glycol solution plus bisacodyl tablets for colon cleansing. Am. J. Gastroenterol. 102: 2238-2246 (2007). *
John Looney R, Huggins J. Use of intravenous immunoglobulin G (IVIG). Best Pract. Res. Clin. Haematol. 19: 3-25 (2006).
Johnsen AK, Schiff MH, Mease PJ, Moreland LW, Maier AL, Coblyn JS, Helfgott SM, Leff JA, Weinblatt ME. Comparison of 2 doses of etanercept (50 vs 100 mg) in active rheumatoid arthritis: a randomized double blind study. J. Rheumatol. 33: 659-664 (2006).
Johnson FR, Ozdemir S, Mansfield C, Hass S, Miller DW, Siegel CA, Sands BE. Crohn's disease patients' risk-benefit preferences: serious adverse event risks versus treatment efficacy. Gastroenterology 133: 769-779 (2007). *
Johnson FR, Ozdemir S, Mansfield C, Hass S, Siegel CA, Sands BE. Are adult patients more tolerant of treatment risks than parents of juvenile patients? Risk Anal. 29: 121-136 (2009).
Johnson IT, Lund EK. Review article: nutrition, obesity and colorectal cancer. Aliment. Pharmacol. Ther. 26: 161-181 (2007). *
Johnston JM, Kurtz CB, Drossman DA, Lembo AJ, Jeglinski BI, Macdougall JE, Antonelli SM, Currie MG. Pilot study on the effect of linaclotide in patients with chronic constipation. Am. J. Gastroenterol. 104: 125-132 (2009). *
Jones DE, Palmer JM, Robe A, Kirby JA. Oral tolerisation to pyruvate dehydrogenase complex as a potential therapy for primary biliary cirrhosis. Autoimmunity 35: 537-544 (2002).
Jones EA, ten Kate FJ, ter Borg F, Houben M, Reesink HW, Chamuleau RA. Combination therapy with mycophenolate mofetil and ursodeoxycholic acid for primary biliary cirrhosis. Eur. J. Gastroenterol. Hepatol. 11: 1165-1169 (1999).
Jones-Caballero M, Unaeze J, Penas PF, Stern RS. Use of biological agents in patients with moderate to severe psoriasis: a cohort-based perspective. Arch. Dermatol. 143: 846-850 (2007). *
Jordan MA, Haywood T. Evaluation of internet websites marketing herbal weight-loss supplements to consumers. J. Altern. Complement. Med. 13: 1035-1043 (2007).
Jorizzo J, Grossman R, Nighland M. Tretinoin microsphere gel in younger acne patients. J. Drugs Dermatol. 7: s9-s13 (2008).
Jouzeau JY, Moulin D, Koufany M, Sebillaud S, Bianchi A, Netter P. Pathophysiological relevance of peroxisome proliferators activated receptors (PPAR) to joint diseases - the pro and con of agonists. J. Soc. Biol. 202: 289-312 (2008).
Joy C, Mumby-Croft R, Joy L. Polyunsaturated fatty acid supplementation for schizophrenia. Cochrane Database Syst. Rev. 3: CD001257 (2006). *
Joyce MR, Fazio VW. Can ileal pouch anal anastomosis be used in Crohn's disease? Adv. Surg. 43: 111-137 (2009).
Judson MA, Silvestri J, Hartung C, Byars T, Cox CE. The effect of thalidomide on corticosteroid-dependent pulmonary sarcoidosis. Sarcoidosis Vasc. Diffuse Lung Dis. 23: 51-57 (2006).
Juillerat P, Felley C, Mottet C, Froehlich F, Vader JP, Burnand B, Gonvers JJ, Michetti P. Drug safety in the treatment of Crohn's disease. Digestion 71: 8-12 (2005).
Juillerat P, Pittet V, Felley C, Mottet C, Froehlich F, Vader JP, Gonvers JJ, Michetti P. Drug safety in Crohn's disease therapy. Digestion 76: 161-168 (2007). *
Julia A, Kovaleva L, Loria S, Alberca I, Hernandez F, Sandoval V, Sierra J, Vidaller A, Ayguasanosa J, Carretero M. Clinical efficacy and safety of Flebogammadif, a new high-purity human intravenous immunoglobulin, in adult patients with chronic idiopathic thrombocytopenic purpura. Transfus. Med. 19: 260-268 (2009). *
Jun JB, Cho DY, Kang C, Bae SC. Thiopurine S-methyltransferase polymorphisms and the relationship between the mutant alleles and the adverse effects in systemic lupus erythematosus patients taking azathioprine. Clin. Exp. Rheumatol. 23: 873-876 (2005).
Jun S, Hua RZ, Min YH, Tian ZX, Dong XS. Meta-analysis: the effect and adverse events of Lactobacilli vs. placebo in maintenance therapy for Crohn's disease. Intern. Med. J. 39: 103-109 (2009). *
Jung Y, Kim HH, Kim H, Kong H, Choi B, Yang Y, Kim Y. Evaluation of 5-aminosalicyltaurine as a colon-specific prodrug of 5-aminosalicylic acid for treatment of experimental colitis. Eur. J. Pharm. Sci. 28: 26-33 (2006).
Jung Y, Park J, Kim TY, Park JH, Jong HS, Im SA, Robertson KD, Bang YJ, Kim TY. Potential advantages of DNA methyltransferase 1 (DNMT1)-targeted inhibition for cancer therapy. J. Mol. Med. 85: 1137-1148 (2007). *
Jurgens M, Laubender RP, Hartl F, Weidinger M, Seiderer J, Wagner J, Wetzke M, Beigel F, Pfennig S, Stallhofer J, Schnitzler F, Tillack C, Lohse P, Goke B, Glas J, Ochsenkuhn T, Brand S. Disease activity, ANCA, and IL23R genotype status determine early response to infliximab in patients with ulcerative colitis. Am. J. Gastroenterol. Mar 2 [Epub ahead of print] (2010). *
Juszczak GR, Swiergiel AH. Properties of gap junction blockers and their behavioural, cognitive and electrophysiological effects: animal and human studies. Prog. Neuropsychopharmacol. Biol. Psychiatry 33: 181-198 (2009).
Kaarniranta K, Salminen A. NF-kappaB signaling as a putative target for omega-3 metabolites in the prevention of age-related macular degeneration (AMD). Exp. Gerontol. 44: 685-688 (2009).
Kaczorowski DJ, Tsung A, Billiar TR. Innate immune mechanisms in ischemia/reperfusion. Front. Biosci. (Elite Ed.) 1: 91-98 (2009).
Kahaleh M, Mishra R, Shami VM, Northup PG, Berg CL, Bashlor P, Jones P, Ellen K, Weiss GR, Brenin CM, Kurth BE, Rich TA, Adams RB, Yeaton P. Unresectable cholangiocarcinoma: comparison of survival in biliary stenting alone versus stenting with photodynamic therapy. Clin. Gastroenterol. Hepatol. 6: 290-297 (2008).
Kahan BD. Sirolimus-based immunosuppression: present state of the art. J. Nephrol. 17 Suppl. 8: S32-S39 (2004).
Kakar S, Aksoy S, Burgart LJ, Smyrk TC. Mucinous carcinoma of the colon: correlation of loss of mismatch repair enzymes with clinicopathologic features and survival. Mod. Pathol. 17: 696-700 (2004). *
Kalden JR, Manger B. Biologic agents in the treatment of inflammatory rheumatic diseases. Curr. Opin. Rheumatol. 9: 206-212 (1997).
Kale-Pradhan PB, Pradhan RS, Wilhelm SM. Multi-matrix system mesalamine: to use or not to use. Ann. Pharmacother. 42: 265-269 (2008).
Kalgutkar AS, Obach RS, Maurer TS. Mechanism-based inactivation of cytochrome P450 enzymes: chemical mechanisms, structure-activity relationships and relationship to clinical drug-drug interactions and idiosyncratic adverse drug reactions. Curr. Drug Metab. 8: 407-447 (2007).
Kalia S, Dutz JP. New concepts in antimalarial use and mode of action in dermatology. Dermatol. Ther. 20: 160-174 (2007). *
Kalsotra A, Du L, Wang Y, Ladd PA, Kikuta Y, Duvic M, Boyd AS, Keeney DS, Strobel HW. Inflammation resolved by retinoid X receptor-mediated inactivation of leukotriene signaling pathways. FASEB J. 22: 538-547 (2008). *
Kaltenthaler EC, Walters SJ, Chilcott J, Blakeborough A, Vergel YB, Thomas S. MRCP compared to diagnostic ERCP for diagnosis when biliary obstruction is suspected: a systematic review. BMC Med. Imaging 6: 9 (2006). *
Kamal MA, Jusko WJ. Interactions of prednisolone and other immunosuppressants used in dual treatment of systemic lupus erythematosus in lymphocyte proliferation assays. J. Clin. Pharmacol. 44: 1034-1045 (2004). *
Kamath AT, Valenti MP, Rochat AF, Agger EM, Lingnau K, von Gabain A, Andersen P, Lambert PH, Siegrist CA. Protective anti-mycobacterial T cell responses through exquisite in vivo activation of vaccine-targeted dendritic cells. Eur. J. Immunol. 38: 1247-1256 (2008). *
Kamili QU, Menter A. Topical treatment of psoriasis. Curr. Probl. Dermatol. 38: 37-58 (2009).
Kamm MA. Review article: biological drugs in Crohn's disease. Aliment. Pharmacol. Ther. 24 Suppl. 3: 80-89 (2006). *
Kamm MA, Lichtenstein GR, Sandborn WJ, Schreiber S, Lees KH, Barrett K, Joseph RE. Randomised trial of once- or twice-daily MMX mesalazine for maintenance of remission in ulcerative colitis. Gut 57: 893-902 (2008). *
Kamoun M, Holmes JH, Israni AK, Kearns JD, Teal V, Yang WP, Rosas SE, Joffe MM, Li H, Feldman HI. HLA-A amino acid polymorphism and delayed kidney allograft function. Proc. Natl. Acad. Sci. U.S.A. 105: 18883-18888 (2008). *
Kanada SA, Kolling WM, Hindin BI. Aspirin hepatotoxicity. Am. J. Hosp. Pharm. 35: 330-336 (1978).
Kanayama T, Kobayashi N, Mamiya S, Nakanishi T, Nishikawa JI. Organotin compounds promote adipocyte differentiation as agonists of the peroxisome proliferator-activated receptor (PPAR) gamma / retinoid X receptor (RXR) pathway. Mol. Pharmacol. 67: 766-774 (2005). *
Kandiel A, Fraser AG, Korelitz BI, Brensinger C, Lewis JD. Increased risk of lymphoma among inflammatory bowel disease patients treated with azathioprine and 6-mercaptopurine. Gut 54: 1121-1125 (2005). *
Kanduc D. Quantifying the possible cross-reactivity risk of an HPV16 vaccine. J. Exp. Ther. Oncol. 8: 65-76 (2009).
Kane CD, Francone OL, Stevens KA. Differential regulation of the cynomolgus, human, and rat acyl-CoA oxidase promoters by PPARalpha. Gene 380: 84-94 (2006). *
Kane SV, Brixner D, Rubin DT, Sewitch MJ. The challenge of compliance and persistence: focus on ulcerative colitis. J. Manag. Care Pharm. 14: S2-S12 (2008).
Kane SV, Schoenfeld P, Sandborn WJ, Tremaine W, Hofer T, Feagan BG. The effectiveness of budesonide therapy for Crohn's disease. Aliment. Pharmacol. Ther. 16: 1509-1517 (2002). *
Kang HY, Valerio L, Bahadoran P, Ortonne JP. The role of topical retinoids in the treatment of pigmentary disorders: an evidence-based review. Am. J. Clin. Dermatol. 10: 251-260 (2009).
Kaniwa N, Saito Y, Aihara M, Matsunaga K, Tohkin M, Kurose K, Sawada JI, Furuya H, Takahashi Y, Muramatsu M, Kinoshita S, Abe M, Ikeda H, Kashiwagi M, Song Y, Ueta M, Sotozono C, Ikezawa Z, Hasegawa R. HLA-B locus in Japanese patients with anti-epileptics and allopurinol-related Stevens-Johnson syndrome and toxic epidermal necrolysis. Pharmacogenomics 9: 1617-1622 (2008).
Kanke K, Hoshino M, Tominaga K, Nakano M, Terano A, Hiraishi H. Selection of anticoagulants for leukocytapheresis therapy in cases of active ulcerative colitis. Blood Purif. 25: 370-376 (2007).
Kaplan AP, Joseph K, Maykut RJ, Geba GP, Zeldin RK. Treatment of chronic autoimmune urticaria with omalizumab. J. Allergy Clin. Immunol. 122: 569-573 (2008). *
Kappos L, Antel J, Comi G, Montalban X, O'Connor P, Polman CH, Haas T, Korn AA, Karlsson G, Radue EW; FTY720 D2201 Study Group. Oral fingolimod (FTY720) for relapsing multiple sclerosis. N. Engl. J. Med. 355: 1124-1140 (2006). *
Kapur N, Bell S, Kolbe J, Chang AB. Inhaled steroids for bronchiectasis. Cochrane Database Syst. Rev. 1: CD000996 (2009).
Karavanaki K, Tsoka E, Liacopoulou M, Karayianni C, Petrou V, Pippidou E, Brisimitzi M, Mavrikiou M, Kakleas K, Dacou-Voutetakis C. Psychological stress as a factor potentially contributing to the pathogenesis of type 1 diabetes mellitus. J. Endocrinol. Invest. 31: 406-415 (2008).
Kardorff R, Melter M, Rodeck B, Brodehl J. Long-term ursodeoxycholic acid treatment of cholestatic liver diseases in childhood - clinical and biochemical effects. Klin. Padiatr. 208: 118-122 (1996).
Karhadkar AS, Schwartz HJ, Arora M, Dutta SK. Severe muscular weakness: an unusual adverse effect of azathioprine therapy. J. Clin. Gastroenterol. 40: 626-628 (2006).
Kariv R, Tiomny E, Grenshpon R, Dekel R, Waisman G, Ringel Y, Halpern Z. Low-dose naltreoxone for the treatment of irritable bowel syndrome: a pilot study. Dig. Dis. Sci. 51: 2128-2133 (2006). *
Karlsson A, Jagervall A, Pettersson M, Andersson AK, Gillberg PG, Melgar S. Dextran sulphate sodium induces acute colitis and alters hepatic function in hamsters. Int. Immunopharmacol. 8: 20-27 (2008).
Karmiris K, Paintaud G, Noman M, Magdelaine-Beuzelin C, Ferrante M, Degenne D, Claes K, Coopman T, Van Schuerbeek N, Van Assche G, Vermeire S, Rutgeerts P. Influence of trough serum levels and immunogenicity on long-term outcome of adalimumab therapy in Crohn's disease. Gastroenterology 137: 1628-1640 (2009). *
Kasai K, Kuroda H, Ushio A, Sawara K, Takikawa Y, Suzuki K. Evaluation of newly developed combination therapy of intra-arterial 5-fluorouracil and systemic pegylated interferon alpha-2b for advanced hepatocellular carcinoma with portal venous invasion: preliminary results. Hepatol. Res. 39: 117-125 (2009). *
Kasimay O, Guzel E, Gemici A, Abdyli A, Sulovari A, Ercan F, Yegen BC. Colitis-induced oxidative damage of the colon and skeletal muscle is ameliorated by regular exercise in rats: the anxiolytic role of exercise. Exp. Physiol. 91: 897-906 (2006). *
Kasliwal R, Wilton LV, Shakir SA. Monitoring the safety of pioglitazone: results of a prescription-event monitoring study of 12,772 patients in England. Drug Saf. 31: 839-850 (2008).
Kasper LH, Everitt D, Leist TP, Ryan KA, Mascelli MA, Johnson K, Raychaudhuri A, Vollmer T; The Multiple Sclerosis Investigators. A phase I trial of an interleukin-12/23 monoclonal antibody in relapsing multiple sclerosis. Curr. Med. Res. Opin. 22: 1671-1678 (2006).
Kasperkiewicz M, Zillikens D. Rituximab (anti-CD20) for the treatment of autoimmune bullous diseases. Hautarzt. 58: 115-121 (2007).
Kastelic M, Koprivsek J, Plesnicar BK, Serretti A, Mandelli L, Locatelli I, Grabnar I, Dolzan V. MDR1 gene polymorphisms and response to acute risperidone treatment. Prog. Neuropsychopharmacol. Biol. Psychiatry Jan 7 [Epub ahead of print] (2010).
Katamura Y, Aikata H, Kimura Y, Azakami T, Kawaoka T, Takaki S, Waki K, Hiramatsu A, Kawakami Y, Takahashi S, Chayama K. Successful treatment of pulmonary metastases associated with advanced hepatocellular carcinoma by systemic 5-fluorouracil combined with interferon-alpha in a hemodialysis patient. Hepatol. Res. 39: 415-420 (2009).
Katano M, Morisaki T, Koga K, Nakamura M, Onishi H, Matsumoto K, Tasaki A, Nakashima H, Akiyoshi T, Nakamura M. Combination therapy with tumor cell-pulsed dendritic cells and activated lymphocytes for patients with disseminated carcinomas. Anticancer Res. 25: 3771-3776 (2005).
Katchamart W, Trudeau J, Phumethum V, Bombardier C. The efficacy and toxicity of methotrexate (MTX) monotherapy vs. MTX combination therapy with non-biologic disease-modifying anti-rheumatic drugs in rheumatoid arthritis: a systematic review and metaanalysis. Ann. Rheum. Dis. 68: 1105-1112 (2009). *
Kato K, Mizuno S, Umesaki Y, Ishii Y, Sugitani M, Imaoka A, Otsuka M, Hasunuma O, Kurihara R, Iwasaki A, Arakawa Y. Randomized placebo-controlled trial assessing the effect of bifidobacteria-fermented milk on active ulcerative colitis. Aliment. Pharmacol. Ther. 20: 1133-1141 (2004). *
Katoh M, Tateno C, Yoshizato K, Yokoi T. Chimeric mice with humanized liver. Toxicology 246: 9-17 (2008). *
Katsanos K, Cavalier E, Ferrante M, Van Hauwaert V, Henckaerts L, Schnitzler F, Katsaraki A, Noman M, Vermeire S, Tsianos EV, Rutgeerts P, Chapelle JP, Van Assche G. Intravenous iron therapy restores functional iron deficiency induced by infliximab. Journal of Crohn's and Colitis 1: 97-105 (2007).
Katz A, Udata C, Ott E, Hickey L, Burczynski ME, Burghart P, Vesterqvist O, Meng X. Safety, pharmacokinetics, and pharmacodynamics of single doses of LXR-623, a novel liver X-receptor agonist, in healthy participants. J. Clin. Pharmacol. 49: 643-649 (2009). *
Katz DP, Manner T, Furst P, Askanazi J. The use of an intravenous fish oil emulsion enriched with omega-3 fatty acids in patients with cystic fibrosis. Nutrition 12: 334-339 (1996).
Katz HI, Waalen J, Leach EE. Acitretin in psoriasis: an overview of adverse effects. J. Am. Acad. Dermatol. 41: S7-S12 (1999).
Katz JA, Antoni C, Keenan GF, Smith DE, Jacobs SJ, Lichtenstein GR. Outcome of pregnancy in women receiving infliximab for the treatment of Crohn's disease and rheumatoid arthritis. Am. J. Gastroenterol. 99: 2385-2392 (2004). *
Katz U, Achiron A, Sherer Y, Shoenfeld Y. Safety of intravenous immunoglobulin (IVIG) therapy. Autoimmun. Rev. 6: 257-259 (2007).
Katz U, Kishner I, Magalashvili D, Shoenfeld Y, Achiron A. Long term safety of IVIg therapy in multiple sclerosis: 10 years experience. Autoimmunity 39: 513-517 (2006).
Kauffman CL, Aria N, Toichi E, McCormick TS, Cooper KD, Gottlieb AB, Everitt DE, Frederick B, Zhu Y, Graham MA, Pendley CE, Mascelli MA. A phase I study evaluating the safety, pharmacokinetics, and clinical response of a human IL-12 p40 antibody in subjects with plaque psoriasis. J. Invest. Dermatol. 123: 1037-1044 (2004). *
Kaumaya PT, Foy KC, Garrett J, Rawale SV, Vicari D, Thurmond JM, Lamb T, Mani A, Kane Y, Balint CR, Chalupa D, Otterson GA, Shapiro CL, Fowler JM, Grever MR, Bekaii-Saab TS, Carson WE 3rd. Phase I active immunotherapy with combination of two chimeric, human epidermal growth factor receptor 2, B-cell epitopes fused to a promiscuous T-cell epitope in patients with metastatic and/or recurrent solid tumors. J. Clin. Oncol. 27: 5270-5277 (2009).
Kaur N, Mahl TC. Pneumocystis jiroveci (carinii) pneumonia after infliximab therapy: a review of 84 cases. Dig. Dis. Sci. 52: 1481-1484 (2007). *
Kaushik P, Soule MR, Ellison WA, Ahmed B, Kaushik R. Cabergoline-associated erythema nodosum. Ann. Pharmacother. 42: 284-287 (2008).
Kav T, Bayraktar Y. Five years' experience with capsule endoscopy in a single center. World J. Gastroenterol. 15: 1934-1942 (2009). *
Kavanaugh A, Keystone EC. The safety of biologic agents in early rheumatoid arthritis. Clin. Exp. Rheumatol. 21 (5 Suppl. 31): S203-S208 (2003).
Kawahata K. Historical review of rheumatology and future directions. Nippon Rinsho 67: 445-457 (2009).
Kawai S, Takagi K, Kusunoki Y, Nishio S, Matsumoto N. Systemic autoimmune diseases. Nippon Rinsho 66: 130-136 (2008).
Kawamoto S, Aki T, Yamashita M, Tategaki A, Fujimura T, Tsuboi S, Katsutani T, Suzuki O, Shigeta S, Murooka Y, Ono K. Toward elucidating the full spectrum of mite allergens - state of the art. J. Biosci. Bioeng. 94: 285-298 (2002). *
Kawashiri SY, Kawakami A, Iwamoto N, Fujikawa K, Aramaki T, Tamai M, Arima K, Ichinose K, Kamachi M, Yamasaki S, Nakamura H, Origuchi T, Ida H, Eguchi K. Switching to the anti-interleukin-6 receptor antibody tocilizumab in rheumatoid arthritis patients refractory to antitumor necrosis factor biologics. Mod. Rheumatol. Oct 3 [Epub ahead of print] (2009). *
Keating GM, Perry CM. Infliximab: an updated review of its use in Crohn's disease and rheumatoid arthritis. BioDrugs 16: 111-148 (2002).
Kefalakes H, Stylianides TJ, Amanakis G, Kolios G. Exacerbation of inflammatory bowel diseases associated with the use of nonsteroidal anti-inflammatory drugs: myth or reality? Eur. J. Clin. Pharmacol. 65: 963-970 (2009).
Kefalides PT, Hanauer SB. Ulcerative colitis: diagnosis and management. Case study and commentary. Hospital Physician June: 53-63 (2002). *
Keller CD, Rivera Gil P, Tolle M, van der Giet M, Chun J, Radeke HH, Schafer-Korting M, Kleuser B. Immunomodulator FTY720 induces myofibroblast differentiation via the lysophospholipid receptor S1P3 and Smad3 signaling. Am. J. Pathol. 170: 281-292 (2007). *
Kelley DS, Daudu PA. Fat intake and immune response. Prog. Food Nutr. Sci. 17: 41-63 (1993).
Kelley DS, Vemuri M, Adkins Y, Gill SH, Fedor D, Mackey BE. Flaxseed oil prevents trans-10, cis-12-conjugated linoleic acid-induced insulin resistance in mice. Br. J. Nutr. 101: 701-708 (2009). *
Kelly D, Jara P, Rodeck B, Lykavieris P, Burdelski M, Becker M, Gridelli B, Boillot O, Manzanares J, Reding R. Tacrolimus and steroids versus ciclosporin microemulsion, steroids, and azathioprine in children undergoing liver transplantation: randomised European multicentre trial. Lancet 364: 1054-1061 (2004). *
Kelly TL, Neaga OR, Schwahn BC, Rozen R, Trasler JM. Infertility in 5,10-methylenetetrahydrofolate reductase (MTHFR)-deficient male mice is partially alleviated by lifetime dietary betaine supplementation. Biol. Reprod. 72: 667-677 (2005). *
Kennedy A, Nelson E, Reeves D, Richardson G, Roberts C, Robinson A, Rogers A, Sculpher M, Thompson D. A randomised controlled trial to assess the impact of a package comprising a patient-orientated, evidence-based self-help guidebook and patient-centred consultations on disease management and satisfaction in inflammatory bowel disease. Health Technol. Assess. 7: 1-126 (2003). *
Kennedy J, Wang CC, Wu CH. Patient disclosure about herb and supplement use among adults in the US. Evid. Based Complement. Alternat. Med. 5: 451-456 (2008). *
Kennedy LD. Nicotine therapy for ulcerative colitis. Ann. Pharmacother. 30: 1022-1023 (1996).
Kennedy RB, Ovsyannikova IG, Jacobson RM, Poland GA. The immunology of smallpox vaccines. Curr. Opin. Immunol. 21: 314-320 (2009).
Keogh KA, Wylam ME, Stone JH, Specks U. Induction of remission by B lymphocyte depletion in eleven patients with refractory antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheum. 52: 262-268 (2005). *
Kerb R, Hoffmeyer S, Brinkmann U. ABC drug transporters: hereditary polymorphisms and pharmacological impact in MDR1, MRP1 and MRP2. Pharmacogenomics 2: 51-64 (2001).
Kerem E, Hirawat S, Armoni S, Yaakov Y, Shoseyov D, Cohen M, Nissim-Rafinia M, Blau H, Rivlin J, Aviram M, Elfring GL, Northcutt VJ, Miller LL, Kerem B, Wilschanski M. Effectiveness of PTC124 treatment of cystic fibrosis caused by nonsense mutations: a prospective phase II trial. Lancet 372: 719-727 (2008). *
Kerkar N, Dugan C, Rumbo C, Morotti RA, Gondolesi G, Shneider BL, Emre S. Rapamycin successfully treats post-transplant autoimmune hepatitis. Am. J.Transplant. 5: 1085-1089 (2005). *
Kessel D, Caruso JA, Reiners JJ Jr. Potentiation of photodynamic therapy by ursodeoxycholic acid. Cancer Res. 60: 6985-6988 (2000). *
Keystone E, Fleischmann R, Emery P, Furst DE, van Vollenhoven R, Bathon J, Dougados M, Baldassare A, Ferraccioli G, Chubick A, Udell J, Cravets MW, Agarwal S, Cooper S, Magrini F. Safety and efficacy of additional courses of rituximab in patients with active rheumatoid arthritis: an open-label extension analysis. Arthritis Rheum. 56: 3896-3908 (2007). *
Keystone EC. The role of tumor necrosis factor antagonism in clinical practice. J. Rheumatol. 26 Suppl. 57: 22-28 (1999).
Keystone EC, Genovese MC, Klareskog L, Hsia EC, Hall ST, Miranda PC, Pazdur J, Bae SC, Palmer W, Zrubek J, Wiekowski M, Visvanathan S, Wu Z, Rahman MU. Golimumab, a human antibody to TNF-alpha given by monthly subcutaneous injections, in active rheumatoid arthritis despite methotrexate: the GO-FORWARD study. Ann. Rheum. Dis. 68: 789-796 (2009). *
Khalili H, Dashti-Khavidaki S, Mohraz M, Etghani A, Almasi F. Antiretroviral induced adverse drug reactions in Iranian human immunodeficiency virus positive patients. Pharmacoepidemiol. Drug Saf. 18: 848-857 (2009).
Kham SK, Soh CK, Aw DC, Yeoh AE. TPMT*26 (208F-->L), a novel mutation detected in a Chinese. Br. J. Clin. Pharmacol. 68: 120-123 (2009).
Khamashta MA. Systemic lupus erythematosus and pregnancy. Best Pract. Res. Clin. Rheumatol. 20: 685-694 (2006).
Khan DA. Chronic urticaria: diagnosis and management. Allergy Asthma Proc. 29: 439-446 (2008).
Khan S, Orenstein SR. Eosinophilic gastroenteritis: epidemiology, diagnosis and management. Paediatr. Drugs 4: 563-570 (2002).
Khanna D, McMahon M, Furst DE. Safety of tumour necrosis factor-alpha antagonists. Drug Saf. 27: 307-324 (2004).
Khanna D, Park GS, Paulus HE, Simpson KM, Elashoff D, Cohen SB, Emery P, Dorrier C, Furst DE. Reduction of the efficacy of methotrexate by the use of folic acid: post hoc analysis from two randomized controlled studies. Arthritis Rheum. 52: 3030-3038 (2005). *
Khashan AS, Henriksen TB, Mortensen PB, McNamee R, McCarthy FP, Pedersen MG, Kenny LC. The impact of maternal celiac disease on birthweight and preterm birth: a Danish population-based cohort study. Hum. Reprod. Nov 24 [Epub ahead of print] (2009).
Khattab M, Emad M, Abdelaleem A, Eslam M, Atef R, Shaker Y, Hamdy L. Pioglitazone improves virological response to peginterferon alpha-2b/ribavirin combination therapy in hepatitis C genotype 4 patients with insulin resistance. Liver Int. 30: 447-454 (2010). *
Khoo BP, Leow YH. A review of inpatients with adverse drug reactions to allopurinol. Singapore Med. J. 41: 156-160 (2000). *
Kidd PM. Integrated brain restoration after ischemic stroke - medical management, risk factors, nutrients, and other interventions for managing inflammation and enhancing brain plasticity. Altern. Med. Rev. 14: 14-35 (2009).
Kim BE, Leung DY, Streib JE, Boguniewicz M, Hamid QA, Howell MD. Macrophage inflammatory protein 3alpha deficiency in atopic dermatitis skin and role in innate immune response to vaccinia virus. J. Allergy Clin. Immunol. 119: 457-463 (2007). *
Kim BK, Oh J, Kwon SY, Choe WH, Ko SY, Rhee KH, Seo TH, Lim SD, Lee CH. Clevudine myopathy in patients with chronic hepatitis B. J. Hepatol. 51: 829-834 (2009).
Kim HJ, Kim JS, Han DS, Yang SK, Hahm KB, Lee WI, Kwon SW, Choi JH, Kim WH, Choi KY, Song IS. Granulocyte and monocyte adsorption apheresis in Korean conventional treatment-refractory patients with active ulcerative colitis: a prospective open-label multicenter study. Korean J. Gastroenterol. 45: 34-44 (2005).
Kim IS, Kim HG, Kim DC, Eom HS, Kong SY, Shin HJ, Hwang SH, Lee EY, Lee GW. ABCG2 Q141K polymorphism is associated with chemotherapy-induced diarrhea in patients with diffuse large B-cell lymphoma who received frontline rituximab plus cyclophosphamide/doxorubicin/ vincristine/prednisone chemotherapy. Cancer Sci. 99: 2496-2501 (2008). *
Kim JH, Cheon JH, Kim WH. The frequency and the course of the adverse effects of azathioprine/6-mercaptopurine treatment in patients with inflammatory bowel disease. Korean J. Gastroenterol. 51: 291-297 (2008).
Kim KH, Kim TN, Jang BI. A case of acute pancreatitis caused by 5-aminosalicylic acid suppositories in a patient with ulcerative colitis. Korean J. Gastroenterol. 50: 379-383 (2007).
Kim SE. Daclizumab treatment for multiple sclerosis. Pharmacotherapy 29: 227-235 (2009).
Kim SH, Kim SH, Bahn JW, Kim YK, Chang YS, Shin ES, Kim YS, Park JS, Kim BH, Jang IJ, Song J, Kim SH, Park HS, Min KU, Jee YK. Genetic polymorphisms of drug-metabolizing enzymes and anti-TB drug-induced hepatitis. Pharmacogenomics 10: 1767-1779 (2009).
Kim SH, Lee JE, Kim SH, Jee YK, Kim YK, Park HS, Min KU, Park HW; The Adverse Drug Reaction Research Group in Korea. Allelic variants of CD40 and CD40L genes interact to promote antibiotic-induced cutaneous allergic reactions. Clin. Exp. Allergy Sep 3 [Epub ahead of print] (2009). *
Kim WG, Kim EY, Kim TY, Ryu JS, Hong SJ, Kim WB, Shong YK. Redifferentiation therapy with 13-cis retinoic acids in radioiodine-resistant thyroid cancer. Endocr. J. 56: 105-112 (2009). *
Kim YS, Ahn Y, Hong MH, Joo SY, Kim KH, Sohn IS, Park HW, Hong YJ, Kim JH, Kim W, Jeong MH, Cho JG, Park JC, Kang JC. Curcumin attenuates inflammatory responses of TNF-alpha-stimulated human endothelial cells. J. Cardiovasc. Pharmacol. 50: 41-49 (2007).
Kimball S, Vieth R. Self-prescribed high-dose vitamin D(3): effects on biochemical parameters in two men. Ann. Clin. Biochem. 45: 106-110 (2008).
Kimbrough RD, Krouskas CA. Human exposure to polychlorinated biphenyls and health effects: a critical synopsis. Toxicol. Rev. 22: 217-233 (2003).
Kimby E. Tolerability and safety of rituximab (MabThera((R))). Cancer Treat. Rev. 31: 456-473 (2005). *
Kindmark A, Jawaid A, Harbron CG, Barratt BJ, Bengtsson OF, Andersson TB, Carlsson S, Cederbrant KE, Gibson NJ, Armstrong M, Lagerstrom-Fermer ME, Dellsen A, Brown EM, Thornton M, Dukes C, Jenkins SC, Firth MA, Harrod GO, Pinel TH, et al. Genome-wide pharmacogenetic investigation of a hepatic adverse event without clinical signs of immunopathology suggests an underlying immune pathogenesis. Pharmacogenomics J. 8: 186-195 (2008). *
King KY, Edwards MS, Word BM. Hepatitis associated with micafungin use in a preterm infant. J. Perinatol. 29: 320-322 (2009).
King P. Is there a role for inhaled corticosteroids and macrolide therapy in bronchiectasis? Drugs 67: 965-974 (2007).
Kinoshita K, Kishimoto K, Shimazu H, Nozaki Y, Sugiyama M, Ikoma S, Funauchi M. Successful treatment with retinoids in patients with lupus nephritis. Am. J. Kidney Dis. Jul 21 [Epub ahead of print] (2009).
Kintscher U, Bramlage P, Paar WD, Thoenes M, Unger T. Irbesartan for the treatment of hypertension in patients with the metabolic syndrome: a sub analysis of the Treat to Target post authorization survey. Prospective observational, two armed study in 14,200 patients. Cardiovasc. Diabetol. 6: 12 (2007). *
Kiorpelidou D, Tsiouri G, Gaitanis G, Akritidis N, Bassukas ID. Efalizumab-induced thrombocytopenia: report of relapse after re-administration. Clin. Exp. Dermatol. 34: e914-e916 (2009).
Kirchheiner J, Schmidt H, Tzvetkov M, Keulen JT, Lotsch J, Roots I, Brockmoller J. Pharmacokinetics of codeine and its metabolite morphine in ultra-rapid metabolizers due to CYP2D6 duplication. Pharmacogenomics J. 7: 257-265 (2007). *
Kircik L. Efficacy and safety of topical calcitriol 3 microg/g ointment, a new topical therapy for chronic plaque psoriasis. J. Drugs Dermatol. 8: s9-s16 (2009).
Kircik L, Bagel J, Korman N, Menter A, Elmets CA, Koo J, Yang YC, Chiou CF, Dann F, Stevens SR; Unite Study Group. Utilization of narrow-band ultraviolet light B therapy and etanercept for the treatment of psoriasis (UNITE): efficacy, safety, and patient-reported outcomes. J. Drugs Dermatol. 7: 245-253 (2008).
Kircik LH. Tretinoin microsphere gel pump 0.04% versus tazarotene cream 0.05% in the treatment of mild-to-moderate facial acne vulgaris. J. Drugs Dermatol. 8: 650-654 (2009).
Kircik LH, Del Rosso JQ. Anti-TNF agents for the treatment of psoriasis. J. Drugs Dermatol. 8: 546-559 (2009).
Kirksey DF, Harto-Truax N. Private practice evaluation of the safety and efficacy of bupropion in depressed outpatients. J. Clin. Psychiatry 44: 143-147 (1983).
Kirou KA, Salmon JE, Crow MK. Soluble mediators as therapeutic targets in systemic lupus erythematosus: cytokines, immunoglobulin receptors, and the complement system. Rheum. Dis. Clin. North Am. 32: 103-119 (2006).
Kirwan J, Power L. Glucocorticoids: action and new therapeutic insights in rheumatoid arthritis. Curr. Opin. Rheumatol. 19: 233-237 (2007).
Kis K, Bodai L, Polyanka H, Eder K, Pivarcsi A, Duda E, Soos G, Bata-Csorgo Z, Kemeny L. Budesonide, but not tacrolimus, affects the immune functions of normal human keratinocytes. Int. Immunopharmacol. 6: 358-368 (2006).
Kishimoto TK, Viswanathan K, Ganguly T, Elankumaran S, Smith S, Pelzer K, Lansing JC, Sriranganathan N, Zhao G, Galcheva-Gargova Z, Al-Hakim A, Bailey GS, Fraser B, Roy S, Rogers-Cotrone T, Buhse L, Whary M, Fox J, Nasr M, Dal Pan GJ, Shriver Z, et al. Contaminated heparin associated with adverse clinical events and activation of the contact system. N. Engl. J. Med. 358: 2457-2467 (2008). *
Kitahara K, Kawai S. Cyclosporine and tacrolimus for the treatment of rheumatoid arthritis. Curr. Opin. Rheumatol. 19: 238-245 (2007).
Kitano H, Oda K. Robustness trade-offs and host-microbial symbiosis in the immune system. Mol. Syst. Biol. 2: 2006.0022 (2006). *
Kitazaki S, Mitsuyama K, Masuda J, Harada K, Yamasaki H, Kuwaki K, Takedatsu H, Sugiyama G, Tsuruta O, Sata M. Clinical trial: comparison of alendronate and alfacalcidol in glucocorticoid-associated osteoporosis in patients with ulcerative colitis. Aliment. Pharmacol. Ther. 29: 424-430 (2009). *
Kivisto KT, Zukunft J, Hofmann U, Niemi M, Rekersbrink S, Schneider S, Luippold G, Schwab M, Eichelbaum M, Fromm MF. Characterisation of cerivastatin as a P-glycoprotein substrate: studies in P-glycoprotein-expressing cell monolayers and mdr1a/b knock-out mice. Naunyn. Schmiedebergs. Arch. Pharmacol. 370: 124-130 (2004). *
Klapman JB, Ene-Stroescu D, Becker MA, Hanauer SB. A lupus-like syndrome associated with infliximab therapy. Inflamm. Bowel Dis. 9: 176-178 (2003). *
Klareskog L, Gaubitz M, Rodriguez-Valverde V, Malaise M, Dougados M, Wajdula J. A long-term, open-label trial of the safety and efficacy of etanercept (Enbrel) in patients with rheumatoid arthritis not treated with other disease-modifying antirheumatic drugs. Ann. Rheum. Dis. 65: 1578-1584 (2006). *
Klareskog L, van der Heijde D, de Jager JP, Gough A, Kalden J, Malaise M, Martin Mola E, Pavelka K, Sany J, Settas L, Wajdula J, Pedersen R, Fatenejad S, Sanda M. Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trial. Lancet 363: 675-681 (2004). *
Klein NP, Ray P, Carpenter D, Hansen J, Lewis E, Fireman B, Black S, Galindo C, Schmidt J, Baxter R. Rates of autoimmune diseases in Kaiser Permanente for use in vaccine adverse event safety studies. Vaccine 28: 1062-1068 (2010). *
Kling C, Steinmann J, Westphal E, Magez J, Kabelitz D. Adverse effects of intradermal allogeneic lymphocyte immunotherapy: acute reactions and role of autoimmunity. Hum. Reprod. 21: 429-435 (2006).
Klingenberg S, Chen W. D-penicillamine for primary sclerosing cholangitis. Cochrane Database Syst. Rev. 1: CD004182 (2006). *
Klotz U. Clinical pharmacokinetics of sulphasalazine, its metabolites and other prodrugs of 5-aminosalicylic acid. Clin. Pharmacokinet. 10: 285-302 (1985).
Klotz U. Colonic targeting of aminosalicylates for the treatment of ulcerative colitis. Dig. Liver Dis. 37: 381-388 (2005).
Klotz U, Schwab M. Topical delivery of therapeutic agents in the treatment of inflammatory bowel disease. Adv. Drug Deliv. Rev. 57: 267-279 (2005). *
Klotz U, Teml A, Schwab M. Clinical pharmacokinetics and use of infliximab. Clin. Pharmacokinet. 46: 645-660 (2007).
Klugmann HJ, Giehler B, Lohmann D, Schiedewitz W. Individualized sulfasalazine treatment of ulcerative colitis and monitoring of patient compliance by determining sulfapyridine serum concentration. Gastroenterol. J. 49: 160-164 (1990).
Knudsen TT, Thorsen S, Jensen SA, Dalhoff K, Schmidt LE, Becker U, Bendtsen F. Effect of intravenous N-acetylcysteine infusion on haemostatic parameters in healthy subjects. Gut 54: 515-521 (2005). *
Ko GD, Nowacki NB, Arseneau L, Eitel M, Hum A. Omega-3 fatty acids for neuropathic pain: case series. Clin. J. Pain 26: 168-172 (2010).
Ko HH, Bressler B. Natalizumab: pharmacology, clinical efficacy and safety in the treatment of patients with Crohn's disease. Expert Rev. Gastroenterol. Hepatol. 1: 29-39 (2007).
Ko JM, Gottlieb AB, Kerbleski JF. Induction and exacerbation of psoriasis with TNF-blockade therapy: a review and analysis of 127 cases. J. Dermatolog. Treat. 20: 100-108 (2009).
Kobori L, Kohalmy K, Porrogi P, Sarvary E, Gerlei Z, Fazakas J, Nagy P, Jaray J, Monostory K. Drug-induced liver graft toxicity caused by cytochrome P450 poor metabolism. Br. J. Clin. Pharmacol. 65: 428-436 (2008). *
Koch RO, Graziadei IW, Schulz F, Nachbaur K, Konigsrainer A, Margreiter R, Vogel W. Long-term efficacy and safety of mycophenolate mofetil in liver transplant recipients with calcineurin inhibitor-induced renal dysfunction. Transpl. Int. 17: 518-524 (2004).
Kocian J, Kocianova J. Current views on the development and course of Crohn's disease. Cas. Lek. Cesk. 138: 486-490 (1999).
Kocis P. Prasterone. Am. J. Health Syst. Pharm. 63: 2201-2210 (2006).
Kodama S, Davis M, Faustman DL. The therapeutic potential of tumor necrosis factor for autoimmune disease: a mechanistically based hypothesis. Cell. Mol. Life Sci. 62: 1850-1862 (2005). *
Koedel U. Toll-like receptors in bacterial meningitis. Curr. Top. Microbiol. Immunol. 336: 15-40 (2009).
Koehler KF, Helguero LA, Haldosen LA, Warner M, Gustafsson JA. Reflections on the discovery and significance of estrogen receptor beta. Endocr. Rev. 26: 465-478 (2005). *
Kohn A, Prantera C, Pera A, Cosintino R, Sostegni R, Daperno M. Infliximab in the treatment of severe ulcerative colitis: a follow-up study. Eur. Rev. Med. Pharmacol. Sci. 8: 235-237 (2004).
Koike R, Harigai M, Atsumi T, Amano K, Kawai S, Saito K, Saito T, Yamamura M, Matsubara T, Miyasaka N. Japan College of Rheumatology 2009 guidelines for the use of tocilizumab, a humanized anti-interleukin-6 receptor monoclonal antibody, in rheumatoid arthritis. Mod. Rheumatol. 19: 351-357 (2009). *
Koike R, Takeuchi T, Eguchi K, Miyasaka N. Update on the Japanese guidelines for the use of infliximab and etanercept in rheumatoid arthritis. Mod. Rheumatol. 17: 451-458 (2007). *
Kojima M, Wakai K, Tokudome S, Suzuki K, Tamakoshi K, Watanabe Y, Kawado M,. Serum levels of polyunsaturated fatty acids and risk of colorectal cancer: a prospective study. Am. J. Epidemiol. 161: 462-471 (2005). *
Kolho KL, Ruuska T, Savilahti E. Severe adverse reactions to infliximab therapy are common in young children with inflammatory bowel disease. Acta Paediatr. 96: 128-130 (2007). *
Kong H, Lee Y, Hong S, Han J, Choi B, Jung Y, Kim YM. Sulfate-conjugated methylprednisolone as a colon-targeted methylprednisolone prodrug with improved therapeutic properties against rat colitis. J. Drug Target 17: 450-458 (2009).
Kong JS, Teuber SS, Gershwin ME. Potential adverse events with biologic response modifiers. Autoimmun. Rev. 5: 471-485 (2006).
Konikoff FM, Leikin-Frenkel A, Goldiner I, Michowitz M, Brezowski E, Harats D, Gilat T. Biliary and systemic effects of fatty acid bile acid conjugates. Eur. J. Gastroenterol. Hepatol. 15: 649-655 (2003).
Konstan MW. Ibuprofen therapy for cystic fibrosis lung disease: revisited. Curr. Opin. Pulm. Med. 14: 567-573 (2008).
Konttinen L, Kankaanpaa E, Luosujarvi R, Blafield H, Vuori K, Hakala M, Rantalaiho V, Savolainen E, Uutela T, Nordstrom D; ROB-FIN Study Group. Effectiveness of anakinra in rheumatic disease in patients naive to biological drugs or previously on TNF blocking drugs: an observational study. Clin. Rheumatol. 25: 882-884 (2006). *
Kooloos WM, de Jong DJ, Huizinga TW, Guchelaar HJ. Potential role of pharmacogenetics in anti-TNF treatment of rheumatoid arthritis and Crohn's disease. Drug Discov. Today 12: 125-131 (2007).
Korkalainen M, Kallio E, Olkku A, Nelo K, Ilvesaro J, Tuukkanen J, Mahonen A, Viluksela M. Dioxins interfere with differentiation of osteoblasts and osteoclasts. Bone 44: 1134-1142 (2009). *
Korniychuk E, Dempster JM, O'Connor E, Alexander JS, Kelley RE, Kenner M, Menon U, Misra V, Hoque R, Gonzalez-Toledo E, Schwendimann RN, Smith S, Minagar A. Evolving therapies for multiple sclerosis. Int. Rev. Neurobiol. 79C: 571-588 (2007).
Korzenik JR, Dieckgraefe BK. An open-labelled study of granulocyte colony-stimulating factor in the treatment of active Crohn's disease. Aliment. Pharmacol. Ther. 21: 391-400 (2005). *
Korzenik JR, Dieckgraefe BK, Valentine JF, Hausman DF, Gilbert MJ. Sargramostim for active Crohn's disease. N. Engl. J. Med. 352: 2193-2201 (2005). *
Korzeniowska-Kowal A, Witkowska D, Gamian A. Molecular mimicry of bacterial polysaccharides and their role in etiology of infectious and autoimmune diseases. Postepy. Hig. Med. Dosw. 55: 211-232 (2001).
Kosoglou T, Statkevich P, Johnson-Levonas AO, Paolini JF, Bergman AJ, Alton KB. Ezetimibe: a review of its metabolism, pharmacokinetics and drug interactions. Clin. Pharmacokinet. 44: 467-494 (2005).
Kostapanos MS, Milionis HJ, Elisaf MS. Rosuvastatin-associated adverse effects and drug-drug interactions in the clinical setting of dyslipidemia. Am. J. Cardiovasc. Drugs 10: 11-28 (2010).
Kota BP, Huang TH, Roufogalis BD. An overview on biological mechanisms of PPARs. Pharmacol. Res. 51: 85-94 (2005). *
Kotrych K, Domanski L, Gornik W, Drozdzik M. MDR1 gene polymorphism in allogeenic kidney transplant patients with tremor. Pharmacol. Rep. 57: 241-245 (2005). *
Kotter I, Hamuryudan V, Ozturk ZE, Yazici H. Interferon therapy in rheumatic diseases: state-of-the-art 2010. Curr. Opin. Rheumatol. Jan 7 [Epub ahead of print] (2010).
Koukouritaki SB, Hines RN. Flavin-containing monooxygenase genetic polymorphism: impact on chemical metabolism and drug development. Pharmacogenomics 6: 807-822 (2005).
Koulaouzidis A, Bhat S, Moschos J, Tan C, De Ramon A. Nitrofurantoin-induced lung- and hepatotoxicity. Ann. Hepatol. 6: 119-121 (2007). *
Kountz DS, Von Feldt JM. Management of rheumatoid arthritis: a primary care perspective. J. Fam. Pract. 56: 59A-74A (2007).
Koutroubakis IE, Oustamanolakis P, Karakoidas C, Mantzaris GJ, Kouroumalis EA. Safety and efficacy of total-dose infusion of low molecular weight iron dextran for iron deficiency anemia in patients with inflammatory bowel disease. Dig. Dis. Sci. Oct 16 [Epub ahead of print] (2009). *
Kowdley KV. Motion - prophylactic banding of esophageal varices is useful: arguments against the motion. Can. J. Gastroenterol. 16: 693-695 (2002). *
Kraemer M, Kirschmeier A, Marth T. Perioperative adjuvant therapy with infliximab in complicated anal Crohn's disease. Int. J. Colorectal Dis. 23: 965-969 (2008). *
Kragballe K, Austad J, Barnes L, Bibby A, de la Brassinne M, Cambazard F, Fleming C, Heikkila H, Jolliffe D, Peyri J, Svensson A, Toole J, Wozel G. A 52-week randomized safety study of a calcipotriol/betamethasone dipropionate two-compound product (Dovobet/Daivobet/Taclonex) in the treatment of psoriasis vulgaris. Br. J. Dermatol. 154: 1155-1160 (2006). *
Kragballe K, Deleuran B. Biological treatment of psoriasis and psoriatic arthritis. Ugeskr. Laeger. 170: 2148-2150 (2008).
Kragballe K, Hoffmann V, Ortonne JP, Tan J, Nordin P, Segaert S. Efficacy and safety of calcipotriol plus betamethasone dipropionate scalp formulation compared with calcipotriol scalp solution in the treatment of scalp psoriasis: a randomized controlled trial. Br. J. Dermatol. 161: 159-166 (2009). *
Kramer W, Glombik H. Bile acid reabsorption inhibitors (BARI): novel hypolipidemic drugs. Curr. Med. Chem. 13: 997-1016 (2006).
Krathen RA, Berthelot CN, Hsu S. Sustained efficacy and safety of infliximab in psoriasis: a retrospective study of 73 patients. J. Drugs Dermatol. 5: 251-254 (2006).
Kremenchutzky M, Morrow S, Rush C. The safety and efficacy of IFN-beta products for the treatment of multiple sclerosis. Expert Opin. Drug Saf. 6: 279-288 (2007).
Kremer JM, Genant HK, Moreland LW, Russell AS, Emery P, Abud-Mendoza C, Szechinski J, Li T, Ge Z, Becker JC, Westhovens R. Effects of abatacept in patients with methotrexate-resistant active rheumatoid arthritis: a randomized trial. Ann. Intern. Med. 144: 865-876 (2006). *
Kremer JM, Jubiz W, Michalek A, Rynes RI, Bartholomew LE, Bigaouette J, Timchalk M, Beeler D, Lininger L. Fish-oil fatty acid supplementation in active rheumatoid arthritis. A double-blinded, controlled, crossover study. Ann. Intern. Med. 106: 497-503 (1987).
Kris-Etherton PM, Lefevre M, Beecher GR, Gross MD, Keen CL, Etherton TD. Bioactive compounds in nutrition and health-research methodologies for establishing biological function: the antioxidant and anti-inflammatory effects of flavonoids on atherosclerosis. Annu. Rev. Nutr. 24: 511-538 (2004). *
Krishnan RS, Hsu S. Serum sickness due to infliximab in a patient with psoriasis. J. Drugs Dermatol. 3: 305-308 (2004).
Kristensen LE, Gulfe A, Saxne T, Geborek P. Efficacy and tolerability of anti-TNF therapy in psoriatic arthritis patients: results from the South Swedish Arthritis Treatment Group Register. Ann. Rheum. Dis. 67: 364-369 (2008).
Kristensen LE, Saxne T, Nilsson JA, Geborek P. Impact of concomitant DMARD therapy on adherence to treatment with etanercept and infliximab in rheumatoid arthritis. Results from a six-year observational study in southern Sweden. Arthritis Res. Ther. 8: R174 (2006). *
Kroegel C, Bergmann N, Heider C, Moeser A, Happe J, Schlenker Y, Bartuschka B, Henzgen M, Walther R, Reissig A, Foerster M. Interferon-alpha as treatment option in severe persistent uncontrolled bronchial asthma: an open label study. Pneumologie 63: 307-313 (2009).
Kropshofer H, Singer T. Overview of cell-based tools for pre-clinical assessment of immunogenicity of biotherapeutics. J. Immunotoxicol. 3: 131-136 (2006).
Krueger GG, Langley RG, Leonardi C, Yeilding N, Guzzo C, Wang Y, Dooley LT, Lebwohl M; CNTO 1275 Psoriasis Study Group. A human interleukin-12/23 monoclonal antibody for the treatment of psoriasis. N. Engl. J. Med. 356: 580-592 (2007). *
Kruis W, Brandes JW, Schreiber S, Theuer D, Krakamp B, Schutz E, Otto P, Lorenz-Mayer H, Ewe K, Judmaier G. Olsalazine versus mesalazine in the treatment of mild to moderate ulcerative colitis. Aliment. Pharmacol. Ther. 12: 707-715 (1998). *
Kruis W, Judmaier G, Kayasseh L, Stolte M, Theuer D, Scheurlen C, Hentschel E, Kratochvil P. Double-blind dose-finding study of olsalazine versus sulphasalazine as maintenance therapy for ulcerative colitis. Eur. J. Gastroenterol. Hepatol. 7: 391-396 (1995).
Kruis W, Schreiber S, Theuer D, Brandes JW, Schutz E, Howaldt S, Krakamp B, Hamling J, Monnikes H, Koop I, Stolte M, Pallant D, Ewald U. Low dose balsalazide (1.5 g twice daily) and mesalazine (0.5 g three times daily) maintained remission of ulcerative colitis but high dose balsalazide (3.0 g twice daily) was superior in preventing relapses. Gut 49: 783-789 (2001). *
Krygier DS, Ko HH, Bressler B. How to manage difficult Crohn's disease: optimum delivery of anti-TNFs. Expert Rev. Gastroenterol. Hepatol. 3: 407-415 (2009).
Kubitz R, Keitel V, Burdelski M, Haussinger D. Regulation of hepatobiliary transporters in chronic cholestasis. Falk Symposium 155. XIII FALK LIVER WEEK (Part I) XIX International Bile Acid Meeting. Bile Acids: Biological Actions and Clinical Relevance, October 6 - 7, 2006 Freiburg (Germany), p. 33-35 (2006). *
Kucharekova M, Winnepenninckx V, Frank J, Poblete-Gutierrez P. Generalized pustulosis induced by adalimumab in a patient with rheumatoid arthritis - a therapeutic challenge. Int. J. Dermatol. 47 Suppl. 1: 25-28 (2008).
Kuda O, Jelenik T, Jilkova Z, Flachs P, Rossmeisl M, Hensler M, Kazdova L, Ogston N, Baranowski M, Gorski J, Janovska P, Kus V, Polak J, Mohamed-Ali V, Burcelin R, Cinti S, Bryhn M, Kopecky J. n-3 Fatty acids and rosiglitazone improve insulin sensitivity through additive stimulatory effects on muscle glycogen synthesis in mice fed a high-fat diet. Diabetologia 52: 941-951 (2009). *
Kuemmerle-Deschner JB, Benseler S. Abatacept in difficult-to-treat juvenile idiopathic arthritis. Biologics 2: 865-874 (2008). *
Kulnigg S, Stoinov S, Simanenkov V, Dudar LV, Karnafel W, Garcia LC, Sambuelli AM, D'Haens G, Gasche C. A novel intravenous iron formulation for treatment of anemia in inflammatory bowel disease: the ferric carboxymaltose (FERINJECT((R))) randomized controlled trial. Am. J. Gastroenterol. 103: 1182-1192 (2008). *
Kumar A, Jha SK, Sharma P, Dubey S, Tyagi P, Sharma BC, Sarin SK. Addition of propranolol and isosorbide mononitrate to endoscopic variceal ligation does not reduce variceal rebleeding incidence. Gastroenterology 137: 892-901.e1 (2009). *
Kumar NB, Allen K, Bell H. Perioperative herbal supplement use in cancer patients: potential implications and recommendations for presurgical screening. Cancer Control 12: 149-157 (2005). *
Kung SJ, Choudhary C, McGeady SJ, Cohn JR. Lack of cross-reactivity between 5-aminosalicylic acid-based drugs: a case report and review of the literature. Ann. Allergy Asthma Immunol. 97: 284-287 (2006).
Kuningas M, May L, Tamm R, van Bodegom D, van den Biggelaar AH, Meij JJ, Frolich M, Ziem JB, Suchiman HE, Metspalu A, Slagboom PE, Westendorp RG. Selection for genetic variation inducing pro-inflammatory responses under adverse environmental conditions in a Ghanaian population. PLoS One 4: e7795 (2009). *
Kuningas M, van Bodegom D, May L, Meij JJ, Slagboom PE, Westendorp RG. Common CFTR gene variants influence body composition and survival in rural Ghana. Hum. Genet. Nov 5 [Epub ahead of print] (2009). *
Kunitomi A, Konaka Y, Yagita M, Nishimoto N, Kishimoto T, Takatsuki K. Humanized anti-interleukin 6 receptor antibody induced long-term remission in a patient with life-threatening refractory autoimmune hemolytic anemia. Int. J. Hematol. 80: 246-249 (2004).
Kuntzen C, Gulberg V, Gerbes AL. Use of a mixed endothelin receptor antagonist in portopulmonary hypertension: a safe and effective therapy? Gastroenterology 128: 164-168 (2005). *
Kurihara T, Akimoto M, Abe K, Ishiguro H, Niimi A, Maeda A, Shigemoto M, Yamashita K, Yokoyama I, Suzuki Y, et al. Experimental use of pravastatin in patients with primary biliary cirrhosis associated with hypercholesterolemia. Clin. Ther. 15: 890-898 (1993).
Kuriyama S, Yoshiji H, Deguchi A, Nakai S, Ogawa M, Nonomura T, Kimura Y, Inoue H, Kinekawa F, Tsujimoto T, Masaki T, Kurokohchi K, Uchida N. Safe and efficient transgene expression in rat hepatocytes induced by adenoviral administration into the biliary tract. Oncol. Rep. 13: 825-830 (2005).
Kurlandsky LE, Bennink MR, Webb PM, Ulrich PJ, Baer LJ. The absorption and effect of dietary supplementation with omega-3 fatty acids on serum leukotriene B4 in patients with cystic fibrosis. Pediatr. Pulmonol. 18: 211-217 (1994).
Kuroda Y, Nacionales DC, Akaogi J, Reeves WH, Satoh M. Autoimmunity induced by adjuvant hydrocarbon oil components of vaccine. Biomed. Pharmacother. 58: 325-337 (2004).
Kutzner M, Sziegoleit W. Adverse effects of allopurinol. Z. Arztl. Fortbild. (Jena) 70: 1017-1020 (1976).
Kvalvik AG, Lefsaker L, Dyvik S, Brun JG. Anti-tumor necrosis factor-alpha therapy in the ordinary clinical setting: three-year effectiveness in patients with rheumatoid arthritis. Joint Bone Spine 74: 606-611 (2007). *
Kwok CS, Loke YK. Meta-analysis: effects of proton pump inhibitors on cardiovascular events and mortality in patients receiving clopidogrel. Aliment. Pharmacol. Ther. Jan 22 [Epub ahead of print] (2010). *
Kwon HJ, Cote TR, Cuffe MS, Kramer JM, Braun MM. Case reports of heart failure after therapy with a tumor necrosis factor antagonist. Ann. Intern. Med. 138: 807-811 (2003). *
Kwon IH, Woo SM, Choi JW, Youn JI. A retrospective review of 20% vs. 10% incremental narrowband UVB regimens to treat psoriasis in skin phototypes III-V Koreans. Photodermatol. Photoimmunol. Photomed. 25: 124-127 (2009).
La Montagna G, Tirri R, Vitello R, Malesci D, Buono R, Mennillo G, Valentini G. Safety of methotrexate in rheumatoid arthritis: a retrospective cohort study in clinical practice. Reumatismo 58: 261-267 (2006).
La Shell MS, England RW. Severe refractory cholinergic urticaria treated with danazol. J. Drugs Dermatol. 5: 664-667 (2006).
Laasila K, Leirisalo-Repo M. Side effects of sulphasalazine in patients with rheumatic diseases or inflammatory bowel disease. Scand. J. Rheumatol. 23: 338-340 (1994).
Labiris G, Katsanos A, Karapetsa M, Mpanaka I, Chatzoulis D. Association between isotretinoin use and central retinal vein occlusion in an adolescent with minor predisposition for thrombotic incidents: a case report. J. Med. Case Reports 3: 58 (2009). *
Lacaille F. Bile acids and their therapeutic use in children. Arch. Pediatr. 2: 1200-1208 (1995).
Lachmann HJ, Kone-Paut I, Kuemmerle-Deschner JB, Leslie KS, Hachulla E, Quartier P, Gitton X, Widmer A, Patel N, Hawkins PN; Canakinumab in CAPS Study Group. Use of canakinumab in the cryopyrin-associated periodic syndrome. N. Engl. J. Med. 360: 2416-25 (2009). *
Ladenheim D, Horn O, Werneke U, Phillpot M, Murungi A, Theobald N, Orkin C. Potential health risks of complementary alternative medicines in HIV patients. HIV Med. 9: 653-659 (2008). *
Laine L, Goldkind L, Curtis SP, Connors LG, Yanqiong Z, Cannon CP. How common is diclofenac-associated liver injury? Analysis of 17,289 arthritis patients in a long-term prospective clinical trial. Am. J. Gastroenterol. 104: 356-362 (2009).
Laine L, Smith R, Min K, Chen C, Dubois RW. Systematic review: the lower gastrointestinal adverse effects of non-steroidal anti-inflammatory drugs. Aliment. Pharmacol. Ther. 24: 751-767 (2006). *
Lakeman P, Plass AM, Henneman L, Bezemer PD, Cornel MC, Ten Kate LP. Three-month follow-up of Western and non-Western participants in a study on preconceptional ancestry-based carrier couple screening for cystic fibrosis and hemoglobinopathies in the Netherlands. Genet. Med. 10: 820-830 (2008).
Laleman W, Van Landeghem L, Van der Elst I, Zeegers M, Fevery J, Nevens F. Nitroflurbiprofen, a nitric oxide-releasing cyclooxygenase inhibitor, improves cirrhotic portal hypertension in rats. Gastroenterology 132: 709-719 (2007). *
Lamba G, Palaniswamy C, Singh T, Shah D, Lal S, Vinnakota R, Charrow EJ, Forman L. Psoriasis induced by losartan therapy: a case report and review of the literature. Am. J. Ther. Dec 19 [Epub ahead of print] (2009).
Lambert GM. Does intestinal resection affect the absorption of essential vitamins, minerals, and bile salts? An overview of the literature. Ostomy Wound Manage. 54: 36-47 (2008).
Lamerson C, Stevens G, Sax K. Treatment of nail psoriasis with efalizumab: a preliminary study. Cutis 82: 217-220 (2008).
Lamet M, Ptak T, Dallaire C, Shah U, Grace M, Spenard J, de Montigny D; Mesalamine Study Group. Efficacy and safety of mesalamine 1 g HS versus 500 mg BID suppositories in mild to moderate ulcerative proctitis: a multicenter randomized study. Inflamm. Bowel Dis. 11: 625-630 (2005). *
Lammert C, Bjornsson E, Niklasson A, Chalasani N. Oral medications with significant hepatic metabolism at higher risk for hepatic adverse events. Hepatology 51: 615-620 (2010).
Lammert C, Einarsson S, Saha C, Niklasson A, Bjornsson E, Chalasani N. Relationship between daily dose of oral medications and idiosyncratic drug-induced liver injury: search for signals. Hepatology 47: 2003-2009 (2008). *
Lammert F, Marschall HU, Matern S. Intrahepatic cholestasis of pregnancy. Curr. Treat. Options Gastroenterol. 6: 123-132 (2003).
Lamprecht A, Ubrich N, Yamamoto H, Schafer U, Takeuchi H, Maincent P, Kawashima Y, Lehr CM. Biodegradable nanoparticles for targeted drug delivery in treatment of inflammatory bowel disease. J. Pharmacol. Exp. Ther. 299: 775-781 (2001). *
Lamprecht A, Yamamoto H, Takeuchi H, Kawashima Y. A pH-sensitive microsphere system for the colon delivery of tacrolimus containing nanoparticles. J. Control Release 104: 337-346 (2005).
Lamprecht A, Yamamoto H, Ubrich N, Takeuchi H, Maincent P, Kawashima Y. FK506 microparticles mitigate experimental colitis with minor renal calcineurin suppression. Pharm. Res. 22: 193-199 (2005).
Lands L, Stanojevic S. Oral non-steroidal anti-inflammatory drug therapy for cystic fibrosis. Cochrane Database Syst. Rev. 4: CD001505 (2007). *
Lands LC, Milner R, Cantin AM, Manson D, Corey M. High-dose ibuprofen in cystic fibrosis: Canadian safety and effectiveness trial. J. Pediatr. 151: 249-254 (2007). *
Lang L. Natural antibiotic against H. pylori in human gastric mucin. Gastroenterology 127: 1025-1026 (2004). *
Lang L. Adverse drug events reported to the food and drug administration seem to have markedly increased. Gastroenterology 133: 1401 (2007). *
Langer LF, Clay TM, Morse MA. Update on anti-CTLA-4 antibodies in clinical trials. Expert Opin. Biol. Ther. 7: 1245-1256 (2007).
Langevitz P, Livneh A, Bank I, Pras M. Benefits and risks of minocycline in rheumatoid arthritis. Drug Saf. 22: 405-414 (2000).
Langmead L, Feakins RM, Goldthorpe S, Holt H, Tsironi E, De Silva A, Jewell DP, Rampton DS. Randomized, double-blind, placebo-controlled trial of oral aloe vera gel for active ulcerative colitis. Aliment. Pharmacol. Ther. 19: 739-747 (2004). *
Langsjoen PH, Langsjoen JO, Langsjoen AM, Lucas LA. Treatment of statin adverse effects with supplemental coenzyme Q10 and statin drug discontinuation. Biofactors 25: 147-152 (2005).
Langton Hewer SC, Smyth AR. Antibiotic strategies for eradicating Pseudomonas aeruginosa in people with cystic fibrosis. Cochrane Database Syst. Rev. 4: CD004197 (2009).
Lankisch TO, Behrens G, Ehmer U, Mobius U, Rockstroh J, Wehmeier M, Kalthoff S, Freiberg N, Manns MP, Schmidt RE, Strassburg CP. Gilbert's syndrome and hyperbilirubinemia in protease inhibitor therapy - an extended haplotype of genetic variants increases risk in indinavir treatment. J. Hepatol. 50: 1010-1018 (2009).
Lankisch TO, Schulz C, Zwingers T, Erichsen TJ, Manns MP, Heinemann V, Strassburg CP. Gilbert's syndrome and irinotecan toxicity: combination with UDP-glucuronosyltransferase 1A7 variants increases risk. Cancer Epidemiol. Biomarkers Prev. 17: 695-701 (2008). *
Lao JI, Montoriol C, Morer I, Beyer K. Genetic contribution to aging: deleterious and helpful genes define life expectancy. Ann. N. Y. Acad. Sci. 1057: 50-63 (2005). *
Lao L, Fan AY, Zhang RX, Zhou A, Ma ZZ, Lee DY, Ren K, Berman B. Anti-hyperalgesic and anti-inflammatory effects of the modified Chinese herbal formula Huo Luo Xiao Ling Dan (HLXL) in rats. Am. J. Chin. Med. 34: 833-844 (2006).
Lapalus MG, Soussan EB, Gaudric M, Saurin JC, D'Halluin PN, Favre O, Filoche B, Cholet F, de Leusse A, Antonietti M, Gaudin JL, Sogni P, Heresbach D, Ponchon T, Dumortier J. Esophageal capsule endoscopy vs. EGD for the evaluation of portal hypertension: a French prospective multicenter comparative study. Am. J. Gastroenterol. 104: 1112-1118 (2009). *
Larche M. Update on the current status of peptide immunotherapy. J. Allergy Clin. Immunol. 119: 906-909 (2007). *
Larche M. Peptide immunotherapy for allergic diseases. Allergy 62: 325-331 (2007). *
Larche M, Akdis CA, Valenta R. Immunological mechanisms of allergen-specific immunotherapy. Nat. Rev. Immunol. 6: 761-771 (2006). *
Larrey D. Epidemiology and individual susceptibility to adverse drug reactions affecting the liver. Semin. Liver Dis. 22: 145-155 (2002).
Larsen PJ, Lykkegaard K, Larsen LK, Fleckner J, Sauerberg P, Wassermann K, Wulff EM. Dissociation of antihyperglycaemic and adverse effects of partial perioxisome proliferator-activated receptor (PPAR-gamma) agonist balaglitazone. Eur. J. Pharmacol. 596: 173-179 (2008).
Lashner BA. Clinical advances in ulcerative colitis. American College of Gastroenterology 68th Annual Scientific Meeting and Postgraduate Course, October 10 - 15, 2003, Baltimore, Maryland (2003).
Lassere MN, Johnson KR, Boers M, Carlton K, Day RO, De Wit M, Edwards IR, Fries JF, Furst DE, Kirwan JR, Tugwell PS, Woodworth TG, Brooks PM. Standardized assessment of adverse events in rheumatology clinical trials: summary of the OMERACT 7 drug safety module update. J. Rheumatol. 32: 2037-2041 (2005).
Latini G, Del Vecchio A, Massaro M, Verrotti A, DE Felice C. In utero exposure to phthalates and fetal development. Curr. Med. Chem. 13: 2527-2534 (2006).
Latini G, Scoditti E, Verrotti A, De Felice C, Massaro M. Peroxisome proliferator-activated receptors as mediators of phthalate-induced effects in the male and female reproductive tract: epidemiological and experimental evidence. PPAR Res. 2008: 359267 (2008). *
Lau JY, Leow CK, Fung TM, Suen BY, Yu LM, Lai PB, Lam YH, Ng EK, Lau WY, Chung SS, Sung JJ. Cholecystectomy or gallbladder in situ after endoscopic sphincterotomy and bile duct stone removal in Chinese patients. Gastroenterology 130: 96-103 (2006). *
Lawrenson RA, Seaman HE, Sundstrom A, Williams TJ, Farmer RD. Liver damage associated with minocycline use in acne: a systematic review of the published literature and pharmacovigilance data. Drug Saf. 23: 333-349 (2000).
Lawson M, Thomas A, Akobeng A. Tumour necrosis factor alpha blocking agents for induction of remission in ulcerative colitis. Cochrane Database Syst. Rev. 3: CD005112 (2006). *
Lazar L, Ofan R, Weintrob N, Avron A, Tamir M, Elias D, Phillip M, Josefsberg Z. Heat-shock protein peptide DiaPep277 treatment in children with newly diagnosed type 1 diabetes: a randomised, double-blind phase II study. Diabetes Metab. Res. Rev. 23: 286-291 (2007).
Lazaridis KN, Lindor KD. Primary biliary cirrhosis. Curr. Treat. Options Gastroenterol. 2: 473-480 (1999).
Lazzaroni M, Battocchia A, Bianchi Porro G. COXIBs and non-selective NSAIDs in the gastroenterological setting: what should patients and physicians do? Dig. Liver Dis. 39: 589-596 (2007).
Lazzerini M, Martelossi S, Marchetti F, Scabar A, Bradaschia F, Ronfani L, Ventura A. Efficacy and safety of thalidomide in children and young adults with intractable inflammatory bowel disease: long-term results. Aliment. Pharmacol. Ther. 25: 419-427 (2007). *
Le Blanc K, Frassoni F, Ball L, Locatelli F, Roelofs H, Lewis I, Lanino E, Sundberg B, Bernardo ME, Remberger M, Dini G, Egeler RM, Bacigalupo A, Fibbe W, Ringden O; Developmental Committee of the European Group for Blood and Marrow Transplantation. Mesenchymal stem cells for treatment of steroid-resistant, severe, acute graft-versus-host disease: a phase II study. Lancet 371: 1579-1586 (2008). *
Le Thi Huong D, Wechsler B, Piette JC. Pregnancy and systemic lupus erythematosus. Rev. Med. Interne. 29: 725-730 (2008).
Lebas D, Staumont-Salle D, Solau-Gervais E, Flipo RM, Delaporte E. Cutaneous manifestations during treatment with TNF-alpha blockers: 11 cases. Ann. Dermatol. Venereol. 134: 337-342 (2007).
Lebwohl M, Ortonne JP, Andres P, Briantais P. Calcitriol ointment 3 microg/g is safe and effective over 52 weeks for the treatment of mild to moderate plaque psoriasis. Cutis 83: 205-212 (2009).
Lee A, Kasama R, Evangelisto A, Elfenbein B, Falasca G. Henoch-Schonlein purpura after etanercept therapy for psoriasis. J. Clin. Rheumatol. 12: 249-251 (2006).
Lee AN, Werth VP. Activation of autoimmunity following use of immunostimulatory herbal supplements. Arch. Dermatol. 140: 723-727 (2004). *
Lee FY, Lee SD, Tsai YT, Lai KH, Chao Y, Lin HC, Wang SS, Lo KJ. A randomized controlled trial of quinidine in the treatment of cirrhotic patients with muscle cramps. J. Hepatol. 12: 236-240 (1991).
Lee JH, Slifman NR, Gershon SK, Edwards ET, Schwieterman WD, Siegel JN, Wise RP, Brown SL, Udall JN Jr, Braun MM. Life-threatening histoplasmosis complicating immunotherapy with tumor necrosis factor alpha antagonists infliximab and etanercept. Arthritis Rheum. 46: 2565-2570 (2002). *
Lee LS, Saltzman JR, Bounds BC, Poneros JM, Brugge WR, Thompson CC. EUS-guided fine needle aspiration of pancreatic cysts: a retrospective analysis of complications and their predictors. Clin. Gastroenterol. Hepatol. 3: 231-236 (2005). *
Lee SJ, Kavanaugh A. Adverse reactions to biologic agents: focus on autoimmune disease therapies. J. Allergy Clin. Immunol. 116: 900-905 (2005). *
Lee SS, Lin HY, Wang SR, Tsai YY. Allopurinol hypersensitivity syndrome. Zhonghua Min Guo Wei Sheng Wu Ji Mian Yi Xue Za Zhi 27: 140-147 (1994).
Lee SW, Kim JH, Park YB, Lee SK. Bortezomib attenuates murine collagen-induced arthritis. Ann. Rheum. Dis. 68: 1761-1767 (2009).
Lee T, Southern K. Topical cystic fibrosis transmembrane conductance regulator gene replacement for cystic fibrosis-related lung disease. Cochrane Database Syst. Rev. 2: CD005599 (2007). *
Lee TW, Iser JH, Sparrow MP, Newnham ED, Headon BJ, Gibson PR. Thiopurines, a previously unrecognised cause for fatigue in patients with inflammatory bowel disease. Journal of Crohn's and Colitis 3: 196-199 (2009).
Lee WM, Senior JR. Recognizing drug-induced liver injury: current problems, possible solutions. Toxicol. Pathol. 33: 155-164 (2005). *
Lees CW, Ali A, Thompson AI, Ho GT, Forsythe RO, Marquez L, Cochrane CJ, Aitken S, Fennell J, Rogers P, Shand AG, Penman ID, Palmer KR, Wilson DC, Arnott ID, Satsangi J. The safety profile of anti-tumour necrosis factor therapy in inflammatory bowel disease in clinical practice: analysis of 620 patient-years follow-up. Aliment. Pharmacol. Ther. 29: 286-297 (2009). *
Lees CW, Ali AI, Thompson AI, Ho GT, Forsythe RO, Marquez L, Cochrane CJ, Aitken S, Fennell J, Rogers P, Shand AG, Penman ID, Palmer KR, Wilson DC, Arnott ID, Satsangi J. The safety profile of anti-tumour necrosis factor therapy in inflammatory bowel disease in clinical practice: analysis of 620 patient-years follow-up. Aliment. Pharmacol. Ther. 29: 286-297 (2009). *
Lees CW, Heys D, Ho GT, Noble CL, Shand AG, Mowat C, Boulton-Jones R, Williams A, Church N, Satsangi J, Arnott ID; ON BEHALF OF THE SCOTTISH SOCIETY OF GASTROENTEROLOGY INFLIXIMAB GROUP. A retrospective analysis of the efficacy and safety of infliximab as rescue therapy in acute severe ulcerative colitis. Aliment. Pharmacol. Ther. 26: 411-419 (2007). *
Lees CW, Mann A, Hansoni B, Arnott SJ. Tolerability and safety of mercaptopurine in azathioprine intolerant patients with inflammatory bowel disease. Aliment. Pharmacol. Ther. 27: 220-227 (2008). *
Lefkowitch JH. Liver histopathology. Clin. Liver Dis. 6: xv-xix (2002). *
Leighton JA, Gralnek IM, Richner RE, Lacey MJ, Papatheofanis FJ. Capsule endoscopy in suspected small bowel Crohn's disease: economic impact of disease diagnosis and treatment. World J. Gastroenterol. 15: 5685-5692 (2009). *
Leite S, Ribeiro JM, Lima SC, Barroso S, Cotter J. Azathioprine in inflamatory bowel disease. Acta Med. Port. 22: 33-40 (2009).
Leithead JA, Simpson KJ, Macgilchrist AJ. Fulminant hepatic failure following overdose of the vitamin A metabolite acitretin. Eur. J. Gastroenterol. Hepatol. 21: 230-232 (2009).
Lemann M. Treatment of chronic inflammatory bowel diseases. Bull. Acad. Natl. Med. 191: 1125-1141 (2007).
Lemann M, Zenjari T, Bouhnik Y, Cosnes J, Mesnard B, Rambaud JC, Modigliani R, Cortot A, Colombel JF. Methotrexate in Crohn's disease: long-term efficacy and toxicity. Am. J. Gastroenterol. 95: 1730-1734 (2000). *
Lembo AJ, Kurtz CB, Macdougall JE, Lavins BJ, Currie MG, Fitch DA, Jeglinski BI, Johnston JM. Linaclotide is effective for patients with chronic constipation. Gastroenterology Dec 31 [Epub ahead of print] (2009). *
Lemere CA. Developing novel immunogens for a safe and effective Alzheimer's disease vaccine. Prog. Brain Res. 175: 83-93 (2009).
Leng XM, Zhao Y, Zhou DB, Situ H, Li TS, Shen T, Zhao YQ, Zeng XF, Zhang FC, Dong Y, Tang FL. A pilot trial for severe, refractory systemic autoimmune disease with stem cell transplantation. Chin. Med. Sci. J. 20: 159-165 (2005).
Lengyel G, Veres Z, Szabo P, Vereczkey L, Jemnitz K. Canalicular and sinusoidal disposition of bilirubin mono- and diglucuronides in sandwich-cultured human and rat primary hepatocytes. Drug Metab. Dispos. 33: 1355-1360 (2005). *
Lennard L, Richards S, Cartwright CS, Mitchell C, Lilleyman JS, Vora A; UK MRC/NCRI Childhood Leukaemia Working Party. The thiopurine methyltransferase genetic polymorphism is associated with thioguanine-related veno-occlusive disease of the liver in children with acute lymphoblastic leukemia. Clin. Pharmacol. Ther. 80: 375-383 (2006). *
Lenoir G, Antypkin YG, Miano A, Moretti P, Zanda M, Varoli G, Monici Preti PA, Aryayev NL. Efficacy, safety, and local pharmacokinetics of highly concentrated nebulized tobramycin in patients with cystic fibrosis colonized with Pseudomonas aeruginosa. Paediatr. Drugs 9 Suppl. 1: 11-20 (2007).
Leombruno JP, Einarson TR, Keystone EC. The safety of anti-tumor necrosis factor treatments in rheumatoid arthritis: meta and exposure adjusted pooled analyses of serious adverse events. Ann. Rheum. Dis. 68: 1136-1145 (2009).
Leonardi CL, Kimball AB, Papp KA, Yeilding N, Guzzo C, Wang Y, Li S, Dooley LT, Gordon KB; for the PHOENIX 1 study investigators. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1). Lancet 371: 1665-1674 (2008). *
Leong RW, Gearry RB, Sparrow MP. Thiopurine hepatotoxicity in inflammatory bowel disease: the role for adding allopurinol. Expert Opin. Drug Saf. 7: 607-616 (2008).
Leslie KS, Lachmann HJ, Bruning E, McGrath JA, Bybee A, Gallimore JR, Roberts PF, Woo P, Grattan CE, Hawkins PN. Phenotype, genotype, and sustained response to anakinra in 22 patients with autoinflammatory disease associated with CIAS-1/NALP3 mutations. Arch. Dermatol. 142: 1591-1597 (2006). *
Lev EI, Solodky A, Harel N, Mager A, Brosh D, Assali A, Roller M, Battler A, Kleiman NS, Kornowski R. Treatment of aspirin-resistant patients with omega-3 fatty acids versus aspirin dose escalation. J. Am. Coll. Cardiol. 55: 114-121 (2010).
Levang J, Muller P, Girardin P, Humbert P. Sweet's syndrome and phenylbutazone-induced sialadenitis. Ann. Dermatol. Venereol. 135: 291-294 (2008).
Levin TR. It's time to make organized colorectal cancer screening convenient and easy for patients. Am. J. Gastroenterol. 104: 939-941 (2009). *
Levine A, Kori M, Dinari G, Broide E, Shaoul R, Yerushalmi B, On A, Bujanover Y, Prols M, Greinwald R; Israeli Pediatric Budesonide Study Group. Comparison of two dosing methods for induction of response and remission with oral budesonide in active pediatric Crohn's disease: a randomized placebo-controlled trial. Inflamm. Bowel Dis. 15: 1055-1061 (2009).
Levy C, Harnois DM, Angulo P, Jorgensen R, Lindor KD. Raloxifene improves bone mass in osteopenic women with primary biliary cirrhosis: results of a pilot study. Liver Int. 25: 117-121 (2005). *
Levy C, Lindor KD. Current management of primary biliary cirrhosis and primary sclerosing cholangitis. J. Hepatol. 38: S24-S37 (2003). *
Levy C, Lindor KD. Treatment options for primary biliary cirrhosis and primary sclerosing cholangitis. Curr. Treat. Options Gastroenterol. 6: 93-103 (2003).
Levy C, Lindor KD. Management of primary biliary cirrhosis. Curr. Treat. Options Gastroenterol. 6: 493-498 (2003).
Levy C, Seeff LD, Lindor KD. Use of herbal supplements for chronic liver disease. Clin. Gastroenterol. Hepatol. 2: 947-956 (2004). *
Levy E, Spahis S, Ziv E, Marette A, Elchebly M, Lambert M, Delvin E. Overproduction of intestinal lipoprotein containing apolipoprotein B-48 in Psammomys obesus: impact of dietary n-3 fatty acids. Diabetologia 49: 1937-1945 (2006). *
Levy G, Villamil F, Samuel D, Sanjuan F, Grazi GL, Wu Y, Marotta P, Boillot O, Muehlbacher F, Klintmalm G; LIS2T Study Group. Results of lis2t, a multicenter, randomized study comparing cyclosporine microemulsion with C2 monitoring and tacrolimus with C0 monitoring in de novo liver transplantation. Transplantation 77: 1632-1638 (2004).
Levy M, Lipshitz M, Eliakim M. Hospital admissions due to adverse drug reactions. Am. J. Med. Sci. 277: 49-56 (1979).
Lewis JD, Lichtenstein GR, Deren JJ, Sands BE, Hanauer SB, Katz JA, Lashner B, Present DH, Chuai S, Ellenberg JH, Nessel L, Wu GD; Rosiglitazone for Ulcerative Colitis Study Group. Rosiglitazone for active ulcerative colitis: a randomized placebo-controlled trial. Gastroenterology 134: 688-695 (2008). *
LeWitt PA, Lyons KE, Pahwa R; SP 650 Study Group. Advanced Parkinson disease treated with rotigotine transdermal system: PREFER study. Neurology 68: 1262-1267 (2007).
Leyendecker JR, Bloomfeld RS, Disantis DJ, Waters GS, Mott R, Bechtold RE. MR enterography in the management of patients with Crohn disease. Radiographics 29: 1827-1846 (2009).
Li D, Wu Y, Zhang AZ, Wahlqvist ML. Omega-3 PUFA status in type 2 diabetes mellitus patients, a case-control study. Asia Pac. J. Clin. Nutr. 14: S101 (2005).
Li HJ, Li GP, Li HY. Clinical observation on acupoint catgut embedding therapy for treatment of ulcerative colitis. Zhongguo Zhen Jiu 26: 261-263 (2006).
Li Y, Qi Y, Huang TH, Yamahara J, Roufogalis BD. Pomegranate flower: a unique traditional antidiabetic medicine with dual PPAR-alpha/-gamma activator properties. Diabetes Obes. Metab. 10: 10-17 (2008).
Li Y, Tian Y, Yu C, Zhu W, Li J. A systematic review and meta-analysis of anti-adhesion molecule therapy in patients with active Crohn's disease. Scand. J. Gastroenterol. 44: 1435-1442 (2009).
Li YY, Perez HD, Zollner TM. Fatalities in natalizumab treatment - a 'no go' for leukocyte recirculation approaches? Expert Opin. Ther. Targets 10: 489-499 (2006).
Liang LQ, Zhan ZP, Ye YJ, Fu D, Xu HS, Yang XY. Clinical study of etanercept for treating ankylosing spondylitis. Nan Fang Yi Ke Da Xue Xue Bao 28: 1349-1351 (2008).
Liangpunsakul S, Chalasani N. Treatment of nonalcoholic fatty liver disease. Curr. Treat. Options Gastroenterol. 6: 455-463 (2003).
Liao Z, Cox JD, Komaki R. Radiochemotherapy of esophageal cancer. J. Thorac. Oncol. 2: 553-568 (2007).
Lichtenstein GR. Approach to corticosteroid-dependent and corticosteroid-refractory Crohn's disease. Inflamm. Bowel Dis. 7 Suppl. 1: S23-S29 (2001). *
Lichtenstein GR, Bengtsson B, Hapten-White L, Rutgeerts P. Oral budesonide for maintenance of remission of Crohn's disease: a pooled safety analysis. Aliment. Pharmacol. Ther. 29: 643-653 (2009). *
Lichtenstein GR, Deren JJ, Katz S, Lewis JD, Kennedy AR, Ware JH. Bowman-Birk inhibitor concentrate: a novel therapeutic agent for patients with active ulcerative colitis. Dig. Dis. Sci. 53: 175-180 (2008). *
Lichtenstein GR, Olson A, Travers S, Diamond RH, Chen DM, Pritchard ML, Feagan BG, Cohen RD, Salzberg BA, Hanauer SB, Sandborn WJ. Factors associated with the development of intestinal strictures or obstructions in patients with Crohn's disease. Am. J. Gastroenterol. 101: 1030-1038 (2006). *
Lieber CS. Microsomal ethanol-oxidizing system (MEOS): the first 30 years (1968-1998) - a review. Alcohol Clin. Exp. Res. 23: 991-1007 (1999). *
Lieber CS. Alcohol, liver, and nutrition. J. Am. Coll. Nutr. 10: 602-632 (1991).
Lieber CS. The discovery of the microsomal ethanol oxidizing system and its physiologic and pathologic role. Drug Metab. Rev. 36: 511-529 (2004). *
Lieber CS, Decarli LM, Leo MA, Mak KM, Ponomarenko A, Ren C, Wang X. Beneficial effects versus toxicity of medium-chain triacylglycerols in rats with NASH. J. Hepatol. 48: 318-326 (2008). *
Liebers V, Raulf-Heimsoth M, Bruning T. Health effects due to endotoxin inhalation (review). Arch. Toxicol. 82: 203-210 (2008). *
Liedorp M, Voskuyl AE, Van Oosten BW. Axonal neuropathy with prolonged sulphasalazine use. Clin. Exp. Rheumatol. 26: 671-672 (2008).
Liem O, Mousa HM, Benninga MA, Di Lorenzo C. Tegaserod use in children: a single-center experience. J. Pediatr. Gastroenterol. Nutr. 46: 54-58 (2008). *
Lien EL. Toxicology and safety of DHA. Prostaglandins Leukot. Essent. Fatty Acids 81: 125-132 (2009). *
Ligumsky M, Badaan S, Lewis H, Meirow D. Effects of 6-mercaptopurine treatment on sperm production and reproductive performance: a study in male mice. Scand. J. Gastroenterol. 40: 444-449 (2005). *
Lilly LB, Grant D. Optimization of cyclosporine for liver transplantation. Transplant. Proc. 36: S267-S270 (2004). *
Lim A, Manley K, Roberts M, Fraenkel M. Fish oil for kidney transplant recipients. Cochrane Database Syst. Rev. 2: CD005282 (2007). *
Lin JJ, Yueh KC, Lin SZ, Harn HJ, Liu JT. Genetic polymorphism of the angiotensin converting enzyme and L-dopa-induced adverse effects in Parkinson's disease. J. Neurol. Sci. 252: 130-134 (2007). *
Lin JJ, Yueh KC, Liu CS, Liu JT, Lin SZ. 5,10-Methylenetetrahydrofolate reductase C677T gene polymorphism can influence age at onset of Parkinson's disease. Acta Neurol. Taiwan 16: 150-157 (2007).
Lin Y, Zou Q, Li H. Tipping the balance: anti-tumour necrosis factor alpha therapy may damage cerebral nerve reservation. Med. Hypotheses 73: 958-960 (2009).
Linchevski I, Klmenet E, Nir-Paz R. Mycoplasma pneumoniae vaccine protective efficacy and adverse reactions: systematic review and meta-analysis. Vaccine 27: 2437-2446 (2009).
Lindberg MC. Hepatobiliary complications of oral contraceptives. J. Gen. Intern. Med. 7: 199-209 (1992).
Linden PK. Treatment options for vancomycin-resistant enterococcal infections. Drugs 62: 425-441 (2002).
Lindholm D, Bornhauser BC, Korhonen L. Mylip makes an Idol turn into regulation of LDL receptor. Cell. Mol. Life Sci. 66: 3399-3402 (2009). *
Lindor KD, Kowdley KV, Luketic VA, Harrison ME, McCashland T, Befeler AS, Harnois D, Jorgensen R, Petz J, Keach J, Mooney J, Sargeant C, Braaten J, Bernard T, King D, Miceli E, Schmoll J, Hoskin T, Thapa P, Enders F. High dose ursodeoxycholic acid for the treatment of primary sclerosing cholangitis. Hepatology 50: 808-814 (2009). *
Lindqvist M, Hindorf U, Almer S, Soderkvist P, Strom M, Hjortswang H, Peterson C. No induction of thiopurine methyltransferase during thiopurine treatment in inflammatory bowel disease. Nucleosides Nucleotides Nucleic Acids 25: 1033-1037 (2006). *
Lionaki S, Siamopoulos K, Theodorou I, Papadimitraki E, Bertsias G, Boumpas D, Boletis J. Inhibition of tumour necrosis factor alpha in idiopathic membranous nephropathy: a pilot study. Nephrol. Dial. Transplant. 24: 2144-2150 (2009).
Lionetti P, Bronzini F, Salvestrini C, Bascietto C, Canani RB, De Angelis GL, Guariso G, Martelossi S, Papadatou B, Barabino A. Response to infliximab is related to disease duration in paediatric Crohn's disease. Aliment. Pharmacol. Ther. 18: 425-431 (2003). *
Liossis SN, Tsokos GC. Monoclonal antibodies and fusion proteins in medicine. J. Allergy Clin. Immunol. 116: 721-729 (2005). *
Lipozencic J. The 1st world congress on gender-specific medicine men, women and medicine a new view of the biology of sex/gender differences and aging. Acta Dermatovenerol. Croat. 14: 132-134 (2006).
Lipozencic J. Keynote from Japan 5th Georg Rajka International Symposium on Atopic Dermatitis, Kyoto, May 11-13, 2008. Acta Dermatovenerol. Croat. 16: 168-169 (2008).
Liscovitch M, Lavie Y. Cancer multidrug resistance: a review of recent drug discovery research. IDrugs 5: 1-7 (2002). *
Lissia M, Mulas P, Bulla A, Rubino C. Toxic epidermal necrolysis (Lyell's disease). Burns Sep 17 [Epub ahead of print] (2009).
Litinsky I, Paran D, Levartovsky D, Wigler I, Kaufman I, Yaron I, Yaron M, Caspi D, Elkayam O. The effects of leflunomide on clinical parameters and serum levels of IL-6, IL-10, MMP-1 and MMP-3 in patients with resistant rheumatoid arthritis. Cytokine 33: 106-110 (2006).
Liu C, Russell RM, Smith DE, Bronson RT, Milbury PE, Furukawa S, Wang XD, Blumberg JB. The effect of dietary glutathione and coenzyme Q10 on the prevention and treatment of inflammatory bowel disease in mice. Int. J. Vitam. Nutr. Res. 74: 74-85 (2004).
Liu J, Manheimer E, Tsutani K, Gluud C. Medicinal herbs for hepatitis C virus infection: a Cochrane hepatobiliary systematic review of randomized trials. Am. J. Gastroenterol. 98: 538-544 (2003). *
Liu Y, Jiao F, Qiu Y, Li W, Qu Y, Tian C, Li Y, Bai R, Lao F, Zhao Y, Chai Z, Chen C. Immunostimulatory properties and enhanced TNF-alpha mediated cellular immunity for tumor therapy by C(60)(OH)(20) nanoparticles. Nanotechnology 20: 415102 (2009).
Liu ZX, Kaplowitz N. Immune-mediated drug-induced liver disease. Clin. Liver Dis. 6: 467-486 (2002).
Liu ZX, Kaplowitz N. Chapter 28. Immune mechanisms in drug-induced hepatotoxicity: therapeutic implications. In "Liver Immunology: Principles and Practice" (eds. Gershwin ME, Vierling JM, Manns MP), Humana Press Inc., Totowa, NJ, p. 363-374 (2007). *
Ljung T, Karlen P, Schmidt D, Hellstrom PM, Lapidus A, Janczewska I, Sjoqvist U, Lofberg R. Infliximab in inflammatory bowel disease: clinical outcome in a population based cohort from Stockholm County. Gut 53: 849-853 (2004). *
Ljung T, Thomsen OO, Vatn M, Karlen P, Karlsen LN, Tysk C, Nilsson SU, Kilander A, Gillberg R, Grip O, Lindgren S, Befrits R, Lofberg R. Granulocyte, monocyte/macrophage apheresis for inflammatory bowel disease: the first 100 patients treated in Scandinavia. Scand. J. Gastroenterol. 42: 221-227 (2007). *
Lloyd A, Reeves P, Conway P, Reynolds A, Baxter G. Economic evaluation of etanercept in the management of chronic plaque psoriasis. Br. J. Dermatol. 160: 380-386 (2009). *
Lloyd DA, Gabe SM. Managing liver dysfunction in parenteral nutrition. Proc. Nutr. Soc. 66: 530-538 (2007). *
Lloyd-Still JD, Powers CA, Hoffman DR, Boyd-Trull K, Lester LA, Benisek DC, Arterburn LM. Bioavailability and safety of a high dose of docosahexaenoic acid triacylglycerol of algal origin in cystic fibrosis patients: a randomized, controlled study. Nutrition 22: 36-46 (2006). *
Lo-Coco F, Ammatuna E, Montesinos P, Sanz MA. Acute promyelocytic leukemia: recent advances in diagnosis and management. Semin. Oncol. 35: 401-409 (2008).
Lobb A. Hepatoxicity associated with weight-loss supplements: a case for better post-marketing surveillance. World J. Gastroenterol. 15: 1786-1787 (2009). *
Lobo D, Trinidad A, Garcia-Berrocal JR, Verdaguer JM, Ramirez-Camacho R. TNFalpha blockers do not improve the hearing recovery obtained with glucocorticoid therapy in an autoimmune experimental labyrinthitis. Eur. Arch. Otorhinolaryngol. 263: 622-626 (2006).
Lofmark S, Edlund C, Nord CE. Metronidazole is still the drug of choice for treatment of anaerobic infections. Clin. Infect. Dis. 50 Suppl. 1: S16-S23 (2010). *
Loftus EV Jr. Biologic therapy in Crohn's disease: review of the evidence. Rev. Gastroenterol. Disord. 7 Suppl. 1: S3-S12 (2007).
Loftus EV, Kane SV, Bjorkman D. Short-term adverse effects of 5-aminosalicylic acid agents in the treatment of ulcerative colitis. Aliment. Pharmacol. Ther. 19: 179-189 (2004). *
Logan RF, van Staa TP. Sulphasalazine and mesalazine: serious adverse reactions re-evaluated on the basis of suspected adverse reaction reports to the Committee on Safety of Medicines. Gut 52: 1530 (2003). *
Lok CE, Allon M, Donnelly S, Dorval M, Hemmelgarn B, Moist L, Oliver MJ, Tonelli M, Stanley K. Design of the fish oil inhibition of stenosis in hemodialysis grafts (FISH) study. Clin. Trials 4: 357-367 (2007).
Lombardo YB, Chicco AG. Effects of dietary polyunsaturated n-3 fatty acids on dyslipidemia and insulin resistance in rodents and humans. A review. J. Nutr. Biochem. 17: 1-13 (2006). *
Lombardo YB, Hein G, Chicco A. Metabolic syndrome: effects of n-3 PUFAs on a model of dyslipidemia, insulin resistance and adiposity. Lipids 42: 427-437 (2007).
Long GG, Reynolds VL, Dochterman LW, Ryan TE. Neoplastic and non-neoplastic changes in F-344 rats treated with naveglitazar, a gamma-dominant PPAR alpha/gamma agonist. Toxicol. Pathol. 37: 741-753 (2009).
Lonjou C, Borot N, Sekula P, Ledger N, Thomas L, Halevy S, Naldi L, Bouwes-Bavinck JN, Sidoroff A, de Toma C, Schumacher M, Roujeau JC, Hovnanian A, Mockenhaupt M; for the RegiSCAR study group. A European study of HLA-B in Stevens-Johnson syndrome and toxic epidermal necrolysis related to five high-risk drugs. Pharmacogenet. Genomics 18: 99-107 (2008).
Lonjou C, Thomas L, Borot N, Ledger N, de Toma C, LeLouet H, Graf E, Schumacher M, Hovnanian A, Mockenhaupt M, Roujeau JC; RegiSCAR Group. A marker for Stevens-Johnson syndrome: ethnicity matters. Pharmacogenomics J. 6: 265-268 (2006).
Lonnerdal B, Kelleher SL. Iron metabolism in infants and children. Food Nutr. Bull. 28: S491-S499 (2007).
Lonnkvist MH, Befrits R, Lundberg JO, Lundahl J, Fagerberg UL, Hjortswang H, van Hage M, Hellstrom PM. Infliximab in clinical routine: experience with Crohn's disease and biomarkers of inflammation over 5 years. Eur. J. Gastroenterol. Hepatol. 21: 1168-1176 (2009).
Loo TW, Clarke DM. Mutational analysis of ABC proteins. Arch. Biochem. Biophys. 476: 51-64 (2008). *
Lopez-Garcia MP, Dansette PM, Coloma J. Kinetics of tienilic acid bioactivation and functional generation of drug-protein adducts in intact rat hepatocytes. Biochem. Pharmacol. 70: 1870-1882 (2005). *
Lopez-Parra M, Claria J, Titos E, Planaguma A, Parrizas M, Masferrer JL, Jimenez W, Arroyo V, Rivera F, Rodes J. The selective cyclooxygenase-2 inhibitor celecoxib modulates the formation of vasoconstrictor eicosanoids and activates PPARgamma. Influence of albumin. J. Hepatol. 42: 75-81 (2005). *
Lopez-Sanroman A, Bermejo F, Carrera E, Garcia-Plaza A. Efficacy and safety of thiopurinic immunomodulators (azathioprine and mercaptopurine) in steroid-dependent ulcerative colitis. Aliment Pharmacol. Ther. 20: 161-166 (2004). *
Louis M, Rauch J, Armstrong M, Fitzcharles MA. Induction of autoantibodies during prolonged treatment with infliximab. J. Rheumatol. 30: 2557-2562 (2003).
Lovas K, Gjesdal C, Christensen M, Wolff AS, Almas B, Svartberg J, Fougner K, Syversen U, Bollerslev J, Falch J, Hunt P, Chatterjee VK, Husebye E. Glucocorticoid replacement therapy and pharmacogenetics in Addison's disease: effects on bone. Eur. J. Endocrinol. 160: 993-1002 (2009).
Lovegrove RE, Tilney HS, Heriot AG, von Roon AC, Athanasiou T, Church J, Fazio VW, Tekkis PP. A comparison of adverse events and functional outcomes after restorative proctocolectomy for familial adenomatous polyposis and ulcerative colitis. Dis. Colon Rectum 49: 1293-1306 (2006). *
Lovell DJ, Ruperto N, Goodman S, Reiff A, Jung L, Jarosova K, Nemcova D, Mouy R, Sandborg C, Bohnsack J, Elewaut D, Foeldvari I, Gerloni V, Rovensky J, Minden K, Vehe RK, Weiner LW, Horneff G, Huppertz HI, Olson NY, Medich JR, Carcereri-De-Prati R, et al. Adalimumab with or without methotrexate in juvenile rheumatoid arthritis. N. Engl. J. Med. 359: 810-820 (2008). *
Low SK, Kiyotani K, Mushiroda T, Daigo Y, Nakamura Y, Zembutsu H. Association study of genetic polymorphism in ABCC4 with cyclophosphamide-induced adverse drug reactions in breast cancer patients. J. Hum. Genet. 54: 564-571 (2009).
Lowenberg M, Peppelenbosch M, Hommes D. Biological therapy in the management of recent-onset Crohn's disease: why, when and how? Drugs 66: 1431-1439 (2006).
Lowenthal KE, Horn PJ, Kalb RE. Concurrent use of methotrexate and acitretin revisited. J. Dermatolog. Treat. 19: 22-26 (2008).
Lowry PW, Weaver AL, Tremaine WJ, Sandborn WJ. Combination therapy with oral tacrolimus (FK506) and azathioprine or 6-mercaptopurine for treatment-refractory Crohn's disease perianal fistulae. Inflamm. Bowel Dis. 5: 239-245 (1999). *
Lozeron P, Denier C, Lacroix C, Adams D. Long-term course of demyelinating neuropathies occurring during tumor necrosis factor-alpha-blocker therapy. Arch. Neurol. 66: 490-497 (2009).
Lu AY. Drug-metabolism research challenges in the new millennium: individual variability in drug therapy and drug safety. Drug Metab. Dispos. 26: 1217-1222 (1998). *
Lu Y, Jacobson D, Bousvaros A. Immunizations in patients with inflammatory bowel disease. Inflamm. Bowel Dis. 15: 1417-1423 (2009). *
Lu Y, Jacobson DL, Ashworth LA, Grand RJ, Meyer AL, McNeal MM, Gregas MC, Burchett SK, Bousvaros A. Immune response to influenza vaccine in children with inflammatory bowel disease. Am. J. Gastroenterol. 104: 444-453 (2009).
Lucas A, Nolan D, Mallal S. HLA-B*5701 screening for susceptibility to abacavir hypersensitivity. J. Antimicrob. Chemother. 59: 591-593 (2007). *
Lucas RM, Ponsonby AL. Considering the potential benefits as well as adverse effects of sun exposure: can all the potential benefits be provided by oral vitamin D supplementation? Prog. Biophys. Mol. Biol. 92: 140-149 (2006). *
Lucas RM, Ponsonby AL, Pasco JA, Morley R. Future health implications of prenatal and early-life vitamin D status. Nutr. Rev. 66: 710-720 (2008). *
Ludvigsson J. Therapy with GAD in diabetes. Diabetes Metab. Res. Rev. 25: 307-315 (2009).
Ludvigsson J, Faresjo M, Hjorth M, Axelsson S, Cheramy M, Pihl M, Vaarala O, Forsander G, Ivarsson S, Johansson C, Lindh A, Nilsson NO, Aman J, Ortqvist E, Zerhouni P, Casas R. GAD treatment and insulin secretion in recent-onset type 1 diabetes. N. Engl. J. Med. 359: 1909-1920 (2008). *
Ludvigsson JF, Ludvigsson J. Coeliac disease in the father affects the newborn. Gut 49: 169-175 (2001). *
Luger TA, Cambazard F, Larsen FG, Bourcier M, Gupta G, Clonier F, Kidson P, Shear NH. A study of the safety and efficacy of calcipotriol and betamethasone dipropionate scalp formulation in the long-term management of scalp psoriasis. Dermatology 217: 321-328 (2008). *
Lukas M, Drastich P, Konecny M, Gionchetti P, Urban O, Cantoni F, Bortlik M, Duricova D, Bulitta M. Exogenous alkaline phosphatase for the treatment of patients with moderate to severe ulcerative colitis. Inflamm. Bowel Dis. Nov 2 [Epub ahead of print] (2009). *
Lumini JA, Magalhaes J, Oliveira PJ, Ascensao A. Beneficial effects of exercise on muscle mitochondrial function in diabetes mellitus. Sports Med. 38: 735-750 (2008).
Lutt JR, Deodhar A. Rheumatoid arthritis: strategies in the management of patients showing an inadequate response to TNFalpha antagonists. Drugs 68: 591-606 (2008).
Luukkonen P, Jarvinen H, Tanskanen M, Kahri A. Pouchitis - recurrence of the inflammatory bowel disease? Gut 35: 243-246 (1994). *
Luxon BA. Autoimmune hepatitis. Making sense of all those antibodies. Postgrad. Med. 114: 79-82, 85-88 (2003).
Lyakhovisky A, Baum S, Shpiro D, Salomon M, Trau H. Thalidomide therapy for discoid lupus erythematosus. Harefuah. 145: 489-492, 551 (2006).
Lyckegaard E, Hakansson K, Bengtsson B. Budesonide in Crohn's disease: findings of a compassionate-use program. Hepatogastroenterology 54: 2024-2027 (2007).
Lynch T, Price A. The effect of cytochrome P450 metabolism on drug response, interactions, and adverse effects. Am. Fam. Physician 76: 391-396 (2007). *
Lyra AC, Soares MB, da Silva LF, Fortes MF, Silva AG, Mota AC, Oliveira SA, Braga EL, de Carvalho WA, Genser B, Dos Santos RR, Lyra LG. Feasibility and safety of autologous bone marrow mononuclear cell transplantation in patients with advanced chronic liver disease. World J. Gastroenterol. 13: 1067-1073 (2007). *
Lyseng-Williamson KA, Keating GM. Ferric carboxymaltose: a review of its use in iron-deficiency anaemia. Drugs 69: 739-756 (2009).
Lyseng-Williamson KA, Plosker GL. Etanercept: a pharmacoeconomic review of its use in rheumatoid arthritis. Pharmacoeconomics 22: 1071-1095 (2004).
Ma C, Panaccione R, Heitman S, Devlin SM, Ghosh S, Kaplan GG. Systematic review: the short- and long-term efficacy of adalimumab following discontinuation of infliximab. Aliment. Pharmacol. Ther. 30: 977-986 (2009). *
Macallister WS, Boyd JR, Holland NJ, Milazzo MC, Krupp LB. The psychosocial consequences of pediatric multiple sclerosis. Neurology 68: S66-S69 (2007).
MacDermott RP. Treatment of irritable bowel syndrome in outpatients with inflammatory bowel disease using a food and beverage intolerance, food and beverage avoidance diet. Inflamm. Bowel Dis. 13: 91-96 (2007). *
Macdonald J, McDonald J. Natalizumab for induction of remission in Crohn's disease. Cochrane Database Syst. Rev. 3: CD006097 (2006). *
Macdonald J, McDonald J. Natalizumab for induction of remission in Crohn's disease. Cochrane Database Syst. Rev. 1: CD006097 (2007). *
Macdonald N, Holden PR, Roberts RA. Addition of peroxisome proliferator-activated receptor alpha to guinea pig hepatocytes confers increased responsiveness to peroxisome proliferators. Cancer Res. 59: 4776-4780 (1999). *
MacIntyre CR, McIntyre PB. MMR, autism and inflammatory bowel disease: responding to patient concerns using an evidence-based framework. Med. J. Aust. 175: 127-128 (2001).
Mackenzie PI, Hu DG, Gardner-Stephen DA. The regulation of UDP-glucuronosyltransferase genes by tissue-specific and ligand-activated transcription factors. Drug Metab. Rev. 42: 95-105 (2010). *
Mackey AC, Green L, Liang LC, Dinndorf P, Avigan M. Hepatosplenic T cell lymphoma associated with infliximab use in young patients treated for inflammatory bowel disease. J. Pediatr. Gastroenterol. Nutr. 44: 265-267 (2007). *
Maddrey WC. Role of antibiotics in the management of hepatic encephalopathy. Rev. Gastroenterol. Disord. 5 Suppl. 1: 3-9 (2005). *
Magin P, Adams J, Heading G, Pond D, Smith W. Experiences of appearance-related teasing and bullying in skin diseases and their psychological sequelae: results of a qualitative study. Scand. J. Caring Sci. 22: 430-436 (2008).
Magin PJ, Adams J, Heading GS, Pond DC, Smith W. Complementary and alternative medicine therapies in acne, psoriasis, and atopic eczema: results of a qualitative study of patients' experiences and perceptions. J. Altern. Complement. Med. 12: 451-457 (2006).
Magnano MD, Chakravarty EF, Broudy C, Chung L, Kelman A, Hillygus J, Genovese MC. A pilot study of tumor necrosis factor inhibition in erosive/inflammatory osteoarthritis of the hands. J. Rheumatol. 34: 1323-1327 (2007).
Magnasco A, Rossi A, Catarsi P, Gusmano R, Ginevri F, Perfumo F, Ghiggeri GM. Cyclosporin and organ specific toxicity: clinical aspects, pharmacogenetics and perspectives. Curr. Clin. Pharmacol. 3: 166-173 (2008).
Mahadevan D, List AF. Targeting the multidrug resistance-1 transporter in AML: molecular regulation and therapeutic strategies. Blood 104: 1940-1951 (2004). *
Mahadevan U, Loftus EV Jr, Tremaine WJ, Sandborn WJ. Safety of selective cyclooxygenase-2 inhibitors in inflammatory bowel disease. Am. J. Gastroenterol. 97: 910-914 (2002). *
Mahadevan U, Marion JF, Present DH. Fistula response to methotrexate in Crohn's disease: a case series. Aliment. Pharmacol. Ther. 18: 1003-1008 (2003). *
Mahadevan U, Sandborn WJ. Evolving medical therapies for Crohn's disease. Curr. Gastroenterol. Rep. 3: 471-476 (2001).
Mahadevan U, Sandborn WJ, Li DK, Hakimian S, Kane S, Corley DA. Pregnancy outcomes in women with inflammatory bowel disease: a large community-based study from Northern California. Gastroenterology 133: 1106-1112 (2007). *
Mahajan S, Koranne RV, Sharma SK. Cutaneous manifestation of diabetes melitus. Indian J. Dermatol. Venereol. Leprol. 69: 105-108 (2003).
Mahmood Z, Shukla Y. Death receptors: targets for cancer therapy. Exp. Cell Res. Dec 17 [Epub ahead of print] (2009). *
Mahmud N, Kamm MA, Dupas JL, Jewell DP, O'Morain CA, Weir DG, Kelleher D. Olsalazine is not superior to placebo in maintaining remission of inactive Crohn's colitis and ileocolitis: a double blind, parallel, randomised, multicentre study. Gut 49: 552-556 (2001). *
Mahmud N, O'Toole D, O'Hare N, Freyne PJ, Weir DG, Kelleher D. Evaluation of renal function following treatment with 5-aminosalicylic acid derivatives in patients with ulcerative colitis. Aliment. Pharmacol. Ther. 16: 207-215 (2002). *
Maitra R, Porter MA, Huang S, Gilmour BP. Inhibition of NFkappaB by the natural product withaferin A in cellular models of cystic fibrosis inflammation. J. Inflamm. (Lond.) 6: 15 (2009). *
Majithia V, Harisdangkul V. Mycophenolate mofetil (CellCept): an alternative therapy for autoimmune inflammatory myopathy. Rheumatology (Oxford) 44: 386-389 (2005). *
Malesci D, Tirri R, Buono R, La Montagna G. Leflunomide in psoriatic arthritis: a retrospective study of discontinuation rate in daily clinical practice compared with methotrexate. Clin. Exp. Rheumatol. 25: 881-884 (2007).
Malinowski JM, Metka K. Elevation of low-density lipoprotein cholesterol concentration with over-the-counter fish oil supplementation. Ann. Pharmacother. 41: 1296-1300 (2007).
Mallampalli A, Guntupalli KK. Smoking and systemic disease. Clin. Occup. Environ. Med. 5: 173-192 (2005).
Mallon P, McKay D, Kirk S, Gardiner K. Probiotics for induction of remission in ulcerative colitis. Cochrane Database Syst. Rev. 4: CD005573 (2007). *
Malouf M, Grimley EJ, Areosa SA. Folic acid with or without vitamin B12 for cognition and dementia. Cochrane Database Syst. Rev. 4: CD004514 (2003). *
Mamula P, Cohen SA, Ferry GD, Kirschner BS, Winter HS, Innes A, Patel J, Baldassano RN; the Pediatric Inflammatory Bowel Disease Consortium. CDP571, a humanized anti-tumor necrosis factor-alpha monoclonal antibody in pediatric Crohn's disease. Inflamm. Bowel Dis. 10: 723-730 (2004). *
Mamula P, Markowitz JE, Cohen LJ, Von Allmen D, Baldassano RN. Infliximab in pediatric ulcerative colitis: two-year follow-up. J. Pediatr. Gastroenterol. Nutr. 38: 298-301 (2004). *
Mamula P, Markowitz JE, Piccoli DA, Klimov A, Cohen L, Baldassano RN. Immune response to influenza vaccine in pediatric patients with inflammatory bowel disease. Clin. Gastroenterol. Hepatol. 5: 851-856 (2007).
Man CB, Kwan P, Baum L, Yu E, Lau KM, Cheng AS, Ng MH. Association between HLA-B*1502 allele and antiepileptic drug-induced cutaneous reactions in Han Chinese. Epilepsia 48: 1015-1018 (2007).
Mandekou-Lefaki I, Delli F, Teknetzis A, Euthimiadou R, Karakatsanis G. Low-dose schema of isotretinoin in acne vulgaris. Int. J. Clin. Pharmacol. Res. 23: 41-46 (2003).
Manfredi M, Benucci M. The role of interleukin-6 in rheumatoid arthritis. Recenti Prog. Med. 99: 291-294 (2008).
Manicassamy S. Sotrastaurin, a protein kinase C inhibitor for the prevention of transplant rejection and treatment of psoriasis. Curr. Opin. Investig. Drugs 10: 1225-1235 (2009).
Mannon PJ, Fuss IJ, Mayer L, Elson CO, Sandborn WJ, Present D, Dolin B, Goodman N, Groden C, Hornung RL, Quezado M, Neurath MF, Salfeld J, Veldman GM, Schwertschlag U, Strober W; Anti-IL-12 Crohn's Disease Study Group. Anti-interleukin-12 antibody for active Crohn's disease. N. Engl. J. Med. 351: 2069-2079 (2004). *
Mansfield JC, Giaffer MH, Cann PA, McKenna D, Thornton PC, Holdsworth CD. A double-blind comparison of balsalazide, 6.75 g, and sulfasalazine, 3 g, as sole therapy in the management of ulcerative colitis. Aliment. Pharmacol. Ther. 16: 69-77 (2002). *
Mansfield JC, Parkes M, Hawthorne AB, Forbes A, Probert CS, Perowne RC, Cooper A, Zeldis JB, Manning DC, Hawkey CJ. A randomized, double-blind, placebo-controlled trial of lenalidomide in the treatment of moderately severe active Crohn's disease. Aliment. Pharmacol. Ther. 26: 421-430 (2007). *
Mansueto P, Montalto G, Pacor ML, Esposito-Pellitteri M, Ditta V, Lo Bianco C, Leto-Barone SM, Di Lorenzo G. Food allergy in gastroenterologic diseases: review of literature. World J. Gastroenterol. 12: 7744-7752 (2006). *
Mantzaris GJ, Christidou A, Sfakianakis M, Roussos A, Koilakou S, Petraki K, Polyzou P. Azathioprine is superior to budesonide in achieving and maintaining mucosal healing and histologic remission in steroid-dependent Crohn's disease. Inflamm. Bowel Dis. 15: 375-382 (2009).
Mantzaris GJ, Sfakianakis M, Archavlis E, Petraki K, Christidou A, Karagiannidis A, Triadaphyllou G. A prospective randomized observer-blind 2-year trial of azathioprine monotherapy versus azathioprine and olsalazine for the maintenance of remission of steroid-dependent ulcerative colitis. Am. J. Gastroenterol. 99: 1122-1128 (2004). *
Manzia TM, De Liguori Carino N, Orlando G, Toti L, De Luca L, D'Andria D, Cardillo A, Anselmo A, Casciani CU, Tisone G. Use of mycophenolate mofetil in liver transplantation: a literature review. Transplant. Proc. 37: 2616-2617 (2005). *
Marangell LB, Martinez JM, Zboyan HA, Chong H, Puryear LJ. Omega-3 fatty acids for the prevention of postpartum depression: negative data from a preliminary, open-label pilot study. Depress. Anxiety 19: 20-23 (2004).
Marcellin P, Gish RG, Gitlin N, Heise J, Halliman DG, Chun E, Rodriguez-Torres M. Safety and efficacy of viramidine versus ribavirin in ViSER2: randomized, double-blind study in therapy-naive hepatitis C patients. J. Hepatol. Oct 23 [Epub ahead of print] (2009).
Marcellini M, Di Ciommo V, Callea F, Devito R, Comparcola D, Sartorelli MR, Carelli F, Nobili V. Treatment of Wilson's disease with zinc from the time of diagnosis in pediatric patients: a single-hospital, 10-year follow-up study. J. Lab. Clin. Med. 145: 139-143 (2005).
Marchesoni A, Zaccara E, Gorla R, Bazzani C, Sarzi-Puttini P, Atzeni F, Caporali R, Bobbio-Pallavicini F, Favalli EG. TNF-alpha antagonist survival rate in a cohort of rheumatoid arthritis patients observed under conditions of standard clinical practice. Ann. N. Y. Acad. Sci. 1173: 837-846 (2009). *
Marehbian J, Arrighi HM, Hass S, Tian H, Sandborn WJ. Adverse events associated with common therapy regimens for moderate-to-severe Crohn's disease. Am. J. Gastroenterol. 104: 2524-2533 (2009). *
Mares D, Simoes JA, Novak RM, Spear GT. TLR2-mediated cell stimulation in bacterial vaginosis. J. Reprod. Immunol. 77: 91-99 (2008).
Margalit M, Israeli E, Shibolet O, Zigmond E, Klein A, Hemed N, Donegan JJ, Rabbani E, Goldin, E, Ilan Y. A double-blind clinical trial for treatment of Crohn's disease by oral administration of Alequel™, a mixture of autologous colon-extracted proteins: a patient-tailored approach. Am. J. Gastroenterol. 101: 561-568 (2006). *
Margioris AN. Fatty acids and postprandial inflammation. Curr. Opin. Clin. Nutr. Metab. Care 12: 129-137 (2009).
Mariette X, Ravaud P, Steinfeld S, Baron G, Goetz J, Hachulla E, Combe B, Puechal X, Pennec Y, Sauvezie B, Perdriger A, Hayem G, Janin A, Sibilia J. Inefficacy of infliximab in primary Sjogren's syndrome: results of the randomized, controlled trial of remicade in primary Sjogren's syndrome (TRIPSS). Arthritis Rheum. 50: 1270-1276 (2004). *
Marinaki AM, Ansari A, Duley JA, Arenas M, Sumi S, Lewis CM, Shobowale-Bakre EM, Escuredo E, Fairbanks LD, Sanderson JD. Adverse drug reactions to azathioprine therapy are associated with polymorphism in the gene encoding inosine triphosphate pyrophosphatase (ITPase). Pharmacogenetics 14: 181-187 (2004).
Marinaki AM, Duley JA, Arenas M, Ansari A, Sumi S, Lewis CM, Shobowale-Bakre M, Fairbanks LD, Sanderson J. Mutation in the ITPA gene predicts intolerance to azathioprine. Nucleosides Nucleotides Nucleic Acids 23: 1393-1397 (2004).
Marino IR, Doria C, Scott VL, Foglieni CS, Lauro A, Piazza T, Cintorino D, Gruttadauria S. Efficacy and safety of basiliximab with a tacrolimus-based regimen in liver transplant recipients. Transplantation 78: 886-891 (2004).
Marion JF, Waye JD, Present DH, Israel Y, Bodian C, Harpaz N, Chapman M, Itzkowitz S, Steinlauf AF, Abreu MT, Ullman TA, Aisenberg J, Mayer L; Chromoendoscopy Study Group at Mount Sinai School of Medicine. Chromoendoscopy-targeted biopsies are superior to standard colonoscopic surveillance for detecting dysplasia in inflammatory bowel disease patients: a prospective endoscopic trial. Am. J. Gastroenterol. 103: 2342-2349 (2008). *
Markatseli TE, Kaltsonoudis ES, Voulgari PV, Zioga A, Drosos AA. Induction of psoriatic skin lesions in a patient with rheumatoid arthritis treated with rituximab. Clin. Exp. Rheumatol. 27: 996-998 (2009).
Markowitz JF. Therapeutic efficacy and safety of 6-mercaptopurine and azathioprine in patients with Crohn's disease. Rev. Gastroenterol. Disord. 3 Suppl. 1: S23-S29 (2003). *
Marks MA, Gravitt PE, Burk RR, Studentsov Y, Farzadegan H, Klein SL. Progesterone and 17beta-estradiol enhance regulatory responses to HPV 16 VLP in peripheral blood mononuclear cells from healthy women. Clin. Vaccine Immunol. Feb 3 [Epub ahead of print] (2010). *
Marks SD, Patey S, Brogan PA, Hasson N, Pilkington C, Woo P, Tullus K. B lymphocyte depletion therapy in children with refractory systemic lupus erythematosus. Arthritis Rheum. 52: 3168-3174 (2005). *
Marks SD, Tullus K. Targeted B-cell depletion therapy in childhood-onset systemic lupus erythematosus: progress to date. Paediatr. Drugs 9: 371-378 (2007).
Marmo R, Rotondano G, Piscopo R, Bianco MA, Cipolletta L. Meta-analysis: capsule enteroscopy vs. conventional modalities in diagnosis of small bowel diseases. Aliment. Pharmacol. Ther. 22: 595-604 (2005). *
Marret S, Marchand L, Kaminski M, Larroque B, Arnaud C, Truffert P, Thirez G, Fresson J, Roze JC, Ancel PY; for the EPIPAGE Study Group. Prenatal low-dose aspirin and neurobehavioral outcomes of children born very preterm. Pediatrics Dec 21 [Epub ahead of print] (2009). *
Marteau P, Nelet F, Le Lu M, Devaux C. Adverse events in patients treated with 5-aminosalicyclic acid: 1993-1994 pharmacovigilance report for Pentasa in France. Aliment. Pharmacol. Ther. 10: 949-956 (1996).
Martin AM, Krueger R, Almeida CA, Nolan D, Phillips E, Mallal S. A sensitive and rapid alternative to HLA typing as a genetic screening test for abacavir hypersensitivity syndrome. Pharmacogenet. Genomics 16: 353-357 (2006).
Martín B, Sanchez-Carazo JL, Perez-Ferriols A, Laguna C, Oliver V, Alegre V. Clinical experience with etanercept in the treatment of psoriasis. Actas Dermosifiliogr. 99: 540-545 (2008).
Martín De Carpi J, Varea V. Response to stopping azathioprine in Crohn's patients on combined treatment with infliximab. An. Pediatr. (Barc.) 70: 271-277 (2009).
Martin de Santa Olalla L, Sanchez Muniz FJ, Vaquero MP. n-3 Fatty acids in glucose metabolism and insulin sensitivity. Nutr. Hosp. 24: 113-127 (2009).
Martin F. Oral 5-aminosalicylic acid preparations in treatment of inflammatory bowel disease. An update. Dig. Dis. Sci. 32: 57S-63S (1987).
Martin SF. T lymphocyte-mediated immune responses to chemical haptens and metal ions: implications for allergic and autoimmune disease. Int. Arch. Allergy Immunol. 134: 186-198 (2004).
Martinez Mengual L, Fernandez Menendez JM, Solis Sanchez G, Fernandez Diaz M, Fernandez Gonzalez N, Malaga Guerrero S. Epidemiological study of juvenile idiopathic arthtitis in the last sixteen years in Asturias (Spain). An. Pediatr. (Barc.) 66: 24-30 (2007).
Martino M, Console G, Dattola A, Callea I, Messina G, Moscato T, Massara E, Irrera G, Fedele R, Gervasi A, Bresolin G, Iacopino P. Short and long-term safety of lenograstim administration in healthy peripheral haematopoietic progenitor cell donors: a single centre experience. Bone Marrow Transplant. 44: 163-168 (2009).
Martyn-Simmons C, Green L, Ash G, Groves R, Smith C, Barker J. Adalimumab for psoriasis patients who are non-responders to etanercept: open-label prospective evaluation. J. Eur. Acad. Dermatol. Venereol. Jul 1 [Epub ahead of print] (2009).
Maruo Y, Iwai M, Mori A, Sato H, Takeuchi Y. Polymorphism of UDP-glucuronosyltransferase and drug metabolism. Curr. Drug Metab. 6: 91-99 (2005).
Marzano A, Ramoni S, Del Papa N, Barbareschi M, Alessi E. Leflunomide-induced subacute cutaneous lupus erythematosus with erythema multiforme-like lesions. Lupus 17: 329-331 (2008). *
Marzano AV, Dassoni F, Caputo R. Treatment of refractory blistering autoimmune diseases with mycophenolic acid. J. Dermatolog. Treat. 17: 370-376 (2006).
Marzoa-Rivas R, Crespo-Leiro MG, Paniagua-Marin MJ, Llinares-Garcia D, Muniz-Garcia J, Aldama-Lopez G, Pinon-Esteban P, Campo-Perez R, Castro-Beiras A. Safety of statins when response is carefully monitored: a study of 336 heart recipients. Transplant. Proc. 37: 4071-4073 (2005). *
Mas A, Rodes J, Sunyer L, Rodrigo L, Planas R, Vargas V, Castells L, Rodriguez-Martinez D, Fernandez-Rodriguez C, Coll I, Pardo A; Spanish Association for the Study of the Liver Hepatic Encephalopathy Cooperative Group. Comparison of rifaximin and lactitol in the treatment of acute hepatic encephalopathy: results of a randomized, double-blind, double-dummy, controlled clinical trial. J. Hepatol. 38: 51-58 (2003). *
Mascheretti S, Schreiber S. Genetic testing in Crohn disease: utility in individualizing patient management. Am. J. Pharmacogenomics 5: 213-222 (2005).
Maser EA, Deconda D, Lichtiger S, Ullman T, Present DH, Kornbluth A. Cyclosporine and infliximab as rescue therapy for each other in patients with steroid-refractory ulcerative colitis. Clin. Gastroenterol. Hepatol. 6: 1112-1116 (2008).
Masharani UB, Becker J. Teplizumab therapy for type 1 diabetes. Expert Opin. Biol. Ther. Jan 24 [Epub ahead of print] (2010).
Maslovsky I. Intravenous iron in a primary-care clinic. Am. J. Hematol. 78: 261-264 (2005). *
Mason A, Nair S. Primary biliary cirrhosis: new thoughts on pathophysiology and treatment. Curr. Gastroenterol. Rep. 4: 45-51 (2002).
Mason AR, Mason J, Cork M, Dooley G, Edwards G. Topical treatments for chronic plaque psoriasis. Cochrane Database Syst. Rev. 2: CD005028 (2009). *
Massara A, Cavazzini L, La Corte R, Trotta F. Sarcoidosis appearing during anti-tumor necrosis factor alpha therapy: a new "class effect" paradoxical phenomenon. Two case reports and literature review. Semin. Arthritis Rheum. Jan 14 [Epub ahead of print] (2009). *
Masson MJ, Collins LA, Pohl LR. The role of cytokines in the mechanism of adverse drug reactions. Handb. Exp. Pharmacol. 196: 195-231 (2010). *
Masson S, Nylander D, Mansfield JC. How important is onset of action in ulcerative colitis therapy? Drugs 65: 2069-2083 (2005).
Mastroianni A, Minutilli E, Mussi A, Bordignon V, Trento E, D'Agosto G, Cordiali-Fei P, Berardesca E. Cytokine profiles during infliximab monotherapy in psoriatic arthritis. Br. J. Dermatol. 153: 531-536 (2005). *
Matsui M. Progress in unravelling the etiology of multiple sclerosis? Rinsho Shinkeigaku 48: 849-852 (2008).
Matsumoto A, Mizukami H, Mizuno S, Umegaki K, Nishikawa JI, Shudo K, Kagechika H, Inoue M. beta-Cryptoxanthin, a novel natural RAR ligand, induces ATP-binding cassette transporters in macrophages. Biochem. Pharmacol. 74: 256-264 (2007). *
Matsumura R, Umemiya K, Sugiyama T, Sueishi M, Umibe T, Ichikawa K, Yoshimura M. Anti-tumor necrosis factor therapy in patients with difficult-to-treat lupus nephritis: a prospective series of nine patients. Clin. Exp. Rheumatol. 27: 416-421 (2009).
Matsushita H, Barrios JA, Shea JE, Miller SC. Dietary fish oil results in a greater bone mass and bone formation indices in aged ovariectomized rats. J. Bone Miner. Metab. 26: 241-247 (2008). *
Matthews EJ, Kruhlak NL, Benz RD, Aragones Sabate D, Marchant CA, Contrera JF. Identification of structure-activity relationships for adverse effects of pharmaceuticals in humans: part C: use of QSAR and an expert system for the estimation of the mechanism of action of drug-induced hepatobiliary and urinary tract toxicities. Regul. Toxicol. Pharmacol. 54: 43-65 (2009).
Matthews EJ, Ursem CJ, Kruhlak NL, Benz RD, Sabate DA, Yang C, Klopman G, Contrera JF. Identification of structure-activity relationships for adverse effects of pharmaceuticals in humans: part B. Use of (Q)SAR systems for early detection of drug-induced hepatobiliary and urinary tract toxicities. Regul. Toxicol. Pharmacol. 54: 23-42 (2009).
Mauss S, Puoti M. CCR5 deficiency exacerbates T-cell-mediated hepatitis in mice - clinical implications for CCR5 inhibition as antiretroviral therapy. Hepatology 43: 879 (2006). *
Mawdsley JE, Rampton DS. Psychological stress in IBD: new insights into pathogenic and therapeutic implications. Gut 54: 1481-1491 (2005). *
Mawdsley JE, Rampton DS. The role of psychological stress in inflammatory bowel disease. Neuroimmunomodulation 13: 327-336 (2006).
May E, Asadullah K, Zugel U. Immunoregulation through 1,25-dihydroxyvitamin D3 and its analogs. Curr. Drug Targets Inflamm. Allergy 3: 377-393 (2004).
McCluggage LK, Scholtz JM. Golimumab: a tumor necrosis factor alpha inhibitor for the treatment of rheumatoid arthritis. Ann. Pharmacother. 44: 135-144 (2010).
McClure SL, Valentine J, Gordon KB. Comparative tolerability of systemic treatments for plaque-type psoriasis. Drug Saf. 25: 913-927 (2002).
McCormack J, Bell S, Senini S, Walmsley K, Patel K, Wainwright C, Serisier D, Harris M, Bowler S. Daily versus weekly azithromycin in cystic fibrosis patients. Eur. Respir. J. 30: 487-495 (2007).
McCoy KS, Quittner AL, Oermann CM, Gibson RL, Retsch-Bogart GZ, Montgomery AB. Inhaled aztreonam lysine for chronic airway Pseudomonas aeruginosa in cystic fibrosis. Am. J. Respir. Crit. Care Med. 178: 921-928 (2008). *
McCoy MK, Tansey MG. TNF signaling inhibition in the CNS: implications for normal brain function and neurodegenerative disease. J. Neuroinflammation 5: 45 (2008).
McCunney RJ. Diverse manifestations of trichloroethylene. Br. J. Ind. Med. 45: 122-126 (1988).
McDonald J, Feagan B, Jewell D, Brynskov J, Stange E, Macdonald J. Cyclosporine for induction of remission in Crohn's disease. Cochrane Database Syst. Rev. 2: CD000297 (2005). *
McGovern DP, Jewell DP. Risks and benefits of azathioprine therapy. Gut 54: 1055-1059 (2005). *
McGowan JW 4th, Johnson CA, Lynn A. Treatment of pyoderma gangrenosum with etanercept. J. Drugs Dermatol. 3: 441-444 (2004).
McGowan MP, Proulx S. Nutritional supplements and serum lipids: does anything work? Curr. Atheroscler. Rep. 11: 470-476 (2009).
McGrath J, McDonald J, Macdonald J. Transdermal nicotine for induction of remission in ulcerative colitis. Cochrane Database Syst. Rev. 4: CD004722 (2004). *
McInnes GT, Lawson DH, Jick H. Acute adverse reactions attributed to allopurinol in hospitalised patients. Ann. Rheum. Dis. 40: 245-249 (1981). *
McKarney C, Everard M, N'Diaye T. Omega-3 fatty acids (from fish oils) for cystic fibrosis. Cochrane Database Syst. Rev. 4: CD002201 (2007). *
McKeage K, Keating GM. Clindamycin/benzoyl peroxide gel (BenzaClin((R))): a review of its use in the management of acne. Am. J. Clin. Dermatol. 9: 193-204 (2008).
McKenna F, Weaver A, Fiechtner JJ, Bello AE, Fort JG. COX-2 specific inhibitors in the management of osteoarthritis of the knee: a placebo-controlled, randomized, double-blind study. J. Clin. Rheumatol. 7: 151-159 (2001).
McKenney JM, Sica D. Role of prescription omega-3 fatty acids in the treatment of hypertriglyceridemia. Pharmacotherapy 27: 715-728 (2007).
McKenzie SG, Chowdhury S, Strandvik B, Hodson ME; on behalf of the Investigators of the Epidemiologic Registry of Cystic Fibrosis. Dornase alfa is well tolerated: data from the Epidemiologic Registry of Cystic Fibrosis. Pediatr. Pulmonol. 42: 928-937 (2007).
McLean E, de Benoist B, Allen LH. Review of the magnitude of folate and vitamin B12 deficiencies worldwide. Food Nutr. Bull. 29: S38-S51 (2008).
McMahon BJ, Bruden D, Bruce MG, Livingston S, Christensen C, Homan C, Hennessy TW, Williams J, Sullivan D, Rosen HR, Gretch D. Adverse outcomes in Alaska natives who recovered from or have chronic hepatitis C infection. Gastroenterology Nov 9 [Epub ahead of print] (2009). *
McMahon BJ, Helminiak C, Wainwright RB, Bulkow L, Trimble BA, Wainwright K. Frequency of adverse reactions to hepatitis B vaccine in 43,618 persons. Am. J. Med. 92: 254-256 (1992).
McMillian M, Nie AY, Parker JB, Leone A, Kemmerer M, Bryant S, Herlich J, Yieh L, Bittner A, Liu X, Wan J, Johnson MD. Inverse gene expression patterns for macrophage activating hepatotoxicants and peroxisome proliferators in rat liver. Biochem. Pharmacol. 67: 2141-2165 (2004). *
McPartland JM. The endocannabinoid system: an osteopathic perspective. J. Am. Osteopath. Assoc. 108: 586-600 (2008). *
Meagher MW, Sieve AN, Johnson RR, Satterlee D, Belyavskyi M, Mi W, Prentice TW, Welsh TH Jr, Welsh CJ. Neonatal maternal separation alters immune, endocrine, and behavioral responses to acute Theiler's virus infection in adult mice. Behav. Genet. Feb 5 [Epub ahead of print] (2010).
Mealey KL, Meurs KM. Breed distribution of the ABCB1-1Delta (multidrug sensitivity) polymorphism among dogs undergoing ABCB1 genotyping. J. Am. Vet. Med. Assoc. 233: 921-924 (2008). *
Mease P. Psoriatic arthritis update. Bull. Hosp. Jt. Dis. 64: 25-31 (2006).
Mease PJ. Adalimumab in the treatment of arthritis. Ther. Clin. Risk Manag. 3: 133-148 (2007). *
Mease PJ, Gladman DD, Keystone EC. Alefacept in combination with methotrexate for the treatment of psoriatic arthritis: results of a randomized, double-blind, placebo-controlled study. Arthritis Rheum. 54: 1638-1645 (2006). *
Mease PJ, Hobbs K, Chalmers A, El-Gabalawy H, Bookman A, Keystone E, Furst DE, Anklesaria P, Heald AE. Local delivery of a recombinant adeno-associated vector containing a tumor necrosis factor-alpha antagonist gene in inflammatory arthritis: a phase 1 dose-escalation safety and tolerability study. Ann. Rheum. Dis. 68: 1247-1254 (2009).
Mease PJ, Kivitz AJ, Burch FX, Siegel EL, Cohen SB, Ory P, Salonen D, Rubenstein J, Sharp JT, Dunn M, Tsuji W. Continued inhibition of radiographic progression in patients with psoriatic arthritis following 2 years of treatment with etanercept. J. Rheumatol. 33: 712-721 (2006).
Mease PJ, Ory P, Sharp JT, Ritchlin CT, van den Bosch F, Wellborne F, Birbara C, Thomson GT, Perdok RJ, Medich J, Wong RL, Gladman DD. Adalimumab for long-term treatment of psoriatic arthritis: two-year data from the Adalimumab Effectiveness in Psoriatic Arthritis Trial (ADEPT). Ann. Rheum. Dis. 68: 702-709 (2009). *
Mease PJ, Signorovitch J, Yu AP, Wu EQ, Gupta SR, Bao Y, Mulani PM. Impact of adalimumab on symptoms of psoriatic arthritis in patients with moderate to severe psoriasis: a pooled analysis of randomized clinical trials. Dermatology Nov 19 [Epub ahead of print] (2009).
Mease PJ, Wei N, Fudman EJ, Kivitz AJ, Schechtman J, Trapp RG, Hobbs KF, Greenwald M, Hou A, Bookbinder SA, Graham GE, Wiesenhutter CW, Willis L, Ruderman EM, Forstot JZ, Maricic MJ, Dao KH, Pritchard CH, Fiske DN, Burch FX, Prupas HM, Anklesaria P, et al. Safety, tolerability, and clinical outcomes after intraarticular injection of a recombinant adeno-associated vector containing a tumor necrosis factor antagonist gene: results of a phase 1/2 study. J. Rheumatol. Dec 23 [Epub ahead of print] (2009).
Mecacci F, Pieralli A, Bianchi B, Paidas MJ. The impact of autoimmune disorders and adverse pregnancy outcome. Semin. Perinatol. 31: 223-226 (2007).
Mehal WZ, Culshaw KD, Tillotson GS, Chapman RW. Antibiotic prophylaxis for ERCP: a randomized clinical trial comparing ciprofloxacin and cefuroxime in 200 patients at high risk of cholangitis. Eur. J. Gastroenterol. Hepatol. 7: 841-845 (1995).
Mehlman MA. Dangerous and cancer-causing properties of products and chemicals in the oil-refining and petrochemical industry. Part XXII: Health hazards from exposure to gasoline containing methyl tertiary butyl ether: study of New Jersey residents. Toxicol. Ind. Health 12: 613-627 (1996).
Mehrabi A, Fonouni H, Ayoub E, Rahbari NN, Muller SA, Morath Ch, Seckinger J, Sadeghi M, Golriz M, Esmaeilzadeh M, Hillebrand N, Weitz J, Zeier M, Buchler MW, Schmidt J, Schmied BM. A single center experience of combined liver kidney transplantation. Clin. Transplant. 23 Suppl. 21: 102-114 (2009).
Mehta J, Frankfurt O, Altman J, Evens A, Tallman M, Gordon L, Williams S, Winter J, Krishnamurthy J, Duffey S, Singh V, Meagher R, Grinblatt D, Kaminer L, Singhal S. Optimizing the CD34 + cell dose for reduced-intensity allogeneic hematopoietic stem cell transplantation. Leuk. Lymphoma 50: 1434-1441 (2009).
Meissner Y, Pellequer Y, Lamprecht A. Nanoparticles in inflammatory bowel disease: particle targeting versus pH-sensitive delivery. Int. J. Pharm. 316: 138-143 (2006). *
Meissner Y, Ubrich N, Ghazouani FE, Maincent P, Lamprecht A. Low molecular weight heparin loaded pH-sensitive microparticles. Int. J. Pharm. 335: 147-153 (2007). *
Melnik BC. Milk - the promoter of chronic Western diseases. Med. Hypotheses 72: 631-639 (2009).
Meloni A, Perniola R, Faa V, Corvaglia E, Cao A, Rosatelli MC. Delineation of the molecular defects in the AIRE gene in autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy patients from Southern Italy. J. Clin. Endocrinol. Metab. 87: 841-846 (2002). *
Mendoza JL, Garcia-Paredes J, Cruz Santamaria DM, Lana R, Ramirez Fernandez E, Rodriguez Asteaga E, Diaz-Rubio M. Infliximab treatment and prognostic factors for response in patients with Crohn's disease. Rev. Esp. Enferm. Dig. 94: 269-279 (2002).
Meneses F, Ney JG, Torres AG, Trugo NM. Erythrocyte membrane and plasma non-esterified n-3 and n-6 polyunsaturated fatty acids of pregnant and non-pregnant Brazilian adolescents. Prostaglandins Leukot. Essent. Fatty Acids 80: 137-142 (2009). *
Menge T, Weber MS, Hemmer B, Kieseier BC, von Budingen HC, Warnke C, Zamvil SS, Boster A, Khan O, Hartung HP, Stuve O. Disease-modifying agents for multiple sclerosis: recent advances and future prospects. Drugs 68: 2445-2468 (2008).
Menghini VV, Arora AS. Infliximab-associated reversible cholestatic liver disease. Mayo Clin. Proc. 76: 84-86 (2001). *
Menon K, Van Voorhees AS, Bebo BF Jr, Gladman DD, Hsu S, Kalb RE, Lebwohl MG, Strober BE; for the National Psoriasis Foundation. Psoriasis in patients with HIV infection: from the Medical Board of the National Psoriasis Foundation. J. Am. Acad. Dermatol. Jul 29 [Epub ahead of print] (2009).
Menon KVN, Stadheim L, Kamath PS, Wiesner RH, Gores GJ, Peine CJ, Shah V. A pilot study of the safety and tolerability of etanercept in patients with alcoholic hepatitis. Am. J. Gastroenterol. 99: 255-260 (2004). *
Menon RT, Feferman T, Aricha R, Souroujon MC, Fuchs S. Suppression of experimental autoimmune myasthenia gravis by combination therapy: pentoxifylline as a steroid-sparing agent. J. Neuroimmunol. 201-202: 128-135 (2008).
Menter A, Gordon K, Carey W, Hamilton T, Glazer S, Caro I, Li N, Gulliver W. Efficacy and safety observed during 24 weeks of efalizumab therapy in patients with moderate to severe plaque psoriasis. Arch. Dermatol. 141: 31-38 (2005). *
Menter A, Reich K, Gottlieb AB, Bala M, Li S, Hsu MC, Guzzo C, Diels J, Gelfand JM. Adverse drug events in infliximab-treated patients compared with the general and psoriasis populations. J. Drugs Dermatol. 7: 1137-1146 (2008).
Merkel C, Marin R, Angeli P, Zanella P, Felder M, Bernardinello E, Cavallarin G, Bolognesi M, Donada C, Bellini B, Torboli P, Gatta A. A placebo-controlled clinical trial of nadolol in the prophylaxis of growth of small esophageal varices in cirrhosis. Gastroenterology 127: 476-484 (2004). *
Merli M, Bragazzi MC, Giubilo F, Callea F, Attili AF, Alvaro D. Atorvastatin-induced prolonged cholestasis with bile duct damage. Clin. Drug Investig. 30: 205-209 (2010).
Merrick S, Harnden S, Shetty S, Chopra P, Clamp P, Kapadia S. An evaluation of the "cut and push" method of percutaneous endoscopic gastrostomy (PEG) removal. JPEN J. Parenter. Enteral Nutr. 32: 78-80 (2008). *
Message L, Bourreille A, Laharie D, Quinton A, Galmiche JP, Lamouliatte H, Alamdari A, Zerbib F. Efficacy of intravenous cyclosporin in moderately severe ulcerative colitis refractory to steroids. Gastroenterol. Clin. Biol. 29: 231-235 (2005).
Metz DC. Clostridium difficile colitis: wash your hands before stopping the proton pump inhibitor. Am. J. Gastroenterol. 103: 2314-2316 (2008). *
Metz DC, Howden CW, Perez MC, Larsen L, O'Neil J, Atkinson SN. Clinical trial: dexlansoprazole MR, a proton pump inhibitor with dual delayed release technology, effectively controls symptoms and prevents relapse in patients with healed erosive esophagitis. Aliment. Pharmacol. Ther. 29: 742-754 (2009). *
Metze D, Reimann S, Beissert S, Luger T. Efficacy and safety of naltrexone, an oral opiate receptor antagonist, in the treatment of pruritus in internal and dermatological diseases. J. Am. Acad. Dermatol. 41: 533-539 (1999).
Meyer UA, Gut J. Genomics and the prediction of xenobiotic toxicity. Toxicology 181-182: 463-466 (2002). *
Meyerhoff JL, Lee JK, Rittase BW, Tsang AY, Yourick DL. Lipoic acid pretreatment attenuates ferric chloride-induced seizures in the rat. Brain Res. 1016: 139-144 (2004).
Meyers S, Sachar DB, Present DH, Janowitz HD. Olsalazine in the treatment of ulcerative colitis among patients intolerant of sulphasalazine: a prospective, randomized, placebo-controlled, double-blind, dose-ranging clinical trial. Scand. J. Gastroenterol. Suppl. 148: 29-37 (1988).
Mian MF, Lauzon NM, Stampfli MR, Mossman KL, Ashkar AA. Impairment of human NK cell cytotoxic activity and cytokine release by cigarette smoke. J. Leukoc. Biol. 83: 774-784 (2008). *
Michaels A, Levy C. The medical management of primary sclerosing cholangitis. Medscape J. Med. 10: 61 (2008). *
Michelson D, Faries D, Wernicke J, Kelsey D, Kendrick K, Sallee FR, Spencer T; Atomoxetine ADHD Study Group. Atomoxetine in the treatment of children and adolescents with attention-deficit/hyperactivity disorder: a randomized, placebo-controlled, dose-response study. Pediatrics 108: e83 (2001). *
Mielants H, Veys EM. HLA-B27 related arthritis and bowel inflammation. Part 1. Sulfasalazine (salazopyrin) in HLA-B27 related reactive arthritis. J. Rheumatol. 12: 287-293 (1985).
Miele E, Pascarella F, Giannetti E, Quaglietta L, Baldassano RN, Staiano A. Effect of a probiotic preparation (VSL#3) on induction and maintenance of remission in children with ulcerative colitis. Am. J. Gastroenterol. 104: 437-443 (2009). *
Migliore A, Bizzi E, Lagan B, Altomonte L, Zaccari G, Granata M, Canzoni M, Marasini B, Massarotti M, Massafra U, Ranieri M, Pilla R, Martin LS, Pezza M, Vacca F, Galluccio A. The safety of anti-TNF agents in the elderly. Int. J. Immunopathol. Pharmacol. 22: 415-426 (2009).
Mignat C. Clinically significant drug interactions with new immunosuppressive agents. Drug Saf. 16: 267-278 (1997).
Mignogna MD, Fortuna G, Leuci S. Oral pemphigus. Minerva Stomatol. 58: 501-518 (2009).
Mignogna MD, Leuci S, Fedele S, Ruoppo E, Adamo D, Russo G, Pagliuca R. Adjuvant high-dose intravenous immunoglobulin therapy can be easily and safely introduced as an alternative treatment in patients with severe pemphigus vulgaris: a retrospective preliminary study. Am. J. Clin. Dermatol. 9: 323-331 (2008).
Miheller P, Lakatos PL, Horvath G, Molnar T, Szamosi T, Cegledi Z, Salamon A, Czimmer J, Rumi G, Palatka K, Papp M, Jakab Z, Szabo A, Gelley A, Lakatos L, Barta Z, Balazs C, Racz I, Zeher M, Dobronte Z, Altorjay I, Hunyady B, Simon L, Papp J, et al. Efficacy and safety of infliximab induction therapy in Crohn's disease in Central Europe - a Hungarian nationwide observational study. BMC Gastroenterol. 9: 66 (2009). *
Miksa M, Das P, Zhou M, Wu R, Dong W, Ji Y, Goyert SM, Ravikumar TS, Wang P. Pivotal role of the alpha(2A)-adrenoceptor in producing inflammation and organ injury in a rat model of sepsis. PLoS ONE 4: e5504 (2009). *
Mikuls TR, Weaver AL. Lessons learned in the use of tumor necrosis factor-alpha inhibitors in the treatment of rheumatoid arthritis. Curr. Rheumatol. Rep. 5: 270-277 (2003).
Milkiewicz P, Baiocchi L, Mills CO, Ahmed M, Khalaf H, Keogh A, Baker J, Elias E. Plasma clearance of cholyl-lysyl-fluorescein: a pilot study in humans. J. Hepatol. 27: 1106-1109 (1997). *
Milkiewicz P, Saksena S, Cardenas T, Mills CO, Elias E. Plasma elimination of cholyl-lysyl-fluorescein (CLF): a pilot study in patients with liver cirrhosis. Liver 20: 330-334 (2000).
Miller JD, Whitehair LH. Concurrent HLA-related response factors mediate recombinant hepatitis B vaccine major adverse events. Autoimmunity 38: 181-194 (2005).
Miller JW. Of race, ethnicity, and rash: the genetics of antiepileptic drug-induced skin reactions. Epilepsy Curr. 8: 120-121 (2008).
Miller VA, Rigas JR, Benedetti FM, Verret AL, Tong WP, Kris MG, Gill GM, Loewen GR, Truglia JA, Ulm EH, Warrell RP Jr. Initial clinical trial of the retinoid receptor pan agonist 9-cis retinoic acid. Clin. Cancer Res. 2: 471-475 (1996). *
Millonig G, Kern M, Ludwiczek O, Nachbaur K, Vogel W. Subfulminant hepatitis B after infliximab in Crohn's disease: need for HBV-screening? World J. Gastroenterol. 12: 974-976 (2006). *
Minasian C, Wallis C, Metcalfe C, Bush A. Bronchial provocation testing with dry powder mannitol in children with cystic fibrosis. Pediatr. Pulmonol. 43: 1078-1084 (2008).
Miner P, Wedel M, Bane B, Bradley J. An enema formulation of alicaforsen, an antisense inhibitor of intercellular adhesion molecule-1, in the treatment of chronic, unremitting pouchitis. Aliment. Pharmacol. Ther. 19: 281-286 (2004). *
Miners JO, Day RO. Relationships between the adverse effects of drugs and genetic polymorphism in genes encoding drug metabolizing enzymes. Br. J. Clin. Pharmacol. 63: 380-381 (2007). *
Minnee RC, Stokkers P, Riemens SC, Hommes DW. Pneumocystis pneumonia during infliximab treatment for active Crohn's colitis. Ned. Tijdschr. Geneeskd. 149: 2290-2295 (2005).
Mirbagheri SA, Nezami BG, Assa S, Hajimahmoodi M. Rectal administration of d-alpha tocopherol for active ulcerative colitis: a preliminary report. World J. Gastroenterol. 14: 5990-5995 (2008). *
Miro-Mur F, Hindie M, Kandhaya-Pillai R, Tobajas V, Schwartz S Jr, Alijotas-Reig J. Medical-grade silicone induces release of proinflammatory cytokines in peripheral blood mononuclear cells without activating T cells. J. Biomed. Mater. Res. B. Appl. Biomater. 90: 510-520 (2009).
Misawa T, Mizusawa H. Tailored therapy for multiple sclerosis. Nippon Rinsho 66: 1135-1139 (2008).
Mischoulon D, Fava M. Role of S-adenosyl-L-methionine in the treatment of depression: a review of the evidence. Am. J. Clin. Nutr. 76: 1158S-1161S (2002). *
Mistry N, Shapero J, Crawford RI. A review of adverse cutaneous drug reactions resulting from the use of interferon and ribavirin. Can. J. Gastroenterol. 23: 677-683 (2009).
Mitchell Phd RJ, Osborne Dmd Med PB, Haubenreich Dds JE. Dental amalgam restorations: daily mercury dose and biocompatibility. J. Long Term Eff. Med. Implants 15: 709-721 (2005).
Mittal R, Malhotra S, Pandhi P, Kaur I, Dogra S. Efficacy and safety of combination acitretin and pioglitazone therapy in patients with moderate to severe chronic plaque-type psoriasis: a randomized, double-blind, placebo-controlled clinical trial. Arch. Dermatol. 145: 387-393 (2009). *
Miura N, Fukutake M, Yamamoto M, Ohtake N, Iizuka S, Imamura S, Tsuchiya N, Ishimatsu M, Nakamura Y, Ishige A, Watanabe K, Kase Y, Takeda S. An herbal medicine orengedokuto prevents indomethacin-induced enteropathy. Biol. Pharm. Bull. 30: 495-501 (2007). *
Miwa H, Nagahara A, Tominaga K, Yokoyama T, Sawada Y, Inoue K, Ashida K, Fukuchi T, Hojo M, Yamashita H, Tomita T, Hori K, Oshima T. Efficacy of the 5-HT1A agonist tandospirone citrate in improving symptoms of patients with functional dyspepsia: a randomized controlled trial. Am. J. Gastroenterol. 104: 2779-2787 (2009). *
Miwako I, Kagechika H. Tamibarotene. Drugs Today (Barc.) 43: 563-568 (2007).
Mix E, Meyer-Rienecker H, Zettl UK. Animal models of multiple sclerosis for the development and validation of novel therapies - potential and limitations. J. Neurol. 255 Suppl. 6: 7-14 (2008).
Miyasaka N, Takeuchi T, Eguchi K. Guidelines for the proper use of etanercept in Japan. Mod. Rheumatol. 16: 63-57 (2006). *
Miyasaka N, Takeuchi T, Eguchi K. Official Japanese guidelines for the use of infliximab for rheumatoid arthritis. Mod. Rheumatol. 15: 4-8 (2005).
Mizrahi M, Adar T, Orenbuch-Harroch E, Elitzur Y. Non-ST elevation myocardial infraction after high dose intravenous immunoglobulin iInfusion. Case Report Med. 2009: 861370 (2009).
Moan J, Porojnicu AC, Dahlback A, Setlow RB. Addressing the health benefits and risks, involving vitamin D or skin cancer, of increased sun exposure. Proc. Natl. Acad. Sci. U.S.A. 105: 668-673 (2008). *
Mocciaro F, Orlando A, Scimeca D, Cottone M. Infliximab in moderate to severe steroid-dependent or steroid-refractory ulcerative colitis. Recenti Prog. Med. 98: 560-564 (2007).
Mockenhaupt M, Viboud C, Dunant A, Naldi L, Halevy S, Bavinck JN, Sidoroff A, Schneck J, Roujeau JC, Flahault A. Stevens-Johnson syndrome and toxic epidermal necrolysis: assessment of medication risks with emphasis on recently marketed drugs. The EuroSCAR-study. J. Invest. Dermatol. 128: 35-44 (2008). *
Mohan N, Edwards ET, Cupps TR, Oliverio PJ, Sandberg G, Crayton H, Richert JR, Siegel JN. Demyelination occurring during anti-tumor necrosis factor alpha therapy for inflammatory arthritides. Arthritis Rheum. 44: 2862-2869 (2001).
Molina-Infante J, Perez-Gallardo B, Fernandez-Bermejo M, Hernandez-Alonso M, Vinagre G, Duenas C, Mateos-Rodriguez JM, Gonzalez-Garcia G, Abadia EG, Gisbert JP. Clinical trial: clarithromycin vs. levofloxacin in first-line triple and sequential regimens for Helicobacter pylori eradication. Aliment. Pharmacol. Ther. Feb 20 [Epub ahead of print] (2010). *
Molitch ME, Gillam MP. Lymphocytic hypophysitis. Horm. Res. 68 Suppl. 5: S145-S150 (2007).
Molloy ES, Langford CA, Clark TM, Gota CE, Hoffman GS. Anti-tumor necrosis factor therapy in patients with refractory Takayasu's arteritis: long-term follow-up. Ann. Rheum. Dis. 67: 1567-1569 (2008).
Monami M, Lamanna C, Marchionni N, Mannucci E. Rosiglitazone and risk of cancer: a meta-analysis of randomized clinical trials. Diabetes Care 31: 1455-1460 (2008). *
Monk JP, Todd PA. Bezafibrate. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in hyperlipidaemia. Drugs 33: 539-576 (1987).
Monneaux F, Muller S. Peptide-based immunotherapy of systemic lupus erythematosus. Autoimmun. Rev. 3: 16-24 (2004). *
Montanari R, Saccoccia F, Scotti E, Crestani M, Godio C, Gilardi F, Loiodice F, Fracchiolla G, Laghezza A, Tortorella P, Lavecchia A, Novellino E, Mazza F, Aschi M, Pochetti G. Crystal structure of the peroxisome proliferator-activated receptor gamma (PPARgamma) ligand binding domain complexed with a novel partial agonist: a new region of the hydrophobic pocket could be exploited for drug design. J. Med. Chem. 51: 7768-7776 (2008). *
Montano-Loza AJ, Carpenter HA, Czaja AJ. Consequences of treatment withdrawal in type 1 autoimmune hepatitis. Liver Int. 27: 507-515 (2007). *
Montgomery EH, Kroeger DC. Use of antibiotics in dental practice. Dent. Clin. North Am. 28: 433-453 (1984).
Montgomery P, Richardson A. Omega-3 fatty acids for bipolar disorder. Cochrane Database Syst. Rev. 2: CD005169 (2008). *
Moore DE, Feurer ID, Speroff T, Gorden DL, Wright JK, Chari RS, Pinson CW. Impact of donor, technical, and recipient risk factors on survival and quality of life after liver transplantation. Arch. Surg. 140: 273-277 (2005). *
Moore JW, Babidge WJ, Millard SH, Roediger WE. Thiolmethyltransferase activity in the human colonic mucosa: implications for ulcerative colitis. J. Gastroenterol. Hepatol. 12: 678-684 (1997).
Moore RA, Derry S. Systematic review and meta-analysis of randomised trials and cohort studies of mycophenolate mofetil in lupus nephritis. Arthritis Res. Ther. 8: R182 (2006). *
Mor E, Yussim A, Chodoff L, Schwartz ME. New immunosuppressive agents for maintenance therapy in organ transplantation. BioDrugs 8: 469-488 (1997).
Morales J, Bono MR, Fierro A, Iniguez R, Zehnder C, Rosemblatt M, Calabran L, Herzog C, Benavente D, Aguilo J, Pefaur J, Alba A, Ferrario M, Simon W, Contreras L, Buckel E. Alemtuzumab induction in kidney transplantation: clinical results and impact on T-regulatory cells. Transplant. Proc. 40: 3223-3228 (2008). *
Morand JJ. What's new in clinical dermatology? Ann. Dermatol. Venereol. 136S7: S393-S406 (2009).
Morard I, Hadengue A. Drug induced diarrhea. Rev. Med. Suisse. 4: 1867-1868, 1870-1872 (2008).
Moravan M, Segal BM. Treatment of CNS sarcoidosis with infliximab and mycophenolate mofetil. Neurology 72: 337-340 (2009).
Moreland LW. Cytokines as targets for anti-inflammatory agents. Ann. N. Y. Acad. Sci. 1182: 88-96 (2009). *
Moreland LW, Weinblatt ME, Keystone EC, Kremer JM, Martin RW, Schiff MH, Whitmore JB, White BW. Etanercept treatment in adults with established rheumatoid arthritis: 7 years of clinical experience. J. Rheumatol. 33: 854-861 (2006).
Moreno C, Deviere J, Louis H. Reply to "CCR5 deficiency exacerbates T-cell-mediated hepatitis in mice - clinical implications for CCR5 inhibition as antiretroviral therapy". Hepatology 43: 879-880 (2006).
Mori M, Takei S, Imagawa T, Imanaka H, Maeno N, Kurosawa R, Kawano Y, Yokota S. Pharmacokinetics, efficacy, and safety of short-term (12 weeks) etanercept for methotrexate-refractory polyarticular juvenile idiopathic arthritis in Japan. Mod. Rheumatol. 15: 397-404 (2005).
Mori TA. Effect of fish and fish oil-derived omega-3 fatty acids on lipid oxidation. Redox Rep. 9: 193-197 (2004).
Moriguchi M, Takayama T, Nakamura M, Aramaki O, Higaki T, Nakayama H, Ohkubo T, Fujii M. Phase I/II study of a fine-powder formulation of cisplatin for transcatheter arterial chemoembolization in hepatocellular carcinoma. Hepatol. Res. Jan 11 [Epub ahead of print] (2010). *
Mortimore M, Gibson PR, Selby WS, Radford-Smith GL, Florin TH; Schering Plough (Australia). Early Australian experience with infliximab, a chimeric antibody against tumour necrosis factor-alpha, in the treatment of Crohn's disease: is its efficacy augmented by steroid-sparing immunosuppressive therapy? The Infliximab User Group. Intern. Med. J. 31: 146-150 (2001).
Moschella SL. Is there a role for infliximab in the current therapy of hidradenitis suppurativa? A report of three treated cases. Int. J. Dermatol. 46: 1287-1291 (2007). *
Moss AC, Morris E, Mac Mathuna P. Palliative biliary stents for obstructing pancreatic carcinoma. Cochrane Database Syst. Rev. 1: CD004200 (2006).
Moss AC, Peppercorn MA. The risks and the benefits of mesalazine as a treatment for ulcerative colitis. Expert Opin. Drug Saf. 6: 99-107 (2007).
Mossallam GI, Abdel Hamid TM, Samra MA. Glutathione S-transferase GSTM1 and GSTT1 polymorphisms in adult acute myeloid leukemia; its impact on toxicity and response to chemotherapy. J. Egypt. Natl. Canc. Inst. 18: 264-273 (2006).
Mossop H, Davies P, Murphy MS. Predicting the need for azathioprine at first presentation in children with inflammatory bowel disease. J. Pediatr. Gastroenterol. Nutr. 47: 123-129 (2008). *
Mota P, Diogo N, Pina J. Multi-drug resistant tuberculosis in a respiratory infectious diseases unit - results from five years. Rev. Port. Pneumol. 11: S44-S45 (2005).
Motani A, Wang Z, Weiszmann J, McGee LR, Lee G, Liu Q, Staunton J, Fang Z, Fuentes H, Lindstrom M, Liu J, Biermann DH, Jaen J, Walker NP, Learned RM, Chen JL, Li Y. INT131: a selective modulator of PPAR gamma. J. Mol. Biol. 386: 1301-1311 (2009).
Mou L, Lankford-Turner P, Leander MV, Bissonnette RP, Donahoe RM, Royal W. RXR-induced TNF-alpha suppression is reversed by morphine in activated U937 cells. J. Neuroimmunol. 147: 99-105 (2004).
Moulari B, Pertuit D, Pellequer Y, Lamprecht A. The targeting of surface modified silica nanoparticles to inflamed tissue in experimental colitis. Biomaterials 29: 4554-4560 (2008). *
Moustou AE, Matekovits A, Dessinioti C, Antoniou C, Sfikakis PP, Stratigos AJ. Cutaneous side effects of anti-tumor necrosis factor biologic therapy: a clinical review. J. Am. Acad. Dermatol. 61: 486-504 (2009).
Moustou AE, Stratigos AJ, Vergou T, Gregoriou S, Georgala S, Danopoulou I. Arthralgia as an adverse event to infliximab: a reactive arthritis or triggering of psoriatic arthritis? Successful management by switching to etanercept. J. Eur. Acad. Dermatol. Venereol. 23: 968-969 (2009). *
Movsesyan N, Ghochikyan A, Mkrtichyan M, Petrushina I, Davtyan H, Olkhanud PB, Head E, Biragyn A, Cribbs DH, Agadjanyan MG. Reducing AD-like pathology in 3xTg-AD mouse model by DNA epitope vaccine - a novel immunotherapeutic strategy. PLoS ONE 3: e2124 (2008). *
Moy L, Levine J. Wireless capsule endoscopy in the pediatric age group: experience and complications. J. Pediatr. Gastroenterol. Nutr. 44: 516-520 (2007). *
Mozaffarian D, Rimm EB. Fish intake, contaminants, and human health: evaluating the risks and the benefits. JAMA 296: 1885-1899 (2006). *
Mraz S, Leonardi C, Colon LE, Johnson LA. Different treatment outcomes with different formulations of clobetasol propionate 0.05% for the treatment of plaque psoriasis. J. Dermatolog. Treat. 19: 354-359 (2008).
Mrowietz U, Reich K. Ten years of infliximab: its role in dermatology. Eur. J. Pharmacol. Oct 15 [Epub ahead of print] (2009). *
Mu JP, Wu HG, Zhang ZQ, Liu HR, Zhu Y, Shi Z, Wang XM. Meta-analysis on acupuncture and moxibustion for treatment of ulcerative colitis. Zhongguo Zhen Jiu 27: 687-690 (2007).
Muellenhoff M, Cukrowski T, Morgan M, Dorton D. Oral pemphigus vulgaris after anthrax vaccine administration: association or coincidence? J. Am. Acad. Dermatol. 50: 136-139 (2004).
Muetze S, Leeners B, Ortlepp JR, Kuse S, Tag CG, Weiskirchen R, Gressner AM, Rudnik-Schoeneborn S, Zerres K, Rath W. Maternal factor V Leiden mutation is associated with HELLP syndrome in Caucasian women. Acta Obstet. Gynecol. Scand. 87: 635-642 (2008).
Mukhtyar C, Luqmani R. Current state of tumour necrosis factor alpha blockade in Wegener's granulomatosis. Ann. Rheum. Dis. 64 Suppl. 4: iv31-iv36 (2005). *
Mulekar SV, Al Eisa A, Delvi MB, Al Issa A, Al Saeed AH. Childhood vitiligo: a long-term study of localized vitiligo treated by noncultured cellular grafting. Pediatr. Dermatol. Oct 4 [Epub ahead of print] (2009).
Muller M. Polyphenol cytotoxicity induced by the bacterial toxin pyocyanin: role of NQO1. Free Radic. Biol. Med. 47: 84-91 (2009).
Mullhaupt B, Kullak-Ublick GA, Ambuhl PM, Stocker R, Renner EL. Successful use of the Molecular Adsorbent Recirculating System (MARS) in a patient with primary biliary cirrhosis (PBC) and treatment refractory pruritus. Hepatol. Res. 25: 442-446 (2003).
Munoz LE, Alcala EG, Cordero P, Martinez MA, Vazquez NY, Galindo S, Mendoza E, Segura JJ. Reversal of hepatorenal syndrome in cirrhotic patients with terlipressin plus albumin. First experience in Mexico. Ann. Hepatol. 8: 207-211 (2009).
Muntinghe FL, Verduijn M, Zuurman MW, Grootendorst DC, Carrero JJ, Qureshi AR, Luttropp K, Nordfors L, Lindholm B, Brandenburg V, Schalling M, Stenvinkel P, Boeschoten EW, Krediet RT, Navis G, Dekker FW. CCR5 deletion protects against inflammation-associated mortality in dialysis patients. J. Am. Soc. Nephrol. 20: 1641-1619 (2009).
Munuswamy-Ramanujam G, Khan KA, Lucas AR. Viral anti-inflammatory reagents: the potential for treatment of arthritic and vasculitic disorders. Endocr. Metab. Immune Disord. Drug Targets 6: 331-343 (2006).
Muratov V, Lundahl J, Ulfgren AK, Elvin K, Fehrman I, Ahlborg N, Ost A, Hittel N, Saniabadi A, Lofberg R. Down-regulation of interferon-gamma parallels clinical response to selective leukocyte apheresis in patients with inflammatory bowel disease: a 12-month follow-up study. Int. J. Colorectal Dis. 21: 493-504 (2006). *
Muro M, Rivera J, Botella C, Campillo JA, Ferrer F, Alvarez-Lopez MR. HLA-DR antibodies in transfusion-related acute lung injury (TRALI): a case report. Transfus. Apher. Sci. 38: 209-212 (2008).
Murphy CC, Ayliffe WH, Booth A, Makanjuola D, Andrews PA, Jayne D. Tumor necrosis factor alpha blockade with infliximab for refractory uveitis and scleritis. Ophthalmology 111: 352-356 (2004). *
Murphy CC, Greiner K, Plskova J, Duncan L, Frost NA, Forrester JV, Dick AD. Cyclosporine vs tacrolimus therapy for posterior and intermediate uveitis. Arch. Ophthalmol. 123: 634-641 (2005). *
Murphy CL, Gibson D, Meyers LS. Inflammatory bowel disease and acne. Am. J. Gastroenterol. 104: 2370 (2009). *
Murphy MM, Douglass JS, Johnson RK, Spence LA. Drinking flavored or plain milk is positively associated with nutrient intake and is not associated with adverse effects on weight status in US children and adolescents. J. Am. Diet. Assoc. 108: 631-639 (2008). *
Muscari A, Puddu GM, Puddu P. Lipid-lowering drugs: are adverse effects predictable and reversible? Cardiology 97: 115-121 (2002).
Musch E, Andus T, Kruis W, Raedler A, Spehlmann M, Schreiber S, Krakamp B, Malek M, Malchow H, Zavada F, Engelberg Feurle G. Interferon-beta-1a for the treatment of steroid-refractory ulcerative colitis: a randomized, double-blind, placebo-controlled trial. Clin. Gastroenterol. Hepatol. 3: 581-586 (2005). *
Musch E, Andus T, Kruis W, Raedler A, Spehlmann M, Schreiber S, Krakamp B, Malek M, Malchow H, Zavada F, Engelberg Feurle G; The European Ulcerative Colitis Study Group. Interferon-beta-1a for the treatment of steroid-refractory ulcerative colitis: a randomized, double-blind, placebo-controlled trial. Clin. Gastroenterol. Hepatol. 3: 581-586 (2006).
Musch E, Andus T, Malek M. Induction and maintenance of clinical remission by interferon-beta in patients with steroid-refractory active ulcerative colitis-an open long-term pilot trial. Aliment. Pharmacol. Ther. 16: 1233-1239 (2002). *
Musteanu M, Blaas L, Mair M, Schlederer M, Bilban M, Tauber S, Esterbauer H, Mueller M, Casanova E, Kenner L, Poli V, Eferl R. Stat3 is a negative regulator of intestinal tumor progression in ApcMin mice. Gastroenterology Dec 3 [Epub ahead of print] (2009). *
Mutlu GM, Mutlu EA, Bellmeyer A, Rubinstein I. Pulmonary adverse events of anti-tumor necrosis factor-alpha antibody therapy. Am. J. Med. 119: 639-646 (2006). *
Myers RP, Shaheen AA, Hubbard JN, Kaplan GG. Characteristics of patients with cirrhosis who are discharged from the hospital against medical advice. Clin. Gastroenterol. Hepatol. 7: 786-792 (2009).
Na JI, Kim JH, Park KC, Youn SW. Low-dose etanercept therapy in moderate to severe psoriasis in Korean. J. Dermatol. 35: 484-490 (2008).
Nadanaciva S, Dykens JA, Bernal A, Capaldi RA, Will Y. Mitochondrial impairment by PPAR agonists and statins identified via immunocaptured OXPHOS complex activities and respiration. Toxicol. Appl. Pharmacol. 223: 277-287 (2007). *
Nagai S, Nannya Y, Hangaishi A, Takahashi T, Kurokawa M. The race and dose of chemotherapy should be considered for optimizing maintenance therapy for acute promyelocytic leukemia. Leuk. Res. 33: 1427-1429 (2009).
Nagalla S, Ballas SK. Drugs for preventing red blood cell dehydration in people with sickle cell disease. Cochrane Database Syst. Rev. 1: CD003426 (2010).
Naganuma M, Funakoshi S, Sakuraba A, Takagi H, Inoue N, Ogata H, Iwao Y, Ishi H, Hibi T. Granulocytapheresis is useful as an alternative therapy in patients with steroid-refractory or -dependent ulcerative colitis. Inflamm. Bowel Dis. 10: 251-257 (2004). *
Nagaoka S, Nakamura M, Senuma A, Sekiguchi A. A clinical trial of low dose methotrexate therapy in patients with rheumatoid arthritis. Nihon Rinsho Meneki Gakkai Kaishi 28: 389-397 (2005).
Nagarkatti M, Rieder SA, Vakharia D, Nagarkatti PS. Evaluation of apoptosis in immunotoxicity testing. Methods Mol. Biol. 598: 241-257 (2010). *
Nagase K, Fukunaga K, Ohnishi K, Kusaka T, Matoba Y, Sawada K. Detection of specific IgE antibodies to nafamostat mesilate as an indication of possible adverse effects of leukocytapheresis using nafamostat mesilate as anticoagulant. Ther. Apher. 8: 45-51 (2004).
Nagy F, Molnar T, Szepes Z, Farkas K, Nyari T, Lonovics J. Efficacy of 6-mercaptopurine treatment after azathioprine hypersensitivity in inflammatory bowel disease. World J. Gastroenterol. 14: 4342-4346 (2008). *
Nahar IK, Shojania K, Marra CA, Alamgir AH, Anis AH. Infliximab treatment of rheumatoid arthritis and Crohn's disease. Ann. Pharmacother. 37: 1256-1265 (2003).
Naisbitt DJ, Britschgi M, Wong G, Farrell J, Depta JP, Chadwick DW, Pichler WJ, Pirmohamed M, Park BK. Hypersensitivity reactions to carbamazepine: characterization of the specificity, phenotype, and cytokine profile of drug-specific T cell clones. Mol. Pharmacol. 63: 732-741 (2003). *
Nakajima H, Munakata A, Yoshida Y. Adverse effects of sulfasalazine and treatment of ulcerative colitis with mesalazine. J. Gastroenterol. 30 Suppl. 8: 115-117 (1995).
Nakajima M, Komagata S, Fujiki Y, Kanada Y, Ebi H, Itoh K, Mukai H, Yokoi T, Minami H. Genetic polymorphisms of CYP2B6 affect the pharmacokinetics/pharmacodynamics of cyclophosphamide in Japanese cancer patients. Pharmacogenet. Genomics 17: 431-445 (2007).
Nakamura H, Masuko K, Yudoh K, Kato T, Nishioka K. Effects of celecoxib on human chondrocytes - enhanced production of chemokines. Clin. Exp. Rheumatol. 25: 11-16 (2007).
Nakamura YK, Omaye ST. Conjugated linoleic acid isomers' roles in the regulation of PPAR-gamma and NF-kappaB DNA binding and subsequent expression of antioxidant enzymes in human umbilical vein endothelial cells. Nutrition 25: 800-811 (2009). *
Nambi V, Ballantyne CM. Combination therapy with statins and omega-3 fatty acids. Am. J. Cardiol. 98: S34-S38 (2006). *
Nancy AL, Yehuda S. Chronic fatigue syndrome with autoantibodies - the result of an augmented adjuvant effect of hepatitis-B vaccine and silicone implant. Autoimmun. Rev. 8: 52-55 (2008).
Nash EF, Stephenson A, Ratjen F, Tullis E. Nebulized and oral thiol derivatives for pulmonary disease in cystic fibrosis. Cochrane Database Syst. Rev. 1: CD007168 (2009).
Nash RA, Bowen JD, McSweeney PA, Pavletic SZ, Maravilla KR, Park MS, Storek J, Sullivan KM, Al-Omaishi J, Corboy JR, DiPersio J, Georges GE, Gooley TA, Holmberg LA, LeMaistre CF, Ryan K, Openshaw H, Sunderhaus J, Storb R, Zunt J, Kraft GH. High-dose immunosuppressive therapy and autologous peripheral blood stem cell transplantation for severe multiple sclerosis. Blood 102: 2364-2372 (2003). *
Nathan DM, Iser JH, Gibson PR. A single center experience of methotrexate in the treatment of Crohn's disease and ulcerative colitis: a case for subcutaneous administration. J. Gastroenterol. Hepatol. 23: 954-958 (2008). *
Navaneethan U, Shen B. Hepatopancreatobiliary manifestations and complications associated with inflammatory bowel disease. Inflamm. Bowel Dis. Mar 2 [Epub ahead of print] (2010). *
Navaneethan U, Shen B. Pros and cons of antibiotic therapy for pouchitis. Expert Rev. Gastroenterol. Hepatol. 3: 547-559 (2009).
Navarro F, Hanauer SB. Treatment of inflammatory bowel disease: safety and tolerability issues. Am. J. Gastroenterol. 98: S18-S23 (2003). *
Navarro-Sarabia F, Ariza-Ariza R, Hernandez-Cruz B, Villanueva I. Adalimumab for treating rheumatoid arthritis. J. Rheumatol. 33: 1075-1081 (2006).
Naz H, Aslan V. Treatment of autoimmune thrombocytopenia in a case of chronic hepatitis C with ursodeoxycholic acid. J. Infect. Dev. Ctries. 3: 644-646 (2009). *
Neff GW, Ruiz P, Madariaga JR, Nishida S, Montalbano M, Meyer D, Levi DM, Tzakis AG, O'Brien CB. Sirolimus-associated hepatotoxicity in liver transplantation. Ann. Pharmacother. 38: 1593-1596 (2004).
Neghab M, Qu S, Bai CL, Caples J, Stacey NH. Raised concentration of serum bile acids following occupational exposure to halogenated solvents, 1,1,2-trichloro-1,2,2-trifluoroethane and trichloroethylene. Int. Arch. Occup. Environ. Health 70: 187-194 (1997). *
Nelson JL, Gillespie KM, Lambert NC, Stevens AM, Loubiere LS, Rutledge JC, Leisenring WM, Erickson TD, Yan Z, Mullarkey ME, Boespflug ND, Bingley PJ, Gale EA. Maternal microchimerism in peripheral blood in type 1 diabetes and pancreatic islet beta cell microchimerism. Proc. Natl. Acad. Sci. U.S.A. 104: 1637-1642 (2007). *
Nelson MR, Bacanu SA, Mosteller M, Li L, Bowman CE, Roses AD, Lai EH, Ehm MG. Genome-wide approaches to identify pharmacogenetic contributions to adverse drug reactions. Pharmacogenomics J. 9: 23-33 (2009).
Nelson MR, Bryc K, King KS, Indap A, Boyko AR, Novembre J, Briley LP, Maruyama Y, Waterworth DM, Waeber G, Vollenweider P, Oksenberg JR, Hauser SL, Stirnadel HA, Kooner JS, Chambers JC, Jones B, Mooser V, Bustamante CD, Roses AD, Burns DK, Ehm MG, Lai EH. The population reference sample, POPRES: a resource for population, disease, and pharmacological genetics research. Am. J. Hum. Genet. 83: 347-358 (2008). *
Nelson R. Non surgical therapy for anal fissure. Cochrane Database Syst. Rev. 4: CD003431 (2006). *
Nelson R. A systematic review of medical therapy for anal fissure. Dis. Colon Rectum 47: 422-431 (2004). *
Nelson RP Jr, Pascuzzi RM, Kessler K, Walsh LE, Faught PP, Ramanuja S, Pescovitz MD, Loehrer PJ Sr. Rituximab for the treatment of thymoma-associated and de novo myasthenia gravis: 3 cases and review. J. Clin. Neuromuscul. Dis. 10: 170-177 (2009).
Nencini C, Barberi L, Runci FM, Micheli L. Retinopathy induced by drugs and herbal medicines. Eur. Rev. Med. Pharmacol. Sci. 12: 293-298 (2008).
Nerome Y, Imanaka H, Nonaka Y, Takei S. Switching the therapy from etanercept to infliximab in a child with rheumatoid factor positive polyarticular juvenile idiopathic arthritis. Mod. Rheumatol. 17: 526-528 (2007). *
Nesse W, Spijkervat FK, Abbis F, Vissink A. Links between periodontal disease and general health. 2. Preterm birth, diabetes and autoimmune diseases. Ned. Tijdschr. Tandheelkd. 113: 191-196 (2006).
Nestel P. Metabolic syndrome: multiple candidate genes, multiple environmental factors - multiple syndromes? Int. J. Clin. Pract. Suppl. 134: 3-9 (2003).
Nettleton JA, Katz R. n-3 Long-chain polyunsaturated fatty acids in type 2 diabetes: a review. J. Am. Diet. Assoc. 105: 428-440 (2005). *
Netto EM, Takahashi D, de Fatima Paim de Oliveira M, Barbosa P, Ferraz N, Paixao A, Oyafuso LK, Bortoletto C, Matos D, Paixao M, da Silva AO, Badaro R. Phase II randomized, placebo-controlled trial of M. vaccae-derived protein (PVAC((R))) for the treatment of psoriasis. Vaccine 24: 5056-5063 (2006). *
Neuberger J. Chapter 32. Acute and chronic rejection of the liver allograft. In "Liver Immunology: Principles and Practice" (eds. Gershwin ME, Vierling JM, Manns MP), Humana Press Inc., Totowa, NJ, p. 423-431 (2007). *
Neumann UP, Guckelberger O, Langrehr JM, Lang M, Schmitz V, Theruvath T, Schonemann C, Menzel S, Klupp J, Neuhaus P. Impact of human leukocyte antigen matching in liver transplantation. Transplantation 75: 132-137 (2003).
Neurath MF, Wanitschke R, Peters M, Krummenauer F, Meyer zum Buschenfelde KH, Schlaak JF. Randomised trial of mycophenolate mofetil versus azathioprine for treatment of chronic active Crohn's disease. Gut 44: 625-628 (1999). *
Neuschwander-Tetri BA, Brunt EM, Wehmeier KR, Oliver D, Bacon BR. Improved nonalcoholic steatohepatitis after 48 weeks of treatment with the PPAR-gamma ligand rosiglitazone. Hepatology 38: 1008-10017 (2003). *
Neustadt J, Pieczenik SR. Medication-induced mitochondrial damage and disease. Mol. Nutr. Food Res. 52: 780-788 (2008). *
Newburger JW, Sleeper LA, McCrindle BW, Minich LL, Gersony W, Vetter VL, Atz AM, Li JS, Takahashi M, Baker AL, Colan SD, Mitchell PD, Klein GL, Sundel RP; Pediatric Heart Network Investigators. Randomized trial of pulsed corticosteroid therapy for primary treatment of Kawasaki disease. N. Engl. J. Med. 356: 663-675 (2007). *
Newton S, Owusu-Agyei S, Filteau S, Gyan T, Kirkwood BR. Vitamin A supplements are well tolerated with the pentavalent vaccine. Vaccine 26: 6608-6613 (2008). *
Ng KP, Cambridge G, Leandro MJ, Edwards JC, Ehrenstein M, Isenberg DA. B cell depletion therapy in systemic lupus erythematosus: long term follow up and predictors of response. Ann. Rheum. Dis. 66: 1259-1262 (2007). *
Ng PC. Use of oral erythromycin for the treatment of gastrointestinal dysmotility in preterm infants. Neonatology 95: 97-104 (2008).
Ng PC, Lee CH, Wong SP, Lam HS, Liu FY, So KW, Lee CY, Fok TF. High-dose oral erythromycin decreased the incidence of parenteral nutrition-associated cholestasis in preterm infants. Gastroenterology 132: 1726-1739 (2007). *
Nguyen BY, Reveille JD. Rheumatic manifestations associated with HIV in the highly active antiretroviral therapy era. Curr. Opin. Rheumatol. 21: 404-410 (2009).
Ni XS, Ouyang J, Zhu WH, Wang C, Chen B. Autologous hematopoietic stem cell transplantation for progressive multiple sclerosis: report of efficacy and safety at three yr of follow up in 21 patients. Clin. Transplant. 20: 485-489 (2006). *
Nichita C, Abdou AE, Maerten P, Herranz M, Mouret N, Thalmann C, Michetti PF, Dorta G. A single dose of intravenous esomeprazole decreases gastric secretion in healthy volunteers. Aliment. Pharmacol. Ther. 30: 1022-1029 (2009). *
Nielsen FH, Stoecker BJ. Boron and fish oil have different beneficial effects on strength and trabecular microarchitecture of bone. J. Trace Elem. Med. Biol. 23: 195-203 (2009).
Nielsen HI, Vinter H. Legionella pneumonia in patients treated with infliximab. Ugeskr. Laeger. 171: 247 (2009).
Nierkens S, Aalbers M, Bol M, Bleumink R, van Kooten P, Boon L, Pieters R. Differential requirement for CD28/CTLA-4-CD80/CD86 interactions in drug-induced type 1 and type 2 immune responses to trinitrophenyl-ovalbumin. J. Immunol. 175: 3707-3714 (2005). *
Nighland M, Grossman R. Tretinoin microsphere gel in facial acne vulgaris: a meta-analysis. J. Drugs Dermatol. 7: s2-s8 (2008).
Nikas SN, Alamanos Y, Voulgari PV, Pliakou XI, Papadopoulos CG, Drosos AA. Infliximab therapy in ankylosing spondylitis: an observational study. Ann. Rheum. Dis. 64: 940-942 (2005). *
Nikfar S, Rahimi R, Rezaie A, Abdollahi M. A meta-analysis of the efficacy of sulfasalazine in comparison with 5-aminosalicylates in the induction of improvement and maintenance of remission in patients with ulcerative colitis. Dig. Dis. Sci. 54: 1157-1170 (2009). *
Nikkels AF, Gillard P, Pierard GE. Etanercept in therapy multiresistant overlapping pityriasis lichenoides. J. Drugs Dermatol. 7: 990-992 (2008).
Nikolaus S, Rutgeerts P, Fedorak R, Steinhart AH, Wild GE, Theuer D, Mohrle J, Schreiber S. Interferon beta-1a in ulcerative colitis: a placebo controlled, randomised, dose escalating study. Gut 52: 1286-1290 (2003). *
Nikulina M, Habich C, Flohe SB, Scott FW, Kolb H. Wheat gluten causes dendritic cell maturation and chemokine secretion. J. Immunol. 173: 1925-1933 (2004).
Nilsson B, Korsgren O, Lambris JD, Ekdahl KN. Can cells and biomaterials in therapeutic medicine be shielded from innate immune recognition? Trends Immunol. 31: 32-38 (2010). *
Nilsson E, Larsson A, Olesen HV, Wejaker PE, Kollberg H. Good effect of IgY against Pseudomonas aeruginosa infections in cystic fibrosis patients. Pediatr. Pulmonol. 43: 892-899 (2008).
Nishie W, Sawamura D, Natsuga K, Shinkuma S, Goto M, Shibaki A, Ujiie H, Olasz E, Yancey KB, Shimizu H. A novel humanized neonatal autoimmune blistering skin disease model induced by maternally transferred antibodies. J. Immunol. 183: 4088-4093 (2009).
Nishiguchi S, Habu D, Kubo S, Shiomi S, Tatsumi N, Tamori A, Takeda T, Ogami M, Tanaka T, Hirohashi K, Kinoshita H, Nakatani T. Effects of alanine in patients with advanced primary biliary cirrhosis: preliminary report. Hepatol. Res. 25: 8-13 (2003). *
Nishimoto N, Miyasaka N, Yamamoto K, Kawai S, Takeuchi T, Azuma J. Long-term safety and efficacy of tocilizumab, an anti-interleukin-6 receptor monoclonal antibody, in monotherapy, in patients with rheumatoid arthritis (the STREAM study): evidence of safety and efficacy in a 5-year extension study. Ann. Rheum. Dis. 68: 1580-1584 (2009). *
Nishimoto N, Miyasaka N, Yamamoto K, Kawai S, Takeuchi T, Azuma J, Kishimoto T. Study of active controlled tocilizumab monotherapy for rheumatoid arthritis patients with an inadequate response to methotrexate (SATORI): significant reduction in disease activity and serum vascular endothelial growth factor by IL-6 receptor … Mod. Rheumatol. 19: 12-19 (2009). *
Nishioka C, Aoyama N, Maekawa S, Shirasaka D, Nakahara T, Tamura T, Fukagawa M, Umezu M, Abe T, Kasuga M. Leukocytapheresis therapy for steroid-naive patients with active ulcerative colitis: its clinical efficacy and adverse effects compared with those of conventional steroid therapy. J. Gastroenterol. Hepatol. 20: 1567-1571 (2005). *
Nissing MH, Hayashi PH. Right hepatic lobe donation adversely affects donor life insurability up to one year after donation. Liver Transpl. 11: 843-847 (2005). *
Niu MT, Davis DM, Ellenberg S. Recombinant hepatitis B vaccination of neonates and infants: emerging safety data from the Vaccine Adverse Event Reporting System. Pediatr. Infect. Dis. J. 15: 771-776 (1996).
Niu MT, Rhodes P, Salive M, Lively T, Davis DM, Black S, Shinefield H, Chen RT, Ellenberg SS. Comparative safety of two recombinant hepatitis B vaccines in children: data from the Vaccine Adverse Event Reporting System (VAERS) and Vaccine Safety Datalink (VSD). J. Clin. Epidemiol. 51: 503-510 (1998).
Niu MT, Salive ME, Ellenberg SS. Neonatal deaths after hepatitis B vaccine: the vaccine adverse event reporting system, 1991-1998. Arch. Pediatr. Adolesc. Med. 153: 1279-1282 (1999).
Nivitabishekam SN, Asad M, Prasad VS. Pharmacodynamic interaction of Momordica charantia with rosiglitazone in rats. Chem. Biol. Interact. 177: 247-253 (2009). *
No authors listed. Ursodeoxycholic acid: a second look. Primary biliary cirrhosis: dashed hopes. Prescrire. Int. 11: 67-69 (2002).
No authors listed. Systemic adverse effects of hepatitis B vaccines are rare. Prescrire. Int. 13: 218-223 (2004).
No authors listed. Quinine and cramp: uncertainty efficacy, major risks. Prescrire. Int. 9: 154-157 (2000).
No authors listed. Don't exaggerate the systemic adverse effects of hepatitis B vaccination: the vaccine benefits people at risk. Prescrire. Int. 9: 59-63 (2000).
No authors listed. Childhood psoriasis: often favorable outcome. Prescrire. Int. 18: 275 (2009).
No authors listed. Isotretinoin and intestinal damage. Prescrire. Int. 17: 154-156 (2008).
No authors listed. Celiac disease in children - modern diagnostic approach. Srp. Arh. Celok. Lek. 136 Suppl. 2: 152-157 (2008).
No authors listed. Ustekinumab: new drug. Suspicion of carcinogenicity: too great a risk for psoriasis patients. Prescrire. Int. 18: 202-204 (2009).
No authors listed. Fungal nail infections: diagnosis and management. Prescrire. Int. 18: 26-30 (2009).
No authors listed. Fewer adverse effects with doxycycline than with minocycline. Prescrire. Int. 18: 213 (2009).
No authors listed. Certolizumab pegol: new drug. As a last resort in Crohn's disease: continue to use other TNF alpha inhibitors. Prescrire. Int. 18: 108-110 (2009).
No authors listed. Infliximab: new indication. Severe Crohn's disease in children: many unknowns. Prescrire. Int. 17: 145 (2008).
Noel B. Lupus erythematosus and other autoimmune diseases related to statin therapy: a systematic review. J. Eur. Acad. Dermatol. Venereol. 21: 17-24 (2007). *
Nogid A, Pham DQ. Role of abatacept in the management of rheumatoid arthritis. Clin. Ther. 28: 1764-1778 (2006).
Noh JY, Asari T, Hamada N, Makino F, Ishikawa N, Abe Y, Ito K, Ito K. Frequency of appearance of myeloperoxidase-antineutrophil cytoplasmic antibody (MPO-ANCA) in Graves' disease patients treated with propylthiouracil and the relationship between MPO-ANCA and clinical manifestations. Clin. Endocrinol. (Oxf.) 54: 651-654 (2001). *
Noiles K, Vender R. Treatment of severe facial psoriasis with adalimumab. J. Drugs Dermatol. 7: 1165-1167 (2008).
Noiles K, Vender R. Biologic survival. J. Drugs Dermatol. 8: 329-333 (2009).
Nolan D. HLA-B*5701 screening prior to abacavir prescription: clinical and laboratory aspects. Crit. Rev. Clin. Lab. Sci. 46: 153-165 (2009).
Norambuena R X, Mallol J, Rios M G, Quevedo R F, Quezada L A. Therapeutic effects of the anti-tumor necrosis factor monoclonal antibody, infliximab, in four children with refractory juvenile idiopathic arthritis. Allergol. Immunopathol. (Madr.) 35: 52-56 (2007).
Norgard B, Pedersen L, Johnsen SP, Tarone RE, McLaughlin JK, Friis S, Sorensen HT. COX-2-selective inhibitors and the risk of upper gastrointestinal bleeding in high-risk patients with previous gastrointestinal diseases: a population-based case-control study. Aliment. Pharmacol. Ther. 19: 817-825 (2004). *
Norval M, Cullen AP, de Gruijl FR, Longstreth J, Takizawa Y, Lucas RM, Noonan FP, van der Leun JC. The effects on human health from stratospheric ozone depletion and its interactions with climate change. Photochem. Photobiol. Sci. 6: 232-251 (2007). *
Nos P, Domenech E. Apheresis in inflammatory bowel disease. Gastroenterol. Hepatol. 32: 509-518 (2009).
Novak J, Benilek M, Hilscherova K. Disruption of retinoid transport, metabolism and signaling by environmental pollutants. Environ. Int. 34: 898-913 (2008).
Novick NL, Lawson W, Schwartz IS. Bilateral nasal bone osteophytosis associated with short-term oral isotretinoin therapy for cystic acne vulgaris. Am. J. Med. 77: 736-739 (1984).
Nowak J. Role of HLA in hematopoietic SCT. Bone Marrow Transplant. 42 Suppl. 2: S71-S76 (2008).
Nua Ez-Cornejo C, Borra S-Blasco J, Gracia-Perez A, Rosique-Robles JD, Lopez-Camps V, Castera E, Abad FJ. Septic shock and community-acquired pneumonia associated with etanercept therapy. Int. J. Clin. Pharmacol. Ther. 46: 193-197 (2008).
Nunes AC, Amaro P, Mac as F, Cipriano A, Martins I, Rosa A, Pimenta I, Donato A, Freitas D. Fosinopril-induced prolonged cholestatic jaundice and pruritus: first case report. Eur. J. Gastroenterol. Hepatol. 13: 279-282 (2001).
Nurmohamed MT. Newer biological agents in the treatment of rheumatoid arthritis: do the benefits outweigh the risks? Drugs 69: 2035-2043 (2009).
O'Brien CE, Anderson PJ, Stowe CD. Use of the chloride channel activator lubiprostone for constipation in adults with cystic fibrosis: a case series. Ann. Pharmacother. Feb 23 [Epub ahead of print] (2010).
O'Connor PW, Li D, Freedman MS, Bar-Or A, Rice GP, Confavreux C, Paty DW, Stewart JA, Scheyer R; Teriflunomide Multiple Sclerosis Trial Group; University of British Columbia MS/MRI Research Group. A phase II study of the safety and efficacy of teriflunomide in multiple sclerosis with relapses. Neurology 66: 894-900 (2006).
O'Daly JA, Lezama R, Rodriguez PJ, Silva E, Indriago NR, Pena G, Colorado I, Gleason J, Rodriguez B, Acuna L, Ovalles T. Antigens from Leishmania amastigotes induced clinical remission of psoriasis. Arch. Dermatol. Res. 301: 1-13 (2009). *
O'Leary S, Lloyd ML, Shellam GR, Robertson SA. Immunization with recombinant murine cytomegalovirus expressing murine zona pellucida 3 causes permanent infertility in BALB/c mice due to follicle depletion and ovulation failure. Biol. Reprod. 79: 849-860 (2008). *
O'Neill JL, Kalb RE. Ustekinumab in the therapy of chronic plaque psoriasis. Biologics 3: 159-168 (2009). *
O'Reilly K, Bailey SJ, Lane MA. Retinoid-mediated regulation of mood: possible cellular mechanisms. Exp. Biol. Med. (Maywood) 233: 251-258 (2008). *
O'Sullivan S, Naot D, Callon K, Porteous F, Horne A, Wattie D, Watson M, Cornish J, Browett P, Grey A. Imatinib promotes osteoblast differentiation by inhibiting PDGFR signaling and inhibits osteoclastogenesis by both direct and stromal cell-dependent mechanisms. J. Bone Miner. Res. 22: 1679-1689 (2007). *
Oble DA, Mino-Kenudson M, Goldsmith J, Hodi FS, Seliem RM, Dranoff G, Mihm M, Hasserjian R, Lauwers GY. alpha-CTLA-4 mAb-associated panenteritis: a histologic and immunohistochemical analysis. Am. J. Surg. Pathol. 32: 1130-1137 (2008).
Obolonczyk L, Obolonczyk L, Siekierska-Hellmann M, Sworczak K. Side effects during interferon-alpha therapy of hepatitis C with special consideration of thyroid dysfunction. Postepy. Hig. Med. Dosw. (Online) 62: 309-321 (2008).
Ochi S, Taniguchi K, Nagashima M. Leflunomide-induced polymyositis in a patient with rheumatoid arthritis. Mod. Rheumatol. 19: 443-446 (2009). *
Ogawa Y, Duru EA, Ameredes BT. Role of IL-10 in the resolution of airway inflammation. Curr. Mol. Med. 8: 437-445 (2008).
Ogino S, Hashikura Y, Katsuyama Y, Ikegami T, Nakazawa Y, Urata K, Terada M, Miyagawa S, Kawasaki S. Conversion from tacrolimus to cyclosporine microemulsion therapy in liver transplant recipients. Transplant. Proc. 36: S299-S301 (2004). *
Ogino S, Nosho K, Baba Y, Kure S, Shima K, Irahara N, Toyoda S, Chen L, Kirkner GJ, Wolpin BM, Chan AT, Giovannucci EL, Fuchs CS. A cohort study of STMN1 expression in colorectal cancer: body mass index and prognosis. Am. J. Gastroenterol. 104: 2047-2056 (2009).
Ohlsson S, Wieslander J, Segelmark M. Circulating cytokine profile in anti-neutrophilic cytoplasmatic autoantibody-associated vasculitis: prediction of outcome? Mediators Inflamm. 13: 275-283 (2004). *
Ohnishi A, Murakami S, Akizuki S, Mochizuki J, Echizen H, Takagi I. In vivo metabolic activity of CYP2C19 and CYP3A in relation to CYP2C19 genetic polymorphism in chronic liver disease. J. Clin. Pharmacol. 45: 1221-1229 (2005). *
Ohno K, Masunaga Y, Ogawa R, Hashiguchi M, Ogata H. A systematic review of the clinical effectiveness of azathioprine in patients with ulcerative colitis. Yakugaku Zasshi 124: 555-560 (2004). *
Ohsawa M. Heavy metal-induced immunotoxicity and its mechanisms. Yakugaku Zasshi 129: 305-319 (2009).
Ohsawa T, Ohtsubo M. Hepatitis associated with allopurinol. Drug Intell. Clin. Pharm. 19: 431-433 (1985).
Ohtsuka T. Combinational effect of low-dose oral corticosteroid and mizoribine for ulcerative colitis in a patient with systemic sclerosis. J. Dermatol. 37: 71-74 (2010).
Ojetti V, Lauritano EC, Barbaro F, Migneco A, Ainora ME, Fontana L, Gabrielli M, Gasbarrini A. Rifaximin pharmacology and clinical implications. Expert Opin. Drug Metab. Toxicol. 5: 675-682 (2009).
Oka M, Fukuda M, Soda H. Anticancer drugs and ABC transporters. Gan To Kagaku Ryoho 32: 585-592 (2005).
Okada H, Takenaka R, Hiraoka S, Makidono C, Hori SI, Kato J, Okazaki H, Kawamoto H, Mizuno M, Shiratori Y. Centrifugal leukocytapheresis therapy for ulcerative colitis without concurrent corticosteroid administration. Ther. Apher. Dial. 10: 242-246 (2006). *
Okada Y, Nakamura K, Kodama T, Ueki K, Tsukada Y, Maezawa A, Tsukamoto N, Nojima Y, Ishizaki T, Horiuchi R, Yamamoto K. Thiopurine methyltransferase genotype and phenotype status in Japanese patients with systemic lupus erythematosus. Biol. Pharm. Bull. 28: 2117-2119 (2005). *
Okajima K. Regulation of inflammatory responses by activated protein C: the molecular mechanism(s) and therapeutic implications. Clin. Chem. Lab. Med. 42: 132-141 (2004).
Okamoto H, Yoshio T, Kaneko H, Yamanaka H. Inhibition of NF-kappaB signaling by fasudil as a potential therapeutic strategy for rheumatoid arthritis. Arthritis Rheum. 62: 82-92 (2009). *
Okey AB, Franc MA, Moffat ID, Tijet N, Boutros PC, Korkalainen M, Tuomisto J, Pohjanvirta R. Toxicological implications of polymorphisms in receptors for xenobiotic chemicals: the case of the aryl hydrocarbon receptor. Toxicol. Appl. Pharmacol. 207: S43-S51 (2005). *
Okino ST, Pookot D, Basak S, Dahiya R. Toxic and chemopreventive ligands preferentially activate distinct aryl hydrocarbon receptor pathways: implications for cancer prevention. Cancer Prev. Res. (Phila. Pa.) 2: 251-256 (2009).
Okoshi K, Kubo H, Nagayama S, Tabata C, Kadokawa Y, Hisamori S, Yonenaga Y, Fujimoto A, Mori A, Onodera H, Watanabe G, Sakai Y. All-trans-retinoic acid attenuates radiation-induced intestinal fibrosis in mice. J. Surg. Res. 150: 53-59 (2008).
Okubo H, Iwamoto M, Yoshio T, Okazaki H, Kato T, Bandoh M, Minota S. Rapidly aggravated Mycobacterium avium infection in a patient with rheumatoid arthritis treated with infliximab. Mod. Rheumatol. 15: 62-64 (2005).
Oldfield V, Dhillon S, Plosker GL. Tocilizumab: a review of its use in the management of rheumatoid arthritis. Drugs 69: 609-632 (2009).
Olin J, Schneider L. Galantamine for Alzheimer's disease. Cochrane Database Syst. Rev. 1: CD001747 (2001).
Olmedo Martin R, Jimenez Perez M, Marin Garcia D, Amo Trillo V, Perez-Olivares Jaen J, Romero Blasco B. Tacrolimus in the treatment of refractory moderate-to-severe inflammatory bowel disease. Gastroenterol. Hepatol. 29: 327-333 (2006).
Olsen NJ. Tailoring arthritis therapy in the wake of the NSAID crisis. N. Engl. J. Med. 352: 2578-2580 (2005). *
Olthof MR, Verhoef P. Effects of betaine intake on plasma homocysteine concentrations and consequences for health. Curr. Drug Metab. 6: 15-22 (2005). *
Omata M, Yoshida H, Toyota J, Tomita E, Nishiguchi S, Hayashi N, Iino S, Makino I, Okita K, Toda G, Tanikawa K, Kumada H. A large-scale, multicentre, double-blind trial of ursodeoxycholic acid in patients with chronic hepatitis C. Gut 56: 1747-1753 (2007). *
Omenn GS, Goodman GE, Thornquist MD, Balmes J, Cullen MR, Glass A, Keogh JP, Meyskens FL, Valanis B, Williams JH, Barnhart S, Hammar S. Effects of a combination of beta carotene and vitamin A on lung cancer and cardiovascular disease. N. Engl. J. Med. 334: 1150-1155 (1996).
Ong HT, Cheah JS. Statin alternatives or just placebo: an objective review of omega-3, red yeast rice and garlic in cardiovascular therapeutics. Chin. Med. J. (Engl.) 121: 1588-1594 (2008). *
Onoue M, Terada T, Kobayashi M, Katsura T, Matsumoto S, Yanagihara K, Nishimura T, Kanai M, Teramukai S, Shimizu A, Fukushima M, Inui K. UGT1A1*6 polymorphism is most predictive of severe neutropenia induced by irinotecan in Japanese cancer patients. Int. J. Clin. Oncol. 14: 136-142 (2009).
Onrust SV, Lamb HM. Infliximab: a review of its use in Crohn's disease and rheumatoid arthritis. BioDrugs 10: 397-422 (1998).
Ooka S, Maeda A, Ito H, Omata M, Yamada H, Ozaki S. Treatment of refractory retrobulbar granuloma with rituximab in a patient with ANCA-negative Wegener's granulomatosis: a case report. Mod. Rheumatol. 19: 80-83 (2009). *
Orbach H, Katz U, Sherer Y, Shoenfeld Y. Intravenous immunoglobulin: adverse effects and safe administration. Clin. Rev. Allergy Immunol. 29: 173-184 (2005).
Orfanos CE, Zouboulis CC, Almond-Roesler B, Geilen CC. Current use and future potential role of retinoids in dermatology. Drugs 53: 358-388 (1997).
Orlando A, Leandro G, Olivo M, Andriulli A, Cottone M. Radiofrequency thermal ablation vs. percutaneous ethanol injection for small hepatocellular carcinoma in cirrhosis: meta-analysis of randomized controlled trials. Am. J. Gastroenterol. 104: 514-524 (2009).
Orlando A, Mocciaro F, Civitavecchia G, Scimeca D, Cottone M. Minimizing infliximab toxicity in the treatment of inflammatory bowel disease. Dig. Liver Dis. 40 Suppl. 2: S236-S246 (2008).
Orlando R, Azzalini L, Orando S, Lirussi F. Bile acids for non-alcoholic fatty liver disease and/or steatohepatitis. Cochrane Database Syst. Rev. 1: CD005160 (2007). *
Ormarsdottir S, Mallmin H, Naessen T, Petren-Mallmin M, Broome U, Hultcrantz R, Loof L. An open, randomized, controlled study of transdermal hormone replacement therapy on the rate of bone loss in primary biliary cirrhosis. J. Intern. Med. 256: 63-69 (2004). *
Ornetti P, Chevillotte H, Zerrak A, Maillefert JF. Anti-tumour necrosis factor-alpha therapy for rheumatoid and other inflammatory arthropathies: update on safety in older patients. Drugs Aging 23: 855-860 (2006).
Ortega R, Gines P, Uriz J, Cardenas A, Calahorra B, De Las Heras D, Guevara M, Bataller R, Jimenez W, Arroyo V, Rodes J. Terlipressin therapy with and without albumin for patients with hepatorenal syndrome: results of a prospective, nonrandomized study. Hepatology 36: 941-948 (2002). *
Ortiz A, Yamauchi PS. A treatment strategy for psoriasis: transitioning from systemic therapy to biologic agents. Skinmed. 5: 285-288 (2006). *
Ortiz B, Wassef L, Shabrova E, Cordeddu L, Banni S, Quadro L. Hepatic retinol secretion and storage are altered by dietary conjugated linoleic acid (CLA): common and distinct actions of CLA c9,t11 and t10,c12 isomers. J. Lipid Res. 50: 2278-2289 (2009). *
Orvis AK, Wesson SK, Breza TS Jr, Church AA, Mitchell CL, Watkins SW. Mycophenolate mofetil in dermatology. J. Am. Acad. Dermatol. 60: 183-199 (2009).
Ostor AJ. Abatacept: a T-cell co-stimulation modulator for the treatment of rheumatoid arthritis. Clin. Rheumatol. 27: 1343-1353 (2008).
Otley A, Steinhart A, Otley A. Budesonide for induction of remission in Crohn's disease. Cochrane Database Syst. Rev. 4: CD000296 (2005). *
Ott J, Nouri K, Stogbauer L, Fischer EM, Lipovac M, Promberger R, Huber JC, Mayerhofer K. Ovarian tissue cryopreservation for non-malignant indications. Arch. Gynecol. Obstet. Sep 22 [Epub ahead of print] (2009).
Otte A. Drug trials in humans. Risks in the light of the London catastrophe. Internist (Berl.) 48: 636-641 (2007).
Ouakaa-Kchaou A, Gargouri D, Trojet S, Hefaiedh R, Elloumi H, Kochlef A, Kilani A, Romani M, Kharrat J, Ghorbel A. Retrobulbar optic neuritis associated with infliximab in a patient with Crohn's disease. Journal of Crohn's and Colitis 3: 131-133 (2009).
Oussalah A, Babouri A, Stancu L, Trouilloux I, Bensenane M, Boucekkine T, Bigard MA, Peyrin-Biroulet L. Adalimumab for Crohn's disease with intolerance or lost response to infliximab: a 3-year single centre experience. Aliment. Pharmacol. Ther. 29: 416-423 (2009). *
Ovetchkine P. Secondary effects of vaccinations. Arch. Pediatr. 8: 316-320 (2001).
Owens DW, Wilson NJ, Hill AJ, Rugg EL, Porter RM, Hutcheson AM, Quinlan RA, van Heel D, Parkes M, Jewell DP, Campbell SS, Ghosh S, Satsangi J, Lane EB. Human keratin 8 mutations that disturb filament assembly observed in inflammatory bowel disease patients. J. Cell Sci. 117: 1989-1999 (2004). *
Ozawa M, Terasaki PI, Castro R, Alberu J, Morales-Buenrostro L, Alvarez I, Toledo R, Alvez H, Monteiro M, Teixeira J, Campbell P, Ciszek M, Charron D, Gautreau C, Christiansen F, Langan L, Conca R, Grosse-Wilde H, Heinemann F, Kamoun M, Kobayashi T, et al. 14th International HLA and Immunogenetics Workshop Prospective Chronic Rejection Project: a three-year follow-up analysis. Clin. Transpl. 2007: 255-260 (2007).
Ozdemir O, Mete E, Catal F, Ozol D. Food intolerances and eosinophilic esophagitis in childhood. Dig. Dis. Sci. 54: 8-14 (2009). *
Ozolins M, Eady EA, Avery A, Cunliffe WJ, O'Neill C, Simpson NB, Williams HC. Randomised controlled multiple treatment comparison to provide a cost-effectiveness rationale for the selection of antimicrobial therapy in acne. Health Technol. Assess. 9: iii-212 (2005). *
Ozorio G, McGarity B, Bak H, Jordan AS, Lau H, Marshall C. Autoimmune hepatitis following infliximab therapy for ankylosing spondylitis. Med. J. Aust. 187: 524-526 (2007). *
P'ng SS, Hughes AS, Cooney JP. A case report of transfusion-related acute lung injury during plasma exchange therapy for thrombotic thrombocytopenia purpura. Ther. Apher. Dial. 12: 78-81 (2008).
Pacileo M, Cirillo P, De Rosa S, Ucci G, Petrillo G, D'Amore SM, Sasso L, Maietta P, Spagnuolo R, Chiariello M. The role of neopterin in cardiovascular disease. Monaldi Arch. Chest Dis. 68: 68-73 (2007).
Padanilam BJ, Prystowsky EN. New antiarrhythmic agents for the prevention and treatment of atrial fibrillation. J. Cardiovasc. Electrophysiol. 17: S62-S66 (2006).
Paghdal KV, Schwartz RA. Topical tar: back to the future. J. Am. Acad. Dermatol. 61: 294-302 (2009).
Pagnoux C, Mahr A, Hamidou MA, Boffa JJ, Ruivard M, Ducroix JP, Kyndt X, Lifermann F, Papo T, Lambert M, Le Noach J, Khellaf M, Merrien D, Puechal X, Vinzio S, Cohen P, Mouthon L, Cordier JF, Guillevin L; the French Vasculitis Study Group. Azathioprine or methotrexate maintenance for ANCA-associated vasculitis. N. Engl. J. Med. 359: 2790-2803 (2008). *
Pagotto U, Vanuzzo D, Vicennati V, Pasquali R. Pharmacological therapy of obesity. G. Ital. Cardiol. (Rome) 9: 83S-93S (2008).
Pallavicini FB, Caporali R, Sarzi-Puttini P, Atzeni F, Bazzani C, Gorla R, Marchesoni A, Favalli EG, Montecucco C. Tumour necrosis factor antagonist therapy and cancer development: analysis of the lorhen registry. Autoimmun. Rev. Jul 29 [Epub ahead of print] (2009).
Paller AS, Siegfried EC, Langley RG, Gottlieb AB, Pariser D, Landells I, Hebert AA, Eichenfield LF, Patel V, Creamer K, Jahreis A; Etanercept Pediatric Psoriasis Study Group. Etanercept treatment for children and adolescents with plaque psoriasis. N. Engl. J. Med. 358: 241-251 (2008). *
Palma J, Reyes H, Ribalta J, Hernandez I, Sandoval L, Almuna R, Liepins J, Lira F, Sedano M, Silva O, Toha D, Silva JJ. Ursodeoxycholic acid in the treatment of cholestasis of pregnancy: a randomized, double-blind study controlled with placebo. J. Hepatol. 27: 1022-1028 (1997). *
Palma J, Reyes H, Ribalta J, Iglesias J, Gonzalez M, Hernandez I, Alvarez C, Molina C, Danitz AM. Effects of ursodeoxycholic acid in patients with cholestasis of pregnancy. Rev. Med. Chil. 119: 169-171 (1991).
Palmieri O, Latiano A, Bossa F, Vecchi M, D'Incà R, Guagnozzi D, Tonelli F, Cucchiara S, Valvano MR, Latiano T, Andriulli A, Annese V. Sequential evaluation of thiopurine methyltransferase, inosine triphosphate pyrophosphatase, and HPRT1 genes polymorphisms to explain thiopurines' toxicity and efficacy. Aliment. Pharmacol. Ther. 26: 737-745 (2007). *
Paltiel M, Gober LM, Deng A, Mikdashi J, Alexeeva I, Saini SS, Gaspari AA. Immediate type I hypersensitivity response implicated in worsening injection site reactions to adalimumab. Arch. Dermatol. 144: 1190-1194 (2008). *
Pan SM, Dehler S, Ciurea A, Ziswiler HR, Gabay C, Finckh A; Swiss Clinical Quality Management Physicians. Comparison of drug retention rates and causes of drug discontinuation between anti-tumor necrosis factor agents in rheumatoid arthritis. Arthritis Rheum. 61: 560-568 (2009). *
Panaccione R; Canadian Consensus Group on the use of infliximab in Crohn's disease. Infliximab for the treatment of Crohn's disease: review and indications for clinical use in Canada. Can. J. Gastroenterol. 15: 371-375 (2001). *
Panagi S, Palka W, Korelitz BI, Taskin M, Lessnau KD. Diffuse alveolar hemorrhage after infliximab treatment of Crohn's disease. Inflamm. Bowel Dis. 10: 274-277 (2004). *
Panes J, Gomollon F, Taxonera C, Hinojosa J, Clofent J, Nos P. Crohn's disease: a review of current treatment with a focus on biologics. Drugs 67: 2511-2537 (2007).
Panes J, Guilera M, Ginard D, Hinojosa J, Gonzalez-Carro P, Gonzalez-Lara V, Varea V, Domenech E, Badia X. Treatment cost of ulcerative colitis. Is apheresis with Adacolumn((R)) cost-effective? Dig. Liver Dis. 39: 617-625 (2007).
Pang M, de la Monte SM, Longato L, Tong M, He J, Chaudhry R, Duan K, Ouh J, Wands JR. PPARdelta agonist attenuates alcohol-induced hepatic insulin resistance and improves liver injury and repair. J. Hepatol. 50: 1192-1201 (2009).
Panjala C, Talwalkar JA, Lindor KD. Risk of lymphoma in primary biliary cirrhosis. Clin. Gastroenterol. Hepatol. 5: 761-764 (2007).
Panteris V, Perdiou A, Tsirimpis V, Karamanolis DG. Acute coronary syndrome after infliximab therapy in a patient with Crohn's disease. World J. Gastroenterol. 12: 6235-6238 (2006). *
Panzer S. Novel approaches in management of immune thrombocytopenia. Thromb. Res. 123 Suppl. 2: S51-S55 (2009).
Paolazzi G, Peccatori S, Cavatorta FP, Morini A. A case of spontaneously recovering multifocal motor neuropathy with conduction blocks (MMNCB) during anti-TNF alpha therapy for ankylosing spondylitis. Clin. Rheumatol. 28: 993-995 (2009). *
Papadimitrakopoulou VA, Lee JJ, William WN Jr, Martin JW, Thomas M, Kim ES, Khuri FR, Shin DM, Feng L, Hong WK, Lippman SM. Randomized trial of 13-cis retinoic acid compared with retinyl palmitate with or without beta-carotene in oral premalignancy. J. Clin. Oncol. 27: 599-604 (2009).
Papageorgiou NP, Altman A, Shoenfeld Y. Inflammatory bowel disease: adverse effect of isotretinoin. Isr. Med. Assoc. J. 11: 505-506 (2009). *
Papaioannou A, Kennedy CC, Freitag A, Ioannidis G, O'Neill J, Webber C, Pui M, Berthiaume Y, Rabin HR, Paterson N, Jeanneret A, Matouk E, Villeneuve J, Nixon M, Adachi JD. Alendronate once weekly for the prevention and treatment of bone loss in Canadian adult cystic fibrosis patients (CFOS Trial). Chest 134: 794-800 (2008). *
Papakostas GI. Evidence for S-adenosyl-L-methionine (SAM-e) for the treatment of major depressive disorder. J. Clin. Psychiatry 70 Suppl. 5: 18-22 (2009).
Papanastasiou L, Vatalas IA, Koutras DA, Mastorakos G. Thyroid autoimmunity in the current iodine environment. Thyroid 17: 729-739 (2007).
Papas KA, Sontag MK, Pardee C, Sokol RJ, Sagel SD, Accurso FJ, Wagener JS. A pilot study on the safety and efficacy of a novel antioxidant rich formulation in patients with cystic fibrosis. J. Cyst. Fibros. 7: 60-67 (2008).
Papi C, Aratari A, Moretti A, Mangone M, Margagnoni G, Koch M, Capurso L. Oral beclomethasone dipropionate as an alternative to systemic steroids in mild to moderate ulcerative colitis not responding to aminosalicylates. Dig. Dis. Sci. Sep 5 [Epub ahead of print] (2009). *
Papp K, Okun M, Vender R. Adalimumab in the treatment of psoriasis: pooled efficacy and safety results from three pivotal studies. J. Cutan. Med. Surg. 13 Suppl. 2: S58-S66 (2009).
Papp KA. The safety of etanercept for the treatment of plaque psoriasis. Ther. Clin. Risk Manag. 3: 245-258 (2007). *
Papp KA. Monitoring biologics for the treatment of psoriasis. Clin. Dermatol. 26: 515-521 (2008).
Papp KA, Bressinck R, Fretzin S, Goffe B, Kempers S, Gordon KB, Caro I, Walicke PA, Wang X, Menter A; the Efalizumab Study Group. Safety of efalizumab in adults with chronic moderate to severe plaque psoriasis: a phase IIIb, randomized, controlled trial. Int. J. Dermatol. 45: 605-614 (2006). *
Papp KA, Camisa C, Stone SP, Caro I, Wang X, Compton P, Walicke PA, Gottlieb AB. Safety of efalizumab in patients with moderate to severe chronic plaque psoriasis: review of clinical data. Part II. J. Cutan. Med. Surg. 9: 313-323 (2005).
Papp KA, Ho V, Langley R, Lynde C, Poulin Y, Shear N, Toole J, Zip C. Strategies for optimizing treatment with efalizumab in moderate to severe psoriasis. J. Cutan. Med. Surg. 9 Suppl. 1: 26-32 (2006). *
Papp KA, Keystone EC, Shear NH. Mechanism of action, pharmacokinetics, and drug interactions of etanercept in dermatology. J. Cutan. Med. Surg. 11 Suppl. 1: S3-S13 (2007).
Papp KA, Langley RG, Lebwohl M, Krueger GG, Szapary P, Yeilding N, Guzzo C, Hsu MC, Wang Y, Li S, Dooley LT, Reich K; for the PHOENIX 2 study investigators. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2). Lancet 371: 1675-1684 (2008). *
Pares A, Caballeria L, Rodes J, Bruguera M, Rodrigo L, Garcia-Plaza A, Berenguer J, Rodriguez-Martinez D, Mercader J, Velicia R. Long-term effects of ursodeoxycholic acid in primary biliary cirrhosis: results of a double-blind controlled multicentric trial. UDCA-Cooperative Group from the Spanish Association for the Study of the Liver. J. Hepatol. 32: 561-566 (2000). *
Pares A, Cisneros L, Salmeron JM, Caballeria L, Mas A, Torras A, Rodes J. Extracorporeal albumin dialysis: a procedure for prolonged relief of intractable pruritus in patients with primary biliary cirrhosis. Am. J. Gastroenterol. 99: 1105-1110 (2004). *
Park JY, Pillinger MH. Interleukin-6 in the pathogenesis of rheumatoid arthritis. Bull. N.Y.U. Hosp. Jt. Dis. 65 Suppl. 1: S4-S10 (2007). *
Pasanen MK, Neuvonen M, Neuvonen PJ, Niemi M. SLCO1B1 polymorphism markedly affects the pharmacokinetics of simvastatin acid. Pharmacogenet. Genomics 16: 873-879 (2006).
Pascale E, Purcaro C, Passarelli E, Guglielmi R, Vestri AR, Passarelli F, Meco G. Genetic polymorphism of angiotensin-converting enzyme is not associated with the development of Parkinson's disease and of L-dopa-induced adverse effects. J. Neurol. Sci. 276: 18-21 (2009).
Pascucci RA. Use of nonsteroidal anti-inflammatory drugs and cyclooxygenase-2 (COX-2) inhibitors: indications and complications. J. Am. Osteopath. Assoc. 102: 487-489 (2002). *
Pascussi JM, Gerbal-Chaloin S, Drocourt L, Assenat E, Larrey D, Pichard-Garcia L, Vilarem MJ, Maurel P. Cross-talk between xenobiotic detoxication and other signalling pathways: clinical and toxicological consequences. Xenobiotica 34: 633-664 (2004).
Pashenkov M, Goess G, Wagner C, Hormann M, Jandl T, Moser A, Britten CM, Smolle J, Koller S, Mauch C, Tantcheva-Poor I, Grabbe S, Loquai C, Esser S, Franckson T, Schneeberger A, Haarmann C, Krieg AM, Stingl G, Wagner SN. Phase II trial of a Toll-like receptor 9-activating oligonucleotide in patients with metastatic melanoma. J. Clin. Oncol. 24: 5716-5724 (2006). *
Passier JL, Srivastava N, van Puijenbroek EP. Isotretinoin-induced inflammatory bowel disease. Neth. J. Med. 64: 52-54 (2006). *
Patel B, Schutte R, Sporns P, Doyle J, Jewel L, Fedorak RN. Potato glycoalkaloids adversely affect intestinal permeability and aggravate inflammatory bowel disease. Inflamm. Bowel Dis. 8: 340-346 (2002). *
Patel VK, Ghosh S. Certolizumab pegol in Crohn's disease. Drugs Today (Barc.) 44: 837-844 (2008).
Paterson BM, Lammers KM, Arrieta MC, Fasano A, Meddings JB. The safety, tolerance, pharmacokinetic and pharmacodynamic effects of single doses of AT-1001 in coeliac disease subjects: a proof of concept study. Aliment. Pharmacol. Ther. 26: 757-766 (2007). *
Patil JJ, O Donohoe B, Loyden CF, Shanahan D. Near fatal spontaneous hepatic rupture associated with anabolic androgenic steroid use: a case report. Br. J. Sports Med. 41: 462-463 (2007).
Pattullo V, Heathcote J. Hepatitis C and diabetes: one treatment for two diseases? Liver Int. 30: 356-364 (2010). *
Patzer II JF, Lopez RC, Zhu Y, Wang ZF, Mazariegos GV, Fung JJ. Bioartificial liver assist devices in support of patients with liver failure. Hepatobiliary Pancreat. Dis. Int. 1: 18-25 (2002). *
Paul KB, Hedge JM, Devito MJ, Crofton KM. Short-term exposure to triclosan decreases thyroxine in vivo via upregulation of hepatic catabolism in young Long-Evans rats. Toxicol. Sci. 113: 367-379 (2010). *
Pauli-Magnus C, Mikus G, Alscher DM, Kirschner T, Nagel W, Gugeler N, Risler T, Berger ED, Kuhlmann U, Mettang T. Naltrexone does not relieve uremic pruritus: results of a randomized, double-blind, placebo-controlled crossover study. J. Am. Soc. Nephrol. 11: 514-519 (2000). *
Pawellek I, Dokoupil K, Koletzko B. Prevalence of malnutrition in paediatric hospital patients. Clin. Nutr. 27: 72-76 (2008).
Pawlotsky JM. Therapy of hepatitis C: from empiricism to eradication. Hepatology 43: S207-S220 (2006). *
Pazirandeh S, Ling PR, Ollero M, Gordon F, Burns DL, Bistrian BR. Supplementation of arachidonic acid plus docosahexaenoic acid in cirrhotic patients awaiting liver transplantation: a preliminary study. JPEN J. Parenter. Enteral Nutr. 31: 511-516 (2007). *
Pearce DJ, Higgins KB, Stealey KH, Balkrishnan R, Crane MM, Camacho F, Fleischer Jr AB, Feldman SR. Adverse events from systemic therapies for psoriasis are common in clinical practice. J. Dermatolog. Treat. 17: 288-293 (2006).
Pearce DJ, Klinger S, Ziel KK, Murad EJ, Rowell R, Feldman SR. Low-dose acitretin is associated with fewer adverse events than high-dose acitretin in the treatment of psoriasis. Arch. Dermatol. 142: 1000-1004 (2006). *
Pedraz J, Dauden E, Perez-Gala S, Goiriz-Valdes R, Fernandez-Penas P, García-Diez A. Hidradenitis suppurativa. Response to treatment with infliximab. Actas Dermosifiliogr. 98: 325-331 (2007).
Pedraza-Sanchez S, Herrera-Barrios MT, Aldana-Vergara R, Neumann-Ordonez M, Gonzalez-Hernandez Y, Sada-Diaz E, de Beaucoudrey L, Casanova JL, Torres-Rojas M. Bacille Calmette-Guerin infection and disease with fatal outcome associated with a point mutation in the interleukin-12/interleukin-23 receptor beta-1 chain in two Mexican families. Int. J. Infect. Dis. Feb 18 [Epub ahead of print] (2010).
Pegorier JP. PPAR receptors and insulin sensitivity: new agonists in development. Ann. Endocrinol. (Paris) 66: 10-17 (2005).
Pellegrini M, Nicolay U, Lindert K, Groth N, Della Cioppa G. MF59-adjuvanted versus non-adjuvanted influenza vaccines: integrated analysis from a large safety database. Vaccine 27: 6959-6965 (2009).
Pellequer Y, Meissner Y, Ubrich N, Lamprecht A. Epithelial heparin delivery via microspheres mitigates experimental colitis in mice. J. Pharmacol. Exp. Ther. 321: 726-733 (2007). *
Pelletier SJ, Vanderwall K, Debroy MA, Englesbe MJ, Sung RS, Magee JC, Fontana RJ, Punch JD. Preliminary analysis of early outcomes of a prospective, randomized trial of complete steroid avoidance in liver transplantation. Transplant. Proc. 37: 1214-1216 (2005). *
Pena-Rossi C, Schreiber S, Golubovic G, Mertz-Nielsen A, Panes J, Rachmilewitz D, Shieh MJ, Simanenkov VI, Stanton D, Graffner H. Clinical trial: a multicentre, randomized, double-blind, placebo-controlled, dose-finding, phase II study of subcutaneous interferon-beta-la in moderately active ulcerative colitis. Aliment. Pharmacol. Ther. 28: 758-767 (2008). *
Pena-Rossi C, Schreiber S, Golubovic G, Mertz-Nielsen A, Panes J, Rachmilewitz D, Shieh MJ, Simanenkov VI, Stanton D, Graffner H. Clinical trial: a multicentre, randomized, double-blind, placebo-controlled, dose-finding, phase II study of subcutaneous interferon-beta-1a in moderately active ulcerative colitis. Aliment. Pharmacol. Ther. 28: 758-767 (2008). *
Pena-Sagredo JL, Farinas MC, Perez-Zafrilla B, Cruz-Valenciano A, Crespo M, Joven-Ibanez B, Riera E, Manero-Ruiz FJ, Chalmeta I, Hernandez MV, Rodríguez-Gomez M, Maiz O, Lopez R, Cobo T, Pita J, Carmona L, Gonzalez-Gay MA. Non-typhi Salmonella infection in patients with rheumatic diseases on TNF-alpha antagonist therapy. Clin. Exp. Rheumatol. 27: 920-925 (2009).
Pena-Sagredo JL, Hernandez MV, Fernandez-Llanio N, Gimenez-Ubeda E, Munoz-Fernandez S, Ortiz A, Gonzalez-Gay MA, Farinas MC. Listeria monocytogenes infection in patients with rheumatic diseases on TNF-alpha antagonist therapy: the Spanish Study Group experience. Clin. Exp. Rheumatol. 26: 854-859 (2008).
Penka M, Bulikova A, Smejkal P, Kissova J, Matyskova M, Gumulec J, Kralova S, Slechtova M, Chlupova G. Preparation of patients with haemostatic disorder for invasive medical interventions. Vnitr. Lek. 54: 632-637 (2008).
Penn R, Williams RX 3rd, Guha-Ray DK, Sawyers WG, Braun SL, Rains KT. An open-label, crossover study of the pharmacokinetics of Insoluble Drug Delivery(R)-MicroParticle fenofibrate in combination with atorvastatin, simvastatin, and extended-release niacin in healthy volunteers. Clin. Ther. 28: 45-54 (2006). *
Peppercorn MA. Sulfasalazine. Pharmacology, clinical use, toxicity, and related new drug development. Ann. Intern. Med. 101: 377-386 (1984).
Pereira C, Pimentel-Nunes P, Brandao C, Moreira-Dias L, Medeiros R, Dinis-Ribeiro M. COX-2 polymorphisms and colorectal cancer risk: a strategy for chemoprevention. Eur. J. Gastroenterol. Hepatol. Jan 13 [Epub ahead of print] (2010).
Pereira C, Tavares B, Carrapatoso I, Loureiro G, Faria E, Machado D, Chieira C. Low-dose intravenous gammaglobulin in the treatment of severe autoimmune urticaria. Allerg. Immunol. (Paris) 39: 237-242 (2007).
Pereira J, Hidalgo P, Ocqueteau M, Blacutt M, Marchesse M, Nien Y, Letelier L, Mezzano D. Glycoprotein Ib/IX complex is the target in rifampicin-induced immune thrombocytopenia. Br. J. Haematol. 110: 907-910 (2000). *
Perera LC, Tymms KE, Wilson BJ, Shadbolt B, Brook AS, Dorai Raj AK, Khoo KB. Etanercept in severe active rheumatoid arthritis: first Australian experience. Intern. Med. J. 36: 625-631 (2006). *
Peretz G, Link G, Pappo O, Bruck R, Ackerman Z. Effect of hepatic iron concentration reduction on hepatic fibrosis and damage in rats with cholestatic liver disease. World J. Gastroenterol. 12: 240-245 (2006). *
Perez OA, Patton T. Novel therapies for pemphigus vulgaris: an overview. Drugs Aging 26: 833-846 (2009).
Perez-Rojas JM, Bobadilla NA. Novel action of aldosterone in CsA nephrotoxicity. Rev. Invest. Clin. 57: 147-155 (2005).
Perkins JD, Levy AE, Duncan JB, Carithers RL Jr. Using root cause analysis to improve survival in a liver transplant program. J. Surg. Res. 129: 6-16 (2005). *
Peros E, Geroldi D, Bugatti S, Caporali R, Rossi P, Montecucco C, D'Angelo A, Emanuele E. Analysis of the apolipoprotein(a) size polymorphism in patients with systemic lupus erythematosus. Int. J. Mol. Med. 15: 661-665 (2005).
Pershadsingh HA. Dual peroxisome proliferator-activated receptor-alpha/gamma agonists in the treatment of type 2 diabetes mellitus and the metabolic syndrome. Treat. Endocrinol. 5: 89-99 (2006).
Pershadsingh HA. Treating the metabolic syndrome using angiotensin receptor antagonists that selectively modulate peroxisome proliferator-activated receptor-gamma. Int. J. Biochem. Cell. Biol. 38: 766-781 (2006). *
Pertuit D, Moulari B, Betz T, Nadaradjane A, Neumann D, Ismaili L, Refouvelet B, Pellequer Y, Lamprecht A. 5-Aminosalicylic acid bound nanoparticles for the therapy of inflammatory bowel disease. J. Control Release 123: 211-218 (2007).
Petermann I, Triggs CM, Huebner C, Han DY, Gearry RB, Barclay ML, Demmers PS, McCulloch A, Ferguson LR. Mushroom intolerance: a novel diet-gene interaction in Crohn's disease. Br. J. Nutr. 102: 506-508 (2009). *
Peternel S, Prpic-Massari L, Guina T, Novak S, Brajac I, Kastelan M. Treatment of severe psoriasis with infliximab: report of two cases. Acta Dermatovenerol. Croat. 17: 204-206 (2009).
Petersen AM, Plomgaard P, Fischer CP, Ibfelt T, Pedersen BK, van Hall G. Acute moderate elevation of TNF-alpha does not affect systemic and skeletal muscle protein turnover in healthy humans. J. Clin. Endocrinol. Metab. 94: 294-299 (2009). *
Peterson E, Stoebner A, Weatherill J, Kutscher E. Case of acute psychosis from herbal supplements. S. D. Med. 61: 173-177 (2008).
Petit E, Langouet S, Akhdar H, Nicolas-Nicolaz C, Guillouzo A, Morel F. Differential toxic effects of azathioprine, 6-mercaptopurine and 6-thioguanine on human hepatocytes. Toxicol. In Vitro 22: 632-642 (2008).
Petitpain N, Gambier N, Wahl D, Chary-Valckenaere I, Loeuille D, Gillet P; French Network of Pharmacovigilance Centers. Arterial and venous thromboembolic events during anti-TNF therapy: a study of 85 spontaneous reports in the period 2000-2006. Biomed. Mater. Eng. 19: 355-364 (2009).
Petkov T, Pehlivanov G, Grozdev I, Kavaklieva S, Tsankov N. Toxic epidermal necrolysis as a dermatological manifestation of drug hypersensitivity syndrome. Eur. J. Dermatol. 17: 422-427 (2007). *
Petropoulos IK, Vaudaux JD, Guex-Crosier Y. Anti-TNF-alpha therapy in patients with chronic non-infectious uveitis: the experience of Jules Gonin Eye Hospital. Klin. Monatsbl. Augenheilkd. 225: 457-461 (2008).
Peura DA, Metz DC, Dabholkar AH, Paris MM, Yu P, Atkinson SN. Safety profile of dexlansoprazole MR, a proton pump inhibitor with a novel dual delayed release formulation: global clinical trial experience. Aliment. Pharmacol. Ther. 30: 1010-1021 (2009). *
Peyrin-Biroulet L, Deltenre P, Ardizzone S, D'Haens G, Hanauer SB, Herfarth H, Lemann M, Colombel JF. Azathioprine and 6-mercaptopurine for the prevention of postoperative recurrence in Crohn's disease: a meta-analysis. Am. J. Gastroenterol. 104: 2089-2096 (2009). *
Peyrin-Biroulet L, Desreumaux P, Sandborn WJ, Colombel JF. Crohn's disease: beyond antagonists of tumour necrosis factor. Lancet 372: 67-81 (2008). *
Pezzone MA, Liang R, Fraser MO. A model of neural cross-talk and irritation in the pelvis: implications for the overlap of chronic pelvic pain disorders. Gastroenterology 128: 1953-1964 (2005). *
Pfohler C, Ugurel S. Cutaneous reactions to molecular targeted therapies. Hautarzt. 59: 814-820 (2008).
Pham CQ, Efros CB, Berardi RR. Cyclosporine for severe ulcerative colitis. Ann. Pharmacother. 40: 96-101 (2006).
Pham T, Fautrel B, Dernis E, Goupille P, Guillemin F, Le Loet X, Ravaud P, Claudepierre P, Miceli-Richard C, de Bandt M, Breban M, Maillefert JF, Masson C, Saraux A, Schaeverbeke T, Wendling D, Mariette X, Combe B. Recommendations of the French Society for Rheumatology regarding TNFalpha antagonist therapy in patients with ankylosing spondylitis or psoriatic arthritis: 2007 update. Joint Bone Spine 74: 638-646 (2007). *
Phan GQ, Weber JS, Sondak VK. CTLA-4 blockade with monoclonal antibodies in patients with metastatic cancer: surgical issues. Ann. Surg. Oncol. 15: 3014-3021 (2008). *
Phillips DI. External influences on the fetus and their long-term consequences. Lupus 15: 794-800 (2006).
Phillips EJ, Mallal SA. HLA and drug-induced toxicity. Curr. Opin. Mol. Ther. 11: 231-242 (2009).
Piccinni C, Sacripanti C, Poluzzi E, Motola D, Magro L, Moretti U, Conforti A, Montanaro N. Stronger association of drug-induced progressive multifocal leukoencephalopathy (PML) with biological immunomodulating agents. Eur. J. Clin. Pharmacol. Oct 17 [Epub ahead of print] (2009). *
Pierard GE, Pierard-Franchimont C, Paquet P, Quatresooz P. Spotlight on adapalene. Expert Opin. Drug Metab. Toxicol. 5: 1565-1575 (2009).
Pierard-Franchimont C, Devillers C, Paquet P, Quatresooz P, Nikkels AF, Pierard GE. First line dermatological emergencies. Rev. Med. Liege. 63: 710-714 (2008).
Pierini A, Mirabella S, Brunati A, Ricchiuti A, Franchello A, Salizzoni M. Mycophenolate mofetil monotherapy in liver transplantation. Transplant. Proc. 37: 2614-2615 (2005). *
Piesman M, Kozarek RA, Brandabur JJ, Pleskow DK, Chuttani R, Eysselein VE, Silverman WB, Vargo JJ 2nd, Waxman I, Catalano MF, Baron TH, Parsons WG 3rd, Slivka A, Carr-Locke DL. Improved oral intake after palliative duodenal stenting for malignant obstruction: a prospective multicenter clinical trial. Am. J. Gastroenterol. 104: 2404-2411 (2009). *
Pietszkowski NC, Carvalho GA, Souza HN, Werka CR Jr, Borazo LA, Graf H, Carvalho M. Antineutrophil cytoplasmic antibody (ANCA)-associated autoimmune disease induced by propylthiouracil. Arq. Bras. Endocrinol. Metabol. 51: 136-141 (2007).
Pijnenburg MW, Cransberg K, Wolff E, Bouquet J, Merkus PJ. Bronchiectasis in children after renal or liver transplantation: a report of five cases. Pediatr. Transplant. 8: 71-74 (2004).
Pillemer SR, Brennan MT, Sankar V, Leakan RA, Smith JA, Grisius M, Ligier S, Radfar L, Kok MR, Kingman A, Fox PC. Pilot clinical trial of dehydroepiandrosterone (DHEA) versus placebo for Sjogren's syndrome. Arthritis Rheum. 51: 601-604 (2004). *
Pillemer SR, Leakan RA, Sankar V, Manny J, Baum BJ, Smith J, Chaudhry U, Fox PC, Radfar L, Ligier S, Brennan MT. Prominent adverse effects of thalidomide in primary Sjogren's syndrome. Arthritis Rheum. 51: 505-506 (2004). *
Pincelli C, Henninger E, Casset-Semanaz F. The incidence of arthropathy adverse events in efalizumab-treated patients is low and similar to placebo and does not increase with long-term treatment: pooled analysis of data from Phase III clinical trials of efalizumab. Arch. Dermatol. Res. 298: 329-338 (2006). *
Pincus T, Luta G, Swearingen CJ. Efficacy of 1-4 mg per day of prednisone in patients with rheumatoid arthritis: a randomized, double-blind, placebo-controlled withdrawal clinical trial. Ann. Rheum. Dis. 68: 1715-1720 (2009). *
Pineyro-Lopez A, Pineyro-Garza E, Torres-Alanis O, Reyes-Araiza R, Gomez-Silva M, Waksman N, E Salazar-Leal M, Lujan-Rangel R. Evaluation of the bioequivalence of single 100-mg doses of two oral formulations of cyclosporin a microemulsion: a randomized, open-label, two-period crossover study in healthy adult male mexican volunteers. Clin. Ther. 29: 2049-2054 (2007).
Pinto AL, Chebli LA, Ribeiro MS, Pace FH, Moraes JP, do Amaral FJ Jr, Gaburri PD, Meirelles de Souza AF, Chebli JM. Azathioprine therapy in steroid-dependent patients with Crohn disease: results of a 10-year longitudinal follow-up study. Med. Sci. Monit. 15: PI19- PI26 (2009).
Pirgon O, Atabek ME, Sert A. Psoriasis following growth hormone therapy in a child. Ann. Pharmacother. 41: 157-160 (2007).
Pirmohamed M. Pharmacogenetics of idiosyncratic adverse drug reactions. Handb. Exp. Pharmacol. 196: 477-491 (2010). *
Pirmohamed M, Arbuckle JB, Bowman CE, Brunner M, Burns DK, Delrieu O, Dix LP, Twomey JA, Stern RS. Investigation into the multidimensional genetic basis of drug-induced Stevens-Johnson syndrome and toxic epidermal necrolysis. Pharmacogenomics 8: 1661-1691 (2007).
Pitarch G, Sanchez-Carazo JL, Mahiques L, Oliver V. Efficacy of etanercept in psoriatic patients previously treated with infliximab. Dermatology 216: 312-316 (2008).
Pitarch G, Sanchez-Carazo JL, Mahiques L, Perez-Ferriols MA, Fortea JM. Treatment of psoriasis with adalimumab. Clin. Exp. Dermatol. 32: 18-22 (2007). *
Plamondon S, Ng SC, Kamm MA. Thalidomide in luminal and fistulizing Crohn's disease resistant to standard therapies. Aliment. Pharmacol. Ther. 25: 557-567 (2007). *
Planinsic RM, van der Meer J, Testa G, Grande L, Candela A, Porte RJ, Ghobrial RM, Isoniemi H, Schelde PB, Erhardtsen E, Klintmalm G, Emre S. Safety and efficacy of a single bolus administration of recombinant factor VIIa in liver transplantation due to chronic liver disease. Liver Transpl. 11: 895-900 (2005). *
Pless RP. Recent differing expert opinions regarding the safety profile of hepatitis B vaccines: is there really a controversy? Expert Opin. Drug Saf. 2: 451-455 (2003).
Pleyer U, Ruokonen P, Schmidt N, Feist E, Hohne M, Stanojlovic S. Mycophenol acid in ocular automimmune disorders - can we optimise this therapy? Klin. Monatsbl. Augenheilkd. 225: 66-69 (2008).
Plosker GL, Figgitt DP. Rituximab: a review of its use in non-Hodgkin's lymphoma and chronic lymphocytic leukaemia. Drugs 63: 803-843 (2003).
Pockros PJ. Novel therapies in hepatitis C virus. Preface. Clin. Liver Dis. 13: xiii (2009). *
Pockros PJ, Schiff ER, Shiffman ML, McHutchison JG, Gish RG, Afdhal NH, Makhviladze M, Huyghe M, Hecht D, Oltersdorf T, Shapiro DA. Oral IDN-6556, an antiapoptotic caspase inhibitor, may lower aminotransferase activity in patients with chronic hepatitis C. Hepatology 46: 324-329 (2007). *
Poggioli G, Laureti S, Pierangeli F, Rizzello F, Ugolini F, Gionchetti P, Campieri M. Local injection of infliximab for the treatment of perianal Crohn's disease. Dis. Colon Rectum 48: 768-774 (2005). *
Poli G, Acerbi D, Pennini R, Soliani Raschini A, Corrado ME, Eichler HG, Eichler I. Clinical pharmacology study of Bramitob((R)), a tobramycin solution for nebulization, in comparison with Tobi((R)). Paediatr. Drugs 9 Suppl. 1: 3-9 (2007).
Polman CH, Kappos L, Dahlke F, Graf R, Beckmann K, Bogumil T, Pozzilli C, Thompson AJ. Interferon beta-1b treatment does not induce autoantibodies. Neurology 64: 996-1000 (2005).
Polman CH, O'Connor PW, Havrdova E, Hutchinson M, Kappos L, Miller DH, Phillips JT, Lublin FD, Giovannoni G, Wajgt A, Toal M, Lynn F, Panzara MA, Sandrock AW; AFFIRM Investigators. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N. Engl. J. Med. 354: 899-910 (2006). *
Polyzos SA, Anastasilakis AD, Efstathiadou Z, Litsas I, Kita M, Panagiotou A, Papatheodorou A, Arsos G, Moralidis E, Barmpalios G, Zafeiriadou E, Triantafillidou E, Makrigiannaki E, Terpos E. Serum homocysteine, folate and vitamin B(12) in patients with Paget's disease of bone: the effect of zoledronic acid. J. Bone Miner. Metab. Oct 21 [Epub ahead of print] (2009). *
Pondugula SR, Dong H, Chen T. Phosphorylation and protein-protein interactions in PXR-mediated CYP3A repression. Expert Opin. Drug Metab. Toxicol. 5: 861-873 (2009).
Ponseti JM, Gamez J, Azem J, Manuel LC, Vilallonga R, Armengol M. Tacrolimus for myasthenia gravis: a clinical study of 212 patients. Ann. N. Y. Acad. Sci. 1132: 254-263 (2008). *
Pontikaki I, Gerloni V, Gattinara M, Luriati A, Salmaso A, De Marco G, Teruzzi B, Valcamonica E, Fantini F. Side effects of anti-TNFalpha therapy in juvenile idiopathic arthritis. Reumatismo 58: 31-38 (2006).
Poo JL, Gongora J, Sanchez-Avila F, Aguilar-Castillo S, Garcia-Ramos G, Fernandez-Zertuche M, Rodriguez-Fragoso L, Uribe M. Efficacy of oral L-ornithine-L-aspartate in cirrhotic patients with hyperammonemic hepatic encephalopathy. Results of a randomized,lactulose-controlled study. Ann. Hepatol. 5: 281-288 (2006). *
Poole P, Black PN. Mucolytic agents for chronic bronchitis or chronic obstructive pulmonary disease. Cochrane Database Syst. Rev. 2: CD001287 (2010).
Popa C, Leandro MJ, Cambridge G, Edwards JC. Repeated B lymphocyte depletion with rituximab in rheumatoid arthritis over 7 yrs. Rheumatology (Oxford) 46: 626-630 (2007). *
Pope JE. The diagnosis and treatment of Raynaud's phenomenon: a practical approach. Drugs 67: 517-525 (2007).
Popov I, Li M, Zheng X, Sun H, Zhang X, Feng B, Vladau C, Zhong R, Garcia B, Strejan G, Inman RD, Min WP, Ichim TE, Suzuki M. Preventing autoimmune arthritis using antigen-specific immature dendritic cells: a novel tolerogenic vaccine. Arthritis Res. Ther. 8: R141 (2006). *
Poppitt SD, Howe CA, Lithander FE, Silvers KM, Lin RB, Croft J, Ratnasabapathy Y, Gibson RA, Anderson CS. Effects of moderate-dose omega-3 fish oil on cardiovascular risk factors and mood after ischemic stroke: a randomized, controlled trial. Stroke 40: 3485-3492 (2009).
Post SM, Duez H, Gervois PP, Staels B, Kuipers F, Princen HM. Fibrates suppress bile acid synthesis via peroxisome proliferator-activated receptor-alpha-mediated downregulation of cholesterol 7alpha-hydroxylase and sterol 27-hydroxylase expression. Arterioscler. Thromb. Vasc. Biol. 21: 1840-1845 (2001). *
Post-White J, Ladas EJ, Kelly KM. Advances in the use of milk thistle (Silybum marianum). Integr. Cancer Ther. 6: 104-109 (2007). *
Poulin Y, Papp K, Bissonnette R, Barber K, Kerrouche N, Villemagne H. Clobetasol propionate shampoo 0.05% is efficacious and safe for long-term control of moderate scalp psoriasis. J. Dermatolog. Treat. Feb 4 [Epub ahead of print] (2010).
Poupardin C, Lemann M, Gendre JP, Sabate JM, Marteau P, Chaussade S, Delchier JC, Bouhnik Y, Chaput JC, Poupon R, Soule JC, Benhamou Y, Grange JD, Coffin B. Efficacy of infliximab in Crohn's disease. Results of a retrospective multicenter study with a 15-month follow-up. Gastroenterol. Clin. Biol. 30: 247-252 (2006). *
Poupeney S, Dray X, Reignier S, Vahedi K, Alhenc M, Belluci S, Marteau P. Decrease in factor V activity: a new adverse effect of purine analogs in inflammatory bowel diseases? Inflamm. Bowel Dis. 14: 1024-1025 (2008). *
Poupon R. Treatment of primary biliary cirrhosis and overlap syndromes: current standards. Falk Symposium 142: GASTROENTEROLOGY WEEK FREIBURG 2004 (Part I) AUTOIMMUNE LIVER DISEASE, Freiburg (Germany), October 12 - 13, 2004, pp. 77-78 (2004). *
Poupon RE, Balkau B, Eschwege E, Poupon R. A multicenter, controlled trial of ursodiol for the treatment of primary biliary cirrhosis. UDCA-PBC Study Group. N. Engl. J. Med. 324: 1548-1554 (1991).
Poupon RE, Huet PM, Poupon R, Bonnand AM, Nhieu JT, Zafrani ES. A randomized trial comparing colchicine and ursodeoxycholic acid combination to ursodeoxycholic acid in primary biliary cirrhosis. UDCA-PBC Study Group. Hepatology 24: 1098-1103 (1996). *
Poveda-Roda R, Bagan JV, Jimenez-Soriano Y, Diaz-Fernandez JM, Gavalda-Esteve C. Retinoids and proliferative verrucous leukoplakia (PVL). A preliminary study. Med. Oral Patol. Oral Cir. Bucal. Aug 13 [Epub ahead of print] (2009).
Powell RJ. Thalidomide: current uses. BioDrugs 11: 409-416 (1999).
Power TE, Adams PC. Psychosocial impact of C282Y mutation testing for hemochromatosis. Genet. Test. 5: 107-110 (2001).
Prandota J. The importance of Toxoplasma gondii infection in diseases presenting with headaches. Headaches and aseptic meningitis may be manifestations of the Jarisch-Herxheimer reaction. Int. J. Neurosci. 119: 2144-2182 (2009).
Prasad AS. The role of zinc in gastrointestinal and liver disease. Clin. Gastroenterol. 12: 713-741 (1983).
Prasad AS. Clinical manifestations of zinc deficiency. Annu. Rev. Nutr. 5: 341-363 (1985). *
Prasad AS. Zinc deficiency in human subjects. Prog. Clin. Biol. Res. 129: 1-33 (1983).
Prasad AS. Zinc in human health: effect of zinc on immune cells. Mol. Med. 14: 353-357 (2008). *
Pratt CM, Reiffel JA, Ellenbogen KA, Naccarelli GV, Kowey PR. Efficacy and safety of prescription omega-3-acid ethyl esters for the prevention of recurrent symptomatic atrial fibrillation: a prospective study. Am. Heart J. 158: 163-169.e1-e3 (2009).
Prefontaine E, Macdonald JK, Sutherland LR. Azathioprine or 6-mercaptopurine for induction of remission in Crohn's disease. Cochrane Database Syst. Rev. 4: CD000545 (2009).
Prefontaine E, Sutherland LR, Macdonald JK, Cepoiu M. Azathioprine or 6-mercaptopurine for maintenance of remission in Crohn's disease. Cochrane Database Syst. Rev. 1: CD000067 (2009).
Prescott WA Jr, Johnson CE. Antiinflammatory therapies for cystic fibrosis: past, present, and future. Pharmacotherapy 25: 555-573 (2005).
Present DH, Rutgeerts P, Targan S, Hanauer SB, Mayer L, van Hogezand RA, Podolsky DK, Sands BE, Braakman T, DeWoody KL, Schaible TF, van Deventer SJ. Infliximab for the treatment of fistulas in patients with Crohn's disease. N. Engl. J. Med. 340: 1398-1405 (1999). *
Preuss F, Tang Y, Laposky AD, Arble D, Keshavarzian A, Turek FW. Adverse effects of chronic circadian desynchronization in animals in a "challenging" environment. Am. J. Physiol. Regul. Integr. Comp. Physiol. 295: R2034-R2040 (2008). *
Prey S, Paul C. Effect of folic or folinic acid supplementation on methotrexate-associated safety and efficacy in inflammatory disease: a systematic review. Br. J. Dermatol. 160: 622-628 (2009). *
Priest VL, Begg EJ, Gardiner SJ, Frampton CM, Gearry RB, Barclay ML, Clark DW, Hansen P. Pharmacoeconomic analyses of azathioprine, methotrexate and prospective pharmacogenetic testing for the management of inflammatory bowel disease. Pharmacoeconomics 24: 767-781 (2006).
Prignano F, Zanieri F, Mokhtarzadeh S, Lotti T. Efalizumab-induced severe thrombocytopenia can be resolved. Biologics 2: 923-927 (2008). *
Prince M, Christensen E, Gluud C. Glucocorticosteroids for primary biliary cirrhosis. Cochrane Database Syst. Rev. 2: CD003778 (2005). *
Prince MI, Mitchison HC, Ashley D, Burke DA, Edwards N, Bramble MG, James OF, Jones DE. Oral antioxidant supplementation for fatigue associated with primary biliary cirrhosis: results of a multicentre, randomized, placebo-controlled, cross-over trial. Aliment. Pharmacol. Ther. 17: 137-143 (2003). *
Pritchard C, Nadarajah K. Tumour necrosis factor alpha inhibitor treatment for sarcoidosis refractory to conventional treatments: a report of five patients. Ann. Rheum. Dis. 63: 318-320 (2004). *
Prommer E. Modafinil: is it ready for prime time? J. Opioid Manag. 2: 130-136 (2006).
Proudman SM, Keen HI, Stamp LK, Lee AT, Goldblatt F, Ayres OC, Rischmueller M, James MJ, Hill CL, Caughey GE, Cleland LG. Response-driven combination therapy with conventional disease-modifying antirheumatic drugs can achieve high response rates in early rheumatoid arthritis with minimal glucocorticoid and nonsteroidal anti-inflammatory drug use. Semin. Arthritis Rheum. 37: 99-111 (2007). *
Pruitt R, Hanson J, Safdi M, Wruble L, Hardi R, Johanson J, Koval G, Riff D, Winston B, Cross A, Doty P, Johnson LK. Balsalazide is superior to mesalamine in the time to improvement of signs and symptoms of acute mild-to-moderate ulcerative colitis. Am. J. Gastroenterol. 97: 3078-3086 (2002). *
Pruthi RK, Mathew P, Valentino LA, Sumner MJ, Seremetis S, Hoots WK; on behalf of the NovoSeven in Surgery Study Investigators. Haemostatic efficacy and safety of bolus and continuous infusion of recombinant factor VIIa are comparable in haemophilia patients with inhibitors undergoing major surgery. Results from an open-label, randomized, multicenter trial. Thromb. Haemost. 98: 726-732 (2007).
Pryce G, Baker D. Control of spasticity in a multiple sclerosis model is mediated by CB(1), not CB(2), cannabinoid receptors. Br. J. Pharmacol. 150: 519-525 (2007). *
Psaltopoulou T, Kyrozis A, Stathopoulos P, Trichopoulos D, Vassilopoulos D, Trichopoulou A. Diet, physical activity and cognitive impairment among elders: the EPIC-Greece cohort (European Prospective Investigation into Cancer and Nutrition). Public Health Nutr. 11: 1054-1062 (2008). *
Pucino F Jr, Harbus PT, Goldbach-Mansky R. Use of biologics in rheumatoid arthritis: where are we going? Am. J. Health Syst. Pharm. 63: S19-S41 (2006).
Puig L. Infliximab: patients selection. Actas Dermosifiliogr. 99 Suppl. 4: 23-29 (2008).
Puig L, Barco D, Alomar A. Treatment of psoriasis with anti-TNF drugs during pregnancy: case report and review of the literature. Dermatology Nov 25 [Epub ahead of print] (2009).
Puig L, Carrascosa JM, Dauden E, Sanchez-Carazo JL, Ferrandiz C, Sanchez-Regana M, Garcia-Bustinduy M, Bordas X, Moreno JC, Hernanz JM, Laguarda S, García-Patos V; Grupo Espanol de Psoriasis de la Academia Espanola de Dermatología y Venereología. Spanish evidence-based guidelines on the treatment of moderate-to-severe psoriasis with biologic agents. Actas Dermosifiliogr. 100: 386-413 (2009).
Puig L, Roe E, Garcia-Navarro X, Corella F, Alomar A. Efalizumab treatment of psoriasis vulgaris: a cohort study in outpatient clinical practice. Clin. Exp. Dermatol. 34: 469-475 (2009). *
Puri BK. Long-chain polyunsaturated fatty acids and the pathophysiology of myalgic encephalomyelitis (chronic fatigue syndrome). J. Clin. Pathol. 60: 122-124 (2007). *
Putschky N, Pott HG, Kuipers JG, Zeidler H, Hammer M, Wollenhaupt J. Comparing 10-day and 4-month doxycycline courses for treatment of Chlamydia trachomatis-reactive arthritis: a prospective, double-blind trial. Ann. Rheum. Dis. 65: 1521-1524 (2006). *
Qasim W, Gaspar HB, Thrasher AJ. Progress and prospects: gene therapy for inherited immunodeficiencies. Gene Ther. 16: 1285-1291 (2009).
Qin Y, Wu X, Huang W, Gong G, Li D, He Y, Zhao Y. Acute toxicity and sub-chronic toxicity of steroidal saponins from Dioscorea zingiberensis C.H. Wright in rodents. J. Ethnopharmacol. 126: 543-550 (2009).
Qing H, Tian YS, Fan JM, Tang BY, Niu HQ, Lu JY. Meridian three-combined therapy for treatment of ordinary psoriasis: a multi-center randomized controlled study. Zhongguo Zhen Jiu 29: 181-184 (2009).
Quaglia M, Stratta P. Idiopathic membranous nephropathy: management strategies. Drugs 69: 1303-1317 (2009).
Quiros JA, Heyman MB, Pohl JF, Attard TM, Pieniaszek HJ, Bortey E, Walker K, Forbes WP. Safety, efficacy, and pharmacokinetics of balsalazide in pediatric patients with mild-to-moderate active ulcerative colitis: results of a randomized, double-blind study. J. Pediatr. Gastroenterol. Nutr. 49: 571-579 (2009).
R Ansari A, Patel N, Sanderson J, O'Donohue J, Duley JA, J Florin TH. Low dose azathioprine or 6-mercaptopurine in combination with allopurinol can bypass many adverse drug reactions in patients with inflammatory bowel disease. Aliment. Pharmacol. Ther. 31: 640-647 (2010). *
Rachmilewitz D. Coated mesalazine (5-aminosalicylic acid) versus sulphasalazine in the treatment of active ulcerative colitis: a randomised trial. BMJ 298: 82-86 (1989). *
Rademaker M. Do women have more adverse drug reactions? Am. J. Clin. Dermatol. 2: 349-351 (2001).
Radonjic M, van Erk MJ, Pasman WJ, Wortelboer HM, Hendriks HF, van Ommen B. Effect of body fat distribution on the transcription response to dietary fat interventions. Genes Nutr. 4: 143-149 (2009). *
Radwan P, lupina T, Radwan-Kwiatek K, Milanowski J. Pulmonary complications in patient with ulcerative colitis, treated with 5-aminosalicylic preparations. Pneumonol. Alergol. Pol. 74: 224-226 (2006).
Raedler A, Behrens C, Bias P. Mesalazine (5-aminosalicylic acid) micropellets show similar efficacy and tolerability to mesalazine tablets in patients with ulcerative colitis - results from a randomized-controlled trial. Aliment. Pharmacol. Ther. 20: 1353-1363 (2004). *
Raghu G, Brown KK, Costabel U, Cottin V, du Bois RM, Lasky JA, Thomeer M, Utz JP, Khandker RK, McDermott L, Fatenejad S. Treatment of idiopathic pulmonary fibrosis with etanercept: an exploratory, placebo-controlled trial. Am. J. Respir. Crit. Care Med. 178: 948-955 (2008). *
Rahier JF, Rahier J, Leclercq I, Geubel AP. Severe acute cholestatic hepatitis with prolonged cholestasis and bile-duct injury following atorvastatin therapy: a case report. Acta Gastroenterol. Belg. 71: 318-320 (2008).
Rahimi R, Mozaffari S, Abdollahi M. On the use of herbal medicines in management of inflammatory bowel diseases: a systematic review of animal and human studies. Dig. Dis. Sci. 54: 471-480 (2009). *
Rahimi R, Nikfar S, Rezaie A, Abdollahi M. Comparison of mesalazine and balsalazide in induction and maintenance of remission in patients with ulcerative colitis: a meta-analysis. Dig. Dis. Sci. 54: 712-721 (2009). *
Rahman MU, Strusberg I, Geusens P, Berman A, Yocum D, Baker D, Wagner C, Han J, Westhovens R. Double-blinded infliximab dose escalation in patients with rheumatoid arthritis. Ann. Rheum. Dis. 66: 1233-1238 (2007). *
Rahme E, Barkun A, Nedjar H, Gaugris S, Watson D. Hospitalizations for upper and lower GI events associated with traditional NSAIDs and acetaminophen among the elderly in Quebec, Canada. Am. J. Gastroenterol. 103: 872-882 (2008). *
Rajakulendran S, Deighton C. Adverse dermatological reactions in rheumatoid arthritis patients treated with etanercept, an anti-TNFalpha drug. Curr. Drug Saf. 1: 259-264 (2006).
Raje D, Scott M, Irvine T, Walshe M, Mukhtar H, Oshowo A, Ingham Clark C. Telephonic management of rectal bleeding in young adults - a prospective randomized controlled trial. Colorectal Dis. 9: 86-89 (2007). *
Rallis E, Korfitis C, Stavropoulou E, Papaconstantis M. Onset of palmoplantar pustular psoriasis while on adalimumab for psoriatic arthritis: a 'class effect' of TNF-alpha antagonists or simply an anti-psoriatic treatment adverse reaction? J. Dermatolog. Treat. Jan 1 [Epub ahead of print] (2009).
Rallis E, Verros C, Karanikola E, Valaskatzi A, Papaconstantis M. Exacerbation of psoriasis under efalizumab therapy. J. Cutan. Med. Surg. 13: 106-109 (2009).
Ram R, Ben-Bassat I, Shpilberg O, Polliack A, Raanani P. The late adverse events of rituximab therapy - rare but there! Leuk. Lymphoma. 50: 1083-1095 (2009).
Ram R, Bonstein L, Gafter-Gvili A, Ben-Bassat I, Shpilberg O, Raanani P. Rituximab-associated acute thrombocytopenia: an under-diagnosed phenomenon. Am. J. Hematol. 84: 247-250 (2009).
Ramachandran J, Eapen C, Kang G, Abraham P, Hubert DD, Kurian G, Hephzibah J, Mukhopadhya A, Chandy GM. Hepatitis E superinfection produces severe decompensation in patients with chronic liver disease. J. Gastroenterol. Hepatol. 19: 134-138 (2004). *
Rambaldi A, Gluud C. Colchicine for alcoholic and non-alcoholic liver fibrosis and cirrhosis. Cochrane Database Syst. Rev. 3: CD002148 (2001). *
Rambaldi A, Gluud C. S-Adenosyl-L-methionine for alcoholic liver diseases. Cochrane Database Syst. Rev. 4: CD002235 (2001). *
Rambaldi A, Gluud C. Colchicine for alcoholic and non-alcoholic liver fibrosis and cirrhosis. Cochrane Database Syst. Rev. 2: CD002148 (2005). *
Rambaldi A, Jacobs BP, Iaquinto G, Gluud C. Milk thistle for alcoholic and/or hepatitis B or C liver diseases - a systematic Cochrane hepato-biliary group review with meta-analyses of randomized clinical trials. Am. J. Gastroenterol. 100: 2583-2591 (2005). *
Ramos-Casals M, Brito-Zeron P. Emerging biological therapies in primary Sjogren's syndrome. Rheumatology (Oxford) 46: 1389-1396 (2007). *
Ramos-Casals M, Soto M, Cuadrado M, Khamashta M. Rituximab in systemic lupus erythematosus. A systematic review of off-label use in 188 cases. Lupus 18: 767-776 (2009). *
Rampal P, Moore N, Van Ganse E, Le Parc JM, Wall R, Schneid H, Verriere F. Gastrointestinal tolerability of ibuprofen compared with paracetamol and aspirin at over-the-counter doses. J. Int. Med. Res. 30: 301-308 (2002).
Ransford RA, Langman MJ. Sulphasalazine and mesalazine: serious adverse reactions re-evaluated on the basis of suspected adverse reaction reports to the Committee on Safety of Medicines. Gut 51: 536-539 (2002). *
Rao SS, Cann PA, Holdsworth CD. Clinical experience of the tolerance of mesalazine and olsalazine in patients intolerant of sulphasalazine. Scand. J. Gastroenterol. 22: 332-336 (1987).
Rao SS, Dundas SA, Holdsworth CD, Cann PA, Palmer KR, Corbett CL. Olsalazine or sulphasalazine in first attacks of ulcerative colitis? A double blind study. Gut 30: 675-679 (1989). *
Rao SS, Paulson J, Mata M, Zimmerman B. Clinical trial: effects of botulinum toxin on levator ani syndrome: a double blind, placebo controlled study. Aliment. Pharmacol. Ther. 29: 985-991 (2009). *
Rathore B, Ali Mahdi A, Nath Paul B, Narayan Saxena P, Kumar Das S. Indian herbal medicines: possible potent therapeutic agents for rheumatoid arthritis. J. Clin. Biochem. Nutr. 41: 12-17 (2007). *
Rattan S, De Godoy MA, Patel CA. Rho kinase as a novel molecular therapeutic target for hypertensive internal anal sphincter. Gastroenterology 131: 108-116 (2006). *
Ravkov EV, Williams MA. The magnitude of CD4+ T cell recall responses is controlled by the duration of the secondary stimulus. J. Immunol. 183: 2382-2389 (2009).
Ravnskjaer K, Frigerio F, Boergesen M, Nielsen T, Maechler P, Mandrup S. PPARdelta is a fatty acid sensor, which enhances mitochondrial oxidation in insulin-secreting cells and protects against fatty acid induced dysfunction. J. Lipid Res. Nov 30 [Epub ahead of print] (2009). *
Ray SD, Parmar M, Syed I, Rathod J, Zinkovsky D, Bulku E, Gigliotti J, Hackman RM, Stohs SJ. Long term exposure effect of a unique metabolic nutrition system containing a diverse group of phytochemicals on serum chemistry and genomic and non-genomic changes in the liver of female B6C3F1 mice. Phytother. Res. 22: 458-471 (2008). *
Rayner CK, Hart AL, Hayward CM, Emmanuel AV, Kamm MA. Azathioprine dose escalation in inflammatory bowel disease. Aliment. Pharmacol. Ther. 20: 65-71 (2004). *
Razonable RR. Cytomegalovirus infection after liver transplantation: current concepts and challenges. World J. Gastroenterol. 14: 4849-4860 (2008). *
Razquin C, Alfredo Martinez J, Martinez-Gonzalez MA, Corella D, Santos JM, Marti A. The Mediterranean diet protects against waist circumference enlargement in 12Ala carriers for the PPARgamma gene: 2 years' follow-up of 774 subjects at high cardiovascular risk. Br. J. Nutr. 102: 672-679 (2009). *
Rebora A. Conventional therapies for psoriasis. Reumatismo 59 Suppl. 1: 77-80 (2007). *
Recchia F, Candeloro G, Necozione S, Accorsi P, Recchia CO, Tombolini V, Rea S. Prolonged disease control after myeloablative chemotherapy, autologous transplantation and immunotherapy in high-risk early breast cancer. Anticancer Res. 30: 209-215 (2010).
Reddy D, Siegel CA, Sands BE, Kane S. Possible association between isotretinoin and inflammatory bowel disease. Am. J. Gastroenterol. 101: 1569-1573 (2006). *
Reese GE, Lovegrove RE, Tilney HS, Yamamoto T, Heriot AG, Fazio VW, Tekkis PP. The effect of Crohn's disease on outcomes after restorative proctocolectomy. Dis. Colon Rectum 50: 239-250 (2007). *
Reese GE, Purkayastha S, Tilney HS, von Roon A, Yamamoto T, Tekkis PP. Strictureplasty vs resection in small bowel Crohn's disease: an evaluation of short-term outcomes and recurrence. Colorectal Dis. 9: 686-694 (2007). *
Reesink HW, Fanning GC, Abou Farha K, Weegink C, Van Vliet A, van 't Klooster G, Lenz O, Aharchi F, Marien K, Van Remoortere P, de Kock H, Broeckaert F, Meyvisch P, Van Beirendonck E, Simmen K, Verloes R. Rapid HCV-RNA decline with once-daily TMC435: a phase I study in healthy volunteers and hepatitis C patients. Gastroenterology Oct 20 [Epub ahead of print] (2009). *
Reesink HW, Weegink CJ. New hope for a cure for chronic hepatitis C. J. Hepatol. 51: 835-837 (2009).
Regueiro M, Schraut W, Baidoo L, Kip KE, Sepulveda AR, Pesci M, Harrison J, Plevy SE. Infliximab prevents Crohn's disease recurrence after ileal resection. Gastroenterology 136: 441-450.e1 (2009). *
Reich K. Approach to managing patients with nail psoriasis. J. Eur. Acad. Dermatol. Venereol. 23 Suppl. 1: 15-21 (2009).
Reichrath J. The challenge resulting from positive and negative effects of sunlight: how much solar UV exposure is appropriate to balance between risks of vitamin D deficiency and skin cancer? Prog. Biophys. Mol. Biol. 92: 9-16 (2006). *
Reinisch W. How to manage loss of response to anti-TNF in Crohn's disease? Curr. Drug Targets Nov 17 [Epub ahead of print] (2009).
Reinisch W, de Villiers W, Bene L, Simon L, Racz I, Katz S, Altorjay I, Feagan B, Riff D, Bernstein CN, Hommes D, Rutgeerts P, Cortot A, Gaspari M, Cheng M, Pearce T, Sands BE. Fontolizumab in moderate to severe Crohn's disease: a phase 2, randomized, double-blind, placebo-controlled, multiple-dose study. Inflamm. Bowel Dis. 16: 233-242 (2010).
Reinisch W, Hommes DW, Van Assche G, Colombel JF, Gendre JP, Oldenburg B, Teml A, Geboes K, Ding H, Zhang L, Tang M, Cheng M, van Deventer SJ, Rutgeerts P, Pearce T. A dose-escalating, placebo-controlled, double-blind, single-dose and multi-dose, safety and tolerability study of fontolizumab, a humanised anti-interferon-gamma antibody, in patients with moderate-to-severe Crohn's disease. Gut 55: 1138-1144 (2006). *
Reinisch W, Panes J, Lemann M, Schreiber S, Feagan B, Schmidt S, Sturniolo GC, Mikhailova T, Alexeeva O, Sanna L, Haas T, Korom S, Mayer H. A multicenter, randomized, double-blind trial of everolimus versus azathioprine and placebo to maintain steroid-induced remission in patients with moderate-to-severe active Crohn's disease. Am. J. Gastroenterol. 103: 2284-2292 (2008). *
Reisinger EC, Fritzsche C, Krause R, Krejs GJ. Diarrhea caused by primarily non-gastrointestinal infections. Nat. Clin. Pract. Gastroenterol. Hepatol. 2: 216-222 (2005). *
Reiter ER, DiNardo LJ, Costanzo RM. Toxic effects on gustatory function. Adv. Otorhinolaryngol. 63: 265-277 (2006).
Reniers DE, Howard JM. Isotretinoin-induced inflammatory bowel disease in an adolescent. Ann. Pharmacother. 35: 1214-1216 (2001).
Repa JJ, Li H, Frank-Cannon TC, Valasek MA, Turley SD, Tansey MG, Dietschy JM. Liver X receptor activation enhances cholesterol loss from the brain, decreases neuroinflammation, and increases survival of the NPC1 mouse. J. Neurosci. 27: 14470-14480 (2007).
Retsch-Bogart GZ, Quittner AL, Gibson RL, Oermann CM, McCoy KS, Montgomery AB, Cooper PJ. Efficacy and safety of inhaled aztreonam lysine for airway pseudomonas in cystic fibrosis. Chest 135: 1223-1232 (2009). *
Reuben A. Alcohol and the liver. Curr. Opin. Gastroenterol. 22: 263-271 (2006).
Reuben JM, Lee BN, Li C, Gomez-Navarro J, Bozon VA, Parker CA, Hernandez IM, Gutierrez C, Lopez-Berestein G, Camacho LH. Biologic and immunomodulatory events after CTLA-4 blockade with ticilimumab in patients with advanced malignant melanoma. Cancer 106: 2437-2444 (2006). *
Rex DK. The science and politics of propofol. Am. J. Gastroenterol. 99: 2080-2083 (2004). *
Rex DK. Colorectal cancer surveillance, screening, and colonoscopy. American College of Gastroenterology 68th Annual Scientific Meeting and Postgraduate Course, October 10 - 15, 2003, Baltimore, Maryland (2003).
Rex DK, Heuss LT, Walker JA, Qi R. Trained registered nurses/endoscopy teams can administer propofol safely for endoscopy. Gastroenterology 129: 1384-1391 (2005). *
Rex DK, Schwartz H, Goldstein M, Popp J, Katz S, Barish C, Karlstadt RG, Rose M, Walker K, Lottes S, Ettinger N, Zhang B. Safety and colon-cleansing efficacy of a new residue-free formulation of sodium phosphate tablets. Am. J. Gastroenterol. 101: 2594-2604 (2006). *
Reyes H. Review: intrahepatic cholestasis. A puzzling disorder of pregnancy. J. Gastroenterol. Hepatol. 12: 211-216 (1997).
Rezzani R. Exploring cyclosporine A-side effects and the protective role-played by antioxidants: the morphological and immunohistochemical studies. Histol. Histopathol. 21: 301-316 (2006).
Rho YH, Oeser A, Chung CP, Milne GL, Stein CM. Drugs used in the treatment of rheumatoid arthritis: relationship between current use and cardiovascular risk factors. Arch. Drug. Inf. 2: 34-40 (2009).
Ribalta J, Reyes H, Gonzalez MC, Iglesias J, Arrese M, Poniachik J, Molina C, Segovia N. S-Adenosyl-L-methionine in the treatment of patients with intrahepatic cholestasis of pregnancy: a randomized, double-blind, placebo-controlled study with negative results. Hepatology 13: 1084-1089 (1991).
Ribeiro CM, Paradiso AM, Schwab U, Perez-Vilar J, Jones L, O'neal W, Boucher RC. Chronic airway infection/Inflammation Induces a Ca2+i-dependent hyperinflammatory response in human cystic fibrosis airway epithelia. J. Biol. Chem. 280: 17798-17806 (2005). *
Ricart E, Esteve M, Andreu M, Casellas F, Monfort D, Sans M, Oudovenko N, Lafuente R, Panes J. Evaluation of 5 versus 10 granulocyteaphaeresis sessions in steroid-dependent ulcerative colitis: a pilot, prospective, multicenter, randomized study. World J. Gastroenterol. 13: 2193-2197 (2007). *
Ricart E, Panaccione R, Loftus EV, Tremaine WJ, Sandborn WJ. Successful management of Crohn's disease of the ileoanal pouch with infliximab. Gastroenterology 117: 429-432 (1999). *
Ricart E, Panaccione R, Loftus EV, Tremaine WJ, Sandborn WJ. Infliximab for Crohn's disease in clinical practice at the Mayo Clinic: the first 100 patients. Am. J. Gastroenterol. 96: 722-729 (2001). *
Ricci M, De Marco G, Desiati F, Mazzocchi D, Rotunno L, Battafarano N, Marchesoni A. Long-term survival of methotrexate in psoriatic arthritis. Reumatismo 61: 125-131 (2009).
Richardson G, Sculpher M, Kennedy A, Nelson E, Reeves D, Roberts C, Robinson A, Rogers A, Thompson D. Is self-care a cost-effective use of resources? Evidence from a randomized trial in inflammatory bowel disease. J. Health Serv. Res. Policy 11: 225-230 (2006).
Richetta A, Mattozzi C, Carlomagno V, Maiani E, Carboni V, Giancristoforo S, D'Epiro S, Bruni F, Calvieri S. A case of infliximab-induced psoriasis. Dermatol. Online J. 14: 9 (2008).
Richter B, Bandeira-Echtler E, Bergerhoff K, Clar C, Ebrahim Sh. Pioglitazone for type 2 diabetes mellitus. Cochrane Database Syst. Rev. 4: CD006060 (2006). *
Richter B, Bandeira-Echtler E, Bergerhoff K, Clar C, Ebrahim Sh. Rosiglitazone for type 2 diabetes mellitus. Cochrane Database Syst. Rev. 3: CD006063 (2007). *
Rigas JR, Dragnev KH. Emerging role of rexinoids in non-small cell lung cancer: focus on bexarotene. Oncologist 10: 22-33 (2005). *
Rigopoulos D, Gregoriou S, Stratigos A, Larios G, Korfitis C, Papaioannou D, Antoniou C, Ioannides D. Evaluation of the efficacy and safety of infliximab on psoriatic nails: an unblinded, nonrandomized, open-label study. Br. J. Dermatol. 159: 453-456 (2008). *
Riley JL, June CH, Blazar BR. Human T regulatory cell therapy: take a billion or so and call me in the morning. Immunity 30: 656-665 (2009). *
Rio J, Tintore M, Nos C, Tellez N, Galan I, Pelayo R, Montalban X. Interferon beta in secondary progressive multiple sclerosis: daily clinical practice. J. Neurol. 254: 849-853 (2007).
Rios Fernandez R, Callejas Rubio JL, Sanchez Cano D, Saez Moreno JA, Ortego Centeno N. Rituximab in the treatment of dermatomyositis and other inflammatory myopathies. A report of 4 cases and review of the literature. Clin. Exp. Rheumatol. 27: 1009-1016 (2009).
Rispo A, Scarpa R, Di Girolamo E, Cozzolino A, Lembo G, Atteno M, De Falco T, Lo Presti M, Castiglione F. Infliximab in the treatment of extra-intestinal manifestations of Crohn's disease. Scand. J. Rheumatol. 34: 387-391 (2005). *
Ritland SR, Leighton JA, Hirsch RE, Morrow JD, Weaver AL, Gendler SJ. Evaluation of 5-aminosalicylic acid (5-ASA) for cancer chemoprevention: lack of efficacy against nascent adenomatous polyps in the Apc(Min) mouse. Clin. Cancer Res. 5: 855-863 (1999). *
Ritter JK. Roles of glucuronidation and UDP-glucuronosyltransferases in xenobiotic bioactivation reactions. Chem. Biol. Interact. 129: 171-193 (2000).
Rivkin A. Certolizumab pegol for the management of Crohn's disease in adults. Clin. Ther. 31: 1158-1176 (2009).
Robert N, Wong GW, Wright JM. Effect of cyclosporine on blood pressure. Cochrane Database Syst. Rev. 1: CD007893 (2010).
Roberts EA. Wilson disease: therapeutic strategies. Falk Symposium 156. XIII Falk Liver Week (Part II). GENETICS IN LIVER DISEASES, Freiburg (Germany), October 8-9, 2006, p. 28 (2006). *
Roberts L, McColl GJ. Tumour necrosis factor inhibitors: risks and benefits in patients with rheumatoid arthritis. Intern. Med. J. 34: 687-693 (2004). *
Roberts SK, Weltman MD, Crawford DH, McCaughan GW, Sievert W, Cheng WS, Rawlinson W, Desmond PV, Marks PS, Yoshihara M, Rizkalla B, Depamphilis JK, Dore GJ; Chariot Study Group. Impact of high-dose peginterferon alfa-2A on virological response rates in patients with hepatitis C genotype 1: a randomized controlled trial. Hepatology 50: 1045-1055 (2009).
Robins SJ, Bloomfield HE. Fibric acid derivatives in cardiovascular disease prevention: results from the large clinical trials. Curr. Opin. Lipidol. 17: 431-439 (2006).
Robinson DM, Keating GM. Infliximab: in ankylosing spondylitis. Drugs 65: 1283-1291 (2005).
Robinson JG. Should we use PPAR agonists to reduce cardiovascular risk? PPAR Res. 2008: 891425 (2008). *
Robinson KA, Odelola OA, Saldanha I, McKoy N. Palivizumab for prophylaxis against respiratory syncytial virus infection in children with cystic fibrosis. Cochrane Database Syst. Rev. 2: CD007743 (2010).
Robinson MG. New oral salicylates in the therapy of chronic idiopathic inflammatory bowel disease. Gastroenterol. Clin. North Am. 18: 43-50 (1989).
Robinson PJ. The effects of cancer chemotherapy on liver imaging. Eur. Radiol. 19: 1752-1762 (2009).
Roche HM. Fatty acids and the metabolic syndrome. Proc. Nutr. Soc. 64: 23-29 (2005). *
Roche HM, Phillips C, Gibney MJ. The metabolic syndrome: the crossroads of diet and genetics. Proc. Nutr. Soc. 64: 371-377 (2005). *
Rockey DC. Update on treatment of portal hypertension. 54th Annual Meeting of the American Association for the Study of Liver Diseases (2003).
Rodrigues MT, Albuquerque DF, Capelozza AL, Faria FA, Santos CF. Oral side effects of isotretinoin chronic intake. N. Y. State Dent. J. 74: 36-39 (2008).
Rodríguez-Blanco I, Toribio J. What is special about adalimumab? Actas. Dermosifiliogr. 99 Suppl. 3: 28-32 (2008).
Rodriguez-Granados MT, Pereira-Rodriguez MJ, Vazquez-Vizoso FL. Therapeutic effectiveness of psoralen-UV-A bath therapy in psoriasis. Actas Dermosifiliogr. 100: 212-221 (2009).
Roe E, Puig L, Corella F, García-Navarro X, Alomar A. Cutaneous adverse effects of biological therapies for psoriasis. Eur. J. Dermatol. 18: 693-699 (2008).
Roediger WE, Kapaniris O, Millard S. Lipogenesis from n-butyrate in colonocytes. Action of reducing agent and 5-aminosalicylic acid with relevance to ulcerative colitis. Mol. Cell. Biochem. 118: 113-118 (1992).
Roglans N, Vazquez-Carrera M, Alegret M, Novell F, Zambon D, Ros E, Laguna JC, Sanchez RM. Fibrates modify the expression of key factors involved in bile-acid synthesis and biliary-lipid secretion in gallstone patients. Eur. J. Clin. Pharmacol. 59: 855-861 (2004). *
Rogler G, Andus T, Scholmerich J. Standards, perspectives and limits of conservative therapy of chronic inflammatory bowel diseases. Zentralbl. Chir. 123: 316-324 (1998).
Rogler G, Holler E. Can NOD2/CARD15 mutations predict intestinal graft-versus-host disease and aid our understanding of Crohn’s disease? Nat. Clin. Pract. Gastroenterol. Hepatol. 1: 62-63 (2004). *
Rogovik AL, Vohra S, Goldman RD. Safety considerations and potential interactions of vitamins: should vitamins be considered drugs? Ann. Pharmacother. Dec 29 [Epub ahead of print] (2009).
Rolandi E, Franceschini R, Cataldi A, Cicchetti V, Carati L, Barreca T. Effects of ursodeoxycholic acid (UDCA) on serum liver damage indices in patients with chronic active hepatitis. A double-blind controlled study. Eur. J. Clin. Pharmacol. 40: 473-476 (1991).
Rolfe V, Fortun P, Hawkey C, Bath-Hextall F. Probiotics for maintenance of remission in Crohn's disease. Cochrane Database Syst. Rev. 4: CD004826 (2006). *
Romanholi DJ, Salgado LR. Exogenous Cushing's syndrome and glucocorticoid withdrawal. Arq. Bras. Endocrinol. Metabol. 51: 1280-1292 (2007).
Romano A, De Santis A, Romito A, Di Fonso M, Venuti A, Gasbarrini GB, Manna R. Delayed hypersensitivity to aminopenicillins is related to major histocompatibility complex genes. Ann. Allergy Asthma Immunol. 80: 433-437 (1998). *
Romas E, Gillespie MT. Inflammation-induced bone loss: can it be prevented? Rheum. Dis. Clin. North Am. 32: 759-773 (2006).
Romero-Mate A, Garcia-Donoso C, Cordoba-Guijarro S. Efficacy and safety of etanercept in psoriasis/psoriatic arthritis: an updated review. Am. J. Clin. Dermatol. 8: 143-155 (2007).
Romieu I, Garcia-Esteban R, Sunyer J, Rios C, Alcaraz-Zubeldia M, Velasco SR, Holguin F. The effect of supplementation with omega-3 polyunsaturated fatty acids on markers of oxidative stress in elderly exposed to PM(2.5). Environ. Health Perspect. 116: 1237-1242 (2008).
Ronaldson KJ, McNeil JJ. Improving drug safety by locating genetic markers for hypersensitivity reactions. Med. J. Aust. 190: 641-643 (2009).
Ronchi F, Cecchi P, Falcioni F, Marsciani A, Minak G, Muratori G, Tazzari PL, Beverini S. Thrombocytopenic purpura as adverse reaction to recombinant hepatitis B vaccine. Arch. Dis. Child. 78: 273-274 (1998). *
Roohk DJ, Varady KA, Turner SM, Emson CE, Gelling RW, Shankaran M, Lindwall G, Shipp LE, Scanlan TS, Wang JC, Hellerstein MK. Differential in vivo effects on target pathways of a novel arylpyrazole glucocorticoid receptor modulator compared to prednisolone. J. Pharmacol. Exp. Ther. Jan 11 [Epub ahead of print] (2010). *
Roomans GM. Pharmacological approaches to correcting the ion transport defect in cystic fibrosis. Am. J. Respir. Med. 2: 413-431 (2003).
Roschlau G. Causes and types of cholestasis from a biopsy viewpoint. Dtsch. Z. Verdau. Stoffwechselkr. 43: 49-55 (1983).
Rose JW, Foley J, Carlson N. Monoclonal antibody treatments for multiple sclerosis. Curr. Neurol. Neurosci. Rep. 8: 419-426 (2008).
Rose JW, Foley JF, Carlson NG. Monoclonal antibody treatments for multiple sclerosis. Curr. Treat. Options Neurol. 11: 211-220 (2009).
Rosen T, Martinelli P. Erythema nodosum associated with infliximab therapy. Dermatol. Online J. 14: 3 (2008).
Rosen T, Unkefer RP. Treatment of pyoderma faciale with isotretinoin in a patient with ulcerative colitis. Cutis 64: 107-109 (1999).
Rosenberg AS. Effects of protein aggregates: an immunologic perspective. AAPS J. 8: E501-E507 (2006). *
Rosenbloom AL. Mecasermin (recombinant human insulin-like growth factor I). Adv. Ther. 26: 40-54 (2009).
Roses AD. The medical and economic roles of pipeline pharmacogenetics: Alzheimer's disease as a model of efficacy and HLA-B(*)5701 as a model of safety. Neuropsychopharmacology 34: 6-17 (2009).
Rosh JR, Lerer T, Markowitz J, Goli SR, Mamula P, Noe JD, Pfefferkorn MD, Kelleher KT, Griffiths AM, Kugathasan S, Keljo D, Oliva-Hemker M, Crandall W, Carvalho RS, Mack DR, Hyams JS. Retrospective evaluation of the safety and effect of adalimumab therapy (RESEAT) in pediatric Crohn's disease. Am. J. Gastroenterol. 104: 3042-3049 (2009). *
Ross AC, Russell RM, Miller SA, Munro IC, Rodricks JV, Yetley EA, Julien E. Application of a key events dose-response analysis to nutrients: a case study with vitamin A (retinol). Crit. Rev. Food Sci. Nutr. 49: 708-717 (2009).
Ross BM, Seguin J, Sieswerda LE. Omega-3 fatty acids as treatments for mental illness: which disorder and which fatty acid? Lipids Health Dis. 6: 21 (2007). *
Ross CJ, Katzov H, Carleton B, Hayden MR. Pharmacogenomics and its implications for autoimmune disease. J. Autoimmun. 28: 122-128 (2007).
Ross CJ, Katzov-Eckert H, Dube MP, Brooks B, Rassekh SR, Barhdadi A, Feroz-Zada Y, Visscher H, Brown AM, Rieder MJ, Rogers PC, Phillips MS, Carleton BC, Hayden MR; the CPNDS Consortium. Genetic variants in TPMT and COMT are associated with hearing loss in children receiving cisplatin chemotherapy. Nat. Genet. 41: 1345-1349 (2009). *
Ross KR, Chmiel JF, Konstan MW. The role of inhaled corticosteroids in the management of cystic fibrosis. Paediatr. Drugs 11: 101-113 (2009).
Rossel P, Sortsoe Jensen H, Qvist P, Arveschoug A. Prognosis of adult-onset idiopathic bile acid malabsorption. Scand. J. Gastroenterol. 34: 587-590 (1999). *
Rost D, Kopplow K, Gehrke S, Mueller S, Friess H, Ittrich C, Mayer D, Stiehl A. Gender-specific expression of liver organic anion transporters in rat. Eur. J. Clin. Invest. 35: 635-643 (2005).
Rost D, Kopplow K, Gehrke S, Stiehl A, Mayer D. Gender-specific expression of liver organic anion transporters. Falk Symposium 141. XVIII International Bile Acid Meeting: Bile Acid Biology and its Therapeutic Implications. Stockholm (Sweden). p. 39. June 18-19 (2004). *
Rostagno C. Recent developments in pharmacologic prophylaxis of atrial fibrillation in patients undergoing surgical revascularization. Cardiovasc. Hematol. Agents Med. Chem. 7: 137-146 (2009).
Roth SH, Shainhouse JZ. Efficacy and safety of a topical diclofenac solution (pennsaid) in the treatment of primary osteoarthritis of the knee: a randomized, double-blind, vehicle-controlled clinical trial. Arch. Intern. Med. 164: 2017-2023 (2004). *
Roth T, White D, Schmidt-Nowara W, Wesnes KA, Niebler G, Arora S, Black J. Effects of armodafinil in the treatment of residual excessive sleepiness associated with obstructive sleep apnea/hypopnea syndrome: a 12-week, multicenter, double-blind, randomized, placebo-controlled study in nCPAP-adherent adults. Clin. Ther. 28: 689-706 (2006). *
Rottenberg Y, Fridlender ZG. Recurrent infusion phlebitis induced by cyclosporine. Ann. Pharmacother. 38: 2071-2073 (2004).
Roujeau JC. Clinical heterogeneity of drug hypersensitivity. Toxicology 209: 123-129 (2005). *
Roumestan C, Gougat C, Jaffuel D, Mathieu M. Glucocorticoids and their receptor: mechanisms of action and clinical implications. Rev. Med. Interne. 25: 636-647 (2004).
Rovin BH. The chemokine network in systemic lupus erythematous nephritis. Front. Biosci. 13: 904-922 (2008).
Roy P, Washizu J, Tilles AW, Yarmush ML, Toner M. Effect of flow on the detoxification function of rat hepatocytes in a bioartificial liver reactor. Cell Transplant. 10: 609-614 (2001).
Rozenbaum M, Boulman N, Slobodin G, Ayubkhanov E, Rosner I. Polyarthritis flare complicating rheumatoid arthritis infliximab therapy: a paradoxic adverse reaction. J. Clin. Rheumatol. 12: 269-271 (2006).
Rubbert-Roth A, Finckh A. Treatment options in patients with rheumatoid arthritis failing initial TNF inhibitor therapy: a critical review. Arthritis Res. Ther. 11 Suppl. 1: S1 (2009). *
Rubegni P, Mandato F, Sbano P, Fimiani M. Terbinafine-induced acute generalized exanthematous pustulosis. G. Ital. Dermatol. Venereol. 143: 151-155 (2008).
Rubenstrunk A, Hanf R, Hum DW, Fruchart JC, Staels B. Safety issues and prospects for future generations of PPAR modulators. Biochim. Biophys. Acta 1771: 1065-1081 (2007). *
Rubin BK. Aerosolized antibiotics for non-cystic fibrosis bronchiectasis. J. Aerosol Med. Pulm. Drug Deliv. 21: 71-76 (2008).
Rubin R. Sulfasalazine-induced fulminant hepatic failure and necrotizing pancreatitis. Am. J. Gastroenterol. 89: 789-791 (1994).
Rubin RA, Kowalski TE, Khandelwal M, Malet PF. Ursodiol for hepatobiliary disorders. Ann. Intern. Med. 121: 207-218 (1994). *
Rude RK, Wei L, James Norton H, Lu SS, Dempster DW, Gruber HE. TNFalpha receptor knockout in mice reduces adverse effects of magnesium deficiency on bone. Growth Factors 27: 370-376 (2009).
Ruder AM. Potential health effects of occupational chlorinated solvent exposure. Ann. N. Y. Acad. Sci. 1076: 207-227 (2006). *
Rudick RA, Stuart WH, Calabresi PA, Confavreux C, Galetta SL, Radue EW, Lublin FD, Weinstock-Guttman B, Wynn DR, Lynn F, Panzara MA, Sandrock AW; SENTINEL Investigators. Natalizumab plus interferon beta-1a for relapsing multiple sclerosis. N. Engl. J. Med. 354: 911-923 (2006). *
Ruemmele FM. Immunomodulation with methotrexate: underused and undervalued? Dig. Dis. 27: 312-314 (2009).
Ruemmele FM, Lachaux A, Cezard JP, Morali A, Maurage C, Ginies JL, Viola S, Goulet O, Lamireau T, Scaillon M, Breton A, Sarles J; Groupe Francophone d'Hepatologie, Gastroenterologie et Nutrition Pediatrique. Efficacy of infliximab in pediatric Crohn's disease: a randomized multicenter open-label trial comparing scheduled to on demand maintenance therapy. Inflamm. Bowel Dis. 15: 388-394 (2009).
Ruepp S, Boess F, Suter L, de Vera MC, Steiner G, Steele T, Weiser T, Albertini S. Assessment of hepatotoxic liabilities by transcript profiling. Toxicol. Appl. Pharmacol. 207: S161-S170 (2005). *
Rufo PA, Bousvaros A. Current therapy of inflammatory bowel disease in children. Paediatr. Drugs 8: 279-302 (2006).
Rumbo C, Emerick KM, Emre S, Shneider BL. Azathioprine metabolite measurements in the treatment of autoimmune hepatitis in pediatric patients: a preliminary report. J. Pediatr. Gastroenterol. Nutr. 35: 391-398 (2002). *
Rumi M, Aghemo A, Prati GM, D'Ambrosio R, Donato MF, Soffredini R, Del Ninno E, Russo A, Colombo M. Randomized study of peginterferon-alpha2a plus ribavirin versus peginterferon-alpha2b plus ribavirin in chronic hepatitis C. Gastroenterology 138: 108-115 (2010). *
Rumi MG. Pegylated interferon alpha2b versus pegylated interferon alpha2a for chronic hepatitis C: the unreached goal of superiority. J. Hepatol. 51: 1097-1099 (2009).
Rumke HC, Visser HK. Childhood vaccinations anno 2004. II. The real and presumed side effects of vaccination. Ned. Tijdschr. Geneeskd. 148: 364-371 (2004).
Ruocco E, Sangiuliano S, Gravina AG, Miranda A, Nicoletti G. Pyoderma gangrenosum: an updated review. J. Eur. Acad. Dermatol. Venereol. 23: 1008-1017 (2009). *
Ruperto N, Lovell DJ, Cuttica R, Wilkinson N, Woo P, Espada G, Wouters C, Silverman ED, Balogh Z, Henrickson M, Apaz MT, Baildam E, Fasth A, Gerloni V, Lahdenne P, Prieur AM, Ravelli A, Saurenmann RK, Gamir ML, Wulffraat N, Marodi L, Petty RE, et al. A randomized, placebo-controlled trial of infliximab plus methotrexate for the treatment of polyarticular-course juvenile rheumatoid arthritis. Arthritis Rheum. 56: 3096-3106 (2007). *
Ruperto N, Lovell DJ, Quartier P, Paz E, Rubio-Perez N, Silva CA, Abud-Mendoza C, Burgos-Vargas R, Gerloni V, Melo-Gomes JA, Saad-Magalhaes C, Sztajnbok F, Goldenstein-Schainberg C, Scheinberg M, Penades IC, Fischbach M, Orozco J, Hashkes PJ, Hom C, et al. Abatacept in children with juvenile idiopathic arthritis: a randomised, double-blind, placebo-controlled withdrawal trial. Lancet 372: 383-391 (2008). *
Rupp H. Omacor(R) (prescription omega-3-acid ethyl esters 90): from severe rhythm disorders to hypertriglyceridemia. Adv. Ther. 26: 675-690 (2009).
Russmann S, Lauterburg B. Life-threatening adverse effects of pharmacologic antihyperuricemic therapy. Ther. Umsch. 61: 575-577 (2004).
Russo EA, Harris AW, Campbell S, Lindsay J, Hart A, Arebi N, Milestone A, Tsai H, Walters J, Carpani M, Westaby D, Thillainayagam A, Bansi D, Ghosh S. Experience of maintenance infliximab therapy for refractory ulcerative colitis from six centres in England. Aliment. Pharmacol. Ther. 29: 308-314 (2009). *
Russo EA, Iacucci M, Lindsay JO, Campbell S, Hart A, Hamlin J, Orchard T, Arebi N, Nightingale J, Jacyna MR, Gabe SM, O'Connor M, Harris AW, O'Morain C, Ghosh S. Survey on the use of adalimumab as maintenance therapy in Crohn's disease in England and Ireland. Eur. J. Gastroenterol. Hepatol. Jun 12 [Epub ahead of print] (2009).
Russo MW, Brown RS Jr. Ethical issues in living donor liver transplantation. Curr. Gastroenterol. Rep. 5: 26-30 (2003).
Russo MW, Galanko JA, Shrestha R, Fried MW, Watkins P. Liver transplantation for acute liver failure from drug induced liver injury in the United States. Liver Transpl. 10: 1018-1023 (2004). *
Rustgi VK, Lee WM, Lawitz E, Gordon SC, Afdhal N, Poordad F, Bonkovsky HL, Bengtsson L, Chandorkar G, Harding M, McNair L, Aalyson M, Alam J, Kauffman R, Gharakhanian S, McHutchison JG; MErimepodib TRiple cOmbination (METRO) study group. Merimepodib, pegylated interferon, and ribavirin in genotype 1 chronic hepatitis C pegylated interferon and ribavirin nonresponders. Hepatology 50: 1719-1726 (2009).
Rutgeerts P. Comparative efficacy of coated, oral 5-aminosalicylic acid (Claversal) and sulphasalazine for maintaining remission of ulcerative colitis. International Study Group. Aliment. Pharmacol. Ther. 3: 183-191 (1989).
Rutgeerts P. Budesonide led to a greater remission rate and fewer severe adverse events than did mesalamine in Crohn's disease. Gut 45: 13-14 (1999). *
Rutgeerts P, Sandborn WJ, Fedorak RN, Rachmilewitz D, Tarabar D, Gibson P, Haagen Nielsen O, Wild G, Schreiber S, Pena Rossi C, Zignani M; Onercept Study Group. Onercept for moderate-to-severe Crohn's disease: a randomized, double-blind, placebo-controlled trial. Clin. Gastroenterol. Hepatol. 4: 888-893 (2006).
Rutgeerts P, Van Assche G, Vermeire S. Optimizing anti-TNF treatment in inflammatory bowel disease. Gastroenterology 126: 1593-1610 (2004). *
Rutgeerts PJ. Conventional treatment of Crohn's disease: objectives and outcomes. Inflamm. Bowel Dis. 7 Suppl. 1: S2-S8 (2001). *
Rutherford AE, Pratt DS. Cholestasis and cholestatic syndromes. Curr. Opin. Gastroenterol. 22: 209-214 (2006). *
Rutjes AW, Nuesch E, Reichenbach S, Juni P. S-Adenosylmethionine for osteoarthritis of the knee or hip. Cochrane Database Syst. Rev. 4: CD007321 (2009). *
Ruzicka T, Larsen FG, Galewicz D, Horvath A, Coenraads PJ, Thestrup-Pedersen K, Ortonne JP, Zouboulis CC, Harsch M, Brown TC, Zultak M. Oral alitretinoin (9-cis-retinoic acid) therapy for chronic hand dermatitis in patients refractory to standard therapy: results of a randomized, double-blind, placebo-controlled, multicenter trial. Arch. Dermatol. 140: 1453-1459 (2004). *
Ruzicka T, Lynde CW, Jemec GB, Diepgen T, Berth-Jones J, Coenraads PJ, Kaszuba A, Bissonnette R, Varjonen E, Hollo P, Cambazard F, Lahfa M, Elsner P, Nyberg F, Svensson A, Brown TC, Harsch M, Maares J. Efficacy and safety of oral alitretinoin (9-cis retinoic acid) in patients with severe chronic hand eczema refractory to topical corticosteroids: results of a randomized, double-blind, placebo-controlled, multicentre trial. Br. J. Dermatol. 158: 808-817 (2008). *
Ryan C, Kirby B, Collins P, Rogers S. Adalimumab treatment for severe recalcitrant chronic plaque psoriasis. Clin. Exp. Dermatol. 34: 784-788 (2009). *
Rylander C, Sandanger TM, Brustad M. Associations between marine food consumption and plasma concentrations of POPs in a Norwegian coastal population. J. Environ. Monit. 11: 370-376 (2009).
Ryley NG, Fleming KA, Chapman RW. Focal destructive cholangiopathy associated with amoxycillin/clavulanic acid (Augmentin). J. Hepatol. 23: 278-282 (1995). *
Saab S, Kalmaz D, Gajjar NA, Hiatt J, Durazo F, Han S, Farmer DG, Ghobrial RM, Yersiz H, Goldstein LI, Lassman CR, Busuttil RW. Outcomes of acute rejection after interferon therapy in liver transplant recipients. Liver Transpl. 10: 859-867 (2004). *
Saad AA, Ashcroft DM, Watson KD, Symmons DP, Noyce PR, Hyrich KL; on behalf of the BSRBR. Efficacy and safety of anti-TNF therapies in psoriatic arthritis: an observational study from the British Society for Rheumatology Biologics Register. Rheumatology (Oxford) Jan 7 [Epub ahead of print] (2010). *
Saad AA, Symmons DP, Noyce PR, Ashcroft DM. Risks and benefits of tumor necrosis factor-alpha inhibitors in the management of psoriatic arthritis: systematic review and metaanalysis of randomized controlled trials. J. Rheumatol. 35: 883-890 (2008). *
Sabate JM, Villarejo J, Lemann M, Bonnet J, Allez M, Modigliani R. An open-label study of thalidomide for maintenance therapy in responders to infliximab in chronically active and fistulizing refractory Crohn's disease. Aliment. Pharmacol. Ther. 16: 1117-1124 (2002). *
Sabater J, Masclans JR, Sacanell J, Chacon P, Sabin P, Planas M. Effects on hemodynamics and gas exchange of omega-3 fatty acid-enriched lipid emulsion in acute respiratory distress syndrome (ARDS): a prospective, randomized, double-blind, parallel group study. Lipids Health Dis. 7: 39 (2008). *
Sabuda DM, Laupland K, Pitout J, Dalton B, Rabin H, Louie T, Conly J. Utilization of colistin for treatment of multidrug-resistant Pseudomonas aeruginosa. Can. J. Infect. Dis. Med. Microbiol. 19: 413-418 (2008).
Sachdeva A, Nagpal J. Efficacy of bovine lactoferrin in Helicobacter pylori eradication. Aliment. Pharmacol. Ther. 29: 720-730 (2009). *
Sackmann M, Pauletzki J, Aydemir U, Holl J, Sauerbruch T, Hasford J, Paumgartner G. Efficacy and safety of ursodeoxycholic acid for dissolution of gallstone fragments: comparison with the combination of ursodeoxycholic acid and chenodeoxycholic acid. Hepatology 14: 1136-1141 (1991).
Saha M, Powell AM, Bhogal B, Black MM, Groves RW. Pulsed intravenous cyclophosphamide and methylprednisolone therapy in refractory pemphigus. Br. J. Dermatol. Nov 18 [Epub ahead of print] (2009). *
Sahagun Flores JE, Soto Ortiz JA, Tovar Mendez CE, Cardenas Ochoa EC, Hernandez Flores G. Síndrome de Stevens Johnson mas colestasis intrahepatica inducido por clindamicina o clorfeniramina. Dermatol. Online J. 15: 12 (2009).
Sahar T, Brezis M, Soares-Weiser K. Antibiotic prophylaxis for bacterial infections in cirrhotic patients with ascites. Cochrane Database Syst. Rev. 2: CD004791 (2004). *
Said A, Einstein M, Lucey MR. Liver transplantation: an update 2007. Curr. Opin. Gastroenterol. 23: 292-298 (2007).
Saint Marcoux B, De Bandt M; on behalf of the CRI (Club Rhumatismes et Inflammation). Vasculitides induced by TNFalpha antagonists: a study in 39 patients in France. Joint Bone Spine 73: 710-713 (2006). *
Saito YA, Locke GR 3rd, Weaver AL, Zinsmeister AR, Talley NJ. Diet and functional gastrointestinal disorders: a population-based case-control study. Am. J. Gastroenterol. 100: 2743-2748 (2005). *
Saito YA, Talley NJ. AJG series: molecular biology for clinicians. Am. J. Gastroenterol. 104: 2583-2587 (2009). *
Sakata H, Kawamura N, Horie T, Ohizumi H, Tamaki T, Kukita K, Meguro J, Yonekawa M, Saitoh M, Kawamura A. Successful treatment of ulcerative colitis with leukocytapheresis using non-woven polyester filter. Therap. Apher. Dial. 7: 536-539 (2003).
Sakata Y, Iwakiri R, Amemori S, Yamaguchi K, Fujise T, Otani H, Shimoda R, Tsunada S, Sakata H, Ikeda Y, Ando T, Nakafusa Y, Fujimoto K. Comparison of the efficacy of granulocyte and monocyte/macrophage adsorptive apheresis and leukocytapheresis in active ulcerative colitis patients: a prospective randomized study. Eur. J. Gastroenterol. Hepatol. 20: 629-633 (2008).
Sakuraba A, Motoya S, Watanabe K, Nishishita M, Kanke K, Matsui T, Suzuki Y, Oshima T, Kunisaki R, Matsumoto T, Hanai H, Fukunaga K, Yoshimura N, Chiba T, Funakoshi S, Aoyama N, Andoh A, Nakase H, Mizuta Y, Suzuki R, Akamatsu T, Iizuka M, Ashida T, Hibi T. An open-label prospective randomized multicenter study shows very rapid remission of ulcerative colitis by intensive granulocyte and monocyte adsorptive apheresis as compared with routine weekly treatment. Am. J. Gastroenterol. 104: 2990-2995 (2009). *
Sakuraba A, Sato T, Naganuma M, Morohoshi Y, Matsuoka K, Inoue N, Takaishi H, Ogata H, Iwao Y, Hibi T. A pilot open-labeled prospective randomized study between weekly and intensive treatment of granulocyte and monocyte adsorption apheresis for active ulcerative colitis. J. Gastroenterol. 43: 51-56 (2008). *
Salama A, Kiesewetter H, Kalus U, Movassaghi K, Meyer O. Massive platelet transfusion is a rapidly effective emergency treatment in patients with refractory autoimmune thrombocytopenia. Thromb. Haemost. 100: 762-765 (2008). *
Salama M, Lawrance IC. Stevens-Johnson syndrome complicating adalimumab therapy in Crohn's disease. World J. Gastroenterol. 15: 4449-4452 (2009). *
Salavert M, Bastida G, Peman J, Nos P. Opportunistic co-infection in a patient with Crohn's disease during infliximab (anti-TNFalpha) therapy. Rev. Iberoam. Micol. 26: 213-217 (2009).
Salim A, Tan E, Ilchyshyn A, Berth-Jones J. Folic acid supplementation during treatment of psoriasis with methotrexate: a randomized, double-blind, placebo-controlled trial. Br. J. Dermatol. 154: 1169-1174 (2006). *
Salinas F M, Letelier S LM. Critically appraised article: effect of homocysteine lowering on mortality and vascular disease in advanced chronic kidney disease and end-stage renal disease. A randomized control led trial. Rev. Med. Chil. 137: 982-985 (2009).
Salvi M, Vannucchi G, Campi I, Curro N, Beck-Peccoz P. New immunomodulators in the treatment of Graves' ophthalmopathy. Ann. Endocrinol. (Paris) 69: 153-156 (2008).
Salzmann J, Lightman S. The potential of newer immunomodulating drugs in the treatment of uveitis: a review. BioDrugs 13: 397-408 (2000).
Sammaritano LR. Therapy insight: guidelines for selection of contraception in women with rheumatic diseases. Nat. Clin. Pract. Rheumatol. 3: 273-281 (2007). *
Sample C, Bailey RJ, Todoruk D, Sadowski D, Gramlich L, Milan M, Cherry R, Ma M, Lalor E, McKaigney J, Sherbaniuk R, Matic K, Switzer C, Fedorak RN. Clinical experience with infliximab for Crohn's disease: the first 100 patients in Edmonton, Alberta. Can. J. Gastroenterol. 16: 165-170 (2002). *
San Andres Rebollo FJ, Gonzalez Rubio M, Postigo C, Garfia C, Cabeza Alvarez CI, Viana Alonso A. Hypersensitivity syndrome caused by allopurinol: report of 2 cases and review of the literature. Rev. Clin. Esp. 191: 426-429 (1992).
Sanchez Carazo JL, Mahiques Santos L, Oliver Martinez V. Safety of etanercept in psoriasis: a critical review. Drug Saf. 29: 675-685 (2006).
Sanchez Hellín V, Gutierrez Rodero F. Toxicogenetics of antiretroviral treatment (II): neurotoxicity, hepatotoxicity, lactic acidosis, kidney damage, and other adverse effects of antiretroviral drugs. Enferm. Infecc. Microbiol. Clin. 26 Suppl. 6: 24-33 (2008).
Sanchez JM, Maldonado JC, Torres EA, Rivera C. Infliximab in Hispanics: characterization of response to infliximab in an ethnic minority with Crohn's disease. P. R. Health Sci. J. 24: 11-17 (2005).
Sanchez-Osorio M, Duarte-Rojo A, Martinez-Benitez B, Torre A, Uribe M. Anabolic-androgenic steroids and liver injury. Liver Int. 28: 278-282 (2008). *
Sandborn W, Sutherland L, Pearson D, May G, Modigliani R, Prantera C. Azathioprine or 6-mercaptopurine for inducing remission of Crohn's disease. Cochrane Database Syst. Rev. 2: CD000545 (2000). *
Sandborn WJ. Optimizing anti-tumor necrosis factor strategies in inflammatory bowel disease. Curr. Gastroenterol. Rep. 5: 501-505 (2003).
Sandborn WJ. New concepts in anti-tumor necrosis factor therapy for inflammatory bowel disease. Rev. Gastroenterol. Disord. 5: 10-18 (2005). *
Sandborn WJ. Preliminary data on the use of apheresis in inflammatory bowel disease. Inflamm. Bowel Dis. 12 Suppl. 1: S15-S21 (2006). *
Sandborn WJ, Colombel JF, Enns R, Feagan BG, Hanauer SB, Lawrance IC, Panaccione R, Sanders M, Schreiber S, Targan S, van Deventer S, Goldblum R, Despain D, Hogge GS, Rutgeerts P. Natalizumab induction and maintenance therapy for Crohn's disease. N. Engl. J. Med. 353: 1912-1925 (2005). *
Sandborn WJ, Feagan BG. Review article: mild to moderate Crohn's disease - defining the basis for a new treatment algorithm. Aliment. Pharmacol. Ther. 18: 263-277 (2003). *
Sandborn WJ, Feagan BG, Fedorak RN, Scherl E, Fleisher MR, Katz S, Johanns J, Blank M, Rutgeerts P; for the Ustekinumab Crohn's Disease Study Group. A randomized trial of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with moderate to severe Crohn's disease. Gastroenterology 135: 1130-1141 (2008). *
Sandborn WJ, Feagan BG, Hanauer SB, Present DH, Sutherland LR, Kamm MA, Wolf DC, Baker JP, Hawkey C, Archambault A, Bernstein CN, Novak C, Heath PK, Targan SR; CDP571 Crohn's Disease Study Group. An engineered human antibody to TNF (CDP571) for active Crohn's disease: a randomized double-blind placebo-controlled trial. Gastroenterology 120: 1330-1338 (2001). *
Sandborn WJ, Feagan BG, Radford-Smith G, Kovacs A, Enns R, Innes A, Patel J. CDP571, a humanised monoclonal antibody to tumour necrosis factor alpha, for moderate to severe Crohn's disease: a randomised, double blind, placebo controlled trial. Gut 53: 1485-1493 (2004). *
Sandborn WJ, Feagan BG, Stoinov S, Honiball PJ, Rutgeerts P, Mason D, Bloomfield R, Schreiber S; the PRECISE 1 Study Investigators. Certolizumab pegol for the treatment of Crohn's disease. N. Engl. J. Med. 357: 228-238 (2007). *
Sandborn WJ, Hanauer SB, Katz S, Safdi M, Wolf DG, Baerg RD, Tremaine WJ, Johnson T, Diehl NN, Zinsmeister AR. Etanercept for active Crohn's disease: a randomized, double-blind, placebo-controlled trial. Gastroenterology 121: 1088-1094 (2001). *
Sandborn WJ, Kamm MA, Lichtenstein GR, Lyne A, Butler T, Joseph RE. MMX Multi Matrix System((R)) mesalazine for the induction of remission in patients with mild-to-moderate ulcerative colitis: a combined analysis of two randomized, double-blind, placebo-controlled trials. Aliment. Pharmacol. Ther. 26: 205-215 (2007). *
Sandborn WJ, Korzenik J, Lashner B, Leighton JA, Mahadevan U, Marion JF, Safdi M, Sninsky CA, Patel RM, Friedenberg KA, Dunnmon P, Ramsey D, Kane S. Once daily dosing of delayed-release oral mesalamine (400 mg tablet) for maintenance of remission of ulcerative colitis: the QDIEM trial. Gastroenterology Jan 8 [Epub ahead of print] (2010). *
Sandborn WJ, Lofberg R, Feagan BG, Hanauer SB, Campieri M, Greenberg GR. Budesonide for maintenance of remission in patients with Crohn's disease in medically induced remission: a predetermined pooled analysis of four randomized, double-blind, placebo-controlled trials. Am. J. Gastroenterol. 100: 1780-1787 (2005). *
Sandborn WJ, Present DH, Isaacs KL, Wolf DC, Greenberg E, Hanauer SB, Feagan BG, Mayer L, Johnson T, Galanko J, Martin C, Sandler RS. Tacrolimus for the treatment of fistulas in patients with Crohn's disease: a randomized, placebo-controlled trial. Gastroenterology 125: 380-388 (2003). *
Sandborn WJ, Regula J, Feagan BG, Belousova E, Jojic N, Lukas M, Yacyshyn B, Krzeski P, Yeh CH, Messer CA, Hanauer SB. Delayed-release oral mesalamine 4.8 g/day (800 mg tablet) is effective for patients with moderately active ulcerative colitis. Gastroenterology 137: 1934-1943.e3 (2009). *
Sandborn WJ, Rutgeerts P, Enns R, Hanauer SB, Colombel JF, Panaccione R, D'Haens G, Li J, Rosenfeld MR, Kent JD, Pollack PF. Adalimumab induction therapy for Crohn disease previously treated with infliximab. A randomized trial. Ann. Intern. Med. 146: 829-838 (2007). *
Sandborn WJ, Rutgeerts P, Feagan BG, Reinisch W, Olson A, Johanns J, Lu J, Horgan K, Rachmilewitz D, Hanauer SB, Lichtenstein GR, de Villiers WJ, Present D, Sands BE, Colombel JF. Colectomy rate comparison after treatment of ulcerative colitis with placebo or infliximab. Gastroenterology 137: 1250-1260 (2009). *
Sandborn WJ, Sands BE, Wolf DC, Valentine JF, Safdi M, Katz S, Isaacs KL, Wruble LD, Katz J, Present DH, Loftus EV Jr, Graeme-Cook F, Odenheimer DJ, Hanauer SB. Repifermin (keratinocyte growth factor-2) for the treatment of active ulcerative colitis: a randomized, double-blind, placebo-controlled, dose-escalation trial. Aliment. Pharmacol. Ther. 17: 1355-1364 (2003). *
Sandborn WJ, Stenson WF, Brynskov J, Lorenz RG, Steidle GM, Robbins JL, Kent JD, Bloom BJ. Safety of celecoxib in patients with ulcerative colitis in remission: a randomized, placebo-controlled, pilot study. Clin. Gastroenterol. Hepatol. 4: 203-211 (2006).
Sandborn WJ, Tremaine WJ. Cyclosporine treatment of inflammatory bowel disease. Mayo Clin. Proc. 67: 981-990 (1992).
Sandborn WJ, Tremaine WJ, Leighton JA, Lawson GM, Zins BJ, Compton RF, Mays DC, Lipsky JJ, Batts KP, Offord KP, Hurt RD, Green J. Nicotine tartrate liquid enemas for mildly to moderately active left-sided ulcerative colitis unresponsive to first-line therapy: a pilot study. Aliment. Pharmacol. Ther. 11: 663-61 (1997).
Sanders CJ, Franchi L, Yarovinsky F, Uematsu S, Akira S, Nunez G, Gewirtz AT. Induction of adaptive immunity by flagellin does not require robust activation of innate immunity. Eur. J. Immunol. 39: 359-371 (2009). *
Sanders TA. DHA status of vegetarians. Prostaglandins Leukot. Essent. Fatty Acids 81: 137-141 (2009). *
Sanderson J. Incidence of adverse reactions to azathioprine in patients with Crohn's disease. Nat. Clin. Pract. Gastroenterol. Hepatol. 2: 510-511 (2005). *
Sanderson J, Ansari A, Marinaki T, Duley J. Thiopurine methyltransferase: should it be measured before commencing thiopurine drug therapy? Ann. Clin. Biochem. 41: 294-302 (2004).
Sanderson K, Scotland R, Lee P, Liu D, Groshen S, Snively J, Sian S, Nichol G, Davis T, Keler T, Yellin M, Weber J. Autoimmunity in a phase I trial of a fully human anti-cytotoxic T-lymphocyte antigen-4 monoclonal antibody with multiple melanoma peptides and montanide ISA 51 for patients with resected stages III and IV melanoma. J. Clin. Oncol. 23: 741-750 (2005). *
Sands BE. Infliximab, adalimumab and certolizumab: beneficial and adverse effects (present). Inflamm. Bowel Dis. 12 Suppl. 3: S6-S7 (2006).
Sands BE, Jacobson EW, Sylwestrowicz T, Younes Z, Dryden G, Fedorak R, Greenbloom S. Randomized, double-blind, placebo-controlled trial of the oral interleukin-12/23 inhibitor apilimod mesylate for treatment of active Crohn's disease. Inflamm. Bowel Dis. Nov 16 [Epub ahead of print] (2009). *
Sands BE, Kozarek R, Spainhour J, Barish CF, Becker S, Goldberg L, Katz S, Goldblum R, Harrigan R, Hilton D, Hanauer SB. Safety and tolerability of concurrent natalizumab treatment for patients with Crohn's disease not in remission while receiving infliximab. Inflamm. Bowel Dis. 13: 2-11 (2007). *
Sands BE, Sandborn WJ, Wolf DC, Katz S, Safdi M, Schwartz DA, Hanauer SB. Pilot feasibility studies of leukocytapheresis with the adacolumn apheresis system in patients with active ulcerative colitis or Crohn disease. J. Clin. Gastroenterol. 40: 482-489 (2006).
Sands BE, Tremaine WJ, Sandborn WJ, Rutgeerts PJ, Hanauer SB, Mayer L, Targan SR, Podolsky DK. Infliximab in the treatment of severe, steroid-refractory ulcerative colitis: a pilot study. Inflamm. Bowel Dis. 7: 83-88 (2001). *
Sane SP, Bhatt AD. Stevens-Johnson syndrome and toxic epidermal necrolysis-challenges of recognition and management. J. Assoc. Physicians India 48: 999-1003 (2000).
Saniabadi AR, Hanai H, Suzuki Y, Ohmori T, Sawada K, Yoshimura N, Saito Y, Takeda Y, Umemura K, Kondo K, Ikeda Y, Fukunaga K, Nakashima M, Beretta A, Bjarnason I, Lofberg R. Adacolumn for selective leukocytapheresis as a non-pharmacological treatment for patients with disorders of the immune system: an adjunct or an alternative to drug therapy? J. Clin. Apheresis 20: 171-184 (2005).
Sanmarti R, Gomez-Puerta JA, Rodriguez-Cros JR, Albaladejo C, Munoz-Gomez J, Canete JD. Etanercept in rheumatoid arthritis patients with a poor therapeutic response to infliximab. Med. Clin. (Barc.) 122: 321-324 (2004).
Sansonetti PJ. War and peace at mucosal surfaces. Nat. Rev. Immunol. 4: 953-964 (2004). *
Santini F, Mantovani A, Cristaudo A, Rago T, Marsili A, Buselli R, Mignani A, Ceccarini G, Bastillo R, Taddei D, Ricco I, Vitti P, Pinchera A. Thyroid function and exposure to styrene. Thyroid 18: 1065-1069 (2008).
Santoro F, Vassena L, Lusso P. Chemokine receptors as new molecular targets for antiviral therapy. New Microbiol. 27 (2 Suppl. 1): 17-29 (2004).
Santos RP, Awa E, Anbar RD. Inhaled tobramycin solution-associated recurrent eosinophilia and severe persistent bronchospasm in a patient with cystic fibrosis: a case report. BMC Pediatr. 7: 11 (2007). *
Saperstein DS, Barohn RJ. Management of myasthenia gravis. Semin. Neurol. 24: 41-48 (2004). *
Sapir T, Blank M, Shoenfeld Y. Immunomodulatory effects of intravenous immunoglobulins as a treatment for autoimmune diseases, cancer, and recurrent pregnancy loss. Ann. N. Y. Acad. Sci. 1051: 743-778 (2005). *
Sari I, Akar S, Birlik M, Sis B, Onen F, Akkoc N. Anti-tumor necrosis factor-alpha-induced psoriasis. J. Rheumatol. 33: 1411-1414 (2006).
Sarzi-Puttini P, Atzeni F, Shoenfeld Y, Ferraccioli G. TNF-alpha, rheumatoid arthritis, and heart failure: a rheumatological dilemma. Autoimmun. Rev. 4: 153-161 (2005).
Sathasivam S. Steroids and immunosuppressant drugs in myasthenia gravis. Nat. Clin. Pract. Neurol. 4: 317-327 (2008).
Sathiaraj E, Murthy S, Mansard MJ, Rao GV, Mahukar S, Reddy DN. Clinical trial: oral feeding with a soft diet compared with clear liquid diet as initial meal in mild acute pancreatitis. Aliment. Pharmacol. Ther. 28: 777-781 (2008). *
Sato S, Miyake T, Tobita H, Oshima N, Ishine J, Hanaoka T, Amano Y, Kinoshita Y. A dose-up of ursodeoxycholic acid decreases transaminases in hepatitis C patients. World J. Gastroenterol. 15: 2782-2786 (2009). *
Satoh J. Interferon-beta therapy in multiple sclerosis. Nippon Rinsho 64: 1297-1309 (2006).
Satoh M, Ishikawa Y, Itoh T, Minami Y, Takahashi Y, Nakamura M. The expression of TNF-alpha converting enzyme at the site of ruptured plaques in patients with acute myocardial infarction. Eur. J. Clin. Invest. 38: 97-105 (2008). *
Sauma L, Franck N, Paulsson JF, Westermark GT, Kjolhede P, Stralfors P, Soderstrom M, Nystrom FH. Peroxisome proliferator activated receptor gamma activity is low in mature primary human visceral adipocytes. Diabetologia 50: 195-201 (2007). *
Saurat JH, Guerin A, Yu AP, Latremouille-Viau D, Wu EQ, Gupta SR, Bao Y, Mulani PM. High prevalence of potential drug-drug interactions for psoriasis patients prescribed methotrexate or cyclosporine for psoriasis: associated clinical and economic outcomes in real-world practice. Dermatology Feb 3 [Epub ahead of print] (2010).
Sawabe T, Imafuku S. Cyclosporin-induced cortical blindness in a patient with dermatomyositis. Mod. Rheumatol. 14: 271-273 (2004).
Sawada K, Egashira A, Ohnishi K, Fukunaga K, Kusaka T, Shimoyama T. Leukocytapheresis (LCAP) for management of fulminant ulcerative colitis with toxic megacolon. Dig. Dis. Sci. 50: 767-773 (2005). *
Sawada K, Kusugami K, Suzuki Y, Bamba T, Munakata A, Hibi T, Shimoyama T. Leukocytapheresis in ulcerative colitis: results of a multicenter double-blind prospective case-control study with sham apheresis as placebo treatment. Am. J. Gastroenterol. 100: 1362-1369 (2005). *
Sawada K, Ohnishi K, Fukunaga K, Chikano S, Egashira A, Satomi M, Shimoyama T. Mechanism of leukocytapheresis effect in the treatment of ulcerative colitis. Nihon Rinsho Meneki Gakkai Kaishi 22: 469-474 (1999).
Sayani FA, Prosser C, Bailey RJ, Jacobs P, Fedorak RN. Thiopurine methyltransferase enzyme activity determination before treatment of inflammatory bowel disease with azathioprine: effect on cost and adverse events. Can. J. Gastroenterol. 19: 147-151 (2005). *
Scali JJ, Visentini S, Salomon J, Sevilla D, Ju YC, Morales E, Ugarte L, Tachdjian A, Pacheco G, Veiga S. Rapid and deep control of inflammation in rheumatoid arthritis with infliximab and its correlation with acute-phase reactants. Ann. N. Y. Acad. Sci. 1110: 389-401 (2007). *
Scandling JD, Busque S, Dejbakhsh-Jones S, Benike C, Millan MT, Shizuru JA, Hoppe RT, Lowsky R, Engleman EG, Strober S. Tolerance and chimerism after renal and hematopoietic-cell transplantation. N. Engl. J. Med. 358: 362-368 (2008). *
Scanlan CN, Burton DR, Dwek RA. Making autoantibodies safe. Proc. Natl. Acad. Sci. U.S.A. 105: 4081-4082 (2008). *
Scanlon JV, Exter BP, Steinberg M, Jarvis CI. Ustekinumab: treatment of adult moderate-to-severe chronic plaque psoriasis. Ann. Pharmacother. 43: 1456-1465 (2009).
Scarino A, Tardif R, Charbonneau M. Influence of ALDH2 polymorphism on ethanol kinetics and pulmonary effects in male and female rats exposed to ethanol vapors. Inhal. Toxicol. 21: 193-199 (2009).
Scarpignato C, Pelosini I. Rifaximin, a poorly absorbed antibiotic: pharmacology and clinical potential. Chemotherapy 51 Suppl. 1: 36-66 (2005).
Scarpignato C, Pelosini I. Experimental and clinical pharmacology of rifaximin, a gastrointestinal selective antibiotic. Digestion 73 Suppl. 1: 13-27 (2006). *
Schacke H, Berger M, Rehwinkel H, Asadullah K. Selective glucocorticoid receptor agonists (SEGRAs): novel ligands with an improved therapeutic index. Mol. Cell. Endocrinol. 275: 109-117 (2007).
Schacke H, Rehwinkel H, Asadullah K, Cato AC. Insight into the molecular mechanisms of glucocorticoid receptor action promotes identification of novel ligands with an improved therapeutic index. Exp. Dermatol. 15: 565-573 (2006). *
Schaeffeler E, Eichelbaum M, Reinisch W, Zanger UM, Schwab M. Three novel thiopurine S-methyltransferase allelic variants (TPMT*20, *21, *22) - association with decreased enzyme function. Hum. Mutat. 27: 976 (2006). *
Schedel J, Godde A, Schutz E, Bongartz TA, Lang B, Scholmerich J, Muller-Ladner U. Impact of thiopurine methyltransferase activity and 6-thioguanine nucleotide concentrations in patients with chronic inflammatory diseases. Ann. N. Y. Acad. Sci. 1069: 477-491 (2006). *
Scheinberg M, Goncalves DP, Laurindo IM. Anti-TNF agents inducing psoriasis: a recognized adverse effect. J. Clin. Rheumatol. 14: 130 (2008).
Scheinberg M, Hamerschlak N, Kutner JM, Ribeiro AA, Ferreira E, Goldenberg J, Kiss MH, Chahade WH. Rituximab in refractory autoimmune diseases: Brazilian experience with 29 patients (2002-2004). Clin. Exp. Rheumatol. 24: 65-69 (2006).
Scheinfeld N. Efalizumab: a review of events reported during clinical trials and side effects. Expert Opin. Drug Saf. 5: 197-209 (2006).
Scherer K, Spoerl D, Bircher AJ. Adverse drug reactions to biological response modifiers. J. Dtsch. Dermatol. Ges. Feb 3 [Epub ahead of print] (2010).
Scherl EJ, Pruitt R, Gordon GL, Lamet M, Shaw A, Huang S, Mareya S, Forbes WP. Safety and efficacy of a new 3.3 g b.i.d. tablet formulation in patients with mild-to-moderately-active ulcerative colitis: a multicenter, randomized, double-blind, placebo-controlled study. Am. J. Gastroenterol. 104: 1452-1459 (2009). *
Schiff MH, Burmester GR, Kent JM, Pangan AL, Kupper H, Fitzpatrick SB, Donovan C. Safety analyses of adalimumab (HUMIRA(R)) in global clinical trials and US postmarketing surveillance of patients with rheumatoid arthritis. Ann. Rheum. Dis. 65: 889-894 (2006). *
Schiff MH, Pritchard C, Huffstutter JE, Rodriguez-Valverde V, Durez P, Zhou X, Li T, Bahrt K, Kelly S, Le Bars M, Genovese MC. The 6-month safety and efficacy of abatacept in patients with rheumatoid arthritis who underwent a washout after anti-TNF therapy or were directly switched to abatacept: the ARRIVE trial. Ann. Rheum. Dis. 68: 1708-1714 (2009). *
Schlenk RF, Dohner K, Kneba M, Gotze K, Hartmann F, Del Valle F, Kirchen H, Koller E, Fischer JT, Bullinger L, Habdank M, Spath D, Groner S, Krebs B, Kayser S, Corbacioglu A, Anhalt A, Benner A, Frohling S, Dohner H. Gene mutations and response to treatment with all-trans retinoic acid in elderly patients with acute myeloid leukemia. Results from the AMLSG trial AML HD98B. Haematologica 94: 54-60 (2009). *
Schlesinger N, Schumacher R, Catton M, Maxwell L. Colchicine for acute gout. Cochrane Database Syst. Rev. 4: CD006190 (2006). *
Schmeling H, Biber D, Heins S, Horneff G. Influence of methylenetetrahydrofolate reductase polymorphisms on efficacy and toxicity of methotrexate in patients with juvenile idiopathic arthritis. J. Rheumatol. 32: 1832-1836 (2005).
Schmidt E. Optimizing therapy in patients with severe autoimmune blistering skin diseases. Hautarzt. 60: 633-640 (2009).
Schmidt E, Brocker EB, Goebeler M. Rituximab in treatment-resistant autoimmune blistering skin disorders. Clin. Rev. Allergy Immunol. 34: 56-64 (2008). *
Schmidt E, Zillikens D. Immunoadsorption in dermatology. Arch. Dermatol. Res. Jan 5 [Epub ahead of print] (2010). *
Schmidt LA, Lim MS. T cell lymphoproliferative disorders associated with anti-tumor necrosis factor alpha antibody therapy for ulcerative colitis: literature summary. J. Hematop. 2: 121-126 (2009). *
Schmidt S, Pleyer U. Cyclosporine monitoring in patients with chronic uveitis. Ophthalmologe 102: 349-354 (2005).
Schmith VD, Campbell DA, Sehgal S, Anderson WH, Burns DK, Middleton LT, Roses AD. Pharmacogenetics and disease genetics of complex diseases. Cell. Mol. Life Sci. 60: 1636-1646 (2003). *
Schmitt J, Ford DE. Psoriasis is independently associated with psychiatric morbidity and adverse cardiovascular risk factors, but not with cardiovascular events in a population-based sample. J. Eur. Acad. Dermatol. Venereol. Dec 10 [Epub ahead of print] (2009). *
Schmitt J, Zhang Z, Wozel G, Meurer M, Kirch W. Efficacy and tolerability of biologic and nonbiologic systemic treatments for moderate-to-severe psoriasis: meta-analysis of randomized controlled trials. Br. J. Dermatol. 159: 513-526 (2008). *
Schmitt-Egenolf M. PsoReg - the Swedish registry for systemic psoriasis treatment. The registry's design and objectives. Dermatology 214: 112-117 (2007). *
Schmitt-Grohe S, Zielen S. Leukotriene receptor antagonists in children with cystic fibrosis lung disease: anti-inflammatory and clinical effects. Paediatr. Drugs 7: 353-363 (2005).
Schnabel D, Grasemann C, Staab D, Wollmann H, Ratjen F; German Cystic Fibrosis Growth Hormone Study Group. A multicenter, randomized, double-blind, placebo-controlled trial to evaluate the metabolic and respiratory effects of growth hormone in children with cystic fibrosis. Pediatrics 119: e1230-e1238 (2007). *
Schoepfer AM, Engel A, Fattinger K, Marbet UA, Criblez D, Reichen J, Zimmermann A, Oneta CM. Herbal does not mean innocuous: ten cases of severe hepatotoxicity associated with dietary supplements from Herbalife((R)) products. J. Hepatol. 47: 521-526 (2007). *
Schoepfer AM, Vavricka SR, Binek J, Felley C, Geyer M, Manz M, Rogler G, de Saussure P, Sauter B, Seibold F, Straumann A, Michetti P. Efficacy and safety of certolizumab pegol induction therapy in an unselected Crohn's disease population: results of the FACTS survey. Inflamm. Bowel Dis. Dec 14 [Epub ahead of print] (2009).
Scholtens S, Wijga AH, Smit HA, Brunekreef B, de Jongste JC, Gerritsen J, Seidell JC. Long-chain polyunsaturated fatty acids in breast milk and early weight gain in breast-fed infants. Br. J. Nutr. 101: 116-121 (2009). *
Scholz H, Lund T, Dahle MK, Collins JL, Korsgren O, Wang JE, Foss A. The synthetic liver X receptor agonist GW3965 reduces tissue factor production and inflammatory responses in human islets in vitro. Diabetologia 52: 1352-1362 (2009). *
Schott E, Paul F, Wuerfel JT, Zipp F, Rudolph B, Wiedenmann B, Baumgart DC. Development of ulcerative colitis in a patient with multiple sclerosis following treatment with interferonbeta 1a. World J. Gastroenterol. 13: 3638-3640 (2007). *
Schramm C, Schirmacher P, Helmreich-Becker I, Gerken G, zum Buschenfelde KH, Lohse AW. Combined therapy with azathioprine, prednisolone, and ursodiol in patients with primary sclerosing cholangitis. A case series. Ann. Intern. Med. 131: 943-946 (1999). *
Schrauder A, von Stackelberg A, Schrappe M, Cornish J, Peters C; ALL-BFM Study Group; EBMT PD WP; I-BFM Study Group. Allogeneic hematopoietic SCT in children with ALL: current concepts of ongoing prospective SCT trials. Bone Marrow Transplant. 41 Suppl. 2: S71-S74 (2008).
Schreiber S. Infliximab, adalimumab and certolizumab: beneficial and adverse effects (future). Inflamm. Bowel Dis. 12 Suppl. 3: S7 (2006).
Schreiber S, Feagan B, D'Haens G, Colombel JF, Geboes K, Yurcov M, Isakov V, Golovenko O, Bernstein CN, Ludwig D, Winter T, Meier U, Yong C, Steffgen J; BIRB 796 Study Group. Oral p38 mitogen-activated protein kinase inhibition with BIRB 796 for active Crohn's disease: a randomized, double-blind, placebo-controlled trial. Clin. Gastroenterol. Hepatol. 4: 325-334 (2006).
Schreiber S, Keshavarzian A, Isaacs KL, Schollenberger J, Guzman JP, Orlandi C, Hanauer SB. A randomized, placebo-controlled, phase II study of tetomilast in active ulcerative colitis. Gastroenterology 132: 76-86 (2007). *
Schreiber S, Khaliq-Kareemi M, Lawrance IC, Thomsen OO, Hanauer SB, McColm J, Bloomfield R, Sandborn WJ; the PRECISE 2 Study Investigators. Maintenance therapy with certolizumab pegol for Crohn's disease. N. Engl. J. Med. 357: 239-250 (2007). *
Schreiber S, Rutgeerts P, Fedorak RN, Khaliq-Kareemi M, Kamm MA, Boivin M, Bernstein CN, Staun M, Thomsen OO, Innes A; CDP870 Crohn's Disease Study Group. A randomized, placebo-controlled trial of certolizumab pegol (CDP870) for treatment of Crohn's disease. Gastroenterology 129: 807-818 (2005). *
Schreibman I, Regev A. Recurrent primary biliary cirrhosis after liver transplantation - the disease and its management. MedGenMed. 8: 30 (2006). *
Schreier G, Hayn D, Kastner P, Koller S, Salmhofer W, Hofmann-Wellenhof R. A mobile-phone based teledermatology system to support self-management of patients suffering from psoriasis. Conf. Proc. IEEE Eng. Med. Biol. Soc. 1: 5338-5341 (2008).
Schroder O, Blumenstein I, Stein J. Combining infliximab with methotrexate for the induction and maintenance of remission in refractory Crohn's disease: a controlled pilot study. Eur. J. Gastroenterol. Hepatol. 18: 11-16 (2006).
Schroder O, Mickisch O, Seidler U, de Weerth A, Dignass AU, Herfarth H, Reinshagen M, Schreiber S, Junge U, Schrott M, Stein J. Intravenous iron sucrose versus oral iron supplementation for the treatment of iron deficiency anemia in patients with inflammatory bowel disease - a randomized, controlled, open-label, multicenter study. Am. J. Gastroenterol. 100: 2503-2509 (2005). *
Schroeder KW. Role of mesalazine in acute and long-term treatment of ulcerative colitis and its complications. Scand. J. Gastroenterol. Suppl. 236: 42-47 (2002). *
Schroeder T, Malago M, Debatin JF, Goyen M, Nadalin S, Ruehm SG. "All-in-one" imaging protocols for the evaluation of potential living liver donors: comparison of magnetic resonance imaging and multidetector computed tomography. Liver Transpl. 11: 776-787 (2005). *
Schuetz E, Strom S. Promiscuous regulator of xenobiotic removal. Nat. Med. 7: 536-537 (2001). *
Schumann M, Preiss JC, Loddenkemper C, Gunther U, Somasundaram R, Siegmund B, Zeitz M. Nodular regenerative hyperplasia: a side effect of azathioprine in a patient with Crohn's disease. Dtsch. Med. Wochenschr. 133: 1897-1900 (2008).
Schupp M, Clemenz M, Gineste R, Witt H, Janke J, Helleboid S, Hennuyer N, Ruiz P, Unger T, Staels B, Kintscher U. Molecular characterization of new selective peroxisome proliferator-activated receptor gamma modulators with angiotensin receptor blocking activity. Diabetes 54: 3442-3452 (2005). *
Schuppan D, Jia JD, Brinkhaus B, Hahn EG. Herbal products for liver diseases: a therapeutic challenge for the new millennium. Hepatology 30: 1099-1104 (1999). *
Schwab M, Reynders V, Loitsch S, Steinhilber D, Stein J, Schroder O. Involvement of different nuclear hormone receptors in butyrate-mediated inhibition of inducible NFkappaB signalling. Mol. Immunol. 44: 3625-3632 (2007). *
Schwartz D, Ferguson JR. Current pharmacologic treatment paradigms for inflammatory bowel disease and the potential role of granulocyte/monocyte apheresis. Curr. Med. Res. Opin. 23: 2715-2728 (2007).
Schwartzman RJ, Simpkins N, Alexander GM, Reichenberger E, Ward K, Lindenberg N, Topolsky D, Crilley P. High-dose cyclophosphamide in the treatment of multiple sclerosis. CNS Neurosci. Ther. 15: 118-127 (2009).
Sciume C, Geraci G, Pisello F, Facella T, Li Volsi F, Modica G. Prevention of clogging of biliary stents by administration of levofloxacin and ursodeoxycholic acid. Chir. Ital. 56: 831-837 (2004).
Scorza FA, Cysneiros RM, Terra VC, Scorza CA, Cavalheiro EA, Ribeiro MO, Gattaz WF. Omega-3 consumption and sudden cardiac death in schizophrenia. Prostaglandins Leukot. Essent. Fatty Acids 81: 241-245 (2009). *
Scott DL. Rheumatoid arthritis: acute presentations and urgent complications. Br. J. Hosp. Med. (Lond.) 67: 235-239 (2006).
Scriba TJ, Tameris M, Mansoor N, Smit E, van der Merwe L, Isaacs F, Keyser A, Moyo S, Brittain N, Lawrie A, Gelderbloem S, Veldsman A, Hatherill M, Hawkridge A, Hill AV, Hussey GD, Mahomed H, McShane H, Hanekom WA. Modified vaccinia ankara-expressing Ag85A, a novel tuberculosis vaccine, is safe in adolescents and children, and induces polyfunctional CD4(+) T cells. Eur. J. Immunol. Dec 16 [Epub ahead of print] (2009). *
Scribano ML. Adverse events of IBD therapies. Inflamm. Bowel Dis. 14 Suppl. 2: S210-S211 (2008). *
Scrimshaw NS, SanGiovanni JP. Synergism of nutrition, infection, and immunity: an overview. Am. J. Clin. Nutr. 66: 464S-477S (1997). *
Scully C, Mignogna M. Oral mucosal disease: pemphigus. Br. J. Oral Maxillofac. Surg. 46: 272-277 (2008).
Sebba A. Tocilizumab: the first interleukin-6-receptor inhibitor. Am. J. Health Syst. Pharm. 65: 1413-1418 (2008). *
Seehafer JR, Rogers RS 3rd, Fleming CR, Dickson ER. Lichen planus-like lesions caused by penicillamine in primary biliary cirrhosis. Arch. Dermatol. 117: 140-142 (1981).
Segarra Canton O, Infante Pina D, Tormo Carnice R. Infliximab therapy for inflammatory bowel disease: seven years on. An. Pediatr. (Barc.) 67: 344-351 (2007).
Seiderer J, Goke B, Ochsenkuhn T. Safety aspects of infliximab in inflammatory bowel disease patients. A retrospective cohort study in 100 patients of a German university hospital. Digestion 70: 3-9 (2004).
Seidman EG, Dirks MH. Capsule endoscopy in the pediatric patient. Curr. Treat. Options Gastroenterol. 9: 416-422 (2006).
Seishima M, Mizutani Y, Shibuya Y, Nagasawa C, Aoki T. Efficacy of granulocyte and monocyte adsorption apheresis for three cases of refractory pyoderma gangrenosum. Ther. Apher. Dial. 11: 177-182 (2007).
Seishima M, Mizutani Y, Shibuya Y, Nagasawa C, Aoki T. Efficacy of granulocyte and monocyte adsorption apheresis for pustular psoriasis. Ther. Apher. Dial. 12: 13-18 (2008).
Sejvar JJ, Labutta RJ, Chapman LE, Grabenstein JD, Iskander J, Lane JM. Neurologic adverse events associated with smallpox vaccination in the United States, 2002-2004. JAMA 294: 2744-2750 (2005). *
Selcoki Y, Uz E, Bayrak R, Sahin S, Kaya A, Uz B, Karanfil A, Ozkara A, Akcay A. The protective effect of erdosteine against cyclosporine A-induced cardiotoxicity in rats. Toxicology 239: 53-59 (2007). *
Semrad CE. Zinc and intestinal function. Curr. Gastroenterol. Rep. 1: 398-403 (1999).
Sendzik J, Lode H, Stahlmann R. Quinolone-induced arthropathy: an update focusing on new mechanistic and clinical data. Int. J. Antimicrob. Agents 33: 194-200 (2009). *
Sener G, Sehirli O, Cetinel S, Midillioglu S, Gedik N, Ayanoglu-Dulger G. Protective effect of taurine against alendronate-induced gastric damage in rats. Fundam. Clin. Pharmacol. 19: 93-100 (2005). *
Sener O, Doganci L, Safali M, Besirbellioglu B, Bulucu F, Pahsa A. Severe dapsone hypersensitivity syndrome. J. Investig. Allergol. Clin. Immunol. 16: 268-270 (2006). *
Senkal M, Geier B, Hannemann M, Deska T, Linseisen J, Wolfram G, Adolph M. Supplementation of omega-3 fatty acids in parenteral nutrition beneficially alters phospholipid fatty acid pattern. JPEN J. Parenter. Enteral Nutr. 31: 12-17 (2007). *
Sentilhes L, Bacq Y. Intrahepatic cholestasis of pregnancy. J. Gynecol. Obstet. Biol. Reprod. (Paris) 37: 118-126 (2008).
Seo P, Min YI, Holbrook JT, Hoffman GS, Merkel PA, Spiera R, Davis JC, Ytterberg SR, St Clair EW, McCune WJ, Specks U, Allen NB, Luqmani RA, Stone JH; WGET Research Group. Damage caused by Wegener's granulomatosis and its treatment: prospective data from the Wegener's granulomatosis Etanercept Trial (WGET). Arthritis Rheum. 52: 2168-2178 (2005). *
Seow CH, Benchimol EI, Griffiths AM, Otley AR, Steinhart AH. Budesonide for induction of remission in Crohn's disease. Cochrane Database Syst. Rev. 3: CD000296 (2008). *
Seow CH, Benchimol EI, Griffiths AM, Steinhart AH. Type I interferons for induction of remission in ulcerative colitis. Cochrane Database Syst. Rev. 3: CD006790 (2008). *
Seow CH, Benchimol EI, Steinhart AH, Griffiths AM, Otley AR. Budesonide for Crohn's disease. Expert Opin. Drug Metab. Toxicol. 5: 971-979 (2009).
Serfaty L. Pioglitazone: the beginning of a new era for NASH? J. Hepatol. 47: 160-162 (2007). *
Serghini M, Karoui S, Meknini M, Matri S, Kallel L, Fekih M, Boubaker J, Filali A. Treatment of Crohn's disease by infliximab. About 20 cases. Tunis. Med. 87: 579-582 (2009).
Serpe L, Canaparo R, Daperno M, Sostegni R, Martinasso G, Muntoni E, Ippolito L, Vivenza N, Pera A, Eandi M, Gasco MR, Zara GP. Solid lipid nanoparticles as anti-inflammatory drug delivery system in a human inflammatory bowel disease whole blood model. Eur. J. Pharm. Sci. Feb 3 [Epub ahead of print] (2010).
Seston EM, Ashcroft DM, Griffiths CE. Balancing the benefits and risks of drug treatment: a stated-preference, discrete choice experiment with patients with psoriasis. Arch. Dermatol. 143: 1175-1179 (2007). *
Sever JL, Brenner AI, Gale AD, Lyle JM, Moulton LH, West DJ; Anthrax Vaccine Export Committee. Safety of anthrax vaccine: a review by the Anthrax Vaccine Expert Committee (AVEC) of adverse events reported to the Vaccine Adverse Event Reporting System (VAERS). Pharmacoepidemiol. Drug Saf. 11: 189-202 (2002).
Severs GA, Lawlor TH, Purcell SM, Adler DJ, Thompson R. Cutaneous adverse reaction to infliximab: report of psoriasis developing in 3 patients. Cutis 80: 231-237 (2007).
Sevilla-Sanchez D, Soy-Muner D, Soler-Porcar N. Usefulness of macrolides as anti-inflammatories in respiratory diseases. Arch. Bronconeumol. Dec 3 [Epub ahead of print] (2009).
Sfikakis PP. The first decade of biologic TNF antagonists in clinical practice: lessons learned, unresolved issues and future directions. Curr. Dir. Autoimmun. 11: 180-210 (2010).
Sfikakis PP, Iliopoulos A, Elezoglou A, Kittas C, Stratigos A. Psoriasis induced by anti-tumor necrosis factor therapy: a paradoxical adverse reaction. Arthritis Rheum. 52: 2513-2518 (2005). *
Sfriso P, Salaffi F, Montecucco CM, Bombardieri S, Todesco S. MonitorNet: the Italian multi-centre observational study aimed at estimating the risk/benefit profile of biologic agents in real-world rheumatology practice. Reumatismo 61: 132-139 (2009).
Shackleton M, Davis ID, Hopkins W, Jackson H, Dimopoulos N, Tai T, Chen Q, Parente P, Jefford M, Masterman KA, Caron D, Chen W, Maraskovsky E, Cebon J. The impact of imiquimod, a Toll-like receptor-7 ligand (TLR7L), on the immunogenicity of melanoma peptide vaccination with adjuvant Flt3 ligand. Cancer Immun. 4: 9 (2004). *
Shaffer JL, Hughes S, Linaker BD, Baker RD, Turnberg LA. Controlled trial of rifampicin and ethambutol in Crohn's disease. Gut 25: 203-205 (1984). *
Shafran I, Burgunder P. Rifaximin for the treatment of newly diagnosed Crohn's disease: a case series. Am. J. Gastroenterol. 103: 2158-2160 (2008). *
Shafran I, Johnson LK. An open-label evaluation of rifaximin in the treatment of active Crohn's disease. Curr. Med. Res. Opin. 21: 1165-1170 (2005).
Shah JA, Edwards CM, Probert CS. Should azathioprine and 5-aminosalicylates be coprescribed in inflammatory bowel disease?: an audit of adverse events and outcome. Eur. J. Gastroenterol. Hepatol. 20: 169-173 (2008).
Shah NL, Caldwell SH, Berg CL. The role of anti-fibrinolytics, rFVIIa and other pro-coagulants: prophylactic versus rescue? Clin. Liver Dis. 13: 87-93 (2009).
Shah P, Mudaliar S. Pioglitazone: side effect and safety profile. Expert Opin. Drug Saf. 9: 347-354 (2010).
Shah SB, Hanauer SB. Risks and benefits of the use of concomitant immunosuppressives and biologics in inflammatory bowel disease. Rev. Gastroenterol. Disord. 8: 159-168 (2008).
Shale M, Ghosh S. Learning the lessons of antitumour necrosis factor therapy-associated psoriasis. Can. J. Gastroenterol. 23: 674-676 (2009).
Shale M, Kaplan GG, Panaccione R, Ghosh S. Isotretinoin and intestinal inflammation: what gastroenterologists need to know. Gut 58: 737-741 (2009). *
Shalev I, Wong KM, Foerster K, Zhu Y, Chan C, Maknojia A, Zhang J, Ma XZ, Yang XC, Gao JF, Liu H, Selzner N, Clark DA, Adeyi O, Phillips MJ, Gorczynski RR, Grant D, McGilvray I, Levy G. The novel CD4+CD25+ regulatory T cell effector molecule fibrinogen-like protein 2 contributes to the outcome of murine fulminant viral hepatitis. Hepatology 49: 387-397 (2009). *
Shamban AT. Current and new treatments of photodamaged skin. Facial Plast. Surg. 25: 337-346 (2009).
Shamir R, Eliakim R. Capsule endoscopy in pediatric patients. World J. Gastroenterol. 14: 4152-4155 (2008). *
Shanahan Jr WR. ISIS 2302, an antisense inhibitor of intercellular adhesion molecule 1. Expert Opin. Investig. Drugs 8: 1417-1429 (1999).
Shao LM, Chen MY, Chen QY, Cai JT. Systematic review: the efficacy and safety of certolizumab pegol in Crohn's disease. Aliment. Pharmacol. Ther. 29: 605-614 (2009). *
Sharma P, Kumar A, Sharma BC, Sarin SK. Early identification of hemodynamic response to pharmacotherapy is essential for primary prophylaxis of variceal bleeding in patients with 'high-risk' varices. Aliment. Pharmacol. Ther. 30: 48-60 (2009). *
Sharma P, Kumar S, Brahmachari V, Sundaramoorthy E, Mahajan A, Sharma A, Sengupta S. Mining literature for a comprehensive pathway analysis: a case study for retrieval of homocysteine related genes for genetic and epigenetic studies. Lipids Health Dis. 5: 1 (2006). *
Sharma SM, Nestel AR, Lee RW, Dick AD. Clinical review: anti-TNFalpha therapies in uveitis: perspective on 5 years of clinical experience. Ocul. Immunol. Inflamm. 17: 403-414 (2009).
Shastry BS. SNPs and haplotypes: genetic markers for disease and drug response (review). Int. J. Mol. Med. 11: 379-382 (2003). *
Shaw DI, Hall WL, Jeffs NR, Williams CM. Comparative effects of fatty acids on endothelial inflammatory gene expression. Eur. J. Nutr. 46: 321-328 (2007). *
Shear NH, Prinz J, Papp K, Langley RG, Gulliver WP. Targeting the interleukin-12/23 cytokine family in the treatment of psoriatic disease. J. Cutan. Med. Surg. 12: S1-S10 (2008).
Sheffield LJ, Phillimore HE. Clinical use of pharmacogenomic tests in 2009. Clin. Biochem. Rev. 30: 55-65 (2009). *
Sheil JM, Frankenberry MA, Schell TD, Brundage KM, Barnett JB. Propanil exposure induces delayed but sustained abrogation of cell-mediated immunity through direct interference with cytotoxic T-lymphocyte effectors. Environ. Health Perspect. 114: 1059-1064 (2006). *
Sheldon AL, Robinson MB. The role of glutamate transporters in neurodegenerative diseases and potential opportunities for intervention. Neurochem. Int. 51: 333-355 (2007). *
Shelton RC, Osuntokun O, Heinloth AN, Corya SA. Therapeutic options for treatment-resistant depression. CNS Drugs 24: 131-161 (2010).
Shen B, Achkar JP, Lashner BA, Ormsby AH, Remzi FH, Brzezinski A, Bevins CL, Bambrick ML, Seidner DL, Fazio VW. A randomized clinical trial of ciprofloxacin and metronidazole to treat acute pouchitis. Inflamm. Bowel Dis. 7: 301-305 (2001). *
Shen B, Brzezinski A, Fazio VW, Remzi FH, Achkar JP, Bennett AE, Sherman K, Lashner BA. Maintenance therapy with a probiotic in antibiotic-dependent pouchitis: experience in clinical practice. Aliment. Pharmacol. Ther. 22: 721-728 (2005). *
Shen B, Fazio VW, Remzi FH, Bennett AE, Lopez R, Brzezinski A, Oikonomou I, Sherman KK, Lashner BA. Combined ciprofloxacin and tinidazole therapy in the treatment of chronic refractory pouchitis. Dis. Colon Rectum 50: 498-508 (2007). *
Shen B, Lashner BA, Bennett AE, Remzi FH, Brzezinski A, Achkar JP, Bast J, Bambrick ML, Fazio VW. Treatment of rectal cuff inflammation (cuffitis) in patients with ulcerative colitis following restorative proctocolectomy and ileal pouch-anal anastomosis. Am. J. Gastroenterol. 99: 1527-1531 (2004). *
Shen B, Pardi DS, Bennett AE, Queener E, Kammer P, Hammel JP, Laplaca C, Harris MS. The efficacy and tolerability of AST-120 (spherical carbon adsorbent) in active pouchitis. Am. J. Gastroenterol. 104: 1468-1474 (2009). *
Shen B, Remzi FH, Lavery IC, Lopez R, Queener E, Shen L, Goldblum J, Fazio VW. Administration of adalimumab in the treatment of Crohn's disease of the ileal pouch. Aliment. Pharmacol. Ther. 29: 519-526 (2009). *
Shen J, Ran ZH, Tong JL, Xiao SD. Meta-analysis: the utility and safety of heparin in the treatment of active ulcerative colitis. Aliment Pharmacol. Ther. 26: 653-663 (2007). *
Sherer Y, Kuechler S, Jose Scali J, Rovensky J, Levy Y, Zandman-Goddard G, Shoenfeld Y. Low dose intravenous immunoglobulin in systemic lupus erythematosus: analysis of 62 cases. Isr. Med. Assoc. J. 10: 55-57 (2008). *
Sherman S, Cheng CL, Costamagna G, Binmoeller KF, Puespoek A, Aithal GP, Kozarek RA, Chen YK, Van Steenbergen W, Tenner S, Freeman M, Monroe P, Geffner M, Deviere J; The Interleukin-10 ERCP Study Group. Efficacy of recombinant human interleukin-10 in prevention of post-endoscopic retrograde cholangiopancreatography pancreatitis in subjects with increased risk. Pancreas 38: 267-274 (2009).
Sheu BS, Huang JJ, Yang HB, Huang AH, Wu JJ. The selection of triple therapy for Helicobacter pylori eradication in chronic renal insufficiency. Aliment. Pharmacol. Ther. 17: 1283-1290 (2003). *
Shewry PR. Wheat. J. Exp. Bot. 60: 1537-1553 (2009). *
Shibayama Y, Takeda Y, Yamada K. Effect of methotrexate treatment on expression levels of organic anion transporter polypeptide 2, P-glycoprotein and bile salt export pump in rats. Biol. Pharm. Bull. 32: 493-496 (2009). *
Shibolet O, Regushevskaya E, Brezis M, Soares-Weiser K. Cyclosporine A for induction of remission in severe ulcerative colitis. Cochrane Database Syst. Rev. 1: CD004277 (2005).
Shibolet O, Regushevskaya ER, Hershko AYH, Soares-Weiser K, Brezis M. Cyclosporine A for induction of remission in steroid refractory ulcerative colitis. Cochrane Database Syst. Rev. 2: CD000302 (2004). *
Shichiri M, Koyama W, Tozuka S, Sakamoto S, Kanayama M. Primary biliary cirrhosis. A patient with adverse reactions to tiopronin and autoimmune hemolytic anemia with reticulocytopenia. Arch. Intern. Med. 144: 89-91 (1984).
Shiffman ML, Pockros P, McHutchison JG, Schiff ER, Morris M, Burgess G. Clinical trial: efficacy and safety of oral PF-03491390, a pancaspase inhibitor - a randomized placebo-controlled study in patients with chronic hepatitis C. Aliment. Pharmacol. Ther. Feb 16 [Epub ahead of print] (2010). *
Shiina S, Teratani T, Obi S, Sato S, Tateishi R, Fujishima T, Ishikawa T, Koike Y, Yoshida H, Kawabe T, Omata M. A randomized controlled trial of radiofrequency ablation with ethanol injection for small hepatocellular carcinoma. Gastroenterology 129: 122-130 (2005). *
Shike M. Copper in parenteral nutrition. Gastroenterology 137: S13-S17 (2009). *
Shimada M, Iwase H, Tsuzuki T, Hirashima N, Kobayashi K, Hibino Y, Watanabe H, Ryuge N, Ando T, Goto H, Yagi Y, Tsujikawa T, Andoh A. A pilot study of leukocytapheresis efficacy with 1.5 liter blood processing volume in patients with ulcerative colitis. Ther. Apher. Dial. 12: 368-373 (2008).
Shin IS, Baer AN, Kwon HJ, Papadopoulos EJ, Siegel JN. Guillain-Barre and Miller Fisher syndromes occurring with tumor necrosis factor alpha antagonist therapy. Arthritis Rheum. 54: 1429-1434 (2006). *
Shiozawa S, Cummins JM, Fox PC. Opening the flood gates: interferon-alpha treatment for Sjogren's syndrome. BioDrugs 13: 305-311 (2000).
Shteingart S, Rapoport M, Grodzovski I, Sabag O, Lichtenstein M, Eavri R, Lorberboum-Galski H. Therapeutic potency of IL2-caspase3 targeted treatment in a murine experimental model of inflammatory bowel disease (IBD). Gut 58: 790-798 (2009).
Siao D, Velayos FS. The good, the bad, and the ugly: adverse events and Crohn's therapies. Inflamm. Bowel Dis. Oct 15 [Epub ahead of print] (2009). *
Sibilia J, Westhovens R. Safety of T-cell co-stimulation modulation with abatacept in patients with rheumatoid arthritis. Clin. Exp. Rheumatol. 25: S46-S56 (2007).
Sicherer SH, Sampson HA. Food allergy: recent advances in pathophysiology and treatment. Annu. Rev. Med. 60: 261-277 (2009). *
Sidoroff A, Dunant A, Viboud C, Halevy S, Bavinck JN, Naldi L, Mockenhaupt M, Fagot JP, Roujeau JC. Risk factors for acute generalized exanthematous pustulosis (AGEP)-results of a multinational case-control study (EuroSCAR). Br. J. Dermatol. 157: 989-996 (2007). *
Sieb JP. Myasthenia gravis: emerging new therapy options. Curr. Opin. Pharmacol. 5: 303-307 (2005).
Sieg A, Friedrich K, Sieg U. Is PillCam colon capsule endoscopy ready for colorectal cancer screening? A prospective feasibility study in a community gastroenterology practice. Am. J. Gastroenterol. 104: 848-854 (2009). *
Siegrist CA, Lewis EM, Eskola J, Evans SJ, Black SB. Human papilloma virus immunization in adolescent and young adults: a cohort study to illustrate what events might be mistaken for adverse reactions. Pediatr. Infect. Dis. J. 26: 979-984 (2007).
Siest G, Ferrari L, Accaoui MJ, Batt AM, Visvikis S. Pharmacogenomics of drugs affecting the cardiovascular system. Clin. Chem. Lab. Med. 41: 590-599 (2003).
Silva IA, Nyland JF, Gorman A, Perisse A, Ventura AM, Santos EC, de Souza JM, Burek CL, Rose NR, Silbergeld EK. Mercury exposure, malaria, and serum antinuclear/antinucleolar antibodies in amazon populations in Brazil: a cross-sectional study. Environ. Health 3: 11 (2004). *
Silva ML, Espírito-Santo LR, Martins MA, Silveira-Lemos D, Peruhype-Magalhaes V, Caminha RC, de Andrade Maranhao-Filho P, Martins MA, de Menezes Martins R, Galler R, Freire MD, Marcovistz R, Homma A, Teuwen DE, Eloi-Santos SM, Andrade MC, et al. Clinical and immunological insights on severe adverse neurotropic/viscerotropic disease following 17D yellow fever vaccination. Clin. Vaccine Immunol. Nov 11 [Epub ahead of print] (2009). *
Silveira MG, Lindor KD. High-dose ursodeoxycholic acid for the treatment of primary sclerosing cholangitis. J. Hepatol. 48: 692-694 (2008). *
Silverstein FE, Faich G, Goldstein JL, Simon LS, Pincus T, Whelton A, Makuch R, Eisen G, Agrawal NM, Stenson WF, Burr AM, Zhao WW, Kent JD, Lefkowith JB, Verburg KM, Geis GS. Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: a randomized controlled trial. Celecoxib Long-term Arthritis Safety Study. JAMA 284: 1247-1255 (2000). *
Simko V, Kelley RE, Dincsoy HP, Gimmon Z, Willmann K. Exercise in rats with liver injury induced by carbon tetrachloride or bile duct obstruction. Blood cholic acid and liver histology. Res. Exp. Med. (Berl.) 181: 135-145 (1982).
Simon D, Prieur AM, Quartier P, Charles Ruiz J, Czernichow P. Early recombinant human growth hormone treatment in glucocorticoid-treated children with juvenile idiopathic arthritis: 3-year randomized study. J. Clin. Endocrinol. Metab. 92: 2567-2573 (2007). *
Simpson D, Plosker GL. Atomoxetine: a review of its use in adults with attention deficit hyperactivity disorder. Drugs 64: 205-222 (2004).
Sinakos E, Marschall HU, Kowdley KV, Befeler A, Keach J, Lindor K. Bile acid changes after high-dose ursodeoxycholic acid treatment in primary sclerosing cholangitis: relation to disease progression. Hepatology [In Press] (2010). *
Singer MV, Schmausser H, Schonfeld G. Efficacy and tolerability of olsalazine (dipentum) in the treatment of patients with ulcerative colitis - results of a field study. Hepatogastroenterology 53: 317-321 (2006).
Singh AK, Trotman BW. Use and safety of aspirin in the chemoprevention of colorectal cancer. J. Assoc. Acad. Minor Phys. 9: 40-44 (1998).
Singh P, Ballas S. Drugs for preventing red blood cell dehydration in people with sickle cell disease. Cochrane Database Syst. Rev. 4: CD003426 (2007). *
Singh S, Kumar A. Leukocyte depletion for safe blood transfusion. Biotechnol. J. 4: 1140-1151 (2009).
Sinha RA, Khare P, Rai A, Maurya SK, Pathak A, Mohan V, Nagar GK, Mudiam MK, Godbole MM, Bandyopadhyay S. Anti-apoptotic role of omega-3-fatty acids in developing brain: perinatal hypothyroid rat cerebellum as apoptotic model. Int. J. Dev. Neurosci. 27: 377-383 (2009).
Sinha S, Taly AB, Prashanth LK, Arunodaya GR, Swamy HS. Successful pregnancies and abortions in symptomatic and asymptomatic Wilson's disease. J. Neurol. Sci. 217: 37-40 (2004). *
Sinicrope FA, Rego RL, Ansell SM, Knutson KL, Foster NR, Sargent DJ. Intraepithelial effector (CD3+):regulatory (FoxP3+) T-cell ratio predicts adverse outcome of human colon carcinoma. Gastroenterology 137: 1270-1279 (2009). *
Sinn PL, Sauter SL, McCray PB. Gene therapy progress and prospects: development of improved lentiviral and retroviral vectors - design, biosafety, and production. Gene Ther. 12: 1089-1098 (2005). *
Sipe JC, Arbour N, Gerber A, Beutler E. Reduced endocannabinoid immune modulation by a common cannabinoid 2 (CB2) receptor gene polymorphism: possible risk for autoimmune disorders. J. Leukoc. Biol. 78: 231-238 (2005). *
Sjoberg RL, Nilsson KW, Nordquist N, Ohrvik J, Leppert J, Lindstrom L, Oreland L. Development of depression: sex and the interaction between environment and a promoter polymorphism of the serotonin transporter gene. Int. J. Neuropsychopharmacol. 9: 443-449 (2006).
Skorpen F, Laugsand E, Klepstad P, Kaasa S. Variable response to opioid treatment: any genetic predictors within sight? Palliat. Med. 22: 310-327 (2008).
Slade BA, Leidel L, Vellozzi C, Woo EJ, Hua W, Sutherland A, Izurieta HS, Ball R, Miller N, Braun MM, Markowitz LE, Iskander J. Postlicensure safety surveillance for quadrivalent human papillomavirus recombinant vaccine. JAMA 302: 750-757 (2009). *
Sliesoraitis S, Khan R, Rothman J. Methotrexate-induced hodgkin disease in a patient with systemic lupus erythematosus. J. Am. Osteopath. Assoc. 109: 325-328 (2009).
Slifman NR, Gershon SK, Lee JH, Edwards ET, Braun MM. Listeria monocytogenes infection as a complication of treatment with tumor necrosis factor alpha-neutralizing agents. Arthritis Rheum. 48: 319-324 (2003). *
Slyk MP, Frazee LA. Nicotine: does it have a role in the treatment of ulcerative colitis? Am. J. Ther. 4: 141-148 (1997).
Small RE, Schraa CC. Chemistry, pharmacology, pharmacokinetics, and clinical applications of mesalamine for the treatment of inflammatory bowel disease. Pharmacotherapy 14: 385-398 (1994).
Smit JV, Franssen ME, de Jong EM, Lambert J, Roseeuw DI, De Weert J, Yocum RC, Stevens VJ, van De Kerkhof PC. A phase II multicenter clinical trial of systemic bexarotene in psoriasis. J. Am. Acad. Dermatol. 51: 249-256 (2004).
Smit LA, Heederik D, Doekes G, Krop EJ, Rijkers GT, Wouters IM. Ex vivo cytokine release reflects sensitivity to occupational endotoxin exposure. Eur. Respir. J. 34: 795-802 (2009).
Smith CH, Jackson K, Bashir SJ, Perez A, Chew AL, Powell AM, Wain M, Barker JN. Infliximab for severe, treatment-resistant psoriasis: a prospective, open-label study. Br. J. Dermatol. 155: 160-169 (2006). *
Smith JA, Thompson DJ, Whitcup SM, Suhler E, Clarke G, Smith S, Robinson M, Kim J, Barron KS. A randomized, placebo-controlled, double-masked clinical trial of etanercept for the treatment of uveitis associated with juvenile idiopathic arthritis. Arthritis Rheum. 53: 18-23 (2005). *
Smith LS, Nelson M, Dolder CR. Certolizumab pegol: a TNF-alpha antagonist for the treatment of moderate-to-severe Crohn's disease. Ann. Pharmacother. Jan 5 [Epub ahead of print] (2010).
Smith M, Marinaki A, Arenas M, Shobowale-Bakre M, Lewis C, Ansari A, Duley J, Sanderson J. Novel pharmacogenetic markers for treatment outcome in azathioprine-treated inflammatory bowel disease. Aliment. Pharmacol. Ther. 30: 375-384 (2009). *
Smith SW. Chiral toxicology: it's the same thing...only different. Toxicol. Sci. 110: 4-30 (2009). *
Smolen JS. What is the place of recently approved T cell-targeted and B cell-targeted therapies in the treatment of rheumatoid arthritis? Lessons from global clinical trials. J. Rheumatol. Suppl. 79: 15-20 (2007). *
Smolen JS, Aletaha D, Koeller M, Weisman MH, Emery P. New therapies for treatment of rheumatoid arthritis. Lancet 370: 1861-1874 (2007). *
Smolen JS, Beaulieu A, Rubbert-Roth A, Ramos-Remus C, Rovensky J, Alecock E, Woodworth T, Alten R; OPTION Investigators. Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomised trial. Lancet 371: 987-997 (2008). *
Smolen JS, Landewe RB, Mease PJ, Brzezicki J, Mason D, Luijtens K, van Vollenhoven RF, Kavanaugh A, Schiff MH, Burmester GR, Strand V, Vencovsky J, van der Heijde DM. Efficacy and safety of certolizumab pegol plus methotrexate in active rheumatoid arthritis: the RAPID 2 study. Ann. Rheum. Dis. 68: 797-804 (2009). *
Smyth A, Garovic VD. Systemic lupus erythematosus and pregnancy. Minerva Urol. Nefrol. 61: 457-474 (2009).
Smyth R, Walters S. Oral calorie supplements for cystic fibrosis. Cochrane Database Syst. Rev. 1: CD000406 (2007). *
Soares Rolim AM, Castro M, Santiago MB. Neonatal antiphospholipid syndrome. Lupus 15: 301-303 (2006).
Sodeyama M, Gardiner KR, Regan MC, Kirk SJ, Efron G, Barbul A. Sepsis impairs gut amino acid absorption. Am. J. Surg. 165: 150-154 (1993).
Soejima M, Sugiura T, Kawaguchi Y, Kawamoto M, Katsumata Y, Takagi K, Nakajima A, Mitamura T, Mimori A, Hara M, Kamatani N. Association of the diplotype configuration at the N-acetyltransferase 2 gene with adverse events by co-trimoxazole in Japanese patients with systemic lupus erythematosus. Arthritis Res. Ther. 9: R23 (2007). *
Soen S. Daily practice along the guideline for prevention and treatment of osteoporosis. The effects of anti-TNF therapy on bone and joint manifestations in rheumatoid arthritis. Clin. Calcium 18: 1169-1175 (2008).
Soerensen H, Schneidewind-Mueller JM, Lange D, Kashiwagi N, Franz M, Yokoyama T, Ramlow W. Pilot clinical study of Adacolumn cytapheresis in patients with systemic lupus erythematosus. Rheumatol. Int. 26: 409-415 (2006). *
Sollinger HW. Mycophenolates in transplantation. Clin. Transplant. 18: 485-492 (2004).
Song DK, Zhao J, Zhang LR. TPMT genotype and its clinical implication in renal transplant recipients with azathioprine treatment. J. Clin. Pharm. Ther. 31: 627-635 (2006). *
Song HJ, Shim KN, Ryu KH, Kim TH, Jung SA, Yoo K. A case of ischemic colitis associated with the herbal food supplement ma huang. Yonsei. Med. J. 49: 496-499 (2008). *
Song IH, Gold R, Straub RH, Burmester GR, Buttgereit F. New glucocorticoids on the horizon: repress, don't activate! J. Rheumatol. 32: 1199-1207 (2005).
Song X, Xu A, Pan W, Wallin B, Kivlin R, Lu S, Cao C, Bi Z, Wan Y. Nicotinamide attenuates aquaporin 3 overexpression induced by retinoic acid through inhibition of EGFR/ERK in cultured human skin keratinocytes. Int. J. Mol. Med. 22: 229-236 (2008). *
Sood A, Midha V, Sood N, Bansal M. Long term results of use of azathioprine in patients with ulcerative colitis in India. World J. Gastroenterol. 12: 7332-7336 (2006). *
Sopori M. Effects of cigarette smoke on the immune system. Nat. Rev. Immunol. 2: 372-377 (2002). *
Soria A, Maubec E, Henry-Feugeas MC, Marinho E, Le Bozec P, Huisse MG, Pocidalo MA, Descamps V, Crickx B. Panniculitis induced by interferon beta vascular toxicity. Ann. Dermatol. Venereol. 134: 374-377 (2007).
Sospedra M, Martin R. Antigen-specific therapies in multiple sclerosis. Int. Rev. Immunol. 24: 393-413 (2005).
Sostres C, Gargallo C, Lanas A. Drug-related damage of the ageing gastrointestinal tract. Best Pract. Res. Clin. Gastroenterol. 23: 849-860 (2009).
Soukiasian SH, Foster CS, Raizman MB. Treatment strategies for scleritis and uveitis associated with inflammatory bowel disease. Am. J. Ophthalmol. 118: 601-611 (1994).
Southern KW, Merelle MM, Dankert-Roelse JE, Nagelkerke A. Newborn screening for cystic fibrosis. Cochrane Database Syst. Rev. 1: CD001402 (2009).
Spada M, Petz W, Bertani A, Riva S, Sonzogni A, Giovannelli M, Torri E, Torre G, Colledan M, Gridelli B. Randomized trial of basiliximab induction versus steroid therapy in pediatric liver allograft recipients under tacrolimus immunosuppression. Am. J. Transplant. 6: 1913-1921 (2006). *
Spadaro A, Scrivo R, Spinelli FR, Valesini G. Monitoring biological therapies in psoriatic arthritis. J. Rheumatol. Suppl. 83: 69-70 (2009).
Spahn TW, Kucharzik T. Modulating the intestinal immune system: the role of lymphotoxin and GALT organs. Gut 53: 456-465 (2004). *
Spanos CP, Mamopoulos A, Tsapas A, Syrakos T, Kiskinis D. Female fertility and colorectal cancer. Int. J. Colorectal Dis. 23: 735-743 (2008). *
Spertini F. New concepts for the therapy of systemic lupus erythematosus. Rev. Med. Suisse. 3: 98-102 (2007).
Spiller R. Serotonin, inflammation, and IBS: fitting the jigsaw together? J. Pediatr. Gastroenterol. Nutr. 45 Suppl. 2: S115-S119 (2007). *
Spiller R, Garsed K. Postinfectious irritable bowel syndrome. Gastroenterology 136: 1979-1988 (2009). *
Spirito MD, Morelli G, Doyle R, Johnson J, McKenney J. Effect of omega-3-acid ethyl esters on steady-state plasma pharmacokinetics of atorvastatin in healthy adults. Expert Opin. Pharmacother. 9: 2939-2945 (2008).
Spoettl T, Paetzel C, Herfarth H, Bencherif M, Schoelmerich J, Greinwald R, Gatto GJ, Rogler G. (E)-metanicotine hemigalactarate (TC-2403-12) inhibits IL-8 production in cells of the inflamed mucosa. Int. J. Colorectal Dis. 22: 303-312 (2007). *
Spolarich AE, Andrews L. An examination of the bleeding complications associated with herbal supplements, antiplatelet and anticoagulant medications. J. Dent. Hyg. 81: 67 (2007).
Sridhar J, Desylva P, Singh YD. Chimeric monoclonal antibody to tumor necrosis factor alpha (infliximab) in psoriasis. Indian J. Dermatol. Venereol. Leprol. 72: 133-135 (2006).
Srinivasan U, Jones E, Carolan J, Feighery C. Immunohistochemical analysis of coeliac mucosa following ingestion of oats. Clin. Exp. Immunol. 144: 197-203 (2006). *
St Charles M, Weiss Smith SR, Beardsley R, Fedder DO, Carter-Pokras O, Cross RK. Gastroenterologists' prescribing of infliximab for Crohn's disease: a national survey. Inflamm. Bowel Dis. 15: 1467-1475 (2009).
St-Amour I, Laroche A, Bazin R, Lemieux R. Activation of cryptic IgG reactive with BAFF, amyloid beta peptide and GM-CSF during the industrial fractionation of human plasma into therapeutic intravenous immunoglobulins. Clin. Immunol. 133: 52-60 (2009). *
Stahn C, Buttgereit F. Genomic and nongenomic effects of glucocorticoids. Nat. Clin. Pract. Rheumatol. 4: 525-533 (2008).
Stahn C, Lowenberg M, Hommes DW, Buttgereit F. Molecular mechanisms of glucocorticoid action and selective glucocorticoid receptor agonists. Mol. Cell. Endocrinol. 275: 71-78 (2007).
Stallmach A, Giese T, Schmidt C, Meuer SC, Zeuzem SS. Severe anaphylactic reaction to infliximab: successful treatment with adalimumab - report of a case. Eur. J. Gastroenterol. Hepatol. 16: 627-630 (2004).
Stamp L, Roberts R, Kennedy M, Barclay M, O'Donnell J, Chapman P. The use of low dose methotrexate in rheumatoid arthritis - are we entering a new era of therapeutic drug monitoring and pharmacogenomics? Biomed. Pharmacother. 60: 678-687 (2006).
Stampfli MR, Anderson GP. How cigarette smoke skews immune responses to promote infection, lung disease and cancer. Nat. Rev. Immunol. 9: 377-384 (2009). *
Stasi R, Provan D. Management of immune thrombocytopenic purpura in adults. Mayo Clin. Proc. 79: 504-522 (2004). *
Stava CJ, Jimenez C, Hu MI, Vassilopoulou-Sellin R. Skeletal sequelae of cancer and cancer treatment. J. Cancer Surviv. 3: 75-88 (2009).
Stavinoha MW, Soloway RD. Current therapy of chronic liver disease. Drugs 39: 814-840 (1990).
Stazi AV, Mantovani A. Celiac disease and its endocrine and nutritional implications on male reproduction. Minerva Med. 95: 243-254 (2004).
Stedman C. Herbal hepatotoxicity. Semin. Liver Dis. 22: 195-206 (2002).
Stefanutti C, Bucci A, Di Giacomo S, Fraone N, Pace A, Mareri M, Musca A, Mammarella A. Efficacy, safety and tolerability of combined low-dose simvastatin-fenofibrate treatment in primary mixed hyperlipidaemia. Clin. Drug Investig. 24: 465-477 (2004).
Stein CM. Allopurinol hypersensitivity. A case report. S. Afr. Med. J. 67: 935-936 (1985).
Stein MR, Nelson RP, Church JA, Wasserman RL, Borte M, Vermylen C, Bichler J; for the IgPro10 in PID study group. Safety and efficacy of Privigen(R), a novel 10% liquid immunoglobulin preparation for intravenous use, in patients with primary immunodeficiencies. J. Clin. Immunol. 29: 137-144 (2009). *
Stein RB, Hanauer SB. Comparative tolerability of treatments for inflammatory bowel disease. Drug Saf. 23: 429-448 (2000).
Steinhagen-Thiessen E, Muller S, Holler HD, Lang PD. Effect of bezafibrate and colestyramine in patients with primary hypercholesterolemia. Arzneimittelforschung 37: 726-728 (1987).
Steinhart AH, Hawkey CJ, Modigliani R. 6-Mercaptopurine and azathioprine for maintenance of remission in ulcerative colitis. Cochrane Database Syst. Rev. 2: CD000478 (2004). *
Steinhart H. Clinical perspectives - biologics in IBD: what's all the fuss? Can. J. Gastroenterol. 15: 799-804 (2001). *
Steinkamp G, Schmitt-Grohe S, Doring G, Staab D, Pfrunder D, Beck G, Schubert R, Zielen S. Once-weekly azithromycin in cystic fibrosis with chronic Pseudomonas aeruginosa infection. Respir. Med. 102: 1643-1653 (2008).
Stengel FM, Petri V, Campbell GA, Dorantes GL, Lopez M, Galimberti RL, Valdez RP, de Arruda LF, Guerra MA, Chouela EN, Licu D; International IMP25161 Study Group. Control of moderate-to-severe plaque psoriasis with efalizumab: 24-week, open-label, phase IIIb/IV Latin American study results. Arch. Drug Inf. 2: 71-78 (2009).
Stepchenkova EI, Tarakhovskaya ER, Spitler K, Frahm C, Menezes MR, Simone PD, Kolar C, Marky LA, Borgstahl GE, Pavlov YI. Functional study of the P32T ITPA variant associated with drug sensitivity in humans. J. Mol. Biol. 392: 602-613 (2009). *
Stephan MT, Ponomarev V, Brentjens RJ, Chang AH, Dobrenkov KV, Heller G, Sadelain M. T cell-encoded CD80 and 4-1BBL induce auto- and transcostimulation, resulting in potent tumor rejection. Nat. Med. 13: 1440-1449 (2007). *
Stephens MC, Shepanski MA, Mamula P, Markowitz JE, Brown KA, Baldassano RN. Safety and steroid-sparing experience using infliximab for Crohn's disease at a pediatric inflammatory bowel disease center. Am. J. Gastroenterol. 98: 104-111 (2003). *
Stern BJ. Neurological complications of sarcoidosis. Curr. Opin. Neurol. 17: 311-316 (2004).
Sternthal MB, Murphy SJ, George J, Kornbluth A, Lichtiger S, Present DH. Adverse events associated with the use of cyclosporine in patients with inflammatory bowel disease. Am. J. Gastroenterol. 103: 937-943 (2008). *
Stick SM. Clinical trials in infants with cystic fibrosis detected following newborn screening. Paediatr. Respir. Rev. 9: 176-180 (2008).
Stickel F. Slimming at all costs: Herbalife(R)-induced liver injury. J. Hepatol. 47: 444-446 (2007). *
Stiebel-Kalish H, Hammel N, Everdingen J, Huna-Baron R, Lee AG. Intravenous immunoglobulin in recurrent-relapsing inflammatory optic neuropathy. Can. J. Ophthalmol. 45: 71-75 (2010).
Stirban A. Drugs for the treatment of diabetes complications. Zycose: a new player in the field? Drugs Today (Barc.) 44: 783-796 (2008).
Stocco G, Martelossi S, Barabino A, Decorti G, Bartoli F, Montico M, Gotti A, Ventura A. Glutathione-S-transferase genotypes and the adverse effects of azathioprine in young patients with inflammatory bowel disease. Inflamm. Bowel Dis. 13: 57-64 (2007). *
Stocco G, Martelossi S, Barabino A, Fontana M, Lionetti P, Decorti G, Malusa N, Bartoli F, Fezzi M, Giraldi T, Ventura A. TPMT genotype and the use of thiopurines in paediatric inflammatory bowel disease. Dig. Liver Dis. 37: 940-945 (2005).
Stocco G, Martelossi S, Sartor F, Toffoli G, Lionetti P, Barabino A, Fontana M, Decorti G, Bartoli F, Giraldi T, Ventura A. Prevalence of methylenetetrahydrofolate reductase polymorphisms in young patients with inflammatory bowel disease. Dig. Dis. Sci. 51: 474-479 (2006). *
Stockbrugger RW. Nonsteroidal anti-inflammatory drugs (NSAIDs) in the prevention of colorectal cancer. Eur. J. Cancer Prev. 8 Suppl. 1: S21-S25 (1999).
Stokkers PC, Deley M, Spek MV, Verberne HJ, Van Deventer SJ, Hommes DW. Intravenous pamidronate in combination with calcium and vitamin D: highly effective in the treatment of low bone mineral density in inflammatory bowel disease. Scand. J. Gastroenterol. 41: 200-204 (2006). *
Stokkers PC, Hommes DW. Novel biological therapies for inflammatory bowel disease. Curr. Treat. Options Gastroenterol. 9: 201-210 (2006).
Stoll M, Schmidt RE. Adverse events of desirable gain in immunocompetence: the Immune Restoration Inflammatory Syndromes. Autoimmun. Rev. 3: 243-249 (2004).
Stolte M, Hartmann FO. Misinterpretation of NSAID-induced colopathy as Crohn's disease. Z. Gastroenterol. Feb 5 [Epub ahead of print] (2010).
Stone JH, Holbrook JT, Marriott MA, Tibbs AK, Sejismundo LP, Min YI, Specks U, Merkel PA, Spiera R, Davis JC, St Clair EW, McCune WJ, Ytterberg SR, Allen NB, Hoffman GS; Wegener's Granulomatosis Etanercept Trial Research Group. Solid malignancies among patients in the Wegener's granulomatosis Etanercept Trial. Arthritis Rheum. 54: 1608-1618 (2006). *
Straatsma BR, Nusinowitz S, Young TA, Gordon LK, Chun MW, Rosen C, Seja E, Economou JS, Glaspy JA, Bozon V, Gomez-Navarro J, Ribas A. Surveillance of the eye and vision in clinical trials of CP-675,206 for metastatic melanoma. Am. J. Ophthalmol. 143: 958-969 (2007). *
Stratigos AJ, Antoniou C, Stamathioudaki S, Avgerinou G, Tsega A, Katsambas AD. Discoid lupus erythematosus-like eruption induced by infliximab. Clin. Exp. Dermatol. 29: 150-153 (2004). *
Stratton KR, Howe CJ, Johnston RB Jr. Adverse events associated with childhood vaccines other than pertussis and rubella. Summary of a report from the Institute of Medicine. JAMA 271: 1602-1605 (1994).
Stremmel W, Braun A, Hanemann A, Ehehalt R, Autschbach F, Karner M. Delayed release phosphatidylcholine in chronic-active ulcerative colitis: a randomized, double-blinded, dose finding study. J. Clin. Gastroenterol. Dec 31 [Epub ahead of print] (2009).
Stremmel W, Ehehalt R, Autschbach F, Karner M. Phosphatidylcholine for steroid-refractory chronic ulcerative colitis: a randomized trial. Ann. Intern. Med. 147: 603-610 (2007). *
Stricker BH, Blok AP, Babany G, Benhamou JP. Fibrin ring granulomas and allopurinol. Gastroenterology 96: 1199-1203 (1989).
Strimpakos AS, Sharma RA. Curcumin: preventive and therapeutic properties in laboratory studies and clinical trials. Antioxid. Redox Signal. 10: 511-546 (2008).
Strobel S. Mechanisms in adverse reactions to food. Mechanisms of tolerance and sensitization in the intestine and other organs of the body. Allergy 50: S18-S25 (1995).
Strober W. The role of cytokines in the pathogenesis of experimental and human inflammatory diseases of the mucosal immune system. Falk Symposium 146: GUT-LIVER INTERACTIONS: BASIC AND CLINICAL CONCEPTS, Innsbruck (Austria), March 11-12, 2005, pp. 20-21 (2005). *
Stuart KA, Fletcher LM, Clouston AD, Lynch SV, Purdie DM, Kerlin P, Crawford DH. Increased hepatic iron and cirrhosis: no evidence for an adverse effect on patient outcome following liver transplantation. Hepatology 32: 1200-1207 (2000). *
Stuby U, Biesenbach G, Pieringer H. Administration of infliximab in general practitioners' offices is safe. Clin. Rheumatol. 26: 1863-1866 (2007). *
Su C, Salzberg BA, Lewis JD, Deren JJ, Kornbluth A, Katzka DA, Stein RB, Adler DR, Lichtenstein GR. Efficacy of anti-tumor necrosis factor therapy in patients with ulcerative colitis. Am. J. Gastroenterol. 97: 2577-2584 (2002). *
Su KP, Huang SY, Chiu TH, Huang KC, Huang CL, Chang HC, Pariante CM. Omega-3 fatty acids for major depressive disorder during pregnancy: results from a randomized, double-blind, placebo-controlled trial. J. Clin. Psychiatry 69: 644-651 (2008).
Su L, Xu J, Ji BX, Wan SG, Lu CY, Dong HQ, Yu YY, Lu DP. Autologous peripheral blood stem cell transplantation for severe multiple sclerosis. Int. J. Hematol. 84: 276-281 (2006).
Subramanian S, Handa R. Biological agents in rheumatoid arthritis. J. Postgrad. Med. 50: 293-299 (2004). *
Sugiura H, Matsubayashi T. Clinical features of CINCA syndrome: effects and problems of IL-1Ra. Nihon Rinsho Meneki Gakkai Kaishi 30: 108-113 (2007).
Sugiyama H, McCormick TS, Cooper KD, Korman NJ. Alefacept in the treatment of psoriasis. Clin. Dermatol. 26: 503-508 (2008).
Sukal SA, Nadiminti L, Granstein RD. Etanercept and demyelinating disease in a patient with psoriasis. J. Am. Acad. Dermatol. 54: 160-164 (2006).
Sukhatme SV, Gottlieb AB. Pediatric psoriasis: updates in biologic therapies. Dermatol. Ther. 22: 34-39 (2009).
Sullivan JR, Watson A. Naltrexone: a case report of pruritus from an antipruritic. Australas. J. Dermatol. 38: 196-198 (1997).
Summers RW. Novel and future medical management of inflammatory bowel disease. Surg. Clin. North Am. 87: 727-741 (2007).
Summers RW, Elliott DE, Qadir K, Urban JF Jr, Thompson R, Weinstock JV. Trichuris suis seems to be safe and possibly effective in the treatment of inflammatory bowel disease. Am. J. Gastroenterol. 98: 2034-2041 (2003). *
Summers RW, Elliott DE, Urban JF Jr, Thompson R, Weinstock JV. Trichuris suis therapy in Crohn’s disease. Gut 54: 87-90 (2005). *
Sun G, Wasko CA, Hsu S. Acneiform eruption following anti-TNF-alpha treatment: a report of three cases. J. Drugs Dermatol. 7: 69-71 (2008).
Sun J, Schiffman J, Raghunath A, Ng Tang D, Chen H, Sharma P. Concurrent decrease in IL-10 with development of immune-related adverse events in a patient treated with anti-CTLA-4 therapy. Cancer Immun. 8: 9 (2008). *
Sun K, Li M, Konopleva M, Konoplev S, Stephens LC, Kornblau SM, Frolova O, Wilkins DE, Ma W, Welniak LA, Andreeff M, Murphy WJ. The synthetic triterpenoid, CDDO, suppresses alloreactive T cell responses and teduces murine early acute graft-versus-host disease mortality. Biol. Blood Marrow Transplant. 13: 521-529 (2007).
Suphioglu C, De Mel D, Kumar L, Sadli N, Freestone D, Michalczyk A, Sinclair A, Ackland ML. The omega-3 fatty acid, DHA, decreases neuronal cell death in association with altered zinc transport. FEBS Lett. Dec 14 [Epub ahead of print] (2009). *
Surrenti C, Pozzi M, Biagini MR, Franco C, Lombardo R, Avanzi G. Effects of plasma exchange (PE) in primary biliary cirrhosis (PBC). A pilot study. Hepatogastroenterology 37: 128-130 (1990).
Suryaprasad AG, Prindiville T. The biology of TNF blockade. Autoimmun. Rev. 2: 346-357 (2003).
Susal C, Dohler B, Sadeghi M, Ovens J, Opelz G. HLA antibodies and the occurrence of early adverse events in the modern era of transplantation: a collaborative transplant study report. Transplantation 87: 1367-1371 (2009).
Sutherland AM, Russell JA. Issues with polymorphism analysis in sepsis. Clin. Infect. Dis. 41 Suppl. 7: S396-S402 (2005). *
Sutherland L, Macdonald J. Oral 5-aminosalicylic acid for maintenance of remission in ulcerative colitis. Cochrane Database Syst. Rev. 2: CD000544 (2006). *
Sutherland L, MacDonald J. Oral 5-aminosalicylic acid for induction of remission in ulcerative colitis. Cochrane Database Syst. Rev. 3: CD000543 (2003). *
Sutherland L, Macdonald J. Oral 5-aminosalicylic acid for induction of remission in ulcerative colitis. Cochrane Database Syst. Rev. 2: CD000543 (2006). *
Sutherland L, Roth D, Beck P, May G, Makiyama K. Oral 5-aminosalicylic acid for maintenance of remission in ulcerative colitis. Cochrane Database Syst. Rev. 4: CD000544 (2002). *
Suttorp M. Innovative approaches of targeted therapy for CML of childhood in combination with paediatric haematopoietic SCT. Bone Marrow Transplant. 42 Suppl. 2: S40-S46 (2008).
Suzuki Y, Yoshimura N, Saniabadi AR, Saito Y. Selective granulocyte and monocyte adsorptive apheresis as a first-line treatment for steroid naive patients with active ulcerative colitis: a prospective uncontrolled study. Dig. Dis. Sci. 49: 565-571 (2004). *
Svoboda RP, Patel DH, Olden KW. Oral formulations of budesonide: a novel treatment for inflammatory bowel disease. Drugs Today (Barc.) 44: 857-863 (2008).
Swaminath A, Ullman T, Rosen M, Mayer L, Lichtiger S, Abreu MT. Early clinical experience with adalimumab in treatment of inflammatory bowel disease with infliximab-treated and naive patients. Aliment. Pharmacol. Ther. 29: 273-278 (2009). *
Sweet BV. Abatacept. Am. J. Health Syst. Pharm. 63: 2065-2077 (2006).
Sweet BV. Natalizumab update. Am. J. Health Syst. Pharm. 64: 705-716 (2007).
Sweiss NJ, Hushaw LL. Biologic agents for rheumatoid arthritis: 2008 and beyond. J. Infus. Nurs. 32: S4-S17 (2009).
Swift GL, Srivastava ED, Stone R, Pullan RD, Newcombe RG, Rhodes J, Wilkinson S, Rhodes P, Roberts G, Lawrie BW, et al. Controlled trial of anti-tuberculous chemotherapy for two years in Crohn's disease. Gut 35: 363-368 (1994). *
Sygnowska E, Waskiewicz A. Evaluation of prevalence and magnitude of vitamins and minerals supplementation in Polish population. Rocz. Panstw. Zakl. Hig. 60: 167-170 (2009).
Szczepanski M, Szyfter W, Jenek R, Wrobel M, Lisewska IM, Zeromski J. Toll-like receptors 2, 3 and 4 (TLR-2, TLR-3 and TLR-4) are expressed in the microenvironment of human acquired cholesteatoma. Eur. Arch. Otorhinolaryngol. 263: 603-607 (2006). *
Szep Z, Danilla T, Buchvald D. Treatment of juvenile pemphigus vulgaris with intravenous immunoglobulins. Cas. Lek. Cesk. 144: 700-703 (2005).
Szigethy E, Whitton SW, Levy-Warren A, Demaso DR, Weisz J, Beardslee WR. Cognitive-behavioral therapy for depression in adolescents with inflammatory bowel disease: a pilot study. J. Am. Acad. Child. Adolesc. Psychiatry 43: 1469-1477 (2004).
Szklarek-Kubicka M, Fijalkowska-Morawska J, Zaremba-Drobnik D, Ucinski A, Czekalski S, Nowicki M. Effect of intradialytic intravenous administration of omega-3 fatty acids on nutritional status and inflammatory response in hemodialysis patients: a pilot study. J. Ren. Nutr. 19: 487-493 (2009). *
Szyper-Kravitz M, Sheinberg P, Sidi Y, Schiffenbauer Y, Trubniykov E, Shoenfeld Y. Hypersensitivity to mycophenolate mofetil in systemic lupus erythematosus: diagnostic measures and successful desensitization. Int. Arch. Allergy Immunol. 138: 334-336 (2005).
Tabb MM, Kholodovych V, Grun F, Zhou C, Welsh WJ, Blumberg B. Highly chlorinated PCBs inhibit the human xenobiotic response mediated by the steroid and xenobiotic receptor (SXR). Environ. Health Perspect. 112: 163-169 (2004). *
Tadini KA, Gaspar LR, Maia Campos PM. Epidermal effects of tretinoin and isotretinoin: influence of isomerism. Pharmazie 61: 453-456 (2006).
Taffet SL, Das KM. Sulfasalazine. Adverse effects and desensitization. Dig. Dis. Sci. 28: 833-842 (1983).
Tagami T, Yamamoto H, Moriyama K, Sawai K, Usui T, Shimatsu A, Naruse M. A selective peroxisome proliferator-activated receptor gamma modulator, telmisartan, binds to the receptor in a different fashion from thiazolidinediones. Endocrinology 150: 862-870 (2009). *
Taha AY, Alizadeh S, Zeng QH, Filo E, McPherson JP, Burnham WM. Assessing the metabolic and toxic effects of anticonvulsant doses of polyunsaturated fatty acids on the liver in rats. J. Toxicol. Environ. Health A 72: 1191-1200 (2009). *
Tahiri L, Allali F, Jroundi I, Abouqal R, Hajjaj-Hassouni N. Therapeutic maintenance level of methotrexate in rheumatoid arthritis. Sante 16: 167-172 (2006).
Taieb D, Malicet C, Garcia S, Rocchi P, Arnaud C, Dagorn JC, Iovanna JL, Vasseur S. Inactivation of stress protein p8 increases murine carbon tetrachloride hepatotoxicity via preserved CYP2E1 activity. Hepatology 42: 176-182 (2005). *
Tajiri H, Tomomasa T, Yoden A, Konno M, Sasaki M, Maisawa S, Sumazaki R, Shimizu T, Toyoda S, Etani Y, Nakacho M, Ushijima K, Kobayashi A. Efficacy and safety of azathioprine and 6-mercaptopurine in Japanese pediatric patients with ulcerative colitis: a survey of the Japanese Society for Pediatric Inflammatory Bowel Disease. Digestion 77: 150-154 (2008). *
Takagi S, Utsunomiya K, Kuriyama S, Yokoyama H, Takahashi S, Iwabuchi M, Takahashi H, Takahashi S, Kinouchi Y, Hiwatashi N, Funayama Y, Sasaki I, Tsuji I, Shimosegawa T. Effectiveness of an 'half elemental diet' as maintenance therapy for Crohn's disease: a randomized-controlled trial. Aliment. Pharmacol. Ther. 24: 1333-1340 (2006). *
Takagi T, Arisawa T, Yamamoto K, Hirata I, Nakano H, Sawada M. Identification of ligands binding specifically to inflammatory intestinal mucosa using phage display. Clin. Exp. Pharmacol. Physiol. 34: 286-289 (2007). *
Takahashi H, Ohara M, Imai K. Collagen diseases with gastrointestinal manifestations. Nihon Rinsho Meneki Gakkai Kaishi 27: 145-155 (2004).
Takahashi H, Razavi H, Thomson D. Recent progress in the discovery of novel glucocorticoid receptor modulators. Curr. Top. Med. Chem. 8: 521-530 (2008).
Takahashi H, Tran PO, LeRoy E, Harmon JS, Tanaka Y, Robertson RP. D-glyceraldehyde causes production of intracellular peroxide in pancreatic islets, oxidative stress, and defective beta cell function via non-mitochondrial pathways. J. Biol. Chem. 279: 37316-37323 (2004). *
Takane H, Shikata E, Otsubo K, Higuchi S, Ieiri I. Polymorphism in human organic cation transporters and metformin action. Pharmacogenomics 9: 415-422 (2008).
Takatori R, Takahashi KA, Tokunaga D, Hojo T, Fujioka M, Asano T, Hirata T, Kawahito Y, Satomi Y, Nishino H, Tanaka T, Hirota Y, Kubo T. ABCB1 C3435T polymorphism influences methotrexate sensitivity in rheumatoid arthritis patients. Clin. Exp. Rheumatol. 24: 546-554 (2006).
Takatsu N, Matsui T, Murakami Y, Ishihara H, Hisabe T, Nagahama T, Maki S, Beppu T, Takaki Y, Hirai F, Yao K. Adverse reactions to azathioprine cannot be predicted by thiopurine S-methyltransferase genotype in Japanese patients with inflammatory bowel disease. J. Gastroenterol. Hepatol. 24: 1258-1264 (2009). *
Takatsuki M, Chen CL, Chen YS, Wang CC, Lin CC, Yang CH, Yong CC, Liu YW. Impact of late conversion from C0 to C2 monitoring of microemulsified cyclosporine in pediatric living donor liver transplant recipients. Clin. Transplant. 18: 694-699 (2004). *
Takazoe M, Matsui T, Motoya S, Matsumoto T, Hibi T, Watanabe M. Sargramostim in patients with Crohn's disease: results of a phase 1-2 study. J. Gastroenterol. 44: 535-543 (2009). *
Takazoe M, Tanaka T, Kondo K, Ichimori T, Shinoda T. The present status and the recent development of the treatment for inflammatory bowel diseases: desirable effect of extracorporeal immunomodulation. Ther. Apher. 6: 305-311 (2002).
Takeshita A, Koibuchi N, Oka J, Taguchi M, Shishiba Y, Ozawa Y. Bisphenol-A, an environmental estrogen, activates the human orphan nuclear receptor, steroid and xenobiotic receptor-mediated transcription. Eur. J. Endocrinol. 145: 513-517 (2001). *
Takeuchi Y, Uedo N, Ishihara R, Iishi H, Kizu T, Inoue T, Chatani R, Hanaoka N, Taniguchi T, Kawada N, Higashino K, Shimokawa T, Tatsuta M. Efficacy of an endo-knife with a water-jet function (flushknife) for endoscopic submucosal dissection of superficial colorectal neoplasms. Am. J. Gastroenterol. Sep 22 [Epub ahead of print] (2009). *
Talbot C, Sagar PM, Johnston MJ, Finan PJ, Burke D. Infliximab in the surgical management of complex fistulating anal Crohn's disease. Colorectal Dis. 7: 164-168 (2005). *
Talley NJ. Gut eosinophilia in food allergy and systemic and autoimmune diseases. Gastroenterol. Clin. North Am. 37: 307-332 (2008).
Talpur R, Cox K, Duvic M. Efficacy and safety of topical tazarotene: a review. Expert Opin. Drug Metab. Toxicol. 5: 195-210 (2009).
Talwalkar JA, Angulo P, Keach JC, Petz JL, Jorgensen RA, Lindor KD. Mycophenolate mofetil for the treatment of primary biliary cirrhosis in patients with an incomplete response to ursodeoxycholic acid. J. Clin. Gastroenterol. 39: 168-171 (2005).
Talwalkar JA, Donlinger JJ, Gossard AA, Keach JC, Jorgensen RA, Petz JC, Lindor KD. Fluoxetine for the treatment of fatigue in primary biliary cirrhosis: a randomized, double-blind controlled trial. Dig. Dis. Sci. 51: 1985-1991 (2006). *
Talwalkar JA, Gossard AA, Keach JC, Jorgensen RA, Petz JL, Lindor KD. Tacrolimus for the treatment of primary sclerosing cholangitis. Liver Int. 27: 451-453 (2007). *
Talwalkar JA, Paul Angulo P, Keach JC, Petz JL, Jorgensen RA, Lindor KD. Mycophenolate mofetil for the treatment of primary sclerosing cholangitis. Am. J. Gastroenterol. 100: 308-312 (2005). *
Tamaki H, Nakase H, Matsuura M, Inoue S, Mikami S, Ueno S, Uza N, Kitamura H, Kasahara K, Chiba T. The effect of tacrolimus (FK-506) on Japanese patients with refractory Crohn's disease. J. Gastroenterol. 43: 774-779 (2008). *
Tamori A, Shinzaki M, Kosaka S, Hayashi T, Iwai S, Enomoto M, Habu D, Sakaguchi H, Kawada N, Hino M, Shiomi S, Nishiguchi S. Thiopurine S-methyltransferase gene polymorphism in Japanese patients with autoimmune liver diseases. Liver Int. 27: 95-100 (2007). *
Tamura N, Matsudaira R, Hirashima M, Ikeda M, Tajima M, Nawata M, Morimoto S, Kaneda K, Kobayashi S, Hashimoto H, Takasaki Y. Two cases of refractory Wegeners granulomatosis successfully treated with rituximab. Intern. Med. 46: 409-414 (2007). *
Tamura S, Sugawara Y, Kishi Y, Akamatsu N, Kaneko J, Murai N, Makuuchi M. Conversion to cyclosporine provides valuable rescue therapy for living donor adult liver transplant patients intolerant to tacrolimus: a single-center experience at the University of Tokyo. Transplant. Proc. 36: 3242-3244 (2004). *
Tan H, Sun MY, Yang J. Effect of retention enema with combination of compound glutamine entero-soluble capsule and glucocorticoids for treatment of ulcerative colitis. Zhongguo Zhong Xi Yi Jie He Za Zhi 28: 645-647 (2008).
Tan T, Lawrance IC. Use of mycophenolate mofetil in inflammatory bowel disease. World J. Gastroenterol. 15: 1594-1599 (2009). *
Tan WC, Ong CK, Kang SC, Razak MA. Two years review of cutaneous adverse drug reaction from first line anti-tuberculous drugs. Med. J. Malaysia 62: 143-146 (2007).
Tanaka A, Hase S, Miyazawa T, Takeuchi K. Up-regulation of cyclooxygenase-2 by inhibition of cyclooxygenase-1: a key to nonsteroidal anti-inflammatory drug-induced intestinal damage. J. Pharmacol. Exp. Ther. 300: 754-761 (2002). *
Tanaka H. Current development of glucocorticoid-targeting drugs. Nippon Rinsho 66: 25-37 (2008).
Tanaka H, Tsugawa K, Oki E, Suzuki K, Ito E. Mizoribine intermittent pulse protocol for induction therapy for systemic lupus erythematosus in children: an open-label pilot study with five newly diagnosed patients. Clin. Rheumatol. 27: 85-89 (2008).
Tanaka H, Umekawa T, Kikukawa T, Toyoda N. Autoimmune hepatitis complicated with antiphospholipid syndrome in pregnancy. Am. J. Reprod. Immunol. 47: 142-145 (2002). *
Tanaka N, Sano K, Horiuchi A, Tanaka E, Kiyosawa K, Aoyama T. Highly purified eicosapentaenoic acid treatment improves nonalcoholic steatohepatitis. J. Clin. Gastroenterol. 42: 413-418 (2008).
Tanaka T, Okanobu H, Yoshimi S, Murakami E, Kogame A, Imagawa H, Numata Y, Kuga Y, Moriya T, Ohya T, Kajiyama G. In patients with ulcerative colitis, adsorptive depletion of granulocytes and monocytes impacts mucosal level of neutrophils and clinically is most effective in steroid naïve patients. Dig. Liver Dis. 40: 731-736 (2008).
Tanaka Y, Yamamoto K, Takeuchi T, Nishimoto N, Miyasaka N, Sumida T, Shima Y, Takada K, Matsumoto I, Saito K, Koike T. A multicenter phase I/II trial of rituximab for refractory systemic lupus erythematosus. Mod. Rheumatol. 17: 191-197 (2007). *
Tandon P, Rowe BH, Vandermeer B, Bain VG. The efficacy and safety of bile acid binding agents, opioid antagonists, or rifampin in the treatment of cholestasis-associated pruritus. Am. J. Gastroenterol. 102: 1528-1536 (2007). *
Tang L, Xu L, Afriyie-Gyawu E, Liu W, Wang P, Tang Y, Wang Z, Huebner HJ, Ankrah NA, Ofori-Adjei D, Williams JH, Wang JS, Phillips TD. Aflatoxin-albumin adducts and correlation with decreased serum levels of vitamins A and E in an adult Ghanaian population. Food Addit. Contam. Part A. Chem. Anal. Control Expo. Risk Assess. 26: 108-118 (2009).
Tani C, Mosca M, Colucci R, Gori G, d'Ascanio A, Ghisu N, Fornai M, Di Paolo A, Blandizzi C, Del Tacca M, Bombardieri S. Genetic polymorphisms of thiopurine S-methyltransferase in a cohort of patients with systemic autoimmune diseases. Clin. Exp. Rheumatol. 27: 321-324 (2009).
Taniai M, Hashimoto E, Tobari M, Yatsuji S, Haruta I, Tokushige K, Shiratori K. Treatment of nonalcoholic steatohepatitis with colestimide. Hepatol. Res. 39: 685-693 (2009). *
Taniguchi A, Urano W, Tanaka E, Furihata S, Kamitsuji S, Inoue E, Yamanaka M, Yamanaka H, Kamatani N. Validation of the associations between single nucleotide polymorphisms or haplotypes and responses to disease-modifying antirheumatic drugs in patients with rheumatoid arthritis: a proposal for prospective pharmacogenomic study in clinical practice. Pharmacogenet. Genomics 17: 383-390 (2007).
Tanikella R, Philips GM, Faulk DK, Kawut SM, Fallon MB. Pilot study of pentoxifylline in hepatopulmonary syndrome. Liver Transpl. 14: 1199-1203 (2008). *
Tanis AA. Azathioprine in inflammatory bowel disease, a safe alternative? Mediators Inflamm. 7: 141-144 (1998). *
Tao S, Zhou K, Tang DZ. The significance of combined therapy of arsenic trioxide and all-trans retinoic acid in treating acute promyelocytic leukemia. Zhongguo Zhong Xi Yi Jie He Za Zhi 29: 111-114 (2009).
Taraborelli M, Andreoli L, Archetti S, Ferrari M, Cattaneo R, Tincani A. Methylenetetrahydrofolate reductase polymorphisms and methotrexate: no association with response to therapy nor with drug-related adverse events in an Italian population of rheumatic patients. Clin. Exp. Rheumatol. 27: 499-502 (2009).
Tarantino G, Di Minno MN, Capone D. Drug-induced liver injury: is it somehow foreseeable? World J. Gastroenterol. 15: 2817-2833 (2009). *
Tararthuch AL, Fernandez R, Malnic G. Cl- and regulation of pH by MDCK-C11 cells. Braz. J. Med. Biol. Res. 40: 687-696 (2007). *
Targan SR, Feagan BG, Fedorak RN, Lashner BA, Panaccione R, Present DH, Spehlmann ME, Rutgeerts PJ, Tulassay Z, Volfova M, Wolf DC, Hernandez C, Bornstein J, Sandborn WJ. Natalizumab for the treatment of active Crohn's disease: results of the ENCORE trial. Gastroenterology 132: 1672-1683 (2007). *
Targan SR, Hanauer SB, van Deventer SJ, Mayer L, Present DH, Braakman T, DeWoody KL, Schaible TF, Rutgeerts PJ. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group. N. Engl. J. Med. 337: 1029-1035 (1997). *
Tarner IH, Neumann E, Gay S, Fathman CG, Muller-Ladner U. Developing the concept of adoptive cellular gene therapy of rheumatoid arthritis. Autoimmun. Rev. 5: 148-152 (2006).
Tasic V, Angjeleska M, Ristoska-Bojkovska N, Petrusevska G, Gucev Z. Autoimmune thyroiditis in a child with steroid-dependent nephrotic syndrome. Eur. J. Pediatr. 168: 229-231 (2009). *
Tassaneeyakul W, Jantararoungtong T, Chen P, Lin PY, Tiamkao S, Khunarkornsiri U, Chucherd P, Konyoung P, Vannaprasaht S, Choonhakarn C, Pisuttimarn P, Sangviroon A, Tassaneeyakul W. Strong association between HLA-B*5801 and allopurinol-induced Stevens-Johnson syndrome and toxic epidermal necrolysis in a Thai population. Pharmacogenet. Genomics 19: 704-709 (2009).
Tata LJ, Card TR, Logan RF, Hubbard RB, Smith CJ, West J. Fertility and pregnancy-related events in women with celiac disease: a population-based cohort study. Gastroenterology 128: 849-855 (2005). *
Taylor JR, Gardner TB, Waljee AK, Dimagno MJ, Schoenfeld PS. Systematic review: efficacy and safety of pancreatic enzyme supplements for exocrine pancreatic insufficiency. Aliment. Pharmacol. Ther. 31: 57-72 (2010). *
Taylor PJ, Kubler PA, Lynch SV, Allen J, Butler M, Pillans PI. Effect of atorvastatin on cyclosporine pharmacokinetics in liver transplant recipients. Ann. Pharmacother. 38: 205-208 (2004).
Tazawa R, Trapnell BC, Inoue Y, Arai T, Takada T, Nasuhara Y, Hizawa N, Kasahara Y, Tatsumi K, Hojo M, Ishii H, Yokoba M, Tanaka N, Yamaguchi E, Eda R, Tsuchihashi Y, Morimoto K, Akira M, Terada M, Otsuka J, Ebina M, Kaneko C, Nukiwa T, Krischer JP, et al. Inhaled granulocyte/macrophage-colony stimulating factor as therapy of pulmonary alveolar proteinosis. Am. J. Respir. Crit. Care Med. Feb 18 [Epub ahead of print] (2010). *
Tehrani R, Nash-Goelitz A, Adams E, Dahiya M, Eilers D. Minocycline-induced cutaneous polyarteritis nodosa. J. Clin. Rheumatol. 13: 146-149 (2007).
Tekkis PP, Heriot AG, Smith O, Smith JJ, Windsor AC, Nicholls RJ. Long-term outcomes of restorative proctocolectomy for Crohn's disease and indeterminate colitis. Colorectal Dis. 7: 218-223 (2005). *
Teml A, Schaeffeler E, Herrlinger KR, Klotz U, Schwab M. Thiopurine treatment in inflammatory bowel disease: clinical pharmacology and implication of pharmacogenetically guided dosing. Clin. Pharmacokinet. 46: 187-208 (2007).
Teml A, Schwab M, Harrer M, Miehsler W, Schaeffeler E, Dejaco C, Mantl M, Schneider B, Vogelsang H, Reinisch W. A prospective, open-label trial of 6-thioguanine in patients with ulcerative or indeterminate colitis. Scand. J. Gastroenterol. 40: 1205-1213 (2005). *
Tennyson H, Levine N. Neurotropic and psychotropic drugs in dermatology. Dermatol. Clin. 19: 179-197, x (2001).
Terai S, Sakaida I. Current status of autologous bone marrow cell infusion therapy for liver cirrhosis patients. Hepatol. Res. 38 (s1: The 6 Japan Society of Hepatology Single Topic Conference: Liver Failure: Recent Progress and Pathogenesis to Management. 28-29 September 2007, Iwate, Japan): S72-S75 (2008). *
Terasaki S, Nakanuma Y, Hoso M, Ogino H, Unoura M, Kobayashi K, Mizuno Y, Nakagawa H, Shimizu M, Kanai M, et al. Three cases of primary biliary cirrhosis associated with bronchial asthma. J. Gastroenterol. 30: 667-671 (1995).
Terg R, Coronel E, Sorda J, Munoz AE, Findor J. Efficacy and safety of oral naltrexone treatment for pruritus of cholestasis, a crossover, double blind, placebo-controlled study. J. Hepatol. 37: 717-722 (2002). *
Teshima CW, Thompson A, Dhanoa L, Dieleman LA, Fedorak RN. Long-term response rates to infliximab therapy for Crohn's disease in an outpatient cohort. Can. J. Gastroenterol. 23: 348-352 (2009).
Thakor P, Padmanabhan M, Johnson A, Pararajasingam T, Thakor S, Jorgensen W. Ramipril-induced generalized pustular psoriasis: case report and literature review. Am. J. Ther. Jun 13 [Epub ahead of print] (2009).
Thakur GA, Tichkule R, Bajaj S, Makriyannis A. Latest advances in cannabinoid receptor agonists. Expert Opin. Ther. Pat. 19: 1647-1673 (2009).
Thaler K, Chandiramani DV, Hansen RA, Gartlehner G. Efficacy and safety of anakinra for the treatment of rheumatoid arthritis: an update of the Oregon Drug Effectiveness Review Project. Biologics 3: 485-498 (2009). *
Thayu M, Mamula P. Treatment of iron deficiency anemia in pediatric inflammatory bowel disease. Curr. Treat. Options Gastroenterol. 8: 411-417 (2005).
Thia KT, Mahadevan U, Feagan BG, Wong C, Cockeram A, Bitton A, Bernstein CN, Sandborn WJ. Ciprofloxacin or metronidazole for the treatment of perianal fistulas in patients with Crohn's disease: a randomized, double-blind, placebo-controlled pilot study. Inflamm. Bowel Dis. 15: 17-24 (2009). *
Thibault L, Beausejour A, de Grandmont MJ, Long A, Goldman M, Chevrier MC. Establishment of an immunoglobulin A-deficient blood donor registry with a simple in-house screening enzyme-linked immunosorbent assay. Transfusion 46: 2115-2121 (2006).
Thiel A, Alexander T, Schmidt CA, Przybylski GK, Kimmig S, Kohler S, Radtke H, Gromnica-Ihle E, Massenkeil G, Radbruch A, Arnold R, Hiepe F. Direct assessment of thymic reactivation after autologous stem cell transplantation. Acta Haematol. 119: 22-27 (2008).
Thielens NM, Tacnet-Delorme P, Arlaud GJ. Interaction of C1q and mannan-binding lectin with viruses. Immunobiology 205: 563-574 (2002).
Thielitz A, Gollnick H. Topical retinoids in acne vulgaris: update on efficacy and safety. Am. J. Clin. Dermatol. 9: 369-381 (2008).
Thielitz A, Krautheim A, Gollnick H. Update in retinoid therapy of acne. Dermatol. Ther. 19: 272-279 (2006). *
Thielitz A, Naser MB, Fluhr JW, Zouboulis CC, Gollnick H. Topical retinoids in acne - an evidence-based overview. J. Dtsch. Dermatol. Ges. 6: 1023-1031 (2008).
Thompson RW, Valentine HL, Valentine WM. Cytotoxic mechanisms of hydrosulfide anion and cyanide anion in primary rat hepatocyte cultures. Toxicology 188: 149-159 (2003). *
Thomson AB. Review article: new developments in the use of 5-aminosalicylic acid in patients with inflammatory bowel disease. Aliment. Pharmacol. Ther. 5: 449-470 (1991).
Thomson EM, Williams A, Yauk CL, Vincent R. Toxicogenomic analysis of susceptibility to inhaled urban particulate matter in mice with chronic lung inflammation. Part. Fibre Toxicol. 6: 6 (2009).
Thorp E, Kuriakose G, Shah YM, Gonzalez FJ, Tabas I. Pioglitazone increases macrophage apoptosis and plaque necrosis in advanced atherosclerotic lesions of nondiabetic low-density lipoprotein receptor null mice. Circulation 116: 2182-2190 (2007). *
Thrasher AJ. Gene therapy: great expectations? Med. J. Aust. 182: 440-441 (2005).
Tierney BC, Martin SW, Franzke LH, Marano N, Reissman DB, Louchart RD, Goff JA, Rosenstein NE, Sever JL, McNeil MM; Centers for Disease Control and Prevention's Anthrax Vaccine and Antimicrobial Availability Program. Serious adverse events among participants in the Centers for Disease Control and Prevention's Anthrax Vaccine and Antimicrobial Availability Program for persons at risk for bioterrorism-related inhalational anthrax. Clin. Infect. Dis. 37: 905-911 (2003). *
Tilg H. Management of fulminant ulcerative colitis. Indian J. Gastroenterol. 25: S37-S38 (2006). *
Tilg H, Vogelsang H, Ludwiczek O, Lochs H, Kaser A, Colombel JF, Ulmer H, Rutgeerts P, Kruger S, Cortot A, D'Haens G, Harrer M, Gasche C, Wrba F, Kuhn I, Reinisch W. A randomised placebo controlled trial of pegylated interferon alpha in active ulcerative colitis. Gut 52: 1728-1733 (2003). *
Tilling L, Townsend S, David J. Methotrexate and hepatic toxicity in rheumatoid arthritis and psoriatic arthritis. Clin. Drug Investig. 26: 55-62 (2006).
Timmer A. Environmental epidemiology. Falk Symposium 140. Inflammatory Bowel Disease: Translation from Basic Research to Clinical Practice. Dubrovnik (Croatia). p. 47. May 7-8 (2004). *
Timmer A, McDonald J, Macdonald J. Azathioprine and 6-mercaptopurine for maintenance of remission in ulcerative colitis. Cochrane Database Syst. Rev. 1: CD000478 (2007). *
Tint GS, Salen G, Colalillo A, Graber D, Verga D, Speck J, Shefer S. Ursodeoxycholic acid: a safe and effective agent for dissolving cholesterol gallstones. Ann. Intern. Med. 97: 351-356 (1982).
Tiwari A, Bansal V, Chugh A, Mookhtiar K. Statins and myotoxicity: a therapeutic limitation. Expert Opin. Drug Saf. 5: 651-666 (2006).
Tlacuilo-Parra A, Guevara-Gutierrez E, Gutierrez-Murillo F, Soto-Ortiz A, Barba-Gomez F, Hernandez-Torres M, Salazar-Paramo M. Pimecrolimus 1% cream for the treatment of discoid lupus erythematosus. Rheumatology (Oxford) 44: 1564-1568 (2005). *
Tobin AM, Kirby B. TNFalpha inhibitors in the treatment of psoriasis and psoriatic arthritis. BioDrugs 19: 47-57 (2005).
Tobon GJ, Canas C, Jaller JJ, Restrepo JC, Anaya JM. Serious liver disease induced by infliximab. Clin. Rheumatol. 26: 578-581 (2007). *
Togawa J, Inamori M, Fujisawa N, Takahashi H, Yoneda M, Kawamura H, Abe Y, Kirikoshi H, Kobayashi N, Sakaguchi T, Takamura T, Nakajima A, Ueno N, Sekihara H. Efficacy of a triple therapy with rabeprazole, amoxicillin, and faropenem as second-line treatment after failure of initial Helicobacter pylori eradication therapy. Hepatogastroenterology 52: 645-648 (2005).
Tomasallo C, Anderson H, Haughwout M, Imm P, Knobeloch L. Mortality among frequent consumers of Great Lakes sport fish. Environ. Res. 110: 62-69 (2010). *
Tommasi AM, Fabris P, Carderi I, Baragiotta A, Baldo V, Venturi C, Giordani MT, Tositti G, Floreani A. Lack of higher frequency of the chemokine receptor 5-Delta32/Delta32 genotype in hepatitis C. J. Clin. Gastroenterol. 40: 440-443 (2006).
Toncev G. Therapeutic value of serum uric acid levels increasing in the treatment of multiple sclerosis. Vojnosanit. Pregl. 63: 879-882 (2006).
Toplak N, Avcin T. Influenza and autoimmunity. Ann. N. Y. Acad. Sci. 1173: 619-626 (2009). *
Toplak N, Avcin T. Vaccination of healthy subjects and autoantibodies: from mice through dogs to humans. Lupus 18: 1186-1191 (2009).
Toquero L, Briggs CD, Bassuini MM, Rochester JR. Anal ulceration associated with Nicorandil: case series and review of the literature. Colorectal Dis. 8: 717-720 (2006). *
Torti DC, Feldman SR. Interleukin-12, interleukin-23, and psoriasis: current prospects. J. Am. Acad. Dermatol. 57: 1059-1068 (2007).
Toscano E, Cotta J, Robles M, Lucena MA, Andrade RJ. Hepatotoxicity induced by new immunosuppressants. Gastroenterol. Hepatol. Nov 2 [Epub ahead of print] (2009).
Toumpanakis C, Garland J, Marelli L, Srirajaskanthan R, Soh J, Davies P, Buscombe J, Caplin ME. Long term results of patients with malignant carcinoid syndrome receiving octreotide LAR. Aliment. Pharmacol. Ther. 30: 733-740 (2009). *
Toussirot E, Wendling D. Late-onset ankylosing spondylitis and related spondylarthropathies: clinical and radiological characteristics and pharmacological treatment options. Drugs Aging 22: 451-469 (2005).
Toussirot E, Wendling D. The use of TNF-alpha blocking agents in rheumatoid arthritis: an overview. Expert Opin. Pharmacother. 5: 581-594 (2004).
Toussirot E, Wendling D. The use of TNF-alpha blocking agents in rheumatoid arthritis: an update. Expert Opin. Pharmacother. 8: 2089-2107 (2007).
Towheed T, Maxwell L, Judd M, Catton M, Hochberg M, Wells G. Acetaminophen for osteoarthritis. Cochrane Database Syst. Rev. 1: CD004257 (2006). *
Tozzi V. Pharmacogenetics of antiretrovirals. Antiviral Res. Sep 7 [Epub ahead of print] (2009). *
Tozzi V, Libertone R, Liuzzi G. HIV pharmacogenetics in clinical practice: recent achievements and future challenges. Curr. HIV Res. 6: 544-554 (2008).
Traber MG. Vitamin E, nuclear receptors and xenobiotic metabolism. Arch. Biochem. Biophys. 423: 6-11 (2004). *
Tracey C, Hawley C, Griffin AD, Strutton G, Lynch S. Generalized, pruritic, ulcerating maculopapular rash necessitating cessation of sirolimus in a liver transplantation patient. Liver Transpl. 11: 987-989 (2005). *
Tran TH, Milea D, Cassoux N, Bodaghi B, Bourgeois P, Lehoang P. Optic neuritis associated with infliximab. J. Fr. Ophtalmol. 28: 201-204 (2005).
Trapnell BC, Maguiness K, Graff GR, Boyd D, Beckmann K, Caras S. Efficacy and safety of Creon(R) 24,000 in subjects with exocrine pancreatic insufficiency due to cystic fibrosis. J. Cyst. Fibros. 8: 370-377 (2009).
Trauner M, Boyer JL. Cholestatic syndromes. Curr. Opin. Gastroenterol. 20: 220-230 (2004). *
Travis S, Yap LM, Hawkey C, Warren B, Lazarov M, Fong T, Tesi RJ; RDP Investigators Study Group. RDP58 is a novel and potentially effective oral therapy for ulcerative colitis. Inflamm. Bowel Dis. 11: 713-719 (2005). *
Tredger JM, Brown NW, Adams J, Gonde CE, Dhawan A, Rela M, Heaton N. Monitoring mycophenolate in liver transplant recipients: toward a therapeutic range. Liver Transpl. 10: 492-502 (2004). *
Treeprasertsuk S, Silachamroon U, Krudsood S, Huntrup A, Suwannakudt P, Vannaphan S, Wilairatana P. Ursodeoxycholic acid and artesunate in the treatment of severe falciparum malaria patients with jaundice. J. Gastroenterol. Hepatol. Oct 9 [Epub ahead of print] (2009). *
Tremaine WJ, Hanauer SB, Katz S, Winston BD, Levine JG, Persson T, Persson A; Budesonide CIR United States Study Group. Budesonide CIR capsules (once or twice daily divided-dose) in active Crohn's disease: a randomized placebo-controlled study in the United States. Am. J. Gastroenterol. 97: 1748-1754 (2002). *
Trent RJ. Oversight and monitoring of clinical research with gene therapy in Australia. Med. J. Aust. 182: 441-442 (2005).
Trevisani V, Castro A, Neves Neto J, Atallah A. Cyclophosphamide versus methylprednisolone for treating neuropsychiatric involvement in systemic lupus erythematosus. Cochrane Database Syst. Rev. 2: CD002265 (2006). *
Triggs CM, Munday K, Hu R, Fraser AG, Gearry RB, Barclay ML, Ferguson LR. Dietary factors in chronic inflammation: food tolerances and intolerances of a New Zealand Caucasian Crohn's disease population. Mutat. Res. Feb 5 [Epub ahead of print] (2010).
Trivedi CD, Pitchumoni CS. Drug-induced pancreatitis: an update. J. Clin. Gastroenterol. 39: 709-716 (2005).
Troch M, Woehrer S, Streubel B, Weissel M, Hoffmann M, Mullauer L, Chott A, Raderer M. Chronic autoimmune thyroiditis (Hashimoto's thyroiditis) in patients with MALT lymphoma. Ann. Oncol. 19: 1336-1339 (2008). *
Troiano M, Lotti T. Rituximab in dermatological diseases. G. Ital. Dermatol. Venereol. 144: 495-499 (2009).
Trzonkowski P, Szarynska M, Mysliwska J, Mysliwski A. Ex vivo expansion of CD4(+)CD25(+) T regulatory cells for immunosuppressive therapy. Cytometry A. 75A: 175-188 (2009).
Tsikunib AD, Kondratova ES. Assessment of the structure and quality of nutrition as a factor that influences thyroid functional activity. Gig. Sanit. 6: 67-70 (2007).
Tsugawa K, Hashizume M, Migou S, Kishihara F, Kawanaka H, Tomikawa M, Tanoue K, Sugimachi K. Endoscopic ligation of oesophageal varices compared with injection sclerotherapy in primary biliary cirrhosis. Eur. J. Gastroenterol. Hepatol. 12: 1111-1115 (2000).
Tsujikawa T, Andoh A, Sakaki M, Ishizuka I, Araki Y, Koyama S, Fujiyama Y. Operative indications for patients with refractory or severe ulcerative colitis. Hepatogastroenterology 52: 1470-1473 (2005).
Tufan F, Kamali S, Erer B, Gul A, Inanc M, Ocal L, Konice M, Aral O. Safety of high-dose intravenous immunoglobulin in systemic autoimmune diseases. Clin. Rheumatol. 26: 1913-1915 (2007). *
Tuli SS, Schultz GS, Downer DM. Science and strategy for preventing and managing corneal ulceration. Ocul. Surf. 5: 23-39 (2007).
Tung JK, Warner AS. Colonic inflammatory bowel disease. Medical therapies for colonic Crohn's disease and ulcerative colitis. Postgrad. Med. 112: 45-48, 51 (2002).
Tung TH. Tacrolimus (FK506): safety and applications in reconstructive surgery. Hand (N. Y.) Apr 11 [Epub ahead of print] (2009).
Turner D, Grossman AB, Rosh J, Kugathasan S, Gilman AR, Baldassano R, Griffiths AM. Methotrexate following unsuccessful thiopurine therapy in pediatric Crohn's disease. Am. J. Gastroenterol. 102: 2804-2812 (2007). *
Turner D, Picot J, Cooper K, Loveman E. Adalimumab for the treatment of psoriasis. Health Technol. Assess. 13 Suppl. 2: 49-54 (2009).
Turner D, Steinhart A, Griffiths A. Omega 3 fatty acids (fish oil) for maintenance of remission in ulcerative colitis. Cochrane Database Syst. Rev. 3: CD006443 (2007). *
Turner D, Zlotkin Sh, Shah P, Griffiths A. Omega 3 fatty acids (fish oil) for maintenance of remission in Crohn's disease. Cochrane Database Syst. Rev. 2: CD006320 (2007). *
Turner D, Zlotkin SH, Shah PS, Griffiths AM. Omega 3 fatty acids (fish oil) for maintenance of remission in Crohn's disease. Cochrane Database Syst. Rev. 1: CD006320 (2009). *
Turner NA, Mughal RS, Warburton P, O'Regan DJ, Ball SG, Porter KE. Mechanism of TNFalpha-induced IL-1alpha, IL-1beta and IL-6 expression in human cardiac fibroblasts: effects of statins and thiazolidinediones. Cardiovasc. Res. 76: 81-90 (2007). *
Twork S, Nippert I, Scherer P, Haas J, Kugler J. Immunomodulating drugs in multiple sclerosis: compliance, satisfaction and adverse effects evaluation in a German multiple sclerosis population. Curr. Med. Res. Opin. 23: 1209-1215 (2007).
Tynjala P, Kotaniemi K, Lindahl P, Latva K, Aalto K, Honkanen V, Lahdenne P. Adalimumab in juvenile idiopathic arthritis-associated chronic anterior uveitis. Rheumatology (Oxford) 47: 339-344 (2008). *
Tynjala P, Vahasalo P, Honkanen V, Lahdenne P. Drug survival of the first and second course of anti-TNF agents in juvenile idiopathic arthritis. Ann. Rheum. Dis. 68: 552-557 (2009).
Tyring S, Gordon KB, Poulin Y, Langley RG, Gottlieb AB, Dunn M, Jahreis A. Long-term safety and efficacy of 50 mg of etanercept twice weekly in patients with psoriasis. Arch. Dermatol. 143: 719-726 (2007). *
Tyring S, Gottlieb A, Papp K, Gordon K, Leonardi C, Wang A, Lalla D, Woolley M, Jahreis A, Zitnik R, Cella D, Krishnan R. Etanercept and clinical outcomes, fatigue, and depression in psoriasis: double-blind placebo-controlled randomised phase III trial. Lancet 367: 29-35 (2006). *
Uchiyama K, Nakamura M, Kubota T, Yamane T, Fujise K, Tajiri H. Thiopurine S-methyltransferase and inosine triphosphate pyrophosphohydrolase genes in Japanese patients with inflammatory bowel disease in whom adverse drug reactions were induced by azathioprine/6-mercaptopurine treatment. J. Gastroenterol. 44: 197-203 (2009). *
Ueda M, Tanaka K. Choosing an immunosuppressive regimen for liver transplantation. BioDrugs 8: 430-438 (1997).
Ueno H, Mochizuki H, Hashiguchi Y, Shimazaki H, Aida S, Hase K, Matsukuma S, Kanai T, Kurihara H, Ozawa K, Yoshimura K, Bekku S. Risk factors for an adverse outcome in early invasive colorectal carcinoma. Gastroenterology 127: 385-394 (2004). *
Uetrecht J. Immune-mediated adverse drug reactions. Chem. Res. Toxicol. 22: 24-34 (2009). *
Uetrecht J. Idiosyncratic drug reactions: past, present, and future. Chem. Res. Toxicol. 21: 84-92 (2008). *
Ufer M, Dilger K, Leschhorn L, Daufresne L, Mosyagin I, Rosenstiel P, Haesler R, Kuehbacher T, Nikolaus S, Schreiber S, Cascorbi I. Influence of CYP3A4, CYP3A5, and ABCB1 genotype and expression on budesonide pharmacokinetics: a possible role of intestinal CYP3A4 expression. Clin. Pharmacol. Ther. 84: 43-46 (2008). *
Uhlen S, Belbouab R, Narebski K, Goulet O, Schmitz J, Cezard JP, Turck D, Ruemmele FM. Efficacy of methotrexate in pediatric Crohn's disease: a French multicenter study. Inflamm. Bowel Dis. 12: 1053-1057 (2006). *
Ulbrich W, Lamprecht A. Targeted drug-delivery approaches by nanoparticulate carriers in the therapy of inflammatory diseases. J. R. Soc. Interface Nov 25 [Epub ahead of print] (2009). *
Ulbrich W, Lamprecht A. Targeted drug-delivery approaches by nanoparticulate carriers in the therapy of inflammatory diseases. J. R. Soc. Interface 7 Suppl. 1: S55-S66 (2010).
Ulbricht C, Basch E, Szapary P, Hammerness P, Axentsev S, Boon H, Kroll D, Garraway L, Vora M, Woods J; Natural Standard Research Collaboration. Guggul for hyperlipidemia: a review by the Natural Standard Research Collaboration. Complement. Ther. Med. 13: 279-290 (2005).
Ulbricht C, Chao W, Costa D, Rusie-Seamon E, Weissner W, Woods J. Clinical evidence of herb-drug interactions: a systematic review by the natural standard research collaboration. Curr. Drug Metab. 9: 1063-1120 (2008).
Umehara Y, Kudo M, Kawasaki M. Endoscopic findings can predict the efficacy of leukocytapheresis for steroid-naive patients with moderately active ulcerative colitis. World J. Gastroenterol. 14: 5316-5321 (2008). *
Underner M, Hadjadj S, Beauchant M, Bridoux F, Debiais F, Meurice JC. Effects of smoking on the thyroid gland, digestive system, kidney and bone. Rev. Mal. Respir. 25: 1261-1278 (2008).
Urquhart BL, Tirona RG, Kim RB. Nuclear receptors and the regulation of drug-metabolizing enzymes and drug transporters: implications for interindividual variability in response to drugs. J. Clin. Pharmacol. 47: 566-578 (2007). *
Uy MC, Talingdan-Te MC, Espinosa WZ, Daez ML, Ong JP. Ursodeoxycholic acid in the prevention of gallstone formation after bariatric surgery: a meta-analysis. Obes. Surg. 18: 1532-1538 (2008).
Vahedi H, Momtahen S, Olfati G, Abtahi A, Hosseini S, Kazzazi AS, Khademi H, Rashtak S, Khaleghnejad R, Tabrizian T, Hamidi Z, Nouraie M, Malekzadeh F, Merat S, Nasseri-Moghaddam S, Sotoudehmanesh R, Larijani B. A case-control study on risk factors of osteoporosisin patients with Crohn's disease. Arch. Iran. Med. 12: 570-575 (2009).
Valdes AMD, Schroeder HF, Roizen GV, Honeyman MJ, Sanchez ML. Efficacy of infliximab in patients with moderate and severe psoriasis treated with infliximab (Remicade(R)). Rev. Med. Chil. 134: 326-331 (2006).
Valentino KL, Gutierrez M, Sanchez R, Winship MJ, Shapiro DA. First clinical trial of a novel caspase inhibitor: anti-apoptotic caspase inhibitor, IDN-6556, improves liver enzymes. Int. J. Clin. Pharmacol. Ther. 41: 441-449 (2003).
Valeyrie-Allanore L, Sassolas B, Roujeau JC. Drug-induced skin, nail and hair disorders. Drug Saf. 30: 1011-1030 (2007).
Van Assche G, Sandborn WJ, Feagan BG, Salzberg B, Silvers D, Monroe P, Pandak WM, Anderson FH, Valentine JF, Wild GE, Geenen DJ, Sprague R, Targan SR, Rutgeerts PJ, Vexler V, Young D, Shames RS. Daclizumab, a humanized monoclonal antibody to the interleukin-2 receptor (CD25), for the treatment of moderately to severely active ulcerative colitis: a randomised, double-blind, placebo-controlled, dose-ranging trial. Gut 55: 1568-1574 (2006). *
Van Assche G, Vermeire S, Rutgeerts P. Safety issues with biological therapies for inflammatory bowel disease. Curr. Opin. Gastroenterol. 22: 370-376 (2006).
van Bodegraven AA, Mulder CJ. Indications for 5-aminosalicylate in inflammatory bowel disease: is the body of evidence complete? World J. Gastroenterol. 12: 6115-6123 (2006). *
Van Bodegraven AA, Pena AS. Treatment of extraintestinal manifestations in inflammatory bowel disease. Curr. Treat. Options Gastroenterol. 6: 201-212 (2003).
van Bommel F, de Man RA, Wedemeyer H, Deterding K, Petersen J, Buggisch P, Erhardt A, Huppe D, Stein K, Trojan J, Sarrazin C, Bocher WO, Spengler U, Wasmuth HE, Reinders JG, Moller B, Rhode P, Feucht HH, Wiedenmann B, Berg T. Long-term efficacy of tenofovir monotherapy for hepatitis B virus-monoinfected patients after failure of nucleoside/nucleotide analogues. Hepatology 51: 73-80 (2010).
van de Kerkhof PC, Hoffmann V, Anstey A, Barnes L, Bolduc C, Reich K, Saari S, Segaert S, Vaillant L. A new scalp formulation of calcipotriol plus betamethasone dipropionate compared with each of its active ingredients in the same vehicle for the treatment of scalp psoriasis: a randomized, double-blind, controlled trial. Br. J. Dermatol. 160: 170-176 (2009). *
van de Putte LB, Atkins C, Malaise M, Sany J, Russell AS, van Riel PL, Settas L, Bijlsma JW, Todesco S, Dougados M, Nash P, Emery P, Walter N, Kaul M, Fischkoff S, Kupper H. Efficacy and safety of adalimumab as monotherapy in patients with rheumatoid arthritis for whom previous disease modifying antirheumatic drug treatment has failed. Ann. Rheum. Dis. 63: 508-516 (2004). *
van den Berg WB, Miossec P. IL-17 as a future therapeutic target for rheumatoid arthritis. Nat. Rev. Rheumatol. 5: 549-553 (2009).
van den Oord JJ, Fevery J, de Groote J, Desmet VJ. Immunohistochemical characterization of inflammatory infiltrates in primary biliary cirrhosis. Liver 4: 264-274 (1984).
van Denderen JC, Peters M, Halm VV, Horst-Bruinsma IV, Dijkmans B, Nurmohamed M. Statin therapy might be beneficial for treating patients with ankylosing spondylitis. Ann. Rheum. Dis. 65: 695-696 (2006). *
van Denderen JC, van der Horst-Bruinsma I, Bezemer PD, Dijkmans BA. Efficacy and safety of mesalazine (Salofalk) in an open study of 20 patients with ankylosing spondylitis. J. Rheumatol. 30: 1558-1560 (2003).
van der Bilt JD, Kranenburg O, Nijkamp MW, Smakman N, Veenendaal LM, Te Velde EA, Voest EE, van Diest PJ, Borel Rinkes IH. Ischemia/reperfusion accelerates the outgrowth of hepatic micrometastases in a highly standardized murine model. Hepatology 42: 165-175 (2005). *
van der Ent CK, Hoekstra H, Rijkers GT. Successful treatment of allergic bronchopulmonary aspergillosis with recombinant anti-IgE antibody. Thorax 62: 276-277 (2007). *
van der Heijde D, Dijkmans B, Geusens P, Sieper J, Dewoody K, Williamson P, Braun J. Efficacy and safety of infliximab in patients with ankylosing spondylitis: results of a randomized, placebo-controlled trial (ASSERT). Arthritis Rheum. 52: 582-591 (2005). *
van der Heijde D, Klareskog L, Rodriguez-Valverde V, Codreanu C, Bolosiu H, Melo-Gomes J, Tornero-Molina J, Wajdula J, Pedersen R, Fatenejad S. Comparison of etanercept and methotrexate, alone and combined, in the treatment of rheumatoid arthritis: two-year clinical and radiographic results from the TEMPO study, a double-blind, randomized trial. Arthritis Rheum. 54: 1063-1074 (2006). *
van der Mei IA, Ponsonby AL, Dwyer T, Blizzard L, Taylor BV, Kilpatrick T, Butzkueven H, McMichael AJ. Vitamin D levels in people with multiple sclerosis and community controls in Tasmania, Australia. J. Neurol. 254: 581-590 (2007). *
van der Poorten D, Katelaris PH. The effectiveness of rifabutin triple therapy for difficult to eradicate Helicobacter pylori in clinical practice. Aliment. Pharmacol. Ther. 26: 1537-1542 (2007). *
Van Gossum A. Therapeutic efficacy of 5-ASA molecules in idiopathic intestinal inflammatory diseases: critical review. Acta Gastroenterol. Belg. 55: 462-471 (1992).
van Hogezand RA, Verspaget HW. New therapies for inflammatory bowel disease: an update on chimeric anti-TNF alpha antibodies and IL-10 therapy. Scand. J. Gastroenterol. Suppl. 223: 105-107 (1997).
Van Pelt FN, Carey MA, Carey JB. Chapter 29. Acute and chronic liver diseases induced by drugs or xenobiotics. In "Liver Immunology: Principles and Practice" (eds. Gershwin ME, Vierling JM, Manns MP), Humana Press Inc., Totowa, NJ, p. 375-388 (2007). *
van Riel PL, Taggart AJ, Sany J, Gaubitz M, Nab HW, Pedersen R, Freundlich B, Macpeek D. Efficacy and safety of combination etanercept and methotrexate versus etanercept alone in patients with rheumatoid arthritis with an inadequate response to methotrexate: the ADORE study. Ann. Rheum. Dis. 65: 1478-1483 (2006). *
van Staa TP. The pathogenesis, epidemiology and management of glucocorticoid-induced osteoporosis. Calcif. Tissue Int. 79: 129-137 (2006). *
Van Staa TP, Travis S, Leufkens HG, Logan RF. 5-Aminosalicylic acids and the risk of renal disease: a large British epidemiologic study. Gastroenterology 126: 1733-1739 (2004). *
Van Thiel DH, Carroll P, Abu-Elmagd K, Rodriguez-Rilo H, Irish W, McMichael J, Starzl TE. Tacrolimus (FK 506), a treatment for primary sclerosing cholangitis: results of an open-label preliminary trial. Am. J. Gastroenterol. 90: 455-459 (1995).
Van Vliet G, Polak M, Ritzen EM. Treating fetal thyroid and adrenal disorders through the mother. Nat. Clin. Pract. Endocrinol. Metab. 4: 675-682 (2008).
Vanags D, Williams B, Johnson B, Hall S, Nash P, Taylor A, Weiss J, Feeney D. Therapeutic efficacy and safety of chaperonin 10 in patients with rheumatoid arthritis: a double-blind randomised trial. Lancet 368: 855-863 (2006). *
Vandell AG, DiPiro JT. Low-dosage methotrexate for treatment and maintenance of remission in patients with inflammatory bowel disease. Pharmacotherapy 22: 613-620 (2002).
Varga L, Biro A, Szeplaki G, Toth L, Horvath A, Fust G, Farkas H. Anti-cholesterol antibody levels in hereditary angioedema. J. Cell. Mol. Med. 11: 1377-1383 (2007). *
Varga Z. Cardioprotective role of omega-3 polyunsaturated fatty acids. Orv. Hetil. 149: 627-637 (2008).
Varma R, Cafardi JA, Cantrell W, Elmets C. Safety and efficacy of subcutaneously administered efalizumab in adults with moderate-to-severe hand and foot psoriasis: an open-label study. Am. J. Clin. Dermatol. 9: 105-109 (2008).
Varness T, Seffrood EE, Connor EL, Rock MJ, Allen DB. Oxandrolone improves height velocity and BMI in patients with cystic fibrosis. Int. J. Pediatr. Endocrinol. 2009: 826895 (2009). *
Varney ME, Hardman WE, Sollars VE. Omega 3 fatty acids reduce myeloid progenitor cell frequency in the bone marrow of mice and promote progenitor cell differentiation. Lipids Health Dis. 8: 9 (2009). *
Varriale M, Salvio A, Giannattasio F, d'Errico T, Montone L, Borgia F, Gentile I, Reynaud L, Borgia G, Rossiello R, Visconti M. Intrahepatic cholestatic jaundice related to administration of ranitidine. A case report with histologic and ultramicroscopic study. Minerva Gastroenterol. Dietol. 50: 339-343 (2004).
Vasiliauskas E. Recent advances in the diagnosis and classification of inflammatory bowel disease. Curr. Gastroenterol. Rep. 5: 493-500 (2003).
Vasudev M, Zacharisen MC. New-onset rheumatoid arthritis after anthrax vaccination. Ann. Allergy Asthma Immunol. 97: 110-112 (2006).
Vasudevan AR, Jones PH. Effective use of combination lipid therapy. Curr. Atheroscler. Rep. 8: 76-84 (2006).
Vasudevan AR, Jones PH. Effective use of combination lipid therapy. Curr. Cardiol. Rep. 7: 471-479 (2005).
Vaughan DF, Clay Hodgin E, Hosgood GL, Bernstein JA. Clinical and histopathological features of pemphigus foliaceus with and without eosinophilic infiltrates: a retrospective evaluation of 40 dogs. Vet. Dermatol. Feb 3 [Epub ahead of print] (2010).
Vazquez-Mellado J, Morales EM, Pacheco-Tena C, Burgos-Vargas R. Relation between adverse events associated with allopurinol and renal function in patients with gout. Ann. Rheum. Dis. 60: 981-983 (2001). *
Vecchi M, Meucci G, Gionchetti P, Beltrami M, Di Maurizio P, Beretta L, Ganio E, Usai P, Campieri M, Fornaciari G, de Franchis R. Oral versus combination mesalazine therapy in active ulcerative colitis: a double-blind, double-dummy, randomized multicentre study. Aliment. Pharmacol. Ther. 15: 251-256 (2001). *
Vedani A, Descloux AV, Spreafico M, Ernst B. Predicting the toxic potential of drugs and chemicals in silico: a model for the peroxisome proliferator-activated receptor gamma (PPAR gamma). Toxicol. Lett. 173: 17-23 (2007).
Velasco-Reynold C, Navarro-Alarcon M, De La Serrana HL, Perez-Valero V, Lopez-Martinez MC. Determination of daily dietary intake of chromium by duplicate diet sampling: in vitro availability study. Food Addit. Contam. 25: 604-610 (2008).
Velayudham LS, Farrell GC. Drug-induced cholestasis. Expert Opin. Drug Saf. 2: 287-304 (2003).
Vena GA, Galluccio A, De Simone C, Mastrandrea V, Buquicchio R, La Greca S, Dattola S, Puglisi Guerra A, Donato L, Cantoresi F, De Pita O, Pezza M, D Agostino M, Vernaci R, Miracapillo A, Valenti G, Cassano N. A multicenter open-label experience on the response of psoriasis to adalimumab and effect of dose escalation in non-responders: the Aphrodite project. Int. J. Immunopathol. Pharmacol. 22: 227-233 (2009).
Ventura MT, Polimeno L, Amoruso AC, Gatti F, Annoscia E, Marinaro M, Di Leo E, Matino MG, Buquicchio R, Bonini S, Tursi A, Francavilla A. Intestinal permeability in patients with adverse reactions to food. Dig. Liver Dis. 38: 732-736 (2006).
Verbeeck RK. Pharmacokinetics and dosage adjustment in patients with hepatic dysfunction. Eur. J. Clin. Pharmacol. 64: 1147-1161 (2008).
Verburg RJ, Kruize AA, van den Hoogen FH, Fibbe WE, Petersen EJ, Preijers F, Sont JK, Barge RM, Bijlsma JW, van de Putte LB, Breedveld FC, van Laar JM. High-dose chemotherapy and autologous hematopoietic stem cell transplantation in patients with rheumatoid arthritis: results of an open study to assess feasibility, safety, and efficacy. Arthritis Rheum. 44: 754-760 (2001). *
Verda L, An Kim D, Ikehara S, Statkute L, Bronesky D, Petrenko Y, Oyama Y, He X, Link C, Vahanian NN, Burt RK. Hematopoietic mixed chimerism derived from allogeneic embryonic stem cells prevents autoimmune diabetes mellitus in NOD mice. Stem Cells 26: 381-386 (2008). *
Verea MM, Del Pozo J, Yebra-Pimentel MT, Porta A, Fonseca E. Psoriasiform eruption induced by infliximab. Ann. Pharmacother. 38: 54-57 (2004).
Veres G, Baldassano RN, Mamula P. Infliximab therapy for pediatric Crohn's disease. Expert Opin. Biol. Ther. 7: 1869-1880 (2007).
Veres G, Baldassano RN, Mamula P. Infliximab therapy in children and adolescents with inflammatory bowel disease. Drugs 67: 1703-1723 (2007).
Verheyen J, Bonig H, Kim YM, Banning U, Mauz-Korholz C, Kramm C, Korholz D. Regulation of interleukin-2 induced interleukin-5 and interleukin-13 production in human peripheral blood mononuclear cells. Scand. J. Immunol. 51: 45-53 (2000). *
Vermersch P, Waucquier N, Michelin E, Bourteel H, Stojkovic T, Ferriby D, de Seze J; on behalf of the G-SEP (Groupe septentrional d'etudes et de prise en charge de la sclerose en plaques). Combination of IFNbeta-1a (Avonex(R)) and mycophenolate mofetil (Cellcept(R)) in multiple sclerosis. Eur. J. Neurol. 14: 85-89 (2007).
Vermes A, Vermes I. Genetic polymorphisms in cytochrome P450 enzymes: effect on efficacy and tolerability of HMG-CoA reductase inhibitors. Am. J. Cardiovasc. Drugs 4: 247-255 (2004).
Verstraeten T, Descamps D, David MP, Zahaf T, Hardt K, Izurieta P, Dubin G, Breuer T. Analysis of adverse events of potential autoimmune aetiology in a large integrated safety database of AS04 adjuvanted vaccines. Vaccine 26: 6630-6638 (2009). *
Verweij CL. Predicting the future of anti-tumor necrosis factor therapy. Arthritis Res. Ther. 11: 115 (2009).
Verzijl JM, van Bodegraven AA. Mesalazine - still a first-line therapy. European Pharmacotherapy, Business Briefing (http://bbriefings.com/pdf/26/ept032_r_26_verzil.pdf), pp. 1-7 (2003). *
Vestergaard ME, Kossard S, Murrell DF. Seborrhoeic keratoses appearing in sites of previous psoriasis plaques during treatment with efalizumab. Clin. Exp. Dermatol. Jun 5 [Epub ahead of print] (2009).
Videlock E, Adeyemo M, Licudine A, Hirano M, Ohning G, Mayer M, Mayer E, Chang L. Childhood trauma is associated with hypothalamic-pituitary-adrenal (HPA) axis responsiveness in irritable bowel syndrome. Gastroenterology 137: 1954-1962 (2009). *
Viglietta V, Bourcier K, Buckle GJ, Healy B, Weiner HL, Hafler DA, Egorova S, Guttmann CR, Rusche JR, Khoury SJ. CTLA4Ig treatment in patients with multiple sclerosis: an open-label, phase 1 clinical trial. Neurology 71: 917-924 (2008).
Vik-Mo AO, Ferno J, Skrede S, Steen VM. Psychotropic drugs up-regulate the expression of cholesterol transport proteins including ApoE in cultured human CNS- and liver cells. BMC Pharmacol. 9: 10 (2009). *
Villani P, Mugnier B, Bouvenot G. Muscle cramps: reevaluation of the effectiveness of quinine salts. Presse. Med. 28: 1309-1312 (1999).
Viola F, Civitelli F, Di Nardo G, Barbato MB, Borrelli O, Oliva S, Conte F, Cucchiara S. Efficacy of adalimumab in moderate-to-severe pediatric Crohn's disease. Am. J. Gastroenterol. 104: 2566-2571 (2009). *
Virovic Jukic L, Duvnjak M, Barsic N, Lerotic I, Tomasic V, Pavic T. Pericarditis in exacerbation of ulcerative colitis. Acta Gastroenterol. Belg. 69: 390-392 (2006).
Visser K, van der Heijde D. Optimal dosage and route of administration of methotrexate in rheumatoid arthritis: a systematic review of the literature. Ann. Rheum. Dis. 68: 1094-1099 (2009). *
VITATOPS Trial Study Group, Hankey GJ, Algra A, Chen C, Wong MC, Cheung R, Wong L, Divjak I, Ferro J, de Freitas G, Gommans J, Groppa S, Hill M, Spence D, Lees K, Lisheng L, Navarro J, Ranawaka U, Ricci S, Schmidt R, Slivka A, Tan K, Tsiskaridze A, et al. VITATOPS, the VITAmins TO prevent stroke trial: rationale and design of a randomised trial of B-vitamin therapy in patients with recent transient ischaemic attack or stroke (NCT00097669) (ISRCTN74743444). Int. J. Stroke 2: 144-150 (2007).
Vo AA, Lukovsky M, Toyoda M, Wang J, Reinsmoen NL, Lai CH, Peng A, Villicana R, Jordan SC. Rituximab and intravenous immune globulin for desensitization during renal transplantation. N. Engl. J. Med. 359: 242-251 (2008). *
Voltarelli JC, Couri CE, Stracieri AB, Oliveira MC, Moraes DA, Pieroni F, Coutinho M, Malmegrim KC, Foss-Freitas MC, Simoes BP, Foss MC, Squiers E, Burt RK. Autologous nonmyeloablative hematopoietic stem cell transplantation in newly diagnosed type 1 diabetes mellitus. JAMA 297: 1568-1576 (2007). *
von Ahsen N, Armstrong VW, Behrens C, von Tirpitz C, Stallmach A, Herfarth H, Stein J, Bias P, Adler G, Shipkova M, Oellerich M, Kruis W, Reinshagen M. Association of inosine triphosphatase 94C>A and thiopurine S-methyltransferase deficiency with adverse events and study drop-outs under azathioprine therapy in a prospective Crohn disease study. Clin. Chem. 51: 2282-2288 (2005).
von der Thusen JH, Kuiper J, van Berkel TJ, Biessen EA. Interleukins in atherosclerosis: molecular pathways and therapeutic potential. Pharmacol. Rev. 55: 133-166 (2003). *
Von Hoff DD, LoRusso PM, Rudin CM, Reddy JC, Yauch RL, Tibes R, Weiss GJ, Borad MJ, Hann CL, Brahmer JR, Mackey HM, Lum BL, Darbonne WC, Marsters JC Jr, de Sauvage FJ, Low JA. Inhibition of the hedgehog pathway in advanced basal-cell carcinoma. N. Engl. J. Med. 361: 1164-1172 (2009). *
von Schacky C. A review of omega-3 ethyl esters for cardiovascular prevention and treatment of increased blood triglyceride levels. Vasc. Health Risk Manag. 2: 251-262 (2006).
Voulgari PV, Markatseli TE, Exarchou SA, Zioga A, Drosos AA. Granuloma annulare induced by anti-tumor necrosis factor therapy. Ann. Rheum. Dis. 67: 567-570 (2008).
Voulgari PV, Venetsanopoulou AI, Exarchou SA, Alamanos Y, Tsifetaki N, Drosos AA. Sustained clinical response and high infliximab survival in psoriatic arthritis patients: a 3-year long-term study. Semin. Arthritis Rheum. 37: 293-298 (2008). *
Vrablik M, Dobiasova M, Stulc T, Kasalova Z, Dolezalova R, Prazny M, Fait T, Ceska R. Fenofibrate and rosiglitazone improve quality of lipoproteins in patients with type 2 diabetes mellitus. Neuro. Endocrinol. Lett. 29: 146-150 (2008).
Vrij AA, Oberndorff-Klein-Woolthuis A, Dijkstra G, de Jong AE, Wagenvoord R, Hemker HC, Stockbrugger RW. Thrombin generation in mesalazine refractory ulcerative colitis and the influence of low molecular weight heparin. J. Thromb. Thrombolysis 24: 175-182 (2007).
Vultaggio A, Matucci A, Parronchi P, Rossi O, Palandri F, Romagnani S, Maggi E. Safety and tolerability of infliximab therapy: suggestions and criticisms based on wide clinical experience. Int. J. Immunopathol. Pharmacol. 21: 367-374 (2008).
Wade DT, Makela PM, House H, Bateman C, Robson P. Long-term use of a cannabis-based medicine in the treatment of spasticity and other symptoms in multiple sclerosis. Mult. Scler. 12: 639-645 (2006). *
Wadworth AN, Fitton A. Olsalazine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in inflammatory bowel disease. Drugs 41: 647-664 (1991).
Wagner S, Janzen RW, Mohs C, Pohlmann S, Klingel R, Grutzmacher PW. Long-term treatment of refractory myasthenia gravis with immunoadsorption. Dtsch. Med. Wochenschr. 133: 2377-2382 (2008).
Waibler Z, Sender LY, Merten C, Hartig R, Kliche S, Gunzer M, Reichardt P, Kalinke U, Schraven B. Signaling signatures and functional properties of anti-human CD28 superagonistic antibodies. PLoS ONE 3: e1708 (2008). *
Wain EM, Darling MI, Pleass RD, Barker JN, Smith CH. Treatment of severe, recalcitrant, chronic plaque psoriasis with fumaric acid esters: a prospective study. Br. J. Dermatol. Jun 12 [Epub ahead of print] (2009).
Wainwright CE, Grimwood K, Carlin JB, Vidmar S, Cooper PJ, Francis PW, Byrnes CA, Whitehead BF, Martin AJ, Robertson IF, Cooper DM, Dakin CJ, Masters IB, Massie RJ, Robinson PJ, Ranganathan S, Armstrong DS, Patterson LK, Robertson CF. Safety of bronchoalveolar lavage in young children with cystic fibrosis. Pediatr. Pulmonol. 43: 965-972 (2008).
Waldman M, Appel GB. Update on the treatment of lupus nephritis. Kidney Int. 70: 1403-1412 (2006). *
Waljee AK, Dimagno MJ, Wu BU, Schoenfeld PS, Conwell DL. Systematic review: pancreatic enzyme treatment of malabsorption associated with chronic pancreatitis. Aliment. Pharmacol. Ther. 29: 235-246 (2009). *
Walker K, Ginsberg G, Hattis D, Johns DO, Guyton KZ, Sonawane B. Genetic polymorphism in N-acetyltransferase (NAT): population distribution of NAT1 and NAT2 activity. J. Toxicol. Environ. Health B. Crit. Rev. 12: 440-472 (2009).
Wallace TM, Veldhuyzen van Zanten SJ. Frequency of use and standards of care for the use of azathioprine and 6-mercaptopurine in the treatment of inflammatory bowel disease: a systematic review of the literature and a survey of Canadian gastroenterologists. Can. J. Gastroenterol. 15: 21-28 (2001). *
Walling HW, Swick BL, Gerami P, Scupham RK. Folliculotropic mycosis fungoides responding to bexarotene gel. J. Drugs Dermatol. 7: 169-171 (2008).
Wallis RS, Broder MS, Wong JY, Hanson ME, Beenhouwer DO. Granulomatous infectious diseases associated with tumor necrosis factor antagonists. Clin. Infect. Dis. 38: 1261-1265 (2004). *
Walsh M, Chaudhry A, Jayne D. Long-term follow-up of relapsing/refractory anti-neutrophil cytoplasm antibody associated vasculitis treated with the lymphocyte depleting antibody alemtuzumab (CAMPATH-1H). Ann. Rheum. Dis. 67: 1322-1327 (2008).
Wamsteker EJ. Updates in biliary endoscopy 2006. Curr. Opin. Gastroenterol. 23: 324-328 (2007).
Wan DW, Marks K, Yantiss RK, Talal AH. Autoimmune hepatitis in the HIV-infected patient: a therapeutic dilemma. AIDS Patient Care STDS 23: 407-413 (2009).
Wang B, Nichol JL, Sullivan JT. Pharmacodynamics and pharmacokinetics of AMG 531, a novel thrombopoietin receptor ligand. Clin. Pharmacol. Ther. 76: 628-638 (2004).
Wang B, Wang J, Huang SQ, Su HH, Zhou SF. Genetic polymorphism of the human cytochrome P450 2C9 gene and its clinical significance. Curr. Drug Metab. 10: 781-834 (2009).
Wang C, Harris WS, Chung M, Lichtenstein AH, Balk EM, Kupelnick B, Jordan HS, Lau J. n-3 Fatty acids from fish or fish-oil supplements, but not alpha-linolenic acid, benefit cardiovascular disease outcomes in primary- and secondary-prevention studies: a systematic review. Am. J. Clin. Nutr. 84: 5-17 (2006). *
Wang XP, Yang RM, Ren MS, Sun BM. Anticopper efficacy of captopril and sodium dimercaptosulphonate in patients with Wilson's disease. Funct. Neurol. 18: 149-153 (2003).
Wang YF, Yang XF, Cheng B, Mei CL, Li QX, Xiao H, Zeng QT, Liao YH, Liu K. Protective effect of Astragalus polysaccharides on ATP binding cassette transporter A1 in THP-1 derived foam cells exposed to tumor necrosis factor-alpha. Phytother. Res. Aug 3 [Epub ahead of print] (2009).
Wang YP, Shi B, Chen YX, Xu J, Jiang CF, Xie WF. Drug-induced liver disease: an 8-year study of patients from one gastroenterological department. J. Dig. Dis. 10: 195-200 (2009). *
Wanten GJ, Calder PC. Immune modulation by parenteral lipid emulsions. Am. J. Clin. Nutr. 85: 1171-1184 (2007). *
Wargo KA, Geveden BN, McConnell VJ. Cannabinoid-induced pancreatitis: a case series. JOP 8: 579-583 (2007). *
Warkentin TE, Makris M, Jay RM, Kelton JG. A spontaneous prothrombotic disorder resembling heparin-induced thrombocytopenia. Am. J. Med. 121: 632-636 (2008).
Warren KG, Catz I. Administration of myelin basic protein synthetic peptides to multiple sclerosis patients. J. Neurol. Sci. 133: 85-94 (1995).
Wassef W. Interventional endoscopy. Curr. Opin. Gastroenterol. 19: 546-556 (2003).
Wasserman HA, Evavold BD. Induction of anergy by antibody blockade of TCR in myelin oligodendrocyte glycoprotein-specific cells. J. Immunol. 180: 7259-7264 (2008). *
Watanabe K, Oshitani N, Kamata N, Inagawa M, Yamagami H, Higuchi K, Arakawa T. Efficacy and endoscopic prediction of cytapheresis therapy in patients with refractory and steroid-dependent ulcerative colitis. Aliment. Pharmacol. Ther. 24 Suppl. 4: 147-152 (2006).
Waterman M, Eliakim R. Capsule enteroscopy of the small intestine. Abdom. Imaging 34: 452-458 (2009). *
Waters V, Ratjen F. Multidrug-resistant organisms in cystic fibrosis: management and infection-control issues. Expert Rev. Anti. Infect. Ther. 4: 807-819 (2006).
Watson GS, Craft S. Insulin resistance, inflammation, and cognition in Alzheimer's disease: lessons for multiple sclerosis. J. Neurol. Sci. 245: 21-33 (2006). *
Wattchow DA, DE Fontgalland D, Bampton PA, Leach PL, McLaughlin K, Costa M. Clinical trial: the impact of cyclooxygenase inhibitors on gastrointestinal recovery after major surgery: a randomised double blind controlled trial of celecoxib or diclofenac versus placebo. Aliment. Pharmacol. Ther. 30: 987-998 (2009). *
Weber J. Review: anti-CTLA-4 antibody ipilimumab: case studies of clinical response and immune-related adverse events. Oncologist 12: 864-872 (2007). *
Weber J. Ipilimumab: controversies in its development, utility and autoimmune adverse events. Cancer Immunol. Immunother. 58: 823-830 (2009).
Weber J, Keam SJ. Ustekinumab. BioDrugs 23: 53-61 (2009).
Weber J, Thompson JA, Hamid O, Minor D, Amin A, Ron I, Ridolfi R, Assi H, Maraveyas A, Berman D, Siegel J, O'Day SJ. A randomized, double-blind, placebo-controlled, phase II study comparing the tolerability and efficacy of ipilimumab administered with or without prophylactic budesonide in patients with unresectable stage III or IV melanoma. Clin. Cancer Res. 15: 5591-5598 (2009).
Webster G, Cargill DI, Quiring J, Vogelson CT, Slade HB. A combined analysis of 2 randomized clinical studies of tretinoin gel 0.05% for the treatment of acne. Cutis. 83: 146-154 (2009).
Wedlake L, Thomas K, Lalji A, Anagnostopoulos C, Andreyev HJ. Effectiveness and tolerability of colesevelam hydrochloride for bile-acid malabsorption in patients with cancer: a retrospective chart review and patient questionnaire. Clin. Ther. 31: 2549-2558 (2009).
Wegener's Granulomatosis Etanercept Trial (WGET) Research Group. Etanercept plus standard therapy for Wegener's granulomatosis. N. Engl. J. Med. 352: 351-361 (2005). *
Wegscheider BJ, El-Shabrawi L, Weger M, Ardjomand N, Hermann J, Aberer E, El-Shabrawi Y. Adverse skin reactions to infliximab in the treatment of intraocular inflammation. Eye 21: 547-549 (2007). *
Wehner NG, Gasper C, Shopp G, Nelson J, Draper K, Parker S, Clarke J. Immunotoxicity profile of natalizumab. J. Immunotoxicol. 6: 115-129 (2009).
Wei W, Zhang LL, Xu JH, Xiao F, Bao CD, Ni LQ, Li XF, Wu YQ, Sun LY, Zhang RH, Sun BL, Xu SQ, Liu S, Zhang W, Shen J, Liu HX, Wang RC. A multicenter, double-blind, randomized, controlled phase III clinical trial of chicken type II collagen in rheumatoid arthritis. Arthritis Res. Ther. 11: R180 (2009). *
Weigand K, Wagner-Thiessen E, Stolte M. Esophagitis in an adolescent patient with Crohn's disease after changing treatment from prednisolone to budesonide. Z. Gastroenterol. 42: 1179-1181 (2004).
Weinberg JM. An overview of infliximab, etanercept, efalizumab, and alefacept as biologic therapy for psoriasis. Clin. Ther. 25: 2487-2505 (2003). *
Weinblatt M, Combe B, Covucci A, Aranda R, Becker JC, Keystone E. Safety of the selective costimulation modulator abatacept in rheumatoid arthritis patients receiving background biologic and nonbiologic disease-modifying antirheumatic drugs: a one-year randomized, placebo-controlled study. Arthritis Rheum. 54: 2807-2816 (2006). *
Weinblatt ME. Rheumatoid arthritis: more aggressive approach improves outlook. Cleve. Clin. J. Med. 71: 409-413 (2004). *
Weinblatt ME, Kavanaugh A, Burgos-Vargas R, Dikranian AH, Medrano-Ramirez G, Morales-Torres JL, Murphy FT, Musser TK, Straniero N, Vicente-Gonzales AV, Grossbard E. Treatment of rheumatoid arthritis with a Syk kinase inhibitor: a twelve-week, randomized, placebo-controlled trial. Arthritis Rheum. 58: 3309-3318 (2008). *
Weinblatt ME, Schiff MH, Goldman A, Kremer JM, Luggen M, Li T, Chen D, Becker JC. Selective co-stimulation modulation using abatacept in patients with active rheumatoid arthritis while receiving etanercept: a randomized clinical trial. Ann. Rheum. Dis. 66: 228-234 (2007). *
Weindl G, Roeder A, Schafer-Korting M, Schaller M, Korting HC. Receptor-selective retinoids for psoriasis: focus on tazarotene. Am. J. Clin. Dermatol. 7: 85-97 (2006).
Weiner HL. The challenge of multiple sclerosis: how do we cure a chronic heterogeneous disease? Ann. Neurol. 65: 239-248 (2009).
Weingarten M, Zalmanovici A, Yaphe J. Dietary calcium supplementation for preventing colorectal cancer and adenomatous polyps. Cochrane Database Syst. Rev. 1: CD003548 (2004). *
Weingarten M, Zalmanovici A, Yaphe J. Dietary calcium supplementation for preventing colorectal cancer and adenomatous polyps. Cochrane Database Syst. Rev. 3: CD003548 (2005). *
Weingarten M, Zalmanovici A, Yaphe J. Dietary calcium supplementation for preventing colorectal cancer and adenomatous polyps. Cochrane Database Syst. Rev. 1: CD003548 (2008). *
Weinshilboum RM. Pharmacogenomics: catechol O-methyltransferase to thiopurine S-methyltransferase. Cell. Mol. Neurobiol. 26: 537-559 (2006). *
Weinstein RS. Glucocorticoids, osteocytes, and skeletal fragility: the role of bone vascularity. Bone Jul 7 [Epub ahead of print] (2009). *
Weisenseel P, Prinz JC. Sequential use of infliximab and etanercept in generalized pustular psoriasis. Cutis 78: 197-199 (2006).
Weisman MH, Paulus HE, Burch FX, Kivitz AJ, Fierer J, Dunn M, Kerr DR, Tsuji W, Baumgartner SW. A placebo-controlled, randomized, double-blinded study evaluating the safety of etanercept in patients with rheumatoid arthritis and concomitant comorbid diseases. Rheumatology (Oxford) 46: 1122-1125 (2007). *
Weiss B, Lerner A, Shapiro R, Broide E, Levine A, Fradkin A, Bujanover Y. Methotrexate treatment in pediatric Crohn disease patients intolerant or resistant to purine analogues. J. Pediatr. Gastroenterol. Nutr. 48: 526-530 (2009).
Welch MG, Welch-Horan TB, Anwar M, Anwar N, Ludwig RJ, Ruggiero DA. Brain effects of chronic IBD in areas abnormal in autism and treatment by single neuropeptides secretin and oxytocin. J. Mol. Neurosci. 25: 259-274 (2005).
Wellington K, Jarvis B. Silymarin: a review of its clinical properties in the management of hepatic disorders. BioDrugs 15: 465-489 (2001).
Wellington K, Perry CM. Efalizumab. Am. J. Clin. Dermatol. 6: 113-118 (2005).
Wells TS, Leardmann CA, Smith TC, Smith B, Jacobson IG, Reed RJ, Ryan MA; Millennium Cohort Study Team. Self-reported adverse health events following smallpox vaccination in a large prospective study of US military service members. Hum. Vaccin. 4: 127-133 (2008).
Wendling D, Balblanc JC, Briancon D, Brousse A, Lohse A, Deprez P, Humbert P, Aubin F. Onset or exacerbation of cutaneous psoriasis during TNFalpha antagonist therapy. Joint Bone Spine 75: 315-318 (2008). *
Weng TC, Shen CC, Chiu YT, Lin YL, Kuo CD, Huang YT. Inhibitory effects of armepavine against hepatic fibrosis in rats. J. Biomed. Sci. 16: 78 (2009). *
Wenzl HH, Reinisch W, Jahnel J, Stockenhuber F, Tilg H, Kirchgatterer A, Petritsch W. Austrian infliximab experience in Crohn's disease: a nationwide cooperative study with long-term follow-up. Eur. J. Gastroenterol. Hepatol. 16: 767-773 (2004).
Werneke U, Turner T, Priebe S. Complementary medicines in psychiatry: review of effectiveness and safety. Br. J. Psychiatry 188: 109-121 (2006). *
Wernicke JF, Kratochvil CJ. Safety profile of atomoxetine in the treatment of children and adolescents with ADHD. J. Clin. Psychiatry 63 Suppl. 12: 50-55 (2002).
Wesoly J, Wessels JA, Guchelaar HJ, Huizinga TW. Genetic markers of treatment response in rheumatoid arthritis. Curr. Rheumatol. Rep. 8: 369-377 (2006).
Wessels JA, de Vries-Bouwstra JK, Heijmans BT, Slagboom PE, Goekoop-Ruiterman YP, Allaart CF, Kerstens PJ, van Zeben D, Breedveld FC, Dijkmans BA, Huizinga TW, Guchelaar HJ. Efficacy and toxicity of methotrexate in early rheumatoid arthritis are associated with single-nucleotide polymorphisms in genes coding for folate pathway enzymes. Arthritis Rheum. 54: 1087-1095 (2006). *
Wessels JA, Kooloos WM, Jonge RD, De Vries-Bouwstra JK, Allaart CF, Linssen A, Collee G, Sonnaville PD, Lindemans J, Huizinga TW, Guchelaar HJ. Relationship between genetic variants in the adenosine pathway and outcome of methotrexate treatment in patients with recent-onset rheumatoid arthritis. Arthritis Rheum. 54: 2830-2839 (2006). *
Westhovens R, Houssiau F, Joly J, Everitt DE, Bouman-Thio E, Zhu Y, Sisco D, Van Hartingsveldt B, Mascelli MA, Graham MA, Durez P. A phase I study assessing the safety, clinical response, and pharmacokinetics of an experimental infliximab formulation for subcutaneous or intramuscular administration in patients with rheumatoid arthritis. J. Rheumatol. 33: 847-853 (2006).
Westhovens R, Robles M, Ximenes AC, Nayiager S, Wollenhaupt J, Durez P, Gomez-Reino J, Grassi W, Haraoui B, Shergy W, Park SH, Genant H, Peterfy C, Becker JC, Covucci A, Helfrick R, Bathon J. Clinical efficacy and safety of abatacept in methotrexate-naive patients with early rheumatoid arthritis and poor prognostic factors. Ann. Rheum. Dis. 68: 1870-1877 (2009). *
Westhovens R, Yocum D, Han J, Berman A, Strusberg I, Geusens P, Rahman MU. The safety of infliximab, combined with background treatments, among patients with rheumatoid arthritis and various comorbidities: a large, randomized, placebo-controlled trial. Arthritis Rheum. 54: 1075-1086 (2006). *
Weterman IT. Fertility and pregnancy in inflammatory bowel disease. Neth. J. Med. 35 Suppl. 1: S67-S75 (1989).
Wheeler J, McHale M, Jackson V, Penny M. Assessing theoretical risk and benefit suggested by genetic association studies of CCR5: experience in a drug development programme for maraviroc. Antivir. Ther. 12: 233-245 (2007).
White ES, Lynch JP 3rd. Current and emerging strategies for the management of sarcoidosis. Expert Opin. Pharmacother. 8: 1293-1311 (2007).
Whiting PW, Clouston A, Kerlin P. Black cohosh and other herbal remedies associated with acute hepatitis. Med. J. Aust. 177: 440-443 (2002).
Whorwell PJ, Altringer L, Morel J, Bond Y, Charbonneau D, O'Mahony L, Kiely B, Shanahan F, Quigley EM. Efficacy of an encapsulated probiotic Bifidobacterium infantis 35624 in women with irritable bowel syndrome. Am. J. Gastroenterol. 101: 1581-1590 (2006). *
Wichmann I, Aguilera I, Sousa JM, Bernardos A, Garcia Nunez EJ, Vigil E, Magarino R, Magarino I, Torres A, Nunez-Roldan A. Antibodies against glutathione S-transferase T1 in non-solid organ transplanted patients. Transfusion 46: 1505-1509 (2006). *
Wiedmann M, Muller C, Lobeck H, Wolke K. Sudden elevation of liver enzymes in a 64-year-old patient: a case report. Cases J. 2: 205 (2009). *
Wiendl H, Hohlfeld R. Therapeutic approaches in multiple sclerosis: lessons from failed and interrupted treatment trials. BioDrugs 16: 183-200 (2002).
Wiens A, Correr CJ, Pontarolo R, Venson R, Quinalha JV, Otuki MF. A systematic review and meta-analysis of the efficacy and safety of etanercept for treating rheumatoid arthritis. Scand. J. Immunol. 70: 337-344 (2009). *
Wierzbicki AS. FIELDS of dreams, fields of tears: a perspective on the fibrate trials. Int. J. Clin. Pract. 60: 442-449 (2006). *
Wiesinger HA, Shah J, White A, Yoshida EM, Frohlich J, Sirrs S, Gill S, Byrne MF. Liver biochemistry abnormalities in a quaternary care lipid clinic database. Ann. Hepatol. 7: 63-66 (2008). *
Wijnen PA, Op den Buijsch RA, Drent M, Kuipers PM, Neef C, Bast A, Bekers O, Koek GH. Review article: the prevalence and clinical relevance of cytochrome P450 polymorphisms. Aliment. Pharmacol. Ther. 26 Suppl. 2: 211-219 (2007). *
Wilcken B, Wiley V. Newborn screening. Pathology 40: 104-115 (2008).
Williams GM, Iatropoulos MJ. Alteration of liver cell function and proliferation: differentiation between adaptation and toxicity. Toxicol. Pathol. 30: 41-53 (2002). *
Williams R, James OF, Warnes TW, Morgan MY. Evaluation of the efficacy and safety of rifaximin in the treatment of hepatic encephalopathy: a double-blind, randomized, dose-finding multi-centre study. Eur. J. Gastroenterol. Hepatol. 12: 203-208 (2000).
Wilson CB, Marcuse EK. Vaccine safety/vaccine benefits: science and the public's perception. Nat. Rev. Immunol. 1: 160-165 (2001). *
Winter TA, Wright J, Ghosh S, Jahnsen J, Innes A, Round P. Intravenous CDP870, a PEGylated Fab' fragment of a humanized antitumour necrosis factor antibody, in patients with moderate-to-severe Crohn's disease: an exploratory study. Aliment. Pharmacol. Ther. 20: 1337-1346 (2004). *
Winter UM, Treudler R, Paasch U, Sticherling M, Simon JC. A case of granulomatous rosacea coinciding with the use of etanercept: no relapse with infliximab. Hautarzt. 59: 724-727 (2008).
Winterfield L, Cather J, Cather J, Menter A. Changing paradigms in dermatology: nuclear hormone receptors. Clin. Dermatol. 21: 447-454 (2003).
Wittkowsky AK. Dietary supplements, herbs and oral anticoagulants: the nature of the evidence. J. Thromb. Thrombolysis 25: 72-77 (2008). *
Wolchok JD, Saenger Y. The mechanism of anti-CTLA-4 activity and the negative regulation of T-cell activation. Oncologist 13 Suppl. 4: 2-9 (2008). *
Wolf CJ, Takacs ML, Schmid JE, Lau C, Abbott BD. Activation of mouse and human peroxisome proliferator-activated receptor alpha (PPARalpha) by perfluoroalkyl acids (PFAAs) of different functional groups and chain lengths. Toxicol. Sci. 106: 162-171 (2008). *
Wolf JM, Lashner BA. Inflammatory bowel disease: sorting out the treatment options. Cleve. Clin. J. Med. 69: 621-626, 629-631 (2002). *
Wolfhagen FH, van Hoogstraten HJ, van Buuren HR, van Berge-Henegouwen GP, ten Kate FJ, Hop WC, van der Hoek EW, Kerbert MJ, van Lijf HH, den Ouden JW, Smit AM, de Vries RA, van Zanten RA, Schalm SW. Triple therapy with ursodeoxycholic acid, prednisone and azathioprine in primary biliary cirrhosis: a 1-year randomized, placebo-controlled study. J. Hepatol. 29: 736-742 (1998). *
Wollina U, Hansel G, Koch A, Schonlebe J, Kostler E, Haroske G. Tumor necrosis factor-alpha inhibitor-induced psoriasis or psoriasiform exanthemata: first 120 cases from the literature including a series of six new patients. Am. J. Clin. Dermatol. 9: 1-14 (2008).
Wong A, Bass D. Laboratory evaluation of inflammatory bowel disease. Curr. Opin. Pediatr. 20: 566-570 (2008).
Wong JM, Wei SC. Efficacy of Pentasa tablets for the treatment of inflammatory bowel disease. J. Formos. Med. Assoc. 102: 613-619 (2003).
Wong LS, Tymms KE, Buckley NA. Potential for methotrexate exposure through contamination during parenteral use as an immunosuppressant. Intern. Med. J. 39: 379-383 (2009). *
Wood JD, Galligan JJ. Function of opioids in the enteric nervous system. Neurogastroenterol. Motil. 16 Suppl. 2: 17-28 (2004).
Woods CG, Burns AM, Bradford BU, Ross PK, Kosyk O, Swenberg JA, Cunningham ML, Rusyn I. WY-14,643-induced cell proliferation and oxidative stress in mouse liver are independent of NADPH oxidase. Toxicol. Sci. 98: 366-374 (2007). *
Woods CG, Heuvel JP, Rusyn I. Genomic profiling in nuclear receptor-mediated toxicity. Toxicol. Pathol. 35: 474-494 (2007). *
Woolacott N, Hawkins N, Mason A, Kainth A, Khadjesari Z, Bravo Vergel Y, Misso K, Light K, Chalmers R, Sculpher M, Riemsma R. Etanercept and efalizumab for the treatment of psoriasis: a systematic review. Health Technol. Assess. 10: 1-252 (2006). *
Wooten J. Adverse drug reactions. South. Med. J. 99: 915 (2006).
Wozel G, Vitez L, Meurer M. Palmoplantar pustular psoriasis: successful therapy with efalizumab after non-response to infliximab. Acta Dermatovenerol. Alp. Panonica Adriat. 17: 133-136 (2008).
Wozniak J, Biederman J, Mick E, Waxmonsky J, Hantsoo L, Best C, Cluette-Brown JE, Laposata M. Omega-3 fatty acid monotherapy for pediatric bipolar disorder: a prospective open-label trial. Eur. Neuropsychopharmacol. 17: 440-447 (2007).
Wright SE, Shaikh ZH, Castillo-Lugo JA, Tanriover B. Aseptic meningitis and abducens nerve palsy as a serious side effect of high dose intravenous immunoglobulin used in a patient with renal transplantation. Transpl. Infect. Dis. 10: 294-297 (2008).
Wu D. Modulation of immune and inflammatory responses by dietary lipids. Curr. Opin. Lipidol. 15: 43-47 (2004).
Wu HY. Induction of mucosal tolerance in SLE: a sniff or a sip away from ameliorating lupus? Clin. Immunol. 130: 111-122 (2009). *
Wu WC, Rathore SS, Wang Y, Radford MJ, Krumholz HM. Blood transfusion in elderly patients with acute myocardial infarction. N. Engl. J. Med. 345: 1230-1236 (2001). *
Wu X, Sun L, Zha W, Studer E, Gurley E, Chen L, Wang X, Hylemon PB, Pandak WM Jr, Sanyal AJ, Zhang L, Wang G, Chen J, Wang JY, Zhou H. HIV protease inhibitors induce endoplasmic reticulum stress and disrupt barrier integrity in intestinal epithelial cells. Gastroenterology 138: 197-209 (2010). *
Wusk B, Kullak-Ublick GA, Rammert C, von Eckardstein A, Fried M, Rentsch KM. Therapeutic drug monitoring of thiopurine drugs in patients with inflammatory bowel disease or autoimmune hepatitis. Eur. J. Gastroenterol. Hepatol. 16: 1407-1413 (2004).
Wust S, Tischner D, John M, Tuckermann JP, Menzfeld C, Hanisch UK, van den Brandt J, Luhder F, Reichardt HM. Therapeutic and adverse effects of a non-steroidal glucocorticoid receptor ligand in a mouse model of multiple sclerosis. PLoS One 4: e8202 (2009). *
Wyneski MJ, Green A, Kay M, Wyllie R, Mahajan L. Safety and efficacy of adalimumab in pediatric patients with Crohn disease. J. Pediatr. Gastroenterol. Nutr. 47: 19-25 (2008). *
Xia VW, Steadman RH. Antifibrinolytics in orthotopic liver transplantation: current status and controversies. Liver Transpl. 11: 10-18 (2005). *
Xin HW, Xiong H, Wu XC, Li Q, Xiong L, Yu AR. Relationships between thiopurine S-methyltransferase polymorphism and azathioprine-related adverse drug reactions in Chinese renal transplant recipients. Eur. J. Clin. Pharmacol. 65: 249-255 (2009).
Xu DX, Wang H, Ning H, Zhao L, Chen YH. Maternally administered melatonin differentially regulates lipopolysaccharide-induced proinflammatory and anti-inflammatory cytokines in maternal serum, amniotic fluid, fetal liver, and fetal brain. J. Pineal Res. 43: 74-79 (2007).
Xu J, Barger SW, Drew PD. The PPAR-gamma agonist 15-deoxy-delta-prostaglandin J(2) attenuates microglial production of IL-12 family cytokines: potential relevance to Alzheimer's disease. PPAR Res. 2008: 349185 (2008). *
Xu Y, Hashizume T, Shuhart M, Davis CL, Nelson WL, Sakaki T, Kalhorn TF, Watkins PB, Schuetz EG, Thummel KE. Intestinal and hepatic CYP3A4 catalyze hydroxylation of 1alpha,25-dihydroxyvitamin D3: implications for drug-induced osteomalacia. Mol. Pharmacol. 69: 56-65 (2006). *
Xu Y, Hubal EA, Little JC. Predicting residential exposure to phthalate plasticizer emitted from vinyl flooring: sensitivity, uncertainty, and implications for biomonitoring. Environ. Health Perspect. 118: 253-258 (2010).
Yachha SK, Aggarwal R, Srinivas S, Srivastava A, Somani SK, Itha S. Antibody testing in Indian children with celiac disease. Indian J. Gastroenterol. 25: 132-135 (2006). *
Yacyshyn B, Chey WY, Wedel MK, Yu RZ, Paul D, Chuang E. A randomized, double-masked, placebo-controlled study of alicaforsen, an antisense inhibitor of intercellular adhesion molecule 1, for the treatment of subjects with active Crohn's disease. Clin. Gastroenterol. Hepatol. 5: 215-220 (2007).
Yamada S, Richardson K, Tang M, Halaschek-Wiener J, Cook VJ, Fitzgerald JM, Elwood K, Marra F, Brooks-Wilson A. Genetic variation in carboxylesterase genes and susceptibility to isoniazid-induced hepatotoxicity. Pharmacogenomics J. Mar 2 [Epub ahead of print] (2010).
Yamagata T, Kinoshita K, Nozaki Y, Sugiyama M, Ikoma S, Funauchi M. Effects of pravastatin in murine collagen-induced arthritis. Rheumatol. Int. 27: 631-639 (2007). *
Yamamoto K, Okamoto A, Fujio K. Antigen-specific immunotherapy for autoimmune diseases. Expert Opin. Biol. Ther. 7: 359-367 (2007).
Yamamoto N, Nakai Y, Sasahira N, Hirano K, Tsujino T, Isayama H, Komatsu Y, Tada M, Yoshida H, Kawabe T, Hiki N, Kaminishi M, Kurosaka H, Omata M. Efficacy of peppermint oil as an antispasmodic during endoscopic retrograde cholangiopancreatography. J. Gastroenterol. Hepatol. 21: 1394-1398 (2006). *
Yamamoto S, Nakase H, Mikami S, Inoue S, Yoshino T, Takeda Y, Kasahara K, Ueno S, Uza N, Kitamura H, Tamaki H, Matsuura M, Inui KI, Chiba T. Long-term effect of tacrolimus therapy in patients with refractory ulcerative colitis. Aliment. Pharmacol. Ther. 28: 589-597 (2008). *
Yamamoto T, Umegae S, Kitagawa T, Yasuda Y, Yamada Y, Takahashi D, Mukumoto M, Nishimura N, Yasue K, Matsumoto K. Granulocyte and monocyte adsorptive apheresis in the treatment of active distal ulcerative colitis: a prospective, pilot study. Aliment. Pharmacol. Ther. 20: 783-792 (2004). *
Yamamoto T, Umegae S, Matsumoto K. Safety and clinical efficacy of granulocyte and monocyte adsorptive apheresis therapy for ulcerative colitis. World J. Gastroenterol. 12: 520-525 (2006). *
Yamamura M. Monitoring of clinical course in TNF inhibitor treatment - efficacy evaluation, adverse effect detection, and prediction of clinical response. Nippon Rinsho 65: 1269-1275 (2007).
Yamanaka H, Tanaka Y, Sekiguchi N, Inoue E, Saito K, Kameda H, Iikuni N, Nawata M, Amano K, Shinozaki M, Takeuchi T. Retrospective clinical study on the notable efficacy and related factors of infliximab therapy in a rheumatoid arthritis management group in Japan (RECONFIRM). Mod. Rheumatol. 17: 28-32 (2007). *
Yamauchi PS, Lowe NJ. Etanercept therapy allows the tapering of methotrexate and sustained clinical responses in patients with moderate to severe psoriasis. Int. J. Dermatol. 47: 202-204 (2008). *
Yamshchikov AV, Desai NS, Blumberg HM, Ziegler TR, Tangpricha V. Vitamin D for treatment and prevention of infectious diseases: a systematic review of randomized controlled trials. Endocr. Pract. 15: 438-449 (2009).
Yan BM, Myers RP. Neurolytic celiac plexus block for pain control in unresectable pancreatic cancer. Am. J. Gastroenterol. 102: 430-438 (2007). *
Yan ZS, Li DP, Jiang EL, Zhou CL, Liu EB, Chen HS, Feng SZ, Han MZ. Development of Sweet syndrome in an acute promyelocyte leukemia patient during treatment with all-trans retinoic acid - case report and literature review. Zhonghua Xue Ye Xue Za Zhi 28: 462-465 (2007).
Yang IA, Fong KM, Zimmerman PV, Holgate ST, Holloway JW. Genetic susceptibility to the respiratory effects of air pollution. Thorax 63: 555-563 (2008).
Yang L, Xu L, He L. A CitationRank algorithm inheriting Google technology designed to highlight genes responsible for serious adverse drug reaction. Bioinformatics 25: 2244-2250 (2009). *
Yao Q, Seol DW, Mi Z, Robbins PD. Intra-articular injection of recombinant TRAIL induces synovial apoptosis and reduces inflammation in a rabbit knee model of arthritis. Arthritis Res. Ther. 8: R16 (2005). *
Yatskar L, Fisher EA, Schwartzbard A. Ezetimibe: rationale and role in the management of hypercholesterolemia. Clin. Cardiol. 29: 52-55 (2006).
Ye L, Li YL, Mellstrom K, Mellin C, Bladh LG, Koehler K, Garg N, Garcia Collazo AM, Litten C, Husman B, Persson K, Ljunggren J, Grover G, Sleph PG, George R, Malm J. Thyroid receptor ligands. 1. Agonist ligands selective for the thyroid receptor beta1. J. Med. Chem. 46: 1580-1588 (2003). *
Yeckes AR, Hoffenberg EJ. Rapid infliximab infusions in pediatric inflammatory bowel disease. J. Pediatr. Gastroenterol. Nutr. 49: 151-154 (2009).
Yeung E, Wong FS, Wanless IR, Shiota K, Guindi M, Joshi S, Gardiner G. Ramipril-associated hepatotoxicity. Arch. Pathol. Lab. Med. 127: 1493-1497 (2003). *
Yeung JM, Alistair J, Simpson D, Tang SW, Armitage NC, Maxwell-Armstrong C. Fibrin glue for the treatment of fistulae in ano - a method worth sticking to? Colorectal Dis. Feb 7 [Epub ahead of print] (2009). *
Yi SH, Singh RH. Protein substitute for children and adults with phenylketonuria. Cochrane Database Syst. Rev. 4: CD004731 (2008).
Yokota S, Imagawa T, Mori M, Miyamae T, Aihara Y, Takei S, Iwata N, Umebayashi H, Murata T, Miyoshi M, Tomiita M, Nishimoto N, Kishimoto T. Efficacy and safety of tocilizumab in patients with systemic-onset juvenile idiopathic arthritis: a randomised, double-blind, placebo-controlled, withdrawal phase III trial. Lancet 371: 998-1006 (2008). *
Yokota S, Miyamae T, Imagawa T, Iwata N, Katakura S, Mori M. Inflammatory cytokines and systemic-onset juvenile idiopathic arthritis. Mod. Rheumatol. 14: 12-17 (2004).
Yokota S, Miyamae T, Imagawa T, Iwata N, Katakura S, Mori M, Woo P, Nishimoto N, Yoshizaki K, Kishimoto T. Therapeutic efficacy of humanized recombinant anti-interleukin-6 receptor antibody in children with systemic-onset juvenile idiopathic arthritis. Arthritis Rheum. 52: 818-825 (2005). *
Yoneyama K, Honda E, Kogo M, Kiuchi Y, Shibata M, Mitamura K. Efficacy and safety of prednisolone in patients with autoimmune hepatitis. Adv. Ther. 23: 74-91 (2006).
Yonezawa A, Masuda S, Yokoo S, Katsura T, Inui KI. Cisplatin and oxaliplatin, but not carboplatin and nedaplatin, are substrates for human organic cation transporters (SLC22A1-3 and MATE family). J. Pharmacol. Exp. Ther. 319: 879-886 (2006). *
Yoon H, Kim N, Lee BH, Hwang TJ, Lee DH, Park YS, Nam RH, Jung HC, Song IS. Moxifloxacin-containing triple therapy as second-line treatment for Helicobacter pylori infection: effect of treatment duration and antibiotic resistance on the eradication rate. Helicobacter 14: 77-85 (2009). *
Yoon JY, Min SY, Park JY, Hong SG, Park SJ, Paik SY, Park YM. A case of allopurinol-induced granulomatous hepatitis with ductopenia and cholestasis. Korean J. Hepatol. 14: 97-101 (2008).
Yoon KH. Proliferation signal inhibitors for the treatment of refractory autoimmune rheumatic diseases. Ann. N. Y. Acad. Sci. 1173: 752-756 (2009). *
Yoshida SH, Swan S, Teuber SS, Gershwin ME. Silicone breast implants: immunotoxic and epidemiologic issues. Life Sci. 56: 1299-1310 (1995).
Yoshihara A, Isozaki O, Okubo Y, Takano K. Anti-glutamic acid decarboxylase antibody in Graves' disease is a possible indicator for the unlikelihood of going into remission with antithyroid agents. Endocr. J. 56: 269-274 (2009). *
Young A, Koduri G. Extra-articular manifestations and complications of rheumatoid arthritis. Best Pract. Res. Clin. Rheumatol. 21: 907-927 (2007).
Yu AS, Cheung RC, Keeffe EB. Hepatitis B vaccines. Clin. Liver Dis. 8: 283-300 (2004). *
Yu CY, Chung EK, Yang Y, Blanchong CA, Jacobsen N, Saxena K, Yang Z, Miller W, Varga L, Fust G. Dancing with complement C4 and the RP-C4-CYP21-TNX (RCCX) modules of the major histocompatibility complex. Prog. Nucleic Acid Res. Mol. Biol. 75: 217-292 (2003).
Yuan J, Gnjatic S, Li H, Powel S, Gallardo HF, Ritter E, Ku GY, Jungbluth AA, Segal NH, Rasalan TS, Manukian G, Xu Y, Roman RA, Terzulli SL, Heywood M, Pogoriler E, Ritter G, Old LJ, Allison JP, Wolchok JD. CTLA-4 blockade enhances polyfunctional NY-ESO-1 specific T cell responses in metastatic melanoma patients with clinical benefit. Proc. Natl. Acad. Sci. U.S.A. 105: 20410-20415 (2008). *
Yuen MF, Han KH, Um SH, Yoon SK, Kim HR, Kim J, Kim CR, Lai CL. Antiviral activity and safety of LB80380 in hepatitis B e antigen-positive chronic hepatitis B patients with lamivudine-resistant disease. Hepatology Nov 30 [Epub ahead of print] (2009). *
Yuhas Y, Berent E, Cohen R, Ashkenazi S. Role of NF-kappaB activation and PPARgamma inhibition in the effect of rifampin on inducible nitric oxide synthase transcription in human lung epithelial cells. Antimicrob. Agents Chemother. 53: 1539-1545 (2009). *
Zabala S, Calpe MJ, Perez G, Lerin FJ, Mouronval L. Neutropenia, thrombocytopenia and hepatic injury associated with dexketoprofen trometamol therapy in a previously healthy 35-year-old woman. J. Clin. Pharm. Ther. 33: 79-81 (2008). *
Zabana Y, Domenech E, Manosa M, Garcia-Planella E, Bernal I, Cabre E, Gassull MA. Infliximab safety profile and long-term applicability in inflammatory bowel disease: 9-year experience in clinical practice. Aliment. Pharmacol. Ther. 31: 553-560 (2010). *
Zachariae C, Mork NJ, Reunala T, Lorentzen H, Falk E, Karvonen SL, Johannesson A, Clareus B, Skov L, Mork G, Walker S, Qvitzau S. The combination of etanercept and methotrexate increases the effectiveness of treatment in active psoriasis despite inadequate effect of methotrexate therapy. Acta Derm. Venereol. 88: 495-501 (2008).
Zagari RM, Bianchi-Porro G, Fiocca R, Gasbarrini G, Roda E, Bazzoli F. Comparison of one and two weeks of omeprazole, amoxicillin and clarithromycin treatment for Helicobacter pylori eradication: the HYPER study. Gut 56: 475-479 (2007). *
Zamberk P, Velazquez D, Campos M, Hernanz J, Lazaro P. Paediatric psoriasis - narrowband UVB treatment. J. Eur. Acad. Dermatol. Venereol. Sep 14 [Epub ahead of print] (2009).
Zanchi M, Favot F, Bizzarini M, Piai M, Donini M, Sedona P. Botulinum toxin type-A for the treatment of inverse psoriasis. J. Eur. Acad. Dermatol. Venereol. 22: 431-436 (2008). *
Zandieh I, Krygier D, Wong V, Howard J, Worobetz L, Minuk G, Witt-Sullivan H, Yoshida EM. The use of budesonide in the treatment of autoimmune hepatitis in Canada. Can. J. Gastroenterol. 22: 388-392 (2008). *
Zane LT, Leyden WA, Marqueling AL, Manos MM. A population-based analysis of laboratory abnormalities during isotretinoin therapy for acne vulgaris. Arch. Dermatol. 142: 1016-1022 (2006). *
Zapata R, Sandoval L, Palma J, Hernandez I, Ribalta J, Reyes H, Sedano M, Toha D, Silva JJ. Ursodeoxycholic acid in the treatment of intrahepatic cholestasis of pregnancy. Liver Int. 25: 548-554 (2005). *
Zaragoza V, Perez A, Sanchez JL, Oliver V, Martinez L, Alegre V. Long-term safety and efficacy of etanercept in the treatment of psoriasis. Actas Dermosifiliogr. 101: 47-53 (2010).
Zeifang F, Oberle D, Nierhoff C, Richter W, Moradi B, Schmitt H. Autologous chondrocyte implantation using the original periosteum-cover technique versus matrix-associated autologous chondrocyte implantation: a randomized clinical trial. Am. J. Sports Med. Dec 4 [Epub ahead of print] (2009).
Zein CO, Jorgensen RA, Clarke B, Wenger DE, Keach JC, Angulo P, Lindor KD. Alendronate improves bone mineral density in primary biliary cirrhosis: a randomized placebo-controlled trial. Hepatology 42: 762-771 (2005). *
Zetterman RK. Clinical topics in liver disease. American College of Gastroenterology 68th Annual Scientific Meeting and Postgraduate Course, October 10 - 15, 2003, Baltimore, Maryland (2003).
Zeuner RA, Euler HH, Schroeder JO. High dose intravenous immunoglobulin in autoimmune rheumatic disorders. BioDrugs 8: 371-386 (1997).
Zhang GL, Huang F, Zhang JL, Li XF. A clinical study of leflunomide and methotrexate therapy in psoriatic arthritis. Zhonghua Nei Ke Za Zhi 48: 570-574 (2009).
Zhang J, Adam DN, Stebbing E, Gerbrandt J, Lui H, Shapiro J, Zhou Y. Efficacy of a day-care program in the treatment of psoriasis. J. Cutan. Med. Surg. 12: 211-216 (2008).
Zhang J, Huang W, Chua SS, Wei P, Moore DD. Modulation of acetaminophen-induced hepatotoxicity by the xenobiotic receptor CAR. Science 298: 422-424 (2002). *
Zhang LX, Bai YP, Song PH, You LP, Yang DQ. Effect of Chinese herbal medicine combined with acitretin capsule in treating psoriasis of blood-heat syndrome type. Chin. J. Integr. Med. 15: 141-144 (2009).
Zhang X, Li JY, Cao K, Lu H, Hong M, Qian S, Wu H, Liu P, Xu W. Cotransplantation of HLA-identical mesenchymal stem cells and hematopoietic stem cells in Chinese patients with hematologic diseases. Int. J. Lab. Hematol. Jul 28 [Epub ahead of print] (2009).
Zhang Z, Schmitt J, Wozel G, Kirch W. Treatment of plaque psoriasis with biologics. A meta-analysis of randomized controlled trials. Med. Klin. (Munich) 104: 125-136 (2009).
Zhao SM, Lin WC, Liu JH. Leucocyte removal and its clinical application. Zhongguo Shi Yan Xue Ye Xue Za Zhi 10: 478-482 (2002).
Zhao Y, Okuyama M, Hashimoto H, Tagawa Y, Jomori T, Yang B. Bezafibrate induces myotoxicity in human rhabdomyosarcoma cells via peroxisome proliferator-activated receptor alpha signaling. Toxicol. In Vitro 24: 154-159 (2010).
Zhao YT, Chen Q, Sun YX, Li XB, Zhang P, Xu Y, Guo JH. Prevention of sudden cardiac death with omega-3 fatty acids in patients with coronary heart disease: a meta-analysis of randomized controlled trials. Ann. Med. 41: 301-310 (2009).
Zhenglu W, Hui L, Shuying Zh, Wenjuan C, Zhongyang Sh. A clinical-pathological analysis of drug-induced hepatic injury after liver transplantation. Transplant. Proc. 39: 3287-3291 (2007).
Zhou J, Weng D, Zhou F, Pan K, Song H, Wang Q, Wang H, Wang H, Li Y, Huang L, Zhang H, Huang W, Xia J. Patient-derived renal cell carcinoma cells fused with allogeneic dendritic cells elicit anti-tumor activity: in vitro results and clinical responses. Cancer Immunol. Immunother. 58: 1587-1597 (2009).
Zhou S, Yung Chan S, Cher Goh B, Chan E, Duan W, Huang M, McLeod HL. Mechanism-based inhibition of cytochrome P450 3A4 by therapeutic drugs. Clin. Pharmacokinet. 44: 279-304 (2005).
Zhou SF. Polymorphism of human cytochrome P450 2D6 and its clinical significance: part II. Clin. Pharmacokinet. 48: 761-804 (2009).
Zhou SF, Liu JP, Chowbay B. Polymorphism of human cytochrome P450 enzymes and its clinical impact. Drug Metab. Rev. 41: 89-295 (2009).
Zhou W, Pool V, Iskander JK, English-Bullard R, Ball R, Wise RP, Haber P, Pless RP, Mootrey G, Ellenberg SS, Braun MM, Chen RT. Surveillance for safety after immunization: Vaccine Adverse Event Reporting System (VAERS) - United States, 1991-2001. MMWR Surveill. Summ. 52: 1-24 (2003).
Zhou YC, Waxman DJ. Activation of peroxisome proliferator-activated receptors by chlorinated hydrocarbons and endogenous steroids. Environ. Health Perspect. 106 Suppl. 4: 983-988 (1998). *
Zhu FS, Liu S, Chen XM, Huang ZG, Zhang DW. Effects of n-3 polyunsaturated fatty acids from seal oils on nonalcoholic fatty liver disease associated with hyperlipidemia. World J. Gastroenterol. 14: 6395-6400 (2008). *
Zhu H, Curry S, Wen S, Wicker NJ, Shaw GM, Lammer EJ, Yang W, Jafarov T, Finnell RH. Are the betaine-homocysteine methyltransferase (BHMT and BHMT2) genes risk factors for spina bifida and orofacial clefts? Am. J. Med. Genet. 135A: 274-277 (2005).
Zhu H, Zhao ZY, Jiang YJ, Liang L, Wang JY, Mao HQ, Zou CC, Chen LQ, Qu YP. Multifactorial analysis of effects of mothers' autoimmune thyroid disease on their infants' intellectual development. Zhonghua Er Ke Za Zhi 43: 340-344 (2005).
Zhu X, Wang B, Zhao G, Gu J, Chen Z, Briantais P, Andres P. An investigator-masked comparison of the efficacy and safety of twice daily applications of calcitriol 3 microg/g ointment vs. calcipotriol 50 microg/g ointment in subjects with mild to moderate chronic plaque-type psoriasis. J. Eur. Acad. Dermatol. Venereol. 21: 466-472 (2007). *
Ziakas PD, Dafni UG, Giannouli S, Tzioufas AG, Voulgarelis M. Thrombocytopaenia in lupus as a marker of adverse outcome - seeking Ariadne's thread. Rheumatology (Oxford) 45: 1261-1265 (2006). *
Ziegenhagen DJ. Biologics - the new horizon for medical therapy. Versicherungsmedizin. 61: 4-9 (2009).
Zigra PI, Maipa VE, Alamanos YP. Probiotics and remission of ulcerative colitis: a systematic review. Neth. J. Med. 65: 411-418 (2007). *
Zimmermann GR, Avery W, Finelli AL, Farwell M, Fraser CC, Borisy AA. Selective amplification of glucocorticoid anti-inflammatory activity through synergistic multi-target action of a combination drug. Arthritis Res. Ther. 11: R12 (2009). *
Zimmermann MB. Iodine: it's important in patients that require parenteral nutrition. Gastroenterology 137: S36-S46 (2009). *
Zimmermann R, Witte A, Voll RE, Strobel J, Frieser M. Coagulation activation and fluid retention associated with the use of black cohosh: a case study. Climacteric Jul 31 [Epub ahead of print] (2009).
Ziora K, Oswiecimska J, Broll-Waska K, Szczepanska M, Szprynger K, Pieniazek W, Pindycka-Piaszczynska M, Sakiel S, Kawecki M. Methimazole-induced toxic epidermal necrolysis in a 12-year-old girl. J. Paediatr. Child. Health 42: 472-473 (2006).
Ziring DA, Wu SS, Mow WS, Martin MG, Mehra M, Ament ME. Oral tacrolimus for steroid-dependent and steroid-resistant ulcerative colitis in children. J. Pediatr. Gastroenterol. Nutr. 45: 306-311 (2007). *
Zisman TL, Cohen RD. Pharmacoeconomics and quality of life of current and emerging biologic therapies for inflammatory bowel disease. Curr. Treat. Options Gastroenterol. 10: 185-194 (2007).
Zivanovic D, Medenica L, Tanasilovic S, Vesic S, Skiljevic D, Tomovic M, Nikolic MM. Dexamethasone-cyclophosphamide pulse therapy in pemphigus: a review of 72 cases. Am. J. Clin. Dermatol. 11: 123-129 (2010).
Zlnay D, Zlnay M, Rovensky J. Ankylosing spondylitis - the current situation and new therapeutic options. Vnitr. Lek. 52: 730-735 (2006).
Zoccali C, Mallamaci F, Tripepi G. It is important to lower homocysteine in dialysis patients. Semin. Dial. 20: 530-533 (2007).
Zoli A, Massi G, Pinnelli M, Di Blasi Lo Cuccio C, Castri F, Ferraccioli G. Interstitial granulomatous dermatitis in rheumatoid arthritis responsive to etanercept. Clin. Rheumatol. Oct 4 [Epub ahead of print] (2009).
Zou W, Devi SS, Sparkenbaugh E, Younis HS, Roth RA, Ganey PE. Hepatotoxic interaction of sulindac with lipopolysaccharide: role of the hemostatic system. Toxicol. Sci. 108: 184-193 (2009). *
Zuckerman AJ. Safety of hepatitis B vaccines. Travel Med. Infect. Dis. 2: 81-84 (2004).

Number of references = 3555


David and Judy Rhodes Last Update: 3/6/2010